2020”N“x –k—¢‘åŠwˆãŠw•”E‘åŠw•a‰@Œ¤‹†‹ÆÑW(HTML”Å)


i’FŒ´–{‚ÅŒäŠm”F‰º‚³‚¢j



‰ð–UŠw (¬ì’PˆÊ)

[Šw‰ïEŒ¤‹†‰ï“™]

723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒqƒƒ_ƒJW’c‚̃qƒGƒ‰ƒ‹ƒL[Œ`¬‚ÉŠÖ‚í‚é”]‚Ì•ªŽqŠî”Ղ̉ð–¾. “n•”—É”nCŸ‘ºŒ[Žj1, ˆÀâV@Œ«, Œä—`^•ä, ’|“àG–¾ (1‰ð–U): “ú–{“®•¨Šw‰ï‘æ91‰ñ‘å‰ï2020 (2020/9/4), WebŠJÃ.

723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒqƒƒ_ƒJW’c‚É‚¨‚¢‚ăqƒGƒ‰ƒ‹ƒL[Œ`¬‚ªƒIƒX‚ƃƒX‚̎ЉïŠÖŒW‚É—^‚¦‚é‰e‹¿. ŽR‰º–GŠG, “n•”—É”n, ˆÀâV@Œ«, Ÿ‘ºŒ[Žj1, Œä—`^•ä, ’|“àG–¾ (1‰ð–U): “ú–{“®•¨Šw‰ï‘æ91‰ñ‘å‰ï2020 (2020/9/4), WebŠJÃ.

723003. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Wavyƒƒ_ƒJ‚É‚¨‚¯‚éÒ’Œœ^‹È‚Ì’è—ʉðÍ‚ÆŒ´ˆöˆâ“`Žq•ÏˆÙ‚Ì’Tõ. Ÿ‘ºŒ[Žj1, “‡“c’¼‰p, ¼ê r”V2, “à“cŒ’‘¾˜Y3, ‚‘Š»Žm3, ¬ìŒ³”V1 (1‰ð–U, 2Œ`‘ÔŒn, 3®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15), WebŠJÃ.

723004. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) LAMP–@‚ðŽg—p‚µ‚½‰ð–U‘Ì‚É‚¨‚¯‚錋Šj‹Û‚̐v‘¬ŒŸ¸. ŽO‰Y³–¾1, Vˆä—Y‘¾1, ‹Ê–؉p–¾2, Ÿ‘ºŒ[Žj1, ¬ìŒ³”V1 (1‰ð–U, 2—Տ°‰ð–U‹³ˆç): ‘æ126‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï/‘æ98‰ñ“ú–{¶—Šw‰ï‘å‰ï ‡“¯‘å‰ï (2021/3/27), WebŠJÃ.

723005. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Quantification of spinal curvature and identification of its candidate genes in wy medaka (Oryzias latipes). Ÿ‘ºŒ[Žj1, “‡“c’¼‰p, “à“cŒ’‘¾˜Y2, ¼ê r”V3, ‚‘Š»Žm2, ¬ìŒ³”V1 (1‰ð–U, 2®ŠO, 3Œ`‘ÔŒn): ‘æ126‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï/‘æ98‰ñ“ú–{¶—Šw‰ï‘å‰ï‡“¯‘å‰ï (2021/3/28-30), WebŠJÃ.

723006. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Rosette agent (Sphaerothecum denstruens) infection in laboratory medaka. ¼ê r”V1, Ÿ‘ºŒ[Žj2, ª–{“TŽq3, “¡’J˜aŽq4, Oota H, Oga A, Okayasu I, Michael L Kent, Oda S, ¬ìŒ³”V2 (1Œ`‘ÔŒn, 2‰ð–U, 3ƒoƒCƒIƒCƒ[ƒWŒ¤‹†ƒZ, 4DNAŽÀŒ±ƒZ): ‘æ126‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï/‘æ98‰ñ“ú–{¶—Šw‰ï‘å‰ï‡“¯‘å‰ï (2021/3/28-30), WebŠJÃ.

732001. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰) ƒƒ_ƒJ‚Æ’T‚él—ސi‰». Ÿ‘ºŒ[Žj (‰ð–U): –ȊіΊìæ¶Œä‘ސE‹L”OƒVƒ“ƒ|ƒWƒEƒ€u¶—l—ÞŠw~Œ|pHŠw~ƒŒƒWƒŠƒGƒ“ƒXv (2021/3/12), WebŠJÃ.

733001. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) –쐶ƒƒ_ƒJW’c‚ð—p‚¢‚½ƒqƒgVŠï«’Ç‹s“®‚ÉŠÖ˜A‚·‚éˆâ“`Žq‚Ì“¯’è. Ÿ‘ºŒ[Žj1, –Ø‘º•¶ºC‘¾“c”ŽŽ÷ (1‰ð–U): uoƒ†[ƒ‰ƒVƒA‚Ì“‡“Il—ÞŽjŠw: •¶–¾‘noƒƒJƒjƒYƒ€‚̉𖾁v‘æ4‰ñ‘S‘̉ï‹c (2021/1/9) , WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šw‰ïEŒ¤‹†‰ï“™]

'19-723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –O˜aH‰–…ˆ’u‚É‚æ‚邲ˆâ‘Ì‚Ì“÷Šá“IE‘gDŠw“IŠŒ©‚ÌŒŸ“¢. ’ÓŒ´‘s•½, ‚‹´N‘¿, “c“‡Œõ·, ‹g‘º—œ¹, Vˆä—Y‘¾1, ŽO‰Y³–¾1, ‹Ê–؉p–¾2, Ÿ‘ºŒ[Žj1, ¬ìŒ³”V1 (1‰ð–U, 2—Տ°‰ð–U‹³ˆç): ‘æ125‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï (2020/3/25), ŽãŠJÃ.

'19-723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰ð–UŽÀKŽº‚É‚¨‚¯‚é”÷¶•¨‚É‚æ‚鉘õ‚Ì–hŽ~•û–@‚ÌŒŸ“¢‚Æ”­¶‚ÌŒ´ˆö’²¸. ŽO‰Y³–¾1, Vˆä—Y‘¾1, ‹Ê–؉p–¾2, Ÿ‘ºŒ[Žj1, ¬ìŒ³”V1 (1‰ð–U, 2—Տ°‰ð–U‹³ˆç): ‘æ125‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï (2020/3/27), ŽãŠJÃ.


‰ð–UŠw (ãã’PˆÊ)

[Šwp˜_•¶]

110001. [Œ´’˜] Discrete localization patterns of Arf6, and its activators EFA6A and BRAG2, and its effector PIP5kinaseƒÁ on myofibrils of myotubes and plasma membranes of myoblasts in developing skeletal muscles of mice. Chomphoo S, Sakagami H1, Kondo H, Hipkaeo W: Acta Histochem 2020/4; 122 (3): 151513. (ãã—ms1: 1‰ð–U)

110002. [Œ´’˜] BRAG2a Mediates mGluR-Dependent AMPA Receptor Internalization at Excitatory Postsynapses through the Interaction with PSD-95 and Endophilin 3. Fukaya M1, Sugawara T1, Hara Y1, Itakura M2, Watanabe M, Sakagami H1: J Neurosci 2020/5; 40 (22): 4277-96. ([’J¹O1, ›Œ´Œ’”V1, Œ´@–FL1, ”‘q@½2, ãã—ms1: 1‰ð–U, 2¶‰»)

110003. [Œ´’˜] Data on the effects of Charcot-Marie-Tooth disease type 2N-associated AARS missense mutation (Arg329-to-His) on the cell biological properties. Imaizumi N, Takeuchi Y, Hirano H, Torii T, Seki Y, Morimoto T, Miyamoto Y, Sakagami H1, Yamauchi J: Data Brief 2019/5; 25: 104029. (ãã—ms1: 1‰ð–U)

110004. [Œ´’˜] The Vps52 subunit of the GARP and EARP complexes is a novel Arf6-interacting protein that negatively regulates neurite outgrowth of hippocampal neurons. Ibuchi K1, Fukaya M2, Shinohara T2, Hara Y2, Shiroshima T3, Sugawara T2, Sakagami H2: Brain Res 2020/10; 1745: 146905. (ˆäŸºŠÑ‘¾1, [’J¹O2, ŽÂŒ´“O˜N2, Œ´@–FL2, é“‡’mŽq3, ›Œ´Œ’”V2, ãã—ms2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‰ð–U, 3Œ`‘ÔŒn)

110005. [Œ´’˜] Nicotine Rescues Depressive-like Behaviors via ƒ¿7-type Nicotinic Acetylcholine Receptor Activation in CaMKIV Null Mice. Moriguchi S, Inagaki R, Yi L, Shibata M, Sakagami H1, Fukunaga K: Mol Neurobiol 2020/12; 57 (12): 4929-40. (ãã—ms1: 1‰ð–U)

'19”N“xˆÈ‘O•ª

[Šw‰ïEŒ¤‹†‰ï“™]

'18-723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Arf6Šˆ«‰»§ŒäˆöŽqcytohesin 2‚̋Ǎ݉ðÍ‚Æáu’ɐ§Œä‹@\‚É‚¨‚¯‚é–ðŠ„. ˆÉ“¡—@Žq1, [’J¹O2, ‰ª–{_Žk1, ãã—ms2 (1–ƒŒ, 2‰ð–U): ‘æ124‰ñ“ú–{‰ð–UŠw‰ï‘S‘ŠwpW‰ï (2019/3/27), VŠƒ.


¶—Šw (ìã’PˆÊ)

[Šw‰ïEŒ¤‹†‰ï“™]

723007. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) _Œo×–Eƒ}[ƒJ[—z«/ƒOƒŠƒA×–Eƒ}[ƒJ[‰A«‚Ì”|—{‚°‚ÁŽ•—Þ’†•_Œo×–E‚͍זE•ª—ô‚·‚é. ”ä—¯ŠÔO”ü (¶—): ‘æ126‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï/‘æ98‰ñ“ú–{¶—Šw‰ï‘å‰ï ‡“¯‘å‰ï (2021/3/28), WebŠJÃ.


¶—Šw (‚‹´’PˆÊ)

[Šwp˜_•¶]

110006. [Œ´’˜] TRPA1 and TRPV1 channels participate in atmospheric-pressure plasma-induced [Ca2+]i response. Kawase M, Chen W, Kawaguchi K, Nyasha MR, Sasaki S, Hatakeyama H1, Kaneko T, Kanzaki M: Sci Rep 2020/6; 10 (1): 9687. (”©ŽR—TN1: 1¶—)

110007. [Œ´’˜] Erythropoietin production by the kidney and the liver in response to severe hypoxia evaluated by Western blotting with deglycosylation. Yasuoka Y1, Fukuyama T2, Izumi Y, Nakayama Y, Inoue H, Yanagita K, Oshima T3, Yamazaki T2, Uematsu T2, Kobayashi N2, Shimada Y2, Nagaba Y2, Mukoyama M, Yamashita T, Sato Y4, Sands JM, Kawahara K1, Nonoguchi H2: Physiol Rep 2020/6; 8 (12): e14485. (ˆÀ‰ª—L‹IŽq1, •ŸŽR@—²2, ‘哈—F”ü3, ŽRè‘å‰ê2, A¼’”V2, ¬—ÑŒ›’‰2, “‡“c–F—²2, ’·ê@‘×2, ²“¡—Yˆê4, ‰ÍŒ´Ž‰ë1, –ìXŒû”ŽŽj2 (1¶—, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3¶•¨•¨—Œn, 4ˆã—Éq¶Šw•”)

110008. [Œ´’˜] MEK/ERK Signaling in ƒÀ-Cells Bifunctionally Regulates ƒÀ-Cell Mass and Glucose-Stimulated Insulin Secretion Response to Maintain Glucose Homeostasis. Matsumoto-Ikushima Y, Awazawa M, Kobayashi N, Osonoi S, Takemiya S, Kobayashi H, Suwanai H, Morimoto Y, Soeda K, Adachi J, Muratani M, Charron J, Mizukami H, Takahashi N1, Ueki K: Diabetes 2021/7; 70 (7): 1519-35. (‚‹´—ÏŽq1: 1¶—)

110009. [Œ´’˜] Differentiation of endogenous erythropoietin and exogenous ESAs by Western blotting. Yasuoka Y1, Fukuyama T2, Izumi Y, Yamashita T, Nakayama Y, Inoue H, Kengo Yanagita K, Oshima T3, Yamazaki T2, Uematsu T2, Kobayashi N2, Shimada Y2, Nagaba Y2, Mukoyama M, Sato Y4, Sands JM, Kawahara K1, Nonoguchi H2: Heliyon 2020/11; 6 (11): e05389. (ˆÀ‰ª—L‹IŽq1, •ŸŽR@—²2, ‘哈—F”ü3, ŽRè‘å‰ê2, A¼’”V2, ¬—ÑŒ›’‰2, “‡“c–F—²2, ’·ê@‘×2, ²“¡—Yˆê4, ‰ÍŒ´Ž‰ë1, –ìXŒû”ŽŽj2 (1¶—, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3¶•¨•¨—Œn, 4ˆã—Éq¶Šw•”)

110010. [Œ´’˜] Melanophilin Accelerates Insulin Granule Fusion without Predocking to the Plasma Membrane. Wang H, Mizuno K, Takahashi N1, Kobayashi E, Shirakawa J, Terauchi Y, Kasai H, Okunishi K, Izumi T: Diabetes 2020/12; 69 (12): 2655-66. (‚‹´—ÏŽq1: 1¶—)

310001. [Ç—á•ñ] The work style and living condition survey of diabetologists and the expectations for the Japan Diabetes Society: results of questionnaires about the current state and the future prospect of their carrier in 2017. Naruse K1, Abiko A1, Nakayama H1, Tanaka N1, Ikeda K1, Imachi H1, Usigome E1, Umayahara Y1, Ota S1, Okada Y1, Kodani N1, Takahashi N1,2, Terai A1, Nakamura A1, Fujikawa R1, Miura J1, Morita E1, Yanagimachi M1, Ueki K1 (1Japan Diabetes Society Committee to Promote Female Diabetologists): Diabetol Int 2020/6; 11 (4): 299-308. (‚‹´—ÏŽq1,2: 2¶—)

522001. [uÀ]y“ÁW: ƒCƒ“ƒXƒŠƒ“•ª”å‹@\‚Æ‚»‚ُ̈íz2. ƒCƒ“ƒXƒŠƒ“ŠJŒû•úo‚̃ƒJƒjƒYƒ€. ‚‹´—ÏŽq (¶—): ŒŽŠ§“œ”A•a 2020/11; 12 (7): 13-9.

[’˜@‘]

620001. [Šwp‘ (•ª’SŽ·•M)]y—Տ°ŒŸ¸ƒKƒCƒh2020”N‰ü’ù”Ł@‚±‚ꂾ‚¯‚Í•K—v‚ÈŒŸ¸‚Ì‚·‚·‚ß‚©‚½Eƒf[ƒ^‚Ì‚æ‚Ý‚©‚½z2. ‘ãŽÓE“à•ª”匟¸@A. “œ‘ãŽÓ@ƒPƒgƒ“EƒPƒgƒ“‘Ì•ª‰æ (ŒŒ‰t‚¨‚æ‚Ñ”A), p.260-2. ‚‹´—ÏŽq1, –å˜e@F (1¶—), •Ò: ‘吼G–¾, Medical Practice•ÒWˆÏˆõ‰ï, •¶Œõ“°, “Œ‹ž, 2020/6”­s.

620002. [Šwp‘ (•ª’SŽ·•M)]y•W€–ò—Šw ‘æ8”Łz‘æIII•Ò@–ò•¨‚Ɗ튯•a‘Ԑ§Œä@‘æ18Í“à•ª”åE‘ãŽÓŒn@äX‘Ÿƒzƒ‹ƒ‚ƒ“, ‘ãŽÓ (“œ”A•aŽ¡—Öò, Ž‰Ž¿ˆÙíÇŽ¡—Öò, ’É•—Ž¡—Öò, ƒrƒ^ƒ~ƒ“—Þ), p.395-419. ”і쐳Œõ, “n糗TŽi, “à“cM–ç, Š£@’¼‹P, ’|“à˜a•F, _’Jç–¾, •£@“™, —é–؏G“T, Îˆä–M–¾, ˆÀˆä³l, ‹àˆäDŽ, –‘@³K, œA£Œª‘¢, ŒÃì“NŽj, •Ÿ–{½“ñ, ‚‹´—ÏŽq1, Žç‰®‹±Ž¢, ‹ËŒËŒh‘¾, ‘º‰z—²”V, –x@³•q, ”n“ˆ³—²2 (1¶—, 2–ò—), ŠÄC: ”і쐳Œõ, •Ò: —é–؏G“T, ‹àˆäDŽ, ˆãŠw‘‰@, “Œ‹ž, 2021/3”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713001. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Potentiation of presynaptic functions by mechanosensing the spine enlargement in rat hippocampus. Ucar H, Watanabe S, Noguchi J, Yagishita S, Morimoto Y, Takahashi N1, Kasai H: The 12th Federation of European Neuroscience Societies Forum (2020/7/11-15), WebŠJÃ. (‚‹´—ÏŽq1: 1¶—)

722001. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) äXƒÀ×–E“à•”‚É‚¨‚¯‚éƒCƒ“ƒXƒŠƒ“•ª”åè÷—±‚Ì‹““®Œv‘ª. ”©ŽR—TN (¶—): ‘æ43‰ñ“ú–{•ªŽq¶•¨Šw‰ï”N‰ï (2020/12/3), WebŠJÃ.

723008. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒEƒFƒXƒ^ƒ“ƒuƒƒbƒeƒBƒ“ƒO‚É‚æ‚錌‰t, ”A’†ƒGƒŠƒXƒƒ|ƒGƒ`ƒ“‚ÌŒŸo. ˆÀ‰ª—L‹IŽq1, •ŸŽR@—², ò—Tˆê˜Y, ‘哈—F”ü2, ²“¡—Yˆê, ŒüŽR­Žu, ŽR‰º“N˜Y, ‰ÍŒ´Ž‰ë, –ìXŒû”ŽŽj (1¶—, 2¶•¨•¨—Œn): ‘æ63‰ñ“ú–{t‘ŸŠw‰ïŠwp‘‰ï (2020/8/19), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723009. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äXƒÀ×–E“à•”‚É‚¨‚¯‚éƒCƒ“ƒXƒŠƒ“•ª”åè÷—±‚Ì‹““®‚ð‚¸“x‚ɉŽ‹‰»Œv‘ª‚·‚邽‚ß‚ÌŽè–@‚ÌŠJ‘ñ. ”©ŽR—TN1, ‘哈—F”ü2, ‚‹´—ÏŽq1 (1¶—, 2¶•¨•¨—Œn): ‘æ63‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï (2020/10/5), WebŠJÃ.

723010. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) GLUT4×–E–ŒˆÚs‚𐧌䂷‚éƒCƒ“ƒXƒŠƒ“‰Šúì—p‰ß’ö‚̍‚¸“x‰ÂŽ‹‰»‰ðÍ. _è@“W, ”©ŽR—TN1 (1¶—): ‘æ63‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï (2020/10/5), WebŠJÃ.

723011. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Single molecule analysis of insulin granule movement within pancreatic ƒÀ-cells. ”©ŽR—TN1, ‘哈—F”ü2, ‚‹´—ÏŽq1 (1¶—, 2¶•¨•¨—Œn): ‘æ126‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï/‘æ98‰ñ“ú–{¶—Šw‰ï‘å‰ï ‡“¯‘å‰ï (2021/3/29), WebŠJÃ.

723012. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (‹³ˆçu‰‰) ×–E‹@”\‚̉Ž‹‰». ‚‹´—ÏŽq (¶—): ‘æ85‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2020/9/25), WebŠJÃ.


¶‰»Šw (ä’PˆÊ)

[Šwp˜_•¶]

110011. [Œ´’˜] Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells. Yamashita K, Kiyonari S1, Tsubota S, Kishida S, Sakai R1, Kadomatsu K: Cancer Sci 2020/7; 111 (7): 2431-9. (´¬Mˆê1, ä@—²ˆê1: 1¶‰»)

110012. [Œ´’˜] Functional maintenance of calcium store by ShcB adaptor protein in cerebellar Purkinje cells. Kakizawa S, Kishimoto Y, Yamamoto S, Onga K, Yasuda K, Miyamoto Y, Watanabe M, Sakai R1, Mori N: Sci Rep 2020/9; 10 (1): 14475. (ä@—²ˆê1: 1¶‰»)

110013. [Œ´’˜] Age-Dependent Shift of AMPA Receptors From Synapses to Intracellular Compartments in Alzheimer's Disease: Immunocytochemical Analysis of the CA1 Hippocampal Region in APP/PS1 Transgenic Mouse Model. Mart’n-Belmonte A, Aguado C, Alfaro-Ru’z R, Itakura M1, Moreno-Mart’nez AE, de la Ossa L, Moln‡r E, Fukazawa Y, Luj‡n R: Front Aging Neurosci 2020/10; 12: 577996. (”‘q@½1: 1¶‰»)

110014. [Œ´’˜] Rats deficient in the GAD65 isoform exhibit epilepsy and premature lethality. Kakizaki T, Ohshiro T, Itakura M1, Konno K, Watanabe M, Mushiake H, Yanagawa Y: FASEB J 2021/2; 35 (2): e21224. (”‘q@½1: 1¶‰»)

[Šw‰ïEŒ¤‹†‰ï“™]

713002. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Functional analysis of FGFR2 binding target protein in scirrhous gastric cancer. Sakai R1, Shirakihara T1: The 14th International Conference on Protein Phosphatase (2020/12/11), Kobe, Japan. (ä@—²ˆê1, ”’–ØŒ´‘ôÆ1: 1¶‰»)

723013. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ`ƒ~ƒWƒ‹Ž_‡¬y‘f‘jŠQÜ‚ÍMYCN‘•Œ^_Œo‰èŽî×–E‚Ì“àˆö«DNA‘¹‚𑣐i‚·‚é. ´¬Mˆê1, ä@—²ˆê1, –叼Œ’Ž¡ (1¶‰»): ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/3), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110001. [Œ´’˜] Advantages of Acute Brain Slices Prepared at Physiological Temperature in the Characterization of Synaptic Functions. Eguchi K, Velicky P, Hollergschwandtner E, Itakura M1, Fukazawa Y, Danzl JG, Shigemoto R: Front Cell Neurosci 2020/3; 14: 63. (”‘q@½1: 1¶‰»)

'19-110002. [Œ´’˜] Homophilic complex formation of CDCP1 via the extracellular CUB2 domain facilitates SFK activation and promotes cancer cell migration. Sawayama T, Katsuhiko Nakashima K, Tohru Ichimura T, Sakai R1, Takamasa Uekita T: Oncol Rep 2019/10; 42 (4): 1507-16. (ä@—²ˆê1: 1¶‰»)


¶‰»Šw (äݑã’PˆÊ)

[Šwp˜_•¶]

110015. [Œ´’˜] Optimizing Nervous System-Specific Gene Targeting with Cre Driver Lines: Prevalence of Germline Recombination and Influencing Factors. Luo L, Ambrozkiewicz MC, Benseler F, Chen C, Dumontier E, Falkner S, Furlanis E, Gomez AM, Hoshina N, Huang W-H, Hutchison MA, Itoh-Maruoka Y, Lavery LA, Li W, Maruo T1, Motohashi J, Ling-Lin Pai E, Pelkey KA, Pereira A, Philips T, Sinclair JL, Stogsdill JA, TraunmŸller L, Wang J, Wortel J, You W, Abumaria N, Beier KT, Brose N, Burgess HA, Cepko CL, Cloutier J-F, Eroglu C, Goebbels S, Kaeser PS, Kay JN, Lu W, Luo L, Mandai K1, McBain CJ, Nave K-A, Prado MAM, Prado VF, Rothstein J, Rubenstein JLR, Saher G, Sakimura K, Sanes JR, Scheiffele P, Takai Y, Umemori H, Verhage M, Yuzaki M, Zoghbi HY, Kawabe H, Ann Marie Craig AM: Neuron 2020/4; 106 (1): 37-65.e5. (ŠÛ”ö’m•F1, äݑ㌤“ñ1: 1¶‰»)

110016. [Œ´’˜] Nectin-2ƒ¿ is localized at cholinergic neuron dendrites and regulates synapse formation in the medial habenula. Shiotani H, Miyata M, Kameyama T, Mandai K1, Yamasaki M, Watanabe M, Mizutani K, Takai Y: J Comp Neurol 2021/2; 529 (2): 450-77. (äݑ㌤“ñ1: 1¶‰»)

110017. [Œ´’˜] Identification of Sox2 and NeuN Double-Positive Cells in the Mouse Hypothalamic Arcuate Nucleus and Their Reduction in Number With Aging. Sugiura A, Shimizu T, Kameyama T, Maruo T1, Kedashiro S, Miyata M, Mizutani K, Takai Y: Front Aging Neurosci 2021/3; 12: 609911. doi: 10.3389/fnagi.2020.609911. eCollection 2020. (ŠÛ”ö’m•F1: 1¶‰»)


•ªŽqˆâ“`Šw

[Šwp˜_•¶]

110018. [Œ´’˜] Gorlin syndrome-induced pluripotent stem cells form medulloblastoma with loss of heterozygosity in PTCH1. Ikemoto Y1, Miyashita T2, Nasu M, Hatsuse H3, Kajiwara K, Fujii K, Motojima T, Kokido I, Toyoda M, Umezawa A: Aging (Albany NY) 2020/5; 12 (10): 9935-47. (’r–{@—D1, ‹{‰ºr”V2, ‰£—m”ü3: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2•ªŽqˆâ“`, 3•a‘ԁEf—ÃŒn)

110019. [Œ´’˜] A phase I/IIa double blind single institute trial of low dose sirolimus for Pendred syndrome/DFNB4. Fujioka M1, Akiyama T, Hosoya M, Kikuchi K, Fujiki Y, Saito Y, Yoshihama K, Ozawa H, Tsukada K, Nishio SY, Usami SI, Matsunaga T, Hasegawa T, Sato Y Ogawa K: Medicine (Baltimore) 2020/5; 99 (19): e19763. (“¡‰ª³l1: 1•ªŽqˆâ“`)

110020. [Œ´’˜] Low-dose rapamycin-induced autophagy in cochlear outer sulcus cells. Saegusa C, Hotoya M, Nishiyama T, Saeki T, Fujimoto C, Okano H, Fujioka M1, Ogawa K: Laryngoscope Investig Otolaryngol 2020/5; 5 (3): 520-8. (“¡‰ª³l1: 1•ªŽqˆâ“`)

110021. [Œ´’˜] Differences in hearing levels between siblings with hearing loss caused by GJB2 mutations. Fujioka M1, Hosoya M, Nara K, Morimoto N, Sakamoto H, Ohtsu M, Nakano A, Arimoto Y, Masauda S, Sugiuchi T, Masuda S, Morita N, Ogawa K, Kaga K, Matsunaga T: Auris Nasus Larynx 2020/12; 47 (6): 938-42. (“¡‰ª³l1: 1•ªŽqˆâ“`)

110022. [Œ´’˜] The common marmoset as suitable nonhuman alternative for the analysis of primate cochlear development. Hosoya M, Fujioka M1, Murayama AY, Okano H, Ogawa K: FEBS J 2021/1; 288 (1): 325-53. (“¡‰ª³l1: 1•ªŽqˆâ“`)

110023. [Œ´’˜] Deficiency of large tumor suppressor kinase 1 causes congenital hearing loss associated with cochlear abnormalities in mice. Nishiyama T, Fujioka M1, Saegusa C, Oishi N, Harada T, Hosoya M, Saya H, Ogawa K: Biochem Biophys Res Commun 2021/1; 534: 921-6. (“¡‰ª³l1: 1•ªŽqˆâ“`)

110024. [Œ´’˜] Specific temperament in patients with nevoid basal cell carcinoma syndrome. Uchikawa H, Fujii K, Shiohama T, Nakazato M, Shimizu E, Miyashita T1, Shimojo N: Pediatr Int 2021/2: 63 (2): 177-82. (‹{‰ºr”V1: 1•ªŽqˆâ“`)

110025. [Œ´’˜] Hydroxyapatite Prostheses in Endoscopic Transcanal Stapes Surgery for Otosclerosis Cases. Hosoya M, Fujioka M1, Ogawa K: Ear Nose Throat J 2021/2; 145561321989143. (“¡‰ª³l1: 1•ªŽqˆâ“`)

110026. [Œ´’˜] Multicenter phase III trial of regenerative treatment for chronic tympanic membrane perforation. Kanemaru SI, Kanai R, Omori K, Yamamoto N, Okano T, Kishimoto I, Ogawa K, Kanzaki S, Fujioka M1, Oishi N, Naito Y, Kakehata S, Nakamura H, Yamada S, Omae K, Kawamoto A, Fukushima M: Auris Nasus Larynx 2021/12; 48 (6): 1054-60. doi: 10.1016/j.anl.2021.02.007. Epub 2021 Mar 26. (“¡‰ª³l1: 1•ªŽqˆâ“`)

120001. [Œ´’˜] ŠOŽ¨“¹ŠàÇ—á22Ž¨‚ÌŒŸ“¢. —é–ؐ¬®, ‘åÎ’¼Ž÷, ¬àVG”V, _è@», “¡‰ª³l1, ¼ŽR’Œo, –ìŒû@Ÿ, ×’J@½, ŠÖ…^—Žq, Ö“¡@^, ¬ì@ˆè (1•ªŽqˆâ“`): “ú–{Ž¨•@ˆôA‰ÈŠw‰ï‰ï•ñ 2021/3; 124 (3): 197-204.

522002. [uÀ]y“ÁW: “ï’®‚ÌŽ¡—Á|Ä¶ˆã—©‚çlH’®ŠoŠí‚܂Łzˆâ“`«“ï’®‚ɑ΂·‚éiPS×–E‘n–ò|ƒyƒ“ƒhƒŒƒbƒhÇŒóŒQ‚ɑ΂·‚é’á—p—ʃVƒƒŠƒ€ƒX—Ö@|. “¡‰ª³l (•ªŽqˆâ“`): ˆãŠw‚Ì‚ ‚ä‚Ý 2021/2; 276 (7): 695-701.

522003. [uÀ]y˜AÚ: Ä¶ˆã—Â͂ǂ±‚܂Ői‚ñ‚¾‚©zvol.12 “àŽ¨«“ï’®‚ɑ΂·‚éiPS×–E‘n–ò. “¡‰ª³l (•ªŽqˆâ“`): ˆãŠw‚Ì‚ ‚ä‚Ý 2020/9; 274 (11): 1119-27.

[’˜@‘]

622001. [Šwp‘ (–|–ó)]yƒpƒ^[ƒ\ƒ“—Տ°ƒAƒŒƒ‹ƒM[Šw (Patterson's Allergic Diseases, 8th Edition)zSection VII ã‹C“¹Ž¾Š³@27 •@ƒ|ƒŠ[ƒv, •@•›•@o‰Š, ‚¨‚æ‚Ñ”ñƒAƒŒƒ‹ƒM[«•@‰Š, p.687-702. “¡‰ª³l (•ªŽqˆâ“`), –ó: ŒcœäƒAƒŒƒ‹ƒM[ƒZƒ“ƒ^[, ŠÄC: •Ÿ‰i‹»ˆë, ŠÄ–ó: ³–؍Ž‹X, X“c‹v”üŽq, Ží£Œ[Žm, _è@», [ì˜aŒÈ, ³‰ªŒš—m, ƒƒfƒBƒJƒ‹EƒTƒCƒGƒ“ƒXEƒCƒ“ƒ^[ƒiƒVƒ‡ƒiƒ‹, “Œ‹ž, 2020/9”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713003. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Tympanoplasty type 1 (TP1) with inlay technique by Transcanal Endoscopic Ear Surgery (TEES). Kitamura M, Hosoya M, Kanzaki S, Ogawa K, Fujioka M1: AAO-HNSF 2020 Virtual Annual Meeting & OTO Experience (2020/9/13-10/25) , WebŠJÃ. (“¡‰ª³l1: 1•ªŽqˆâ“`)

722002. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Š²×–EˆãŠw‚ð‰ž—p‚µ‚½Åæ’[‚̈ã—Ã-Š´‰¹“ï’®‚Ö‚Ì’§í-. “¡‰ª³l (•ªŽqˆâ“`): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27-5/18), WebŠJÃ.

722003. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒfƒWƒ^ƒ‹ƒwƒ‹ƒX‚ÆiPS×–E‹Zp‚É‚æ‚é’®—́E•½tŠo‚̃Gƒ“ƒhƒ^ƒCƒv‰ðÍ‚ƌ•ʉ»ˆã—Ã. “¡‰ª³l (•ªŽqˆâ“`): ‘æ20‰ñ“ú–{R‰Á—îˆãŠw‰ï‘‰ï (2020/9/26), WebŠJÃ.

723014. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆê‘¤«’†Ž¨æ“VŠïŒ`‚Ì’®—͉ü‘PŽèp‘OŒã‚É‚¨‚¯‚é‘S”]ƒRƒlƒNƒg[ƒ€‚̕ω». “¡‰ª³l1, ‘åÎ’¼Ž÷, ×’J@½, –k‘º@[, ’·’J•”‰ÄŠó, “s’zL‰À, _è@», ¬ì@ˆè (1•ªŽqˆâ“`): ‘æ65‰ñ“ú–{’®ŠoˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/10/7-9), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723015. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îŽÒ‚Ì’®Šo‚Æ•é‚炵•û‚ÆŒ’N‚ÉŠÖ‚·‚éŠwp’²¸ (‘æ3•ñ): 85|89Î‚Ì’®—Í•ª•z. œ«“c‚©‚¨‚è, “¡‰ª³l1, –ìŒû@Ÿ, –x@–¾”ü, –òŽtŠÛ—ߎq, ¼ŽR’Œo, Îì@“O, —é–ؐ¬®, ×’J@½, –k‘º@[, ’·’J•”‰ÄŠó, ‰ª–{NG, ‘åÎ’¼Ž÷, _è@», ¬ì@ˆè (1•ªŽqˆâ“`): ‘æ65‰ñ“ú–{’®ŠoˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/10/7-9), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723016. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) AlportÇŒóŒQ9‰ÆŒn‚É‚¨‚¯‚éƒTƒuƒ^ƒCƒv•Ê’®Šo‚¨‚æ‚Ñ’®—ÍŒo‰ß‚ÌŒŸ“¢. ¼ø“²‰hŽq, ¼‰i’B—Y, –±‘ä‰pŽ÷, “ޗǐ´Œõ, ˆäã¹‘, ×’J@½, “¡‰ª³l1, ¬ì@ˆè (1•ªŽqˆâ“`): ‘æ65‰ñ“ú–{’®ŠoˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/10/7-9), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723017. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) _ŒoüˆÛŽîÇ2Œ^‚ɑ΂·‚éVEGFRƒƒNƒ`ƒ“‚̗Տ°ŽŽŒ± (A clinical study of VEGF receptor peptide vaccine in Neurofibromatosis type 2). ŒË“c³”Ž, “c‘º—º‘¾, “¡‰ª³l1, X–{—C‹I“Þ, ”öŒ´Œ’‘¾˜Y, ¬™Œ’ŽO, ‘åÎ—T”üŽq, ²“¡m, “¡Œ´L˜a, ˆø’n“N˜Y, –ì˜H‚µ‚Ì‚Ô, ‘åÎ’¼Ž÷, ¬ì@ˆè, ‰Íã@—T, ‘啽‹M”V, ‹g“cˆê¬ (1•ªŽqˆâ“`): ‘æ79‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ï‘‰ï (2020/10/15-17), ‰ªŽR.

723018. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –Ô—…“Iˆâ“`Žq”­Œ»‰ðÍ‚É‚æ‚éV‹KŽ©ŒÈ–Ɖu«“ï’®ƒ‚ƒfƒ‹ƒ}ƒEƒX‚Ì•ªŽq¶•¨Šw“IŒŸ“¢. ŽOŽ}’q, “¡‰ª³l1, ×’J@½, _è@», ¬ì@ˆè (1•ªŽqˆâ“`): ‘æ30‰ñ“ú–{Ž¨‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/12) , •Ÿ‰ª.

723019. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “àŽ¨Š´Šoã”ç‚ւ̖ƉuŠ°—e”j’]‚É‚æ‚éT×–EˆË‘¶«Ž©ŒÈ–Ɖu«“ï’®ƒgƒ‰ƒ“ƒXƒWƒFƒjƒbƒNƒ}ƒEƒX‚ÌŽ÷—§‚Æ‹@”\‰ðÍ. “¡‰ª³l1, …‘«–M—Y, ŽOŽ}’q, _è@», ¬ì@ˆè (1•ªŽqˆâ“`): ‘æ30‰ñ“ú–{Ž¨‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/12) , •Ÿ‰ª.

723020. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)“–‰È‚É‚¨‚¯‚é“àŽ‹‹¾‰ºŽ¨¬œŠïŒ`ŽèpÇ—á17—á‚ÌŒŸ“¢. ¯–ì—LŽÑ, ×’J@½, “¡‰ª³l1, _è@», ‘åÎ’¼Ž÷, ’·’J•”‰ÄŠó, –k‘º@[, “s’zL‰À, ¬ì@ˆè (1•ªŽqˆâ“`): ‘æ30‰ñ“ú–{Ž¨‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/13), •Ÿ‰ª.

723021. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒoŠOŽ¨“¹“I“àŽ‹‹¾‰ºŽ¨‰ÈŽèp‚É‚æ‚èf’fCŽ¡—Âðs‚Á‚½’†Ž¨Žîᎂ̈ê—á. {“cŒåŽj, –k‘º@[, ’·’J•”‰ÄŠó, “s’zL‰À, ×’J@½, ‘åÎ’¼Ž÷, _è@», ìˆä“c‚Ý‚Ù, ‹TŽRD, “¡‰ª³l1, ¬ì@ˆè (1•ªŽqˆâ“`): ‘æ30‰ñ“ú–{Ž¨‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/13), •Ÿ‰ª.

723022. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) PendredÇŒóŒQ16—á‚É‚¨‚¯‚é’®—Í‚Æ‘O’ë‹@”\‚Ì•Ï“®. œ«“c‚©‚¨‚è, ŽR–ì糋`°, “¡‰ª³l1, –òŽtŠÛ—ߎq, –x@–¾”ü, ¬ì@ˆè (1•ªŽqˆâ“`): ‘æ79‰ñ“ú–{‚ß‚Ü‚¢•½tˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/25-27), ‰¡•l.

723023. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ê”Á«Šî’ê×–EŠàÇŒóŒQ‚ÌŽîᇕa•Ï‚ɑ΂µƒCƒ~ƒLƒ‚ƒhŠO—pŽ¡—Âðs‚Á‚½ˆê—á. ŽÄ“c’m”V, Šâ‰ºé•F, “n•Ó@“µ, ‚ŠÔŠ°”V, ‘哈—Yˆê˜Y, “n•Ó‘å•ã, ‹{‰ºr”V1 (1•ªŽqˆâ“`): ‘æ36‰ñ“ú–{”畆ˆ««Žîᇊw‰ïŠwp‘å‰ï (2021/1/8-9), ‰¡•l.

733002. [Šw‰ï (Œ¤‹†‰ïE’n•û‰ï)] (ˆê”ʍu‰‰) Ž¾Š³“®•¨ƒ‚ƒfƒ‹•sÝ‚ÌiPS×–E‘n–òŒ¤‹†. “¡‰ª³l (•ªŽqˆâ“`): ‘æ15‰ñScience-ome (2020/7/22) , WebŠJÃ.

733003. [Šw‰ï (Œ¤‹†‰ïE’n•û‰ï)] (ˆê”ʍu‰‰) •·‚±‚¦‚̒ቺ‚ð–h‚®‚É‚Í? Ž¡‚·‚É‚Í? “¡‰ª³l (•ªŽqˆâ“`): 2020”N“x‘æ1‰ñ“sˆãŠwŒ¤“s–¯uÀ (2020/9/18), WebŠJÃ.

733004. [Šw‰ï (Œ¤‹†‰ïE’n•û‰ï)] (ˆê”ʍu‰‰) common marmoset‚Ì“ï’®ƒ‚ƒfƒ‹‚É‚¨‚¯‚éMRS‰ðÍ. •½—ÑŒ¹Šó, ŒIŒ´@Â, ‹gŠÛ‘å•ã, ”¨@ƒˆê, “¡‰ª³l1, ¬“‡”ŽŒÈ, ‰ª–ìJames—m® (1•ªŽqˆâ“`): ‘æ10‰ñ“ú–{ƒ}[ƒ‚ƒZƒbƒgŒ¤‹†‰ï‘å‰ï (2021/1/26-27), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-120001. [Œ´’˜] ’®Šo‰ß•q‚ðŽå‘i‚Æ‚µ‚½•¡”‚ÌŠ´Šo‰ß•q‚ð—L‚·‚éÇ—á‚ÌŒŸ“¢: "Sensory Modulation Disorder"‚Æ‚¢‚¤Ž¾Š³ŠT”O‚ÆŽ¨•@ˆôA‰Èˆã‚ª—¯ˆÓ‚·‚ׂ«“_‚ɂ‚¢‚Ä. _è@», ŒFè”Žˆê, •Ð‰ª‚¿‚È‚Â, “c•›^”ü, —é–Ø–@b, ¼è²‰hŽq, ””’JŒ’l, “¡‰ª³l1, ‘åÎ’¼Ž÷, ¬ì@ˆè (1•ªŽqˆâ“`): “ú–{Ž¨•@ˆôA‰ÈŠw‰ï‰ï•ñ 2020/3; 123 (3): 236-42.

'19-522001. [uÀ]y“ÁW: “ï’®‚ð‚È‚¨‚·-2020”N”ŁzŠ´‰¹“ï’®‚ÆiPS‘n–ò. “¡‰ª³l1, ×’J@½ (1•ªŽqˆâ“`): JOHNS 2020/1; 36 (1): 101-4.

[Šw‰ïEŒ¤‹†‰ï“™]

'19-713001. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Cochlear development of a Non-Human primate model animal, Common Marmoset. Hosoya M, Fujioka M1, Ogawa K: ARO 2020 43rd Annual MidWinter Meeting, (2020/1/25-29), San Jose, USA. (“¡‰ª³l1: 1•ªŽqˆâ“`)

'19-713002. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Selective and super-selective induction of cochlear hair cells from human iPS cells. Saeki T, Hosoya M, Fujioka M1, Ogawa K, Okano H: ARO 2020 43rd Annual MidWinter Meeting, (2020/1/25-29), San Jose, USA. (“¡‰ª³l1: 1•ªŽqˆâ“`)

'19-713003. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Investigating the effects of exonic and intronic variants of NF2 on pre-mRNA splicing. Noguchi M, Fujioka M1, Oishi N, Mutai H, Nara K, Matsunaga T, Ogawa K, Wasano K: ARO 2020 43rd Annual MidWinter Meeting, (2020/1/25-29), San Jose, USA. (“¡‰ª³l1: 1•ªŽqˆâ“`)

'19-713004. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) LATS1 deficiency cause congenital hearing loss associated with mouse cochlea abnormally. Nishiyama T, Fujioka M1, Hosoya M, Oishi N, Harada T, Ogawa K: ARO 2020 43rd Annual MidWinter Meeting, (2020/1/25-29), San Jose, USA. (“¡‰ª³l1: 1•ªŽqˆâ“`)


–ò—Šw

[Šwp˜_•¶]

110027. [Œ´’˜] EP3 signaling in dendritic cells promotes liver repair by inducing IL-13-mediated macrophage differentiation in mice. Nakamoto S1, Ito Y2, Nishizawa N3, Goto T1, Kojo K4, Kumamoto Y3, Watanabe M5, Narumiya S, Majima M2: FASEB J 2020/4; 34 (4): 5610-27. (’†–{CŽi1, ˆÉ“¡‹`–ç2, ¼àVL‹±3, Œã“¡‘ì–ç1, ŒÃé@Œ›4, ŒGŒ³—Y‰î3, “n粏¹•F5, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4‰º•”Á‰»ŠÇŠO, 5–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110028. [Œ´’˜] RAMP1 signaling in immune cells regulates inflammation-associated lymphangiogenesis. Tsuru S1, Ito Y2, Matsuda H1, Hosono K2, Inoue T3, Nakamoto S4, Kurashige C1, Mishima T5, Tsujikawa K, Okamoto H1, Majima M2: Lab Invest 2020/5; 100 (5): 738-50. (’ׯ¢—¢1, ˆÉ“¡‹`–ç2, ¼“cO”ü1, ×–ì‰Á“ÞŽq2, ˆäã’qm3, ’†–{CŽi4, åUdçŠG1, ”ü“‡—˜º5, ‰ª–{_Žk1, ”n“ˆ³—²2: 1–ƒŒ, 2–ò—, 3Á‰»Ší“à, 4‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 5S‘ŸŒŒŠÇŠO)

110029. [Œ´’˜] Lymphangiogenesis induced by vascular endothelial growth factor receptor 1 signaling contributes to the progression of endometriosis in mice. Hattori K1, Ito Y2, Honda M1, Sekiguchi K3, Hosono K2, Shibuya M, Unno N3, Majima M2: J Pharmacol Sci 2020/8; 143 (4): 255-63. (•ž•”‹¿Žq1, ˆÉ“¡‹`–ç2, –{“c‰ëŽq1, ŠÖŒû˜aŠé3, ×–ì‰Á“ÞŽq2, ŠC–ìM–ç3, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3ŽY‰È)

110030. [Œ´’˜] Prostaglandin E receptor EP4 stimulates lymphangiogenesis to promote mucosal healing during DSS-induced colitis. Hosono K1, Kojo K2, Narumiya S, Majima M1, Ito Y1: Biomed Pharmacother 2020/8; 128: 110264. (×–ì‰Á“ÞŽq1, ŒÃé@Œ›2, ”n“ˆ³—²1, ˆÉ“¡‹`–ç1: 1–ò—, 2‰º•”Á‰»ŠÇŠO)

110031. [Œ´’˜] Lymphangiogenesis and accumulation of reparative macrophages contribute to liver repair after hepatic ischemia-reperfusion injury. Nakamoto S1, Ito Y2, Nishizawa N3, Goto T1, Kojo K4, Kumamoto Y3, Watanabe M5, Majima M2: Angiogenesis 2020/8; 23 (3): 395-410. (’†–{CŽi1, ˆÉ“¡‹`–ç2, ¼àVL‹±3, Œã“¡‘ì–ç1, ŒÃé@Œ›4, ŒGŒ³—Y‰î3, “n粏¹•F5, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4‰º•”Á‰»ŠÇŠO, 5–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110032. [Œ´’˜] Inhibition of receptor activity-modifying protein 1 suppresses the development of endometriosis and the formation of blood and lymphatic vessels. Honda M1, Ito Y2, Hattori K1, Hosono K2, Sekiguchi K3, Unno N3, Majima M2: J Cell Mol Med 2020/10; 24 (20): 11984-97. (–{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq1, ×–ì‰Á“ÞŽq2, ŠÖŒû˜aŠé3, ŠC–ìM–ç3, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3ŽY‰È)

110033. [Œ´’˜] Platelets prevent the development of monocrotaline-induced liver injury in mice. Otaka F1, Ito Y2, Goto T1, Eshima K3, Amano H2, Koizumi W4, Majima M2: Toxicol Lett 2020/12; 335: 71-81. (‘卂Žj¹1, ˆÉ“¡‹`–ç2, Œã“¡‘ì–ç1, ]“‡k“ñ3, “V–ì‰pŽ÷2, ¬ò˜aŽO˜Y4, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3–Ɖu, 4Á‰»Ší“à)

[Šw‰ïEŒ¤‹†‰ï“™]

722004. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘gDC•œ‚É‚¨‚¯‚郊ƒ“ƒpŠÇV¶‚𐧌䂷‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“PGE2‚Ì‹@”\“I–ðŠ„. ˆÉ“¡‹`–ç1, ×–ì‰Á“ÞŽq1, “V–ì‰pŽ÷1, ”n“ˆ³—²1 (1–ò—): ‘æ41‰ñ“ú–{‰ŠÇEÄ¶ˆãŠw‰ï (2020/7/8-9), WebŠJÃ.

722005. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‰ŠÇŽž‚̃Šƒ“ƒpŠÇV¶‚𑝋­‚·‚é×–E“ÁˆÙ“Iƒgƒƒ“ƒ{ƒLƒTƒ“Žó—e‘̃VƒOƒiƒ‹‚Ì–ðŠ„. ×–ì‰Á“ÞŽq1, ˆÉ“¡‹`–ç1, ”n“ˆ³—²1 (1–ò—): ‘æ44‰ñ“ú–{ƒŠƒ“ƒpŠw‰ï‘‰ï (2020/9/11), ‘å‹{.

722006. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒŠƒ“ƒpŠÇV¶‚𐧌䂷‚é_Œoƒyƒvƒ`ƒhCGRP‚Ì–ðŠ„. ×–ì‰Á“ÞŽq1, ˆÉ“¡‹`–ç1, ’ׯ¢—¢2, “V–ì‰pŽ÷1, ”n“ˆ³—²1 (1–ò—, 2–ƒŒ): ‘æ44‰ñ“ú–{ƒŠƒ“ƒpŠw‰ï‘‰ï (2020/9/11-12), ‘å‹{.

723024. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒ}ƒEƒXŽq‹{“à–ŒÇ‚É‚¨‚¯‚éRAMP1‚ÌŒŒŠÇEƒŠƒ“ƒpŠÇV¶‘£iì—p. –{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq1, ×–ì‰Á“ÞŽq2, ’†–{CŽi1, ‘卂Žj¹1, ’ׯ¢—¢3, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3–ƒŒ): ‘æ41‰ñ“ú–{‰ŠÇEÄ¶ˆãŠw‰ï (2020/7/8-9), WebŠJÃ.

723025. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒgƒƒ“ƒ{ƒLƒTƒ“A2Žó—e‘̃VƒOƒiƒ‹‚Í, ƒ‚ƒmƒNƒƒ^ƒŠƒ“—U“±ŠÌáŠQ‚ð—}§‚·‚é. ‘卂Žj¹1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq1, –{“c‰ëŽq1, ‘å‹v•Û”Ž¢3, ×–ì‰Á“ÞŽq2, ¬ò˜aŽO˜Y4, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3S‘ŸŒŒŠÇŠO, 4Á‰»Ší“à): ‘æ41‰ñ“ú–{‰ŠÇEÄ¶ˆãŠw‰ï (2020/7/8-9), WebŠJÃ.

723026. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) EP4ƒVƒOƒiƒ‹‚̓Šƒ“ƒpŠÇŒ`¬‚Ì‘‹­‚É‚æ‚èDSS—U”­‘å’°‰ŠŒã‚Ì”S–Œ‘gDC•œ‚ð‰ü‘P‚·‚é. ×–ì‰Á“ÞŽq1, ˆÉ“¡‹`–ç1, ”n“ˆ³—²1 (1–ò—): ‘æ41‰ñ“ú–{‰ŠÇEÄ¶ˆãŠw‰ï (2020/7/8-9), WebŠJÃ.

723027. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒ}ƒEƒXŽq‹{“à–ŒÇ‚É‚¨‚¯‚éRAMP1‚̃Šƒ“ƒpŠÇV¶‘£iì—p. –{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq1, ×–ì‰Á“ÞŽq2, ‘卂Žj¹1, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—): ‘æ44‰ñ“ú–{ƒŠƒ“ƒpŠw‰ï‘‰ï (2020/9/11-12), ‘å‹{.

723028. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒ‚ƒmƒNƒƒ^ƒŠƒ“—U“±ŠÌáŠQŒã‚̊̏C•œ‚É‚ÍSDF-1/CXCR4‚ð‰î‚µ‚ă}ƒNƒƒtƒ@[ƒW‚ªŠÖ—^‚·‚é. ˆÉ“¡‹`–ç1, ‘卂Žj¹2, Œã“¡‘ì–ç2, ×–ì‰Á“ÞŽq1, ”¨’†@Œö1, “V–ì‰pŽ÷1 (1–ò—, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ï (2021/3/8-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723029. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) LPS—U”­• –Œ‰Šƒ}ƒEƒX‚̉¡Šu–ŒƒŠƒ“ƒpŠÇV¶, ƒŠƒ“ƒpƒhƒŒƒi[ƒW‹@”\‚É‚¨‚¯‚éƒgƒƒ“ƒ{ƒLƒTƒ“Žó—e‘̃VƒOƒiƒ‹‚Ì–ðŠ„. ×–ì‰Á“ÞŽq1, ˆÉ“¡‹`–ç1, ¼“cO”ü2, ’ׯ¢—¢2, ”¨’†@Œö1, ”n“ˆ³—²1, ¬‹{@Žü, “V–ì‰pŽ÷1 (1–ò—, 2–ƒŒ): ‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ï (2021/3/8-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723030. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Role of NKT cells in liver repair after hepatic ischemia-reperfusion injury in mice. Œã“¡‘ì–ç1, ˆÉ“¡‹`–ç2, ’†–{CŽi1, ²“¡@‰ë3, ×–ì‰Á“ÞŽq2, ”¨’†@Œö2, “V–ì‰pŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3–Ɖu): ‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ï (2021/3/8-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723031. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒuƒŒƒIƒ}ƒCƒVƒ“—U”­”xüˆÛÇƒ‚ƒfƒ‹‚É‚¨‚¯‚éVEGFR1-TKƒVƒOƒiƒ‹‚Ì–ðŠ„. “V–ì‰pŽ÷1, ¼ˆäŒ[•v2, ˆÉ“¡‹`–ç1, ]“‡k“ñ3, ”¨’†@Œö1, ×–ì‰Á“ÞŽq1, a’J³Žj, ”n“ˆ³—²1 (1–ò—, 2ŒÄ‹zŠíŠO, 3–Ɖu): ‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ï (2021/3/8-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723032. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ŒŒ¬”‚̓‚ƒmƒNƒƒ^ƒŠƒ“—U“±ŠÌáŠQ‚ðŒyŒ¸‚·‚é. ‘卂Žj¹1, ˆÉ“¡‹`–ç2, ×–ì‰Á“ÞŽq2, ”¨’†@Œö2, ¬ò˜aŽO˜Y3, “V–ì‰pŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3Á‰»Ší“à): ‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ï (2021/3/8-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723033. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‹}«ŠÌáŠQŒã‚̊̏C•œ‚ɂ̓Šƒ“ƒpŠÇV¶‚ƃ}ƒNƒƒtƒ@[ƒW‚ªŠñ—^‚·‚é. ’†–{CŽi1, ˆÉ“¡‹`–ç2, Œã“¡‘ì–ç1, ×–ì‰Á“ÞŽq2, ”¨’†@Œö2, ”n“ˆ³—²2, “V–ì‰pŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—): ‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ï (2021/3/8-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723034. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “÷‰è‘gDŒ`¬‚𑣐i‚·‚émPGES-1/PGE2Œo˜H‚Ì–ðŠ„. •º“ª“O–ç, “V–ì‰pŽ÷1, ˆÉ“¡‹`–ç1, ×–ì‰Á“ÞŽq1, ”¨’†@Œö1, ]“‡k“ñ2, A¼@’q, R—ǐÒj, •“c@Œ[3 (1–ò—, 2–Ɖu, 3Œ`¬E”üŠO): ‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ï (2021/3/8-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

733005. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ|ƒXƒ^[) ŠÌ—Þ“´•ÂÇÇŒóŒQ‚É‚¨‚¯‚錌¬”‚̖ðŠ„. ‘卂Žj¹1, ˆÉ“¡‹`–ç2, Œã“¡‘ì–ç1, ×–ì‰Á“ÞŽq2, ”¨’†@Œö2, ¬ò˜aŽO˜Y3, “V–ì‰pŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3Á‰»Ší“à): ‘æ143‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ï (2020/10/24), WebŠJÃ.

733006. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ|ƒXƒ^[) mPGES-1/PGE2axis‚É‚æ‚é“÷‰è‘gDŒ`¬ƒƒJƒjƒYƒ€‚ÌŒŸ“¢. •º“ª“O–ç, “V–ì‰pŽ÷1, ˆÉ“¡‹`–ç1, ×–ì‰Á“ÞŽq1, ”¨’†@Œö1, ]“‡k“ñ2, A¼@’q, R—ǐÒj, •“c@Œ[3 (1–ò—, 2–Ɖu, 3Œ`¬E”üŠO): ‘æ143‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ï (2020/10/24), WebŠJÃ.


”÷¶•¨Šw

[Šwp˜_•¶]

110034. [Œ´’˜] Micromonospora pelagivivens sp. nov., a new species of the genus Micromonospora isolated from deep-sea sediment in Japan. Intra B, Panbangred W, Inahashi Y, TakŽ A1, Mori M, Omura S, Matsumoto A: Int J Syst Evol Microbiol 2020/5; 70 (5): 3069-75. (•@@W1: 1”÷¶•¨)

110035. [Œ´’˜] IgE reactivity to fish allergens from Pacific cod (Gadus macrocephalus) in atopic dogs. Imanishi I1, Uchiyama J, Mizukami K, Kamiie J, Kurata K, Iyori K, Fujimura M, Shimakura K, Nishifuji K, Sakaguchi M: BMC Vet Res 2020/9; 16 (1): 341. (¡¼Žs˜N1: 1”÷¶•¨)

110036. [Œ´’˜] Analysis of a plasmid encoding botulinum neurotoxin type G gene in Clostridium argentinense. Sakaguchi Y1, Uchiyama J, TakŽ A1, Gotoh K, Sakaguchi M, Suzuki T, Yamamoto Y, Hosomi K, Kohda T, Mukamoto M, Kozaki S, Hayashi S1, Oguma K: Anaerobe 2020/12; 66: 102281. (ãŒû‹`•F1, •@@W1, —с@rŽ¡1: 1”÷¶•¨)

110037. [Œ´’˜] Detection of Penicillin G Produced by Penicillium chrysogenum with Raman Microspectroscopy and Multivariate Curve Resolution-Alternating Least-Squares Methods. Horii S, Ando M, Samuel AZ, TakŽ A1, Nakashima T, Matsumoto A, Takahashi Y, Takeyama H: J Nat Prod 2020/11; 83 (11): 3223-9. (•@@W1: 1”÷¶•¨)

521001. [‰ðà]yHelicobacterV‹ÛŽí”­Œ©!z2020”N‚ɏ³”F‚³‚ꂽHelicobacter‘®‚̐V‹ÛŽí‚̏Љî|•ñ˜_•¶‚æ‚è|. —с@rŽ¡ (”÷¶•¨): Helicobacter Research 2020/11; 24 (2): 226-8.

521002. [‰ðà] }‰ð|”^”çÇ —Տ°ˆã‚É’m‚Á‚Ä‚Ù‚µ‚¢•\Ý«”^”çÇ. ¡¼Žs˜N (”÷¶•¨): bˆã—Տ°”畆‰È2021/3; 27 (1): 33-40.

522004. [uÀ]y‹Ù‹}“ÁW: VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ (COVID-19)`–h‹Û–hꀂ̊ϓ_‚©‚ç`z6. VŒ^ƒRƒƒiƒEƒCƒ‹ƒXƒpƒ“ƒfƒ~ƒbƒNŠú‚É‚¨‚¯‚銴õŠÇ—‚ÆŠÅŒì. ˆÉ“¡“¹Žq1, —с@rŽ¡2 (1ŠÅŒìŠw•”, 2”÷¶•¨): “ú–{–h‹Û–hꀊw‰ïŽ 2020/9; 48 (9): 481-6.

530001. [‚»‚Ì‘¼ (Erratum)] Corrigendum: Micromonospora pelagivivens sp. nov., a new species of the genus Micromonospora isolated from deep-sea sediment in Japan. Intra B, Panbangred W, Inahashi Y, TakŽ A1, Mori M, Omura S, Matsumoto A: Int J Syst Evol Microbiol 2020/8; 70 (8): 4843. (•@@W1: 1”÷¶•¨)

540001. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]y2019”N“x–k—¢‘åŠwˆãŠw•”‚¯‚â‚«‰ïŒ¤‹†•¬uƒNƒƒXƒgƒŠƒfƒBƒIƒCƒfƒXEƒfƒBƒtƒBƒVƒ‹Š´õÇ‚ÌŽ¡—ÂɗL—p‚È•úü‹Û‚Ì•ª—£‚Æ‚»‚ÌŽ¡—Âւ̉ž—p (Œ¤‹†ŠúŠÔ: 2019”N“x)vzŒ¤‹†‘ã•\ŽÒ: •@@W1, ‹¤“¯Œ¤‹†ŽÒ: ãŒû‹`•F1, —с@rŽ¡1, “àŽR~•½, Œã“¡˜a‹`, –…”ö[•q, ‰Á“¡‚Í‚é, ˆî‹´—C‹N2, ¼–{ŒúŽq2 (1”÷¶•¨, 2–k—¢¶–½‰ÈŠwŒ¤‹†Š):uƒNƒƒXƒgƒŠƒfƒBƒIƒCƒfƒXEƒfƒBƒtƒBƒVƒ‹Š´õÇ‚ÌŽ¡—ÂɗL—p‚È•úü‹Û‚Ì•ª—£‚Æ‚»‚ÌŽ¡—Âւ̉ž—pv2019”N“x•ñ‘ 2020/4.

540002. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]y‰ÈŠwŒ¤‹†”ï•â•‹àEŠî”ÕŒ¤‹† (C)uƒfƒBƒtƒBƒVƒ‹‹ÛƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚̏hŽå”FŽ¯‹@\‚̉𖾋y‚ÑŽ¡—ÂƗ\–h‚ւ̉ž—p (Œ¤‹†ŠúŠÔ: 2019”N“x`2021”N“x)vzŒ¤‹†‘ã•\ŽÒ: ãŒû‹`•F1, Œ¤‹†•ª’SŽÒ: ‰Á“¡‚Í‚é, ‘å‹{’¼–Ø, “àŽR~•½, Œã“¡˜a‹`, –…”ö[•q, —с@rŽ¡1 (1”÷¶•¨:uƒfƒBƒtƒBƒVƒ‹‹ÛƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚̏hŽå”FŽ¯‹@\‚̉𖾋y‚ÑŽ¡—ÂƗ\–h‚ւ̉ž—pv2019”N“xŽÀŽ{ó‹µ•ñ‘ 2020/5; https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-19K07560/19K075602019hokoku/.

540003. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]y‰ÈŠwŒ¤‹†”ï•â•‹àEŠî”ÕŒ¤‹† (C)uƒtƒ@[ƒW“àÝ‰»‚É‚æ‚éƒsƒƒŠ‹Û‚ÌŽ‘±Š´õ‹@\‚ÌŒŸØ (Œ¤‹†ŠúŠÔ: 2018”N“x`2020”N“x)vzŒ¤‹†‘ã•\ŽÒ: “àŽR~•½, Œ¤‹†•ª’SŽÒ: ¼è–ΓW, —с@rŽ¡1, ãŒû‹`•F1, ŽOŽºm”ü (1”÷¶•¨):uƒtƒ@[ƒW“àÝ‰»‚É‚æ‚éƒsƒƒŠ‹Û‚ÌŽ‘±Š´õ‹@\‚ÌŒŸØv2019”N“xŽÀŽ{ó‹µ•ñ‘ 2020/5; https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-18K07127/18K071272019hokoku/.

540004. [‚»‚Ì‘¼ (L•ñŽ)] ˆãŠw•”‚¯‚â‚«‰ïŒ¤‹†•¬‚ðŽó‚¯‚Ä. ¡¼Žs˜N (”÷¶•¨): –k—¢‘åŠwˆãŠw•”ƒjƒ…[ƒY 2020/10; 406: 3.

540005. [‚»‚Ì‘¼ (L•ñŽ)] ‚­‚·‚Ì‚«. ãŒû‹`•F (”÷¶•¨): –k—¢‘åŠwˆãŠw•”ƒjƒ…[ƒY 2020/11; 407: 17.

540006. [‚»‚Ì‘¼ (L•ñŽ)] 2020”N“x•¶•”‰ÈŠwÈ‰ÈŠwŒ¤‹†”¬‚ðŽó‚¯‚Ä. •@@W (”÷¶•¨): –k—¢‘åŠwˆãŠw•”ƒjƒ…[ƒY 2020/11; 407: 9.

540007. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]y‚₸‚âH‚ÆŒ’NŒ¤‹†ŠE2019”N“xŒ¤‹†•¬Œ¤‹†uH•¨‚ª‚à‚½‚ç‚·Œ’N‚Æ‚ÌŠÖ˜A|—L—p«•úü‹Û‚Ì’°“à‚É‚¨‚¯‚é–ðŠ„|(Œ¤‹†ŠúŠÔ: 2019”N“x)vzŒ¤‹†‘ã•\ŽÒ: •@@W1, Žw“±ŽÒ: ãŒû‹`•F1, ‹¤“¯Œ¤‹†ŽÒ: ‰Á“¡‚Í‚é, —с@rŽ¡1 (1”÷¶•¨):uH•¨‚ª‚à‚½‚ç‚·Œ’N‚Æ‚ÌŠÖ˜A|—L—p«•úü‹Û‚Ì’°“à‚É‚¨‚¯‚é–ðŠ„|v2019”N“x’†ŠÔ•ñ‘ 2021/1.

[’˜@‘]

620003. [Šwp‘ (•ª’SŽ·•M)]yƒsƒƒŠ‹Ûœ‹ÛŽ¡—Ãp[ƒtƒFƒNƒgƒKƒCƒh ‘æ3”Łz‘æ5Í ƒsƒƒŠœ‹ÛŽ¡—Âƈ݊à@1ƒsƒƒŠ‹Û‚ÌŠî‘b’mŽ¯@’m‚Á‚Ä‚¨‚«‚½‚¢ƒsƒƒŠ‹Û‚̍׋ۊw“I“Á’¥, p.193-5. å@MœA, ¼‹vˆÐŽj, ÂŽRL˜Y, ”É“c‚³‚Æ‚Ý, ‚–Ø“ÖŽi, ‰«–{’‰‹`, ‘ºã˜a¬, ’†“‡Ž ”ü, ‚‹´Mˆê, ŠÔ•”Ž—T, ²“¡‹Mˆê, Šâ–{~ˆê, aã—TŽm, ’†‘º¹‘¾˜Y, —é–؏G˜a, ¼àVrG, rìœAŽu, ¬ˆäŒËŒO—Y, ‘呐•qŽj, •x“cŽõ•F, ŽO—Ö—ml, ‰–’JºŽq, ˆä–{ˆê˜Y, ŒÃ“c—²‹v, ŽRo”ü•äŽq, ‹¾@‘ì”n, —é–ؐ’O, ”óŒû—F—m, “¿‰iŒ’Œá, ‰Á“¡°ˆê, ‰œ“c^Žì”ü, ²‰Y—´‘¾˜Y, “¡–ì“N˜N, âV“¡@•É, •Ÿ“c”\Œ[, ŒIŒ´’¼l, ˆÉ“¡œÄ–F, ‰ºŽR@Ž, tŠÔ@Œ«, ––œA–ž•F, ‰Í–{”Ž•¶, ŽR–{’B’j, ‘¾“c_—Ç, Ô¼‘׎Ÿ, ŽR‰ª‹g¶, ™ŽR•q˜Y, ™Z‹Ê‰ë–¾, “¡‰ª—˜¶, …–쌳•v, •@@i, —с@rŽ¡1, ã‘º’¼ŽÀ, ‹e’n³Œå, ‰Á“¡Œ³Žk, ó³”Ž, ¬—ѐ³–¾, ˆäã˜a•F, ˆÉ“¡ŒöŒP (1”÷¶•¨), •Ò’˜: å@MœA, “ú–{ˆãŽ–V•ñŽÐ, “Œ‹ž, 2020/10”­s.

620004. [Šwp‘ (ŠÄCE•ÒW)]yƒRƒ“ƒpƒNƒg”÷¶•¨Šw ‰ü’ù‘æ5”Łz‘æ2Í×‹Û, ‘æ4Í^‹Û, ‘æ7Í–ŋۂƏÁ“Å. ¬ŒFœ¨“ñ, –x“c@”Ž, —с@rŽ¡1, ÎŒË@‘, ùŒ´“S•½, ãŒû‹`•F1, ”—@Nm, ‰¡“cŒ›Ž¡, ŒÃŽR—T‹K, “¡“c’¼‹v, ŽR“c‰ë•v, “¡—FŒ‹ŽÀŽq, Œ`ŽR—DŽq, ’†¼‰ëŽ÷, Ÿ“ñˆè•v, ¼‰º@Ž¡ (1”÷¶•¨), ŠÄC: ¬ŒFœ¨“ñ, –x“c@”Ž, •Ò: —с@rŽ¡1, ÎŒË@‘ “ì]“°, “Œ‹ž, 2021/3”­s.

620005. [Šwp‘ (•ª’SŽ·•M)]yƒRƒ“ƒpƒNƒg”÷¶•¨Šw ‰ü’ù‘æ5”Łz‘æ2Í×‹Û@G. –³‰è–E•Î«Œ™‹C«‹Û, p.53-4, H. —L‰è–E•Î«Œ™‹C«‹Û, p.55-7. ¬ŒFœ¨“ñ, —с@rŽ¡1, ùŒ´“S•½, ãŒû‹`•F1, ÎŒË@‘, ”—@Nm, ‰¡“cŒ›Ž¡, ‹gŽR—T‹K, “¡“c’¼‹v, ŽR“c‰ë•v, “¡—FŒ‹ŽÀŽq, Œ`ŽR—DŽq, ’†¼‰ëŽ÷, Ÿ“ñˆè’j, ¼‰º@Ž¡ (1”÷¶•¨), ŠÄC: ¬ŒFœ¨“ñ, –x“c@”Ž, •Ò: —с@rŽ¡1, ÎŒË@‘ “ì]“°, “Œ‹ž, 2021/3”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713004. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Analysis of botulinum neurotoxin type B6 gene-encoding plasmid in Clostridium botulinum type B. Sakaguchi Y1, Hosomi K, Kohda T, Umeda K, Uchiyama J, Take A1, Goto K, Senoh M, Hayashi S1, Kozaki S, Mukamoto M: ASM microbe 2020 (2020/6/18), Chicago, USA. (ãŒû‹`•F1, •@@W1, —с@rŽ¡1: 1”÷¶•¨)

721001. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) Clostridioides difficileŠ´õÇ‚ɑ΂·‚镳•Ö”÷¶•¨ˆÚA‚̉e‹¿`ƒqƒg’°“à”÷¶•¨‘p‹y‚уƒ^ƒ{ƒ[ƒ€‚̉ðÍ`. ãŒû‹`•F1, Œã“¡˜a‹`, •@@W1, ”öø“”¹l, é‘ãN‹M, ˜a‹v“cŒõ‹B, —с@rŽ¡1, ‘å‹{’¼–Ø, ‰Á“¡‚Í‚é (1”÷¶•¨): ‘æ94‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2021/3/23), WebŠJÃ.

722007. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “ú–{ƒwƒŠƒRƒoƒNƒ^[Šw‰ïHelicobacter pylori–òÜ‘ϐ«Šî€ƒpƒlƒ‹‚̍쐻. ‰¡“cŒ›Ž¡, —с@rŽ¡1, ’|“àŒ[W, ‰¡“cLˆê, ‘åø“ŒhŽq (1”÷¶•¨): ‘æ26‰ñ“ú–{ƒwƒŠƒRƒoƒNƒ^[Šw‰ïŠwpW‰ï (2021/1/8), •l¼.

722008. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ’°“à”÷¶•¨‘p‚̍¡. ãŒû‹`•F1, Œ´@‰pŽ÷ (1”÷¶•¨): ‘æ94‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2021/3/23), WebŠJÃ.

722009. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒuƒhƒE‹…‹Û‚ÌŠO•ª”å“Å‘f‚ƃjƒbƒ`‚̍\’z. ¡¼Žs˜N1, Šâ£’‰s, ¼“¡ŒöŽi (1”÷¶•¨): ‘æ94‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2021/3/23), WebŠJÃ.

723035. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒCƒk‚̏ƒŒŒŽíƒRƒƒj[‚ð—˜—p‚µ‚½ƒAƒgƒs[«”畆‰Š‚ÉŠÖ˜A‚µ‚½ŒûoE’°“à×‹Û‘p‚Ì•Ï“®‚̉ðÍ. ŠC–ì’©, ¡¼Žs˜N1, …ãŒ\“ñ˜Y, ‘å‹÷‘¸Žj, ŒÜ\—’Š°‚, ‘ºã—TM, “‡@ˆ», ÎŒ´ŒºŠî, ‰Fª—L”ü, ãŒû‰ëO, “àŽR~•½ (1”÷¶•¨): ‘æ163‰ñ“ú–{bˆãŠw‰ïŠwpW‰ï (2020/9/14-30), WebŠJÃ.

723036. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Staphylococcus pseudintermedius‚̃CƒkƒAƒgƒs[«”畆‰Š‘ˆ«ˆöŽq‚Ì’Tõ. ’߈ä‘劲, “‡‘qGŸ, “àŽR~•½, ¡¼Žs˜N1, â–{CŽm, ”óŒû‘ô–, ˆÉœnŒc‘¾, ‰º’rŒ’‘¾, “¡‘º³l, ãŒû‰ëO (1”÷¶•¨): ‘æ163‰ñ“ú–{bˆãŠw‰ïŠwpW‰ï (2020/9/14-30), WebŠJÃ.

723037. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H•¨‚©‚番—£‚µ‚½•úü‹Û‚Ì’°“àŠÂ‹«¶‘¶”\‚Ì•]‰¿. •@@W1, ãŒû‹`•F1, ˆî‹´—C‹N, Œã“¡˜a‹`, —с@rŽ¡1, ‘å‹{’¼–Ø, ‰Á“¡‚Í‚é (1”÷¶•¨): ‘æ94‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2021/3/23), WebŠJÃ.

723038. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒtƒ@[ƒW—R—ˆ—n‹Ûy‘fS25-3LYS‚̃Cƒk•\Ý«”^”çÇ‚ɑ΂·‚é—Տ°‰ž—p«‚ÌŒŸ“¢. ¡¼Žs˜N1, ¼“¡ŒöŽi, ’©”ä“Þ—Ç‘¾, —с@rŽ¡1, ’Ëvˆä—˜L, “àŽR~•½ (1”÷¶•¨): ‘æ94‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2021/3/23), WebŠJÃ.

723039. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –òÜ‘ϐ«Helicobacter pylori‹ÛŠ”‚̊ƒpƒlƒ‹. —с@rŽ¡1, ‘åø“ŒhŽq, ’|“àŒ[W, ‰¡“cŒ›Ž¡, ‰¡“cLˆê, —ÑŒ´ŠG”üŽq (1”÷¶•¨): ‘æ94‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2021/3/25), WebŠJÃ.

723040. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •³•Ö”÷¶•¨ˆÚA‚É‚æ‚èClostridioides difficileŠ´õÇ‚̍Ĕ­—\–hŒø‰Ê‚ðŽ¦‚µ‚½Ç—á‚É‚¨‚¯‚é’°“à”÷¶•¨‘p‹y‚Ñ‚»‚Ì‘ãŽÓŽY•¨‚̉ðÍ. ãŒû‹`•F1, Œã“¡˜a‹`, •@@W1, ”öø“”¹l, é‘ãN‹M, ˜a‹v“cŒõ‹B, —с@rŽ¡1, ‰Á“¡‚Í‚é, ‘å‹{’¼–Ø (1”÷¶•¨): “ú–{–òŠw‰ï‘æ141”N‰ï (2021/3/26), WebŠJÃ.

733007. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) •¡”‚̏bˆãŒn‹@ŠÖ‚É‚¨‚¯‚éƒCƒk‚Ì”^”çÇ‚âƒAƒŒƒ‹ƒM[«”畆‰Š‚ɑ΂·‚éR‹Û–ò”ñˆË‘¶“I‚ÈŽæ‚è‘g‚Ý. “àŽR~•½, ¡¼Žs˜N1, ¼“¡ŒöŽi, •ŸŽR•ü‹G, ˆÉœnŒc‘¾, ’Ëvˆä—˜L, ãŒû‰ëO (1”÷¶•¨): ‘æ65‰ñ“ú–{ƒuƒhƒE‹…‹ÛŒ¤‹†‰ï (2020/10/16), WebŠJÃ.

733008. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‹ÛŽí“¯’è‚É“ïa‚µ‚½Š´õ«S“à–Œ‰Š‚Ì1—á. ‰ª‘º@x, –¾é³”Ž, ™‰º–õ”V, “c•”ˆäŽjŽq, ²“¡—D‰À—, ¡¼Žs˜N1, “àŽR~•½, ˆÉœnŒc‘¾, ‘\˜a—T”V (1”÷¶•¨): “ú–{“à‰ÈŠw‰ï‘æ666‰ñŠÖ“Œ’n•û‰ï (2021/2/7), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-530001. [‚»‚Ì‘¼ (Letter)] Abnormal whiskers in a Persian cat resembling shaft disorder of Abyssinian cats. Miyata C, Imanishi I1, Shimazaki Y, Ida R, Nishifuji K: Jpn J Vet Dermatol (bˆã—Տ°”畆‰È) 2020/3; 26 (3): 145-6. (¡¼Žs˜N1: 1”÷¶•¨)


Šñ¶’ŽŠwE”M‘шãŠw

[Šwp˜_•¶]

110038. [Œ´’˜] Natural nodular worm infection in goats induces eosinophil extracellular DNA trap (EET) formation. Anisuzzaman , Anas A, Yasin MG, Labony SS, Hossain MM, Begum N, Hatta T1, Tsuji N1, Alim MA: Parasitol Int 2020/12; 79: 102178. ”ª“cŠxŽm1, ’ҁ@®—˜1 (1Šñ¶’ŽE”M‘шãŠw)

110039. [Œ´’˜] Prevalence of Trichinella T9 in Japanese black bears (Ursus thibetanus japonicus) in Iwate prefecture, Japan. Tominaga T, Aoki M, Biswas PG, Hatta T1, Itagaki T: Parasitol Int 2021/2; 80: 102217. ”ª“cŠxŽm1 (1Šñ¶’ŽE”M‘шãŠw)

520001. [‘à] ƒ}ƒ_ƒj‚̐lH‹zŒŒ`‰ß‹ŽEŒ»ÝE–¢—ˆ`. ”ª“cŠxŽm (Šñ¶’ŽE”M‘шãŠw): ‰q¶“®•¨ 2020/3; 71 (1): 15-23.

[’˜@‘]

620006. [Šwp‘ (•ª’SŽ·•M)]y‰Æ’{“`õ•aƒnƒ“ƒhƒuƒbƒNz2. “͏o“`õ•a@2-61ƒƒCƒRƒ`ƒgƒ][ƒ“Ç, p.262-3. ”ª“cŠxŽm1, ‘¼47–¼ (1Šñ¶’ŽE”M‘шãŠw), •Ò: ‘ºãŒ«“ñ, •F–ìOˆê, ’©‘q‘“X, “Œ‹ž, 2020/11”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

723041. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒtƒ^ƒgƒQƒ`ƒ}ƒ_ƒjL’·ˆöŽq1ƒ¿ (EF1ƒ¿) ˆâ“`Žq‚̏㗬—̈æ‰ðÍ. ƒGƒ}ƒjƒ…ƒGƒ‹ƒwƒ‹ƒiƒ“ƒfƒX, ƒRƒtƒBƒRƒtƒB, ’ؐì‘åŒå1, ŽOã–[Žq, ¼—с@½, ’ҁ@®—˜1, “c’‡“N–ç, ”ª“cŠxŽm1 (1Šñ¶’ŽE”M‘шãŠw): ‘æ72‰ñ“ú–{‰q¶“®•¨Šw‰ï‘å‰ï (2020/4/17-19), ‘å‰ï‚ª’†Ž~‚ׂ݂̈ȂµŠJÃ.

723042. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒtƒ^ƒgƒQƒ`ƒ}ƒ_ƒj‚Ìã󔭐¶‚É‚¨‚¯‚éŒÃ“T“Iƒgƒ‰ƒ“ƒXƒNƒŠƒvƒg[ƒ€‰ðÍ. ƒRƒtƒBƒRƒtƒB, ƒGƒ}ƒjƒ…ƒGƒ‹ƒwƒ‹ƒiƒ“ƒfƒX, ƒTƒ~ƒ…ƒGƒ‹ƒ_ƒW, ƒ_ƒjƒGƒ‹ƒ‰ƒ[ƒNƒ|, ’ؐì‘åŒå1, ŽOã–[Žq, ¼—с@½, Šâ‰iŽj˜N, ’ҁ@®—˜1, ”ª“cŠxŽm1 (1Šñ¶’ŽE”M‘шãŠw): ‘æ72‰ñ“ú–{‰q¶“®•¨Šw‰ï‘å‰ï (2020/4/17-19), ‘å‰ï‚ª’†Ž~‚ׂ݂̈ȂµŠJÃ.


•a—Šw (‘º‰_’PˆÊ)

[Šwp˜_•¶]

110040. [Œ´’˜] STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy. Arwert EN, Milford EL, Rullan A, Derzsi S, Hooper S, Kato T1, Mansfield D, Melcher A, Harrington KJ, Sahai E: Nat Cell Biol 2020/7; 22 (7): 758-66. (‰Á“¡‘ôÆ1: 1•a—)

110041. [Œ´’˜] Expression of CA2 and CA9 carbonic anhydrases in ulcerative colitis and ulcerative colitis-associated colorectal cancer Nakada N1, Mikami T, Horie K, Nagashio R2, Sakurai Y1, Sanoyama I1, Yoshida T1, Sada M3, Kobayashi K3,4, Sato Y2, Okayasu I, Murakumo Y1: Pathol Int 2020/8; 70 (8): 523-32. (’‡“c“TL1, ’·‰–@—º2, ŸNˆä–õ‚1, áÁŽR@“ž1, ‹g“c@Œ÷1, ²“c”ü˜a3, ¬—ѐ´“T3,4, ²“¡—Yˆê2, ‘º‰_–FŽ÷1: 1•a—, 2ˆã—Éq¶Šw•”, 3Á‰»Ší“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110042. [Œ´’˜] SSEA-3 and 4 are not essential for the induction or properties of mouse iPS cells. Hamamura K, Hotta H, Murakumo Y1, Shibuya H, Kondo Y, Furukawa K: J Oral Sci 2020/9; 62 (4): 393-6. (‘º‰_–FŽ÷1: 1•a—)

110043. [Œ´’˜] Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors. Sakurai Y1, Ichinoe M1, Yoshida K, Nakazato Y, Saito S, Satoh M2, Nakada N1, Sanoyama I1, Umezawa A3, Numata Y3, Shi-Xu J1, Ichihara M, Takahashi M, Murakumo Y1: Cancer Lett 2020/10; 489: 100-10. (ŸNˆä–õ‚1, ˆêŒË¹–¾1, ²“¡@‰ë2, ’‡“c“TL1, áÁŽR@“ž1, ”~‘ò“ÖŽq3, À“c‰êŽq3, Ó@àV“1, ‘º‰_–FŽ÷1: 1•a—, 2–Ɖu, 3Œ`‘ÔŒn)

110044. [Œ´’˜] CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF-ƒÀ signaling. Taki T, Shiraki Y, Enomoto A, Weng L, Chen C, Asai N, Murakumo Y1, Yokoi K, Takahashi M, Mii S: Cancer Sci 2020/12; 111 (12): 4616-28. (‘º‰_–FŽ÷1: 1•a—)

[Šw‰ïEŒ¤‹†‰ï“™]

723043. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) HŠw“I‰ðÍ‹Zp‚É‚æ‚鈫«’†”çŽî‚Ì‹qŠÏ“If’fŽw•W\’z. –Ø‘º•¶ˆê, ’ÓcŠó, ‘哇Œ’Œá, ŽRŒû‰ë_, ‘º‰_–FŽ÷1, ²“¡”Vr2 (1•a—, 2ŒÄ‹zŠíŠO): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20), WebŠJÃ.

723044. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆ««•FŽî‚É‚¨‚¯‚éREV7‚Ì‹@”\‰ðÍ. ¯–쏺–F1, ˆêŒË¹–¾1, ŸNˆä–õ‚1, ‘º‰_–FŽ÷1 (1•a—) ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723045. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ßˆÊˆË‘¶«ƒrƒIƒ`ƒ“•WŽ¯–@‚É‚æ‚éV‹KREV7Œ‹‡ƒ^ƒ“ƒpƒNŽ¿‚Ì“¯’è. ’Å–¼—E‹M1, ŸNˆä–õ‚2, ‰Á“¡‘ôÆ2, ˆêŒË¹–¾2, ‘º‰_–FŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2•a—): ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723046. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ×–EŠÔÚ’…‚ƍזEŠOƒ}ƒgƒŠƒNƒX•ª‰ð‚Ì‘ŠŒÝì—p‚́CG•½ã”çŠà‚̐Zƒpƒ^[ƒ“‚Ɛ¬’·‚ð‹¦’²“I‚ÉŒˆ’è‚·‚é. ‰Á“¡‘ôÆ1, ‘º‰_–FŽ÷1 (1•a—) ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723047. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽèpŒŸ‘Ì‚ð—p‚¢‚½äXŠà‚É‚¨‚¯‚éBRCAness‚̉ðÍ. äøŒ´«—Ç1, ‰Á“¡‘ôÆ2, ˆÀ’B@‰õ1, ŸNˆä–õ‚2, ˆêŒË¹–¾2, ‘º‰_–FŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2•a—): ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723048. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äX‘ŸŠà‚Ì—\Œã‚É‚¨‚¯‚éCD109”­Œ»‚̈Ӌ`‚̉ðÍ. ˆÀ’B@‰õ1, ŸNˆä–õ‚2, ‰Á“¡‘ôÆ2, ˆêŒË¹–¾2, ‘º‰_–FŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2•a—): ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723049. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬×–E”xŠà‚É‚¨‚¯‚éREV7”­Œ»‚̐¶•¨Šw“IˆÓ‹`. áÁŽR@“ž1, ˆêŒË¹–¾1, ŸNˆä–õ‚1, ‘º‰_–FŽ÷1 (1•a—) ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

'19”N“xˆÈ‘O•ª

[Šw‰ïEŒ¤‹†‰ï“™]

'19-723003. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¶B×–EˆÛŽ‚¨‚æ‚ѐ¸ŽqŒ`¬‚É‚¨‚¯‚éDNA‘¹‰ž“š’`”’REV7‚̏d—v«. ˆéŠL“ށXŽq, ŸNˆä–õ‚1, ‰Á“¡‘ôÆ1, ˆêŒË¹–¾1, À“c‰êŽq2, ”~‘ò“ÖŽq2, ‘º‰_–FŽ÷1 (1•a—, 2Œ`‘ÔŒn): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/9), “Œ‹ž.


•a—Šw (ŽOŽ}’PˆÊ)

[Šwp˜_•¶]

110045. [Œ´’˜] S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma. Tochimoto M1, Oguri Y2, Hashimura M2, Konno R, Matsumoto T1, Yokoi A3, Kodera Y, Saegusa M1: Lab Invest 2020/5; 100 (5): 682-95. (“È–{¹F1, ¬ŒINŽq2, ‹´‘º”ü‹I2, ¼–{r‰p1, ‰¡ˆäˆ¤3, ŽOŽ}@M1: 1•a—, 2Œ`‘ÔŒn, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110046. [Œ´’˜] Upregulation of fibronectin following loss of p53 function is a poor prognostic factor in ovarian carcinoma with a unique immunophenotype. Yokoi A1, Matsumoto T2, Oguri Y3, Hasegawa Y, Tochimoto M1, Nakagawa M, Saegusa M2: Cell Commun Signal 2020/7; 18 (1): 103. (‰¡ˆäˆ¤1, ¼–{r‰p2, ¬ŒINŽq3, “È–{¹F1, ŽOŽ}@M2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2•a—, 3Œ`‘ÔŒn)

110047. [Œ´’˜] S100A4/Nonmuscle Myosin IIA/p53 Axis Contributes to Aggressive Features in Ovarian High-Grade Serous Carcinoma. Hiruta A1, Oguri Y2, Yokoi A1, Matsumoto T3, Oda Y1, Tomohiro M, Hashimura M2, Jiang Z, Tochimoto M3, Nakagawa M1, Saegusa M3: Am J Pathol 2020/11; 190 (11): 2304-16. (•g“c@ˆ¤1, ¬ŒINŽq2, ‰¡ˆäˆ¤1, ¼–{r‰p3, ¬“c—S‰î1, ‹´‘º”ü‹I2, “È–{¹F3, ’†ì䝗S1, ŽOŽ}@M3: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Œ`‘ÔŒn, 3•a—)

110048. [Œ´’˜] Requirements of LEFTY and Nodal overexpression for tumor cell survival under hypoxia in glioblastoma. Matsumoto T1, Chino H, Akiya M1, Hashimura M2, Yokoi A3, Tochimoto M1, Nakagawa M3, Jiang Z, Saegusa M1: Mol Carcinog 2020/12; 59 (12): 1409-19. (¼–{r‰p1, H’J¹Žj1, ‹´‘º”ü‹I2, ‰¡ˆäˆ¤3, “È–{¹F1, ’†ì䝗S3, ŽOŽ}@M1: 1•a—, 2Œ`‘ÔŒn, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

[Šw‰ïEŒ¤‹†‰ï“™]

722010. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) •a—ŒŸ‘Ì‚ð—p‚¢‚½—‘‘ƒ–¾×–EŠà‚̐V‹KƒoƒCƒIƒ}[ƒJ[’Tõ: Lefty‚Ì“¯’è‚Æ‚»‚̗Տ°“IˆÓ‹`‚ÌŒŸ“¢. H’J¹Žj1, ì“‡—S‰î, ¬Ž›‹`’j, ‰¡ˆäˆ¤2, ¬ŒINŽq3, ‹´‘º”ü‹I3, ŽOŽ}@M1 (1•a—, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3Œ`‘ÔŒn): ‘æ71‰ñ“ú–{“d‹C‰j“®Šw‰ï‘‰ï (2020/11/13), WebŠJÃ.

723050. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —‘‘ƒ–¾×–EŠà‚Ìp53/Fibronectin axis‚͐V‹K—\ŒãˆöŽq‚Å‚ ‚é. ‰¡ˆäˆ¤1, ¬ŒINŽq2, ¼–{r‰p3, ŽOŽ}@M3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Œ`‘ÔŒn, 3•a—): ‘æ109‰ñ“ú–{•a—Šw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723051. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) isŠú‘å’°Šà‚̃À-ƒJƒeƒjƒ“CPD1/PDL1‚É‚æ‚éŠàŠ²×–Eƒjƒbƒ`Œ`¬‚ÆNCRTŽ¡—ÃŒø‰Ê. “n糓s”T1, ‚‹´”Ž”V2, ‹´‘º”ü‹I3, Œ¢Ž”@‰~4, M‘¾ºŽq5, ŽOŽ}@M5 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3Œ`‘ÔŒn, 4”]ŠO, 5•a—): ‘æ109‰ñ“ú–{•a—Šw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723052. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —‘‘ƒŠà‚É‚¨‚¯‚éALK—z«Šà‚Ì“¯’è‚Æ‚»‚̐¶•¨Šw“I“Á«‚̉ð–¾. ¬“c—S‰î1, ¼–{r‰p2, ŽOŽ}@M2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2•a—): ‘æ109‰ñ“ú–{•a—Šw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723053. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) S100A4‚É‚æ‚éisŠú’¼’°Šà‚̏p‘O‰»Šw•úŽËü—Ö@’ïR”\Šl“¾‹@\‚̉ð–¾. M‘¾ºŽq1, ‚‹´”Ž”V2, ‹´‘º”ü‹I3, ¬ŒINŽq3, ¼–{r‰p1, ŽOŽ}@M1 (1•a—, 2ˆã—Éq¶Šw•”, 3Œ`‘ÔŒn): ‘æ109‰ñ“ú–{•a—Šw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723054. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –UŒŸt‚Ì•W–{ì»‚ɂ‚¢‚Ä‚ÌŒŸ“¢. H’J¹Žj1, “È–{¹l1, ŽOŽ}@M1 (1•a—) ‘æ109‰ñ“ú–{•a—Šw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723055. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Žq‹{Šà“÷Žî‚ÌS100A4/”ñ‹Ø×–Eƒ~ƒIƒVƒ“IIŒn‚É‚æ‚é“÷Žî¬•ª—U“±‹@\‚̉ð–¾. “È–{¹F1, ¬ŒINŽq2, ®–ì@—º, ¼–{r‰p1, ¬Ž›‹`’j, ŽOŽ}@M1 (1•a—, 2Œ`‘ÔŒn): ‘æ109‰ñ“ú–{•a—Šw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723056. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EBP50‚Í—‘‘ƒ–¾×–EŠà‚̍Ĕ­E—\Œã•s—LjöŽq‚Å‚ ‚é. ¼–{r‰p1, ‰¡ˆäˆ¤2, ®–ì@—º, ¬Ž›‹`’j, ŽOŽ}@M1 (1•a—, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ109‰ñ“ú–{•a—Šw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723057. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —‘‘ƒŸ÷‰tŠà‚̐i“W‰ß’ö‚É‚¨‚¯‚éS100A4/Myosin9Œn‚̉ʂ½‚·–ðŠ„. •g“c@ˆ¤1, ¬ŒINŽq2, ‰¡ˆäˆ¤1, ŽOŽ}@M3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Œ`‘ÔŒn, 3•a—): ‘æ109‰ñ“ú–{•a—Šw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.


‰q¶Šw

[Šwp˜_•¶]

110049. [Œ´’˜] Predictors of post-cancer diagnosis resignation among Japanese cancer survivors. Endo M, Muto G1, Imai Y, Mitsui K, Nishimura K, Hayashi K: J Cancer Surviv 2020/4; 14 (2): 106-13. (•“¡@„1: 1‰q¶)

110050. [Œ´’˜] Exposure Assessment of Cadmium in Female Farmers in Cadmium-Polluted Areas in Northern Japan. Horiguchi H1, Oguma E2, Sasaki S, Miyamoto K, Hosoi Y, Ono A3, Kayama F: Toxics 2020/6; 8 (2): 44. (–xŒû•º„1, ¬ŒF‰xŽq2, ¬–ì@W3: 1‰q¶, 2—\–hˆãŠwŒn, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110051. [Œ´’˜] Comparative ƒÁ-H2AX analysis for assessment of the genotoxicity of six aromatic amines implicated in bladder cancer in human urothelial cell line. Qi Y1, Toyooka T, Nie J, Ohta H, Koda S, Wang RS: Toxicol In Vitro 2020/8; 66: 104880. (Yonggang Qi1: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110052. [Œ´’˜] Combined effects of occupational exposure to hazardous operations and lifestyle-related factors on cancer incidence. Fukai K, Kojimahara N, Hoshi K1, Toyota A, Tatemichi M: Cancer Sci 2020/12; 111 (12): 4581-4593. (¯@‰À–F1: 1‰q¶)

110053. [Œ´’˜] Predictors of resignation and sick leave after cancer diagnosis among Japanese breast cancer survivors: a cross-sectional study. Mitsui K, Endo M, Imai Y, Ueda Y, Ogawa H, Muto G1, Yan Y, Deshpande GA, Terao Y, Takeda S, Tanigawa T, Nishimura K, Hayashi K, Saito M, Kokaze A: BMC Public Health 2021/1; 21 (1): 138. (•“¡@„1: 1‰q¶)

110054. [Œ´’˜] Social participation and mortality according to company size of the longest-held job among older men in Japan: A 6-year follow-up study from the JAGES. Kanamori S, Kondo N, Takamiya T, Kikuchi H, Inoue S, Tsuji T, Kai Y, Muto G1, Kondo K: J Occup Health 2021/1; 63 (1): e12216. (•“¡@„1: 1‰q¶)

110055. [Œ´’˜] Reassessment of the threshold of the blood lead level to increase urinary ƒÂ-aminolevulinic acid based on their relationship in recent lead workers in Japan. Ono A1, Horiguchi H2: J Occup Health 2021/1; 63 (1): e12202. (¬–ì@W1, –xŒû•º„2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‰q¶)

110056. [Œ´’˜] The relationship of hospital stay and readmission with employment status. Kojimahara N, Hoshi K1, Tatemichi M, Toyota A: Ind Health 2021/2; 59 (1): 18-26. (¯@‰À–F1: 1‰q¶)

120002. [Œ´’˜] ‘S‘˜JÐ•a‰@‚É‚¨‚¯‚é”j—ô”]“®–¬áŽ3,963—á‚Ì•”ˆÊE«·E”N—î‚ÉŠÖ‚·‚錟“¢. –L“cÍG, —§“¹¹K, ¬“‡Œ´“TŽq, ¯@‰À–F1 (1‰q¶): ”]‘²’† 2020/7; 42 (4): 233-8.

120003. [Œ´’˜] ‘S‘˜JÐ•a‰@‚É‚¨‚¯‚é”j—ô”]“®–¬áŽ3,963 —á‚Ì•”ˆÊE«·E”N—î‚ÉŠÖ‚·‚錟“¢. –L“cÍG, —§“¹¹K, ¬“‡Œ´“TŽq, ¯@‰À–F1 (1‰q¶): ”]‘²’† 2020/7; 42 (4): 233-8.

120004. [Œ´’˜] ŠÇ—‰h—{Žm‚ÌŠˆ—p‚É‚æ‚è“Á’è•ÛŒ’Žw“±‚ÌŽÀŽ{—¦Œüã‚ÉŒü‚¯‚½Œ’f‹@ŠÖ‚ÌŽæ‚è‘g‚Ý. ꎓ¡‰ØŽq, ‘å‘O—˜’Ê, ’߉ª®Žu, •“¡@„1, ‘å‘O—R”ü, “V–ì”ü—¢, ¼–{@•–, r–Ø“Þ“ß, Žá—Ñ”üK, ŽRèˆß’ÃŽq (1‰q¶): “ú–{Œ’Nˆã—Êw‰ïŽGŽ 2020; 8: 21-6.

120005. [Œ´’˜] VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õŠg‘å‚É”º‚¤‹Ù‹}Ž–‘Ԑ錾’†‚ÌŽY‹Æ•ÛŒ’Šˆ“®. Žç“c—Sì, ÎàV“N˜Y, Š–ؔɔV, ŸN–؉€Žq, àV“c—LŠìŽq, ŽíŽsÛŽq, •“¡@„1, _“c‹´GŽ¡ (1‰q¶): ŽY‹Æ‰q¶ŠwŽGŽ 2021/3; J-STAGE‘ŠúŒöŠJ: 1-29.

520002. [‘à] ‰“Šu‹@Ší‚ð—p‚¢‚½˜J“­ŽÒ‚ÌŒ’NŠÇ—: ŽY‹Æ•ÛŒ’—̈æ‚É‚¨‚¯‚鉓Šu‹@Ší‚ð—p‚¢‚½Œ’NŠÇ—‚̃VƒXƒeƒ}ƒeƒBƒbƒNƒŒƒrƒ…[‚Ɖ“ŠuŽY‹Æˆã–ʐڂɊւ·‚é–@§“x‚ÌŒ»ó. _“c‹´GŽ¡, ÎàV“N˜Y, Š–ؔɔV, •“¡@„1, Žç“c—Sì, ‘å_@–¾ (1‰q¶): ŽY‹ÆˆãŠwƒŒƒrƒ…[ 2020/5; 33 (1): 59-81.

520003. [‘à] “ú–{l‚É‚¨‚¯‚éH•i‚©‚ç‚̃Jƒhƒ~ƒEƒ€”˜˜I‚ÌŒ»ó. –xŒû•º„ (‰q¶): –k—¢ˆãŠw 2020/12; 50 (2): 77-85.

522005. [uÀ]y“ÁW: ŠO‘l˜J“­ŽÒ‚̐Eê‚̈À‘S‰q¶z7. ŠO‘Œ—og˜J“­ŽÒ‚ÌŒ’N‰Û‘è‚Æ‰ðŒˆ‚Ö‚Ì“W–]|ƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX, Š´õÇ‚ƈã—Ñ̐§. •“¡@„1, •x“c@–Î, ‰““¡Œ¹Ž÷, ‰¡ŽR˜am (1‰q¶): ŽY‹ÆˆãŠwƒWƒƒ[ƒiƒ‹ 2020/5; 43 (3): 41-6.

522006. [uÀ]y‘æ66‰ñ ¡T‚̃e[ƒ}zŠ³ŽÒ‚ÌŽ¡—ÂƎdŽ–‚Ì—¼—§Žx‰‡ (‘˜_E‘O•Ò). •“¡@„ (‰q¶): “ú–{ˆãŽ–V•ñ 2020/7; 5019: 12-3.

522007. [uÀ]y‘æ67‰ñ ¡T‚̃e[ƒ}zŠ³ŽÒ‚ÌŽ¡—ÂƎdŽ–‚Ì—¼—§Žx‰‡ (‘˜_EŒã•Ò). •“¡@„ (‰q¶): “ú–{ˆãŽ–V•ñ 2020/7; 5020: 12-3.

522008. [uÀ] ‰“Šu‚ōs‚¤ƒRƒ“ƒTƒ‹ƒ^ƒ“ƒgŠˆ“®Ž–—á. Š–ؔɔV, Îˆä—“Þ, •“¡@„1, _“c‹´G–è (1‰q¶): ˆÀ‘S‰q¶ƒRƒ“ƒTƒ‹ƒ^ƒ“ƒg 2020/7; 40 (135): 57-62.

522009. [uÀ]y“ÁW: ¶–½EŠÂ‹«—Ï—‚ƃŠƒeƒ‰ƒV[z‰»Šw•¨Ž¿“™‚̊‹«–â‘è‚ɑ΂·‚郊ƒXƒNƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“|Ž‘±‰Â”\‚ȎЉï‚ÌŽÀŒ»‚ÉŒü‚¯‚½‘S¢‘ãŒ^SDG‚“ŠÂ‹«EŒ’NƒŠƒeƒ‰ƒV[‚Ì“W–]|. •“¡@„1, Î‹´÷Žq, ‰““¡Œ¹Ž÷, ‘åX—R‹I1, ‰¡ŽR˜am (1‰q¶): •ÛŒ’‚̉Ȋw 2020/10; 62 (10): 678-685.

540008. [‚»‚Ì‘¼ (Plain language summary–|–ó)] “ÁW†: ƒRƒƒiƒEƒCƒ‹ƒX (COVID-19):ƒpƒ“ƒfƒ~ƒbƒNŽž‚Ì‹Ö‰Œ‚ÉŒø‰Ê“I‚È‘I‘ðŽˆ (Cochrane Special Collections: Coronavirus (COVID-19): effective options for quitting smoking during the pandemic. Hartmann-Boyce, Nicola Lindson, Toby Lasserson, Monaz Mehta). –|–ó: ¯@‰À–F1, ŠÄ–ó: ´Œ´N‰î (1‰q¶): 2020/4; https://www.cochrane.org/ja/effective-options-for-quitting-smoking-during-the-covid-19-pandemic.

540009. [‚»‚Ì‘¼ (Plain language summary–|–ó)] ‹i‰ŒŽÒ‚ª‹Ö‰Œ–ò‚ÌŽg—p‚𑝂₷‚±‚Æ‚ðŽx‰‡‚Å‚«‚é‚©? (Interventions to increase adherence to medications for tobacco dependence. Hollands GJ, Naughton F, Farley A, Lindson N, Aveyard P). –|–ó: ¯@‰À–F1, ŠÄ–ó: ´Œ´N‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 8. Art. No.: CD009164. DOI: 10.1002/14651858.CD009164.pub3. 2020/5; https://www.cochrane.org/ja/CD009164/TOBACCO_chi-yan-zhe-gajin-yan-yao-noshi-yong-wozeng-yasukotowozhi-yuan-dekiruka.

540010. [‚»‚Ì‘¼ (•¶Œ£Ð‰î)] Ž––±ŠŠÂ‹«‚Æ‹C•ª‚ÉŠÖ‚·‚錤‹†‚Ì•¶Œ£ŒŸ“¢. ‰Yì‰Á‘ãŽq, ‰¡ŽR˜am, •“¡@„1 (1‰q¶): ŽY‹ÆˆãŠwƒWƒƒ[ƒiƒ‹ 2020/9; 43 (5): 99-106.

540011. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]y“Æ—§s­–@l˜J“­ŽÒŒ’NˆÀ‘S‹@\u—ߘa2”N“xE“ü‰@Š³ŽÒ•aE—𒲍¸Šî‘b‰ðÍ (2005 ”N“x`2018 ”N“x•aE—ðƒf[ƒ^Žg—p)vz—§“¹¹K, ¬“‡Œ´“TŽq, ¯@‰À–F1, –L“cÍG (1‰q¶):u—ߘa2”N“xE“ü‰@Š³ŽÒ•aE—𒲍¸Šî‘b‰ðÍ (2005 ”N“x`2018 ”N“x•aE—ðƒf[ƒ^Žg—p)vŒ¤‹†•ñ‘ 2021/2: p.1-102. https://www.research.johas.go.jp/bs/doc/20210402.pdf.

540012. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]yŒö‰v–@lƒtƒ@ƒCƒU[ƒwƒ‹ƒXƒŠƒT[ƒ`U‹»à’c@Œ¤‹†•¬‹àz •“¡@„ (‰q¶): ƒtƒ@ƒCƒU[ƒwƒ‹ƒXƒŠƒT[ƒ`U‹»à’c Œ¤‹†¬‰Ê•ñ‘ 2021/3.

540013. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]yˆê”ʍà’c–@lƒwƒ‹ƒXƒTƒCƒGƒ“ƒXƒZƒ“ƒ^[Œ¤‹†•¬‹àz •“¡@„ (‰q¶): ˆê”ʍà’c–@lƒwƒ‹ƒXƒTƒCƒGƒ“ƒXƒZƒ“ƒ^[Œ¤‹†•¬‹à Œ¤‹†ŽÀÑ•ñ‘ 2021/3.

540014. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]y˜JÐŽ¾•a—Տ°Œ¤‹†Ž–‹Æ”ï•â•‹à (190402-01)uŽ––±Š‰q¶Šî€‹K‘¥‚ÉŠÖ‚·‚錤‹†|‘Ó–«‚ƍ‘ÛŠî€‚Æ‚Ì’²˜a|vz•“¡@„1, ‰Ô—¢^“¹, ‹´–{t’j, ꎓ¡G”V, ’†‘º—T”V, ‰¡ŽR˜am, ¼•½@_, ‰““¡Œ¹Ž÷ (1‰q¶): —ߘa2”N“x‘Š‡E•ª’S•ñ‘ 2021/3.

540015. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]y˜JÐŽ¾•a—Տ°Œ¤‹†Ž–‹Æ”ï•â•‹à (180703-01)uE‹Æ«ƒXƒgƒŒƒXŠÈˆÕ’²¸•[‚ÌŠO‘”ō쐬‚ÉŠÖ‚·‚錤‹†vz‰¡ŽR˜am, “’óŽ‘”V, ˜a“ckŽ¡, ’Jì@•, ‰““¡Œ¹Ž÷, ‰Yì‰Á‘ãŽq, •“¡@„1, ¬“cØ—DŽq, “c’†Œõ‹I (1‰q¶): —ߘa2”N“x“Š‡E•ª’S•ñ‘ 2021/3.

[’˜@‘]

620007. [Šwp‘ (•ª’SŽ·•M)]yŽY‹ÆˆãƒKƒCƒh‘æ3”Łz‘æ10Í“­‚«•û‰üŠv@4Ž¡—ÂƎdŽ–‚Ì—¼—§Žx‰‡|˜J“­ŽÒ–{l‚𒆐S‚Æ‚µ‚½Ž–‹Æê‚ƈã—Ë@ŠÖ‚̘A‘ѐ„i‚ð–ÚŽw‚µ‚ā|, p.588. •Ÿ–{³Ÿ, š¢“¡‹áŽj, ‘“cKO, ‘“c‹M”üŽq, •ô@—²”V, ‘å’Î’q”V, ’†’J@“Ö, ŽO‘î—T“ñ, ‰Á“¡Œ›’‰, à_–{˜j’j, ŒÜ\—’ç‘ã, ‘å–ì–¾•F, [àVŒ’“ñ, •l“c“ĘY, ¼”WA‹KG, •Ÿ“c^–ç, ‘º“c@Ž, Ä“¡­•F, ŽR“à@”Ž, ‚“c—çŽq, ¬ìN‹±, ‹{‰z—Yˆê, œ\•y”ü“ÞŽq, ‘å‹´@—Í, ‰FŽm@”Ž, ²“¡L˜a, ŽR–{Œ’–ç, {‰ê–œ’q, ‹{–{r–¾, ‚–ì’mŽ÷, ‹g‘º–õŽi, •–ؐé•v, ŒjìCˆê, ˆ°Œ´@—¤, Îì_“ñ, ’†ì˜a”ü, ŽRŽ›@˜j, ’†’Ò‚ß‚®‚Ý, ˆäoLK, —L”nGW, —Oˆä”ü˜aŽq, ¬“cØ—DŽq, ‰ºŒõ‹Pˆê, ’JŽR‰À’ÃŽq, ŒÜ–¡G•ä, ‘å—¢@Œú, Š}Œ´‰x•v, ŽR–{®Žõ, ˆê™³m, ‰Á•”@—E, ‹{“à”ŽK, Ž›“c—El, ŒE“c¹Ži, ‰ªè˜aŒõ, ‰Á“¡@Œ³, ’†–숤Žq, Xè”ü“ÞŽq, ¬Œ´@V, ––‰iT‰î, ›”–Ø”Žˆê, “‡–ƒˆßŽq, “Œì–ƒŽq, •“¡@„1, ‰““¡Œ¹Ž÷, ¬“‡Œ´“TŽq, ¼‰içH, ‹gì@“O, ‰–àV—F‹K, ¬‰’N”Í, ˆîŠ_@’†, ŒÜ–¡œÄ‘¾˜Y, ²X–Ø•q, —с@—mŽq, “‡’Ö¾l, ’ç@–¾ƒ2, ŒÃŠÕ”ä“lŽu, ŽíŽsÛŽq, ¡ˆä“S•½, ¬”¨ŠG”üŽq (1‰q¶, 2ŒöO‰q¶), •Ò: “ú–{ŽY‹Æ‰q¶Šw‰ïŠÖ“ŒŽY‹Æˆã•”‰ï, “ú–{ˆãŽ–V•ñŽÐ, “Œ‹ž, 2020/12”­s.

620008. [Šwp‘ (ŠÄCE•ÒWE‚»‚Ì‘¼)]y‘‡f—Ðê–匤C|ŒöŽ®ƒeƒLƒXƒgƒuƒbƒN|z‘æ8Íl—¶‚·‚ׂ«ŽÐ‰ïî¨§“x@ŽÐ‰ï•ÛŒ¯…B. •“¡@„ (‰q¶), •Ò: “ú–{ê–åˆã‹@\‘‡f—Ðê–åˆãŒŸ“¢ˆÏˆõ‰ï, “úŒoBP, “Œ‹ž, 2020/12”­s.

620009. [Šwp‘ (•ª’SŽ·•M)]y‘–¯‚̉h—{”’‘2020”N“x”Å Š´õÇ‚Ì—¬s‚Ɖh—{‚̍¡Œãz‘æ2•”–Ɖu‹@”\‚É‚¨‚¯‚é‰h—{‚Ì–ðŠ„@‘æ1Í–ƉuŒn‚Ì‚µ‚­‚݁|¶‘Ì–hŒä‚É‚¨‚¯‚鉊Ç‚Ɖh—{, p.73. ’†‘º’šŽŸ, ŠÛÎ»–òŠ”Ž®‰ïŽÐ, Žðˆä@“O, ˜@‘º—FŽ÷‹v, ‰º“c@Ã, ”[Œ[ˆê˜Y, –xŒûˆíŽq, •“¡@„1, O“c—Ê“ñ, Œ´@_—S, ŽÄ“cdM, —é–ØŽu•ÛŽq, •“c˜a—R, ’JŒû‰pŠì, NPO–@l‚Û‚¯‚Á‚ƃXƒe[ƒVƒ‡ƒ“, ’†‘ºˆçŽq, ]•”@“µ, –ìŒûÊ‰À (1‰q¶), ŠÄC: ’†‘º’šŽŸ, “ú–{ˆã—Êé‰æ, “Œ‹ž, 2020/12”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722011. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒCƒ^ƒCƒCƒ^ƒC•a‚Ì“W–]`¡Œã‚Ì—\‘ª‚Ƒ΍ô. –xŒû•º„ (‰q¶): ‘æ91‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2021/3/8), WebŠJÃ.

723058. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘æ3ŽŸŽY‹Æ‚Ì‹Æ–±ˆÏ‘õ‰º¿\‘¢‚É‹Nˆö‚·‚éˆÀ‘S‰q¶‚̉ۑè:“¯ˆêì‹ÆC“¯ˆêˆÀ‘S‰q¶‚Ö. ‘åX—R‹I1, •“¡@„1, ‰¡ŽR˜am, ‰““¡Œ¹Ž÷, •Ÿ“c@—m, ‘å–î‚ß‚®‚Ý, ŽRè—Fä, ¼•½@_ , Îˆä—“Þ, –xŒû•º„1 (1‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12), ŽãŠJÃEWebŠJÃ.

723059. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) AI‚ð—p‚¢‚½Eˆæ50–œlƒf[ƒ^/ƒƒ^ƒ{ƒnƒCƒŠƒXƒNŽÒ‚ÌŒ’fŒãŽófs“®—\‘ªƒ‚ƒfƒ‹‚ÌŠJ”­. •“¡@„1, •Ð‹Ë—ÈŽq, ‰““¡Œ¹Ž÷, •Ÿ“c@—m, ‰¡ŽR˜am, –k‘º•¶•F, ‘å–î‚ß‚®‚Ý, Îˆä—“Þ, ‘åX—R‹I1, –xŒû•º„1 (1‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12), ŽãŠJÃEWebŠJÃ.

723060. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž¡—ÂƏA˜J‚Ì—¼—§Žx‰‡loT/AIƒVƒXƒeƒ€‚ÌŠJ”­. ‰““¡Œ¹Ž÷, •“¡@„1, ꎓ¡Œõ], ò@”Ž”V (1‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ.

723061. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ`ƒFƒbƒNƒŠƒXƒg30‚ð—p‚¢‚½’†¬Šé‹Æ‚Å‚ÌŽ¡—ÂƎdŽ–‚Ì—¼—§Žx‰‡ƒCƒ“ƒ^[ƒlƒbƒg’²¸. ì–”‰Ø‘ã, “¡ˆä•üŽq, •“¡@„1, ‚ŽR”ŽŒõ, ¼—t@Ä, ‰ª@Œh”V, ¼•½@_ (1‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ.

723062. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ’Nf’f‚ÆŽ–Œã‘[’uE¶ŠˆKŠµ•aŽw“±7. •“¡@„ (‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ.

723063. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ÁŽêŒ’Nf’f‚ÌŽóf—ð‚Æ‚ª‚ñ‚̜늳‚ÉŠÖ‚·‚錟“¢|‘S‘˜JÐ•a‰@•aE—𒲍¸ƒf[ƒ^‚æ‚è|. [ˆäq‘¾, ¬“‡Œ´“TŽq, ¯@‰À–F1, –L“cÍG, —§“¹¹K (1‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ, “ú–{ŽY‹Æ‰q¶Šw‰ïu‰‰W “ú–{ŽY‹Æ‰q¶Šw‰ïŽ 2020/5; 62 (—ÕŽž‘Š§†): 505.

723064. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘S‘˜JÐ•a‰@E“ü‰@Š³ŽÒ•aE—𒲍¸‚É‚¨‚¯‚銳ŽÒ‚Æ‚µ‚Ă̈ãŽt‚Ì“­‚«•û‚Ɛ¶ŠˆKŠµ‚̕ω». ¯@‰À–F1, ¬“‡Œ´“TŽq, —§“¹¹K, –L“cÍG (1‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ, “ú–{ŽY‹Æ‰q¶Šw‰ïu‰‰W “ú–{ŽY‹Æ‰q¶Šw‰ïŽ 2020/5; 62 (—ÕŽž‘Š§†): 539.

723065. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒJƒhƒ~ƒEƒ€“Š—^ƒ‰ƒbƒg‚É‚¨‚¯‚é––½ŒŒ’†ƒGƒŠƒXƒƒ|ƒGƒ`ƒ“‚Ɛt‘Ÿ‚ł̃GƒŠƒXƒƒ|ƒGƒ`ƒ“”­Œ»‚Æ‚ÌŠÖŒW. –xŒû•º„1, ¬ŒF‰xŽq, ˆÀ‰ª—L‹IŽq2, ‘åX—R‹I1, ‰ÍŒ´Ž‰ë, –ìXŒû”ŽŽj (1‰q¶, 2¶—): ‘æ47‰ñ“ú–{“Ő«Šw‰ïŠwp”N‰ï (2020/6/29), WebŠJÃ.

723066. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒtƒŒƒCƒ‹ó‘Ô‚É‚ ‚éŠÖßƒŠƒEƒ}ƒ`Š³ŽÒ‚Æ’nˆæÝZ‚—îŽÒ‚Ì”äŠrŒŸ“¢. ã’n“m, ¬“ˆ‰ë‘ã, ˆÀ‰ªŽÀ‰ÀŽq, •“¡@„1, ”Ñ’ËŒº–¾, Ö“¡@–¯, “n糔ü‹M, —é–Ø’å•v, ’|“àŒ¤Žž, ŽáˆäŒšŽu, ”ö“‡r”V, ‹ß“¡Ž‘¥ (1‰q¶): ‘æ79‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï (2020/10/20-22), WebŠJÃ.

723067. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽÐ‰ïŽQ‰Á‚ƃtƒŒƒCƒ‹: ŠÖßƒŠƒ…ƒEƒ}ƒ`Š³ŽÒ‚ƁuŒ’N‚Æ‚­‚炵‚Ì’²¸2016vŽQ‰ÁŽÒ‚Ì”äŠr. ¬“ˆ‰ë‘ã, ˆÀ‰ªŽÀ‰ÀŽq, •“¡@„1, ”Ñ’ËŒº–¾, Ö“¡@–¯, “n糔ü‹M, —é–Ø’å•v, ’|“àŒ¤Žž, ŽáˆäŒšŽu, ”ö“‡r”V, ‹ß“¡Ž‘¥ (1‰q¶): ‘æ79‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï (2020/10/20-22), WebŠJÃ.

723068. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’j«‚—îŽÒ‚É‚¨‚¯‚éÅ’·E‚ÌŠé‹Æ‹K–͕ʂ̎ЉïŽQ‰Á‚ÆŽ€–S‚ÌŠÖ˜A: JAGESƒXƒ^ƒfƒB. ‹àX@Œå, ‹ß“¡®ŒÈ, ‚‹{•üŽq, ‹e’rGK, ˆäã@–Î, ’ҁ@‘åŽm, b”ã—TŽq, •“¡@„1, ‹ß“¡Ž‘¥ (1‰q¶): ‘æ79‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï (2020/10/20-22), WebŠJÃ.

723069. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šé‹Æ‚É‚¨‚¯‚鎡—ÂƎdŽ–‚Ì—¼—§Žx‰‡‚ÌŒ»ó‚ÉŠÖ‚·‚錟“¢. “¡ˆä•üŽq, ‰ª@Œh”V, •“¡@„1, XŒûŽŸ˜Y, ¬ŽR‘PŽq, ¼•½@_ (1‰q¶): ‘æ79‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï (2020/10/20-22), WebŠJÃ.

723070. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·z(‰“ŠuŽY‹Æ‰q¶Œ¤‹†Ž©—RW‰ïƒOƒ‹[ƒvŒŸ“¢‰ï) Ž–—á‚©‚çŠw‚Ô, ‰“Šu–ʐڂ̑£i—vˆöE‘jŠQ—vˆö`•K—v\•ªðŒ‚ðŒŸ“¢‚·‚é`. ŸN–؉€Žq, •“¡@„1 (1‰q¶): ‘æ30‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï‘S‘‹¦‹c‰ï (2020/11/20-30), WebŠJÃ.

723071. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 2-ƒƒ‹ƒJƒvƒgƒxƒ“ƒ]ƒ`ƒAƒ][ƒ‹ì—p‚É‚æ‚éƒÁ-H2AX¶¬‚Æ‚»‚Ì—U“±ƒƒJƒjƒYƒ€‚ÉŠÖ‚·‚錤‹†. ŒV@‰i„, –L‰ª’BŽm, –xŒû•º„1, ‰¤@¶, b“c–ÎŽ÷ (1‰q¶): “ú–{ŠÂ‹«•ÏˆÙŒ´Šw‰ï‘æ49‰ñ‘å‰ï (2020/11/26-27), À’Ã, “ú–{ŠÂ‹«•ÏˆÙŒ´Šw‰ï‘æ49‰ñ‘å‰ï—vŽ|W 2020/11; p.92.

723072. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆê”Ê•a‰@‚̐tŽ¾Š³Š³ŽÒ‚É‚¨‚¯‚鍂ƒÀ2-ƒ~ƒNƒƒOƒƒuƒŠƒ“”AÇ. –xŒû•º„1, ¬ŒF‰xŽq, ‘åX—R‹I1, ¬—Ñ“Žq2, ¼ìŠx‹v, àV‘º¹l, ‹e’nFÆ, ˆÉ“¡Œ\Œá, ‹{“‡]—¢Žq, ‚‹´@—É3 (1‰q¶, 2—\–hˆãŠwŒn, 3t‘Ÿ“à): ‘æ91‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2021/3/6), WebŠJÃ.

723073. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‰ŠÇ«’°Ž¾Š³‚ƍŒ·E‹Æ—ð‚Æ‚ÌŠÖ˜A|‘S‘˜JÐ•a‰@•aE—ðƒf[ƒ^ƒx[ƒX‚æ‚è|. ŒÃ‰®—CŽq, [ˆäq‘¾, ’†àVËŽq, ¬“‡Œ´“TŽq, ¯@‰À–F1, –L“cÍG, —§“¹¹K (1‰q¶): ‘æ91‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2021/3/6-8), WebŠJÃ, ‘æ91‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ïu‰‰W “ú–{‰q¶ŠwŽGŽ 2021/3; 76 (suppl): s179.

723074. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) —LŠQì‹Æ‚Ì‹Æ–±—ð‚Æ‹i‰Œ‚Ì•¡‡“I”˜˜I‚ª”x‚ª‚ñœëŠ³‚É‹y‚Ú‚·‰e‹¿. [ˆäq‘¾, ¬“‡Œ´“TŽq, ¯@‰À–F1, ŒÃ‰®—CŽq, –L“cÍG, —§“¹¹K (1‰q¶): ‘æ91‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2021/3/6-8), WebŠJÃ, ‘æ91‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ïu‰‰W “ú–{‰q¶ŠwŽGŽ 2021/3; 76 (suppl): s186.

723075. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽáŽèŠˆ«‰»ŠÖ˜AŠé‰æuŽáŽè‚©‚ç‚̐t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (Šw‰ï) ‚Ö‚Ì’ñŒ¾vt‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̉^“®ƒvƒƒOƒ‰ƒ€‚Æ•]‰¿‚ÉŠÖ‚·‚é’ñŒ¾. —é–Ø—T‘¾1, Œ´“cˆ¤‰i, ¯@‰À–F2, ”’Šâ@Œ’, •Ÿ“c@Œh, ¼‰i“Ä•F3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‰q¶, 3ˆã—Éq¶Šw•”): ‘æ11‰ñ“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2021/3/20), WebŠJÃ, “ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€E´˜^W 2021; 11th: 162.

733009. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) t”A×ŠÇ‹@”\áŠQ‚ðŠÜ‚ޏW’c‚É‚¨‚¯‚錌’†E”A’†ƒJƒhƒ~ƒEƒ€”Z“x‚Ì”˜˜IŽw•W‚Æ‚µ‚Ă̑Ó–«‚ÌŒŸ“¢. –xŒû•º„1, ¬ŒF‰xŽq, ‘º“cŸŒh, ²X–Ø•q, ‹{–{‰À‘ãŽq, ‘å–ì’qŽq, ¬¼“c“Ö, ŒFàV—R”üŽq (1‰q¶): ƒƒ^ƒ‹ƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†‰ï2020 (2020/11/6), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-540001. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]y˜JÐŽ¾•a—Տ°Œ¤‹†Ž–‹Æ”ï•â•‹à (170401-01)zŠé‹ÆEŽY‹Æ•ÛŒ’ƒXƒ^ƒbƒtEˆã—Ë@ŠÖ‚̘AŒg‚É‚æ‚é—¼—§Žx‰‡ƒVƒXƒeƒ€‚ÌŠJ”­: Ž¡—ÂƎdŽ–‚Ì—¼—§Žx‰‡‚É‚¨‚¯‚éˆã—Ë@ŠÖ‚Ì–ðŠ„|’†¬Šé‹Æ‚ðŠÜ‚ß‚½EˆæEŽY‹Æˆã‚Ƃ̘AŒg‚Ì•ªÍ‚ÆŽæ‘g‚݁|. ¼•½@_ (Žå”CŒ¤‹†ŽÒ), ‰¡ŽR˜am, •“¡@„1 (1‰q¶): •½¬29”N-—ߘaŒ³”N“x‘‡Œ¤‹†•ñ‘ 2020/3; p.36-43.

[Šw‰ïEŒ¤‹†‰ï“™]

'19-723004. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒpƒ‰ƒ^ƒ‹ƒo[‚̈ʒu‚̈Ⴂ‚ª”­ŒêŽž‚Ì”]Šˆ“®‚É—^‚¦‚é‰e‹¿. •Ð‰ª‰Á“ÞŽq, ¶“c—´•½, “¡Œ´@Šî, çŒ´@W, ¬—с@„, ¯@‰À–F1, ¬–ì‹|ŠG, ‹Ê’uŸŽi (1‰q¶): Œö‰vŽÐ’c–@l“ú–{•â’ÔŽ•‰ÈŠw‰ï‘æ128‰ñŠwp‘å‰ï (2019/5/12), ŽD–y, “ú–{•â’ÔŽ•‰ÈŠw‰ïŽ ‘æ128‰ñ“ú–{•â’ÔŽ•‰ÈŠw‰ï Šwp‘å‰ïƒvƒƒOƒ‰ƒ€´˜^W2019; 11 (128‰ñ“Á•Ê†): 173. https://www.knt.co.jp/ec/2019/jps128/pdf/shoroku2.pdf.

'19-723005. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘S‘˜JÐ•a‰@•aE—𒲍¸ƒf[ƒ^‚ð—p‚¢‚½EŽí‚Æ”]ESŒŒŠÇŽ¾Š³‚Ì”­Ç‚ÉŠÖ‚·‚錟“¢. [ˆäq‘¾, —§“¹¹K, ¬“‡Œ´“TŽq, ¯@‰À–F1, –L“cÍG (1‰q¶): ‘æ30‰ñ“ú–{‰uŠw‰ïŠwp‘‰ï (2020/2/20-22), ‹ž“s, ‘æ30‰ñ“ú–{‰uŠw‰ïŠwp‘‰ïu‰‰W 2020/2; 30 (suppl): 129.

'19-733001. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) f—ÃKƒCƒhƒ‰ƒCƒ“‚̏o—ˆ•û‚Æ“Ç‚Ý•û. ¯@‰À–F (‰q¶): “ú–{—L•aŽÒŽ•‰Èˆã—Êw‰ï‘æ9‰ñŠwp‹³ˆçƒZƒ~ƒi[ (2019/11/17), “Œ‹ž, ‘æ9‰ñŠwp‹³ˆçƒZƒ~ƒi[ƒvƒƒOƒ‰ƒ€E´˜^W p.16-7.

'19-733002. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) –«‰ŠÇ (Th2Œ^) ”­Ç‹@˜‚ÉŠÖ‚·‚é–Ɖu §Œä‚Ɗ‹«—vˆö‚ÌŒŸ“¢. •“¡@„ (‰q¶): ‘æ13‰ñƒvƒƒOƒŒƒXƒŒƒ|[ƒg‰ï‹c (2020/1/15), ‘Š–ÍŒ´.


ŒöO‰q¶Šw

[Šwp˜_•¶]

110057. [Œ´’˜] Internal consistency reliability, construct validity, and item response characteristics of the Kessler 6 scale among hospital nurses in Vietnam. Kawakami N, Tran TTT, Watanabe K, Imamura K, Nguyen HT, Sasaki N, Kuribayashi K, Sakuraya A, Nguyen QT, Nguyen NT, Bui TM, Nguyen GTH, Minas H, Tsutsumi A1: PLoS One 2020/5; 15 (5): e0233119. (’ç@–¾ƒ1: 1ŒöO‰q¶)

110058. [Œ´’˜] The Association Between Unit-Level Workplace Social Capital and Intention to Leave Among Employees in Health Care Settings: A Cross-Sectional Multilevel Study. Iida M, Watanabe K, Ando E, Tsuno K, Inoue A1, Kurioka S, Kawakami N: J Occup Environ Med 2020/5; 62 (5): e186-91. (ˆäã²b1: 1ŒöO‰q¶)

110059. [Œ´’˜] Cumulative Exposure to Long Working Hours and Occurrence of Ischemic Heart Disease: Evidence From the CONSTANCES Cohort at Inception. Fadel M, Li J, Sembajwe G, Gagliardi D, Pico F, Ozguler A, Evanoff BA, Baer M, Tsutsumi A1, Iavicoli S, Leclerc A, Roquelaure Y, Siegrist J, Descatha A: J Am Heart Assoc 2020/6; 9 (12): e015753. (’ç@–¾ƒ1: 1ŒöO‰q¶)

110060. [Œ´’˜] Combined effect of high stress and job dissatisfaction on long-term sickness absence: a 1-year prospective study of Japanese employees. Inoue A1, Kachi Y1, Eguchi H1, Shimazu A, Kawakami N, Tsutsumi A1: Environmental and Occupational Health Practice 2020/6; 2 (1): eohp.2020-0002-OA. (ˆäã²b1, ‰Â’m—IŽq1, ]Œû@®1, ’ç@–¾ƒ1: 1ŒöO‰q¶)

110061. [Œ´’˜] Workplace social capital and refraining from seeking medical care in Japanese employees: a 1-year prospective cohort study Inoue A1, Tsutsumi A1, Eguchi H1, Kachi Y1, Shimazu A, Miyaki K, Takahashi M, Kurioka S, Enta K, Kosugi Y, Totsuzaki T, Kawakami N: BMJ Open 2020/8; 10 (8): e036910. (ˆäã²b1, ’ç@–¾ƒ1, ]Œû@®1, ‰Â’m—IŽq1: 1ŒöO‰q¶)

110062. [Œ´’˜] Construct validity and test-retest reliability of the World Mental Health Japan version of the World Health Organization Health and Work Performance Questionnaire Short Version: a preliminary study. Kawakami N, Inoue A1, Tsuchiya M, Watanabe K, Imamura K, Iida M, Nishi D: Ind Health 2020/8; 58 (4): 375-87. (ˆäã²b1: 1ŒöO‰q¶)

110063. [Œ´’˜] The effect of exposure to long working hours on ischaemic heart disease: A systematic review and meta-analysis from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury. Li J, Pega F, Ujita Y, Brisson C, Clays E, Descatha A, Ferrario MM, Godderis L, Iavicoli S, Landsbergis PA, Metzendorf MI, Morgan RL, Pachito DV, Pikhart H, Richter B, Roncaioli M, Rugulies R, Schnall PL, Sembajwe G, Trudel X, Tsutsumi A1, Woodruff TJ, Johannes Siegrist J: Environ Int 2020/9; 142: 105739. (’ç@–¾ƒ1: 1ŒöO‰q¶)

110064. [Œ´’˜] Psychosocial Work Environment Explains the Association of Job Dissatisfaction With Long-term Sickness Absence: A One-Year Prospect Study of Japanese Employees. Inoue A1, Tsutsumi A1, Kachi Y1, Eguchi H1, Shimazu A, Kawakami N: J Epidemiol 2020/9; 30 (9): 390-5. (ˆäã²b1, ’ç@–¾ƒ1, ‰Â’m—IŽq1, ]Œû@®1: 1ŒöO‰q¶)

110065. [Œ´’˜] Parental cohabitation and mental well-being amongst young adults in the world's densest population with least affordable housing: Evidence from the FAMILY cohort. Hikichi H1, Ni MY, Leung GM: J Affect Disord 2020/9; 274: 698-703. (ˆø’n”Ž”V1: 1ŒöO‰q¶)

110066. [Œ´’˜] The effect of exposure to long working hours on stroke: A systematic review and meta-analysis from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury. Descatha A, Sembajwe G, Pega F, Ujita Y, Baer M, Boccuni F, Di Tecco C, Duret C, Evanoff BA, Gagliardi D, Godderis L, Kang SK, Kim BJ, Li J, Magnusson Hanson LL, Marinaccio A, Ozguler A, Pachito D, Pell J, Pico F, Ronchetti M, Roquelaure Y, Rugulies R, Schouteden M, Siegrist J, Tsutsumi A1, Iavicoli S: Environ Int 2020/9; 142: 105746. (’ç@–¾ƒ1: 1ŒöO‰q¶)

110067. [Œ´’˜] Which autistic traits are related to depressive symptoms in Japanese workers?. Suzuki T, Miyaki K, Tsutsumi A1: Ind Health 2020/10; 58 (5): 414-22. (’ç@–¾ƒ1: 1ŒöO‰q¶)

110068. [Œ´’˜] What Kind of Intervention Is Effective for Improving Subjective Well-Being Among Workers? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Sakuraya A, Imamura K, Watanabe K, Asai Y, Ando E, Eguchi H1, Nishida N, Kobayashi Y, Arima H, Iwanaga M, Otsuka Y, Sasaki N, Inoue A1, Inoue R, Tsuno K, Hino A, Shimazu A, Tsutsumi A1, Kawakami N: Front Psychol 2020/11; 11: 528656. (]Œû@®1, ˆäã²b1: ’ç@–¾ƒ1: 1ŒöO‰q¶)

110069. [Œ´’˜] Associations Between Community Social Capital and Preservation of Functional Capacity in the Aftermath of a Major Disaster. Gero K, Hikichi H1, Aida J, Kondo K, Kawachi I: Am J Epidemiol 2020/11; 189 (11): 1369-78. (ˆø’n”Ž”V1: 1ŒöO‰q¶)

110070. [Œ´’˜] Andropause symptoms and sickness absence in Japanese male workers: a prospective study. Hirokawa K, Fujii Y, Taniguchi T, Takaki J, Tsutsumi A1: Aging Male 2020/12; 23 (5): 1545-52. (’ç@–¾ƒ1: 1ŒöO‰q¶)

110071. [Œ´’˜] Household income and the risk of incident hypertension in employees at multiple workplaces in Japan: J-HOPE. Yanagiya S, Nakamura K, Ukawa S, Tsutsumi A1, Atsumi T, Tamakoshi A: Hypertens Res 2020/12; 43 (12): 1445-53. (’ç@–¾ƒ1: 1ŒöO‰q¶)

110072. [Œ´’˜] Work Engagement and Work Performance Among Japanese Workers: A 1-Year Prospective Cohort Study. Eguchi H1, Inoue A1, Kachi Y1, Miyaki K, Tsutsumi A1: J Occup Environ Med 2020/12; 62 (12): 993-7. (]Œû@®1, ˆäã²b1, ‰Â’m—IŽq1, ’ç@–¾ƒ1: 1ŒöO‰q¶)

110073. [Œ´’˜] Mothers' nonstandard work schedules and adolescent obesity: a population-based cross-sectional study in the Tokyo metropolitan area. Kachi Y1, Abe A, Eguchi H1, Inoue A1, Tsutsumi A1: BMC Public Health 2021/1; 21 (1): 237. (‰Â’m—IŽq1, ]Œû@®1, ˆäã²b1, ’ç@–¾ƒ1: 1ŒöO‰q¶)

110074. [Œ´’˜] Association between maternity harassment and depression during pregnancy amid the COVID-19 state of emergency. Kachi Y1, Fujiwara T, Eguchi H1, Inoue A1, Baba S, Ohta H1, Tsutsumi A1: J Occup Health 2021/1; 63 (1): e12196. (‰Â’m—IŽq1, ]Œû@®1, ˆäã²b1, ‘¾“c@Š°1, ’ç@–¾ƒ1: 1ŒöO‰q¶)

110075. [Œ´’˜] Mothers' nonstandard work schedules and adolescent obesity: a population-based cross-sectional study in the Tokyo metropolitan area. Kachi Y1, Abe A, Eguchi H1, Inoue A1, Tsutsumi A1: BMC Public Health 2021/1; 21 (1): 237. (‰Â’m—IŽq1, ]Œû@®1, ˆäã²b1, ’ç@–¾ƒ1: 1ŒöO‰q¶)

110076. [Œ´’˜] Six-year follow-up study of residential displacement and health outcomes following the 2011 Japan Earthquake and Tsunami. Hikichi H1, Aida J, Kondo K, Kawachi I: Proc Natl Acad Sci U S A 2021/1; 118 (2): e2014226118. (ˆø’n”Ž”V1: 1ŒöO‰q¶)

110077. [Œ´’˜] Effects of Smartphone-Based Stress Management on Improving Work Engagement Among Nurses in Vietnam: Secondary Analysis of a Three-Arm Randomized Controlled Trial Sasaki N, Imamura K, Tran TTT, Nguyen HT, Kuribayashi K, Sakuraya A, Bui TM, Nguyen QT, Nguyen NT, Nguyen GTH, Zhang MW, Minas H, Sekiya Y, Watanabe K, Tsutsumi A1, Shimazu A, Kawakami N: J Med Internet Res 2021/2; 23 (2): e20445. (’ç@–¾ƒ1: 1ŒöO‰q¶)

220001. [€Œ´’˜ (’²¸•ñ)] ]‹Æˆõ8–¼‚̏¬‹K–Í—ë×Šé‹Æ‚É‚¨‚¯‚éŽQ‰ÁŒ^Eê‰ü‘Pƒ‚ƒfƒ‹Ž–‹Æ‚Ì2”NŠÔ‚ÌŽæ‚è‘g‚Ý. •–ؐm”ü, XŒûŽŸ˜Y, “à“c—z”V, ‘å‹´ŽjŽq, ŒÜ\—’ç‘ã, ¬“cØ—DŽq, “‡’Ö¾l, ’ç@–¾ƒ1, ‹ÑŒË“TŽq, Œ´’J—²Žj, ‹gì‰xŽq, ‹gì@“O, ìãŒ›l (1ŒöO‰q¶): ŽY‹Æ‰q¶ŠwŽGŽ 2020/11; 62 (6): 249-60.

510001. [‘à] Cross-sectional association between working and depression prevalence in cancer survivors: a literature review. Ota A, Kawada K, Tsutsumi A1, Yatsuya H: Environmental and Occupational Health Practice 2020/6; 2 (1): eohp.2020-0006-RA. (’ç@–¾ƒ1: 1ŒöO‰q¶)

510002. [‘à] Implementation and effectiveness of the Stress Check Program, a national program to monitor and control workplace psychosocial factors in Japan: a systematic review. Translated secondary publication. Tsutsumi A1, Sasaki N, Komase Y, Watanabe K, Inoue A1, Imamura K, Kawakami N: International Journal of Workplace Health Management 2020/12; 13 (6): 649-70. (’ç@–¾ƒ1, ˆäã²b1: 1ŒöO‰q¶)

522010. [uÀ]y“ÁW: áŠQŽÒŒÙ—p‚ÆŽY‹ÆƒXƒgƒŒƒX1záŠQ‚Ì‚ ‚é˜J“­ŽÒ‚̏A‹Æã‚̃XƒgƒŒƒX‚ÆŽx‰‡‚ÆŽY‹Æ•ÛŒ’E‚Ì–ðŠ„. ]Œû@® (ŒöO‰q¶): ŽY‹ÆƒXƒgƒŒƒXŒ¤‹† 2020/4; 27 (2): 193-201.

522011. [uÀ]y“ÁW: ‹ÆŽíEEŽí‚ÆŽY‹ÆƒXƒgƒŒƒX‘΍ôzE‹ÆŠÔ‚É‚¨‚¯‚éS‚ÌŒ’NŠi·|E‹Æ«ƒXƒgƒŒƒX‚ւ̃Aƒvƒ[ƒ`|. ˆäã²b (ŒöO‰q¶): ŽY‹ÆƒXƒgƒŒƒXŒ¤‹† 2020/8; 27 (3): 309-18.

522012. [uÀ]y˜AÚ: Åæ’[ˆã—Â̍¡zE‚Ì•sˆÀ’萫‚ƐS—“IƒXƒgƒŒƒX”½‰ž‚Æ‚ÌŠÖ˜A‚ɑ΂·‚éŽdŽ–‚ÌŽ‘Œ¹‚̊ɏՌø‰Ê. ˆäã²b (ŒöO‰q¶): Medical Science Digest 2020/12; 46 (14): 878-81.

530002. [‚»‚Ì‘¼ (Opinions)] Workstyle reform for Japanese doctors. Tsutsumi A1: Environmental and Occupational Health Practice 2020/6; 2 (1): eohp.2020-0008-OP. (’ç@–¾ƒ1: 1ŒöO‰q¶)

530003. [‚»‚Ì‘¼ (Editorial)] Emerging issues in the occupational health field. Tsutsumi A1: Environ Occup Health Practice 2020/6; 2 (1). doi.org/10.1539/eohp.2.1-ED. (’ç@–¾ƒ1: 1ŒöO‰q¶)

530004. [‚»‚Ì‘¼ (Opinion)] Suicide prevention for workers in the era of with- and after-Corona. Tsutsumi A1: Environmental and Occupational Health Practice 2021/3; 3 (1): 2020-0020-OP. (’ç@–¾ƒ1: 1ŒöO‰q¶)

540016. [‚»‚Ì‘¼ (˜_’d)] ƒeƒŒƒ[ƒN‚ƃƒ“ƒ^ƒ‹ƒwƒ‹ƒX. ’ç@–¾ƒ (ŒöO‰q¶): ŽY‹ÆˆãŠwƒWƒƒ[ƒiƒ‹ 2020/11; 43 (6): 106-8.

540017. [‚»‚Ì‘¼ (Šw‰ï•ñ)]yŽY‹Æ•ÛŒ’‘“àŠÖ˜Aƒjƒ…[ƒXz‘æ36‰ñ“ú–{ƒXƒgƒŒƒXŠw‰ïŠwp‘‰ïŠJÃ•ñ. ˆäã²b1, ’ç@–¾ƒ1 (1ŒöO‰q¶): ŽY‹ÆˆãŠwƒWƒƒ[ƒiƒ‹ 2021/3; 44 (2): 58-62.

540018. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]y˜JÐŽ¾•a—Տ°Œ¤‹†Ž–‹Æ”ï•â•‹àuŽ–‹Æê‚É‚¨‚¢‚ÄŽ¡—ÂƎdŽ–‚Ì—¼—§Žx‰‡‚ð‚·‚é‚½‚ß‚Ì”z—¶‚Æ‚»‚ÌŒˆ’èƒvƒƒZƒX‚É‚©‚ñ‚·‚錤‹†vz]Œû@®1 (Œ¤‹†‘ã•\ŽÒ), ’ç@–¾ƒ1, ²X–ØŽ¡ˆê˜Y2, {‰ê–œ’q, “n•Ó@“N, ŽR–ì‰Ã‹v, Ä“¡@‘, ŒÃ‰®”Žs, X“c“N–ç, Š–ؔɔV, –k‹@–¾, X‰i—Y‘¾, •“¡@„3, ˆäã²b1 (1ŒöO‰q¶, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3‰q¶): —ߘa2”N“x‘Š‡E•ª’SŒ¤‹†•ñ‘ 2021/3.

[’˜@‘]

610001. [Šwp‘ (•ª’SŽ·•M)]yHealth in Japan: Social Epidemiology of Japan since the 1964 Tokyo OlympicszJapan's Miracle Decades: Harmony, Hard Work, and Health, p.85-100. Tsutsumi A1, Editors: Brunner E, Cable N, IsoH, Oxford University Press, UK, 2020/8. (’ç@–¾ƒ1: 1ŒöO‰q¶)

620010. [Šwp‘ (•ª’SŽ·•M)]yŽÐ‰ïEŠÂ‹«‚ÆŒ’N@ŒöO‰q¶Šw@2021”N“x”ŁzCHAPTER 9@¸_Ž¾Š³, p.95-100. ’ç@–¾ƒ (ŒöO‰q¶), •Ò’˜: –öì@—m, ”ö“‡r”V, ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ, “Œ‹ž, 2021/1”­s.

620011. [Šwp‘ (•ª’SŽ·•M)]yŽÐ‰ïEŠÂ‹«‚ÆŒ’N@ŒöO‰q¶Šw@2021”N“x”ŁzCHAPTER 10@Ž©ŽE, •s—¶‚ÌŽ–ŒÌ, ‹s‘Ò, –\—Í, p.101-4. ’ç@–¾ƒ (ŒöO‰q¶), •Ò’˜: –öì@—m, ”ö“‡r”V, ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ, “Œ‹ž, 2021/1”­s.

620012. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj 2021”N”Ł@Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚éz16. ¸_Ž¾Š³@Eê•s“K‰žÇ, p.1114-5. ’ç@–¾ƒ (ŒöO‰q¶), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@½, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2021/1”­s.

620013. [Šwp‘ (•ª’SŽ·•M)]yŽY‹ÆˆãƒKƒCƒh‘æ3”Łz‘æ11ÍŽY‹Æ‰q¶Šˆ“®‚ɖ𗧂’mŽ¯@7 ˜J“­¶ŽY«‚ÆŽY‹Æ•ÛŒ’, p.674-81. ’ç@–¾ƒ (ŒöO‰q¶), •Ò: “ú–{ŽY‹Æ‰q¶Šw‰ïŠÖ“ŒŽY‹Æˆã•”‰ï, “ú–{ˆãŽ–V•ñŽÐ, “Œ‹ž, 2020/12”­s.

620014. [Šwp‘ (•ª’SŽ·•M)]yƒ\[ƒVƒƒƒ‹EƒLƒƒƒsƒ^ƒ‹‚ÆŒ’NE•ŸŽƒ@ŽÀØŒ¤‹†‚ÌŽè–@‚©‚琭ôEŽÀ‘H‚ւ̉ž—p‚܂Łz‘æ13ÍEˆæ‚Å‚ÌŒ’N‚­‚è‚ƃ\[ƒVƒƒƒ‹EƒLƒƒƒsƒ^ƒ‹|‰uŠwŒ¤‹†‚Ì“ž’B“_‚Ɖۑè, p.238-53. ˆäã²b1, ‚”ö‘Ži (1ŒöO‰q¶), •Ò’˜: ‹ß“¡Ž‘¥, ƒ~ƒlƒ‹ƒ”ƒ@‘–[, ‹ž“s, 2020/4”­s.

620015. [Šwp‘ (•ª’SŽ·•M)]yƒAƒNƒeƒBƒuŒöO‰q¶Šwƒ‰[ƒjƒ“ƒOz2 Œ’N‚Æ‚Í (ŽÐ‰ï‰uŠw), p.23-42. ‰Â’m—IŽq (ŒöO‰q¶), •Ò: “¡’JŽŒÈ, ‘ëŒû@“O, ƒEƒCƒlƒbƒg, VŠƒ, 2020/7”­s.

620016. [Šwp‘ (’P’˜)]y•Ûˆç‰€‚É’Ê‚¦‚È‚¢Žq‚Ç‚à‚½‚¿|u–³‰€Ž™v‚Æ‚¢‚¤ˆÅz‰Â’m—IŽq (ŒöO‰q¶), ’}–€‘–[, “Œ‹ž, 2020/4”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722012. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) EêŠÂ‹«‰ü‘P. ’ç@–¾ƒ (ŒöO‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ.

722013. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Organizational justice and refraining from seeking medical care among Japanese employees: a 1-year prospective cohort study. ˆäã²b (ŒöO‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ.

722014. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˜J“­ŽÒ‚̃ƒ“ƒ^ƒ‹ƒwƒ‹ƒX‚ÆŽ©ŽE‘΍ô. ’ç@–¾ƒ (ŒöO‰q¶): ‘æ79‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï (2020/10/20), WebŠJÃ.

722015. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ”N‘ã•Ê‚̈ø‚«‚±‚à‚è‚ÌŽ¾Š³C—\–hE‘΍ô. ’ç@–¾ƒ (ŒöO‰q¶): ‘æ79‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï (2020/10/22), WebŠJÃ.

722016. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒXƒgƒŒƒXƒ`ƒFƒbƒN‚ÌŒ»ó‚ƍ¡Œã‚̉ۑè. ’ç@–¾ƒ (ŒöO‰q¶): ‘æ28‰ñ“ú–{ŽY‹ÆƒXƒgƒŒƒXŠw‰ï (2020/12/4), WebŠJÃ.

723076. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ƒXƒgƒŒƒX‚ƐE–±•s–ž‘«‚Ì‘g‡‚¹‚ª’·ŠúŽ¾•a‹x‹Æ‚É‹y‚Ú‚·‰e‹¿: lŽ–‹L˜^‚É‚æ‚éc’fŒ¤‹†. ˆäã²b1, ‰Â’m—IŽq1, ]Œû@®1, “‡’Ö¾l, ìãŒ›l, ’ç@–¾ƒ1 (1ŒöO‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/5/14), ˆ®ì (Ž

723077. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Eê‚̃nƒ‰ƒXƒƒ“ƒg‚ÌŒoÏ‘¹Ž¸: Ž¾•a‹x‹ÆE˜J“­¶ŽY«E—£E‚ÌŠÏ“_‚©‚ç. ’Ö썁“Þ”ü, ìãŒ›l, ’ç@–¾ƒ1, “‡’Ö¾l, ˆäã²b1, ‹gì@“O, ¬“cØ—DŽq, ‰ºŒõ‹Pˆê (1ŒöO‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ.

723078. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽÐ‰ïŒoÏ“IŽw•W‚ƃAƒ‹ƒfƒXƒeƒƒ“‚Æ‚ÌŠÖ˜A: J-HOPEŒ¤‹†‚̉¡’f•ªÍ. ‰Â’m—IŽq1, ˆäã²b1, ]Œû@®1, ’ç@–¾ƒ1 (1ŒöO‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ.

723079. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽdŽ–‚Ì—v‹“xƒRƒ“ƒgƒ[ƒ‹ƒTƒ|[ƒgƒ‚ƒfƒ‹‹y‚Ñ“w—Í•ñV•s‹Ïtƒ‚ƒfƒ‹‚ÆHRQoL‚ÌŠÖ˜A. “ú‚Œ‹ˆß, ìãŒ›l, ¡‘ºK‘¾˜Y, ˆäã²b1, “‡’Ö¾l, ‹gì@“O, œA@®“T, óˆä—T”ü, ¬“cØ—DŽq, ‹gì‰xŽq, “n•Ó˜aL, ’ç@–¾ƒ1 (1ŒöO‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ.

723080. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ[ƒNƒGƒ“ƒQƒCƒWƒƒ“ƒg‚ÌŽdŽ–‚̃pƒtƒH[ƒ}ƒ“ƒX‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢ ]Œû@®1, ’ç@–¾ƒ1, ˆäã²b1, ‰Â’m—IŽq1, ‹{–؍Kˆê (1ŒöO‰q¶): ‘æ93‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2020/6/12-28), ŽãŠJÃEWebŠJÃ.

723081. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ}ƒ^ƒjƒeƒBƒnƒ‰ƒXƒƒ“ƒg‚Æ”DP’†‚Ì—}‚¤‚‚Ƃ̊֘A: VŒ^ƒRƒƒiƒEƒCƒ‹ƒX‹Ù‹}Ž–‘Ԑ錾‰º‚Å‚ÌŒŸ“¢. ‰Â’m—IŽq1, “¡Œ´•’j, ]Œû@®1, ˆäã²b1, ”nêKŽq, ‘¾“c@Š°1, ’ç@–¾ƒ1 (1ŒöO‰q¶): ‘æ36‰ñ“ú–{ƒXƒgƒŒƒXŠw‰ïŠwp‘‰ï (2020/10/24-25), WebŠJÃ.

723082. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž©•ÂÇ“Á«‚Æ‹Æ–±ƒpƒtƒH[ƒ}ƒ“ƒX‚Æ‚ÌŠÖ˜A‚ɑ΂·‚éŽdŽ–‚̃Rƒ“ƒgƒ[ƒ‹‚̏CüŒø‰Ê. ˆäã²b1, ]Œû@®1, ‰Â’m—IŽq1, ‹{–؍Kˆê, —é–Ø’mŽq, ’ç@–¾ƒ1 (1ŒöO‰q¶): ‘æ36‰ñ“ú–{ƒXƒgƒŒƒXŠw‰ïŠwp‘‰ï (2020/10/24-25), WebŠJÃ.

723083. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽžŠÔŠO˜J“­ŽžŠÔ‚Ɛ¸_“IŒ’N‚Æ‚ÌŠÖ˜A: 1”NŠÔ‚̏c’fŒ¤‹†. ˆäã—äŽq1, ’ç@–¾ƒ2, Šâ“c@¸, ˆäã²b2, ]Œû@®2, ‰Â’m—IŽq2, rˆä—L”ü3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ŒöO‰q¶, 3ˆã—Â̎¿EˆÀ‘S„iŽº): ‘æ30‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï‘S‘‹¦‹c‰ï (2020/11/22), WebŠJÃ.

723084. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ƒe‚̈玙ŽQ‰Á‚ð‘jŠQE‘£i‚·‚é—vˆö‚Ì’Tõ|“ñ\ˆê¢‹Io¶Ž™c’f’²¸‚æ‚è. ‰z’q^“Þ”ü, ‰Á“¡³•F, ‰Â’m—IŽq1, ’|Œ´Œ’“ñ (1ŒöO‰q¶): ‘æ31‰ñ“ú–{‰uŠw‰ïŠwp‘‰ï (2021/1/27-29), WebŠJÃ.

732002. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˜J“­ŽÒ‚̃XƒgƒŒƒX‚ÆŒ’N‘΍ô. ’ç@–¾ƒ (ŒöO‰q¶): ‰ß˜JŽ€“™–hŽ~‘΍ô„iƒVƒ“ƒ|ƒWƒEƒ€ (2020/11/11), “Œ‹ž.

732003. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒŠƒ‚[ƒgƒ[ƒN‚̉ۑè. ’ç@–¾ƒ (ŒöO‰q¶): ‰ß˜JŽ€“™–hŽ~‘΍ô„iƒVƒ“ƒ|ƒWƒEƒ€ (2020/11/16), ‘åã.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110003. [Œ´’˜] Reliability and validity of the Vietnamese version of the 9-item Utrecht Work Engagement Scale. Tran TTT, Watanabe K, Imamura K, Nguyen HT, Sasaki N, Kuribayashi K, Sakuraya A, Nguyen NT, Bui TM, Nguyen QT, Truong TQ, Nguyen GTH, Minas H, Tsustumi A1, Shimazu A, Kawakami N: J Occup Health 2020/1; 62 (1): e12157. (’ç@–¾ƒ1: 1ŒöO‰q¶)

'19-110004. [Œ´’˜] Effect of implementing an overwork-prevention act on working hours and overwork-related disease: A mediation analysis. Lin RT, Liang YW, Takahashi M, Eguchi H1, Tsutsumi A1, Lin SH: J Occup Health 2020/1; 62 (1): e12148. (]Œû@®1, ’ç@–¾ƒ1: 1ŒöO‰q¶)

'19-110005. [Œ´’˜] Socio-Economic Disparities in Early Childhood Education Enrollment: Japanese Population-Based Study. Kachi Y1, Kato T, Kawachi I: J Epidemiol 2020/3; 30 (3): 143-50. (‰Â’m—IŽq1: 1ŒöO‰q¶)

'19-522002. [uÀ]y“ÁW: “ÁW ŽY‹ÆƒXƒgƒŒƒX‚Ə­Žq‰»‘΍ôz“w—́|•ñV•s‹Ïtƒ‚ƒfƒ‹. ’ç@–¾ƒ (ŒöO‰q¶): ŽY‹ÆƒXƒgƒŒƒXŒ¤‹† 2019/4; 26 (2): 243-8.


–@ˆãŠw

[Šwp˜_•¶]

110078. [Œ´’˜] Circumstances and factors of sleep-related sudden infancy deaths in Japan. Osawa M, Ueno Y, Ikeda N, Ikematsu K, Yamamoto T, Irie W1, Kozawa S, Kotani H, Hamayasu H, Murase T, Shingu K, Sugimoto M, Nagao R, Kakimoto Y: PLoS One 2020/4; 15 (8): e0233253. (“ü]@Â1: 1–@ˆã)

110079. [Œ´’˜] Individual identification using the RapidHITTM ID system for forensic samples. Murakami C1, Wataru Irie W1, Sasaki C1, Nakamaru N2, Sakamoto M2, Nagato J2, Satoh F1: Leg Med (Tokyo) 2020/11; 47: 101776. (‘ºãçŽq1, “ü]@Â1, ²X–ؐçŽõŽq1, ’†ŠÛ®”ü2, ã–{“Žq2, ’·–參•½2, ²“¡•¶Žq1: 1–@ˆã, 2Œ`‘ÔŒn)

320001. [Ç—á•ñ] æ“V«Ò’Œ‘¤œ^Ç‚ð‡•¹‚µ‚½ƒ}ƒ‹ƒtƒ@ƒ“ÇŒóŒQ‚Ì—cŽ™–UŒŸ—á. ²“¡•¶Žq1, “ü]@Â1, ‘ºãçŽq1, ²X–ؐçŽõŽq1 (1–@ˆã): “ú–{SIDSE“û—cŽ™“Ë‘RŽ€—\–hŠw‰ïŽGŽ 2020/12; 20 (1): 37-42.

520004. [‘à] –@ˆã‰ð–UŽž‚É“¾‚½î•ñ‚ÉŠî‚­SUID‚ÌŽÀ‘ԂƊ‹«—vˆö‚Ì’²¸. ‘åàVŽ‘Ž÷1, ã–ìˆÕO2, ’r“c“Tº3, ’r¼˜aÆ4, ŽR–{‘ô–5, “ü]@Â6, ¬àVŽü“ñ7, ¬’J‘׈ê8 (1“ŒŠC‘åŠwˆãŠw•”Šî”Րf—ÊwŒn–@ˆãŠw, 2_ŒË‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È’nˆæŽÐ‰ïˆãŠwŒ’N‰ÈŠwuÀ–@ˆãŠw•ª–ì, 3‹ãB‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰@–@ˆãŠw•ª–ì, 4’·è‘åŠw‘åŠw‰@ˆãŽ•–òŠw‘‡Œ¤‹†‰Èˆã—ÉȊwêUŽÐ‰ïˆã—ÉȊwuÀ–@ˆãŠw•ª–ì, 5•ºŒÉˆã‰È‘åŠw–@ˆãŠwuÀ, 6–@ˆã, 7ŽOd‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰ÈŠî‘bˆãŠwŒnuÀ–@ˆã–@‰ÈŠw•ª–ì, 8‹ž“s‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È–@ˆãŠwuÀ): “ú–{SIDSE“û—cŽ™“Ë‘RŽ€—\–hŠw‰ïŽGŽ 2020/12; 20 (1): 1-5.

[Šw‰ïEŒ¤‹†‰ï“™]

723085. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) –@ˆã‰ð–UŽž‚É“¾‚½î•ñ‚ÉŠî‚­SUID‚ÌŽÀ‘ԂƊ‹«—vˆö‚Ì’²¸. ‘åàVŽ‘Ž÷1, ã–ìˆÕO2, ’r“c“Tº3, ’r¼˜aÆ4, ŽR–{‘ô–5, “ü]@Â6, ¬àVŽü“ñ7, ¬’J‘׈ê8 (1“ŒŠC‘åŠw, 2_ŒË‘åŠw, 3‹ãB‘åŠw, 4’·è‘åŠw, 5•ºŒÉˆã‰È‘åŠw, 6–@ˆã, 7ŽOd‘åŠw, 8‹ž“s‘åŠw): ‘æ26‰ñ“ú–{SIDSE“û—cŽ™“Ë‘RŽ€—\–hŠw‰ïŠwpW‰ï (2020/8/28), WebŠJÃ, ´˜^W p.26.

723086. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) LC-MS/MS‚É‚æ‚é17ŽíEƒÀŽó—e‘ÌŽÕ’f–ò‚̈êÄ•ªÍ–@‚ÌŠJ”­. “a‰ªŒbŽq1, Ž›“c@Œ«1, ²X–ؐçŽõŽq2, ²“¡•¶Žq2, ŽÂ’Ë’B—Y1 (1‰¡•l–ò‰È‘åŠw•a‘Ԑ¶—Šw, 2–@ˆã): ‘æ42‰ñ“ú–{’†“ÅŠw‰ï‘‰ïEŠwpW‰ï (2020/9/7), WebŠJÃ, ’†“ÅŒ¤‹†, 2020/9; 33 (2): 171.

723087. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) RapidHIT ID system‚ð—p‚¢‚½–@ˆãŠw“IŽŽ—¿‚É‚æ‚éŒÂlŽ¯•Ê‚Ì—L—p«‚ÌŒŸ“¢. ‘ºãçŽq1, “ü]@Â1, ²X–ؐçŽõŽq1, ’†ŠÛ®”ü2, ’·–參•½2, ˆäã“úØŽq3, ²“¡•¶Žq1 (1–@ˆã, 2Œ`‘ÔŒn, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ104ŽŸ“ú–{–@ˆãŠw‰ïŠwp‘S‘W‰ï (2020/9/24), ‹ž“s, “ú–{–@ˆãŠwŽGŽ 2020/8; 74 (1): 77.

723088. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) –¢f’f‚ÌŒ´”­¶S‘ŸŽîᇂɂæ‚é“ûŽ™“Ë‘RŽ€‚̈ê–UŒŸ—á. “ü]@Â1, ‘ºãçŽq1, ²X–ؐçŽõŽq1, ’†ŠÛ®”ü2, ã–{“Žq2, ’·–參•½2, ˆäã“úØŽq3, A“c‰]4, ²“¡•¶Žq1 (1–@ˆã, 2Œ`‘ÔŒn, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4‘—§zŠÂŠí•aŒ¤‹†ƒZƒ“ƒ^[•a—•”): ‘æ104ŽŸ“ú–{–@ˆãŠw‰ïŠwp‘S‘W‰ï (2020/9/25), ‹ž“s, “ú–{–@ˆãŠwŽGŽ 2020/8; 74 (1): 54.

723089. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒgƒŠƒJƒuƒg•ž—pŽ©ŽE—á‚É‚¨‚¯‚鐶‘ÌŽŽ—¿’†ƒAƒRƒjƒ`ƒ“—Þ‚ÌLC-MS/MS•ªÍ. ²X–ؐçŽõŽq1, ‘ºãçŽq1, “ü]@Â1, ’†ŠÛ®”ü2, ’·–參•½2, ˆäã“úØŽq3, ²“¡•¶Žq1 (1–@ˆã, 2Œ`‘ÔŒn, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ104ŽŸ“ú–{–@ˆãŠw‰ïŠwp‘S‘W‰ï (2020/9/25), ‹ž“s, “ú–{–@ˆãŠwŽGŽ 2020/8; 74 (1): 67.

723090. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “û—cŽ™“Ë‘RŽ€—á‚É‚¨‚¯‚é—\–hÚŽí—ð‚Ì’²¸. ‘åàVŽ‘Ž÷1, ’·”ö—ÁŽq1, Š_–{—R•z1, Š_“àNG1, ’؈äH’j1, ²“¡•¶Žq2 (1“ŒŠC‘åŠwˆãŠw•”Šî”Րf—ÊwŒn–@ˆãŠw, 2–@ˆã): ‘æ104ŽŸ“ú–{–@ˆãŠw‰ïŠwp‘S‘W‰ï (2020/9/25), ‹ž“s, “ú–{–@ˆãŠwŽGŽ 2020/8; 74 (1): 92.

733010. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ|ƒXƒ^[) ‹}«‘å“®–¬‰ð—£‚É‚¨‚¯‚é•a—‘gDŠw“IŒŸ“¢|“®–¬d‰»Ç‚Æ‚Ì”äŠr|. ˆäã“úØŽq1, ²“¡•¶Žq2, “ü]@Â2, ‘ºãçŽq2, ²X–ؐçŽõŽq2, ’†ŠÛ®”ü3, ’·–參•½3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–@ˆã, 3Œ`‘ÔŒn): ‘æ89‰ñ“ú–{–@ˆãŠw‰ïŠwpŠÖ“Œ’n•ûW‰ï (2020/10/10), “Œ‹ž, u‰‰—vŽ|W 2020/10; p.23.


ŽÀŒ±“®•¨Šw

[Šwp˜_•¶]

110080. [Œ´’˜] Effect of retinoic acid signaling on Ripply3 expression and pharyngeal arch morphogenesis in mouse embryos. Okubo T1, Hara K, Azuma S1, Takada S: Dev Dyn 2021/7; 250 (7): 1036-50. doi: 10.1002/dvdy.301. Epub 2021 Jan 25. (‘å‹v•Û’¼1, “Œ@’åG1: 1(ŽÀ“®)

110081. [Œ´’˜] Quantitative proteomic analysis and single-protein-derived tryptic peptide profiling indicate qualitative alterations of annexin A6 in the brain of wobbler mice. Nakamura M1, Mizutani K2, Kato K3, Konno R, Itakura M4, Kodera Y, Nishiyama K5, Sato T2: Kitasato Med J 2021/3; 50 (1): 76-83. (’†‘ºŠ²º1, …’J˜aŠ°2, ‰Á“¡—˜‰À3, ”‘q@½4, ¼ŽR˜a—˜5, ²“¡rÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ŽÀ“®, 3ˆâ“`Žq‰ðÍƒZ, 4¶‰», 5”]_Œo“à)

[Šw‰ïEŒ¤‹†‰ï“™]

733011. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‹ØˆÞk«‘¤õd‰»Çƒ‚ƒfƒ‹‚̍쐬‚ƉðÍ. ²“¡rÆ (ŽÀ“®): 2020”N“x”]Œ¤‹†Š‹¤“¯—˜—p‹¤“¯Œ¤‹† (ù‰ª”Ç) ‡“¯ƒZƒ~ƒi[ (2021/1/20), WebŠJÃ.


–ƉuŠw

[Šwp˜_•¶]

110082. [Œ´’˜] NF-ƒÈB-inducing kinase contributes to normal development of cortical thymic epithelial cells: its possible role in shaping a proper T-cell repertoire. Eshima K1, Misawa K, Ohashi C, Noma H, Iwabuchi K1: Immunology 2020/6; 160 (2): 198-208. (]“‡k“ñ1, ŠâŸº˜a–ç1: 1–Ɖu)

110083. [Œ´’˜] Attenuation of experimental autoimmune uveoretinitis in mice by IKKƒÀ inhibitor IMD-0354. Liu Y, Kitaichi N, Wu D, Hase K, Satoh M1, Iwata D, Namba K, Kanda A, Noda K, Itai A, Iwabuchi K1, Ishida S: Biochem Biophys Res Commun 2020/7; 525 (3): 589-94. (²“¡@‰ë1, ŠâŸº˜a–ç1: 1–Ɖu)

110084. [Œ´’˜] The protective function of invariant natural killer T cells in the relapse of experimental autoimmune uveoretinitis. Tajiri N1, Kato T1, Satoh M2, Iizuka M3, Taniguchi M, Kitaichi N, Iwabuchi K2: Exp Eye Res 2021/2; 203: 108406. (“cK‰ÄŠC1, ‰Á“¡‘¾Šì1, ²“¡@‰ë2, ”Ñ’Ë‚Ý‚³‚ð3, ŠâŸº˜a–ç2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–Ɖu, 3—\–hˆãŠwŒn)

522013. [uÀ]yƒx[ƒ`ƒFƒbƒg•a|Šî‘b‚ƗՏ°‚̍ŐV’mŒ©|zII. Šî‘bŒ¤‹†@5. ŽÀŒ±“IŽ©ŒÈ–Ɖu«‚Ô‚Ç‚¤–Œ‰Šƒ‚ƒfƒ‹‚̉ŠÇ§Œä. ŠâŸº˜a–ç1, “cK‰ÄŠC2, ‰Á“¡‘¾Šì2, ²“¡@‰ë1 (1–Ɖu, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): “ú–{—Õଠ2021/6; 79 (6): 843-9.

[Šw‰ïEŒ¤‹†‰ï“™]

723091. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) X˜A½«–«“÷‰èŽîÇƒ‚ƒfƒ‹gp91phoxknock-out mouse‚Ö‚Ì“÷‰èŽîŒ`¬—U“±‚ÆNOX2ˆË‘¶“I×–EŽ€‚ÌŠÖ˜A‚ɂ‚¢‚Ä. ’|“àŒb”üŽq1, ‘å’Á@^, ’|“àN—Y2 (1–Ɖu, 2t‘Ÿ“à): ‘æ48‰ñ“ú–{—Տ°–ƉuŠw‰ï‘‰ï (2020/10/16), WebŠJÃ.

733012. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‹¹‘B”玿ã”ç×–E‚Ì‹@”\‚É‚¨‚¯‚éNF-ƒÈB-inducing kinase‚ÌŠñ—^‚ɂ‚¢‚Ä. ]“‡k“ñ1, ŽOàV‰À“Þ, ŠâŸº˜a–ç1 (1–Ɖu): ‘æ40‰ñ“ú–{‹¹‘BŒ¤‹†‰ï (2021/2/6), WebŠJÃ.


’nˆæŽ™“¶¸_‰Èˆã—Êw


Ä¶ˆã—ÃŒ`¬ŠO‰ÈŠw


’nˆæ‘‡ˆã—Êw


‰ŠÇ«’°Ž¾Š³‹³ˆçE—Տ°Œ¤‹†Šw


¬Ž™|¬Ž™zŠÂŠí’nˆæˆã—Êw


Á‰»Ší“à‰ÈŠw

[Šwp˜_•¶]

110085. [Œ´’˜] A retrospective study of definitive chemoradiotherapy in patients with resectable small cell neuroendocrine carcinoma of the esophagus. Katada C1, Komori S2, Yoshida T3, Kawakami S2, Watanabe A1, Ishido K1, Azuma M1, Wada T1, Hosoda K4,, Yamashita K4,5, Hiki N4,, Tanabe S1,6, Ishiyama H2, Koizumi W1: Esophagus 2020/4; 17 (2): 135-40. (Œ˜“ce—˜1, ¬X³Žq2, ‹g“c@Œ÷3, ìã³Œå2, “n糍WŽ¯1, ÎŒËŒªŽŸ1, “Œ@’q1, ˜a“c‘ñ–ç1 ×“c@Œj4, ŽR‰ºŒpŽj4,5, ”äŠé’¼Ž÷4,, “c糁@‘1,6, ÎŽR”ŽžŠ2, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2•úŽËü (Žîá‡), 3•a—, 4,ã•”Á‰»ŠÇŠO, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 6V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110086. [Œ´’˜] Association between macrocytosis and metachronous squamous cell carcinoma of the esophagus after endoscopic resection in men with early esophageal squamous cell carcinoma. Katada C1, Yokoyama T, Yano T, Oda I, Shimizu Y, Doyama H, Koike T, Takizawa K, Hirao M, Okada H, Yoshii T, Kubota Y, Yamanouchi T, Tsuda T, Omori T, Kobayashi N, Suzuki H, Tanabe S1,2, Hori K, Nakayama N1, Kawakubo H, Kakushima N, Matsuo Y, Ishikawa H, Yokoyama A, Muto M: Esophagus 2020/4; 17 (2): 149-58. (Œ˜“ce—˜1, “c糁@‘1,2, ’†ŽR¸“T1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110087. [Œ´’˜] Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Uojima H1, Chuma M, Tanaka Y1, Hidaka H1, Nakazawa T1, Iwabuchi S, Kobayashi S, Hattori N, Ogushi K, Morimoto M, Kagawa T, Tanaka K, Kako M, Koizumi W1: Liver Cancer 2020/4; 9 (2): 193-206. (‹›“ˆ°‹I1, “c’†Œ«–¾1 “ú‚@‰›1, ’†àV‹MG1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à)

110088. [Œ´’˜] Multicenter database registry for endoscopic retrograde cholangiopancreatography: Japan Endoscopic Database Project. Kato M1, Tanaka K1,2, Kida M1,3, Ryozawa S1, Matsuda K1,2, Fujishiro M1,2, Saito Y1,2, Ohtsuka K1, Oda I1, Katada C1,3, Kobayashi K1,3,4, Hoteya S1, Horimatsu T1, Kodashima S1, Matsuda T1, Muto M1, Yamamoto H1, Iwakiri R2, Kutsumi H2, Miyata H2, Kato M2, Haruma K2, Fujimoto K2, Uemura N2, Kaminishi M2, Tajiri H2 (1Minimal Standard Endoscopic Database (MSED-J) Creation Subcommittee, Japan Gastroenterological Endoscopy Society, 2Japan Endoscopy Database (JED) Project Committee, Japan Gastroenterological Endoscopy Society): Dig Endosc 2020/5; 32 (4): 494-502. (–Ø“cŒõL1,3, Œ˜“ce—˜1,3, ¬—ѐ´“T1,3,4: 3Á‰»Ší“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110089. [Œ´’˜] Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H1, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T: J Gastroenterol Hepatol 2020/5; 35 (5): 855-61. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

110090. [Œ´’˜] Diagnostic efficacy of white core cutoff lengths obtained by EUS-guided fine-needle biopsy using a novel 22G franseen biopsy needle and sample isolation processing by stereomicroscopy for subepithelial lesions. Okuwaki K1, Masutani H2, Kida M1, Yamauchi H1, Iwai T1, Miyata E1, Hasegawa R1, Kaneko T1, Imaizumi H1, Watanabe M1, Kurosu T1, Tadehara M2, Adachi K2, Tamaki A2, Koizumi W1: Endosc Ultrasound 2020/5-6; 9 (3): 187-92. (‰œ˜e‹»‰î1, ¡’JŠ°ˆÈ2, –Ø“cŒõL1, ŽR“à_Žj1, Šâˆä’m‹v1, ‹{“c‰pŽ¡1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ¡ò@O1, “n•Ó^ˆè1, •{‹M_1, äøŒ´«—Ç2, ˆÀ’B@‰õ2, ‹Ê’u–¾Š°2, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110091. [Œ´’˜] Usefulness of argon plasma coagulation for superficial esophageal squamous cell neoplasia in patients at high risk or with limited endoscopic resectability. Kubota Y1, Tanabe S2,3, Ishido K3, Yano T3, Wada T3, Watanabe A3, Azuma M3, Katada C3, Koizumi W3: Turk J Gastroenterol 2020/7; 31 (7): 529-37. (‹v•Û“c—z1, “c糁@‘2,3, ÎŒËŒªŽŸ3, –î–ì‹MŽj3, ˜a“c‘ñ–ç3, “n糍WŽ¯3, “Œ@’q3, Œ˜“ce—˜3, ¬ò˜aŽO˜Y3: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3Á‰»Ší“à)

110092. [Œ´’˜] Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. Atsukawa M, Tsubota A, Takaguchi K, Toyoda H, Iwasa M, Ikegami T, Chuma M, Nozaki A, Uojima H1, Hiraoka A, Fukunishi S, Yokohama K, Tada T, Kato K, Abe H, Tani J, Okubo H, Watanabe T, Hattori N, Tsutsui A, Senoh T, Yoshida Y, Okubo T, Itokawa N, Nakagawa-Iwashita A, Kondo C, Arai T, Michitaka K, Iio E, Kumada T, Tanaka Y, Takei Y, Iwakiri K: J Gastroenterol Hepatol 2020/7; 35 (7): 1229-37. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

110093. [Œ´’˜] Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan. Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H1, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T: J Gastroenterol Hepatol 2020/8; 35 (8): 1420-5. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

110094. [Œ´’˜] The Alcohol Use Disorders Identification Test and the risk of metachronous cancer after endoscopic resection of esophageal cancer. Yokoyama A, Katada C1, Yokoyama T, Takizawa K, Yano T, Oda I, Shimizu Y, Nakanishi H, Koike T, Hirao M, Okada H, Yoshii T, Katagiri A, Yamanouchi T, Matsuo Y, Kawakubo H, Kobayashi N, Ishikawa H, Muto M: Carcinogenesis 2020/8; 41 (8): 1049-56. (Œ˜“ce—˜1: 1Á‰»Ší“à)

110095. [Œ´’˜] Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study. Hidaka H1, Uojima H1, Nakazawa T1, Shao X, Hara Y1, Iwasaki S1, Wada N1, Kubota K1, Tanaka Y1, Shibuya A1, Kanoh Y2, Kokubu S1, Koizumi W1: Hepatol Res 2020/9; 50 (9): 1083-90. (“ú‚@‰›1, ‹›“ˆ°‹I1, ’†àV‹MG1, Œ´@—E•ã1, ŠâèGˆê˜Y1, ˜a“c®‹v1, ŒE“cK‰î1, “c’†Œ«–¾1, a’J–¾—²1, Žë–ì—Lì2, š •ª–ΔŽ1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2—ÕŒŸŠw)

110096. [Œ´’˜] Effectiveness of planned surveillance for detecting second primary head and neck cancers after endoscopic resection of esophageal squamous cell carcinoma. Shinozaki T, Katada C1, Shiga K, Asakage T, Yokoyama T, Yano T, Oda I, Shimizu Y, Takemura K, Ishikawa H, Yokoyama A, Muto M: Jpn J Clin Oncol 2020/9; 50 (10): 1162-7. (Œ˜“ce—˜1: 1Á‰»Ší“à)

110097. [Œ´’˜] An international, multi-institution survey on performing EUS-FNA and fine needle biopsy. Guo J, Sahai AV, Teoh A, Arcidiacono PG, Larghi A, Saftoiu A, Siddiqui AA, Arturo Arias BL, Jenssen C, Adler DG, Lakhtakia S, Seo D-W, Itokawa F, Giovannini M, Mishra G, Sabbagh L, Irisawa A, Iglesias-Garcia J, Poley JW, Vila JJ, Jesse L, Kubota K, Kalaitzakis E, Kida M1, El-Nady M, Mukai SU, Ogura T, Fusaroli P, Vilmann P, Rai P, Nguyen NQ, Ponnudurai R, Achanta CR, Baron TH, Yasuda I, Wang H-P, Hu J, Duan B, Bhutani MS, Sun S: Endosc Ultrasound 2020/9-10; 9 (5): 319-28. (–Ø“cŒõL1: 1Á‰»Ší“à)

110098. [Œ´’˜] Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis. Ogushi K, Chuma M, Uojima H1, Hidaka H1, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T1, Wada N1, Iwasaki S1, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S: Clin Exp Gastroenterol 2020/10; 13: 385-96. (‹›“ˆ°‹I1, “ú‚@‰›1, ’†àV‹MG1, ˜a“c®‹v1, ŠâèGˆê˜Y1: 1Á‰»Ší“à)

110099. [Œ´’˜] Endoscopic ultrasound-guided tissue acquisition with or without macroscopic on-site evaluation: randomized controlled trial. Chong CCN, Lakhtakia S, Nguyen N, Hara K, Chan WK, Puri R, Almadi MA, Ang TL, Kwek A, Yasuda I, Doi S, Kida M1, Wang H-P, Cheng T-Y, Jiang Q, Yang A, Chan AWH, Chan S, Tang R, Iwashita T, Teoh AYB: Endoscopy 2020/10; 52 (10): 856-63. (–Ø“cŒõL1: 1Á‰»Ší“à)

110100. [Œ´’˜] Long-term observation in patients with esophageal varices after endoscopic variceal ligation accompanied with 24-hour pH monitoring. Hidaka H1, Tanabe S1,2, Uojima H1, Shao X, Iwasaki S1, Wada N1, Kubota K1, Tanaka Y1, Nakazawa T1, Shibuya A1, Kokubu S1, Koizumi W1: Hepatol Res 2020/11; 50 (11): 1255-63. (“ú‚@‰›1, “c糁@‘1,2, ‹›“ˆ°‹I1, ŠâèGˆê˜Y1, ˜a“c®‹v1, ŒE“cK‰î1, “c’†Œ«–¾1, ’†àV‹MG1, a’J–¾—²1, š •ª–ΔŽ1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110101. [Œ´’˜] Long-term outcome of endoscopic resection for intramucosal esophageal squamous cell cancer: a secondary analysis of the Japan Esophageal Cohort study. Oda I, Shimizu Y, Yoshio T, Katada C1, Yokoyama T, Yano T, Suzuki H, Abiko S, Takemura K, Koike T, Takizawa K, Hirao M, Okada H, Yoshii T, Katagiri A, Yamanouchi T, Matsuo Y, Kawakubo H, Kobayashi N, Shimoda T, Ochiai A, Ishikawa H, Yokoyama A, Muto M: Endoscopy 2020/11; 52 (11): 967-75. (Œ˜“ce—˜1: 1Á‰»Ší“à)

110102. [Œ´’˜] Optimal extent of lymph node dissection for remnant advanced gastric carcinoma after distal gastrectomy: a retrospective analysis of more than 3000 patients from the nationwide registry of the Japanese Gastric Cancer Association. Katai H1, Ishikawa T1, Akazawa K1, Fukagawa T1, Isobe Y1, Miyashiro I1, Oda I1, Tsujitani S1, Ono H1, Tanabe S1,2,3, Nunobe S1, Suzuki S1, Kakeji Y1 (1Registration Committee of the Japanese Gastric Cancer Association): Gastric Cancer 2020/11; 23 (6): 1091-101. (“c糁@‘1,2,3: 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3Á‰»Ší“à)

110103. [Œ´’˜] Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B. Itokawa N, Atsukawa M, Tsubota A, Takaguchi K, Nakamuta M, Hiraoka A, Kato K, Abe H, Mikami S, Shimada N, Chuma M, Nozaki A, Uojima H1, Ogawa C, Asano T, Tani J, Morishita A, Senoh T, Yamashita N, Oikawa T, Matsumoto Y, Koeda M, Yoshida Y, Tanabe T, Okubo T, Arai T, Hayama K, Iwashita-Nakagawa A, Kondo C, Tada T, Toyoda H, Kumada T, Iwakiri K: JGH Open 2020/11; 5 (1): 34-40. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

110104. [Œ´’˜] Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: the Japan Polyp Study Workgroup. Matsuda T, Fujii T, Sano Y, Kudo S, Oda Y, Hotta K, Shimoda T, Saito Y, Kobayashi N, Sekiguchi M, Konishi K, Ikematsu H, Iishi H, Takeuchi Y, Igarashi M, Kobayashi K1, Sada M1, Yamaguchi Y, Hasuda K, Shinohara T, Ishikawa H, Murakami Y, Taniguchi H, Fujimori T, Ajioka Y, Yoshida S: Gut 2020/11; 70 (8): 1469-78. (¬—ѐ´“T1, ²“c”ü˜a1: 1Á‰»Ší“à)

110105. [Œ´’˜] Cholecystitis after Placement of Covered Self-Expandable Metallic Stents in Patients with Distal Malignant Biliary Obstructions. Watanabe M1, Okuwaki K1, Woo J, Kida M1, Imaizumi H1, Iwai T1, Yamauchi H1, Kaneko T1, Hasegawa R1, Kurosu T1, Minato N1, Haradome H2,3, Koizumi W1: Clin Endosc 2021/7; 54 (4): 589-95. doi: 10.5946/ce.2020.136. Epub 2020 Nov 17. (“n•Ó^ˆè1, ‰œ˜e‹»‰î1, –Ø“cŒõL1, ¡ò@O1, Šâˆä’m‹v1, ŽR“à_Žj1, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, •{‹M_1, –©@®‹M1, Œ´—¯OŽ÷2,3, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3•úŽËü (‰æ‘œ))

110106. [Œ´’˜] Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Atsukawa M1, Tsubota A1, Kondo C1, Toyoda H1, Nakamuta M1, Takaguchi K1, Watanabe T1, Hiraoka A1, Uojima H1,2, Ishikawa T1, Iwasa M1, Tada T1, Nozaki A1, Chuma M1, Fukunishi S1, Asai A1, Asano T1, Ogawa C1, Abe H1, Hotta N1, Shima T1, Iio E1, Mikami S1, Tachi Y1, Fujioka S1, Okubo H1, Shimada N1, Tani J1, Hidaka I1, Moriya A1, Tsuji K1, Akahane T1, Yamashita N1, Okubo T1, Arai T1, Morita K1, Kawata K1, Tanaka Y1, Okanoue T1, Maeda S1, Kumada T1, Iwakiri K1 (1KTK49 Liver Study Group): Infect Dis Ther 2020/12; 9 (4): 851-66. (‹›“ˆ°‹I1,2: 2Á‰»Ší“à)

110033. [Œ´’˜] Platelets prevent the development of monocrotaline-induced liver injury in mice. Otaka F1, Ito Y2, Goto T1, Eshima K3, Amano H2, Koizumi W4, Majima M2: Toxicol Lett 2020/12; 335: 71-81. (‘卂Žj¹1, ˆÉ“¡‹`–ç2, Œã“¡‘ì–ç1, ]“‡k“ñ3, “V–ì‰pŽ÷2, ¬ò˜aŽO˜Y4, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3–Ɖu, 4Á‰»Ší“à)

110107. [Œ´’˜] Near-focus magnification and second-generation narrow-band imaging for early gastric cancer in a randomized trial. Kakushima N, Yoshida N, Doyama H, Yano T, Horimatsu T, Uedo N, Yamamoto Y, Kanzaki H, Hori S, Yao K, Oda I, Tanabe S1,2, Yokoi C, Ohata K, Yoshimura K, Ishikawa H, Muto M: J Gastroenterol 2020/12; 55 (12): 1127-37. (“c糁@‘1,2: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2Á‰»Ší“à)

110108. [Œ´’˜] Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Matsumoto T1, Okuwaki K1, Imaizumi H1, Kida M1,2, Iwai T1, Yamauchi H1, Kaneko T1, Hasegawa R1, Masutani H3, Tadehara M3, Adachi K3, Watanabe M1, Kurosu T1, Tamaki A3, Kikuchi H1, Ohno T1, Koizumi W1: Dig Dis Sci 2021/1. doi: 10.1007/s10620-020-06782-6. Online ahead of print. (¼–{‚–¾1, ‰œ˜e‹»‰î1, ¡ò@O1, –Ø“cŒõL1,2, Šâˆä’m‹v1, ŽR“à_Žj1, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ¡’JŠ°ˆÈ3, äøŒ´«—Ç3, ˆÀ’B@‰õ3, “n•Ó^ˆè1, •{‹M_1, ‹Ê’u–¾Š°3, ‹e’nG•F1, ‘å–ì@—²1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110109. [Œ´’˜] EUS-guided transanastomotic drainage for severe biliopancreatic anastomotic stricture using a forward-viewing echoendoscope in patients with surgically altered anatomy. Iwai T1, Kida M1, Yamauchi H1, Okuwaki K1, Kaneko T1, Hasegawa R1, Watanabe M1, Kurosu T1, Imaizumi H1, Koizumi W1: Endosc Ultrasound 2021/1-2; 10 (1): 33-8. (Šâˆä’m‹v1, –Ø“cŒõL1, ŽR“à_Žj1, ‰œ˜e‹»‰î1, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, “n•Ó^ˆè1, •{‹M_1, ¡ò@O1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à)

110110. [Œ´’˜] Comparison of the reproducibility of endoscopic scores in patients with ulcerative colitis: MES, UCEIS, and EAI scores. Kawagishi K1, Yokoyama K1, Kobayashi K1,2, Koizumi W1: Kitasato Med J 2021/3; 51 (1): 1-9. (ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ¬—ѐ´“T1,2, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110111. [Œ´’˜] Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging. Yoshida N, Doyama H, Yano T, Horimatsu T, Uedo N, Yamamoto Y, Kakushima N, Kanzaki H, Hori S, Yao K, Oda I, Katada C1, Yokoi C, Ohata K, Yoshimura K, Ishikawa H, Muto M: Gut 2021/1; 70 (1): 67-75. (Œ˜“ce—˜1: 1Á‰»Ší“à)

110112. [Œ´’˜] A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. Katada C1, Sugawara M2, Hara H, Fujii H, Eguchi -Nakajima T, Ando T, Kojima T, Watanabe A1, Sakamoto Y, Ishikawa H, Hosokawa A, Hamamoto Y, Muto M, Tahara M, Koizumi W1: Jpn J Clin Oncol 2021/2; 51 (2): 199-204. (Œ˜“ce—˜1, ›Œ´[L2, “n糍WŽ¯1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–òÜ•”)

110113. [Œ´’˜] Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Watanabe C, Nagahori M, Fujii T, Yokoyama K1, Yoshimura N, Kobayashi T2,3, Yamagami H, Kitamura K, Takashi K, Nakamura S, Naganuma M, Ishihara S, Esaki M, Yonezawa M, Kunisaki R, Sakuraba A, Kuji N, Miura S, Hibi T2,3, Suzuki Y, Hokari R: Dig Dis Sci 2021/2; 66 (2): 577-86. (‰¡ŽR@ŒO1, ¬—с@‘ñ2,3, “ú”ä‹I•¶2,3: 1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110114. [Œ´’˜] Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Chuma M, Uojima H1, Hiraoka A, Kobayashi S, Toyoda H, Tada T, Hidaka H1, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouso K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S: Hepatol Res 2021/2; 51 (2): 201-15. (‹›“ˆ°‹I1, “ú‚@‰›1: 1Á‰»Ší“à)

110115. [Œ´’˜] Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. Fujitani K, Shitara K, Takashima A, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Hosaka H, Komatsu Y, Shimada K, Kawabata R, Ohdan H, Kodera Y, Nakamura M, Eguchi-Nakajima T, Miyata Y, Moriwaki T, Kusumoto T, Nishikawa K, Ogata K, Shimura M, Morita S, Koizumi W1: Gastric Cancer 2021/3; 24 (2): 467-76. (¬ò˜aŽO˜Y1: 1Á‰»Ší“à)

110116. [Œ´’˜] A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010). Takizawa K1, Ono H1, Hasuike N1, Takashima A1, Minashi K1, Boku N1, Kushima R1, Katayama H1, Ogawa G1, Fukuda H1, Fujisaki J1, Oda I1, Yano T1, Hori S1, Doyama H1, Hirasawa K1, Yamamoto Y1, Ishihara R1, Tanabe S1,2,3, Niwa Y1, Nakagawa M1, Terashima M1, Muto M1 (1Gastrointestinal Endoscopy Group (GIESG) and the Stomach Cancer Study Group (SCSG) of Japan Clinical Oncology Group): Gastric Cancer 2021/3; 24 (2): 479-91. (“c糁@‘1,2,3: 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3Á‰»Ší“à)

110117. [Œ´’˜] Current status of diagnostic and therapeutic colonoscopy in Japan: The Japan Endoscopic Database Project. Saito Y1,2, Kodashima S1, Matsuda T1, Matsuda K1,2, Fujishiro M1,2, Tanaka K1,2, Kobayashi K1,3,4, Katada C1,4, Horimatsu T1, Muto M1, Ohtsuka K1, Oda I1, Kato M1, Kida M1,4,5, Hoteya S1, Yamamoto H1, Ryozawa S1, Iwakiri R2, Kutsumi H2, Kato M2, Haruma K2, Fujimoto K2, Iishi H2, Ogata H2, Uemura N2, Kaminishi M2, Tajiri H2, Inoue H2 (1MSED-J (Minimal Standard Endoscopic Database) Creation Subcommittee, Japan Gastroenterological Endoscopy Society, 2JED (Japan Endoscopy Database) Project Committee, Japan Gastroenterological Endoscopy Society): Dig Endosc 2021/3. doi: 10.1111/den.13980. Online ahead of print. (¬—ѐ´“T1,3,4, Œ˜“ce—˜1,4, –Ø“cŒõL1,4,5: 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4Á‰»Ší“à, 5–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110118. [Œ´’˜] Cholecystitis after Placement of Covered Self-Expandable Metallic Stents in Patients with Distal Malignant Biliary Obstructions. Watanabe M1, Okuwaki K1, Woo J, Kida M1, Imaizumi H1, Iwai T1, Yamauchi H1, Kaneko T1, Hasegawa R1, Kurosu T1, Minato N1, Haradome H2,3, Koizumi W1: Clin Endosc 2021/7; 54 (4): 589-95. doi: 10.5946/ce.2020.136. Epub 2020 Nov 17. (“n•Ó^ˆè1, ‰œ˜e‹»‰î1, –Ø“cŒõL1, ¡ò@O1, Šâˆä’m‹v1, ŽR“à_Žj1, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, •{‹M_1, –©@®‹M1, Œ´—¯OŽ÷2,3, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3•úŽËü (‰æ‘œ))

120006. [Œ´’˜] ‘å’°ŒeŽºoŒŒ‚ɑ΂·‚é“àŽ‹‹¾“IŽ~ŒŒ–@‚ÌŽ¡—ЬÑ. ìŠÝ‰Á“Þ1, ¬—ѐ´“T1,2, ‹ààV@1, âV“¡—FÆ1, ¼–{ˆçG1, •Êác•üL1, Œ}@”üK1, ‰¡ŽR@ŒO1, ²“c”ü˜a1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): Progress of Digestive Endoscopy 2020/6; 96 (1): 30-4.

210001. [€Œ´’˜ (Research Letter)] Protein Kinase D1 (PKD1) Signaling Induces Growth-Promoting Effects in Murine Enteroids. Shimizu Y1, Sinnett-Smith J, Tenggara M, Martin MG, Rozengurt E: Cell Mol Gastroenterol Hepatol 2020/10; 10 (2): 430-3.e9. (´…—T‹M1: 1Á‰»Ší“à)

310002. [Ç—á•ñ] Successful Hemostasis Using an Over-the-scope Clip for a Dieulafoy's Lesion in the Greater Curvature of the Fundus. Kubota Y1, Yamauchi H2, Nakatani K3, Tanabe S2,4, Koizumi W2: Endoscopy 2020/5; 52 (5): E164-5. (‹v•Û“c—z1, ŽR“à_Žj2, ’†’JŒ¤“l3, “c糁@‘2,4, ¬ò˜aŽO˜Y2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Á‰»Ší“à, 3‹~–½, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã)

310003. [Ç—á•ñ] Pancreatic pseudocyst-portal vein fistula: a case treated with EUS-guided cyst-drainage and a review of the literature. Masuda S, Koizumi K, Uojima H1, Tazawa T, Kimura K, Nishino T, Tasaki J, Ichita C, Sasaki A, Egashira H, Kako M: Clin J Gastroenterol 2020/8; 13 (4): 597-606. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

310004. [Ç—á•ñ] Multiple gastrointestinal metastasis after endoscopic submucosal dissection for poorly differentiated gastric adenocarcinoma. Kubota Y1, Katada C2, Yoshida T3, Wada T2, Hosoda K4, Kawakami S5, Ishido K2, Watanabe A2, Yamashita K4,6, Ishiyama H5, Hiki N4, Tanabe S2,7, Koizumi W2: Clin J Gastroenterol 2020/10; 13 (5): 717-21. (‹v•Û“c—z1, Œ˜“ce—˜2, ‹g“c@Œ÷3, ˜a“c‘ñ–ç2, ×“c@Œj4, ìã³Œå5, ÎŒËŒªŽŸ2, “n糍WŽ¯2, ŽR‰ºŒpŽj4,6, ÎŽR”ŽžŠ5, ”äŠé’¼Ž÷4, “c糁@‘2,7, ¬ò˜aŽO˜Y2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Á‰»Ší“à, 3•a—, 4ã•”Á‰»ŠÇŠO, 5•úŽËü (Žîá‡), 6V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 7V¢‹Iˆã—ÁEæ’[ˆã—Ã)

310005. [Ç—á•ñ] Barrett's Esophageal Adenocarcinoma Involving a White Globe Appearance within the Long-Segment Barrett's Esophagus. Kubota Y1, Tanabe S2,3, Harada Y3, Nakatani S3, Furue Y3, Wada T3, Watanabe A3, Ishido K3, Katada C3, Koizumi W3: Case Rep Gastroenterol 2020/10; 14 (3): 510-5. (‹v•Û“c—z1, “c糁@‘2,3, Œ´“c—m•½3, ’†’JªŒá3, ŒÃ]N–¾3, ˜a“c‘ñ–ç3, “n糍WŽ¯3, ÎŒËŒªŽŸ3, Œ˜“ce—˜3, ¬ò˜aŽO˜Y3: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3Á‰»Ší“à)

310006. [Ç—á•ñ] Undifferentiated Embryonal Sarcoma of the Liver Identified after the Initial Diagnosis of a Hepatic Cyst. Manabe Y1, Uojima H1, Hidaka H1, Shao X, Iwasaki S1, Wada N1, Kubota K1, Tanaka Y1, Nakazawa T1, Shibuya A1, Ichinoe M2, Kumamoto Y3, Kaizu T3, Koizumi W1: Intern Med 2020/10; 59 (19): 2375-82. (áÁ•”—Dì1, ‹›“ˆ°‹I1, “ú‚@‰›1, ŠâèGˆê˜Y1, ˜a“c®‹v1, ŒE“cK‰î1, “c’†Œ«–¾1, ’†àV‹MG1, a’J–¾—²1, ˆêŒË¹–¾2, ŒGŒ³—Y‰î3, ŠC’ËMŽj3, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2•a—, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO)

310007. [Ç—á•ñ] Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy. Masuda S, Koizumi K, Moriya H, Nishino T, Uojima H1, Tazawa T, Kimura K, Tasaki J, Ichita C, Sasaki A, Kako M, Hidaka S, Kudo M: Intern Med 2021/1; 60 (2): 251-7. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

520005. [‘à] ‘å’°Žîᇂɑ΂·‚é“àŽ‹‹¾f’f‚̐i•à|‘Šú‘å’°Šà‚𒆐S‚Ɂ|. ¬—ѐ´“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): –k—¢ˆãŠw 2020/6; 50 (1): 1-8.

522014. [uÀ]y“ÁW: H“¹Ž¾Š³‚ɑ΂·‚éÅV‚Ì“àŽ‹‹¾f’f‚ÆŽ¡—Áz3-1. ˆô“ª•\ÝŠà‚ɑ΂·‚é“àŽ‹‹¾f’f. Œ˜“ce—˜1, ‰Á”[Fˆê2, ×–ì_Žj2, ˆêŒË¹–¾3, ŽR‰º@‘ñ2, “c糁@‘1,4, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2Ž¨•@ˆôAE“ªèò•”, 3•a—, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã): Á‰»Ší“à‰È 2020/5; 2 (6): 69-75.

522015. [uÀ]y“ÁW: ŠF‚Őf‚é! IBD: ‘½EŽí˜AŒg‚Æ’nˆæˆã—Áz‘½EŽí˜AŒg|ŠCŠO‚ÌŽÀ‘ԁ|. ‰¡ŽR@ŒO (Á‰»Ší“à): IBD Ressearch 2020/6; 14 (2): 101-6.

522016. [uÀ]y˜AÚ: ŒŸ¸’l‚Ì“Ç‚Ý•ûzƒTƒ‰ƒ]ƒXƒ‹ƒtƒ@ƒsƒŠƒWƒ“•ž—pŒã‚É”­¶‚µ‚½2•ô«‚̊̏áŠQ‚Ì1—á. ‹›“ˆ°‹I1, “ú‚@‰›1, “c’†Œ«–¾1, ”’ˆä‹ž”ü2 (1Á‰»Ší“à, 2”畆): —ÕଏÁ‰»Ší“à‰È 2020/6; 35 (6): 655-60.

522017. [uÀ]y“ÁW: \“ñŽw’°‚Í‚±‚¤f‚éz1. \“ñŽw’°‚Ö‚Ì“àŽ‹‹¾‘}“ü‚ÆŠÏŽ@‚ÌŽÀÛ@[Še˜_] ’´‰¹”g“àŽ‹‹¾‚É‚æ‚é\“ñŽw’°•a•Ï‚̐f’f. Šâˆä’m‹v1, –Ø“cŒõL1, ‰œ˜e‹»‰î1, ŽR“à_Žj1, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, äøŒ´«—Ç2, ˆÀ’B@‰õ2, “n•Ó^ˆè1, •{‹M_1, ¡ò@O1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): Á‰»Ší“àŽ‹‹¾ 2020/7; 32 (7): 971-80.

522018. [uÀ]y“ÁW: ‚±‚êˆêû‚Å‚·‚ׂĂ킩‚éÁ‰»Ší’´‰¹”gŒŸ¸z4-2-2-c ‘æIVÍ Á‰»ŠÇ’´‰¹”gŒŸ¸@2. ’´‰¹”g“àŽ‹‹¾ŒŸ¸@…AÁ‰»ŠÇã”琫Žîᇂ̐[’B“xf@c. ‘å’°Šà‚̐[’B“xf’f. ¬—ѐ´“T1,2, ìŠÝ‰Á“Þ2, Œ}@”üK2, ‰¡ŽR@ŒO2, ²“c”ü˜a2,¬ò˜aŽO˜Y2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): —ÕଏÁ‰»Ší“à‰È 2020/8; 35 (9): 244-9.

522019. [uÀ]y“ÁW: –«äX‰Š|ƒKƒCƒhƒ‰ƒCƒ“‰ü’ù‚ÉŒü‚¯‚āz6-3. –«äX‰Š‚ÌŽ¡—Á@(3) ‰¼«ùN–EE’_ŠÇ‹·ó‚Ì“àŽ‹‹¾Ž¡—Ã. Šâˆä’m‹v1, –Ø“cŒõL1, ‰œ˜e‹»‰î1, ŽR“à_Žj1, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, äøŒ´«—Ç2, ˆÀ’B@‰õ2, ¡ò@O1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): —ÕଏÁ‰»Ší“à‰È 2020/10; 35 (11): 1369-76.

522020. [uÀ]y“ÁW: ŠÌd•Ï‚̃g[ƒ^ƒ‹ƒ}ƒlƒWƒƒ“ƒgz8) –å–¬ŒŒðÇ‚ɑ΂·‚éf’f‚ÆŽ¡—Ã. “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰»Ší“à): ŠÌ‘ŸƒNƒ‹ƒjƒJƒ‹ƒAƒbƒvƒf[ƒg 2020/10; 6 (2): 181-6.

522021. [uÀ]y“ÁW: i‰»‚·‚éEUSz2. Ž¡—ÓIEUS@[Še˜_] EUS‰ºäX‰¼«ùN–EƒhƒŒƒi[ƒW. Šâˆä’m‹v1, –Ø“cŒõL1, ‰œ˜e‹»‰î1, ŽR“à_Žj1, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, äøŒ´«—Ç2, ˆÀ’B@‰õ2, ¡ò@O1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): Á‰»Ší“àŽ‹‹¾ 2020/11 32 (11): 1701-6.

522022. [uÀ]yŽå‘èII: ‘å’°NET@f’f‚ÆŽ¡—Â̍őOüzI. ‘å’°NETf’f‚Ìup-to-date. ¬—ѐ´“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): “ú–{‘å’°ãè–å•aŠw‰ïŽGŽ 2020/11; 73 (10): 442-51.

522023. [uÀ]yÀ’k‰ïzwŠÌd•Ïf—ÃKƒCƒhƒ‰ƒCƒ“2020x‚̃|ƒCƒ“ƒg. ‹gŽ¡mŽu, “ú‚@‰›1, ã–ì‹`”V, ´…‰ëm, ’J‡–ƒ‹IŽq (1Á‰»Ší“à): “ú–{Á‰»Ší•aŠw‰ïŽGŽ 2021/1; 118 (1): 46-54.

522024. [uÀ]y“ÁWI: ŠÌd•Ïf—ÃKƒCƒhƒ‰ƒCƒ“‚̉ü³‚ð‚ß‚®‚Á‚āz–å–¬ˆ³˜´iÇ (H“¹‚¨‚æ‚шݐÖ¬áŽ) ‚ÌŽ¡—Ã. “ú‚@‰›1, ‹›“ˆ°‹I1, š •ª–ΔŽ1 (1Á‰»Ší“à): Á‰»ŠíEŠÌ‘Ÿ“à‰È 2021/2; 9 (2): 149-53.

522025. [uÀ]y“ÁW: ‚¢‚Ü‚³‚ç•·‚¯‚È‚¢!@ŠÌ’_äXŽ¾Š³@‚Ý‚È‚³‚ñ‚̃Mƒ‚ƒ“‚É“š‚¦‚Ü‚·z¡ŠÌd•Ï‚̐f’f‚ƍ‡•¹Ç‚ɑ΂·‚鎡—Á@–å–¬ŒŒðÇ‚ð‚Ç‚ñ‚ȏꍇ‚É‹^‚¢, ÅVŽ¡—Âðs‚¤‚©. “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰»Ší“à): medicina 2021/3; 58 (3): 454-7.

530005. [‚»‚Ì‘¼ (Practice Guideline)] Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Ishihara R1, Arima M1, Iizuka T1, Oyama T1, Katada C1,2, Kato M1, Goda K1, Goto O1, Tanaka K1, Yano T1, Yoshinaga S1, Muto M1, Kawakubo H1, Fujishiro M1, Yoshida M1, Fujimoto K1, Tajiri H1, Inoue H1 (1Japan Gastroenterological Endoscopy Society Guidelines Committee of ESD/EMR for Esophageal Cancer): Dig Endosc 2020/5; 32 (4): 452-93. (Œ˜“ce—˜1,2: 2Á‰»Ší“à)

530006. [‚»‚Ì‘¼ (Practice Guideline)] Evidence-based diagnosis and clinical practice guidelines for intestinal Beh?et's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. Watanabe K, Tanida S, Inoue N, Kunisaki R, Kobayashi K1,2, Nagahori M, Arai K, Uchino M, Koganei K, Kobayashi T, Takeno M, Ueno F, Matsumoto T, Mizuki N, Suzuki Y, Hisamatsu T: J Gastroenterol 2020/7; 55 (7): 679-700. (¬—ѐ´“T1,2: 1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à)

530007. [‚»‚Ì‘¼ (Erratum)] Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. Fujitani K, Shitara K, Takashima A, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Hosaka H, Komatsu Y, Shimada K, Kawabata R, Ohdan H, Kodera Y, Nakamura M, Eguchi-Nakajima T, Miyata Y, Moriwaki T, Kusumoto T, Nishikawa K, Ogata K, Shimura M, Morita S, Koizumi W1: Gastric Cancer 2021/3; 24 (2): 477-8. (¬ò˜aŽO˜Y1: 1Á‰»Ší“à)

[’˜@‘]

620017. [Šwp‘ (•ª’SŽ·•M)]y•Êû“ú–{—Õଠ—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY No.11@Á‰»ŠÇÇŒóŒQ (‘æ3”Å) III|‚»‚Ì‘¼‚̏Á‰»ŠÇŽ¾Š³‚ðŠÜ‚߂ā|zVI. ‹ó’°, ‰ñ’°, –Ó’°, Œ‹’°, ’¼’° (ã)@1. Š´õÇ@(8) ’°Œ‹Šj, p.36-40. ²“c”ü˜a1, ¬—ѐ´“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã), “ú–{—Õ଎Ð, “Œ‹ž, 2020/4”­s.

620018. [Šwp‘ (•ª’SŽ·•M)]y’m‚Á‚Ä‚¨‚«‚½‚¢V‚½‚ȏˆ’u‹ï|“Á’¥‚Æ‚»‚ÌŠJ”­ˆÓ} (Á‰»Ší“àŽ‹‹¾6ŒŽ‘‘卆)z[Še˜_] I. Øœ—p/ØŠJ—pˆ’u‹ï@ƒR[ƒ‹ƒhEƒ|ƒŠƒyƒNƒgƒ~[‚Ì‚½‚߂̏ˆ’u‹ï, p.831-3. ¬—ѐ´“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/6”­s.

620019. [Šwp‘ (•ª’SŽ·•M)]y‚È‚ñ‚¶‚Ⴑ‚è‚á? Part 2 (Á‰»Ší“àŽ‹‹¾10ŒŽ‘‘卆)z[‘å’°] “ÁˆÙ‚ÈŒ`‘Ô‚ð’悵‚½‘å’°—²‹N«•a•Ï‚Ì1—á, p.1571-2. ¬—ѐ´“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/10”­s.

620020. [Šwp‘ (•ª’SŽ·•M)]y‘å’°Ž¾Š³ƒAƒgƒ‰ƒXupdate (Á‰»Ší“àŽ‹‹¾32Šª‘Š§†)zI. Žîá‡, Žîᇐ«•a•Ï@ˆ««ã”琫Žîᇁ@‘ŠúŠà (T1Šà‚𒆐S‚É): ’×ᇐ«‘å’°‰ŠŠÖ˜AŽîá‡, p.28-9. ²“c”ü˜a1, ¬—ѐ´“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/11”­s.

620021. [Šwp‘ (•ª’SŽ·•M)]y‘å’°Ž¾Š³ƒAƒgƒ‰ƒXupdate (Á‰»Ší“àŽ‹‹¾32Šª‘Š§†)zI. Žîá‡, Žîᇐ«•a•Ï@ˆ««ã”琫Žîᇁ@ˆ««”ñã”琫Žîᇁ@ƒŠƒ“ƒpŽî (‘å’°•a•Ï): Á‰»ŠÇŠÔŽ¿Žîá‡, p.52-3. ¬—ѐ´“T1,2, ‰¡ŽR@ŒO2, ²“c”ü˜a2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/11”­s.

620022. [Šwp‘ (•ª’SŽ·•M)]y‘å’°Ž¾Š³ƒAƒgƒ‰ƒXupdate (Á‰»Ší“àŽ‹‹¾32Šª‘Š§†)zII. Š´õÇ@×‹Û«@‹}«: •aŒ´«‘å’°‹Û’°‰Š (O157‚È‚Ç), p.140-1. ¬—ѐ´“T1,2, ‰¡ŽR@ŒO2, ²“c”ü˜a2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/11”­s.

620023. [Šwp‘ (•ª’SŽ·•M)]y‘å’°Ž¾Š³ƒAƒgƒ‰ƒXupdate (Á‰»Ší“àŽ‹‹¾32Šª‘Š§†)zV. ‚»‚Ì‘¼@Angioectasia, p.264-5. ‰¡ŽR@ŒO1, ¬—ѐ´“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/11”­s.

620024. [Šwp‘ (•ª’SŽ·•M)]y•Êû“ú–{—Õଠ—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY No.13@ŠÌE’_“¹ŒnÇŒóŒQ (‘æ3”Å) I@‚»‚Ì‘¼‚̊́E’_“¹ŒnŽ¾Š³‚ðŠÜ‚߂ā|ŠÌ‘Ÿ•Ò (ã)zVI. ŒŒsˆÙí@5. ŠÌ“àŒ^–å–¬ˆ³˜´iÇ, p.249-52. “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰»Ší“à): “ú–{—Õ଎Ð, “Œ‹ž, 2021/1”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

712001. [Šw‰ï (‘Û)] (µ‘ҍu‰‰) Recent Advancement of Endoscopic Ultrasound. Kida M1,2: ƒnƒ“ƒKƒŠ[Á‰»Ší•aŠw‰ïWEB (2020/11/6), Budapest, Hungary (–Ø“cŒõL1,2: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

712002. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Autoimmune Pancreatitis - A Challenging Differential Diagnosis -. Kida M1,2: ‘æ5‰ñEUS-ERCP connection WEB (2020/12/18), Turin, Italy. (–Ø“cŒõL1,2: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

712003. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Role of Intraductal Ultrasonography (IDUS) for diagnosing Bilio-Pancreatic Diseases. Kida M1,2: 3rd India EUS summit 2021 (2021/1/16), Delhi, india. (–Ø“cŒõL1,2: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

712004. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) How to get clear image. Kida M1,2: WEO International School of EUS (WISE) (2021/3/13), WebŠJÃ. (–Ø“cŒõL1,2: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

721002. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ’·Šú—\Œã‰ü‘P‚ð–ÚŽw‚µ‚½ŠÌ«”]ÇŠÇ—. ‹›“ˆ°‹I (Á‰»Ší“à): ‘æ106‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2020/8/11-31), ŽãŠJÃ (WEBŠJÃ).

721003. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ‚±‚ê‚©‚ç‚Ì–å–¬ˆ³˜´iÇ2020`ŠÌd•Ïf—ÃKƒCƒhƒ‰ƒCƒ“‰ü’ù‚ɍ‡‚킹‚ā`. “ú‚@‰› (Á‰»Ší“à): ‘æ106‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2020/8/11-31), ŽãŠJÃ (WEBŠJÃ).

721004. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ‘å‚«‚­•Ï‚í‚Á‚½‰ŠÇ«’°Ž¾Š³‚Ì“à‰ÈŽ¡—Ã. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ41‰ñ“ú–{ƒAƒtƒFƒŒƒVƒXŠw‰ïŠwp‘å‰ï (2020/10/23), ç—t (ƒnƒCƒuƒŠƒbƒhŠJÃ).

721005. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ŠÌd•Ï‡•¹ÇŽ¡—ẪŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒg`–œ‚ªˆê‚Ì‚½‚߂Ɂ`. “ú‚@‰› (Á‰»Ší“à): JDDW 2020 KOBE (2020/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

721006. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) LECS‚͍‚—îŽÒˆÝ‚ª‚ñ‚ɑ΂·‚éV‚µ‚¢ƒIƒvƒVƒ‡ƒ“‚Æ‚È‚é‚©. “c糁@‘1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2Á‰»Ší“à): JDDW 2020 KOBE (2020/11/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

721007. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) Á‰»ŠÇ“àŽ‹‹¾Ž¡—Ã. “c糁@‘1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2Á‰»Ší“à): JDDW 2020 KOBE (2020/11/7), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

721008. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) “ú–{‘å’°ãè–å•aŠw‰ï‚Ì—Ï—Žwj‚Æ—Ï—\¿‚̍ۂ̒ˆÓŽ–€. ¬—ѐ´“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): ‘æ75‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2020/11/13-14), WEBŠJÃ.

721009. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ‘‰Á‚·‚鎡—ÑI‘ðŽˆ‚ÆŠî–{–ò5-ASA‚̈ʒu‚¯. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ17‰ñ“ú–{Á‰»ŠÇŠw‰ï‘‰ïŠwpW‰ï (2021/2/19-21), WEBŠJÃ.

721010. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) “à‰È—̈æ‚ÌŒ»ó‚Æ“W–]. “c糁@‘1,2, ¬–ì—T”V3, —é–ؐ°‹v4, Îì@‘ì5, Š|’n‹gO6 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2Á‰»Ší“à, 3Ã‰ªŒ§—§Ã‰ª‚ª‚ñƒZƒ“ƒ^[“àŽ‹‹¾‰È, 4‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@“àŽ‹‹¾‰È, 5VŠƒ‘åŠwˆãŽ•Šw‘‡•a‰@ˆã—Ïî•ñ•”, 6_ŒË‘åŠw‘åŠw‰@H“¹ˆÝ’°ŠO‰È): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3-5), WEBŠJÃ.

722017. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y“ªèò•”•\ÝŠà‚̐f’f‚ÆŽ¡—Áz“ªèò•”•\ÝŠà‚Ì“àŽ‹‹¾f’f‚ÆŽ¡—Ã. Œ˜“ce—˜1, ‰Á”[Fˆê2, ×–ì_Žj2, ŽR‰º@‘ñ2 (1Á‰»Ší“à, 2Ž¨•@ˆôAE“ªèò•”ŠO): ‘æ44‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2020/7/17-27), WebŠJÃ.

722018. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) –«ŠÌŽ¾Š³‚É‘±”­‚µ‚½“ñŽŸ«–Ɖu«ŒŒ¬”ÂŒ¸­Ç‚ɑ΂·‚éƒgƒƒ“ƒ{ƒ|ƒGƒ`ƒ“Žó—e‘̃AƒSƒjƒXƒg‚Ì—L—p«. ‹›“ˆ°‹I1, ˜a“c®‹v1, ‰êŒÃ@áÁ2 (1Á‰»Ší“à, 2Ã“슙‘q‘‡•a‰@): ‘æ56‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ï (2020/8/28-29), ‘åã (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722019. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) –«ŠÌáŠQ‚ð‡•¹‚·‚éƒAƒ‹ƒR[ƒ‹ˆË‘¶ÇŠ³ŽÒ‚ɑ΂·‚éƒiƒ‹ƒƒtƒFƒ““Š—^‚ÉŠÖ‚·‚é‘OŒü‚«ŒŸ“¢. ‹›“ˆ°‹I1, ŠâèGˆê˜Y1, “ú‚@‰›1, ‰êŒÃ@áÁ2 (1Á‰»Ší“à, 2Ã“슙‘q‘‡•a‰@): ‘æ56‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ï (2020/8/28-29), ‘åã (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722020. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) Interventional EUS ‚ÌŒ»ó‚Ə«—ˆ“W–]. –Ø“cŒõL (Á‰»Ší“à): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722021. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) –{–M‚É‚¨‚¯‚é‹i‰ŒEˆùŽðó‹µ‚Ì•]‰¿‚ðŠÜ‚ß‚½H“¹“àŽ‹‹¾ŒŸ¸‚ÌŒ»ó|Japan Endoscopy Database (JED) ‚É‚æ‚錟“¢|. Œ˜“ce—˜1, –x¼‚”Ž, •“¡@Šw (1Á‰»Ší“à): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/2), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722022. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) “–‰@‚É‚¨‚¯‚é“àŽ‹‹¾“I“û“ªØœp‚ÌŒŸ“¢‚Ɖۑè. ’·’Jì—Í–ç1, –Ø“cŒõL1, •{‹M_1 (1Á‰»Ší“à): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722023. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ’_“¹Ž¾Š³‚ɑ΂·‚é“àŽ‹‹¾f’f‚ÆŽ¡—Ã. Šâˆä’m‹v (Á‰»Ší“à): ‘æ44‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïƒZƒ~ƒi[ (2020/9/30-10/28), WEBŠJÃ.

722024. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ‰ŠÇ«’°Ž¾Š³‚ɑ΂·‚é“à‰ÈŽ¡—Âð‚à‚¤ˆê“x®—‚·‚é. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ44‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïƒZƒ~ƒi[ (2020/9/30-10/28), WEBŠJÃ.

722025. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ŠÌ«”]Ç‚ɑ΂·‚郌ƒ{ƒJƒ‹ƒjƒ`ƒ“+ƒŠƒtƒ@ƒLƒVƒ~ƒ“•¹—p—Ö@‚ÉŠÖ‚·‚郉ƒ“ƒ_ƒ€•ÀsŒQŠÔ”äŠrŽŽŒ±. ‹›“ˆ°‹I1, “ú‚@‰›1, ‰êŒÃ@áÁ2 (1Á‰»Ší“à, 2Ã“슙‘q‘‡•a‰@EÁ‰»Ší•aƒZƒ“ƒ^[): JDDW 2020 KOBE (2020/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722026. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ERCP¢“ï—á‚ɑ΂·‚éEUS‰ºäXŠÇƒhƒŒƒi[ƒW‚̐¬Ñ‚ÆŽè‹Z‚̍H•v. “n•Ó^ˆè1, ‰œ˜e‹»‰î1, –Ø“cŒõL1 (1Á‰»Ší“à): JDDW 2020 KOBE (2020/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722027. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) H“¹•\ÝG•½ã”çŠà“àŽ‹‹¾ØœŒã‚É”­¶‚·‚éˆÙŽž«“ªèò•”H“¹Šà‚ÆAlcohol Use Disorders Identification Test (AUDIT) ‚ÌŠÖ˜A. Œ˜“ce—˜1, ‰¡ŽR@Œ°2, •“¡@Šw3 (1Á‰»Ší“à, 2‘—§‹v—¢•lˆã—ÃZƒ“ƒ^[, 3‹ž“s‘啍‘®•a‰@EŽîᇓà‰È): JDDW 2020 KOBE (2020/11/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722028. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) Lenvatinib‚Ì–å–¬ŒŒs“®‘Ô‚É—^‚¦‚é‰e‹¿`“Š—^‘OŒã‚ł̃vƒ‰’´‰¹”g‚ð—p‚¢‚½ŒŸ“¢‚©‚ç`. Œ´@—E•ã1, “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰»Ší“à): JDDW 2020 KOBE (2020/11/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722029. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) Crohn•a‚ÌŽ¡—ÑI‘ð|ŠO‰ÈŽ¡—ªæ‚©“à‰ÈŽ¡—ªæ‚©“à‰Èˆã‚Ì‘I‘ð|. ‰¡ŽR@ŒO1, ¬—ѐ´“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ75‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2020/11/13-14), WEBŠJÃ.

723025. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒgƒƒ“ƒ{ƒLƒTƒ“A2Žó—e‘̃VƒOƒiƒ‹‚Í, ƒ‚ƒmƒNƒƒ^ƒŠƒ“—U“±ŠÌáŠQ‚ð—}§‚·‚é. ‘卂Žj¹1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq1, –{“c‰ëŽq1, ‘å‹v•Û”Ž¢3, ×–ì‰Á“ÞŽq2, ¬ò˜aŽO˜Y4, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3S‘ŸŒŒŠÇŠO, 4Á‰»Ší“à): ‘æ41‰ñ“ú–{‰ŠÇEÄ¶ˆãŠw‰ï (2020/7/8-9), WebŠJÃ.

723092. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) äXˆ««Žîᇂɑ΂·‚éEUS-FNAB‚É‚¨‚¯‚éúŽhj‚ÌŒ`ó‚̈Ⴂ‚É‚æ‚éf’f¬Ñ‚Ì”äŠrŒŸ“¢. “n•Ó^ˆè1, ‰œ˜e‹»‰î1, •{‹M_1, äøŒ´«—Ç2, ˆÀ’B@‰õ2, ¡’JŠ°ˆÈ2, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1, Šâˆä’m‹v1, ¡ò@O1, –Ø“cŒõL1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ106‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2020/8/11-31), ŽãŠJÃ (WEBŠJÃ).

723093. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒNƒ[ƒ“•a‚ɍ‡•¹‚µ‚½¬’°Šà‚̗Տ°•a—Šw“IŒŸ“¢. “c糔ü“Þ1, ¬—ѐ´“T1,2, •Êác•üL1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‰¡ŽR@ŒO1, ‹v•Û“c”ü˜a1, ¬ò˜aŽO˜Y1, ŽOŽ}@M3 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3•a—): ‘æ106‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2020/8/11-31), ŽãŠJÃ (WEBŠJÃ).

723094. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Crohn•a‚É‚¨‚¯‚錌´ˆŸ‰”’l‚ÉŠÖ‚·‚é—Տ°“IŒŸ“¢. ‰Ô‰ª‘¾˜Y1, ‰¡ŽR@ŒO1, ¬—ѐ´“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ106‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2020/8/11-31), ŽãŠJÃ (WEBŠJÃ).

723095. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) NUDT15ˆâ“`Žq‘½Œ`ŒŸ¸‚͉ŠÇ«’°Ž¾Š³ (IBD) ‚É‚¨‚¯‚éƒ`ƒIƒvƒŠƒ“»ÜŽ¡—Âð•Ï‚¦‚½‚©? ‹ààV@1, ‰¡ŽR@ŒO1, ¬—ѐ´“T1,2, •Êác•üL1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‹v•Û“c”ü˜a1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ106‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2020/8/11-31), ŽãŠJÃ (WEBŠJÃ).

723096. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) œŠi‹Ø“÷—Ê‚ª—^‚¦‚郌ƒ“ƒoƒ`ƒjƒu‚ɑ΂·‚é”E—e«‚Æ—\Œã‚ÌŒŸ“¢. ‹›“ˆ°‹I1, ‰êŒÃ@áÁ2, “ú‚@‰›1 (1Á‰»Ší“à, 2Ã“슙‘q‘‡•a‰@): ‘æ56‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ï (2020/8/28-29), ‘åã (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723097. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “–‰@‚É‚¨‚¯‚éØœ•s”\‚ȐisEÄ”­ˆÝ‚ª‚ñ‚ɑ΂·‚éƒjƒ{ƒ‹ƒ}ƒu‚ÌŽ¡—ЬÑ. ÎŒËŒªŽŸ1, ˜a“c‘ñ–ç1, ¬ò˜aŽO˜Y1, ‹v•Û“c—z2, “n•ÓWŽ¯1, “Œ@’q1, Œ˜“ce—˜1, “c糁@‘1,3 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/2-3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723098. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) pŒãäX’_ŠÇ‹ó’°•«‡•”‹·ó‚É‚¨‚¯‚éƒoƒ‹[ƒ“¬’°‹¾‰ºERCP ¢“ï—á‚ɑ΂·‚é“–‰@‚̍H•v. •{‹M_1, –Ø“cŒõL1, ¬ò˜aŽO˜Y1, ŽR“à_Žj1, “n•Ó^ˆè1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ‰œ˜e‹»‰î1, Šâˆä’m‹v1 (1Á‰»Ší“à): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/2-3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723099. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) R‹ÃŒÅ–ò“à•žÇ—á‚Ì‘Šúã•”Á‰»ŠÇŽîᇂɑ΂·‚éESDŒãoŒŒ‚ÌŒŸ“¢. ˜a“c‘ñ–ç1, “c糁@‘1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/2-3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723100. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “àŽ‹‹¾“I“EœŒã‚Ì‘å’°T1 (SM) Šà‚̒ljÁ’°Øœ‚Ì“K‰žŠî€‚̑Ó–«‚ÌŒŸ“¢. Œ}@”üK1, ¬—ѐ´“T1,2, ‹v•Û“c (²“c) ”ü˜a1, •Êác•üL1, ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/2-3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723101. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) RŒŒð–ò•ž—pŠ³ŽÒ‚É‚¨‚¯‚éCold polypectomy‚̈À‘S«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ˆî—t‹IŽq1, ìŠÝ‰Á“Þ1, ‹v•Û“c (²“c) ”ü˜a1, •Êác•üL1, Œ}@”üK1, ‰¡ŽR@ŒO1, ¬—ѐ´“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/2-3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723102. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ESDŒãፍ­‹ß–T‚َ̈ž‘½”­•a•Ï‚ÌŒŸ“¢. –kŒ´@Œ¾1, ÎŒËŒªŽŸ1, “c糁@‘1,2, ‹v•Û“c—z3, “n•ÓWŽ¯1, ˜a“c‘ñ–ç1, “Œ@’q1, Œ˜“ce—˜1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/2-3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723103. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) –¢•ª‰»Œ^‘ŠúˆÝŠà‚É‚¨‚¯‚éH.pyloriŠ´õó‹µ‚ƗՏ°•a—Šw“I“Á’¥. ‹v•Û“c—z1, “c糁@‘2,3, ÎŒËŒªŽŸ3, ˜a“c‘ñ–ç3, “n•ÓWŽ¯3, “Œ@’q3, Œ˜“ce—˜3, ¬ò˜aŽO˜Y3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3Á‰»Ší“à): ‘æ99‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ï (2020/9/2-3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723104. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Á‰»ŠíŠà‰»Šw—Ö@‚É‚¨‚¢‚čœŠi‹Ø—Ê‚ª—^‚¦‚é‰e‹¿‚ÉŠÖ‚·‚錟“¢. ŠâèGˆê˜Y1, ‹›“ˆ°‹I1, “ú‚@‰›1, “c糁@‘1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723105. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) WHO2019•ª—ނɏ€‹’‚µ‚½äX_Œo“à•ª”åŽîᇂ̗Տ°•a—Šw“I“Á’¥‚Æ—\ŒãˆöŽq‚ÌŒŸ“¢. áÁ•”—Dì1, ‰œ˜e‹»‰î1, –Ø“c[L1, Šâˆä’m‹v1, ŽR“à_Žj1, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, “n•Ó^ˆè1, •{‹M_1, ¡ò@O1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723106. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‚—î”­Ç‚Ì’×ᇐ«‘å’°‰Š‚ÌŽ¾Š³Šˆ“®«‚͍‚‚¢‚Ì‚©?|”ñ‚—î”­Ç‚Æ‚ÌŽ¡—Â̔äŠr‚©‚ç|. ˆÉ“¡—²Žm1, ‰¡ŽR@ŒO1, ¬—ѐ´“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723107. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”÷¬ˆÝŠà‚ɑ΂µ‚Ä“àŽ‹‹¾“I”S–Œ‰º‘w”—£p (ESD) ‚ÌŽ¡—ЬÑ‚ƗՏ°•a—Šw“I“Á’¥. Î‹´@˜Ð1, “c糁@‘1,2, ÎŒËŒªŽŸ1, ‹v•Û“c—z3, “n粍WŽ¯1, ˜a“c‘ñ–ç1, Œ˜“ce—˜1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723108. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Œ´ˆö•s–¾‚̏Á‰»ŠÇoŒŒ‚ɑ΂·‚é“àŽ‹‹¾f’fEŽ¡—ЬÑ. ìŠÝ‰Á“Þ1, ¬—ѐ´“T1,2, •Êác•üL1, Œ}@”üK1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723109. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‰“ˆÊˆ««’_“¹‹·ó‚ɑ΂·‚éƒtƒŒƒA–³‚µ‘SƒJƒo[•t‚«’_ŠÇ‹à‘®ƒXƒeƒ“ƒg‚Ì—LŒø«‚ƈÀ‘S«‚ÉŠÖ‚·‚錟“¢. ²–ì’BÆ1, ’·’Jì—Í–ç1, –Ø“cŒõL1, ¡ò@O1, Šâˆä’m‹v1, ‰œ˜e‹»‰î1, ŽR“à_Žj1, ‹àŽq@‹œ1, “n•Ó^ˆè1, •{‹M_1 (1Á‰»Ší“à): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723110. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚¯‚éäXŠà‚ɑ΂·‚é˜A‘±äX‰t×–Ef‚̐¬Ñ. ¬–쎛—§1, “n•Ó^ˆè1, ‰œ˜e‹»‰î1, ‹Ê’u–¾Š°2, •{‹M_1, ˆÀ’B@‰õ2, äøŒ´«—Ç2, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1, Šâˆä’m‹v1, ¡ò@O1, –Ø“cŒõL1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723111. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) SVWC cut-off value‚ÉŠî‚¢‚½EUS-FNAB‚̐f’f¬Ñ‚ÉŠÖ‚·‚éŒãŒü‚«ŒŸØ. ‹Ê’u–¾Š°1, ‰œ˜e‹»‰î2, ¡’JŠ°ˆÈ1, “n•Ó^ˆè2, –Ø“cŒõL2, Šâˆä’m‹v2, ŽR“à_Žj2, ‹àŽq@‹œ2, ’·’Jì—Í–ç2, •{‹M_2, ¡ò@O2, ¬ò˜aŽO˜Y2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Á‰»Ší“à): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723112. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚¯‚é–Ú“I•Ê‚É‚Ý‚½‘å’°ƒXƒeƒ“ƒg—¯’uÇ—á‚ÌŒŸ“¢. •Êác•üL1, ‹ààV@1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬—ѐ´“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723113. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‘å’°Žîᇂɑ΂·‚éJNET‘å’°Šg‘åNBI•ª—ނ̗Տ°“I—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. Œ}@”üK1, ¬—ѐ´“T1,2, •Êác•üL1, ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): JDDW 2020 KOBE (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723114. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma. Šâˆä’m‹v1, Tsujie M, Kubo S, Ura T, Hatano E, Sakai D, Takeda Y, Kaibori M, Kobayashi T, Katanuma A, Katayose Y, Fukase K, Sakurai N, Ito Y, Sato F, Maeda A, Asada M, Morizane C (1Á‰»Ší“à): ‘æ18‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï (2021/2/18-21), WEBŠJÃ.

723115. [Šw‰ï (‘S‘)] (êCˆãƒZƒbƒVƒ‡ƒ“) ‘å’°ŒeŽºoŒŒ‚É“®–¬Çðp‚ª‘tŒø‚µ‚»‚ÌŒã‚ɉóás«’Ž‚‰Š‚ð‚«‚½‚µ‚½‚—îŽÒ‚Ì1—á. ¡ˆäŒ’‘¾1, ‰¡ŽR@ŒO1, –kŒ´@Œ¾1, •Êác•üL1, ìŠÝ‰Á“Þ1, ‹ààV@1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1, ¬—ѐ´“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ17‰ñ“ú–{Á‰»ŠÇŠw‰ï‘‰ïŠwpW‰ï (2021/2/19-21), WEBŠJÃ.

723116. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “–‰@‚É‚¨‚¯‚éØœ•s”\isÄ”­ˆÝŠà‚ɑ΂·‚é2ŽŸŽ¡—Ãnab-PTX+R-mab‚Ì—L—p«. â•”—E‘¾1, ÎŒËŒªŽŸ1, ‹v•Û“c—z2, ŒÃ]N–¾1, “n糍WŽ¯1, ˜a“c‘ñ–ç1, Œ˜“ce—˜1, “c糁@‘1,3, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3-5), WEBŠJÃ.

723117. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚¯‚éNivolumab“Š—^’†‚ÉACTH’P“ÆŒ‡‘¹Ç‚𗈂µ‚½2Ç—á. “y‹“푾˜Y1, ÎŒËŒªŽŸ1, ‹v•Û“c—z2, ŒÃ]N–¾1, ˜a“c‘ñ–ç1, “n•ÓWŽ¯1, Œ˜“ce—˜1, “c糁@‘1,3, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3-5), WEBŠJÃ.

723032. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ŒŒ¬”‚̓‚ƒmƒNƒƒ^ƒŠƒ“—U“±ŠÌáŠQ‚ðŒyŒ¸‚·‚é. ‘卂Žj¹1, ˆÉ“¡‹`–ç2, ×–ì‰Á“ÞŽq2, ”¨’†@Œö2, ¬ò˜aŽO˜Y3, “V–ì‰pŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3Á‰»Ší“à): ‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ï (2021/3/8-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

731001. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ‚—îŽÒ’×ᇐ«‘å’°‰Š‚É‚¨‚¯‚éŽÀ—Տ°. ‰¡ŽR@ŒO (Á‰»Ší“à): ƒCƒ€ƒ‰ƒ“WEBƒZƒ~ƒi[ (2020/10/8), WEBŠJÃ.

731002. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) IBDŠ³ŽÒ‚³‚ñ‚̃‚ƒ`ƒx[ƒVƒ‡ƒ“ƒAƒbƒv‚ð–ÚŽw‚µ‚Ä. ‰¡ŽR@ŒO (Á‰»Ší“à): IBDf—Õ׋­‰ï (2020/10/10), WEBŠJÃ.

731003. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ’×ᇐ«‘å’°‰ŠŽ¡—Öò‚̐i•à‚ƃEƒXƒeƒLƒkƒ}ƒu‚Ì–ðŠ„. ‰¡ŽR@ŒO (Á‰»Ší“à): ƒXƒeƒ‰\ƒ‰UC“K‰ž’ljÁƒZƒ~ƒi[ in _“ސì (2020/11/10), WEBŠJÃ.

731004. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ƒNƒ[ƒ“•a‚Ì“à‰È“IƒAƒvƒ[ƒ`. ‰¡ŽR@ŒO (Á‰»Ší“à): IBD Collaboration Seminar (2020/11/20), WEBŠJÃ.

731005. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ‘‚¦‚Ä‚¢‚鉊Ç«’°Ž¾Š³‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒX‚ւ̑Ήž. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ35‰ñ_Œo“ï•aŒ¤C‰ï (2020/12/7), _“ސì.

731006. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ’×ᇐ«‘å’°‰Š‚Ì•a‘Ô‚Æ“à‰ÈŽ¡—Â̍ŐVî•ñ|VŒ^ƒRƒƒi‚ւ̑Ήž‚ðŠÜ‚ß‚Ä. ¬—ѐ´“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): Œ§‰›’×ᇐ«‘å’°‰ŠŽ¡—ÃZƒ~ƒi[ (2020/12/14), ŠC˜V–¼.

731007. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) “–‰@‚É‚¨‚¯‚éIBDf—Â̌»ó‚ƍ¡Œã‚̈ã—ØAŒg‚ɂ‚¢‚Ä. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘½–€E‘Š–ÍŒ´’n‹æIBD’nˆæˆã—ØAŒg‚̉ï (2021/1/21), WEBŠJÃ.

731008. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õŠg‘剺‚É‚¨‚¯‚é’×ᇐ«‘å’°‰Š‚̐f—Ã. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ70‰ñ•½’ËŽsÁ‰»ŠíŒ¤‹†‰ï (2021/2/3), WEBŠJÃ.

731009. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒX‚É‚æ‚è’×ᇐ«‘å’°‰ŠŽ¡—Â͕ςí‚Á‚½‚Ì‚©? ‰¡ŽR@ŒO (Á‰»Ší“à): UCŽ¡—Õaf˜AŒgƒZƒ~ƒi[ (2021/2/5), WEBŠJÃ.

731010. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õ‰º‚Ì’×ᇐ«‘å’°‰ŠŽ¡—Ã. ‰¡ŽR@ŒO (Á‰»Ší“à): ¬“cŒ´’n‹æIBD WEBƒZƒ~ƒi[ (2021/2/16), WEBŠJÃ.

731011. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ’×ᇐ«‘å’°‰ŠŽ¡—Öò‚̐i•à‚ƃEƒXƒeƒLƒkƒ}ƒu‚Ì–ðŠ„. ‰¡ŽR@ŒO (Á‰»Ší“à): ƒXƒeƒ‰\ƒ‰’×ᇐ«‘å’°‰ŠWEBƒZƒ~ƒi[ in _“ސì (2021/2/18), WEBŠJÃ.

732004. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ‚—îŽÒ’×ᇐ«‘å’°‰Š‚Ì“ü‰@—á‚É‚¨‚¯‚é“àŽ‹‹¾ŠŒ©‚ÆŽ¡—ÑI‘ð‚ÌŠÖ˜A‚ɂ‚¢‚Ä. ˆÉ“¡—²Žm1, ‰¡ŽR@ŒO1, ¬—ѐ´“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ110‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/5/30-31), WEBŠJÃ.

732005. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) H“¹Ã–¬áŽ‚ɑ΂·‚éEVLŽ¡—ÑOŒã‚ł̐H“¹ˆÝ•«‡•”‚ÌpH’l‚ɉž‚¶‚½PPI“Š—^–@‚ÌŒŸ“¢. “ú‚@‰›1 š •ª–ΔŽ2, “c糁@‘1,3, ‹›“ˆ°‹I1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V•S‡ƒ–‹u‘‡•a‰@ŠÌŽ¾Š³’áNPŽ¡—ÃZƒ“ƒ^[E“àŽ‹‹¾ƒZƒ“ƒ^[, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ110‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/5/30-31), WEBŠJÃ.

732006. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒrƒfƒIƒ[ƒNƒVƒ‡ƒbƒv) oŒŒ«ˆÝ’×ᇂɑ΂·‚éover-the-scope clip (OTSC) system‚ÌŽg—pŒoŒ±. ‹v•Û“c—z1, ŽR“à_Žj2, ’†’JŒ¤“l3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Á‰»Ší“à, 3‹~–½): ‘æ110‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/5/30-31), WEBŠJÃ.

732007. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒrƒfƒIƒVƒ“ƒ|ƒWƒEƒ€) äXŽîᇂɑ΂·‚éEUS-FNA‚É‚¨‚¯‚éstereomicroscopic on-site evaluation‚Ì—L—p«. “n•Ó^ˆè1, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, –Ø“cŒõL1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à): ‘æ111‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/12/19-20), WEBŠJÃ.

732008. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) dÇoŒŒ«Á‰»«’×ᇂɑ΂·‚é“àŽ‹‹¾“IŽ~ŒŒ¢“ïˆöŽq‚ÌŒŸ“¢. ‹v•Û“c—z1, ŽR“à_Žj2, ’†’JŒ¤“l3, “c糁@‘2,4 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Á‰»Ší“à, 3‹~–½, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ111‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/12/19-20), WEBŠJÃ.

732009. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ[ƒNƒVƒ‡ƒbƒv) ’_äX“àŽ‹‹¾Ž¡—Âɂ¨‚¯‚éƒiƒCƒ`ƒm[ƒ‹»8üƒXƒpƒCƒ‰ƒ‹ƒoƒXƒPƒbƒg‚ð‰ž—p‚µ‚½ƒgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO. •{‹M_1, –Ø“cŒõL1, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à): ‘æ111‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/12/19-20), WEBŠJÃ.

733013. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) f’f‚É‹ê—¶‚µtotal biopsy–Ú“I‚É“àŽ‹‹¾“I”S–Œ‰º‘w”—£p‚ðs‚Á‚½‘ŠúˆÝŠà‚Ì1—á. ”ä—¯ŠÔ’q‹I1, “n•ÓWŽ¯1, “c糁@‘1,2, ˜a“c‘ñ–ç1, ÎŒËŒªŽŸ1, Œ˜“ce—˜1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ110‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/5/30-31), WEBŠJÃ.

733014. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) ƒVƒ“ƒOƒ‹ƒoƒ‹[ƒ““àŽ‹‹¾‚Å“Eœ‚µ‚¦‚½‰ñ’°‰ßŒëŽî‚Ì1—á. Žs糉ԓÞ1, ‰¡ŽR@ŒO1, –kŒ´@Œ¾1, ‹ààV@1, ìŠÝ‰Á“Þ1, •Ê•x•üL1, ‹v•Û“c”ü˜a1, ¬—ѐ´“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ110‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/5/30-31), WEBŠJÃ.

733015. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) ƒpƒeƒ“ƒV[ƒJƒvƒZƒ‹‚ª‘Ø—¯‚µ‚½•úŽËü«¬’°‰Š‚Ì1—á. Œ´“c—m•½1, ‹ààV@1, •Êác•üG1, ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1, ¬—ѐ´“T1,2, ‚‹´”Ž”V3 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ˆã—Éq¶Šw•”): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ360‰ñ—á‰ï (2020/8/3-31), WEBŠJÃ.

733016. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) äX_Œo“à•ª”åŽîᇂƂ̊ӕʂɋꗶ‚µ‚½äXsolid-pseudopapillary neoplasm ‚̈ê—á. —§ìŽÑŒŽ1,2, –Ø“cŒõL1,2, –kŒ´@Œ¾1,2, ãŒ´ˆê”¿1,2, ‹àŽq@‹œ1,2, ‘å’ˏr˜a1,2, “cŒ´‹v”üŽq1, “n粐^²1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰»Ší“à): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ360‰ñ—á‰ï (2020/8/3-31), WEBŠJÃ.

733017. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) ’_ŠÇ“à‚É–À“ü‚µ‚½äXŠÇ‹ó’°•«‡•”ƒƒXƒgƒXƒeƒ“ƒg‚ð“àŽ‹‹¾‰º‚ɉñŽû‚µ“¾‚½ˆê—á. •½ˆä“N•F1, “n•Ó^ˆè1, •{‹M_1, ’·’Jì—Í–ç1, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, ¡ò@O1, –Ø“cŒõL1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”—á‰ï‘æ361‰ñ—á‰ï (2020/9/12), WEBŠJÃ.

733005. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ|ƒXƒ^[) ŠÌ—Þ“´•ÂÇÇŒóŒQ‚É‚¨‚¯‚錌¬”‚̖ðŠ„. ‘卂Žj¹1, ˆÉ“¡‹`–ç2, Œã“¡‘ì–ç1, ×–ì‰Á“ÞŽq2, ”¨’†@Œö2, ¬ò˜aŽO˜Y3, “V–ì‰pŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3Á‰»Ší“à): ‘æ143‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ï (2020/10/24), WebŠJÃ.

733018. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ƒNƒ[ƒ“•a‰Šú•a•Ï‚Ì“àŽ‹‹¾‚̍lŽ@. ‹ààV@1, ‰¡ŽR@ŒO1, ¬—ѐ´“T1,2, ‹v•Û“c (²“c) ”ü˜a1, •Êác•üL1, ìŠÝ‰Á“Þ1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ27‰ñ_“ސìIBDŒ¤‹†‰ï (2020/11/26), WEBŠJÃ.

733019. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) “–Ñ”¯’áŒ`¬Ç‚ð”wŒi‚ɏd“Ä‚ÈŒo‰ß‚ð’H‚Á‚½–«’_`‚¤‚Á‘ØŒ^‚̊̍d•ÏÇ‚̈ê—á. ƒã‘¾˜Y1, ‹›“ˆ°‹I1, ŠâèGˆê˜Y1, ˜a“c®‹v1, ŒE“cK‰î1, “ú‚@‰›1, ’†àV‹MG1, a’J–¾—²1, ¬ò˜aŽO˜Y1, ]”gŒËF•ã2 (1Á‰»Ší“à, 2¬Ž™): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ362‰ñ—á‰ï (2020/12/5), WEBŠJÃ.

733020. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) “–‰@‚ÅŒoŒ±‚µ‚½”~“Ő«’¼’°‰Š‚Ì1—á. ‰¡‘qqˆê1, •Êác•üL1, ‹ààV@1, ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬—ѐ´“T1,2, ‘º‰_–FŽ÷3 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3•a—): ‘æ111‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/12/19-20), WEBŠJÃ.

733021. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) ’†‹K–Í•a‰@‚É‚¨‚¯‚éäXŽîᇂɑ΂·‚éSample Isolation Processing by Stereomicroscopy‚ð—p‚¢‚½EUS-FNAB“±“ü‰Šú‚̐f’f”\‚ÌŒŸØ. ˆä‰ô—C‰î1,2, ¡ò@O1,2, ˆî—t‹IŽq1,2, ‹à@–¾“N1,2, ŽOŽ}—zˆê1, Îèƒ˜Y2, ‹Ê’u–¾Š°3, “n•Ó^ˆè2, ¡’JŠ°ˆÈ3, ‹v•Û“c—z3, ‰œ˜e‹»‰î2 (1‘Š–Í–ì•a‰@Á‰»Ší“à‰È, 2Á‰»Ší“à, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ111‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/12/19-20), WEBŠJÃ.

733022. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (Œ¤CˆãƒZƒbƒVƒ‡ƒ“) ‘¼‘ŸŠíŠàƒŠƒ“ƒpß“]ˆÚ‚É”º‚¤ˆ««H“¹‹·ó‚ɑ΂µOTSC‚𕹗p‚µH“¹ƒXƒeƒ“ƒg‚ð—¯’u‚µ‚½2—á. –쑺“Þ‰›1, ˜a“c‘ñ–ç1, ŒÃ]N–¾1, “n•ÓWŽ¯1, ÎŒËŒªŽŸ1, Œ˜“ce—˜1, “c糁@‘1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ111‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/12/19-20), WEBŠJÃ.

733023. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) ƒAƒtƒ^—l•a•Ï‚©‚ç’·ŠúŒo‰ß‚Å“TŒ^“IƒNƒ[ƒ“•a‚ɐi“W‚µ‚½ˆê—á. ”Ñ“c~‹M1, ‹ààV@1, ‰¡ŽR@ŒO1, •Êác•üL1, ìŠÝ‰Á“Þ1, ‹v•Û“c (²“c) ”ü˜a1, ¬—ѐ´“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ363‰ñ—á‰ï (2021/2/27), WEBŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

H29-522001. [uÀ]y“ÁWII: –å–¬ˆ³˜´iÇŽ¡—Â̐i•àz–å–¬ˆ³˜´iÇ‚Ì–ò•¨—Ö@. ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰»Ší“à): Á‰»ŠíEŠÌ‘Ÿ“à‰È 2017/11; 2 (5): 534-41.

[’˜@‘]

'18-620001. [Šwp‘ (•ª’SŽ·•M)]y’´‰¹”g“àŽ‹‹¾‰ºúŽhp‚Ì‚½‚ß‚Ì ƒRƒ“ƒxƒbƒNƒX‘–¸Ž®’´‰¹”g“àŽ‹‹¾‚É‚æ‚é•W€“I•`o–@zhttps://www.olympusprofed.com/jp/gi/eus/26920/. ƒRƒ“ƒxƒbƒNƒX‘–¸Ž®’´‰¹”g“àŽ‹‹¾•`o–@•W€‰»ŒŸ“¢•”‰ï. ŠÄC: –Ø“cŒõL1,2, ŽR—YŒ’ŽŸ (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰»Ší“à), ƒIƒŠƒ“ƒpƒX, “Œ‹ž, 2019/3.

'19-620001. [Šwp‘ (•ª’SŽ·•M)]yƒ‰ƒWƒAƒ‹‘–¸Ž®’´‰¹”g“àŽ‹‹¾‚É‚æ‚éäXE’_“¹—̈æ‚Ì•W€“I•`o–@zhttps://www.olympusprofed.com/jp/gi/eus/27686/. ƒ‰ƒWƒAƒ‹‘–¸Ž®’´‰¹”g“àŽ‹‹¾‚É‚æ‚éäXE’_“¹—̈æ‚Ì•W€“I•`o–@•W€‰»ŒŸ“¢•”‰ï. ŠÄC: –Ø“cŒõL1,2, ˆÀ“cŒ’Ž¡˜N (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰»Ší“à), ƒIƒŠƒ“ƒpƒX, “Œ‹ž, 2020/3.

‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È@Á‰»Ší“à‰ÈŠw
Šñ•uÀu‰ŠÇ«’°Ž¾Š³—Տ°Œ¤‹†uÀv

[Šwp˜_•¶]

110119. [Œ´’˜] Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. Naganuma M1, Yokoyama Y1, Motoya S1, Watanabe K1, Sawada K1, Hirai F1, Yamamoto T1, Hanai H1, Omori T1, Kanai T1, Hibi T1,2,3 (1CAPTAIN study Group): J Gastroenterol 2020; 55 (4): 390-400. (“ú”ä‹I•¶1,2,3: 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110120. [Œ´’˜] Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. Naganuma M, Kobayashi T1,2, Nasuno M, Motoya S, Kato S, Matsuoka K, Hokari R, Watanabe C, Sakamoto H, Yamamoto H, Sasaki M, Watanabe K, Iijima H, Endo Y, Ichikawa H, Ozeki K, Tanida S, Ueno N, Fujiya M, Sako M, Takeuchi K, Sugimoto S, Abe T, Hibi T1,2, Suzuki Y, Kanai T: Clin Gastroenterol Hepatol 2020/5; 18 (5): 1102-11.e5. (¬—с@‘ñ1,2, “ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110121. [Œ´’˜] Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. Kobayashi T1,2, Uda A, Udagawa E, Hibi T1,2: J Crohns Colitis 2020/6; 14 (5): 617-23. (¬—с@‘ñ1,2, “ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110122. [Œ´’˜] A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn's disease. Bamba S, Sakemi R, Fujii T, Takeda T, Fujioka S, Takenaka K, Kitamoto H, Umezawa S, Sakuraba H, Inokuchi T, Fukata N, Mizuno S, Yamashita M, Shinzaki S, Tanaka H, Takedatsu H, Ozaki R, Moriya K, Ishii M, Kinjo T, Ozeki K, Ooi M, Hayashi R, Kakimoto K, Shimodate Y, Kitamura K, Yamada A, Sonoda A, Nishida Y, Yoshioka K, Ashizuka S, Takahashi F, Shimokawa T, Kobayashi T1,2, Andoh A, Hibi T1,2: J Gastroenterol 2020/6; 55 (6): 615-26. (¬—с@‘ñ1,2, “ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110123. [Œ´’˜] Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. Sagami S1, Kobayashi T1,2, Aihara K, Umeda M, Morikubo H1, Matsubayashi M, Kiyohara H, Nakano M1, Ohbu M, Hibi T1,2: Aliment Pharmacol Ther 2020/6; 51 (12): 1373-83. (²ãW‘¾˜Y1, ¬—с@‘ñ1,2, X‹v•Û‘ñ1, ’†–ì@‰ë1, “ú”ä‹I•¶1,2: 1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110124. [Œ´’˜] Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. Vermeire S, Su C, Lawendy N, Kobayashi T1,2, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, PanŽs J: J Crohns Colitis 2021/7; 15 (7): 1130-41. (¬—с@‘ñ1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110125. [Œ´’˜] Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. Kobayashi T1,2, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T1,2: Intest Res 2020/8. doi: 10.5217/ir.2020.00026. Online ahead of print. (¬—с@‘ñ1,2, “ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110126. [Œ´’˜] Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. Matsubayashi M, Kobayashi T1,2, Okabayashi S, Nakano M2, Sagami S2, Ozaki R, Kiyohara H, Morikubo H2, Asonuma K2, Miyatani Y2, Maeda S, Hibi T1,2: J Gastroenterol Hepatol 2021/4; 36 (4): 943-50. doi: 10.1111/jgh.15220. Epub 2020 Sep 3. (¬—с@‘ñ1,2, ’†–ì@‰ë2, ²ãW‘¾˜Y2, X‹v•Û‘ñ2, ˆ¢‘]À–M‰›2, ‹{’J˜Ð—C2, “ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110127. [Œ´’˜] Efficacy of biologic therapies for biologic-na?ve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. Hibi T1,2, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H: Intest Res 2021/1; 19 (1): 53-61. (“ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

510003. [‘à] Ulcerative colitis. Kobayashi T1,2, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T1,2: Nat Rev Dis Primers 2020/9; 6 (1): 74. (¬—с@‘ñ1,2, “ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

522026. [uÀ]y“ÁW: ƒNƒ[ƒ“•a¬’°‹·ó•a•Ï‚ɑ΂·‚é“àŽ‹‹¾“Iƒoƒ‹[ƒ“Šg’£p|Šî–{‚©‚çƒsƒbƒgƒtƒH[ƒ‹‚܂Łz4. ŠCŠO‚Ì•¶Œ£‚ð“Ç‚Ý‰ð‚­|ƒNƒ[ƒ“•a‹·ó•a•Ï‚ɑ΂·‚éØŠJ–@‚Í—LŒø‚©? ¬—с@‘ñ1,2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@), INTESTINE 2020/8; 24 (3): 256-8.

522027. [uÀ]y“ÁW: ‰ŠÇ«’°Ž¾Š³|‰ŠÇ«’°Ž¾Š³‚Ì•a‘Ô‚Æ•Ï‚í‚è‚ä‚­Ž¡—Ð헪z<Ž¡—Á^‡•¹Ç‚╹‘¶Ç‚ðŒ©˜‚¦‚½Å“KŽ¡—Ã>@‰ŠÇ«’°Ž¾Š³‚̐V‹KŽ¡—Öò‚Æ‚»‚Ì“K‰ž|JAK‘jŠQ–ò, RIL-12/23R‘̐»Ü, Rƒ¿4ƒÀ7ƒCƒ“ƒeƒOƒŠƒ“R‘̂Ȃǂ͂ǂ̂悤‚È–òÜ‚łǂ̂悤‚ÉŽg—p‚·‚é‚Ì‚©?|. ¬—с@‘ñ1,2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@) Medical Practice 2020/12; 37 (12): 1917-20.

[’˜@‘]

620025. [Šwp‘ (•ª’SŽ·•M)] y•Êû“ú–{—Õଠ—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY No.11@Á‰»ŠÇÇŒóŒQ (‘æ3”Å) III|‚»‚Ì‘¼‚̏Á‰»ŠÇŽ¾Š³‚ðŠÜ‚߂ā|zVI. ‹ó’°, ‰ñ’°, –Ó’°, Œ‹’°, ’¼’° (ã)@2. ‰ŠÇ«Ž¾Š³@(19) Á‰»ŠÇƒAƒ~ƒƒCƒh[ƒVƒX, p.190-3. ¬—с@‘ñ1,2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@), “ú–{—Õ଎Ð, “Œ‹ž, 2020/4”­s.

620026. [Šwp‘ (•ª’SŽ·•M)] y‘å’°Ž¾Š³ƒAƒgƒ‰ƒXupdate (Á‰»Ší“àŽ‹‹¾32Šª‘Š§†)zIII. Ž©ŒÈ–ƉuŽ¾Š³EäPŒ´•aEŒŒŠÇ‰Š‚Ȃǁ@Crohn•a, p.182-3. ¬—с@‘ñ1,2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/11”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722030. [Šw‰ï (‘S‘)] (ƒuƒŒƒbƒNƒtƒ@[ƒXƒgƒZƒ~ƒi[) UCŽ¡—Âɂ¨‚¯‚é•Ö’†ƒJƒ‹ƒvƒƒeƒNƒ`ƒ“‚̃xƒXƒgƒ†[ƒX. ¬—с@‘ñ1,2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ62‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ï (JDDW 2020 KOBE) (2020/11/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722031. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ’×ᇐ«‘å’°‰Š‚É‚¨‚¯‚éŒo‰ï‰A•¹—p’°ŠÇƒGƒR[‚Ì’ZŠú—\Œã—\‘ª”\. ²ãW‘¾˜Y1, ¬—с@‘ñ1,2, X‹v•Û‘ñ1, ‘ŠŒ´‰À“ߎq, ”~“c”üç, ¬“c“‡ˆêO, ‹{’J˜Ð—C1, ¼—ѐ^‰›, ´Œ´—T‹M, ˆ¢‘]À–M‰›1, ’†–ì@‰ë1, “ú”ä‹I•¶1,2 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ11‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïŠwpW‰ï (JSIBD) (2020/12/5), WebŠJÃ.

723118. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘ÌŠOŽ®’´‰¹”gŒŸ¸‚Ì’×ᇐ«‘å’°‰Š‚É‚¨‚¯‚é’ZŠú—\Œã—\‘ª”\‚̉ðÍ. X‹v•Û‘ñ1, ²ãW‘¾˜Y1, ¬—с@‘ñ1,2, ‘ŠŒ´‰À“ߎq, ”~“c”üç, ‹à‘ò“O—Y, —с@‹K—², ‹{’J˜Ð—C1, ¼—ѐ^‰›, ´Œ´—T‹M, ˆ¢‘]À–M‰›1, ’†–ì@‰ë1, “ú”ä‹I•¶1,2 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ57‰ñ“ú–{Á‰»Ší–ƉuŠw‰ï‘‰ï (2020/7/2-3), ‹ž“s (ŽãŠJÃ).

723119. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’°ŠÇƒ}ƒNƒƒtƒ@[ƒW‚Ì“ÁŽê«‚Æ‚»‚̉ŠÇ«’°Ž¾Š³•a‘Ô‚É‚¨‚¯‚éŠÖ—^. ¬—с@‘ñ1,2, ’|“à@C, •À@’q (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ48‰ñ“ú–{—Տ°–ƉuŠw‰ï‘‰ï (2020/10/15), WebŠJÃ.

723120. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒNƒ[ƒ“•a¬’°•a•Ï‚̃‚ƒjƒ^ƒŠƒ“ƒO‚É‚¨‚¯‚éƒoƒCƒIƒ}[ƒJ[‚Ì—LŒø«. ˆ¢‘]À–M‰›1, ¬—с@‘ñ1,2, ²ãW‘¾˜Y1, ¼—ѐ^‰›, X‹v•Û‘ñ1, ´Œ´—T‹M, ‹{’J˜Ð—C1, ’†–ì@‰ë1, “ú”ä‹I•¶1,2 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ62‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ï (JDDW 2020 KOBE) (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723121. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’°ŠÇƒGƒR[‚Í’×ᇐ«‘å’°‰Š‚É‚¨‚¯‚銰‰ð“±“üŽ¡—Âɑ΂·‚锽‰ž‚ð—\‘ª‚Å‚«‚é‚©? X‹v•Û‘ñ1, ²ãW‘¾˜Y1, ¬—с@‘ñ1,2, ‘ŠŒ´‰À“ߎq, ”~“c”üç, ‹à‘ò“O—Y, —с@‹K—², ‹{’J˜Ð—C1, ¼—ѐ^‰›, ´Œ´—T‹M, ˆ¢‘]À–M‰›1, ’†–ì@‰ë1, “ú”ä‹I•¶1,2 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ62‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ï (JDDW 2020 KOBE) (2020/11/5-8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723122. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒX‰Š´õ‚É‚æ‚éŠÌ‰Š, \“ñŽw’°‰Š‚𔭏ǂµ‚½Š°‰ðŠúƒNƒ[ƒ“•a‚̈ê—á. ŠC]“c—S‘¾, X‹v•Û‘ñ1, ¬—с@‘ñ1,2, ‹{’J˜Ð—C1, •Ÿ“c’mL1, ˆ¢‘]Àˆè‰›1, ²ãW‘¾˜Y1, ’†–ì@‰ë1, ‘O“cˆê˜Y1,3, “ú”ä‹I•¶1,2 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3•a—): ‘æ11‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïŠwpW‰ï (JSIBD) (2020/12/5), WebŠJÃ.

732010. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ‹ßˆÊ‘å’°‚ª”S–ŒŽ¡–ü‚É‚ ‚é’×ᇐ«‘å’°‰Š‚̉“ˆÊ‚É‚Ì‚ÝŽc‘¶‚·‚鉊Ç‚͏¬‚³‚ȍĔR‚̃ŠƒXƒN‚ɂ͂Ȃ邪‘å‚«‚ȍĔR‚ɂ͉e‹¿‚µ‚È‚¢. ˆ¢‘]À–M‰›1, ¬—с@‘ñ1,2, ²ãW‘¾˜Y1, ’†–ì@‰ë1, “ú”ä‹I•¶1,2 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ110‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/5/30-31), WebŠJÃ.

733024. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Crohn•a‚ɍ‡•¹‚µ‚½Øœ•s”\‘å’°Šà‚ɑ΂·‚é5-FU“Š—^‚ō‚ƒAƒ“ƒ‚ƒjƒAŒŒÇ‚𔺂¤ˆÓŽ¯áŠQ‚ð‚«‚½‚µ‚½ˆê—á. ’¼‹{‹¿•½1, ¼‘º@Œ«1, ’†ŽR¸“T, ˆ¢‘]À–M‰›1, ²ãW‘¾˜Y1, ¬—с@‘ñ1,2, “ú”ä‹I•¶1,2, —Ž‡‘åŽ÷1, Îˆä—ǍK1,3, ‹g“c“ÄŽj, X‹v•Û‘ñ1, ‹{’J˜Ð—C1, ´Œ´—T‹M, ¼—ѐ^‰›, ’†–ì@‰ë1 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‰º•”Á‰»ŠÇŠO): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”@‘æ359‰ñ—á‰ï (2020/5/1-29), WebŠJÃ.

733025. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘S‘å’°‰ŠŒ^’×ᇐ«‘å’°‰Š‚̉“ˆã‚Ì‚Ý‚ÉŽc‘¶‚·‚鉊Ç‚Í—\Œã‚É—LˆÓ‚ȉe‹¿‚ð—^‚¦‚È‚¢. ˆ¢‘]À–M‰›1, ¬—с@‘ñ1,2, ’†–ì@‰ë1, •–Ø—Dˆê˜Y, “ú”ä‹I•¶1,2 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ111‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/12/20), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110006. [Œ´’˜] High-resolution melt analysis enables simple genotyping of complicated polymorphisms of codon 18 rendering the NUDT15 diplotype Kakuta Y, Izumiyama Y, Okamoto D, Nakano T, Ichikawa R, Naito T, Moroi R, Kuroha M, Kanazawa Y, Kimura T, Shiga H, Kudo H, Minegishi N, Kawai Y, Tokunaga K, Nagasaki M, Kinouchi Y, Suzuki Y, Masasmune A, Collaborators: MENDEL study group (Kobayashi T1,2): J Gastroenterol 2020/1; 55 (1): 67-77. (¬—с@‘ñ1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-110007. [Œ´’˜] Somatic inflammatory gene mutations in human ulcerative colitis epithelium. Nanki K, Fujii M, Shimokawa M, Matano M, Nishikori S, Date S, Takano A, Toshimitsu K, Ohta Y, Takahashi S, Sugimoto S, Ishimaru K, Kawasaki K, Nagai Y, Ishii R, Yoshida K, Sasaki N, Hibi T1,2, Ishihara S, Kanai T, Sato T: Nature 2020/1; 577 (7789): 254-9. (“ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-110008. [Œ´’˜] Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study. Saruta M, Park DI, Kim Y-H, Yang S-K, Jang B-I, Cheon JH, Im JP, Kanai T, Katsuno T, Ishiguro Y, Nagaoka M, Isogawa N, Li Y, Banerjee A, Ahmad A, Hassan-Zahraee M, Clare R, Gorelick KJ, Cataldi F, Watanabe M, Hibi T1,2: Intest Res 2020/1; 18 (1): 45-55. (“ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-110009. [Œ´’˜] Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. Hibi T1,2, Naganuma M, Oda E, Yamada Y, Chujoh Y, Yoshihara R, Watanabe M: Intest Res 2020/1; 18 (1): 56-68. (“ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-110010. [Œ´’˜] Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. Naganuma M1, Sugimoto S1, Fukuda T1, Mitsuyama K1, Kobayashi T1,2,3, Yoshimura N1, Ohi H1, Tanaka S1, Andoh A1, Ohmiya N1, Saigusa K1, Yamamoto T1, Morohoshi Y1, Ichikawa H1, Matsuoka K1, Hisamatsu T1, Watanabe K1, Mizuno S1, Abe T1, Suzuki Y1, Kanai T1 (1INDIGO Study Group): J Gastroenterol 2020/2; 55 (2): 169-80. (¬—с@‘ñ1,2,3: 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-110011. [Œ´’˜] Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Sandborn WJ, Baert F, Danese S, Krznari«c Z, Kobayashi T1,2, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S: Gastroenterology 2020/2; 158 (3): 562-72.e12. (¬—с@‘ñ1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-110012. [Œ´’˜] Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. Kobayashi T1,2, Udagawa E, Uda A, Hibi T1,2, Hisamatsu T: J Gastroenterol Hepatol 2020/2; 35 (2): 225-32. (¬—с@‘ñ1,2, “ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-110013. [Œ´’˜] Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. Hibi T1,2, Ishibashi T, Ikenoue Y, Yoshihara R, Nihei A, Kobayashi T1,2: Inflamm Intest Dis 2020/2; 5 (1): 27-35. (“ú”ä‹I•¶1,2, ¬—с@‘ñ1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-110014. [Œ´’˜] Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T1,2: J Gastroenterol 2020/3; 55 (3): 291-306. (“ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-510001. [‘à] Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns? Okabayashi S, Kobayashi T1,2, Hibi T1,2: J Anus Rectum Colon 2020/1; 4 (1): 1-13. (¬—с@‘ñ1,2, “ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-530002. [‚»‚Ì‘¼ (Erratum)] Correction to: High-resolution melt analysis enables simple genotyping of complicated polymorphisms of codon 18 rendering the NUDT15 diplotype Kakuta Y, Izumiyama Y, Okamoto D, Nakano T, Ichikawa R, Naito T, Moroi R, Kuroha M, Kanazawa Y, Kimura T, Shiga H, Kudo H, Minegishi N, Kawai Y, Tokunaga K, Nagasaki M, Kinouchi Y, Suzuki Y, Masasmune A, Collaborators: MENDEL study group (Kobayashi T1,2): J Gastroenterol 2020/1; 55 (1): 132. (¬—с@‘ñ1,2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)


zŠÂŠí“à‰ÈŠw

[Šwp˜_•¶]

110128. [Œ´’˜] Physical exertion as a trigger of acute coronary syndrome caused by plaque erosion. Kato A1, Minami Y2, Katsura A1, Muramatsu Y2, Sato T2, Kakizaki R2, Nemoto T2, Hashimoto T2, Fujiyoshi K2, Meguro K2, Shimohama T2, Ako J2: J Thromb Thrombolysis 2020/4; 49 (3): 377-85. (‰Á“¡Ê”ü1, “ì@®Œ«2, Œj@—L’q1, ‘º¼—T‰î2, ²“¡r[2, Š`è—Ç‘¾2, ª–{Æ¢Žu2, ‹´–{‘ñ–í2, “¡‹g˜a”Ž2, –ڍ•Œ’‘¾˜Y2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à)

110129. [Œ´’˜] A combination of depression and decreased physical function further worsens the prognosis of patients with chronic cardiovascular disease. Osada K1, Yamaoka-Tojo M2, Obara S3, Kariya H3, Kato Y1, Yuyama A1, Kamiya K2, Matsunaga A2, Ako J4: J Cardiovasc Med Cardiol 2020/4; 7 (2): 63-71. (’·“cŒ’Æ1, “ŒžŠ”ü“ÞŽq2, ‰“Œ´^ˆê3, Š¡’J‰p‹I3, ‰Á“¡—m•½1, —MŽR¸”Í1, _’JŒ’‘¾˜Y2, ¼‰i“Ä•F2, ˆ¢ŒÃÆ4: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“à)

110130. [Œ´’˜] Design of Functional Electrospun Scaffolds Based on Poly (glycerol sebacate) Elastomer and Poly (lactic acid) for Cardiac Tissue Engineering. Flaig F, Ragot H, Simon A, Revet G, Kitsara M, Kitasato L1, HŽbraud A, Agbulut O, Schlatter G: ACS Biomater Sci Eng 2020/4; 6 (4): 2388-400. (–k—¢—œ¹1: 1zŠÂŠí“à)

110131. [Œ´’˜] Effect of cardiac rehabilitation on cognitive function in elderly patients with cardiovascular diseases. Fujiyoshi K1, Minami Y1, Yamaoka-Tojo M2, Kutsuna T, Obara S3, Aoyama A4, Ako J1: PLoS One 2020/5; 15 (5): e0233688. (“¡‹g˜a”Ž1, “ì@®Œ«1, “ŒžŠ”ü“ÞŽq2, ‰“Œ´^ˆê3, ÂŽRW‘å4, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110132. [Œ´’˜] Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm. Sato R, Sakamoto K, Kaikita K, Tsujita K, Nakao K, Ozaki Y, Kimura K, Ako J1, Noguchi T, Yasuda S, Suwa S, Fujimoto K, Nakama Y, Morita T, Shimizu W, Saito Y, Hirohata A, Morita Y, Inoue T, Okamura A, Mano T, Hirata K, Tanabe K, Shibata Y, Owa M, Funayama H, Kokubu N, Kozuma K, Uemura S, Toubaru T, Saku K, Ohshima S, Nishimura K, Miyamoto Y, Ogawa H, Ishihara M: J Clin Med 2020/6; 9 (6): 1686. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110133. [Œ´’˜] Evaluation of an Integrated Device Diagnostics Algorithm to Risk Stratify Heart Failure Patients - Results From the SCAN-HF Study. Okumura K, Sasaki S, Kusano K, Mine T, Fujii K, Iwasa A, Sunagawa O, Yamabe H, Takahashi N, Ishii S1, Takeishi Y, Tsuboi N, Shizuta S, Aonuma K, Shimane A, Tada H, Ishikawa T, Tsunoda R, Numata T, Mukai Y, Kihara Y, Koehler J, Hidaka K, Sharma V: Circ J 2020/6; 84 (7): 1118-23. (Îˆär•ã1: 1zŠÂŠí“à)

110134. [Œ´’˜] Endothelial glycocalyx and severity and vulnerability of coronary plaque in patients with coronary artery disease. Nemoto T1, Minami Y1, Yamaoka-Tojo M2, Kato A3, Katsura A3, Sato T1, Muramatsu Y1, Kakizaki R1, Fujiyoshi K1, Hashimoto T1, Meguro K1, Shimohama T1, Ako J1: Atherosclerosis 2020/6; 302: 1-7. (ª–{Æ¢Žu1, “ì@®Œ«1, “ŒžŠ”ü“ÞŽq2, ‰Á“¡Ê”ü3, Œj@—L’q3, ²“¡r[1, ‘º¼—T‰î1, Š`è—Ç‘¾1, “¡‹g˜a”Ž1, ‹´–{‘ñ–í1, –ڍ•Œ’‘¾˜Y1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110135. [Œ´’˜] Healed Plaques in Patients With Stable Angina Pectoris. Russo M, Fracassi F, Kurihara O, Kim HO, Thondapu V, Araki M, Shinohara H, Sugiyama T, Yamamoto E, Lee H, Vergallo R, Crea F, Biasucci LM, Yonetsu T, Minami Y1, Soeda T, Fuster V, Jang I-K: Arterioscler Thromb Vasc Biol 2020/6; 40 (6): 1587-97. (“ì@®Œ«1: 1zŠÂŠí“à)

110136. [Œ´’˜] Ethnic Differences in the Pathobiology of Acute Coronary Syndromes Between Asians and Whites. Russo M, Kim HO, Thondapu V, Kurihara O, Araki M, Shinohara H, Yamamoto E, Lee H, Yonetsu T, Minami Y1, Adriaenssens T, Boeder NF, Nef HM, Crea F, Soeda T, Jang I-K: Am J Cardiol 2020/6; 125 (12): 1757-64. (“ì@®Œ«1: 1zŠÂŠí“à)

110137. [Œ´’˜] Seasonal Variations in the Pathogenesis of Acute Coronary Syndromes. Kurihara O, Takano M, Yamamoto E, Yonetsu T, Kakuta T, Soeda T, Yan BP, Crea F, Higuma T, Kimura S, Minami Y1, Adriaenssens T, Boeder NF, Nef HM, Kim CJ, Thondapu V, Kim HO, Russo M, Sugiyama T, Fracassi F, Lee H, Mizuno K, Jang I-K: J Am Heart Assoc 2020/7; 9 (13): e015579. (“ì@®Œ«1: 1zŠÂŠí“à)

110138. [Œ´’˜] Accuracy of a novel stress echocardiography pattern for myocardial bridging in patients with angina and no obstructive coronary artery disease - A retrospective and prospective cohort stud. Paragaonkar VS, Rogers IS, Su J, Forsdahl SH, Kameda R1, Schreiber D, Chan FP, Becker HC, Fleischmann D, Tremmel JA, Schnittger I: Int J Cardiol 2020/7; 311: 107-13. (‹T“c@—Ç1: 1zŠÂŠí“à)

110139. [Œ´’˜] Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials. Kobayashi T, Sotomi Y, Suzuki S, Suwannasom P, Nakatani S, Morino Y, Ako J1, Kozuma K, Hirayama A, Sakata Y, Higuchi Y: Cardiovasc Interv Ther 2020/7; 35 (3): 250-8. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110140. [Œ´’˜] Prediction of Long-Term Outcomes in ST-Elevation Myocardial Infarction and Non-ST Elevation Myocardial Infarction with and without Creatinine Kinase Elevation-Post-Hoc Analysis of the J-MINUET Study. Toyoda S, Sakuma M, Abe S, Inoue T, Nakao K, Ozaki Y, Kimura K, Ako J1, Noguchi T, Suwa S, Fujimoto K, Nakama Y, Morita T, Shimizu W, Saito Y, Hirohata A, Morita Y, Okamura A, Mano T, Wake M, Tanabe K, Shibata Y, Owa M, Tsujita K, Funayama H, Kokubu N, Kozuma K, Toubaru T, Saku K, Ohshima S, Miyamoto Y, Ogawa H, Ishihara M: J Clin Med 2020/8; 9 (8): 2667. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110141. [Œ´’˜] Spatial Distribution of Vulnerable Plaques: Comprehensive In Vivo Coronary Plaque Mapping. Araki M, Soeda T, Kim HO, Thondapu V, Russo M, Kurihara O, Shinohara H, Minami Y1, Higuma T, Lee H, Yonetsu T, Kakuta T, Jang I-K: JACC Cardiovasc Imaging 2020/9; 13 (9): 1989-99. (“ì@®Œ«1: 1zŠÂŠí“à)

110142. [Œ´’˜] Predictors of Rapid Plaque Progression: An Optical Coherence Tomography Study. Araki M, Yonetsu T, Kurihara O, Nakajima A, Lee H, Soeda T, Minami Y1, McNulty I, Uemura S, Kakuta T, Jang I-K: JACC Cardiovasc Imaging 2020/9; S1936-878X(20)30736-1. (“ì@®Œ«1: 1zŠÂŠí“à)

110143. [Œ´’˜] Optimal interlesion distance in ablation index-guided pulmonary vein isolation for atrial fibrillation. Kobayshi S1, Fukaya H2, Oikawa J2, Saito D1, Sato T1, Matsuura G1, Arakawa Y1, Shirakawa Y1, Nishinarita R2, Horiguchi A2, Ishizue N2, Kishihara J2, Niwano S2, Ako J2: J Interv Card Electrophysiol 2020/9. doi: 10.1007/s10840-020-00881-0. Online ahead of print. (¬—ÑŽü•½1, [’J‰p•½2, ‹yì@~2, âV“¡‘åŽ÷1, ²“¡“N˜Y1, ¼‰Y@Œ³1, rì—Y‹I1, ”’ì—TŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ŠÝŒ´@~2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†—Ã, 2zŠÂŠí“à)

110144. [Œ´’˜] Scaffold underexpansion and late lumen loss after bioresorbable scaffold implantation: Insights from ABSORB JAPAN trial. Okada K1, Honda Y1, Kitahara H1, Ikutomi M1, Kameda R1,2, Brooke Hollak M1, Yock PG1, Popma JJ1, Kusano H1, Cheong W-F1, Sudhir K1, Fitzgerald PJ1, Kimura T1 (1ABSORB Japan Investigators): Int J Cardiol Heart Vasc 2020/9; 31: 100623. (‹T“c@—Ç1,2: 2zŠÂŠí“à)

110145. [Œ´’˜] Prognostic Impact of B-Type Natriuretic Peptide on Long-Term Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Myocardial Infarction Without Creatine Kinase Elevation. Takahashi N1, Ogita M1, Suwa S1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Yasuda S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, YSaito Y1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Mano T1, Hirata K1, Tanabe K1, Shibata Y1, Owa M1, Tsujita K1, Funayama H1, Kokubu N1, Kozuma K1, Uemura S1, Tobaru T1, Saku K1, Oshima S1, Nishimura K1, Miyamoto Y1, Ogawa H1, Ishihara M1 (1J-MINUET investigators): Int Heart J 2020/9; 61 (5): 888-95. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110146. [Œ´’˜] Prediction of Lethal Arrhythmic Events Through Remote Monitoring Using Heart Rate Variability Analysis in Patients with an Implantable Cardioverter Defibrillator. Shirakawa Y1, Niwano S2, Oikawa J2, Saito D1, Sato T1, Matsuura G1, Arakawa Y1, Kobayashi S1, Nishinarita R2, Horiguchi A2, Ishizue N2, Kishihara J2, Fukaya H2, Ako J2: Int Heart J 2020/9; 61 (5): 927-35. (”’ì—TŠî1, ’ë–ìTˆê2, ‹yì@~2, âV“¡‘åŽ÷1, ²“¡“N˜Y1, ¼‰Y@Œ³1, rì—Y‹I1, ¬—ÑŽü•½1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ŠÝŒ´@~2, [’J‰p•½2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à)

110147. [Œ´’˜] Impact of peripheral artery disease on prognosis after myocardial infarction: The J-MINUET study. Akahori H1, Masuyama T1, Imanaka T1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Suwa S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Saito Y1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Mano T1, Hirata K1, Tanabe K1, Shibata Y1, Owa M1, Tsujita K1, Funayama H1, Kokubu N1, Kozuma K1, Uemura S1, Tobaru T1, Saku K1, Oshima S1, Nishimura K1, Miyamoto Y1, Ogawa H1, Ishihara M1 (1J-MINUET investigators): J Cardiol 2020/10; 76 (4): 402-6. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110148. [Œ´’˜] Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy. Matsumoto S, Nakazawa G, Ohno Y, Ishihara M, Sakai K, Nakamura N, Murakami T, Natsumeda M, Kabuki T, Shibata A, Kida K, Konishi M, Ishii S1, Ikeda T, Ikari Y: ESC Heart Fail 2020/10; 7 (6): 4172-81. (Îˆär•ã1: 1zŠÂŠí“à)

110149. [Œ´’˜] Clinical and procedure characteristics in patients treated with polytetrafluoroethylene-covered stents after coronary perforation: a CIRC-8U multicenter registry and literature review. Itoh T1, Kimura T1, Kudo A1, Morino Y1, Ikari Y1, Yoshioka K1, Nakano M1, Natsumeda M1, Sakuma M1, Inami S1, Ako J1,2, Nishinari M1,2, Shimohama T1,2, Komatsu T1, Ishikawa T1, Taguchi I1, Sugimura H1, Mitarai T1, Akashi Y1, Suzuki N1, Sugi K1, Matsumoto K1, Kohshoh H1, Yoshino H1 (1CIRC-8U Study Group): Cardiovasc Interv Ther 2020/10. doi: 10.1007/s12928-020-00716-9. Online ahead of print. (ˆ¢ŒÃÆ1,2, ¼¬^‹Õ1,2, ‰º•lF˜Y1,2: 2zŠÂŠí“à)

110150. [Œ´’˜] Impact of hemodialysis on clinical and angiographic outcomes in in-stent restenotic lesions following optical coherence tomography-guided drug-coated balloon treatment. Aoki J1, Nakazawa G1, Ando K1, Nakamura S1, Tobaru T1, Sakurada M1, Okada H1, Hibi K1, Zen K1, Ikuta A1, Fujii K1, Habara M1, Ako J1,2, Asano T1, Ozaki S1, Fusazaki T1, Kozuma K1 (1ELEGANT investigators): Cardiovasc Interv Ther 2020/10. doi: 10.1007/s12928-020-00718-7. Online ahead of print. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110151. [Œ´’˜] Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes. Kakizaki R1, Minami Y1, Katamine M2, Katsura A2, Muramatsu Y1, Hashimoto T1, Meguro K1, Shimohama T1, Ako J1: Cardiovasc Diabetol 2020/10; 19 (1): 162. (Š`è—Ç‘¾1, “ì@®Œ«1, •Ð•ô³á©2, Œj@—L’q2, ‘º¼—T‰î1, ‹´–{‘ñ–í1, –ڍ•Œ’‘¾˜Y1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110152. [Œ´’˜] Predictors for layered coronary plaques: an optical coherence tomography study. Araki M, Yonetsu T, Russo M, Kurihara O, Kim HO, Shinohara H, Thondapu V, Soeda T, Minami Y1, Higuma T, Lee H, Kakuta T, Jang I-K: J Thromb Thrombolysis 2020/11; 50 (4): 886-94. (“ì@®Œ«1: 1zŠÂŠí“à)

110153. [Œ´’˜] Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial. Tanaka A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima KR, Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M1, Ueda S, Higashi Y, Node K: J Diabetes Investig 2020/11; 11 (6): 1551-63. (“ŒžŠ”ü“ÞŽq1: 1ˆã—Éq¶Šw•”)

110154. [Œ´’˜] Clinical Outcomes of Off-Label Underdosing of Direct Oral Anticoagulants After Ablation for Atrial Fibrillation. Wakamatsu Y, Nagashima K, Watanabe R, Arai M, Yokoyama K, Matsumoto N, Otsuka T, Suzuki S, Hirata A, Murakami M, Takami M, Kimura M, Fukaya H1, Nakahara S, Kato T, Hayashi H, Iwasaki YK, Shimizu W, Nakajima I, Harada T, Koyama J, Okumura K, Tokuda M, Yamane T, Tanimoto K, Momiyama Y, Nonoguchi N, Soejima K, Ejima K, Hagiwara N, Harada M, Sonoda K, Inoue M, Kumagai K, Hayashi H, Yazaki Y, Satomi K, Watari Y, Okumura Y: Int Heart J 2020/11; 61 (6): 1165-73. ([’J‰p•½1: 1zŠÂŠí“à)

110155. [Œ´’˜] Clinical outcomes of ablation versus non-ablation therapy for atrial fibrillation in Japan: analysis of pooled data from the AF Frontier Ablation Registry and SAKURA AF Registry. Iso K1, Nagashima K1, Arai M1, Watanabe R1, Yokoyama K1, Matsumoto N1, Otsuka T1, Suzuki S1, Hirata A1, Murakami M1, Takami M1, Kimura M1, Fukaya H1,2, Nakahara S1, Kato T1, Hayashi H1, Iwasaki YK1, Shimizu W1, Nakajima I1, Harada T1, Koyama J1, Okumura K1, Tokuda M1, Yamane T1, Tanimoto K1, Momiyama Y1, Nonoguchi N1, Soejima K1, Ejima K1, Hagiwara N1, Harada M1, Sonoda K1, Inoue M1, Kumagai K1, Hayashi H1, Yazaki Y1, Satomi K1, Watari Y1, Okumura Y1 (1AF Ablation Frontier Registry investigators): Heart Vessels 2021/4; 36 (4): 549-60. doi: 10.1007/s00380-020-01721-x. Epub 2020 Nov 24. ([’J‰p•½1,2: 2zŠÂŠí“à)

110156. [Œ´’˜] Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE-HF cohort study. Matsue Y, Kamiya K1, Saito H, Saito K, Ogasahara Y, Maekawa E2, Konishi M, Kitai T, Iwata K, Jujo K, Wada H, Kasai T, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Yonezawa R3, Oka K, Momomura SI, Kagiyama N: Eur J Heart Fail 2020/11; 22 (11): 2112-9. (_’JŒ’‘¾˜Y1, ‘OìŒb”ü2, •ÄàV—²‰î3: 1ˆã—Éq¶Šw•”, 2zŠÂŠí“à, 3ƒŠƒnƒrƒŠ•”)

110157. [Œ´’˜] Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): a multicenter, randomized, double-blind, placebo-controlled trial. Asakura M1, Ito S1, Yamada T1, Saito Y1, Kimura K1, Yamashina A1, Hirayama A1, Kobayashi Y1, Hanatani A1, Tsujimoto M1, Yasuda S1, Abe Y1, Higashino Y1, Tamaki Y1, Sugino H1, Niinuma H1, Okuhara Y1, Koitabashi T1,2, Momomura SI1, Asai K1, Nomura A1, Kawai H1, Satoh Y1, Yoshikawa T1, Hirata KI1, Yokoi Y1, Tanaka J1, Shibata Y1, Maejima Y1, Tamaki S1, Kawta H1, Iwahashi N1, Kobayashi M1, Higuchi Y1, Kada A1, Yamamoto H1, Kitakaze M1 (1EARLIER investigators and study coordinators): Eur Heart J Cardiovasc Pharmacother 2020/11; pvaa132. doi: 10.1093/ehjcvp/pvaa132. Online ahead of print. (¬”‹´r”ü1,2: 2zŠÂŠí“à)

110158. [Œ´’˜] Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design. Fujiki S1, Iijima K1, Okabe M1, Niwano S1,2, Tsujita K1, Naito S1, Ando K1, Kusano K1, Kato R1, Nitta J1, Miura T1, Mitsuhashi T1, Kario K1, Kondo Y1, Ieda M1, Hagiwara N1, Murohara T1, Takahashi K1, Tomita H1, Takeishi Y1, Anzai T1, Shimizu W1, Watanabe M1, Morino Y1, Kato T1, Tada H1, Nakagawa Y1, Yano M1, Maemura K1, Kimura T1, Yoshida H1, Ota K1, Tanaka T1, Kitamura N1, Node K1, Aizawa Y1, Shimizu I1, Izumi D1, Ozaki K1, Minamino T1 (1EMPA-ICD investigators): Diabetes Ther 2020/11; 11 (11): 2739-55. (’ë–ìTˆê1,2: 2zŠÂŠí“à)

110159. [Œ´’˜] Novel volumetric analysis for stent expansion after drug-eluting stent implantation: An optical coherence tomography study. Katsura A1, Minami Y2, Kato A1, Muramatsu Y2, Sato T2, Hashimoto T2, Meguro K2, Shimohama T2, Ako J2: Catheter Cardiovasc Interv 2020/11; 96 (5): E501-7. (Œj@—L’q1, “ì@®Œ«2, ‰Á“¡Ê”ü1, ‘º¼—T‰î2, ²“¡r[2, ‹´–{‘ñ–í2, –ڍ•Œ’‘¾˜Y2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à)

110160. [Œ´’˜] Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2. Watanabe H1, Morimoto T1, Ogita M1, Suwa S1, Natsuaki M1, Suematsu N1, Koeda Y1, Morino Y1, Nikaido A1, Hata Y1, Doi M1, Hibi K1, Kimura K1, Yoda S1, Kaneko T1, Nishida K1, Kawai K1, Yamaguchi K1, Wakatsuki T1, Tonoike N1, Yamamoto M1, Shimizu S1, Shimohama T1,2, Ako J1,2, Kimura T1 (1STOPDAPT-2 Investigators): Cardiovasc Interv Ther 2020/11. doi: 10.1007/s12928-020-00719-6. Online ahead of print. (‰º•lF˜Y1,2, ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110161. [Œ´’˜] Energy loss by right ventricular pacing: Patients with versus without hypertrophic cardiomyopathy. Arakawa Y1, Fukaya H2, Kakizaki R2, Oikawa J2, Saito D1, Sato T1, Matsuura G1, Kobayashi S1, Shirakawa Y1, Nishinarita R2, Horiguchi A2, Ishizue N2, Nabeta T2, Kishihara J2, Niwano S2, Ako J2: J Arrhythm 2020/12; 37 (1): 203-11. (rì—Y‹I1, [’J‰p•½2, Š`è—Ç‘¾2, ‹yì@~2, âV“¡‘åŽ÷1, ²“¡“N˜Y1, ¼‰Y@Œ³1, ¬—ÑŽü•½1, ”’ì—TŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, “ç“c@Œ’2, ŠÝŒ´@~2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†—Ã, 2zŠÂŠí“à)

110162. [Œ´’˜] Characteristics of non-culprit plaques in acute coronary syndrome patients with layered culprit plaque. Russo M, Kim HO, Kurihara O, Araki M, Shinohara H, Thondapu V, Yonetsu T, Soeda T, Minami Y1, Higuma T, Lee H, Fracassi F, Vergallo R, Niccoli G, Crea F, Fuster V, Jang I-K: Eur Heart J Cardiovasc Imaging 2020/12; 21 (12): 1421-30. (“ì@®Œ«1: 1zŠÂŠí“à)

110163. [Œ´’˜] Guideline adherence and long-term clinical outcomes in patients with acute myocardial infarction: a Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET) substudy. Wada H1, Ogita M1, Suwa S1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Yasuda S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Saito Y1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Mano T1, Hirata K1, Tanabe K1, Shibata Y1, Owa M1, Tsujita K1, Funayama H1, Kokubu N1, Kozuma K1, Uemura S1, Toubaru T1, Saku K1, Oshima S1, Nishimura K1, Miyamoto Y1, Ogawa H1, Ishihara M1 (1J-MINUET investigators): Eur Heart J Acute Cardiovasc Care 2020/12; 9 (8): 939-47. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110164. [Œ´’˜] 1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y 12 Receptor Inhibitor Monotherapy Using a Bioabsorbable Polymer Sirolimus-Eluting Stent. Kozuma K1, Kinoshita Y1, Hioki H1, Nanasato M1, Ito Y1, Yamaguchi J1, Shiode N1, Hibi K1, Tanabe K1, Ako J1,2, Morino Y1, Hirohata A1, Sonoda S1, Nakagawa Y1, Ikari Y1: (1MODEL U-SES Study Investigators): Circ J 2020/12; 85 (1): 19-26. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110165. [Œ´’˜] Invasive assessment of myocardial bridging in patients with angina and no obstructive coronary artery disease. Paragaonkar VS, Kimura T, Kameda R1, Tanaka S, Yamada R, Schwarts JG, Perl L, Rogers IS, Honda Y, Fitzgerald P, Schnittger I, Tremmel JA: EuroIntervention 2021/1; 16 (13): 1070-8. (‹T“c@—Ç1: 1zŠÂŠí“à)

110166. [Œ´’˜] Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model. Nishinarita R1, Niwano S1, Niwano H, Nakamura H1, Saito D2, Sato T2, Matsuura G2, Arakawa Y2, Kobayashi S2, Shirakawa Y2, Horiguchi A1, Ishizue N1, Igarashi T1, Yoshizawa T1, Oikawa J1, Hara Y3, Katsumura T3, Kishihara J1, Satoh A1, Fukaya H1, Sakagami H3, Ako J1: J Am Heart Assoc 2021/1; 10 (2): e017483. (¼¬“c—º1, ’ë–ìTˆê1, ’†‘º—m”Í1, âV“¡‘åŽ÷2, ²“¡“N˜Y2, ¼‰Y@Œ³2, rì—Y‹I2, ¬—ÑŽü•½2, ”’ì—TŠî2, –xŒû@ˆ¤1, Î––¬Æ1, ŒÜ\—’Œš1, ‹gàV’qŽ¡1, ‹yì@~1, Œ´@–FL3, Ÿ‘ºŒ[Žj3, ŠÝŒ´@~1, ²“¡@—z1, [’J‰p•½1, ãã—ms3, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‰ð–U)

110167. [Œ´’˜] Characteristics of non-culprit plaques in acute coronary syndrome patients with calcified plaque at the culprit lesion. Kim HO, Kim CJ, Cho J-M, Soeda T, Kurihara O, Russo M, Araki M, Lee H, Minami Y1, Jang I-K: Catheter Cardiovasc Interv 2021/2; 97 (3): E298-305. (“ì@®Œ«1: 1zŠÂŠí“à)

110168. [Œ´’˜] Circadian variations in pathogenesis of ST-segment elevation myocardial infarction: an optical coherence tomography study. Araki M, Yonetsu T, Kurihara O, Nakajima A, Lee H, Soeda T, Minami Y1, Higuma T, Kimura S, Takano M, Yan BP, Adriaenssens T, Boeder NF, Nef HM, Kim CJ, Crea F, Kakuta T, Jang I-K: J Thromb Thrombolysis 2021/2; 51 (2): 379-87. (“ì@®Œ«1: 1zŠÂŠí“à)

110169. [Œ´’˜] Achilles tendon thickening is associated with higher incidence of adverse cardiovascular event in patients with coronary artery disease. Hashimoto T1, Minami Y1, Asakura K2, Katamine M2, Kato A2, Katsura A2, Sato T1, Muramatsu Y1, Kakizaki R1, Fujiyoshi K1, Ishida K1, Kameda R1, Meguro K1, Shimohama T1, Ako J1: Heart Vessels 2021/2; 36 (2): 163-9. (‹´–{‘ñ–í1, “ì@®Œ«1, ’©‘q´Žj2, •Ð•ô³á©2, ‰Á“¡Ê”ü2, Œj@—L’q2, ²“¡r[1, ‘º¼—T‰î1, Š`è—Ç‘¾1, “¡‹g˜a”Ž1, Î“cO‹B1, ‹T“c@—Ç1, –ڍ•Œ’‘¾˜Y1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110170. [Œ´’˜] Day-to-Day Variation of Early Repolarization Pattern Predicts Life-Threatening Arrhythmias in Patients With Brugada Syndrome. Ishizue N1, Niwano S1, Fukaya H1, Oikawa J1, Kishihara J1, Ako J1: Circ J 2021/2; 85 (3): 300-8. (Î––¬Æ1, ’ë–ìTˆê1, [’J‰p•½1, ‹yì@~1, ŠÝŒ´@~1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110171. [Œ´’˜] Late gadolinium enhancement for re-worsening left ventricular ejection fraction in patients with dilated cardiomyopathy. Nabeta T1, Ishii S1, Ikeda Y1, Maemura K2, Oki T2, Yazaki M2, Fujita T1, Y, Naruke T1, Inomata T1,3, Ako J1: ESC Heart Fail 2021/2; 8 (1): 615-24. (“ç“c@Œ’1, Îˆär•ã1, ’r“c—S‹B1, ‘O‘ºŒ’Ž¡2, ‘å–Ø‘ì–¤2, –îè–ƒ—R2, “¡“c“S•½1, ¬–с@’1, ’––”FŒ³1,3, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110172. [Œ´’˜] Prevalence and prognostic value of the coexistence of anaemia and frailty in older patients with heart failure. Tanaka S, Kamiya K1, Saito H, Saito K, Ogasahara Y, Maekawa E2, Konishi M, Kitai T, Iwata K, Jujo K, Wada H, Kasai T, Hamazaki N3, Nozaki K3, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Wakaume K, Oka K, Momomura SI, Kagiyama N, Matsue Y: ESC Heart Fail 2021/2; 8 (1): 625-33. (_’JŒ’‘¾˜Y1, ‘OìŒb”ü2, à_èL–¾3, –ìèN•½3: 1ˆã—Éq¶Šw•”, 2zŠÂŠí“à, 3ƒŠƒnƒrƒŠ•”)

110173. [Œ´’˜] Clinical significance of left atrial geometry in dilated cardiomyopathy patients: A cardiovascular magnetic resonance study. Yazaki M1, Nabeta T2, Inomata T2,3, Maemura K1, Oki T1, Fujita T2, Ikeda Y2, Ishii S2, Naruke T2, Inoue Y4, Ako J2: Clin Cardiol 2021/2; 44 (2): 222-9. (–îè–ƒ—R1, “ç“c@Œ’2, ’––”FŒ³2,3, ‘O‘ºŒ’Ž¡1, ‘å–Ø‘ì–¤1, “¡“c“S•½2, ’r“c—S‹B2, Îˆär•ã2, ¬–с@’2, ˆäã—D‰î4, ˆ¢ŒÃÆ2: 1‘åŠwˆãŠwˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 4•úŽËü (‰æ‘œ))—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110174. [Œ´’˜] Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. Nakamura M, Ako J1, Arai H, Hirayama A, Nohara A, Murakami Y, Ozaki A, Harada-Shiba M: J Atheroscler Thromb 2021/2. doi: 10.5551/jat.59543. Online ahead of print. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110175. [Œ´’˜] Clinical characteristics and in-hospital outcomes in patients aged 80 years or over with cardiac troponin-positive acute myocardial infarction -J-MINUET study. Soeda T1, Okura H1, Saito Y1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Suwa S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Mano T1, Hirata K1, Tanabe K1, Shibata Y1, Owa M1, Tsujita K1, Funayama H1, Kokubu N1, Kozuma K1, Uemura S1, Toubaru T1, Saku K1, Oshima S1, Miyamoto Y1, Ogawa H1, Ishihara M1 (1J-MINUET investigators): J Cardiol 2021/2; 77 (2): 139-46. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110176. [Œ´’˜] A novel risk stratification system ""Angiographic GRACE Score"" for predicting in-hospital mortality of patients with acute myocardial infarction: Data from the K-ACTIVE Registry. Mitarai T, Tanabe Y, Akashi YJ, Maeda A, Ako J1, Ikari Y, Ebina T, Namiki A, Fukui K, Michishita I, Kimura K, Suzuki H: J Cardiol 2021/2; 77 (2): 179-85. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110177. [Œ´’˜] Comparison of post-stent optical coherence tomography findings among three subtypes of calcified culprit plaques in patients with acute coronary syndrome. Nakajima A, Araki M, Kurihara O, Minami Y1, Soeda T, Yonetsu T, Crea F, Takano M, Higuma T, Kakuta T, Adriaenssens T, Lee H, Nakamura S, Jang I-K: Catheter Cardiovasc Inter. 2021/3; 97 (4): 634-45. (“ì@®Œ«1: 1zŠÂŠí“à)

110178. [Œ´’˜] Additional posterior wall isolation is associated with gastric hypomotility in catheter ablation of atrial fibrillation. Oikawa J1, Fukaya H1, Wada T2, Horiguchi A1, Kishihara J1, Satoh A, Saito D3, Sato T3, Matsuura G3, Arakawa Y3, Kobayashi S3, Shirakawa Y3, Nishinarita R1, Ishizue N1, Katada C2, Tanabe S2,4, Niwano S1, Ako J1: Int J Cardiol 2021/3; 326: 103-8. (‹yì@~1, [’J‰p•½1, ˜a“c‘ñ–ç2, –xŒû@ˆ¤1, ŠÝŒ´@~1, âV“¡‘åŽ÷3, ²“¡“N˜Y3, ¼‰Y@Œ³3, rì—Y‹I3, ¬—ÑŽü•½3, ”’ì—TŠî3, ¼¬“c—º1, Î––¬Æ1, Œ˜“ce—˜2, “c糁@‘2,4, ’ë–ìTˆê1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2Á‰»Ší“à, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110179. [Œ´’˜] Impact of Age on Gender Difference in Long-term Outcome of Patients With Acute Myocardial Infarction (from J-MINUET). Kimura T1, Akahori H1, Asakura M1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Suwa S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Saito Y1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Mano T1, Wake M1, Tanabe K1, Shibata Y1, Owa M1, Tsujita K1, Funayama H1, Kokubu N1, Kozuma K1, Uemura S1, Toubara T1, Saku K1, Oshima S1, Nishimura K1, Miyamoto Y1, Ogawa H1, Ishihara M1: (1MINUET Investigators): Am J Cardiol 2021/3; 142: 5-13. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

310008. [Ç—á•ñ] Severe hypoperistalsis caused by a 3-min single shot cryoballoon ablation for paroxysmal atrial fibrillation: A case report. Fukaya H1, Niwano S1, Tanabe S2,3, Kishihara J1, Shirakawa Y4, Kobayashi S4, Arakawa Y4, Nishinarita R1, Horiguchi A1, Ishizue N1, Wada T3, Oikawa J1, Ako J1: J Cardiol Cases 2020/4; 22 (1): 26-8. ([’J‰p•½1, ’ë–ìTˆê1, “c糁@‘2,3, ŠÝŒ´@~1, ”’ì—TŠî4, ¬—ÑŽü•½4, rì—Y‹I4, ¼¬“c—º1, –xŒû@ˆ¤1, Î––¬Æ1, ˜a“c‘ñ–ç3, ‹yì@~1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3Á‰»Ší“à, 4‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

310009. [Ç—á•ñ] Simultaneous Transaortic Transcatheter Aortic Valve Implamtation, OffPump Coronary Artery Bypass Grafting and Pulmonary Vein Isolation. Ogiso S1, Kitamura T2, Meguro K1, Ako J1, Miyaji K2: Annals of Case Reports 2020/5; 14 (6): 308-11. (¬–Ø‘]ãÄ1, –k‘º@—¥2, –ڍ•Œ’‘¾˜Y1, ˆ¢ŒÃÆ1, ‹{’n@ŠÓ2: 1zŠÂŠí“à, 2S‘ŸŒŒŠÇŠO)

310010. [Ç—á•ñ] Recurrent In-Stent Restenosis With Eccentric Neointimal Hyperplasia at a Lesion With Hingelike Motion. Ishida K1, Minami Y1, Fujiyoshi K1, Ishida M1, Ako J1, Inomata T1,2: JACC Cardiovasc Interv 2020/6; 13 (11): e103-4. (Î“cO‹B1, “ì@®Œ«1, “¡‹g˜a”Ž1, Î“cŽO˜a1, ˆ¢ŒÃÆ1, ’––”FŒ³1,2: 1zŠÂŠí“à, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

310011. [Ç—á•ñ] Precise Signals with a High-Density Grid Mapping Catheter Are Useful for an Entrainment Study. Oikawa J1, Fukaya H1, Niwano S1, Saito D2, Sato T2, Matsuura G2, Arakawa Y2, Kobayashi S2, Shirakawa Y2, Horiguchi A1, Nishinarita R1, Ishizue N1, Kishihara J1, Ako J1: Int Heart J 2020/7; 61 (4): 838-42. (‹yì@~1, [’J‰p•½1, ’ë–ìTˆê1, âV“¡‘åŽ÷2, ²“¡“N˜Y2, ¼‰Y@Œ³2, rì—Y‹I2, ”’ì—TŠî2, ¬—ÑŽü•½2, –xŒû@ˆ¤1, ¼¬“c—º1, Î––¬Æ1, ŠÝŒ´@~1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

310012. [Ç—á•ñ] Tako-tsubo-like left ventricular dysfunction in a patient with COVID-19 demonstrated by non-invasive multi-modality imaging. Fujiyoshi K1, Ako J1, Ishida K1, Ishida M1, Minami Y1, Inomata T1,2: J Nucl Cardiol 2020/10; 1-3. doi: 10.1007/s12350-020-02367-y. Online ahead of print. (“¡‹g˜a”Ž1, ˆ¢ŒÃÆ1, Î“cO‹B1, Î“cŽO˜a1, “ì@®Œ«1, ’––”FŒ³1,2: 1zŠÂŠí“à, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

310013. [Ç—á•ñ] Left Ventricular Contraction Sequence in a Case Where the QRS Changed from Left to Atypical Right Bundle Branch Block. Hara H, Nagata T1, Ito H, Niwano S2, Ako J2: Int Med Case Rep J 2020/11; 13: 573-9. (‰i“c‹MŽq1, ’ë–ìTˆê2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à)

310014. [Ç—á•ñ] Unique feature of novel activation mapping to identify the successful ablation site of atrial tachycardia. Kishihara J1, Fukaya H1, Oikawa J1, Ako J1: Heart Rhythm 2021/4; 18 (4): 653-4. doi: 10.1016/j.hrthm.2020.12.024. Epub 2020 Dec 29. (ŠÝŒ´@~1, [’J‰p•½1, ‹yì@~1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

310015. [Ç—á•ñ] An Irreversible Worsening Cardiac Function after Withdrawing Medical Treatments in a Patient with Dilated Cardiomyopathy: A Pathological Analysis. Yazaki M1, Nabeta T2, Inomata T2,3, Ako J2: Intern Med 2021/2; 60 (4): 553-6. (–îè–ƒ—R1, “ç“c@Œ’2, ’––”FŒ³2,3, ˆ¢ŒÃÆ2: 1‘åŠwˆãŠwˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

510004. [‘à] Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. Li J-J, Hui-Hui Liu H-H, Wu N-Q, Yeo KK, Tan K, Ako J1, Krittayaphong R, Tan RS, Aylward PE, Baek SH, Dalal J, Fong AYY, Li Y-H, O'Brien RC, Lim TSE, Koh SYN, Scherer DJ, Tada H, Kang V, Nicholls BJSJ: Expert Opin Drug Metab Toxicol 2020/9; 16 (9): 837-51. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

510005. [‘à] Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19. Yamaoka-Tojo M1: Biomed J 2020/10; 43 (5): 399-413. (“ŒžŠ”ü“ÞŽq1: 1ˆã—Éq¶Šw•”)

510006. [‘à] Vascular Endothelial Glycocalyx Damage in COVID-19. Yamaoka-Tojo M1: Int J Mol Sci 2020/12; 21 (24): 9712. (“ŒžŠ”ü“ÞŽq1: 1ˆã—Éq¶Šw•”)

510007. [‘à] Clinical expert consensus document on rotational atherectomy from the Japanese association of cardiovascular intervention and therapeutics. Sakakura K, Ito Y, Shibata Y, Okamura A, Kashima Y, Nakamura S, Hamazaki Y, Ako J1, Yokoi H, Kobayashi Y, Ikari Y: Cardiovasc Inter

510008. [‘à] 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y 12 Receptor Antagonists in the Asia-Pacific Region. Tan JW, Chew DP, Abdul Kader MAS, Ako J1, Bahl VK, Chan M, Park KW, Chandra P, Hsieh I-C, Huan DQ, Johar S, Juzar DA, Kim B-K, Lee CW, Lee MK, Li Y-H, Almahmeed W, Sison EO, Tan D, Wang Y-C, Yeh SJ, Montalescot G: Eur Cardiol 2021/3; 16: e02. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

511001. [‰ðà] Editorial to ""Infection and migration incidence of Cardiac Implantable Electrical Devices in Japan: Web-based survey results"". Niwano S1: J Arrhythm 2020/5; 36 (4): 784. (’ë–ìTˆê1: 1zŠÂŠí“à)

511002. [‰ðà] Editorial to ""Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri-Procedural Period of Catheter Ablation for Atrial Fibrillation"". Fukaya H1: J Arrhythm 2020; 36 (4): 642-3. ([’J‰p•½1: 1zŠÂŠí“à)

522028. [uÀ]y“ÁW: “œ”A•aŠ³ŽÒ‚̐SŒŒŠÇ•aœëŠ³ƒŠƒXƒN‚É‚Ç‚¤—§‚¿Œü‚©‚¤‚©zŽ¡‚·8@“œ”A•aŠ³ŽÒ‚ÌŠ¥“®–¬Ž¾Š³‚ð‚Ç‚¤Ž¡—·‚é? ’r“c—S‹B1, ˆ¢ŒÃÆ2 (1‹~–½, 2zŠÂŠí“à): Heart View 2020/7; 24 (7): 625-31.

522029. [uÀ]y“ÁW: •s®–¬–ò•¨Ž¡—ÃupdatezS–[×“®‚É‚¨‚¯‚é“´’²—¥ˆÛŽ—Ö@|–ò•¨—Ö@‚̈Ӌ`‚ƃAƒuƒŒ[ƒVƒ‡ƒ“‚Ƃ̃nƒCƒuƒŠƒbƒhŽ¡—Ð헪. ’ë–ìTˆê (zŠÂŠí“à): zŠÂŠí“à‰È 2020/8; 88 (2): 137-44.

522030. [uÀ]y“ÁW: Ž‰Ž¿ˆÙíÇ‚Æ“®–¬d‰»updatezŠ¥“®–¬Ž¾Š³“ñŽŸ—\–hŠ³ŽÒ‚ÌŽ‰Ž¿ŠÇ—. ’©‘q´Žj1, ‹´–{‘ñ–í1, “ì@®Œ«1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): “œ”A•aE“à•ª”å‘ãŽÓ‰È 2020/8; 51 (2): 110-7.

522031. [uÀ]y“ÁW: RŒŒð—Ö@|“úí—Տ°‚Å‚Ì‹^–â‚ɉž‚¦‚éz¡II. ‹•ŒŒ«SŽ¾Š³E‰ºŽˆ“®–¬Ž¾Š³‚ɑ΂·‚éRŒŒð—Ö@@P2Y12‘jŠQ‚É‚æ‚éRŒŒ¬”–ò (ƒNƒƒsƒhƒOƒŒƒ‹Eƒvƒ‰ƒXƒOƒŒƒ‹Eƒ`ƒJƒOƒŒƒƒ‹) ‚Í“Á’¥‚É‚æ‚è‚Ç‚¤Žg‚¢•ª‚¯‚é‚©? ‹T“c@—Ç1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): zŠÂŠíƒWƒƒ[ƒiƒ‹ 2020/10; 68 (4): 632-40.

522032. [uÀ]y“ÁW: ÅVƒKƒCƒhƒ‰ƒCƒ“catch-up! •s®–¬‚Ì–ò•¨—Ö@z¡•s®–¬‚ÌŠÇ—@–ò•¨•›ì—pƒ‚ƒjƒ^ƒŠƒ“ƒO. ’ë–ìTˆê (zŠÂŠí“à): ŒŽŠ§–òŽ– 2020/11; 62 (15): 2965-71.

522033. [uÀ]y“ÁW: —Տ°‚ɖ𗧂½‚¹‚é! ŠeŽíSƒGƒR[‹Zp‚ÌŠˆ—p–@zS‹ØŽ¾Š³‚Å‚ÌŠˆ—p–@. ¬”‹´r”ü (zŠÂŠí“à): SƒGƒR[ 2020/12; 21 (12): 1158-68.

522034. [uÀ]y“ÁW: Š¥“®–¬Ž¾Š³‚ƍRŒŒð—Ö@zDOAC‚Ì“K‰ž‚ƐV‚½‚ȉ”\«. –؉º‘厑1, [’J‰p•½1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): zŠÂŠí“à‰È 2020/12; 88 (6): 604-10.

522035. [uÀ]y“ÁW: ”ñ•Ù–ŒÇ«S–[×“®‚É‚¨‚¯‚é“KØ‚ȍR‹ÃŒÅ—Ö@z”ñ•Ù–ŒÇ«S–[×“®‚Æ‹•ŒŒ«SŽ¾Š³‡•¹‚É‚¨‚¯‚é“KØ‚ȍRŒŒð—Ö@. ˆ¢ŒÃÆ (zŠÂŠí“à): “ú–{ŒŒðŽ~ŒŒŠw‰ïŽ 2020/12; 31 (6): 562-70.

522036. [uÀ]yÀ’k‰ïz2020”N‰ü’ù”Å •s®–¬–ò•¨Ž¡—ÃKƒCƒhƒ‰ƒCƒ“|‰ü’ù‚̃|ƒCƒ“ƒg|. ¬—Ñ‹`“T, ’r“c—²“¿, Šâè—YŽ÷, ’ë–ìTˆê1 (1zŠÂŠí“à): —Տ°ˆã‚Ì‚½‚߂̏zŠÂŠíf—à 2020; 33: 3-21.

522037. [uÀ]y“ÁW: ƒtƒŒƒCƒ‹‚ƏzŠÂŠíf—Áz1. ƒtƒŒƒCƒ‹‚Æ‹}«Š¥ÇŒóŒQ. ‰i“c‹MŽq, “ì@®Œ«1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): S‘Ÿ 2021/2; 53 (2): 112-6.

530008. [‚»‚Ì‘¼ (Comment)] Response by Russo et al Regarding Article, ""Healed Plaques in Patients With Stable Angina Pectoris"". Russo M, Fracassi F, Kurihara O, Kim HO, Thondapu V, Araki M, Shinohara H, Sugiyama T, Yamamoto E, Lee H, Vergallo R, Crea F, Biasucci LM, Yonetsu T, Minami Y1, Soeda T, Fuster V, Jang I-K: Arterioscler Thromb Vasc Biol 2020/9; 40 (9): e258-9. (“ì@®Œ«1: 1zŠÂŠí“à)

530009. [‚»‚Ì‘¼ (Erratum)] Correction to: Clinical expert consensus document on rotational atherectomy from the Japanese association of cardiovascular intervention and therapeutics. Sakakura K, Ito Y, Shibata Y, Okamura A, Kashima Y, Nakamura S, Hamazaki Y, Ako J1, Yokoi H, Kobayashi Y, Ikari Y: Cardiovasc Interv Ther 2021/1; 36 (1): 19. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

530010. [‚»‚Ì‘¼ (Erratum)] Correction to: Influence of CYP2C19 genotypes for the effect of 1 month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12 month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT 2. Watanabe H1, Morimoto T1, Ogita M1, Suwa S1, Natsuaki M1, Suematsu N1, Koeda Y1, Morino Y1, Nikaido A1, Hata Y1, Doi M1, Hibi K1, Kimura K1, Yoda S1, Kaneko T1, Nishida K1, Kawai K1, Yamaguchi K1, Wakatsuki T1, Tonoike N1, Yamamoto M1, Shimizu S1, Shimohama T1,2, Ako J1,2, Kimura T1 (1STOPDAPT-2 Investigators): Cardiovasc Interv Ther 2021/2. doi: 10.1007/s12928-020-00741-8. Online ahead of print. (‰º•lF˜Y1,2, ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à

540019. [‚»‚Ì‘¼ (Comment)] ‘åˆä“c˜_•¶‚ɑ΂·‚éEditorial Comment. ’ë–ìTˆê (zŠÂŠí“à): S‘Ÿ 2020/4; 52 (4): 436.

540020. [‚»‚Ì‘¼ (Comment)] ¬–ì˜_•¶‚ɑ΂·‚éEditorial Comment: ‰“Šuƒ‚ƒjƒ^ƒŠƒ“ƒO‚̗Տ°‰ž—p–͍õ‚Ì•K—v«. ’ë–ìTˆê (zŠÂŠí“à): S‘Ÿ 2020/10; 52 (10): 1153.

540021. [‚»‚Ì‘¼ (Comment)] ¯˜_•¶‚ɑ΂·‚éEditorial Comment. “ç“c@Œ’ (zŠÂŠí“à): S‘Ÿ 2020/12; 52 (12): 1403.

[’˜@‘]

620027. [Šwp‘ (•ª’SŽ·•M)]y‚Ç‚¤Œø‚­? ‚Ç‚¤Žg‚¤? ‚ª‚܂邲‚Æ‚í‚©‚é@zŠÂŠí‚Ì–òÜƒJƒ^ƒƒO143 (ƒn[ƒgƒi[ƒVƒ“ƒO2020”Nt‹G‘Š§)z‘æ3Í R•s®–¬–ò, p.44-64. ŠÝŒ´@~1 (1zŠÂŠí“à), •Ò: ’––”FŒ³1,2 (2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@), ƒƒfƒBƒJo”Å, ‘åã, 2020/4”­s.

620028. [Šwp‘ (•ª’SŽ·•M)]y‹É‚ß‚ézŠÂŠí—Šw—Ö@@zŠÂŠí•a‚ð—L‚·‚銳ŽÒ‚̏áŠQ‘œ‚É’§‚ށzPart I —Šw—Ö@‚©‚猩‚ézŠÂŠí•a‚ɑ΂·‚郊ƒnƒrƒŠƒe[ƒVƒ‡ƒ“@2. zŠÂŠíˆã‚©‚猩‚½zŠÂŠí—Šw—Ö@‚ً̈c, p.6-10. ’––”FŒ³1,2 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2zŠÂŠí“à), •Ò: Ä“¡G”V, ‰Á“¡@_, –Ø‘º‰ë•F, •¶Œõ“°, “Œ‹ž, 2020/7”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713005. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Time course of left ventricular reverse remodeling in response to cardiac resynchronization therapy - Late response is a prognostic indicator similar to early response. Oki T1, Ishii S2, Maemura K1, Yazaki M1, Fujita T2, Ikeda Y3, Nabeta T2, Maekawa E2, Naruke T2, Koitabashi T2, Inomata T2,4, Ako J2: ESC heart failure 2020 (2020/5/23-26), Barcelona, Spain. (‘å–Ø‘ì–¤1, Îˆär•ã2, ‘O‘ºŒ’Ž¡1, –îè–ƒ—R1, “¡“c“S•½2, ’r“c—S‹B3, “ç“c@Œ’2, ‘OìŒb”ü2, ¬–с@’2, ¬”‹´r”ü2, ’––”FŒ³2,4, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à, 3‹~–½, 4–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

713006. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Relationship late gadolinium enhancement on cardiovascular magnetic resonance and longitudinal ejection fraction change in patients with recent onset dilated cardiomyopathy. Nabeta T1, Ishii S1, Ikeda Y2, Oki T3, Maemura K3, Yazaki Y3, Fujita T1, Naruke T1, Ako J1: ESC heart failure 2020 (2020/5/23-26), Barcelona, Spain. (“ç“c@Œ’1, Îˆär•ã1, ’r“c—S‹B2, ‘å–Ø‘ì–¤3, ‘O‘ºŒ’Ž¡3, –îè–ƒ—R3, “¡“c“S•½1, ¬–с@’1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

713007. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Decline in left ventricular ejection fraction is associated with heart failure hospitalization and sudden death in patients with cardiac sarcoidosis. Takigami Y1, Nabeta T1, Ishii S1, Maemura K2, Oki T2, Yazaki M2, Fujita T1, Ikeda Y3, Naruke T1, Ako J1: ESC heart failure 2020 (2020/5/23-26), Barcelona, Spain. (‘ëã@—I1, “ç“c@Œ’1, Îˆär•ã1, ‘O‘ºŒ’Ž¡2, ‘å–Ø‘ì–¤2, –îè–ƒ—R2, “¡“c“S•½1, ’r“c—S‹B3, ¬–с@’1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‹~–½)

713008. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Dyslipidemia : how low to go? Ako J1: APSC JCS 2020 (2020/7/27-8/1), Webinar. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

713009. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Predictors for rapid progression of coronary calcification: an optical coherence tomography (OCT) study. Nakajima A, Araki M, Kurihara O, Minami Y1, Soeda T, Higuma T, Kakuta T, Lee H, Malhotra R, Nakamura S, Jang IK: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (“ì@®Œ«1: 1zŠÂŠí“à)

713010. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Circadian variations in pathogenesis of ST-segment elevation myocardial infarction. Araki M, Yonetsu T, Kurihara O, Nakajima A, Lee H, Soeda T, Minami Y1, Yan BP, Adriaenssens T, Boeder NF, Nef HM, Kim CJ, Crea F, Kakuta T, Jang IK: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (“ì@®Œ«1: 1zŠÂŠí“à)

713011. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Predictors of rapid plaque progression: an optical coherence tomography study. Araki M, Yonetsu T, Kurihara O, Nakajima A, Lee H, Soeda T, Minami Y1, Uemura S, Kakuta T, Jang IK: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (“ì@®Œ«1: 1zŠÂŠí“à)

713012. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Remote monitoring can predict lethal arrhythmic events through time-domain analysis of heart rate variability in patients with implantable cardioverter defibrillator. Shirakawa Y1, Niwano S2, Oikawa J2, Matsuura G1, Arakawa Y1, Kobayashi S1, Nishinarita R2, Horiguchi A2, Ishizue N2, Kishihara J2, Fukaya H2, Ako J2: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (”’ì—TŠî1, ’ë–ìTˆê2, ‹yì@~2, ¼‰Y@Œ³1, rì—Y‹I1, ¬—ÑŽü•½1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ŠÝŒ´@~2, [’J‰p•½2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à)

713013. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Salusin ƒÀ, a novel bio marker for risk of fatal arrhythmia in Brugada syndrome. Nishinarita R1, Niwano S1, Ishizue N1, Saito D2, Sato T2, Matsuura G2, Arakawa Y2, Kobayashi S2, Shirakawa Y2, Horiguchi A1, Nakamura H1, Igarashi G, Oikawa J1, Kishihara J1, Satoh A, Fukaya H1, Ako J1: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (¼¬“c—º1, ’ë–ìTˆê1, Î––¬Æ1, âV“¡‘åŽ÷2, ²“¡“N˜Y2, ¼‰Y@Œ³2, rì—Y‹I2, ¬—ÑŽü•½2, ”’ì—TŠî2, –xŒû@ˆ¤1, ’†‘º—m”Í1, ‹yì@~1, ŠÝŒ´@~1, [’J‰p•½1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

713014. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Clinical significance of left atrial geometry in patients with dilated cardiomyopathy: a cardiovascular magnetic resonance study. Yazaki M1, Nabeta T2, Inomata T2,3, Maemura K1, Oki T1, Fujita T2, Ikeda Y4, Ishii S2, Naruke T2, Ako J2: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (–îè–ƒ—R1, “ç“c@Œ’2, ’––”FŒ³2,3 , ‘O‘ºŒ’Ž¡1, ‘å–Ø‘ì–¤1, “¡“c“S•½2, ’r“c—S‹B4, Îˆär•ã2, ¬–с@’2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@ 4‹~–½)

713015. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Plaque erosion is associated with less systemic atherosclerosis than other plaque types of acute coronary syndrome. Kato A1, Minami Y2, Asakura K1, Katamine M1, Katsura A1, Muramatsu Y2, Sato T2, Kakizaki R2, Hashimoto T2, Meguro K2, Shimohama T2, Ako J2: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (‰Á“¡Ê”ü1, “ì@®Œ«2, ’©‘q´Žj1, •Ð•ô³á©1, Œj@—L’q1, ‘º¼—T‰î2, ²“¡rˆò2, Š`è—Ç‘¾2, ‹´–{‘ñ–í2, –ڍ•Œ’‘¾˜Y2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à)

713016. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Higher level of high sensitivity C-reactive protein is associated with more fibrocalcific plaque and longer lesion in patients with acute coronary syndrome. Katamine M1, Minami Y2, Asakura K1, Kato A1, Katsura A1, Sato T2, Muramatsu Y2, Hashimoto T2, Kameda R2, Meguro K2, Shimohama T2, Ako J2: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (•Ð•ô³á©1, “ì@®Œ«2, ’©‘q´Žj1, ‰Á“¡Ê”ü1, Œj@—L’q1, ²“¡rˆò2, ‘º¼—T‰î2, ‹´–{‘ñ–í2, ‹T“c@—Ç2, –ڍ•Œ’‘¾˜Y2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à)

713017. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Left ventricular recovery during long-term medical treatment in comparison among morphological types of QRS complex in patients with dilated cardiomyopathy. Maemura K1, Ikeda Y2, Oki T1, Yazaki M1, Fujita T3, Nabeta T3, Ishii S3, Maekawa E3, Naruke T3, Koitabashi T3, Inomata T3,4, Ako J3: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (‘O‘ºŒ’Ž¡1, ’r“c—S‹B2, ‘å–Ø‘ì–¤1, –îè–ƒ—R1, “¡“c“S•½3, “ç“c@Œ’3, Îˆär•ã3, ‘OìŒb”ü3, ¬–с@’3, ¬”‹´r”ü3, ’––”FŒ³3,4, ˆ¢ŒÃÆ3: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‹~–½, 3zŠÂŠí“à, 4–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

713018. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Prognostic implications of late gadolinium enhancement for re-worsening left ventricular ejection fraction in patients with dilated cardiomyopathy: A longitudinal study of left ventricular function. Nabeta T1, Ishii S1, Ikeda Y2, Oki T3, Maemura K3, Yazaki M3, Fujita T1, Naruke T1, Inomata T1,4, Ako J1: European Society of Cardiology (ESC) 2020 Annual Meeting (2020/8/29-9/1), Amsterdam, Netherlands. (“ç“c@Œ’1, Îˆär•ã1, ’r“c—S‹B2, ‘å–Ø‘ì–¤3, ‘O‘ºŒ’Ž¡3, –îè–ƒ—R3, “¡“c“S•½1, ¬–с@’1, ’––”FŒ³1,4, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

713019. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Untreated Sleep Apnea Syndrome is Associated With Higher Incidence of Cardiovascular Events After Percutaneous Coronary Intervention. Fujiyoshi K1, Minami Y1, Ishida K1, Ishida M1, Wakabayashi K, Ako J1, Inomata T1,2: American Heart Association (AHA) 2020 Scientific Session (2020/11/13-17), Dallas, USA. (“¡‹g˜a”Ž1, “ì@®Œ«1, Î“cO‹B1, Î“cŽO˜a1, ˆ¢ŒÃÆ1, ’––”FŒ³1,2: 1zŠÂŠí“à, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

713020. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Higher triglyceride level is associated with higher frequency of macrophage accumulation in coronary plaques. Asakura K1, Minami Y2, Katamine M1, Kato A1, Katsura A1, Sato T2, Muramatsu Y2, Hashimoto T2, Kameda R2, Meguro K2, Shimohama T2, Ako J2: American Heart Association (AHA) 2020 Scientific Session (2020/11/13-17), Dallas, USA. (’©‘q´Žj1, “ì@®Œ«2, •Ð•ô³á©1, ‰Á“¡Ê”ü1, Œj@—L’q1, ²“¡rˆò2, ‘º¼—T‰î2, ‹´–{‘ñ–í2, ‹T“c@—Ç2, –ڍ•Œ’‘¾˜Y2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à)

713021. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Smaller stent area and eccentric expansion are associated with increased adverse events after drug-eluting stent implantation in hemodialysis patients. Katsura A1, Minami Y2, Asakura K1, Katamine M1, Kato A1, Hashimoto T2, Meguro K2, Shimohama T2, Ako J2: American Heart Association (AHA) 2020 Scientific Session (2020/11/13-17), Dallas, USA. (Œj@—L’q1, “ì@®Œ«2, ’©‘q´Žj1, •Ð•ô³á©1, ‰Á“¡Ê”ü1, ‹´–{‘ñ–í2, –ڍ•Œ’‘¾˜Y2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à)

713022. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) COVID-19 management strategies. Ako J1: ESC Acute CardioVascular Care 2021 (2021/3/14), WebŠJÃ. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

722032. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) PCIŽ{sŠ³ŽÒ‚É‚¨‚¯‚éRŒŒð—Ö@. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ52‰ñ“ú–{“®–¬d‰»Šw‰ï‘‰ïEŠwpW‰ï (2020/7/17-31), webŠJÃ.

722033. [Šw‰ï (‘S‘)] (Change practice) Change Practice in Antithrombotic Therapy after PCI. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

722034. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) 2020”N“xf—ÕñV‰ü’è‚Ì“®Œü‚ƍ¡Œã‚Ì•ÛŒ¯f—Â̂ ‚è•û. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

722035. [Šw‰ï (‘S‘)] (Topics) Management of Atrial Fibrillation in Patients with High Bleeding Risk. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

722036. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÇðŒ¹•s–¾‚Ì”]ÇðÇ (ESUS) ‚ƐSƒGƒR[zŠïˆÙ«”]Çð‚Ì•a‘Ô: ÇðŒ¹‚Æ‚µ‚Ä‚Ì—‘‰~EŠJ‘¶f’f. ¬”‹´r”ü (zŠÂŠí“à): ˆê”ÊŽÐ’c–@l“ú–{SƒGƒR[}Šw‰ï‘æ31‰ñŠwpW‰ï (2020/8/14-15), “‡ª.

722037. [Šw‰ï (‘S‘)] (‹³ˆçŠé‰æ) MitraClip‚ðˆÓŽ¯‚µ‚½ŒoH“¹ƒGƒR[‚É‚æ‚é‘m–X•Ù‚Ì•]‰¿. ‘OìŒb”ü1, ¬”‹´r”ü1, “¡“c“S•½1, ŒSŽRŒbŽq2, –ڍ•Œ’‘¾˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘‡f—Ã): ˆê”ÊŽÐ’c–@l“ú–{SƒGƒR[}Šw‰ï‘æ31‰ñŠwpW‰ï (2020/8/14-15), “‡ª.

722038. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) S‘ŸCT, S‘ŸMRI, S‹ØƒVƒ“ƒ` S•s‘S‚̐f’f‚ÉŠeŒŸ¸‚ðŠˆ‚©‚·. “ç“c@Œ’ (zŠÂŠí“à): ‘æ24‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2020/10/15-17), webŠJÃ.

722039. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) SŒŒŠÇƒCƒxƒ“ƒg—}§‚ðŒ©˜‚¦‚½“œ”A•aŽ¡—Ð헪. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ29‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï (2021/2/19), WebŠJÃ.

723123. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Achilles Tendon Thickening is Associated with Higher Incidence of Adverse Cardiac Event in Patients with Coronary Artery Disease. ‹´–{‘ñ–í1, “ì@®Œ«1, ’©‘q´Žj2, •Ð•ô³á©2, ‰Á“¡Ê”ü2, Œj@—L’q2, ²“¡rˆò1, ‘º¼—T‰î1, Š`è—Ç‘¾1, “¡‹g˜a”Ž1, Î“cO‹B1, ‹T“c@—Ç1, –ڍ•Œ’‘¾˜Y1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

723124. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Frequency of non-sustained ventricular tachycardia is related to lethal arrhythmia in patients with cardiac sarcoidosis implanted with cardiac electronic devices. rì—Y‹I1, ‹yì@~2, [’J‰p•½2, “ç“c@Œ’2, Ö“¡‘åŽ÷1, ²“¡“N˜Y1, ¼‰Y@Œ³1, ¬—ÑŽü•½1, ”’ì—TŠî1, Î––¬Æ2, ŠÝŒ´@~2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

723125. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Optimized lesion size index (o-LSI): the novel predictor for sufficient ablation of pulmonary vein isolation. ¼‰Y@Œ³1, ŠÝŒ´@~2, [’J‰p•½2, ‹yì@~2, Î––¬Æ2, Ö“¡‘åŽ÷1, ²“¡“N˜Y1, rì—Y‹I1, ¬—ÑŽü•½1, ”’ì—TŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

723126. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Canagliflozin suppresses the Electrophysiological Changes in Isoproterenol-induced Myocardial Injury Rat Model. ¬—ÑŽü•½1, ’ë–ìTˆê2, ’ë–ì—TŒb, Ö“¡‘åŽ÷1, ²“¡“N˜Y1, ¼‰Y@Œ³1, rì—Y‹I1, ”’ì—TŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ‹yì@~2, ŠÝŒ´@~2, [’J‰p•½2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

723127. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Reduced atrial conduction velocity is associated with the recurrence of atrial fibrillation after catheter ablation: Insight from an electro-anatomical mapping study. ²“¡“N˜Y1, [’J‰p•½2, ‹yì@~2, Ö“¡‘åŽ÷1, ¼‰Y@Œ³1, rì—Y‹I1, ¬—ÑŽü•½1, ”’ì—TŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ŠÝŒ´@~2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

723128. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Clinical Impact of Ischemia-like Electrocardiography Findings during Acute Heart Failure in Patients with Nonischemic Left Ventricular Dysfunction. ‘O‘ºŒ’Ž¡1, ’r“c—S‹B2, ‘å–Ø‘ì–¤1, –îè–ƒ—R1, “¡“c“S•½3, “ç“c@Œ’3, Îˆär•ã3, ‘OìŒb”ü3, ¬”‹´r”ü3, ’––”FŒ³3,4, ˆ¢ŒÃÆ3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‹~–½, 3zŠÂŠí“à, 4–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

723129. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Reduction of Intraventricular Flow Energy Loss is Associated with Ventricular Recovery after Cardiac Resynchronization Therapy. ‘O‘ºŒ’Ž¡1, ’r“c—S‹B2, Š`è—Ç‘¾3, ‘å–Ø‘ì–¤1, –îè–ƒ—R1, “¡“c“S•½3, “ç“c@Œ’3, Îˆär•ã3, ‘OìŒb”ü3, ¬”‹´r”ü3, ’––”FŒ³3,4, ˆ¢ŒÃÆ3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‹~–½, 3zŠÂŠí“à, 4–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

723130. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Relationship between extent of late gadolinium enhancement and re-worsening left ventricular ejection fraction in patients with recent-onset non-ischemic dilated cardiomyopathy. “ç“c@Œ’1, ¬–с@’1, ’r“c—S‹B2, ‘å–Ø‘ì–¤3, ‘O‘ºŒ’Ž¡3, –îè–ƒ—R3, “¡“c“S•½1, Îˆär•ã1 ’––”FŒ³1,4, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ84‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2020/7/27-8/2), webŠJÃ.

723131. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •s‰Â‹t“I‚ȐS“à–ŒáŠQ‚ð”F‚ß‚½‚½‚±‚‚ڌ^S‹ØÇ‚̈ê—á. ŒÕŠâ‚ß‚®‚Ý1, ‹yì@~1, “ç“c@Œ’1, [’J‰p•½1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): ˆãŠw¶EŒ¤Cˆã‚Ì“ú–{“à‰ÈŠw‰ï‚±‚Æ‚Í‚¶‚ß 2020 (2020/8/8), “Œ‹ž (webŠJÃ).

723132. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) f’f‚É‹ê—¶‚µ‚½Sƒ^ƒ“ƒ|ƒi[ƒf‚̈ê—á. t–Ø—s‰î1, ‹yì@~1, [’J‰p•½1, r‹Lt“Þ2, –k‘º@—¥2, ‹{’n@ŠÓ2, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2S‘ŸŒŒŠÇŠO): ˆãŠw¶EŒ¤Cˆã‚Ì“ú–{“à‰ÈŠw‰ï‚±‚Æ‚Í‚¶‚ß 2020 (2020/8/8), “Œ‹ž (webŠJÃ).

723133. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’፶S‹@”\‚ÌŒ´ˆöf’f‚É“ïa‚µ‚½‘å“®–¬•Ù‹t—¬Ç‚ð‡•¹‚µ‚½–Œ—l•”SŽº’†ŠuŒ‡‘¹Ç‚̈ê—á. “¡“c“S•½1, ¬”‹´r”ü1, ‹´–{F–¾, ŒSŽRŒbŽq2, ‘OìŒb”ü1, ‹{–{—²Ži3, ‹{’n@ŠÓ3, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘‡f—Ã, 3S‘ŸŒŒŠÇŠO): ˆê”ÊŽÐ’c–@l“ú–{SƒGƒR[}Šw‰ï‘æ31‰ñŠwpW‰ï (2020/8/14-15), “‡ª.

723134. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œo”ç“IŠ¥“®–¬Œ`¬p‚ðŽ{s‚³‚ꂽŠàŠ³ŽÒ‚Ìfollow upŒŸ¸‚Æ‚»‚ÌŒã‚ÌŽ¡—Õûj‚ÌŒ»ó. ‘º¼—T‰î1, “ì@®Œ«1, ‰Á“¡Ê”ü2, Œj@—L’q2, ²“¡rˆò1, ‹´–{‘ñ–í1, –ڍ•Œ’‘¾˜Y1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ3‰ñ“ú–{ŽîᇏzŠÂŠíŠw‰ïŠwpW‰ï (2020/9/11-12), webŠJÃ.

723135. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ûŠà‚ɍ‡•¹‚µ‚½‹}«”xÇðÇŽ¡—ÃŒã‚É”­Ç‚µ‚½PTTM‚Ì1—á. Îˆär•ã1, ‘å–Ø‘ì–¤2, ‘O‘ºŒ’Ž¡2, –îè–ƒ—R2, “¡“c“S•½1, ’r“c—S‹B3, “ç“c@Œ’1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‹~–½): ‘æ5‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ï (2020/9/26-27), webŠJÃ.

723136. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Efficacy of pulmonary vasodilators for withdrawal from mechanical circulatory support in both ventricular dysfunction caused by fulminant myocarditis. ‘å–Ø‘ì–¤1, Îˆär•ã2, ‘O‘ºŒ’Ž¡1, –îè–ƒ—R1, “¡“c“S•½1, ’r“c—S‹B3, “ç“c@Œ’2, ‘OìŒb”ü2, ¬–с@’2, ¬”‹´r”ü2, ’––”FŒ³2,4, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à, 3‹~–½, 4–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ24‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2020/10/15-17), webŠJÃ.

723137. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A Case of Takayasu Arteritis with Giant Negative T-wave newly appearing after Mitra Clip. ¬”‹´r”ü1, “¡“c“S•½1, ‘O‘ºŒ’Ž¡2, ‘å–Ø‘ì–¤2, –îè–ƒ—R2, ’r“c—S‹B3, “ç“c@Œ’1, Îˆär•ã1, ŒSŽRŒbŽq4, ‘OìŒb”ü1, –ڍ•Œ’‘¾˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‹~–½, 4‘‡f—Ã): ‘æ24‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2020/10/15-17), webŠJÃ.

723138. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Rapid Progression of Pulmonary Vascular Resistance in a case with Double-Chambered Right Ventricle with Ventricular Septal Defect. “¡“c“S•½1, ¬”‹´r”ü1, ‘ëã@—I1, ‘O‘ºŒ’Ž¡2, ‘å–Ø‘ì–¤2, –îè–ƒ—R2, ’r“c—S‹B3, “ç“c@Œ’1, Îˆär•ã1, ŒSŽRŒbŽq4, ‘OìŒb”ü1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‹~–½, 4‘‡f—Ã): ‘æ24‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2020/10/15-17), webŠJÃ.

723139. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Decline in left ventricular ejection fraction is associated with heart failure hospitalization and sudden death in patients with cardiac sarcoidosis. ‘ëã@—I1, “ç“c@Œ’1, Îˆär•ã1, ‘O‘ºŒ’Ž¡2, ‘å–Ø‘ì–¤2, –îè–ƒ—R2, “¡“c“S•½1, ’r“c—S‹B3, ¬–с@’1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‹~–½): ‘æ24‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2020/10/15-17), webŠJÃ.

723140. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Mechanical circulatory support for cardiopulmonary collapse type of amniotic fluid embolism. ‘O‘ºŒ’Ž¡1, ’r“c—S‹B2, ‘å–Ø‘ì–¤1, –îè–ƒ—R1, “¡“c“S•½3, “ç“c@Œ’3, Îˆär•ã3, ‘OìŒb”ü3, ¬”‹´r”ü3, ’––”FŒ³3, ˆ¢ŒÃÆ3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‹~–½, 3zŠÂŠí“à): ‘æ24‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2020/10/15-17), webŠJÃ.

723141. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘¢‰eÜ–¢Žg—p‚É‚æ‚éOCTƒKƒCƒh‰ºPCI. “ì@®Œ« (zŠÂŠí“à): ARIA (Alliance for Revolution and Interventional Cardiology Advancement) 2020 in Silico (2020/11/22), webŠJÃ.

723142. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lH•Ù—Ö‚ðŽg—p‚µ‚Ä‚¢‚È‚¢‘m–X•ÙŒ`¬pŒã‚É—nŒŒ«•nŒŒ‚𐶂¶‚½ˆê—á. ‘OìŒb”ü1, ¬”‹´r”ü1, ‹´–{F–¾, ‹yì@~1, ŒSŽRŒbŽq2, r‹Lt“Þ3, –k‘º@—¥3, ‹{’n@ŠÓ3, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘‡f—Ã, 3S‘ŸŒŒŠÇŠO): “ú–{’´‰¹”gˆãŠw‰ï‘æ93‰ñŠwpW‰ï (2020/12/1-3), webŠJÃ, ’´‰¹”gˆãŠw 2020/11; 47 (Suppl): S212.

723143. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Current Status of MCS and CHIP in Japan. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ29‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï (2021/2/19), WebŠJÃ.

723144. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) AUGUSTUS, ENTRUST-PCI. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ29‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï (2021/2/20), WebŠJÃ.

723145. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’N‚ªLAAC‚Ì—Ç‚¢“K‰ž‚©. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ29‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï (2021/2/20), WebŠJÃ.

723146. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) HBR-Complex‚ÌŠ³ŽÒ‚ÆBleeding‚Ƃ̐܂荇‚¢‚ð‚Ç‚¤‚‚¯‚é‚©|ÅV‚Ì’mŒ©‚©‚ç. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ29‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï (2021/2/21), WebŠJÃ.

723147. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) PCI‚̍‡•¹Ç-ƒXƒeƒ“ƒgŒŒðÇ. ˆ¢ŒÃÆ (zŠÂŠí“à): CVIT-TV WEB‹³ˆçƒZƒ~ƒi[ (2021/3/11), WebŠJÃ.

723148. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) zŠÂŠíŽ¾Š³‚ðŒ©˜‚¦‚½“œ”A•aŽ¡—Á`V‚½‚ȃGƒrƒfƒ“ƒX‚ð‚Ђà‚Æ‚­`. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ85‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2021/3/26), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723149. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž‰Ž¿ŠÇ—‚ðŠÜ‚ß‚½“ñŽŸ—\–h–ò•¨—Ö@ -‚ƒ“xEPA‚ðŠˆ‚©‚·. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ85‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2021/3/27), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723150. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (‹³ˆçu‰‰) SŒŒŠÇ•a—\–h‚Ì‚½‚߂̉h—{Žw“±ABC. “ŒžŠ”ü“ÞŽq (ˆã—Éq¶Šw•”): “ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï‘æ5‰ñŠÖ“ŒbM‰zŽx•”’n•û‰ï (2020/11/28), webŠJÃ.

733026. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “KØ‚ȘAŒg‚É‚æ‚葁Šúf’f‚µ“¾‚½‘Sg«ƒAƒ~ƒƒCƒh[ƒVƒX‚̈ê—á. ¼“c‘׋I1, “ç“c@Œ’1, ˆ¢ŒÃÆ11 –x•Ä—Cˆê2 (1zŠÂŠí“à, 2ŒŒ‰t“à): “ú–{“à‰ÈŠw‰ï‘æ662‰ñŠÖ“Œ’n•û‰ï (2020/9/13), “Œ‹ž (webŠJÃ).

733027. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “œ”A•aŠ³ŽÒ‚É‚¨‚¯‚éXience‚ÆU-SES‚̗Տ°¬Ñ‚Ì”äŠr. “ì@®Œ« (zŠÂŠí“à): ‘æ105‰ñ_“ސìPTCAŒ¤‹†‰ï (2020/11/27), webŠJÃ.

733028. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “œ”A•aŠ³ŽÒ‚É‚¨‚¯‚éXience‚ÆU-SES‚̗Տ°¬Ñ‚Ì”äŠr. “ì@®Œ« (zŠÂŠí“à): ‘æ10‰ñ–L‹´ƒ‰ƒCƒuƒfƒ‚ƒ“ƒXƒgƒŒ[ƒVƒ‡ƒ“ƒR[ƒX (2020/11/28), webŠJÃ.

733029. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) SŽº×“®‚Å”À‘—‚³‚ꂽ•p–¬—U”­«S‹ØÇÄ”­—á. ¬–Ø‘]ãÄ1, [’J‰p•½1, –îè–ƒ—R2, “ç“c@Œ’1, ŠÝŒ´@~1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): “ú–{“à‰ÈŠw‰ï‘æ665‰ñŠÖ“Œ’n•û‰ï (2020/12/12), “Œ‹ž (webŠJÃ).

733030. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ƒLƒƒƒbƒXƒ‹ƒ}ƒ“•aŠ³ŽÒ‚ª”­Ç‚µ‚½‚ÖƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒ¸­Ç (HIT) ‚Ì1—á. ¼“c‘׋I1, ‰––ì•û–¾1, ²“¡‘å•ã1, ŽO’J—D‘¾˜Y1 (1zŠÂŠí“à): ‘æ258‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/12/12-14), webŠJÃ.

733031. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) R‹ÃŒÅ—Ö@‰º‚É”­Ç‚µ‚½—¼S–[ŒŒðÇ‚̈ê—á. ‹´‘º”ü•Û1, •yˆä‘å“ñ˜Y1, ‹´–{‘ñ–í1, ]“c—DŽq1, ”Ñ‘q‘‰fŽq1, ‹T“c@—Ç1, ¬”‹´r”ü1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): ‘æ258‰ñ“ú–{zŠÂŠíŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/12/12-14), webŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110015. [Œ´’˜] Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure. Yazaki M1, Nabeta T2, Inomata T2,3, Maemura K1, Ooki T1, Fujita T2, Iida Y2, Ikeda Y2, Ishii S2, Naruke T2, Ako J2: Circ Rep 2019/12; 2 (1): 51-9. (–îè–ƒ—R1, “ç“c@Œ’2, ’––”FŒ³2,3, ‘O‘ºŒ’Ž¡1, ‘å–Ø‘ì–¤1, “¡“c“S•½2, ”Ñ“c—Sˆê˜Y2, ’r“c—S‹B2, Îˆär•ã2, ¬–с@’2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

'19-522003. [uÀ]y“ÁW: ˆË—Š“à—e‚©‚çSŽ¾Š³‚ð’T‚é! SƒGƒR[ŒŸ¸‚̃cƒ{zSŠg‘å‚ÌŒŸ¸‚̃cƒ{. ¬”‹´r”ü (zŠÂŠí“à): SƒGƒR[ 2019/11; 20 (11): 1102-13.

'19-522004. [uÀ]y“ÁW: ƒOƒŠƒRƒJƒŠƒbƒNƒXzŒŒŠÇ“à”çƒOƒŠƒRƒJƒŠƒbƒNƒX‚Æ“®–¬d‰». “ŒžŠ”ü“ÞŽq (ˆã—Éq¶Šw•”): —Տ°‰»Šw 2020/1; 49 (1): 5-13.

'19-540002. [‚»‚Ì‘¼ (Comment)] ¬o˜_•¶‚ɑ΂·‚éEditorial Comment. ¬”‹´r”ü (zŠÂŠí“à): S‘Ÿ 2020/3; 52 (3): 327.

[’˜@‘]

'19-620002. [Šwp‘ (•ª’SŽ·•M)]y‚±‚Ì1û‚ňÀS! ŽüpŠú‚̐¶—‹@”\ŒŸ¸ŠÛ‚²‚ƃKƒCƒh (Medical Technology 2019”N12ŒŽ—ÕŽž‘Š§†)z3. ŽüpŠú‚É‚¨‚¯‚鐶—ŒŸ¸‚ÌŽÀÛ@2) S‘Ÿ‚ÌŽüpŠú’´‰¹”gŒŸ¸@(3) S–[’†ŠuŒ‡‘¹. ¬”‹´r”ü (zŠÂŠí“à), ˆãŽ•–òo”Å, “Œ‹ž, 2019/12”­s.

'19-620003. [Šwp‘ (•ª’SŽ·•M)]yƒKƒCƒhƒ‰ƒCƒ“‚ɐSƒGƒR[‚𐶂©‚·zIII S‹ØÇ@8 S‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒX, p.84-91. ¬”‹´r”ü (zŠÂŠí“à), •Ò: £”ö—RL, ã“ˆ“¿‹v, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

'19-620004. [Šwp‘ (•ª’SŽ·•M)]yi“WƒXƒe[ƒW•Ê‚É—‰ð‚·‚éS•s‘SŠÅŒìz‘æ2Í S•s‘SƒXƒe[ƒWB‚ÌŠÅŒì@S•s‘S‚Ì”­Ç‚ð—\–h‚·‚é@A ŠíŽ¿“ISŽ¾Š³‚̐i“W—\–h‚Ì‚½‚ß‚ÌŽ¡—Ã, p.46-57. “ŒžŠ”ü“ÞŽq (ˆã—Éq¶Šw•”), •Ò: áÁŠ‚Ý‚ä‚«, ˆãŠw‘‰@, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

'19-713005. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A case of LGE negative cardiac sarcoidosis@with FDG-PET and myocardial biopsy leading to early diagnosis. Koitabashi T1, Maemura K2, Ooki T2, Yazaki M2, Fujita T1, Ikeda Y3, Nabeta T1, Ishii S1, Ryo-Kooriyama K4, Maekawa E1, Naruke T1, Ako J1: WASOG2019/The 39th Annual Meeting of JSSOG (2019/10/11), Yokohama, Japan. (¬”‹´r”ü1, ‘O‘ºŒ’Ž¡2, ‘å–Ø‘ì–¤2, –îè–ƒ—R2, “¡“c“S•½1, ’r“c—S‹B3, “ç“c@Œ’1, Îˆär•ã1, ŒSŽRŒbŽq4, ‘OìŒb”ü1, ¬–с@’1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‹~–½, 4‘‡f—Ã)

'19-713006. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Comprehensive In Vivo Coronary Plaque Mapping: A 3-Vessel Optical Coherence Tomography Study. Araki M, Soeda T, Kim HO, Thondapu V, Russo M, Kurihara O, Shinohara H, Minami Y1, Higuma T, Lee H, Yonetsu T, Kakuta T, Jang IK.: American College Cardiology (ACC) 2020 Scientific Session (2020/3/28-30), Chicago, USA. (“ì@®Œ«1: 1zŠÂŠí“à)

'19-713007. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Age- and gender-related differences in plaque composition of coronary lesions: an optical coherence tomography study. Sato T1, Minami Y1, Asakura K2, Kato A2, Katsura A2, Kakizaki R1, Nemoto T1, Hashimoto T1, Fujiyoshi K1, Meguro K1, Shimohama T1, Ako J1: American College Cardiology (ACC) 2020 Scientific Session (2020/3/28-30), Chicago, USA. (²“¡rˆò1, “ì@®Œ«1, ’©‘q´Žj2, ‰Á“¡Ê”ü2, Œj@—L’q2, Š`è—Ç‘¾1, ª–{Æ¢Žu1, ‹´–{‘ñ–í1, “¡‹g˜a”Ž1, –ڍ•Œ’‘¾˜Y1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

'19-713008. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Comparison of post-stent optical coherence tomography findings among three subtypes of calcified culprit plaques in patients with acute coronary syndrome. Nakajima A, Araki M, Kurihara O, Minami Y1, Soeda T, Yonetsu T, Crea F, Takano M, Higuma T, Kakuta T, Adriaenssens T, Lee H, Nakamura S, Jang IK: American College Cardiology (ACC) 2020 Scientific Session (2020/3/28-30), Chicago, USA. (“ì@®Œ«1: 1zŠÂŠí“à)

'19-713009. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Healed Plaques in Patients With Stable Angina Pectoris. Russo M, Fracassi F, Kurihara O, Kim HO, Thondapu V, Araki M, Shinohara H, Sugiyama T, Yamamoto E, Lee H, Vergallo R, Crea F, Biasucci LM, Yonetsu T, Minami Y1, Soeda T, Fuster V, Jang IK: American College Cardiology (ACC) 2020 Scientific Session (2020/3/28-30), Chicago, USA. (“ì@®Œ«1: 1zŠÂŠí“à)

'19-713010. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) First-in-Human Study of the Second-Generation, Thin-Strut, Everolimus-Eluting Bioresorbable Scaffold: Final IVUS and OCT Results From the FAST Clinical Trial Nishi T, Kameda R1, Okada K, Ikutomi M, Hollak MB, Yock P, Popma J, Seneviratne S, Walters D, Whitbourn R, Stewart J, El-Jack S, Allocco D, Meredith I, Fitzgerald PJ, Honda Y: American College Cardiology (ACC) 2020 Scientific Session (2020/3/28-30), Chicago, USA. (‹T“c@—Ç1: 1zŠÂŠí“à)

'19-721001. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ÅVƒKƒCƒhƒ‰ƒCƒ“‚ɉˆ‚Á‚½SƒGƒR[‚̐i‚ß•û‚Æ‚»‚̍l‚¦•û|•Ù–ŒŽ¾Š³|. ¬”‹´r”ü (zŠÂŠí“à): ‘æ44‰ñ“ú–{’´‰¹”gŒŸ¸Šw‰ïŠwpW‰ï (2019/4/28), ‰¡•l.

'19-721002. [Šw‰ï (‘S‘)] (“Á•Êu‰‰)yŽüŽYŠú‚ƐS‘Ÿ•a: ŽüŽYŠúS‹ØÇzzŠÂŠí“à‰È‚́eŽY‰Èf—Áf‚Ö‚Ì‚©‚©‚í‚è•û`ŽüŽYŠúS‹ØÇƒnƒCƒŠƒXƒNÇ—á‚É‚¨‚¯‚éŽY‰È‚Ƃ̘AŒg`. ¬”‹´r”ü1, “¡“c“S•½1, ’r“c—S‹B2, –]ŒŽƒŽq3, ŠC–ìM–ç3, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‹~–½, 3ŽY‰È): ‘æ67‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï (2019/9/13), –¼ŒÃ‰®.

'19-722001. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ¶ŠU•a‚Æ‚µ‚Ă̐æ“V«SŽ¾Š³: ƒtƒ@ƒ[Žl’¥Ç|‘ål‚É‚È‚Á‚½ƒtƒ@ƒ[Žl’¥Ç‚Ì‘½—l«|. ¬”‹´r”ü1, ŒSŽRŒbŽq2, ‘O‘ºŒ’Ž¡3, “¡“c“S•½1, ’r“c—S‹B4, “ç“c@Œ’1, ‘OìŒb”ü1, âV–؍G•¶, ‹{–{—²Ži5, ‹{’n@ŠÓ5, æèG–¾6,7, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘‡f—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4‹~–½, 5S‘ŸŒŒŠÇŠO, 6V¢‹Iˆã—ÁEæ’[ˆã—Ã, 7¬Ž™): ˆê”ÊŽÐ’c–@l“ú–{SƒGƒR[}Šw‰ï‘æ30‰ñŠwpW‰ï (2019/5/12), ¼–{.

'19-722002. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ’´‰¹”gŒŸ¸‚ÅŒ©”²‚­|‘Sg«Ž¾Š³ƒTƒ‹ƒRƒCƒh[ƒVƒX‚ł̐S•a•Ï|. ¬”‹´r”ü1, b”ã“c–L“ñ1, “¡“c“S•½1, ’r“c—S‹B2, “ç“c@Œ’1, ŒSŽRŒbŽq3, ‘OìŒb”ü1, ¬–с@’1, ’––”FŒ³1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‹~–½, 3‘‡f—Ã): “ú–{’´‰¹”gˆãŠw‰ï‘æ92‰ñŠwpW‰ï (2019/5/24), “Œ‹ž.

'19-722003. [Šw‰ï (‘S‘)] (‰ï’·—v–]‰‰‘è) ¬læ“V«SŽ¾Š³‚ɑ΂·‚éS”x‰^“®•‰‰×ŽŽŒ±‚ðŠˆ—p‚µ‚½S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“. ‘OìŒb”ü (zŠÂŠí“à): ‘æ22‰ñ“ú–{¬læ“V«SŽ¾Š³Šw‰ï‘‰ïEŠwpW‰ï (2020/1/17-19), “Œ‹ž.

'19-723006. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Experience Using Selexipag in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension and Eisenmenger Syndrome. ¬”‹´r”ü1, “¡“c“S•½1, ‘O‘ºŒ’Ž¡2, ’r“c—S‹B3, ŒSŽRŒbŽq4, ‘OìŒb”ü1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‹~–½, 4‘‡f—Ã): ‘æ22‰ñ“ú–{¬læ“V«SŽ¾Š³Šw‰ï‘‰ïEŠwpW‰ï (2020/1/17), “Œ‹ž.

'19-723007. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) is«‚̉ES‹@”\•s‘S‚Ɗ̍d•Ï‚̍‡•¹Ç‚ª‹^‚í‚ê‚éŽá”Nƒtƒ@ƒ[Žl’¥ÇŠ³ŽÒ‚Ö‚ÌŽ¡—ÑI‘ð. “¡“c“S•½1, ‘å–Ø‘ì–¤2, ‘OìŒb”ü1, ŒSŽRŒbŽq3, ¬–с@’1, ¬”‹´r”ü1, “cŠ—S‹I4, ”ªŒLˆê‹M4, ‹{–{—²Ži4, ‹{’n@ŠÓ4, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‘‡f—Ã, 4S‘ŸŒŒŠÇŠO): ‘æ22‰ñ“ú–{¬læ“V«SŽ¾Š³Šw‰ï‘‰ïEŠwpW‰ï (2020/1/17), “Œ‹ž.

'19-723008. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “Á”­«SŽº×“®‚ɑ΂·‚銮‘S”牺Až‚ÝŒ^œ×“®Ší (S-ICD) ‚É‚æ‚è‹à‘®ƒAƒŒƒ‹ƒM[‚𐶂¶‚½ˆê—á. ²“¡“N˜Y1, ŠÝŒ´@~2, Ö“¡‘åŽ÷1, ¼‰Y@Œ³1, rì—Y‹I1, ¬—ÑŽü•½1, ”’ì—TŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ‹yì@~2, [’J‰p•½2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ12‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (2020/2/6), –¼ŒÃ‰®.

'19-723009. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒŠ[ƒhƒŒƒXƒy[ƒXƒ[ƒJA‚¦ž‚Ý‚É‚æ‚芥“®–¬‘¹‚𗈂µ‚½1—á. rì—Y‹I1, [’J‰p•½2, Ö“¡‘åŽ÷1, ²“¡“N˜Y1, ¼‰Y@Œ³1, ¬—ÑŽü•½1, ”’ì—TŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ‹yì@~2, ŠÝŒ´@~2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ12‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (2020/2/6), –¼ŒÃ‰®.

'19-723010. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’ág’·’á‘̏d‚̍‚—«‚ɑ΂·‚é ƒŠ[ƒhƒŒƒXƒy[ƒXƒ[ƒJAž‚ݏp‚ÌŒŸ“¢. ¼‰Y@Œ³1, ŠÝŒ´@~2, ŽR‰ºŒ«”V‰î, ÎŠ_¬h, âV“¡‘åŽ÷1, ²“¡“N˜Y1, rì—Y‹I1, ”’ì—TŠî1, ¬—ÑŽü•½1, –xŒû@ˆ¤2, ¼¬“c—º2, Î––¬Æ2, ‹yì@~2, [’J‰p•½2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ12‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (2020/2/6), –¼ŒÃ‰®.

'19-723011. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) DDDƒy[ƒXƒ[ƒJAž‚ݏpŒã‚ɍ¶ã˜rŒŒð«Ã–¬‰Š‚ð‚«‚½‚µ‚½SƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈ê—á. ¼¬“c—º1, [’J‰p•½1, ŠÝŒ´@~1, Ö“¡‘åŽ÷2, ¼‰Y@Œ³2, ²“¡“N˜Y2, rì—Y‹I2, ¬—ÑŽü•½2, ”’ì—TŠî2, –xŒû@ˆ¤1, ’†‘º—m”Í1, Î––¬Æ1, ‹yì@~1, ’ë–ìTˆê1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ12‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (2020/2/7), –¼ŒÃ‰®.

'19-723012. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Torsades de pointes‚Å”­Ç‚µ‚½ƒy[ƒXƒ[ƒJpŒã‹}«Šú‚½‚±‚‚ڐS‹ØÇ‚̈ê—á. –xŒû@ˆ¤1, ŠÝŒ´@~1, ¬–с@’1, Ö“¡‘åŽ÷2, ‘å–Ø‘ìŒÈ2, ¼‰Y@Œ³2, rì—Y‹I2, ¬—ÑŽü•½2, ”’ì—TŠî2, ¼¬“c—º1, Î––¬Æ1, ‹yì@~1, [’J‰p•½1, ’ë–ìTˆê1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ12‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (2020/2/7), –¼ŒÃ‰®.

'19-723013. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ÆŽã‚ȃŠ[ƒh‚ɑ΂µŠO‰ÈE“à‰È‡“¯‚É‚æ‚éWŠw“IŽ¡—ÂŔ²‹Ž‚µ‚¦‚½ƒy[ƒXƒ[ƒJ[ƒ|ƒPƒbƒgŠ´õ‚̈ê—á. [’J‰p•½1, ’¹ˆäWŽO2, ‘ëã@—I1, Ö“¡‘åŽ÷3, ¼‰Y@Œ³3, ²“¡“N˜Y3, rì—Y‹I3, ¬—ÑŽü•½3, ”’ì—TŠî3, –xŒû@ˆ¤1, ¼¬“c—º1, Î––¬Æ1, ‹yì@~1, ŠÝŒ´@~1, ’ë–ìTˆê1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2’nˆæˆã—˳ˆç, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ12‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (2020/2/8), –¼ŒÃ‰®.

'19-723014. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚郊[ƒhƒŒƒXƒy[ƒXƒ[ƒJ“oê‚É‚æ‚éƒy[ƒVƒ“ƒOƒfƒoƒCƒX‚ÌŒ»ó. ¬—ÑŽü•½1, ŠÝŒ´@~2, Ö“¡‘åŽ÷1, ¼‰Y@Œ³1, ²“¡“N˜Y1, rì—Y‹I1, ”’ì—SŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ‹yì@~2, [’J‰p•½2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ12‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (2020/2/8), –¼ŒÃ‰®.

'19-723015. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰“Šuƒ‚ƒjƒ^ƒŠƒ“ƒO‚ƐS”•Ï“®‰ðÍ‚ð—p‚¢‚½Až‚ÝŒ^œ×“®ŠíÇ—á‚Ì’vŽ€“I•s®–¬ƒCƒxƒ“ƒg‚Ì—\‘ª. ”’ì—TŠî1, ’ë–ìTˆê2, ‹yì@~2, Ö“¡‘åŽ÷1, ²“¡“N˜Y1, ¼‰Y@Œ³1, rì—Y‹I1, ¬—ÑŽü•½1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ŠÝŒ´@~2, [’J‰p•½2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ12‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (2020/2/8), –¼ŒÃ‰®.

'19-723016. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Early inappropriate shock in S-ICD due to subcutaneous air. ŠÝŒ´@~ (zŠÂŠí“à): ‘æ12‰ñAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘å‰ï (2020/2/8), –¼ŒÃ‰®.

'19-723017. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŒs“®‘Ô•sˆÀ’è‚ȍ¶Žº—¬o˜HŒ^Ž‘±«SŽº•p”‚ɑ΂µ, ƒ‰ƒ“ƒWƒIƒ[ƒ‹‚ª’˜Œø‚µ‚½1—á. ‹gàV’qŽ¡1, “ŒžŠ‘å‹P1, ‘ºŽR—F‰î, Š`è—Ç‘¾1, ²“¡L—m2, ‹yì@~1, [’J‰p•½1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‹~–½): ‘æ47‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2020/3/7), –¼ŒÃ‰®.

'19-723018. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) S-ICD–„‚ߍž‚ÝŒã‚̉EŽº—¬o˜HŒ^Ž‘±«SŽº•p”‚ɑ΂µ, ƒ‰ƒ“ƒWƒIƒ[ƒ‹‚ª’˜Œø‚µ‚½1—á. ‹gàV’qŽ¡1, “ŒžŠ‘å‹P1, ‘ºŽR—F‰î, Š`è—Ç‘¾1, ²“¡L—m2, ‹yì@~1, [’J‰p•½1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‹~–½): ‘æ47‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2020/3/7), –¼ŒÃ‰®.

'19-732001. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) S‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒX‚̐SƒGƒR[f’f`f’fŠî€‚̉ü’ù‚É”º‚¤SƒGƒR[}ŒŸ¸‚̈ʒu‚¯‚Ì•Ï‘J. b”ã“c–L“ñ1, “¡“c“S•½1, ’r“c—S‹B2, “ç“c@Œ’1, ŒSŽRŒbŽq3, ‘OìŒb”ü1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‹~–½, 3‘‡f—Ã): “ú–{’´‰¹”gˆãŠw‰ï‘æ31‰ñŠÖ“ŒbM‰z’n•û‰ïŠwpW‰ï (2019/10/19), “Œ‹ž.

'19-733003. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “Á”­«SŽº×“®‚ɑ΂·‚銮‘S”牺Až‚ÝŒ^œ×“®Ší (S-ICD) ‚É‚æ‚è‹à‘®ƒAƒŒƒ‹ƒM[‚𐶂¶‚½ˆê—á. ²“¡“N˜Y1, ŠÝŒ´@~2, Ö“¡‘åŽ÷1, ¼‰Y@Œ³1, rì—Y‹I1, ¬—ÑŽü•½1, ”’ì—TŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ‹yì@~2, [’J‰p•½2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ32‰ñ—Տ°•s®–¬Œ¤‹†‰ï (2020/1/11), “Œ‹ž.

'19-733004. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) f’f‚É‹ê—¶‚µ‚½SŽºŠúŠOŽûk‚̈ê—á. ¼‰Y@Œ³1, [’J‰p•½2, ꎓ¡‘åŽ÷1, ²“¡“N˜Y1, ¬—ÑŽü•½1, rì—Y‹I1, ”’ì—TŠî1, ¼¬“c—º2, –xŒû@ˆ¤2, Î––¬Æ2, ‹yì@~2, ŠÝŒ´@~2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2zŠÂŠí“à): ‘æ29‰ñ_“ސìES“d}•×‹­‰ï (2020/1/17), ‰¡•l.

'19-733005. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Ž¸”s—áEŽ¸”s‚µ‚»‚¤‚É‚È‚Á‚½Ç—á‚©‚çŠw‚ÔCase conference ‘å“®–¬•Ù’uŠ·pŒã12“ú–ڂɍĎèp‚Æ‚È‚Á‚½ˆê—á. ¬”‹´r”ü (zŠÂŠí“à): “ú–{SƒGƒR[}Šw‰ï‘æ24‰ñ“~ŠúuK‰ï (2020/1/25), ‘åã.

'19-733006. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) case‚ÅŠw‚Ԑæ“V«SŽ¾Š³ ’Pƒ«æ“V«SŽ¾Š³. ¬”‹´r”ü (zŠÂŠí“à): ‘æ22‰ñƒGƒR[ƒEƒ“ƒ^[ƒZƒ~ƒi[ (2020/2/9), ¼–{.


”]_Œo“à‰ÈŠw

[Šwp˜_•¶]

110180. [Œ´’˜] Pregnancy outcomes in anti-NMDA receptor encephalitis. Joubert B, Garc’a-Serra A, Planagumˆ J, Mart’nez-Hernandez E, Kraft A, Palm F, Iizuka T1, Honnorat J, Leypoldt F, Graus F, Dalmau J: Neurol Neuroimmunol Neuroinflam 2020/5; 7 (3): e668. (”ђˍ‚_1: 1”]_Œo“à)

110181. [Œ´’˜] Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Martinez-Hernandez E, Guasp M, Anna Garc’a-Serra A, Maudes E, Arin H, Sepulveda M, ArmanguŽ T1, Ramos AP, Ben-Hur T, Iizuka T1, Saiz A, Graus F, Dalmau J: Neurology 2020/6; 94 (22): e2302-10. (”ђˍ‚_1: 1”]_Œo“à)

110182. [Œ´’˜] Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus. Yanagida A1, Kanazawa N2, Kaneko J1, Kaneko A1, Iwase R1, Suga H1, Nonoda Y3, Onozawa Y4, Kitamura E1, Nishiyama K1, Iizuka T1: Neuroinflamm 2020/7; 7 (5): e849. (–ö“c“ÖŽq1, ‹ààV’¼”ü2, ‹àŽq~‘¾˜Y1, ‹àŽq@Œú1, Šâ£—ÈŽq1, {‰ê—TŽ÷1, –ìX“c–L3, ¬–ìàV—T–ç4, –k‘º‰p“ñ1, ¼ŽR˜a—˜1, ”ђˍ‚_1: 1”]_Œo“à, 2•a‘ԁEf—ÃŒn, 3¬Ž™, 4—ÕŒŸ•”)

110183. [Œ´’˜] Liver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with Riluzole. Kawano C1, Isozaki Y, Nakagawa A, Hirayama T1, Nishiyama K2, Kuroyama M: Yakugaku Zasshi 2020/7; 140 (7): 923-28. (ì–ìçq1, •½ŽR•Ži1, ¼ŽR˜a—˜2: 1–òŠw•”, 2”]_Œo“à)

110184. [Œ´’˜] Differential effects of thyrotropin releasing hormone (TRH) on motor execution and motor adaptation process in patients with spinocerebellar degeneration. Shimiz Tu, Tsutsumi R, Shimizu K, Tominaga N1,2, Nagai M1, Ugawa Y, Nishiyama K2, Hanajima R: J Neurol Sci 2020/8; 415: 116927. (•x‰i“Þ•Û”ü1,2, ‰iˆä^‹MŽq2, ¼ŽR˜a—˜2: 1‘‡f—Ã, 2”]_Œo“à)

110185. [Œ´’˜] Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review. Lewis RA1, Cornblath DR1, Hartung HP1, Sobue G1, Lawo JP1, Mielke O1, Durn BL1, Bril V1, Merkies ISJ1, Bassett P1, Cleasby A1, van Schaik IN1 (1PATH study group), Collaborators: Nishiyama K1,2: J Peripher Nerv Syst 2020/9; 25 (3): 230-7. (¼ŽR˜a—˜1,2: 2”]_Œo“à)

110186. [Œ´’˜] Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations. Kano M, Takanashi M, Oyama G, Yoritaka A, Hatano T, Shiba-Fukushima K, Nagai M1, Nishiyama K1, Hasegawa K, Inoshita T, Ishikawa K, Akamatsu W, Imai Y, Bolognin S, Schwamborn JC, Hattori N: NPJ Parkinsons Dis 2020/11; 6 (1): 33. (‰iˆä^‹MŽq1, ¼ŽR˜a—˜1: 1”]_Œo“à)

110187. [Œ´’˜] Functional Connectivity in Migraineurs with Photo-, Phono-, Osmophobia: Static and Dynamic Resting-state Functional Magnetic Resonance Imaging Study. Imai N, Moriya A, Kitamura E1: Neurology and Clinical Neuroscience 2020/11; 8 (6): 390-8. (–k‘º‰p“ñ1: 1”]_Œo“à)

110188. [Œ´’˜] Generation of gene-corrected iPSCs line (KEIUi001-A) from a PARK8 patient iPSCs with familial Parkinson's disease carrying the I2020T mutation in LRRK2. Ohta E1, Sone T, Ukai H, Hisamatsu T2, Kitagawa T2, Ishikawa M, Nagai M3, Ueda H, Obata F4, Okano H: Stem Cell Res 2020/12; 49: 102073. (‘¾“c‰x˜N1, ‹v¼’mŽq2, –kì‹GŽq2, ‰iˆä^‹MŽq3, ¬”¦•¶Æ4: 1ˆã—Éq¶Šw•”, 2—ÕŒŸ•”, 3”]_Œo“à, 4–k—¢‘åŠw•ÛŒ’‰q¶ê–åŠw‰@)

110189. [Œ´’˜] Left Atrial Size and Ischemic Events after Ischemic Stroke or Transient Ischemic Attack in Patients with Nonvalvular Atrial Fibrillation. Tokunaga K1, Koga M1, Yoshimura S1, Okada Y1, Yamagami H1, Todo K1, Itabashi R1, Kimura K1, Sato S1, Terasaki T1, Inoue M1, Shiokawa Y1, Takagi M1, Kamiyama K1, Tanaka K1, Takizawa S1, Shiozawa M1, Okuda S1, Kameda T1, Nagakane Y1, Hasegawa Y1, Shibuya S1, Ito Y1, Matsuoka H1, Takamatsu K1, Nishiyama K1,2, Kario K1, Yagita Y1, Mizoguchi T1, Fujita K1, Ando D1, Kumamoto M1, Miwa K1, Arihiro S1, Toyoda K1 (1the SAMURAI Study Investigators): Cerebrovasc Dis 2020/12; 49: 619-24. (¼ŽR˜a—˜1,2: 2”]_Œo“à)

110190. [Œ´’˜] Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-BarrŽ syndrome. Yamagishi Y, Kuwahara M, Suzuki H, Masahiro Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida K, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K1, Sobue G, Kusunoki S: J Neurol Neurosurg Psychiatry 2020/12; 91 (12): 1339-42. (¼ŽR˜a—˜1: 1”]_Œo“à)

110191. [Œ´’˜] HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data. Watanabe M, Nakamura Y, Sato S, Niino M, Fukaura H, Tanaka M, Ochi H, Kanda T, Takeshita Y, Yokota T, Nishida Y, Matsui M, Nagayama S, Kusunoki S, Miyamoto K, Mizuno M, Kawachi I, Saji E, Ohashi T, Shimohama S, Hisahara S, Nishiyama K1, Iizuka T1, Nakatsuji Y, Okuno T, Ochi K, Suzumura A, Yamamoto K, Kawano Y, Tsuji S, Hirata M, Sakate R, Kimura T, Shimizu Y, Nagaishi A, Okada K, Hayashi F, Sakoda A, Masaki K, Shinoda K, Isobe N, Matsushita T, Kira J: Sci Rep 2021/1; 11 (1): 607. (¼ŽR˜a—˜1, ”ђˍ‚_1: 1”]_Œo“à)

110192. [Œ´’˜] SIRT1 decelerates morphological processing of oligodendrocyte cell lines and regulates the expression of cytoskeleton-related oligodendrocyte proteins. Hisahara S, Iwahara N, Matsushita T, Suzuki S, Matsumura A, Fujikura M, Yokokawa K, Saito T, Manabe T, Kawamata J1, Horio Y, Shimohama S: Biochem Biophys Res Commun 2021/3; 546: 7-14. (ì–”@ƒ1: 1”]_Œo“à)

110081. [Œ´’˜] Quantitative proteomic analysis and single-protein-derived tryptic peptide profiling indicate qualitative alterations of annexin A6 in the brain of wobbler mice. Nakamura M1, Mizutani K2, Kato K3, Konno R, Itakura M4, Kodera Y, Nishiyama K5, Sato T2: Kitasato Med J 2021/3; 50 (1): 76-83. (’†‘ºŠ²º1, …’J˜aŠ°2, ‰Á“¡—˜‰À3, ”‘q@½4, ¼ŽR˜a—˜5, ²“¡rÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ŽÀ“®, 3ˆâ“`Žq‰ðÍƒZ, 4¶‰», 5”]_Œo“à)

210002. [’Z•ñ] Clinically based score predicting cryptogenic NORSE. Iizuka T1, Yanagida A1: Clin Exp Neuroimmunol 2020/11; 11 (4): 207-8. (”ђˍ‚_1, –ö“c“ÖŽq1: 1”]_Œo“à)

310016. [Ç—á•ñ] Neuroimaging pattern and pathophysiology of cerebellar stroke-like lesions in MELAS with m.3243A>G mutation: a case report. Oyama M, Iizuka T1, Nakahara J, Izawa Y: BMC Neurol 2020/5; 20 (1): 167. (”ђˍ‚_1: 1”]_Œo“à)

310017. [Ç—á•ñ] A Case of Subcortical Hemorrhage in the Left Temporal Lobe Caused by Multiple Dural Arteriovenous Fistulas. Usui R1, Ishima D1, Abe Y1, Sato Y1, Kimura A1, Kimoto T1, Nagashima M1, Adachi T1, Nagata N1, Niki J, Yamamoto D, Akutsu T1, Nishiyama K1: J Stroke Cerebrovasc Dis 2020/5; 29 (5): 104712. (‰Oˆä@—É1, ˆä“‡‘å•ã1, ˆ¢•”—L‹N1, ²“¡@—I1, –Ø‘º•¶«1, –Ø‹–‘ñ”n1, ’·“‡@½1, ˆÀ’B’q”ü1, ’·“c“ޏ”ü1, ˆ¢‹v’Óñ•v1, ¼ŽR˜a—˜1: 1”]_Œo“à)

310018. [Ç—á•ñ] Hyperemesis-induced Wernicke-Korsakoff Syndrome due to Hypergastrinemia during Long-term Treatment with Proton Pump Inhibitors. Miyanaga R, Hisahara S, Ohhashi I, Yamamoto D, Matsumura A, Suzuki S, Tanimoto K, Hirakawa M, Kawamata J1, Kato J, Shimohama S: Intern Med 2020/11; 59 (21): 2783-7. (ì–”@ƒ1: 1”]_Œo“à)

521003. [‰ðà]yˆÏˆõ‰ï’ñŒ¾z“ú–{_ŒoŠw‰ï‚É‚æ‚éÐŠQ‘΍ô: _Œo“ï•aƒŠƒGƒ]ƒ“Šˆ“®‚̐„i. ’†ªr¬1, aŒûŒ÷ˆê1, ˆ¢•”N“ñ1, ”M“c’¼Ž÷1, ˆäŒû•Û”V1, ’r“c‰À¶1, Š@—´™Z1, ‹Tˆä@‘1, –kìˆê•v1, –Ø‘º˜a”ü1, —é–ؐ³•F1, ‚“ˆ@”Ž1, Ž›ŽR–õ•v1, ¼ŽR˜a—˜1,2, ŒÃ’J”Ž˜a1, ¼Œ´‰x˜N1, ‘º¼Tˆê1, ŽR‘º@C1, •“c@“Ä1, ˆÉ“ŒG•¶1 (1“ú–{_ŒoŠw‰ïÐŠQ‘΍ôˆÏˆõ‰ï, 2”]_Œo“à): —Տ°_ŒoŠw 2020/10; 60 (10): 643-2.

521004. [‰ðà] ‹}«Šú”][Ç.¼ŽR˜a—˜ (”]_Œo“à): ƒhƒNƒ^[ƒTƒƒ“ 2020/10; 64 (11): 863-6.

521005. [‰ðà] ƒ‰ƒNƒi[Ç‚ɍRŒŒ¬”–ò“Š—^‚Í•K—v‚©H¼ŽR˜a—˜ (”]_Œo“à): “ú–{ˆãŽ–V•ñ 2021/1; 5048: 51.

522038. [uÀ]y“ÁW: Œƒ“®‚·‚é”]‘²’†f—Á|”]‘²’†EzŠÂŠí•a‘΍ôŠî–{–@‚Æ‚Í?zG. Še˜_5: ‚»‚Ì‘¼‚Ì”]ŒŒŠÇáŠQ‚̐f—Â̓®Œü@MELAS/CADASIL/CARASIL. ”ђˍ‚_ (”]_Œo“à): Clinical Neuroscience 2020/5; 38 (5): 643-6.

522039. [uÀ]yˆÏˆõ‰ï’ñŒ¾ (‘æ60‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï@‹Ù‹}ƒVƒ“ƒ|ƒWƒEƒ€´˜^W)z_Œo“à‰Èê–åˆãŠî–{—̈扻‚ɉ½‚ª•K—v‚©: —h‚ê‚éê–åˆã§“x‚ÆŠî–{—̈æê–åˆã‚ÌŽg–½. ‰€¶‰ëO1, ”—ˆä³[1, “n•Ó@Œ›1, •y–{G˜a1, ˆÀ“¡“N˜N1, ¼ŽR˜a—˜1,2, ‚‹´—Ç•ã1, ŒË“c’BŽj1 (1“ú–{_ŒoŠw‰ï_Œo“à‰Èê–åˆãŠî–{—̈扻„i‘΍ô–{•”, 2”]_Œo“à): —Տ°_ŒoŠw 2020/8; 60 (8): 515-9.

522040. [uÀ]y“ÁW: _ŒoÇŒóŠw‚Ɛ_Œof’fŠw|?AI‚Í–¡•û‚©“G‚©?zC. “ÁˆÙ“IÇó‚̏njóŠwEf’fŠw‚ÆAI@•¡Ž‹. ”ђˍ‚_ (”]_Œo“à): Clinical Neuroscience 2020/11; 38 (11): 1417-20.

522041. [uÀ]y˜AÚ: Œ©“¦‚µ‚Ä‚Í‚¢‚¯‚È‚¢g‘̏ŠŒ©z15. _Œo‚̐f‚©‚½|ˆÓŽ¯áŠQ.¼ŽR˜a—˜ (”]_Œo“à): “ú–{ˆãŽt‰ïŽGŽ 2020/12; 149 (9): 1604-5.

522042. [uÀ]y“ÁW: ƒGƒCƒWƒ“ƒOzC. ‰Á—î‚Ɛ_ŒoŽ¾Š³@Ž©ŒÈ–Ɖu«”]‰Š. ”ђˍ‚_1, –ö“c“ÖŽq1, ‹ààV’¼”ü2 (1”]_Œo“à, 2•a‘ԁEf—ÃŒn): Clinical Neuroscience 2021/1; 39 (1): 103-6.

522043. [uÀ] ƒRƒƒi‰ÐŽž‘ã‚É‚©‚©‚è‚‚¯ˆã‚ª’ˆÓ‚µ‚½‚¢”]‘²’†f—Â̍ŐVî•ñ.¼ŽR˜a—˜ (”]_Œo“à): _“ސ쌧“à‰ÈˆãŠw‰ïŽGŽ 2021/1; 84: 10.

540022. [‚»‚Ì‘¼]y˜AÚ: ƒRƒƒi‰Ð, ˆã—ÕN”—‚ƃƒNƒ`ƒ“‚Ì“oê‚ŐV‚½‚ȃtƒF[ƒY‚ցz1. Šª“ªŒ¾.¼ŽR˜a—˜ (”]_Œo“à): MMJ 2021/2; 2E3ŒŽ†: 1.

[’˜@‘]

620029. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj 2021”N”Ł@Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚éz‘æ15Í _ŒoE‹ØŽ¾Š³@”]ŒŒŠÇáŠQ‚̍‡•¹Ç (Œëš‹«”x‰Š‚𒆐S‚É), p.950-1. ¼ŽR˜a—˜ (”]_Œo“à), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@½, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2021/1”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713023. [Šw‰ï (‘Û)] (Virtual Session) Status epilepticus suspected autoimmune: antibody frequency and main clinical features. Suga H1, Iizuka T1, Kaneko J1, Yanagida A2, Kaneko A1, Kitamura E1, Kanazawa N3, Dalmau J, Nishiyama K1: AAN 2020 (The 72nd AAN Annual Meeting) (2020/4/26), Toronto, Canada. ({‰ê—TŽ÷1, ”ђˍ‚_1, ‹àŽq~‘¾˜Y1, –ö“c“ÖŽq2, ‹àŽq@Œú1, –k‘º‰p“ñ1, ‹ààV’¼”ü3, ¼ŽR˜a—˜1: 1”]_Œo“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3•a‘ԁEf—ÃŒn)

713024. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Bilaterally synchronized faciobrachial dystonic seizures in anti-LGI1 Encephalitis: a case report. Mikami T, Amano E, Iizuka T1, Machida A: AAN 2020 (2020/4/25-5/1), WebŠJÃ. (”ђˍ‚_1: 1”]_Œo“à)

713025. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Clinical features, immunotherapy, and outcome in patients with cryptogenic NORSE. Iizuka T1, Yanagida A2, Kaneko J1, Nonoda Y3, Iwase R1, Suga H1, Koizumi K, Nakamura T, Ueno H, Shishido T, Sakamoto M, Imai K, Terasawa Y, Itagaki Y, Hattori K, Ayano M, Hosoi Y, Ohara H, Kanazawa N4, Nishiyama K1: AAN 2020 (2020/4/26), WebŠJÃ. (”ђˍ‚_1, –ö“c“ÖŽq2, ‹àŽq~‘¾˜Y1, –ìX“c–L3, Šâ£—ÈŽq1, {‰ê—TŽ÷1, ‹ààV’¼”ü4, ¼ŽR˜a—˜1: 1”]_Œo“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3¬Ž™, 4•a‘ԁEf—ÃŒn)

713026. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Clinical and immunological investigation in patients with suspected autoimmune post-herpes simplex encephalitis. Kaneko J1, Iizuka T1, Iwase R1, Nagai T1, Kaneko A1, Kitamura E1, Tomita H, Igarashi S, Irioka T, Arai M, Kanazawa K2, Nishiyama K1: AAN 2020 (2020/4/25-5/1), WebŠJÃ. (‹àŽq~‘¾˜Y1, ”ђˍ‚_1, Šâ£—ÈŽq1, ‰iˆärs1, ‹àŽq@Œú1, –k‘º‰p“ñ1, ‹ààV’¼”ü2, ¼ŽR˜a—˜1: 1”]_Œo“à, 2•a‘ԁEf—ÃŒn)

722040. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Ž©ŒÈ–Ɖu«”]‰Š‚É‚¨‚¯‚é‰^“®ˆÙíÇ‚Æ‚Ä‚ñ‚©‚ñ”­ì‚Ì”­Œ»‹@\. ”ђˍ‚_ (”]_Œo“à): ‘æ61‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2020/9/1), ‰ªŽR.

722041. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) –¢—ˆ (30”NŒã) ‚̐_Œo–ƉuŽ¾Š³‚ÌŽ¡—ÃI-3 Ž©ŒÈ–Ɖu«”]‰Š‚ÌŽ¡—Â̖¢—ˆ. ”ђˍ‚_ (”]_Œo“à): ‘æ32‰ñ“ú–{_Œo–ƉuŠw‰ïŠwpW‰ï (2020/10/1), ‹à‘ò.

722042. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ”]_Œo“à‰Èˆã‚ªf‚é‚ׂ«ƒTƒ‹ƒRƒCƒh[ƒVƒX. ¼ŽR˜a—˜ (”]_Œo“à): ‘æ38‰ñ“ú–{_ŒoŽ¡—Êw‰ïŠwpW‰ï (2020/10/28), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722043. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) Ž©ŒÈ–Ɖu«”]‰Š‚¨‚æ‚Ñ‚»‚Ì—Þ‰Ž¾Š³‚É‚¨‚¯‚éUp to Date. ”ђˍ‚_ (”]_Œo“à): ‘æ38‰ñ“ú–{_ŒoŽ¡—Êw‰ïŠwpW‰ï (2020/10/29), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722044. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‹}«Šú‚̍RŒŒð—Ö@. ¼ŽR˜a—˜ (”]_Œo“à): ‘æ46‰ñ“ú–{”]‘²’†Šw‰ïŠwpW‰ï (2021/3/11), •Ÿ‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723151. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒãÒ‘“®–¬ÇŒóŒQ‚Ì1—á. –؉ºØX, _è^ŽÀ1, Šâ£—ÈŽq1, ‚@‹`Ž÷, –k‘º‰p“ñ1, ˆ¢‹v’Óñ•v1, ¼ŽR˜a—˜1 (1”]_Œo“à): ˆãŠw¶EŒ¤Cˆã‚Ì“ú–{“à‰ÈŠw‰ï‚±‚Æ‚Í‚¶‚ß 2020 (‘æ117‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ï) (2020/8/8), WebŠJÃ.

723152. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”]’ê“®–¬ÇðÇ‚É‚¨‚¯‚éŒã‘å”]“®–¬‚Ì•`o‚Æ’†”]E‹´[Ç‚Æ‚ÌŠÖŒW. ˆ¢‹v’Óñ•v1, ‰Pˆäk‘¾˜Y1, –Ø‘º•¶«1, {‰ê—TŽ÷1, ŒI“c‰l—Žq1, ‰Oˆä@—É1, ˆä“‡‘å•ã1, –k‘º‰p“ñ1, ”ђˍ‚_1, ¼ŽR˜a—˜1 (1”]_Œo“à): STROKE 2020 (2020/8/24), WebŠJÃ.

723153. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹}«Šú”]oŒŒ‚ɍ‡•¹‚·‚é‹}«Šú”][Ç‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‰iˆärs (”]_Œo“à): STROKE 2020 (2020/8/24), WebŠJÃ.

723154. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Status epilepticus suspected autoimmune: antibody frequency and its main clinical features. {‰ê—TŽ÷1, ”ђˍ‚_1, ‹àŽq~‘¾˜Y1, –ö“c“ÖŽq2, ‹àŽq@Œú1, –k‘º‰p“ñ1, ‹ààV’¼”ü3, ˆ¢‹v’Óñ•v1, ¼ŽR˜a—˜1 (1”]_Œo“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3•a‘ԁEf—ÃŒn): ‘æ61‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2020/8/31), ‰ªŽR.

723155. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Association between low body temperature and cortical spreading depression. –k‘º‰p“ñ1, ‹ààV’¼”ü2, ”ђˍ‚_1, ¼ŽR˜a—˜1 (1”]_Œo“à, 2•a‘ԁEf—ÃŒn): ‘æ61‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2020/8/31), ‰ªŽR.

723156. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”­ÇŒã‹}‘¬‚ɏǏ󂪉ü‘P‚·‚é”]oŒŒ‚Ì“Á’¥. ˆ¢‹v’Óñ•v1, ‰iˆärs1, ‰Pˆäk‘¾˜Y1, –Ø‘º•¶«1, ˆ¢•”—L‹N1, ‹àŽq@Œú1, {‰ê—TŽ÷1, ‰Oˆä@—É1, ŒI“c‰l—Žq1, ˆä“‡‘å•ã1, ‹àŽq~‘¾˜Y1, –k‘º‰p“ñ1, ”ђˍ‚_1, ¼ŽR˜a—˜1 (1”]_Œo“à): ‘æ61‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2020/9/2), ‰ªŽR.

723157. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘̉·•Ï‰»‚Æcortical spreading depression‚ÌŠÖŒW. –k‘º‰p“ñ1, ‹ààV’¼”ü2, ”ђˍ‚_1, ¼ŽR˜a—˜1 (1”]_Œo“à, 2•a‘ԁEf—ÃŒn): ‘æ48‰ñ“ú–{“ª’ÉŠw‰ï‘‰ï (2020/11/7-8), WebŠJÃ.

731012. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) COVID-19‚Ɛ_Œo“à‰ÈŽ¾Š³C_Œo“ï•a. ¼ŽR˜a—˜ (”]_Œo“à): ‘æ35‰ñ_“ސ쌧_Œo“ï•aŒ¤C‰ï (2020/12/7), ‘Š–ÍŒ´.

732011. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) ‚±‚̏Ǘá‚̐f’f‚ÆŽ¡—ÂÍ?yã‹‰•Òz. ¼ŽR˜a—˜ (”]_Œo“à): ‘æ3‰ñ“ú–{_ŒoŠw‰ï”]‘²’†“Á•Ê‹³ˆçŒ¤C‰ï (2020/9/20), ‘åã (ƒnƒCƒuƒŠƒbƒhŠJÃ).

733032. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Parry-RombergÇŒóŒQ‚É‚à‚â‚à‚â•a‚ð‡•¹‚µ•p‰ñ‚Ɉê‰ß«”]‹•ŒŒ”­ì‚ðŒJ‚è•Ô‚µ‚½44Î—«—á. Šâ£—ÈŽq1, ˆä“‡‘å•ã1, ‰Pˆäk‘¾˜Y1, –Ø‘º•¶«1, ‰Oˆä@—É1, ‘àV^”üŽq2, ŽR–{‘å•ã3, ˆ¢‹v’Óñ•v1, ¼ŽR˜a—˜1 (1”]_Œo“à, 2”畆, 3”]ŠO): ‘æ235‰ñ“ú–{_ŒoŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/12/5), WebŠJÃ.

733033. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ƒvƒŠƒIƒ“’`”’ˆâ“`Žq‚É120bp‚Ì‘}“ü•ÏˆÙ‚ð”F‚ß‚½‰Æ‘°«ƒvƒŠƒIƒ“•a‚Ì53Î—«—á. –Ø‘º•¶«1, ‰iˆä^‹MŽq1, ”ђˉë‹M1, ’·“c“ޏ”ü1, ˆ¢‹v’Óñ•v1, ”ђˍ‚_1, ¼ŽR˜a—˜1 (1”]_Œo“à): ‘æ236‰ñ“ú–{_ŒoŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/3/6), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110016. [Œ´’˜] Hashimoto encephalopathy in the 21st century. Mattozzi S, Sabater L, Escudero D, Arino H, Armangue T, Simabukuro M, Iizuka T1, Hara M, Saiz A, Sotgiu S, Dalmau J, Graus F: Neurology 2020/1; 94 (2): e217-24. (”ђˍ‚_1: 1”]_Œo“à)

'19-310001. [Ç—á•ñ] Infantile Refsum Disease Associated with Hypobetalipoproteinemia. Matsuo M, Akutsu T1, Kanazawa N2, Shimozawa N: J Pediatr Neurol 2019; 17 (6): 210-2. (ˆ¢‹v’Óñ•v1, ‹ààV’¼”ü2: 1”]_Œo“à, 2•a‘ԁEf—ÃŒn)

'19-310002. [Ç—á•ñ] Anti-HMGCR myopathy following acute Epstein-Barr virus infection. Shimizu T, Kondo Y1, Kanazawa N2, Kaneko A1, Tominaga N1, Nagai M1, Iizuka T1, Nishino I, Nishiyama K1: Muscle Nerve 2020/1; 61 (1): E5-8. (‹ß“¡—TŽq1, ‹ààV’¼”ü2, ‹àŽq@Œú1, •x‰i“Þ•Û”ü1, ‰iˆä^‹MŽq1, ”ђˍ‚_1, ¼ŽR˜a—˜1: 1”]_Œo“à, 2•a‘ԁEf—ÃŒn)

'19-310003. [Ç—á•ñ] A Case of Bilaterally Synchronized Faciobrachial Dystonic Seizures in Anti-Leucine-Rich Glioma Inactivated-1 Encephalitis. Mikami T, Amano E, Iizuka T1, Machida A: Mov Disord Clin Pract 2020/3; 7 (4): 470-1. (”ђˍ‚_1: 1”]_Œo“à)

'19-540003. [‚»‚Ì‘¼]yŠª“ªŒ¾zMMJ‚̕ҏWˆÏˆõ‚ð”q–½‚µ‚Ä.¼ŽR˜a—˜ (”]_Œo“à): MMJ 2019/4; 4ŒŽ†: 33.

'19-540004. [‚»‚Ì‘¼]yŠª“ªŒ¾z—ߘa‚Æ‚Æ‚à‚É”]‘²’†Ž•ž‚Ì–‹‚ªŠJ‚­.¼ŽR˜a—˜ (”]_Œo“à): MMJ 2020/2; 2E3ŒŽ†: 1.

[’˜@‘]

'19-620005. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj 2020”N”Ł@Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚éz‘æ15Í _ŒoE‹ØŽ¾Š³@ˆê‰ß«”]‹•ŒŒ”­ì‚Ì“à‰È“IŽ¡—Ã, p.929-30. ¼ŽR˜a—˜ (”]_Œo“à), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@½, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2020/1”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

'18-722004. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ”][Ç‚Ì“ñŽŸ—\–h: ŠëŒ¯ˆöŽq‚ÌŠÇ—. ¼ŽR˜a—˜ (”]_Œo“à): ‘æ44‰ñ“ú–{”]‘²’†Šw‰ïŠwpW‰ï (2019/3/22), ‰¡•l.


ŒŒ‰t“à‰ÈŠw

[Šwp˜_•¶]

110193. [Œ´’˜] Changes in estimate glomerular filtration rate associated with long-term tyrosine kinase inhibitor treatment in patinets with chronic myelogenous leukemia. Motohashi T1, Kamata H2, Hayama K1, Michishita Y2, Horigome Y2, Tadera N2, Okina S2, Suzuki T2: Kitasato Med J 2021/3; 51 (1): 32-41. (–{‹´’m”ü1, Š™“c_–«2, ‰HŽRŒdˆÈ1, “¹‰º—Y‰î2, –x•Ä—Cˆê2, “cŽ›”͍s2, ‰¥@‘c½2, —é–Ø—²_2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ŒŒ‰t“à)

320002. [Ç—á•ñ] ”DP‘æ2Šú‚É”­Ç‚µ‚½‹}«”’ŒŒ•a. –x•Ä—Cˆê1, “cŽ›”͍s1, “¹‰º—Y‰î1, –{‹´’m”ü2, Î“c@—²3, ‰¥@‘c½1, Š™“c_–«1, ‹{ø“_“ñ3, —é–Ø—²_1 (1ŒŒ‰t“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3—AŒŒE×–EˆÚA): —Տ°ŒŒ‰t 2020/8; 61 (8): 865-9.

522044. [uÀ]y“ÁW: —Տ°ŒŒ‰tŠw|f’f‚ÆŽ¡—Âɂ¨‚¯‚éƒpƒ‰ƒ_ƒCƒ€ƒVƒtƒg2020 (ÔŒŒ‹…ŒnŽ¾Š³)|z“S‘ãŽÓ‚Æ“SÜ•s‰ž«“SŒ‡–R«•nŒŒ. —é–Ø—²_ (ŒŒ‰t“à): —Տ°ŒŒ‰t 2020/5; 61 (5): 475-83.

522045. [uÀ]y‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï‹³ˆçu‰‰“ÁWz—AŒŒŒã“S‰ßèÇ‚̐f—Ã. —é–Ø—²_ (ŒŒ‰t“à): —Տ°ŒŒ‰t 2020/9; 61 (9): 1205-11.

522046. [uÀ]y“ÁW: •nŒŒ@ÅV‚Ì–ò•¨Ž¡—Ð헪‚ÆŽÀ‘Hƒ|ƒCƒ“ƒgz¡‚±‚ñ‚È‚Æ‚«‚Ç‚¤‚·‚é? ƒvƒ‚ª‹³‚¦‚éŽÀ‘Hƒ|ƒCƒ“ƒgQ&A!@“S‰ßè‚Ì‚Æ‚«‚É‚Í‚Ç‚¤‘Ήž‚·‚é‚©?@“SƒLƒŒ[ƒgÜ‚Í‚Ç‚ÌŠ³ŽÒ‚É‚Ç‚¤Žg‚¤? —é–Ø—²_ (ŒŒ‰t“à): –ò‹Ç 2020/9; 71 (10): 3181-6.

522047. [uÀ]y“ÁW: ŒŒŽZ‚ð‹É‚ß‚éz<ŒŒŽZ‚ُ̈í‚̊ӕʐf’f>@•nŒŒ‚̊ӕʐf’f. —é–Ø—²_ (ŒŒ‰t“à): “à‰È 2020/10: 126 (4): 705-9.

[’˜@‘]

620030. [Šwp‘ (•ª’SŽ·•M)]y“ü–åŽîᇓà‰ÈŠw ‰ü’ù‘æ3”ŁzII Še˜_@13 ‘¢ŒŒŠí@3. œ‘ˆÙŒ`¬ÇŒóŒQ, p.251-4. —é–Ø—²_ (ŒŒ‰t“à), •Ò: “ú–{—Տ°Žîᇊw‰ï, “ì]“°, “Œ‹ž, 2020/7”­s.

620031. [Šwp‘ (•ª’SŽ·•M)]y‘¢ŒŒŠíŽîᇊw (‘æ2”Å)|Šî‘b‚ƗՏ°‚̍ŐVŒ¤‹†“®Œü|(“ú–{—Õà¬78Šª‘Š§†3)zIV. œ‘ŒnŽîᇂ̗Տ°@6. œ‘ˆÙŒ`¬ÇŒóŒQ@(3) œ‘ˆÙŒ`¬ÇŒóŒQ‚Ì—\ŒãˆöŽq, p.389-94. —é–Ø—²_ (ŒŒ‰t“à), “ú–{—Õ଎Ð, “Œ‹ž, 2020/8”­s.

620032. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj@2021”N“x”Łz11. ‘ãŽÓŽ¾Š³@“S‰ßèÇ (ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX), p.789-90. —é–Ø—²_ (ŒŒ‰t“à), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@½, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2021/1”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713027. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Real-World Assessment of Nationwide Health Economic Burden and Treatment-Based Survival for Current Myelodysplastic Syndromes Treatment Practice in Japan. Tsutsue S, Suzuki T1, Kim H, Kuan YH W, Crawford B: The American Society of Hematology 62nd Annual Meeting and Exposition (2020/12/5-8), WebŠJÃ. (—é–Ø—²_1: 1ŒŒ‰t“à)

722045. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) —AŒŒŒã“S‰ßèÇ‚ÌŽ¡—ÃŽwj‚ƍ¡Œã‚Ì“WŠJ. —é–Ø—²_ (ŒŒ‰t“à): ‘æ68‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïŠwp‘‰ï (2020/5/28-30), ŽãŠJÃ, “ú–{—AŒŒ×–EŽ¡—Êw‰ïŽ 2020/4; 66 (2): 127.

722046. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘¢ŒŒŠíŽ¾Š³‚Æ—AŒŒŒã“S‰ßèÇ. —é–Ø—²_ (ŒŒ‰t“à): ‘æ44‰ñ“ú–{“SƒoƒCƒIƒTƒCƒGƒ“ƒXŠw‰ïŠwpW‰ï (2020/9/5-6), ŽãŠJÃ, “ú–{“SƒoƒCƒIƒTƒCƒGƒ“ƒXŠw‰ïWEB; ‘æ44‰ñ“ú–{“SƒoƒCƒIƒTƒCƒGƒ“ƒXŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€: ƒVƒ“ƒ|ƒWƒEƒ€1.

722047. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) —AŒŒŒã“S‰ßèÇ‚̐f—Ã. —é–Ø—²_ (ŒŒ‰t“à): ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2020/10/10-11/8), WebŠJÃ, —Տ°ŒŒ‰t 2020/8; 61 (8): ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€: ‹³ˆçu‰‰11.2-5D.

723158. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Š¦—â‹ÃW‘fÇ‚ł̓Šƒ“ƒp«Žîᇂª‚—¦‚ɍ‡•¹‚·‚é: ’PŽ{ÝŒã•ûŽ‹“I‰ðÍ‚ÌŒ‹‰Ê. “cŽ›”͍s1, ‰HŽRŒdˆÈ2, ‰¡ŽR^Šì1, òŽR˜a‹v1, ]”¨Wˆê1, “¹‰º—Y‰î1, –x•Ä—Cˆê1, Š™“c_–«1, ‰¥@‘c½1, ‹{ú±_“ñ3, —é–Ø—²_1 (1ŒŒ‰t“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3—AŒŒE×–EˆÚA): ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2020/10/10-11/8), WebŠJÃ, ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€ 2020; WEB.

723159. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ_ƒTƒ`ƒjƒuŠÖ˜A’°‰Š‚Ì”­Ç‚ÆŽ¡—Âɂ‚¢‚Ä‚Ì’PŽ{ÝŒã•ûŽ‹“I‰ðÍ. òŽR˜a‹v1, ‰¥@‘c½1, ]”¨Wˆê1, ‰HŽRŒdˆÈ2, ‰¡ŽR^Šì1, “cŽ›”͍s1, –x•Ä—Cˆê1, “¹‰º—Y‰î1, Š™“c_–«1, ‹{ú±_“ñ3, —é–Ø—²_1 (1ŒŒ‰t“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3—AŒŒE×–EˆÚA): ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2020/10/10-11/8), WebŠJÃ, ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€ 2020; WEB.

723160. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ä”­E“«‘½”­«œ‘Žî‚É‚¨‚¯‚é’á—p—ÊŠJŽnƒCƒLƒTƒ]ƒ~ƒu—Ö@‚Ì—L—p«‚ɂ‚¢‚Ä‚ÌŒã•ûŽ‹“IŒŸ“¢. –x•Ä—Cˆê1, ‰¥@‘c½1, Š™“c_–«1, “cŽ›”͍s1, ‰HŽRŒdˆÈ2, ‰¡ŽR^Šì1, “¹‰º—Y‰î1, òŽR˜a‹v1, ]”¨Wˆê1, —é–Ø—²_1 (1ŒŒ‰t“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2020/10/10-11/8), WebŠJÃ, ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€ 2020; WEB.

723161. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒGƒ~ƒVƒYƒ}ƒu’èŠú“Š—^Š³ŽÒ‚̏d“ĂȏoŒŒ«Ž–Û‚ɑ΂µ‚ÄrFVIII»Ü‚Ì•â[—Ö@‚ÅŠÇ—‚µ‚½Ç—á‚ɂ‚¢‚Ä. ‰¡ŽR^Šì1, Vˆäãđ¾1, ]”¨Wˆê1, òŽR˜a‹v1, ‰HŽRŒdˆÈ2, –x•Ä—Cˆê1, “cŽ›”͍s1, Š™“c_–«1, ‰¥@‘c½1, —é–Ø—²_1, ‹{ú±_“ñ3 (1ŒŒ‰t“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3—AŒŒE×–EˆÚA): ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2020/10/10-11/8), WebŠJÃ, ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€ 2020; WEB.

723162. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 5q-‚ðœ‚­FAB-RAÇ—á‚Å‚ÌŠeŒŒ‹…Œn“‚ٌ̈`¬‚ª—^‚¦‚é—\Œã‚ւ̉e‹¿: “Á”­«‘¢ŒŒáŠQ’²¸Œ¤‹†”Ç•ñ. ‘O“c’q–ç, ¼“c@W, æ|“c~–ç, ì’[@_, Îì—²”V, ’ÊŽR@ŒO, rŠÖ‚©‚â‚Ì, V•Û@Œh, ”g‘½’qŽq, —é–Ø—²_1, Š–ìGˆê, ‰P‹nŒ›—S, V“°^‹I, —L”n–õ‰À, ’¼ì‹§°, ‘¾“c»Žq, ç—t@Ž , ‹{è‘׎i, ’†”öáÁ“ñ, ¬àVŒh–ç, rˆär–ç, •ì•ô•v, ‚ÜWŽj, ŽO’JŒ¦Žq (1ŒŒ‰t“à): ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2020/10/10-11/8), WebŠJÃ, ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€ 2020; WEB.

733034. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‰Â‹t«Œã“ª—t”’Ž¿”]Ç (PRES) ‚𔭏ǂµ‚½Ph—z«‹}«ƒŠƒ“ƒp‰è‹…«”’ŒŒ•a (Ph + ALL). Vˆäãđ¾1, –x•Ä—Cˆê1, ‰¥@‘c½1, Š™“c_–«1, “cŽ›”͍s1, “¹‰º—Y‰î1, ‰¡ŽR^‹I1, ‰HŽRŒdˆÈ2, òŽR˜a‹v1, ]”¨Wˆê1, ¬¼G–¾1, ŽO‰Y‹v‹X1, ‹{ú±_“ñ3, —é–Ø—²_1 (1ŒŒ‰t“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3—AŒŒE×–EˆÚA): ‘æ14‰ñ“ú–{ŒŒ‰tŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/3/20), “Œ‹ž, —Տ°ŒŒ‰t 2021; 62 (6): 673.


ŒÄ‹zŠí“à‰ÈŠw

[Šwp˜_•¶]

110194. [Œ´’˜] Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer. Igawa S1, Ono T1, Kasajima M1, Manabe H1, Fukui T1, Mitsufuji H2, Yokoba M3, Kubota M3, Katagiri M3, Sasaki J1,4, Naoki K1: Cancer Manag Res 2020/6; 12: 4911-21. (ˆäì@‘1, ¬–ì‘ו½1, Š}“‡^Žu1, áÁ糉p–¾1, •Ÿˆä•ü–ç1, ŽO“¡@‹v2, ‰¡ê³“T3, ‹v•Û“cŸ3, •Ð‹Ë^l3, ²X–ØŽ¡ˆê˜Y1,4, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ŠÅŒìŠw•”, 3ˆã—Éq¶Šw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110195. [Œ´’˜] Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma. Nagashio R1, Kuchitsu Y1, Igawa S2, Kusuhara S2, Naoki K2, Satoh Y3, Ichinoe M4, Murakumo Y4, Saegusa M4, Sato Y1: Biomed Res 2020/6; 41 (3): 149-59. (’·‰–@—º1, ‹€’×L‹I1, ˆäì@‘2, “팴­ˆê˜Y2, —P–؍Ž•F2, ²“¡”Vr3, ˆêŒË¹–¾4, ‘º‰_–FŽ÷4, ŽOŽ}@M4, ²“¡—Yˆê1: 1ˆã—Éq¶Šw•”, 2ŒÄ‹zŠí“à, 3ŒÄ‹zŠíŠO, 4•a—)

110196. [Œ´’˜] Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors. Ono T1, Igawa S1, Kurahayashi S1, Okuma Y1, Sugimoto A1, Kusuhara S1, Ozawa T1, Fukui T1, Sasaki J1,2, Mitsufuji H3, Yokoba M4, Kubota M4, Katagiri M4, Naoki K1: Invest New Drugs 2020/6; 38 (3): 885-93. (¬–ì‘ו½1, ˆäì@‘1, ‘q—ѐT‘¾˜Y1, ‘åŒF—F—œŽq1, ™–{@—•1, “팴­ˆê˜Y1, ¬àV‹M—T1, •Ÿˆä•ü–ç1, ²X–ØŽ¡ˆê˜Y1,2, ŽO“¡@‹v3, ‰¡ê³“T4, ‹v•Û“cŸ4, •Ð‹Ë^l4, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ŠÅŒìŠw•”, 4ˆã—Éq¶Šw•”)

110197. [Œ´’˜] Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. Igawa S1, Naoki K1, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Takiguchi Y, Miyaoka E, Okumura M, Yoshino I: Lung Cancer 2020/8; 146: 160-4. (ˆäì@‘1, —P–؍Ž•F1: 1ŒÄ‹zŠí“à)

110198. [Œ´’˜] Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab. Fukui T1, Hosotani S1, Soda I2, Ozawa T1, Kusuhara S1, Kakegawa-I M1, Kasajima M1, Hiyoshi Y1, Igawa S1, Yokoba M3, Mitsufuji H4, Kubota M3, Katagiri M3, Sasaki J1,5, Ishiyama H2, Naoki K3: Thorac Cancer 2020/8; 11 (4): 1005-14. (•Ÿˆä•ü–ç1, ×’J^Ži1, ‘“c@Ši2, ¬àV‹M—T1, “팴­ˆê˜Y1, Š|ì–¢ŠóŽq1, Š}“‡^Žu1, “ú‹gNO1, ˆäì@‘1, ‰¡ê³“T3, ŽO“¡@‹v4, ‹v•Û“cŸ3, •Ð‹Ë^l3, ²X–ØŽ¡ˆê˜Y1,5, ÎŽR”ŽžŠ2, —P–؍Ž•F1: 3ŒÄ‹zŠí“à, 2•úŽËü (Žîá‡), 3ˆã—Éq¶Šw•”, 4ŠÅŒìŠw•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110199. [Œ´’˜] Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells. Ohgino K, Terai H, Yasuda H, Nukaga S, Hamamoto J, Tani T, Kuroda A, Arai D, Ishioka K, Masuzawa K, Ikemura S, Kawada I, Naoki K1, Fukunaga K, Soejima K: Cancer Sci 2020/10; 111 (10): 3793-801. (—P–؍Ž•F1: 1ŒÄ‹zŠí“à)

110200. [Œ´’˜] MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. Nishiyama A, Takeuchi S, Adachi Y, Otani S1, Tanimoto A, Sasaki M, Matsumoto S, Goto K, Yano S: Cancer Sci 2020/10; 111 (10): 3813-23. (‘å’JçŽq1: 1ŒÄ‹zŠí“à)

110201. [Œ´’˜] Comparison between quantitative computed tomography, scintigraphy, and anatomical methods for prediction of postoperative FEV 1 and DLCO: effects of chronic obstructive pulmonary disease status and resected lobes. Yokoba M1, Ichikawa T, Harada S2, Shiomi K3, Mikubo M3, Ono M3, Sonoda D2, Satoh Y3, Hanawa H, Naoki K4, Katagiri M1: J Thorac Dis 2020/10; 12 (10): 5269-80. (‰¡ê³“T1, Œ´“c^–ç2, ‰–Œ©@˜a3, ŽOŒE«Žj3, ¬–쌳Žk3, ‰€“c@‘å3, ²“¡”Vr3, —P–؍Ž•F4, •Ð‹Ë^l1: 1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ŒÄ‹zŠíŠO, 4ŒÄ‹zŠí“à)

110202. [Œ´’˜] Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: Perforin as a biomarker. Ota T, Fukui T1, Nakahara Y1, Takeda T, Uchino J, Mouri T, Kudo K, Nakajima S, Suzumura T, Fukuoka M: Thorac Cancer 2020/11; 11 (11): 3223-33. (•Ÿˆä•ü–ç1, ’†Œ´‘P˜N1: 1ŒÄ‹zŠí“à)

110203. [Œ´’˜] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer. Igawa S1, Ono T1, Kasajima M1, Kusuhara S1, Otani S1, Fukui T1, Yokoba M2, Kubota M2, Katagiri M2, Mitsufuji H3, Sasaki J1,4, Naoki K1: Invest New Drugs 2020/12; 38 (6): 1906-14. (ˆäì@‘1, ¬–ì‘ו½1, Š}“‡^Žu1, “팴­ˆê˜Y1, ‘å’JçŽq1, •Ÿˆä•ü–ç1, ‰¡ê³“T2, ‹v•Û“cŸ2, •Ð‹Ë^l2, ŽO“¡@‹v3, ²X–ØŽ¡ˆê˜Y1,4, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3ŠÅŒìŠw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110204. [Œ´’˜] Suppression of interleukin-6 gene expression and protein production by mechanical stretching combined with weak, PEEP-like stretching of human pulmonary artery endothelial cells. Kobayashi K1, Kokubo K2, Inaoka H2, Noshiro M, Kubota M1, Kobayashi H1: Kitasato Med J 2021/3; 51 (1): 24-31. (¬—Ñ‚±‚¸Œb1, ¬‹v•ÛŒªˆê2, ˆî‰ªGžû2, –ìé^—2, ‹v•Û“cŸ1, ¬—эO—S1: 1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

520006. [‘à] ¬×–E”xŠà‚ÌŽ¡—Ã. ˆäì@‘1, ˆÉ“¡O‹I1, ŠÔ’†”Ž–ç1, ¬–ì‘ו½1, —P–؍Ž•F1 (1ŒÄ‹zŠí“à): –k—¢ˆãŠw 2020/12; 50 (2): 69-75.

[’˜@‘]

620033. [Šwp‘ (•ª’SŽ·•M)]yf’f‚ÆŽ¡—Â̎è‹Z|fŽ@Žº‚±‚ê1û|(f’f‚ÆŽ¡—à 2021”N Vol.109 No.‘Š§†)z‘æ1•”f’f@‘æ3Í—Տ°ŒŸ¸@13 ‹¹…ŠŒ©, p.184-7. —P–؍Ž•F (ŒÄ‹zŠí“à), f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 2021/3”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713028. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Evaluation of blood cell adhesion and solute removal performance by an ex vivo experiment of a polysulfone hemofilter using an NV polymer membrane for continuous renal replacement therapy. Kurihara Y, Ueki S, Kobayashi K, Kokubo K, Kobayashi H, Kubota M1: 57th ERA-EDTA Virtual Congress (2020/6/6), WebŠJÃ. (‹v•Û“cŸ1: 1ˆã—Éq¶Šw•”)

713029. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Lung expansion and alternation of low attenuation volume in lobectomized patients. Yokoba M1, Ichikawa T, Harada S2, Ozawa T3, Kusuhara S3, Fukui T3, Igawa S3, Mitsufuji H4, Kubota M1, Sasaki J3,5, Naoki K3, Sato Y1, Katagiri M1: ERS International Congress 2020 (2020/9/5-9), WEBŠJÃ, European Respiratory Journal 2020; 56: (Suppl 64): 3129. (‰¡ê³“T1, Œ´“c^–ç2, ¬àV‹M—T3, “팴­ˆê˜Y3, •Ÿˆä•ü–ç3, ˆäì@‘3, ŽO“¡@‹v4, ‹v•Û“cŸ1, ²X–ØŽ¡ˆê˜Y3,5, —P–؍Ž•F3, ²“¡—Yˆê1, •Ð‹Ë^l1: 1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ŒÄ‹zŠí“à, 4ŠÅŒìŠw•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

713030. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, nonsmall cell lung cancer (TORG1632). Igawa S1, Noro R, Kubota K, Naoki K, Bessho A, Hirose T, Shimokawa T, Nakashima M, Minato K, Seki N, Tokito T, Harada T, Sasada S, Miyamoto S, Tanaka Y, Furuya N, Kaburagi T, Hayashi H, Lihara H, Okamoto H: ESMO Asia Virtual Congress 2020 (2020/11/20), WebŠJÃ. (ˆäì@‘1: 1ŒÄ‹zŠí“à)

713031. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Impact of Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibitors. Ono T1, Igawa S1, Yamada K1, Kameda A1, Oguri A1, Yamamoto H1, Manabe H1, Ozawa T1, Kusuhara S1, Kasajima M1, Kakegawa M1, Otani S1, Fukui T1, Sasaki J1,2, Naoki K1: IASLC 2020 WCLC World Conference on Lung Cancer (2021/1/28-31), WEBŠJÃ. (¬–ì‘ו½1, ˆäì@‘1, ŽR“cŒO—œ1, ‹T“c–ƒÊŽÀ1, ¬ŒI–¾l1, ŽR–{_‹M1, áÁ糉p–¾1, ¬àV‹M—T1, “팴­ˆê˜Y1, Š}“‡^Žu1, Š|ì–¢ŠóŽq1, ‘å’JçŽq1, •Ÿˆä•ü–ç1, ²X–ØŽ¡ˆê˜Y1,2, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

713032. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Dynamic Risk Prediction for Disease Control With Nivolumab in Advanced or Recurrent Non-Small Cell Lung Cancer Patients (NewEpoch). Fukui T1, Igawa S1, Goto Y, Yoh K, Hosomi Y, Kato T, Usui K, Hirano K, Tanaka H, Saito R, Bessho A, Aono H, Tamura A, Ohashi Y, Taguri M, Sasaki J1,2, Naoki K1, Kunitoh H: IASLC 2020 WCLC World Conference on Lung Cancer (2021/1/28-31), WEBŠJÃ. (•Ÿˆä•ü–ç1, ˆäì@‘1, ²X–ØŽ¡ˆê˜Y1,2, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

713033. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Real-world experience of the utility in afatinib therapy for patients with EGFR-mutant advanced NSCLC. Igawa S1, Ono T1, Kasajima M1, Yamada K1, Oguri A1, Kameda A1, Yamamoto H1, Kakegawa M1, Hiyoshi Y1, Kusuhara S1, Ozawa T1, Otani S1, Fukui T1, Kubota M2, Yokoba M2, Katagiri M2, Mitsufuji H3, Sasaki J1,4, Naoki K1: IASLC 2021 World Conference on Lung Cancer (2021/1/29), Singapore. (ˆäì@‘1, ¬–ì‘ו½1, Š}“‡^Žu1, ŽR“cŒO—œ1, ¬ŒI–¾l1, ‹T“c–ƒÊŽÀ1, ŽR–{_‹M1, Š|ì–¢ŠóŽq1, “ú‹gNO1, “팴­ˆê˜Y1, ¬àV‹M—T1, ‘å’JçŽq1, •Ÿˆä•ü–ç1, ‹v•Û“cŸ2, ‰¡ê³“T2, •Ð‹Ë^l2, ŽO“¡@‹v3, ²X–ØŽ¡ˆê˜Y1,4, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3ŠÅŒìŠw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

722048. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) ”xŠà. —P–؍Ž•F (ŒÄ‹zŠí“à): ‘æ58‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2020/10/23), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722049. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) PS•s—ǏǗá‚ɑ΂·‚é–ò•¨—Ö@`×–EáŠQ«R‚ª‚ñÜ‚ÌŠÏ“_‚©‚ç`. Žsì–õŽq, •ÊŠºG, ‰ª–{_–¾, —P–؍Ž•F1, ×Œ©K¶, ŠâàVrˆê˜Y, Žž”C‚Í, ŠÖ@‡•F (1ŒÄ‹zŠí“à): ‘æ61‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2020/11/14), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723163. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EGFR-TKI’ïR«‚ÌT790M—z«NSCLC‚É‚¨‚¯‚éƒIƒVƒƒ‹ƒ`ƒjƒu‚̈â“`Žq•ÏˆÙƒ^ƒCƒv•Ê‚ÌŒø‰Ê‚ÌŒŸ“¢ (‘OŒü‚«ŠÏŽ@Œ¤‹†). ‘q—ѐT‘¾˜Y1, ˆäì@‘1, ‘åŒF—F—œŽq1, ™“cŒi—C1, ¬–ì‘ו½1, ™–{@—•1, ‘]ª‰p”V1, ×’J^Ži1, •Ÿˆä•ü–ç1, ‹v•Û“cŸ2, ŽO“¡@‹v3, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3ŠÅŒìŠw•”): ‘æ43‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï (2020/6/26), Ž†ãŠJÃ.

723164. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ûŠàpŒã•úŽËüÆŽËŒã‚É”­Ç‚µTBLB‚ɂĐf’f‚µ‚½ŠíŽ¿‰»”x‰Š‚̈ê—á. ¬–ì‘ו½1, ŽO“¡@‹v2, áÁ糉p–¾1, ŽR–{_‹M1, ”ªã—L—¢1, ˆÉ“¡O‹I1, ¬àV‹M—T1, “팴­ˆê˜Y1, “ú‹gNO1, Š}“‡^Žu1, Š|ì–¢ŠóŽq1, •Ÿˆä•ü–ç1, ˆäì@‘1, ‹v•Û“cŸ3, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ŠÅŒìŠw•”, 3ˆã—Éq¶Šw•”): ‘æ43‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹¾Šw‰ïŠwpW‰ï (2020/6/27), Ž†ãŠJÃ.

723165. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒIƒVƒƒ‹ƒ`ƒjƒu“Š—^Œã‚̐SŒŒŠÇƒCƒxƒ“ƒg‚ÉŠÖ‚·‚錟“¢. áÁ糉p–¾1, Š|ì–¢ŠóŽq1, ŽR–{_‹M1, ”ªã—L—¢1, ˆÉ“¡O‹I1, “ú‹gNG1, •Ÿˆä•ü–ç1, ˆäì@‘1, ²X–ØŽ¡ˆê˜Y1,2, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ˆãŠw¶EŒ¤Cˆã‚Ì“ú–{“à‰ÈŠw‰ï‚±‚Æ‚Í‚¶‚ß2020 (‘æ117‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ï), (2020/8/8), WebŠJÃ.

723166. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EGFR-TKI’ïR«‚ÌT790M—z«NSCLC‚É‚¨‚¯‚éƒIƒVƒƒ‹ƒ`ƒjƒu‚̈â“`Žq•ÏˆÙƒ^ƒCƒv•Ê‚ÌŒø‰Ê‚ÌŒŸ“¢ (‘OŒü‚«ŠÏŽ@Œ¤‹†). ˆÉ“¡O‹I1, ¬–ì‘ו½1, ˆäì@‘1, ”ªã—L—¢1, áÁ粉p–¾1, ŽR–{_‹M1, •Ÿˆä•ü–ç1, ŽO“¡@‹v2, ²X–ØŽ¡ˆê˜Y1,3, ‹v•Û“cŸ4, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ŠÅŒìŠw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4ˆã—Éq¶Šw•”): ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï (2020/9/21), WebŠJÃ.

723167. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”x—tØœpŽ{s”xŠàŠ³ŽÒ‚ÌŽc‘¶”x‹@”\—\‘ª’l‚̐؏œ”x—t•Ê”äŠr. ‰¡ê³“T1, Žsì@‹B, Œ´“c^–ç2, ²“¡”Vr3, —P–؍Ž•F4, •Ð‹Ë^l1 (1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ŒÄ‹zŠíŠO, 4ŒÄ‹zŠí“à): ‘æ60‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï, (2020/9/21), WEBŠJÃ.

723168. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ_ƒCƒAƒ‰ƒCƒU‚Ìin vitro«”\•]‰¿‚É‚¨‚¯‚镪Žq—Ê3–œ—̈æ‚̃}[ƒJ•¨Ž¿‚ÌŒŸ“¢. ¬‹v•ÛŒªˆê1, ŒIŒ´‰ÀF, d“cD”ü, ‹à“c’¼l, ¬—Ñ‚±‚¸Œb1, ‹v•Û“cŸ1 (1ˆã—Éq¶Šw•”): ‘æ26‰ñ“ú–{HDFˆãŠw‰ïŠwpW‰ïE‘‰ï (2020/10/10), WebŠJÃ.

723169. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ‹Šj«‹¹–Œ‰Š‚Å‚Ì”|—{—z«—¦Œüã‚É‚¨‚¯‚é‹ÇŠ–ƒŒ‰º‹¹o‹¾ŒŸ¸‚Ì—L—p«. ¬àV‹M—T1, ŽO“¡@‹v2, áÁ糉p–¾1, ŽR–{_‹M1, ”ªã—L—¢1, ŠL’ːéŽ÷1, ˆÉ“¡O‹I1, ‘å]r‘¾˜Y, ‘åŒF—F—œŽq1, ™–{@—•1, ‘q—ѐT‘¾˜Y1, ¬–ì‘ו½1, Œ´“c^–ç3, “팴­ˆê˜Y1, “ú‹gNO1, Š}“‡^Žu1, Š|ì–¢ŠóŽq1, •Ÿˆä•ü–ç1, ˆäì@‘1, ‰¡ê³“T4, ²X–ØŽ¡ˆê˜Y1,5, ‹v•Û“cŸ4, •Ð‹Ë^l4, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ŠÅŒìŠw•”, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4ˆã—Éq¶Šw•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ95‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/10/11-12), WebŠJÃ.

723170. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠùŽ¡—Í‚—îi“WŒ^¬×–E”xŠàŠ³ŽÒ‚ւ̃Aƒ€ƒ‹ƒrƒVƒ“’PÜ—Ö@‚̗Տ°Œø‰Ê‚ɂ‚¢‚Ä‚ÌŒŸ“¢. áÁ糉p–¾1, ˆäì@‘1, ŽR–{_‹M1, ”ªã—L—¢1, ‘å’JçŽq1, •Ÿˆä•ü–ç1, ‰¡ê³“T2, ŽO“¡@‹v3, ‹v•Û“cŸ2, •Ð‹Ë^l2, ²X–ØŽ¡ˆê˜Y1,4, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3ŠÅŒìŠw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ61‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2020/11/12), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723171. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EGFRˆâ“`Žq•ÏˆÙ—z«is”ñ¬×–E”xŠà‚ɑ΂·‚é’á—p—ʃAƒtƒ@ƒ`ƒjƒu‚Ì‘æ‡U‘ŠŽŽŒ±: TORG1632ŽŽŒ±. •ÊŠºG, –ì˜C—Ñ‘¾˜Y, ”~–ì‹M—T, —P–؍Ž•F1, ˆäì@‘1, œA£@Œh, ‘º“c‘׋K, ‰ºìP¶, ’†›¸Œ«®, –©@_ˆê, ŠÖ@‡•F, Žž”C‚Í, Œ´“c•q”V, ù“c^Ž , —с@GŽ÷, ”ÑŒ´‘å–«, ‰ª–{_–¾, ‹v•Û“cŠ] (1ŒÄ‹zŠí“à): ‘æ61‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2020/11/12), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723172. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ÇŠis”ñ¬×–E”xŠàŠ³ŽÒ‚É‚¨‚¯‚鉻Šw•úŽËü—Ö@Œã‚Ì‘Šú‘ˆ«‚¨‚æ‚Ñ’·Šú¶‘¶‚ÉŠÖ‚í‚éˆöŽq‚ÌŒŸ“¢. ŽR–{_‹M1, •Ÿˆä•ü–ç1, ‘åŒF—F—œŽq1, ¬–ì‘ו½1, ‘q—ѐT‘¾˜Y1, ™–{@—•1, ™“cŒi—C1, ¬àV‹M—T1, “팴­ˆê˜Y1, Œ´“c^–ç2, Š|ì–¢ŠóŽq1, Š}“‡^Žu1, ‘å’JçŽq1, ˆäì@‘1, ²X–ØŽ¡ˆê˜Y1,3, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ61‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2020/11/12), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723173. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Impact of EGFR genotype on efficacy of Osimertinib in patients with NSCLC: A prospective observational study. ŽR“cŒO—œ1, ˆäì@‘1, ¬–ì‘ו½1, Š}“‡^Žu1, ¬ŒI–¾l1, ‹T“c–ƒÊŽÀ1, ŽR–{_‹M1, Š|ì–¢ŠóŽq1, “ú‹gNO1, “팴­ˆê˜Y1, ¬àV‹M—T1, ‘å’JçŽq1, •Ÿˆä•ü–ç1, ‰¡ê³“T2, ‹v•Û“cŸ2, •Ð‹Ë^l2, ŽO“¡@‹v3, ²X–ØŽ¡ˆê˜Y1,4, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3ŠÅŒìŠw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ18‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï (2021/2/18), WebŠJÃ.

733035. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) \‰¹áŠQEš‹‰ºáŠQ‚Å”­Œ©‚³‚ꂽCollett-Sicard Syndrome‡•¹”x‘BŠà‚̈ê—á. ‘åŒF—F—œŽq1, “팴­ˆê˜Y1, ‹T“c–ƒÊŽÀ1, ŽR–{_‹M1, ‘]ª‰p”V1, ¬–ì‘ו½1, ‘q—ѐT‘¾˜Y1, Š|ì–¢ŠóŽq1, ‘å’JçŽq1, •Ÿˆä•ü–ç1, ˆäì@‘1, ‰¡ê³“T2, ²X–ØŽ¡ˆê˜Y1,3, ŽO“¡@‹v4, ‹v•Û“cŸ2, •Ð‹Ë^l2, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4ŠÅŒìŠw•”): ‘æ179‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ïŠÖ“ŒŽx•”Šw‰ï/‘æ243‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠÖ“Œ’n•û‰ï‡“¯Šw‰ï (2021/2/13), WebŠJÃ.

733036. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) äX”ö•”äXŠà‚ɑ΂·‚éEUS-FNAŒã‚ÉäX«‹¹…‚ð‚«‚½‚µ‚½1—á. ¬ŒI–¾l1, ŽR“cŒO—œ1, ”ªã—L—¢1, ™“cŒi—C1, ™–{@—•1, ¬àV‹M—T1, Š|ì–¢ŠóŽq1, Š}“‡^Žu1, ‘å’JçŽq1, •Ÿˆä•ü–ç1, ˆäì@‘1, ‰¡ê³“T2, ²X–ØŽ¡ˆê˜Y1,3, ŽO“¡@‹v4, ‹v•Û“cŸ2, •Ð‹Ë^l2, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4ŠÅŒìŠw•”): ‘æ179‰ñ“ú–{Œ‹ŠjE”ñŒ‹Šj«RŽ_‹ÛÇŠw‰ïŠÖ“ŒŽx•”Šw‰ï/‘æ243‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠÖ“Œ’n•û‰ï‡“¯Šw‰ï (2021/2/13), WebŠJÃ.

733037. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) • –Œ”dŽí‚ŏpŒãÄ”­‚µ‚½BRAFˆâ“`Žq•ÏˆÙ—z«”xŠà‚ɑ΂µƒ_ƒuƒ‰ƒtƒFƒjƒu/ƒgƒ‰ƒƒ`ƒjƒu•¹—p—Ö@‚ª‘tŒø‚µ‚½1—á. ”ªã—L—¢1, ‘å’JçŽq1, ‘]ª‰p”V1, ™–{@—•1, ¬–ì‘ו½1, •Ÿˆä•ü–ç1, ˆäì@‘1, ‹v•Û“cŸ2, ²X–ØŽ¡ˆê˜Y1,3, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ189‰ñ“ú–{”xŠàŠw‰ïŠÖ“ŒŽx•”ŠwpW‰ï (2021/3/27), WebŠJÃ.


“à•ª”å‘ãŽÓ“à‰ÈŠw

[Šwp˜_•¶]

110205. [Œ´’˜] Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial. Johannsson G, Gordon MB, Rasmussen MH, Haokonsson IH, Karges W, Sv¾rke C, Tahara S, Takano K1, Biller BMK: J Clin Endocrinol Metab 2020/4; 105 (4): e1358-76. (‚–ìK˜H1: 1“à•ª”å‘ãŽÓ“à)

110206. [Œ´’˜] Use of Noncontact Infrared Skin Thermometer for Peripheral Arterial Disease Screening in Patients With and Without Diabetes. Hayashi A1, Shichiri M1: Angiology 2020/8; 71 (7): 650-7. (—с@“N”Í1, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à)

110207. [Œ´’˜] Short-term Change in Resting Energy Expenditure and Body Compositions in Therapeutic Process for Graves' Disease. Hayashi A1, Takano K1, Kawakami Y2, Hitomi M2, Ohata Y1, Suzuki A1, Kamata Y1, Shichiri M1: Intern Med 2020/8; 59 (15): 1827-33. (—с@“N”Í1, ‚–ìK˜H1, ìã—IŽq2, lŒ©–ƒ”üŽq2, ‘唩NG1, —é–؍V–¼1, Š™“c—T“ñ1, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à, 2‰h—{•”)

110208. [Œ´’˜] Comparison of accuracy between flash glucose monitoring and continuous glucose monitoring in patients with type 2 diabetes mellitus undergoing hemodialysis. Matoba K1,2, Hayashi A1, Shimizu N1, Moriguchi I, Kobayashi N, Shichiri M1: J Diabetes Complications 2020/11; 34 (11): 107680. (“IêŒ’‘¾1,2, —с@“N”Í1, ´…‡–ç1, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à, 2—ÕŒŸŠw)

110209. [Œ´’˜] The effectiveness of growth hormone replacement on energy expenditure and body composition in patients with adult growth hormone deficiency. Momozono A1, Hayashi A2, Takano K1, Shichiri M1: Endocr J 2021/4; 68 (4): 469-75. doi: 10.1507/endocrj.EJ20-0644. Epub 2020 Dec 22. (“‰€@–¾1, —с@“N”Í2, ‚–ìK˜H1, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à‰ÈŠw, 2—ÕŒŸŠw)

110210. [Œ´’˜] Suprabasin-derived bioactive peptides identified by plasma peptidomics. Taguchi T1, Kodera Y, Oba K2, Saito T, Nakagawa Y, Kawashima Y, Shichiri M2: Sci Rep 2021/1; 11 (1): 1047. (“cŒû@•ü1, ‘å’ë˜al2, Žµ—¢áÁ‹`2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2“à•ª”å‘ãŽÓ“à)

110211. [Œ´’˜] Circulating prorenin: its molecular forms and plasma concentrations. Fujimoto K1, Kawamura S2, Bando S2, Kamata Y1, Kodera Y, Shichiri M1: Hypertens Res 2021/6; 44 (6): 674-684. doi: 10.1038/s41440-020-00610-0. Epub 2021 Feb 10. (“¡–{˜aŽÀ1, ì‘º¹—FŠó2, â“Œ@Œd2, Š™“c—T“ñ1, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110212. [Œ´’˜] Glucose-dependent insulinotropic polypeptide stimulates the release of a spectrum of biologically active proteins in human endothelial cells. Masaki T1, Shichiri M2: Kitasato Med J 2021/3; 51 (1): 42-8. (³–ØŽkl1, Žµ—¢áÁ‹`2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2“à•ª”å‘ãŽÓ“à)

110213. [Œ´’˜] Molecular components and concentrations of human serum prorenin. Kawamura S1, Fujimoto K2, Kamata Y2, Shichiri M2: Kitasato Med J 2021/3; 51 (1): 63-9. (ì‘º¹—FŠó1, “¡–{˜aŽÀ2, Š™“c—T“ñ2, Žµ—¢áÁ‹`2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2“à•ª”å‘ãŽÓ“à)

110214. [Œ´’˜] Isolation and detection of cell surface angiotensin II receptor using chemical crosslinking. Sasaki S1, Taguchi T1, Kodera Y, Shichiri M2: Kitasato Med J 2021/3; 51 (1): 70-5. (²X–ØŽÑ–ç‰Á1, “cŒû@•ü1, ¬Ž›‹`’j, Žµ—¢áÁ‹`2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2“à•ª”å‘ãŽÓ“à)

521006. [‰ðà] ‹@”\«_Œo“à•ª”åŽîᇂ̐f’f‚Æ“à•ª”åÇó‚Ì“à‰ÈŽ¡—Ã. ‚–ìK˜H (“à•ª”å‘ãŽÓ“à): Á‰»ŠíEŠÌ‘Ÿ“à‰È 2020/7; 8 (1): 107-12.

[’˜@‘]

620034. [Šwp‘ (•ª’SŽ·•M)]y•a‹C‚Æ‚­‚·‚è2020 Šî‘b‚ÆŽÀ‘HExpertfs Guide (–ò‹Ç2020”N‘Š§†)z10. ‘ãŽÓŒn‚Ì•a‹C‚Æ‚­‚·‚è@E“œ”A•a (‡•¹Ç‚ðŠÜ‚Þ), p.886-900. —с@“N”Í1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à), “ìŽR“°, “Œ‹ž, 2020/4”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713034. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Once-weekly somapacitan in Japanese adults with growth hormone deficiency was well tolerated, with similar efficacy to daily growth hormone: a randomised trial. Otsuka F, Takahashi Y, Tahara S, Michael H?jby Rasmussen, Ogawa Y, Takano K1: 22nd European Congress of Endocrinology (ECE) 2020 (2020/9/5), WEBŠJÃ. (‚–ìK˜H1: 1“à•ª”å‘ãŽÓ“à)

722050. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) äXEÁ‰»ŠÇ_Œo“à•ª”åŽîᇂɑ΂·‚éƒ\ƒ}ƒgƒXƒ^ƒ`ƒ“ƒAƒiƒƒOŽ¡—Ã. ‚–ìK˜H (“à•ª”å‘ãŽÓ“à): ‘æ93‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï (2020/7/20), WebŠJÃ.

723174. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘Sg‚̋؈ޏk‚ð”F‚ß‚½bó‘B’†“Ő«ƒ~ƒIƒpƒ`[‚̈ê—á. “¡“ˆ@—à1, “yŠò‘ì–ç1, Žsì—‹Žt1, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ93‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï (2020/7/20-8/31), •l¼ (WebŠJÃ), “ú–{“à•ª”åŠw‰ïŽGŽ 2020; 96 (1): 311.

723175. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒoƒZƒhƒE•a‚̉Á—Ã’†‚É‘½”­«ŠÖß‰Š‚ƃhƒPƒ‹ƒoƒ“•a‚𔭏ǂµ‚½ˆê—á. “cŒû@•ü1, ´…‡–ç2, Š™“c—œˆß“ß, Š™“c—T“ñ2, ‚–ìK˜H2, Žµ—¢áÁ‹`2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2“à•ª”å‘ãŽÓ“à): ‘æ63‰ñ“ú–{bó‘BŠw‰ïŠwpW‰ï (2020/11/19-12/15), “Þ—Ç (WebŠJÃ), “ú–{“à•ª”åŠw‰ïŽGŽ 2020; 96 (1): 385.

723176. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) bó‘B’†“ŏǐ«”’Ž¿”]Ç‚𗈂µ‚½Basedow•a‚̈ê—á. ´…‡–ç1, “yŠò‘ì–ç1, {‰ê—TŽ÷2, “cŒû@•ü3, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2”]_Œo“à, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ63‰ñ“ú–{bó‘BŠw‰ïŠwpW‰ï (2020/11/19-12/15), “Þ—Ç (WebŠJÃ), “ú–{“à•ª”åŠw‰ïŽGŽ 2020; 96 (1): 385.

723177. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘±”­«bó‘B‹@”\’ቺÇ‚𓖏‰‹^‚Á‚½—L’ɐ«‹Øáz¹‚𔺂¤TSBAb—z«‚ÌŒ´”­«bó‘B‹@”\’ቺÇ‚̈ê—á. Š™“c—T“ñ1, ´…‡–ç1, “cŒû@•ü2, Š™“c—œˆß“ß, Žsì—‹Žt1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ63‰ñ“ú–{bó‘BŠw‰ïŠwpW‰ï (2020/11/19-12/15), “Þ—Ç (WebŠJÃ), “ú–{“à•ª”åŠw‰ïŽGŽ 2020; 96 (1): 385.

723178. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) GH•â[—Ö@‚É‚æ‚éŠÌ‘Ÿ“àŽ‰–b‚Ö‚ÌŒø‰Ê‚ðIDEAL IQ–@‚ð—p‚¢‚Ä•]‰¿‚µ‚½ŒŸ“¢. “cŒû@•ü1, ‚–ìK˜H2, Žµ—¢áÁ‹`2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2“à•ª”å‘ãŽÓ“à): ‘æ31‰ñ“ú–{ŠÔ”]‰º‚‘ÌŽîᇊw‰ï, (2021/2/19-28), “Œ‹ž (WebŠJÃ), “ú–{“à•ª”åŠw‰ïŽGŽ 2021; 97 (1): 311.

733038. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ’YŽ_ƒŠƒ`ƒEƒ€‚É‚æ‚ét«”A•öÇ‚ª‹^‚í‚ꂽ‚ª’†•«”A•öÇ‚Ɛf’f‚µ‚½1—á. ’ҁ@@—@1, ˆê“‡—R‰ÁŽq1, –Ø‘º—¢1, ¬“c@Œd1, œA£³r1, “¡“ˆ@—à1, —é–؍V–¼1, ´…‡–ç1, Žsì—‹Žt1, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ21‰ñ“ú–{“à•ª”åŠw‰ïŠÖ“ŒbM‰zŽx•”ŠwpW‰ï (2020/9/18-19), VŠƒ (WebŠJÃ), “ú–{“à•ª”åŠw‰ïŽGŽ 2020; 96 (1): 385.

733039. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒEƒCƒ‹ƒXAŒ^Š´õ‚É‚æ‚é‚à‚Ì‚ªŽ¦´‚³‚ꂽŒ€Ç1Œ^“œ”A•a‚̈ê—á. œA£³r1, —é–Ø—z•F1, ˆê“‡—R‰ÁŽq1, Žsì—‹Žt1, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ58‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/1/30-31), “Œ‹ž (WebŠJÃ), “œ”A•a 2021; 64 (8): 579.

733040. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‰ð–UŠw“I‚Ȉُí‚ð”F‚ß‚¸t”^á‡‚ð‚­‚è•Ô‚µ‚½2Œ^“œ”A•a‚̈ê—á. ’ҁ@@—@1, “yŠò‘ì–ç1, ‚‹´˜ÐŽq, “¡“ˆ@—à1, ´…‡–ç1, —é–؍V–¼1, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ58‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/1/30-31), “Œ‹ž (WebŠJÃ), “œ”A•a 2021; 64 (8): 579.

'19”N“xˆÈ‘O•ª

[’˜@‘]

'19-620006. [Šwp‘ (•ª’SŽ·•M)]yŒŒ“œŠÇ—‚Ì‚½‚ß‚Ì“œ”A•aŽ¡—ÖòŠˆ—pƒ}ƒjƒ…ƒAƒ‹z6Í ƒCƒ“ƒXƒŠƒ“‚ÌŽg‚¢•û@6-7 Ž©ŒÈŒŒ“œ‘ª’èŠí, CGM, CSII, SAP‚ÌŽg‚¢•û, p.185-90. —с@“N”Í1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à), •Ò: Ž›“àN•v, ”’ì@ƒ, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2020/3”­s.


t‘Ÿ“à‰ÈŠw

[Šwp˜_•¶]

310019. [Ç—á•ñ] A case of hemodialysis and steroid therapy for carbamazepine-induced eosinophilic granulomatosis with polyangiitis: a case report with literature review. Abe T1, Nishiyama K1, Yamazaki T1, Miyasaka R1, Honma Y1, Tominaga T1, Hashimoto K1, Masaki T1, Kamata F2, Kamata M1, Aoyama T1, Sano T1, Takeuchi Y1, Naito S1: Renal Replacement Therapy 2020/5; 26: Article number 6. (ˆ¢•”“N–ç1, ¼ŽRŒiŽq1, ŽRè‘ñ–ç1, ‹{â—³”n1, –{ŠÔ—F—¢1, •x‰i‘åŽu1, ‹´–{ŒbŽq1, ³–Ø‹M‹³1, Š™“c•‡”ü2, Š™“c^—Žq1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1, “à“¡³‹g1: 1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

310020. [Ç—á•ñ] Initiation of peritoneal dialysis in a patient with chronic renal failure associated with tetralogy of Fallot: a case report. Abe T1, Aoyama T1, Sano K1, Miyasaka R1, Yamazaki T1, Honma Y1, Tominaga H1, Ida M1, Arao A1, Sakakibara M1, Hashimoto K1, Takahashi H1, Sakai T1, Naito S1, Koitabashi T2, Sano T1, Takeuchi Y1: BMC Nephrol 2020/7; 21 (1): 277. (ˆ¢•”“N–ç1, ÂŽR“ŒŒÜ1, ²–ìŒiŽq1, ‹{â—³”n1, ŽRè‘ñ–ç1, –{ŠÔ—F—¢1, •x‰i‘åŽu1, ˆä“c^¶Žq1, r”ö@Ê1, åŒ´–ƒ—FŽq1, ‹´–{ŒbŽq1, ‚‹´@—y1, ŽðˆäŒ’Žu1, “à“¡³‹g1, ¬”‹´r”ü2, ²–ì@—²1, ’|“àN—Y1: 1t‘Ÿ“à, 2zŠÂŠí“à)

320003. [Ç—á•ñ] COVID-19‚𔭏ǂµ‚½“œ”A•a‡•¹ˆÛŽ“§ÍŠ³ŽÒ‚̈ê—á. “à“¡³‹g1, ì‘º¹—R”ü2, ˜a“c’B•F3, ŽRè‘ñ–ç1, ‹{â—³”n1, ²–ìŒiŽq1, åŒ´–ƒ—FŽq1, ‚‹´@—É1, ‰i‰ª–¢—ˆ1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ‚ŽR—zŽq4, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3äPŒ´•aEŠ´õ“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “§Í‰ïŽ 2020/11; 53 (11): 567-72.

540023. [‚»‚Ì‘¼ (Šw‰ï´˜^)]y‘æ25‰ñ“ú–{• –Œ“§ÍˆãŠw‰ïz‡•¹Ç (Š´õÇ): • –Œ“§ÍŠÖ˜AŠ´õÇ‚Ì‘Šú”­Ç‚Æ“Á’¥. ˆ¢•”“N–ç1, ÂŽR“ŒŒÜ1, ŽðˆäŒ’Žj1, “à“¡³‹g1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à): ˆÝ‚Æ“§Í 2020/9; 89 (•Êû): 220-1.

’˜@‘]

620035. [Šwp‘ (•ª’SŽ·•M)]yŒŸ¸’l‚ð“Ç‚Þ2020 (“à‰È Vol.125 No.4 2020”N4ŒŽ‘‘卆)z19ÍŽ©ŒÈ–ƉuŒŸ¸@RŽ…‹…‘ÌŠî’ê–ŒR‘Ì (RGBMR‘Ì), p.878. ²–ì@—²1, â–{®“o2 (1t‘Ÿ“à, 2ˆã—ËZp‹³ˆç), “ì]“°, “Œ‹ž, 2020/4”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

723179. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “œŽ‰Ž¿GM3‚É‚æ‚éƒ|ƒhƒTƒCƒg•ÛŒìŒø‰Ê. ŽRŒû˜a‰Ô, ì“‡‰iŽq1, ŽR‰º@‹§, “à“¡³‹g1 (1t‘Ÿ“à): ‘æ63‰ñ“ú–{t‘ŸŠw‰ïŠwp‘‰ï (2020/8/20), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723180. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒoƒ‹ƒvƒŽ_‚̍RƒlƒtƒŠƒ“R‘Ì—U“±«FSGS—\–hEŽ¡—ÃŒø‰Ê. “à“¡³‹g1, ÎŠ_’¼Žq, ’‡ŽRŒ«ˆê, ì“‡‰iŽq1 (1t‘Ÿ“à): ‘æ63‰ñ“ú–{t‘ŸŠw‰ïŠwp‘‰ï (2020/8/20), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723181. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒoƒ‹ƒvƒŽ_‚̍R‘Ì—U“±«‘ƒóŽ…‹…‘̍d‰»Ç (FSGS) —\–hEŽ¡—ÃŒø‰Ê‚ÌŒŸ“¢. ì“‡‰iŽq1, ÎŠ_’¼Žq, ’‡ŽRŒ«ˆê, “à“¡³‹g1 (1t‘Ÿ“à): ‘æ93‰ñ“ú–{¶‰»Šw‰ï‘å‰ï (2020/9/14), WebŠJÃ.

723182. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V‹K–«t‘Ÿ•aƒ‚ƒfƒ‹“®•¨‚̉ðÍ. ŽRŒû˜a‰Ô, ì“‡‰iŽq1, ÎŠ_’¼Žq, ‰iª‘劲, ŽR‰º@‹§, “à“¡³‹g1 (1t‘Ÿ“à): ‘æ93‰ñ“ú–{¶‰»Šw‰ï‘å‰ï (2020/9/16), WebŠJÃ.

723183. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŒŸ÷ŒðŠ·—Ö@‚ƃAƒiƒtƒBƒ‰ƒLƒV[‚ÉŠÖ‚·‚錟“¢. ˆ¢•”“N–ç1, ÂŽR“ŒŒÜ1, ì‘º¹—R”ü2, ŽRè‘ñ–ç1, ²–ìŒiŽq1, ‹{â—³”n1, åŒ´–ƒ—FŽq1, ŽðˆäŒ’Žj1, “à“¡³‹g1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ65‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2020/11/2), WebŠJÃ.

723184. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •¡”‹Û‚É‚æ‚é• –Œ“§ÍŠÖ˜A• –Œ‰Š‚̈ê—á. ¼ŽRŒiŽq1, ˆ¢•”“N–ç1, ì‘º¹—R”ü2, åŒ´–ƒ—FŽq1, ‹{â—³”n1, ŽRè‘ñ–ç1, ˆä“c^¶Žq1, ŽðˆäŒ’Žj1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ65‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2020/11/2), WebŠJÃ.

733041. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) DŽ_‹…‘‘½Ç‚𔺂¤“§Í¢“ïÇ‚̑Ήž‚É‹ê—¶‚µ‚½ˆê—á. ²–ìŒiŽq1, ‚‹´@—É1, ì‘º¹—R”ü2, åŒ´–ƒ—FŽq1, ‹{â—³”n1, ŽRè‘ñ–ç1, ‰i‰ª–¢—ˆ1, ŽðˆäŒ’Žj1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ50‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2020/9/26-27), WebŠJÃ.

733042. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‚ƒgƒŠƒOƒŠƒZƒŠƒh (TG) ŒŒÇ‚É‚æ‚édÇ‹}«äX‰Š‚ɑ΂µ‚ÄŒŒŸ÷ŒðŠ·—Ö@‚ª—LŒø‚Å‚ ‚Á‚½3—á. ‹{â—³”n1, ‚‹´@—É1, ì‘º¹—R”ü2, åŒ´–ƒ—FŽq1, ²–ìŒiŽq1, ŽRè‘ñ–ç1, ‰i‰ª–¢—ˆ1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ50‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2020/9/26-27), WebŠJÃ.

733043. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) R¶ÜŠÜ—LƒXƒeƒƒCƒhŠO—p–ò‚É‚Ä”A×ŠÇŠÔŽ¿«t‰Š‚𗈂µ‚½ˆê—á. åŒ´–ƒ—FŽq1, ²–ì@—²1, ì‘º¹—R”ü2, ²–ìŒiŽq1, ŽRè‘ñ–ç1, ‹{â—³”n1, ‰i‰ª–¢—ˆ1, ‚‹´@—É1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ50‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2020/9/26-27), WebŠJÃ.

733044. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Š£á‚ÌŽ¡—Âʼnü‘P‚µ‚½–Œ«‘B«Ž…‹…‘̐t‰Š‚Ì1—á. ŽRè‘ñ–ç1, ‚‹´@—É1, ŽðˆäŒ’Žj1, ì‘º¹—R”ü2, åŒ´–ƒ—FŽq1, ²–ìŒiŽq1, ‹{â—³”n1, ‰i‰ª–¢—ˆ1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ50‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2020/9/26-27), WebŠJÃ.

733045. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) V‹Kƒ|ƒhƒTƒCƒgáŠQƒ‚ƒfƒ‹‚ð—p‚¢‚½V–ò‘no‚ÖŒü‚¯‚Ä. “à“¡³‹g1, ì“‡‰iŽq1 (1t‘Ÿ“à): 2020”N“x‘æ8‰ñ—Šw•”ƒZƒ~ƒi[ (2020/12/22), ‘Š–ÍŒ´.

'19”N“xˆÈ‘O•ª

[Šw‰ïEŒ¤‹†‰ï“™]

'19-733007. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) V‹K’`”’”AŽ¡—ÖòŠJ”­‚ÉŒü‚¯‚ā`V‚½‚ȃ‚ƒfƒ‹“®•¨Ž÷—§‚©‚ç‘n–ò‚ð–ÚŽw‚·`. “à“¡³‹g1, ì“‡‰iŽq1 (1t‘Ÿ“à): ‘æ12‰ñƒvƒƒOƒŒƒXƒŒƒ|[ƒg‰ï‹c (2019/11/20), ‘Š–ÍŒ´.


äPŒ´•aEŠ´õ“à‰ÈŠw

[Šwp˜_•¶]

110215. [Œ´’˜] Serological comparison of systemic lupus erythematosus with neuropsychiatric lupus using synthetic nucleic acid antigens. Khatri S, Psaraftis N, Funaro A, Arinuma Y1, Fujieda Y, Mader S, J›rgensen CD, Astakhova K: J Transl Autoimmun 2020/10; 3: 100068. (—LÀ—ǍK1: 1äPŒ´•a¥Š´õ“à)

110216. [Œ´’˜] Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Kameda H, Takeuchi T, Yamaoka K1, Oribe M, Kawano M, Zhou Y, Othman AA, Pangan AL, Asabe S, Kitamura S, Meerwein S, Tanaka Y: Rheumatology (Oxford) 2020/11; 59 (11): 3303-13. (ŽR‰ª–MG1: 1äPŒ´•a¥Š´õ“à)

110217. [Œ´’˜] Clinical and Microbiological Features of Asymptomatic SARS-CoV-2 Infection and Mild COVID-19 in Seven Crewmembers of a Cruise Ship. Hoshiyama T1, Wada T1, Nihonyanagi S2, Kameda R3, Yamaoka-Tojo M4, Fukuda M4, Ako J3, Yamaoka K1, Takayama Y5: Intern Med 2020/12; 59 (24): 3135-40. (¯ŽR—²s1, ˜a“c’B•F1, “ñ–{–öL2, ‹T“c@—Ç3, “ŒžŠ”ü“ÞŽq4, •Ÿ“c—Ï–ç4, ˆ¢ŒÃÆ3, ŽR‰ª–MG1, ‚ŽR—zŽq5: 1äPŒ´•aEŠ´õ“à, 2Š´õŠÇ—Žº, 3zŠÂŠí“à, 4ˆã—Éq¶Šw•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

310021. [Ç—á•ñ] Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir. Wada T1, Shimode K1, Hoshiyama T1, Takayama Y2, Yamaoka K1: Front Med (Lausanne) 2020/5; 7: 241. (˜a“c’B•F1, ‰ºŽèŒö‰î1, ¯ŽR—²s1, ‚ŽR—zŽq2, ŽR‰ª–MG1: 1äPŒ´•aEŠ´õ“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

310022. [Ç—á•ñ] Haemophilus influenzae Non-type b Infection in an Adult Patient with Systemic Lupus Erythematosus. Hasegawa Y1, Arinuma Y2, Tanaka S2, Tono T2, Tanaka T2, Muramatsu T1, Kondo J1, Matsueda Y2, Hoshiyama T2, Wada T2, Takayama Y3, Yamaoka K2: Intern Med 2020/12; 59 (23): 3097-101. (’·’Jì–õ_1, —LÀ—ǍK2, “c’†Z–¾2, “Œ–ìr—m2, “c’†’mŽ÷2, ‘º¼@ 1, ‹ß“¡“Õˆê1, ¼Ž}@—C2, ¯ŽR—²s2, ˜a“c’B•F2, ‚ŽR—zŽq3, ŽR‰ª–MG2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2äPŒ´•a¥Š´õ“à, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

310023. [Ç—á•ñ] A case of anti-MDA5 antibody-positive dermatomyositis developing reversible cerebral vasospasm syndrome successfully treated by multi-immunosuppressant combination including mycophenolate mofetil. Muramatsu T1, Tono T2, Kanayama Y1, Hasegawa Y1, Kondo J1, Hoshiyama T2, Wada T2, Arinuma Y2, Tanaka S2, Yamaoka K2: Mod Rheumatol Case Rep 2021/1; 5 (1): 69-75. (‘º¼@ 1, “Œ–ìr—m2, ‹àŽR–F˜Y1, ’·’Jì–õ_1, ‹ß“¡“Õˆê1, ¯ŽR—²s2, ˜a“c’B•F2, —LÀ—ǍK2, “c’†Z–¾2, ŽR‰ª–MG2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2äPŒ´•a¥Š´õ“à)

510009. [‘à] Developmental process in diffuse psychological/neuropsychiatric manifestations of neuropsychiatric systemic lupus erythematosus. Arinuma Y1, Yamaoka K1: Immunol Med 2021/3; 44 (1): 16-22. (—LÀ—ǍK1, ŽR‰ª–MG1: 1äPŒ´•a¥Š´õ“à)

522048. [uÀ]y“ÁW: Ž©ŒÈ–ƉuŽ¾Š³EAIDS ‚ÆDDS: –ƉuˆÙíE–Ɖu•s‘S‚ւ̐V‚µ‚¢’§íz3. Ž©ŒÈ–ƉuŽ¾Š³Ž¡—Â̔­“W‚Ɖۑè. ŽR‰ª–MG (äPŒ´•aEŠ´õ“à): Drug Delivery System 2020/11; 35 (5): 376-83.

522049. [uÀ]y˜AÚ: Ž„‚ÌŽ¡—ÁzƒŠƒEƒ}ƒ`«‘½”­‹Ø’ÉÇ (PMR). ŽR‰ª–MG (äPŒ´•aEŠ´õ“à): “ú–{ˆãŽ–V•ñ 2020/4; 5009: 47.

[’˜@‘]

620036. [Šwp‘ (•ª’SŽ·•M)]yŠÔŽ¿«”xŽ¾Š³f—Ã}ƒjƒ…ƒAƒ‹ ‰ü’ù‘æ3”ŁzIV ŠÔŽ¿«”xŽ¾Š³‚Ì•a‘Ô‚ÆŽ¡—Ã}ƒjƒ…ƒAƒ‹@B äPŒ´•a”x‚Æ—Þ‰Ž¾Š³@6. ¬‡«Œ‹‡‘gD•a (MCTD), p.367-70. ˜a“c’B•F (äPŒ´•aEŠ´õ“à), ŠÄC: ‹v•Ûœ¨Žk, •Ò: “¡“cŽŸ˜Y, ŠìŽÉê’©—Y, “ì]“°, “Œ‹ž, 2020/6”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722051. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) COVID-19ƒpƒ“ƒfƒ~ƒbƒNŠÂ‹«‰º‚É‚¨‚¯‚éƒCƒxƒ‹ƒƒNƒ`ƒ“ˆãŽtŽå“±Ž¡Œ±‚©‚猩‚¦‚Ä‚«‚½‰Û‘è. ŽR‰ª–MG1, ˜a“c’B•F1, –ì’†”ü˜a2, ‘O“cŽÀ‰Ô3, ŒF’J—YŽ¡4 (1äPŒ´•aEŠ´õ“à, 2ƒOƒ[ƒoƒ‹—Տ°Œ¤‹†Žx‰‡ƒZ, 3–òÜ•”, 4—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg): “ú–{—Տ°ŽŽŒ±Šw‰ï‘æ12‰ñŠwpW‰ï‘‰ï (2021/2/12-13), WEBŠJÃ, ƒvƒƒOƒ‰ƒ€E´˜^W 2021; p.72.

'19”N“xˆÈ‘O•ª

[’˜@‘]

'19-620007. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj 2020”N”Ł@Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚éz‘æ14Í äPŒ´•a‚¨‚æ‚Ñ—Þ‰Ž¾Š³@IgG4ŠÖ˜AŽ¾Š³, p.903-4. ŽR‰ª–MG (äPŒ´•aEŠ´õ“à), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@½, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2020/1”­s.


“û‘BEbó‘BŠO‰ÈŠw

[Šwp˜_•¶]

110218. [Œ´’˜] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer. Masuda T, Fujimoto H, Teranaka R, Kuroda M, Aoyagi Y, Nagashima T, Sangai T1, Takada M, Nakagawa A, Kubota Y, Yokote K, Ohtsuka M: Breast Cancer Res Treat 2020/4; 180 (3): 625-34. (ŽOŠK‹MŽj1: 1“û‘BEbó‘BŠO)

110219. [Œ´’˜] The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. Iwamoto T, Fujisawa T, Shien T, Araki K, Sakamaki K, Sangai T1, Kikawa Y, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N: Breast Cancer 2020/9; 27 (5): 973-81. (ŽOŠK‹MŽj1: 1“û‘BEbó‘BŠO)

110220. [Œ´’˜] Detection of Nonpalpable Tiny Axillary Lymph Nodes Surrounded by Adipose Tissue Using a Near-Infrared Camera. Akita S, Yamaji Y, Takeuchi N, Wakai K, Azuma K, Nakagawa A, Fujimoto H, Sangai T1, Nagashima T, Mitsukawa N, Ikehara Y: Lymphat Res Biol 2020/10; 18 (5): 455-63. (ŽOŠK‹MŽj1: 1“û‘BEbó‘BŠO)

[Šw‰ïEŒ¤‹†‰ï“™]

723185. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) AIRSEAL systemŽg—p‚É‚æ‚銮‘S‹¾Ž‹‰ºbó‘BŽèp‚É‚¨‚¯‚鎋–ìƒXƒgƒŒƒXŒyŒ¸Œø‰Ê. ’r“c‰ÀŽj, âV“¡ŒcK, ‰¡“cŒõ‰›1, åÎ‹I•F2, “n粏¹•F3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2“û‘BEbó‘BŠO, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13-15), WebŠJÃ.

723186. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) p‘O‰»Šw—Ö@‚ðŽ{s‚µ‚½ƒgƒŠƒvƒ‹ƒlƒKƒeƒBƒu“ûŠà‚̍Ĕ­E—\ŒãˆöŽq‚ÌŒŸ“¢. ‹e’r^—Žq1, ¬â–ùŒ«1, “c’†—uŽq, ‰¡“cŒõ‰›2, ¼‹{—mŽj1, ‰Á“¡@O1, åÎ‹I•F1 (1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13-15), WebŠJÃ.

723187. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚éBRACAnalysis‚ÌŒŸ“¢ The experience of BRACAnalysis system in our hospital. ˜m’J”ü“Þ1, ¬â–ùŒ«1, “c’†—uŽq, ‹e’r^—Žq1, ¼‹{—mŽj1, ¬›¸Œc‘¾, ‰HœAŒ’m, —с@‹žŽq1, “‡’Á@«, ’ѺGN2, ‚“cŽj’j3, åÎ‹I•F1 (1“û‘BEbó‘BŠO, 2”å”AŠí, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723188. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŸfƒZƒ“ƒ^[‚É‚¨‚¯‚éÎŠD‰»•a•Ï‚Ì•]‰¿‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‰ª–{—²‰p, ‰H”ö‹`‹P, ’zª—zŽq, _ŽR‘¾˜Y, ˆ¢•”@–L, ˆÉ“Œ–¾”ü, •Šâ”üŠG, “àŽR’‰¶, ‰œ–{’‰”V, åÎ‹I•F1 (1“û‘BEbó‘BŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723189. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’j«”ñZ«”X–E“à“ûŠà‚Ì1—á. ”Ñ’Ë”ü, ˆäã€l, ‹e’r^—Žq1, ¬â–ùŒ«1, åÎ‹I•F1 (1“û‘BEbó‘BŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723190. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “û‚ª‚ñpŒãBMI30ˆÈã‚̑Α¤“ûŠà‚ÌŒŸ“¢. —с@‹žŽq1, ˜m’J”ü“Þ1, ‰HœAŒ’m, ¬›¸Œc‘¾, åÎ‹I•F1 (1“û‘BEbó‘BŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723191. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒããüâ|ƒŠƒ“ƒpßÄ”­‚ð’悵‚½BRCAˆâ“`Žq•ÏˆÙ—z«Š³ŽÒ‚ɃIƒ‰ƒpƒŠƒu‚ðŽg—p‚µ‚½1—á. ¼‹{—mŽj1, “c’†—uŽq, ‰¡“cŒõ‰›2, ‹e’r^—Žq1, “‡’Á@«, ’ѺGN3, ‰Á“¡@O1, ¬â–ùŒ«1, ‚“cŽj’j2, åÎ‹I•F1 (1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3”å”AŠí): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723192. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘Α¤ƒŠƒXƒN’ጸ“û–[Øœp‚ðs‚¢C”ñZ«“ûŠÇŠà‚ª”­Œ©‚³‚ꂽˆâ“`«“ûŠà—‘‘ƒŠàÇŒóŒQ‚Ì1—á. ¬â–ùŒ«1, ‰¡“cŒõ‰›2, “c’†—uŽq, ‹e’r^—Žq1, ¼‹{—mŽj1, ˜m’J”ü“Þ1, ‰Á“¡@O1, Š“cç”ü”T3, “‡’Á@«, ’ѺGN4, ‚“cŽj’j2, åÎ‹I•F1 (1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3•a—, 4”å”AŠí): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723193. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) TDM1 (ƒgƒ‰ƒXƒcƒYƒ}ƒuƒGƒ€ƒ^ƒ“ƒVƒ“) ‚ª’·Šú‘tŒ÷‚µ‚Ä‚¢‚é1Ç—á. åÎ‹I•F1, “à“¡‰Â“ÞŽq2, “¡–ìŽjD3, “c’†—uŽq, ‹e’r^—Žq1, ¼‹{—mŽj1, ‰Á“¡@O1, ¬â–ùŒ«1 (1“û‘BEbó‘BŠO, 2‰º•”Á‰»ŠÇŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723194. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒAƒxƒ}ƒVƒNƒŠƒu‚É‚æ‚éŠÔŽ¿«”x‰Š‚ð”F‚ß‚½1—á. “à“¡‰Â“ÞŽq1, ‹e’r^—Žq2, ‘å–ØŒcŽq1, ‰¡“cŒõ‰›3, “c’†—uŽq, ¼‹{—mŽj2, ‰Á“¡@O2, ¬â–ùŒ«2, åÎ‹I•F2 (1‰º•”Á‰»ŠÇŠO, 2“û‘BEbó‘BŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723195. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚éƒAƒxƒ}ƒVƒNƒŠƒu‚ÌŽg—pŒoŒ±. ‘å–ØŒcŽq1, ‹e’r^—Žq2, “à“¡‰Â“ÞŽq1, ‰¡“cŒõ‰›3, “c’†—uŽq, ¼‹{—mŽj2, ‰Á“¡@O2, ¬â–ùŒ«2, åÎ‹I•F2 (1‰º•”Á‰»ŠÇŠO, 2“û‘BEbó‘BŠO,3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723196. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚é“ûŠàp‘O‰»Šw—Ö@‚ÌŒø‰ÊCÄ”­C—\Œã‚ÉŠÖ‚·‚錟“¢. ‹e’r^—Žq1, ¬â–ùŒ«1, “à“¡‰Â“ÞŽq2, ‘å–ØŒcŽq2, ‰¡“cŒõ‰›3, “c’†—uŽq, ¼‹{—mŽj1, ‰Á“¡@O1, åÎ‹I•F1, ŽOŠK‹MŽj1 (1“û‘BEbó‘BŠO, 2‰º•”Á‰»ŠÇŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723197. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒnƒCƒŠƒXƒN‚ɏ€‚¶‚½ƒT[ƒxƒCƒ‰ƒ“ƒX‰æ‘œŒŸ¸‚ŋǏŠÄ”­‚ðf’f‚µ‚½BRCA1 VUS•ÛŽŽÒ“ûŠà‚̏Ǘá. ’†’Ðì’qŽq, ŽOŠK‹MŽj1, “¡–{_Ži, ‚“c@Œì, åŒ´~‘¾, Ž›’†—º‘¾˜Y, â“cŽ¡l, ’·“ˆ@Œ’ (1“û‘BEbó‘BŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723198. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã’·ŠúŠÔ–³Ä”­¶‘¶’†‚̐isŠú”DPŠÖ˜A“ûŠà‚Ì1—á. â–{—z‰î, ‚“c@Œì, Ž›’†—º‘¾˜Y, åŒ´~‘¾, “¡–{_Ži, ŽOŠK‹MŽj1, ’·“ˆ@Œ’, ‘å’ˏ«”V (1“û‘BEbó‘BŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723199. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) nab-PTX‚Ì––½_ŒoáŠQ—\–h‚ɑ΂·‚éƒtƒ[ƒYƒ“ƒOƒ[ƒuC’e«ƒXƒgƒbƒLƒ“ƒO‚É‚æ‚é‘æII‘ŠŽŽŒ± (SPOTŽŽŒ±). ”—t‹§Š°, ’†ŽR‹MŠ°, ŽOŠK‹MŽj1, X–{@‘ì, ”ª\“‡Gs, ŽR–{@–L, ŒF’J^Ÿ, ˆÀŒ´‰Á“Þ, ‹g“cƒ~ƒi, ‰ª–{‘׎q, ŽR’†’|t, ‘å–ì^Ži, ‘“cTŽO (1“û‘BEbó‘BŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723200. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ûŠàŽüpŠú‰»Šw—Ö@‚É‚¨‚¯‚é”­”M«D’†‹…”Œ¸­Ç‚ÉŠÖ‚·‚é‘OŒü‚«’²¸: CSPOR-BC Study. ¼‘ºG‹I, Îì@F, âŠªŒ°‘¾˜Y, ¬ˆäˆê—², ŽOŠK‹MŽj1, ‹ÊéŒ¤‘¾˜Y, ’·’Jì‘PŽ}, “n粌’ˆê, ›ÀLN, Œüˆä”Ž•¶ (1“û‘BEbó‘BŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.


ˆê”ʁE¬Ž™EŠÌ’_äXŠO‰ÈŠw

[Šwp˜_•¶]

110027. [Œ´’˜] EP3 signaling in dendritic cells promotes liver repair by inducing IL-13-mediated macrophage differentiation in mice. Nakamoto S1, Ito Y2, Nishizawa N3, Goto T1, Kojo K4, Kumamoto Y3, Watanabe M5, Narumiya S, Majima M2: FASEB J 2020/4; 34 (4): 5610-27. (’†–{CŽi1, ˆÉ“¡‹`–ç2, ¼àVL‹±3, Œã“¡‘ì–ç1, ŒÃé@Œ›4, ŒGŒ³—Y‰î3, “n粏¹•F5, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4‰º•”Á‰»ŠÇŠO, 5–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110221. [Œ´’˜] Validation and performance of three-level procedure-based classification for laparoscopic liver resection. Kawaguchi Y, Tanaka S, Fuks D, Kanazawa A, Takeda Y, Hirokawa F, Nitta H, Nakajima T, Kaizu T1, Kaibori M, Kojima T, Otsuka Y, Kubo S, Hasegawa K, Kokudo N, Kaneko H, Wakabayashi G, Gayet B: Surg Endosc 2020/5; 34 (5): 2056-66. (ŠC’ËMŽj1: 1ˆê”ʁE¬Ž™EŠÌ’_äXŠO)

110031. [Œ´’˜] Lymphangiogenesis and accumulation of reparative macrophages contribute to liver repair after hepatic ischemia-reperfusion injury. Nakamoto S1, Ito Y2, Nishizawa N3, Goto T1, Kojo K4, Kumamoto Y3, Watanabe M5, Majima M2: Angiogenesis 2020/8; 23 (3): 395-410. (’†–{CŽi1, ˆÉ“¡‹`–ç2, ¼àVL‹±3, Œã“¡‘ì–ç1, ŒÃé@Œ›4, ŒGŒ³—Y‰î3, “n粏¹•F5, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4‰º•”Á‰»ŠÇŠO, 5–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110222. [Œ´’˜] Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN). Fujiyama Y1, Kumamoto Y2, Nishizawa N2, Nakamoto S1, Harada H3, Yokota K4, Tanaka Y, Igarashi K2, Oiki H, Okuwaki K5, Iwai T5, Kajita S6, Takahashi H7, Tajima H2, Kaizu T2, Sasaki J8, Watanabe M9, Yamashita K8: Ann Surg Oncol 2020/10; 27 (10): 4007-16. (“¡ŽR–FŽ÷1, ŒGŒ³—Y‰î2, ¼àVL‹±2, ’†–{CŽi1, Œ´“cG‹P3, ‰¡“c˜aŽq4, ŒÜ\—’ˆê°2, ‰œ˜e‹»‰î5, Šâˆä’m‹v5, Š“cç”ü”T6, ‚‹´”Ž”V7, “c“‡@O2, ŠC’ËMŽj2, ²X–ØŽ¡ˆê˜Y8, “n粏¹•F9, ŽR‰ºŒpŽj8: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3ã•”Á‰»ŠÇŠO, 4‰º•”Á‰»ŠÇŠO, 5Á‰»Ší“à, 6•a—, 7ˆã—Éq¶Šw•”, 8V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 9–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110223. [Œ´’˜] Assembling a library of typical surgery video clips to construct a system for assessing the surgical difficulty of laparoscopic cholecystectomy. Kurata M, Iwashita Y, Ohyama T, Endo I, Hibi T, Umezawa A, Suzuki K, Watanabe M, Asai K, Mori Y, Higashida M, Kumamoto Y1, Shindoh J, Yoshida M, Honda G, Misawa T, Abe Y, Nagakawa Y, Toyota N, Yamada S, Norimizu S, Matsumura N, Sata N, Sunagawa H, Ito M, Takeda Y, Nakamura Y, Rikiyama T, Higuchi R, Gocho T, Ueno K, Kumagai Y, Kanaji S, Takada T, Yamamoto M: J Hepatobiliary Pancreat Sci 2021/3; 28 (3): 255-62. (ŒGŒ³—Y‰î1: 1ˆê”ʁE¬Ž™EŠÌ’_äXŠO)

120007. [Œ´’˜] ‹ÉE’´’áo¶‘̏dŽ™‚̏¬’°ƒXƒg[ƒ}•Â½p‚ÌŽŠ“KŽžŠú‚ÉŠÖ‚·‚錟“¢. ŽR–{—T‹P1, “c’†@Œ‰1,2, o‰Æ‹œˆê1, ’ǖ؍Gé1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): “ú–{¬Ž™ŠO‰ÈŠw‰ïŽ 2020/8; 56 (4): 365-9.

522050. [uÀ]y“ÁW: ¬Ž™ŠO‰Èˆã‚ªK“¾‚·‚ׂ«ŒŸ¸|Žè‹Z‚Ɛf’fz‹}«’Ž‚‰Š (• •”’PƒXü, ’´‰¹”g). “c’†@Œ‰1,2, o‰Æ‹œˆê2, “n•”–õ˜Y2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ¬Ž™ŠO‰È 2020/8; 52 (8): 841-5.

522051. [uÀ]y“ÁW: ¬Ž™ŠO‰È‚ð‚ß‚®‚邳‚Ü‚´‚Ü‚È–â‘è‚Ə«—ˆ‚Ì“W–]zƒgƒ‰ƒ“ƒWƒVƒ‡ƒ“ˆã—Â̌»‹µ‚Ɖۑè. ”ö‰Ô˜aŽq, “c•—TŽq, “c’†@Œ‰1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ¬Ž™ŠO‰È 2021/1; 53 (1): 61-6.

522052. [uÀ]y“ÁW: •KŒg! ŠO‚ÆŠO‰ÈŽ¾Š³‚ւ̑Ήžz[Še˜_] v‘¬‚È”»’f‚ð•K—v‚Æ‚·‚鎾Š³@‹}«’Ž‚‰Š: ‹Ù‹}Žèp vs interval appendectomy (úE«, ”^ᇌ`¬«). “c’†@Œ‰1,2, o‰Æ‹œˆê2, “n•”–õ˜Y2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ¬Ž™“à‰È 2021/2; 53 (2): 217-22.

540024. [‚»‚Ì‘¼ (’Ç“‰•¶)] ŽèŒËˆê˜Yæ¶‚ðŽÃ‚ñ‚Å. “c’†@Œ‰1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): “ú–{¬Ž™ŠO‰ÈŠw‰ïŽGŽ 2020/8; 56 (4): 339-41.

[’˜@‘]

620037. [Šwp‘ (•ª’SŽ·•M)]y‘‚í‚©‚è–D‡E•«‡‚Ì‚·‚×‚Ä (—Տ°ŠO‰È Vol.75 No.11 2020”N10ŒŽ† (‘Š§†))z¡4ÍpŽ®•Ê‚Ì–D‡E•«‡–@@äX‘Ÿ@äX|‹ó’°•«‡ Š`“c–@, p.289-93. ŒGŒ³—Y‰î1, ŠC’ËMŽj1, “c“‡@O1, ¼àVL‹±1, ‹v•Û”CŽj1, ŒÜ\—’ˆê°1, ’†–{CŽi2, “¡ŽR–FŽ÷2, ‰ª–{Œõ‹FŽq1, æс@—T—º2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È), ˆãŠw‘‰@, “Œ‹ž, 2020/10”­s.

620038. [Šwp‘ (•ª’SŽ·•M)]yƒfƒBƒx[ƒg‚©‚çŠw‚ԏpŽ®‚̉œ‹`EŽè‹Z‚̔錍m’_“¹EäX‘Ÿ•ÒnzƒT[ƒWƒJƒ‹ƒfƒBƒx[ƒg6äX‹ó’°•«‡@(2) Š`“c–@, p.155-64. ŒGŒ³—Y‰î (ˆê”ʁE¬Ž™EŠÌ’_äXŠO), •Ò: ”’ÎŒ›’j (ŽåŠ²), –kì—T‹v, V“c_K, ŽRŒû–ÎŽ÷, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ “Œ‹ž, 2020/12”­s.

620039. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚̏¬Ž™Ž¡—ÃŽwj ‘æ17”Łz‘æ13Í Á‰»ŠíŽ¾Š³, ŠÌŽ¾Š³@Á‰»ŠÇƒ|ƒŠ[ƒvEƒ|ƒŠƒ|[ƒVƒX, p.457-8. “c’†@Œ‰1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO), ‘•ÒW: …Œû@‰ë, Žs‹´@Œõ, èŽR@O, ˆÉ“¡Gˆê, ˆãŠw‘‰@, “Œ‹ž, 2020/12”­s.

620040. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj 2021”N”Ł@Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚éz‘æ23Í ¬Ž™‰ÈŽ¾Š³@‘lŒaƒwƒ‹ƒjƒA, ä`ƒwƒ‹ƒjƒA, p.1485-6. “c’†@Œ‰1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@½, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2021/1”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722052. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) • o‹¾‰ºŒn““IŠÌØœ‚Ì•W€‰»‚¨‚æ‚Ñ‚»‚̈À‘S«. ŠC’ËMŽj1, “c“‡@O1, ¼àVL‹±1, ‹v•Û”CŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723201. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) CDO1ˆâ“`ŽqDNAƒƒ`ƒ‹‰»‚É‚æ‚éäXŠàV‹Kf’f–@‚Ì—L—p«‚ÌŒŸ“¢. ¼àVL‹±1, ŽR‰ºŒpŽj2,3, “¡ŽR–FŽ÷4, ’†–{CŽi4, ‹v•Û”CŽj1, “c“‡@O1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ã•”Á‰»ŠÇŠO, 4‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/15), WebŠJÃ.

723202. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹¾‰ºŠÌØœ‚É‚¨‚¯‚鈟‹æˆæˆÈãŠÌØœ‚̈À‘S«|’PŽ{Ý450—á‚ÌŒŸ“¢. ŠC’ËMŽj1, “c“‡@O1, ¼àVL‹±1, ‹v•Û”CŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/15), WebŠJÃ.

723203. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å’°ŠàŠÌ“]ˆÚÇ—á‚ɑ΂·‚é• o‹¾‰ºŽèp‚̈À‘S«|117—á‚ÌŒŸ“¢|. “¡ŽR–FŽ÷1, ŠC’ËMŽj2, ‰i@Ž ‹³, ’†–{CŽi1, ¼àVL‹±2, ‹v•Û”CŽj2, “c“‡@O2, ŒGŒ³—Y‰î2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/15), WebŠJÃ.

723204. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Á‰»ŠÇúEpŒã, lHãè–å•Â½pŒã‚ɐlHãè–åãè–呤‚̏¬’°‹·ó‚ōĎèp‚ª•K—v‚Æ‚È‚Á‚½’´’áo¶‘̏dŽ™‚Ì1—á. ’ǖ؍Gé1, “c’†@Œ‰1,2, ŽR–{—T‹P1, o‰Æ‹œˆê1, ã¼—R¹1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ57‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠwpW‰ï (2020/9/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723205. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽüpŠú—\–h“IR‹Û–ò‚Ì“Š—^ŠúŠÔ‚ɂ‚¢‚Ä‚ÌŒŸ“¢`æ“V«’_“¹Šg’£Ç‚É‚æ‚錟Ø`. o‰Æ‹œˆê1, “c’†@Œ‰1,2, ŽR–{—T‹P1, ’ǖ؍Gé1, ã¼—R¹1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ57‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠwpW‰ï (2020/9/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723206. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹•Â½ÇpŒã‚Ì•«‡•”‹·ó‚̃uƒW[‚ŐH“¹”xᑂ𗈂µ‚½ˆê—á. ŽR–{—T‹P1, “c’†@Œ‰1,2, o‰Æ‹œˆê1, ’ǖ؍Gé1, ƒEƒbƒhƒnƒ€ƒX—æŽq3 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3•úŽËü (‰æ‘œ)): ‘æ57‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠwpW‰ï (2020/9/21), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723207. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ú—î49, ‘̏d950g‚ÅŠ‹¼Žèp‚ðŽ{s‚µ‚½’´’áo¶‘̏dŽ™’_“¹•Â½Ç‚Ì1—á. ã¼—R¹1, “c’†@Œ‰1,2, ŽR–{—T‹P1, o‰Æ‹œˆê1, ’ǖ؍Gé1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ57‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠwpW‰ï (2020/9/21), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723208. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å’°ŠàŠÔŽ¿‚É‚¨‚¯‚éSPARC”­Œ»‚ð‰î‚µ‚½Wnt/ƒÀ-cateninŒo˜HŠˆ«‰»‚Ɖ“Šu“]ˆÚ‹@˜‚̉ð–¾. “¡ŽR–FŽ÷1, ’†–{CŽi1, ¼àVL‹±2, æс@—T—º1, “¡–ìŽjD1, Œã“¡‘ì–ç1, ‰¡“cŒõ‰›1, “Y–ìF•¶1, b”ã“c•Žu1, ‰¡“c˜aŽq, ¬›¸Œc‘¾, “à“¡@„3, ŒGŒ³—Y‰î2, ŽR‰ºŒpŽj4,5 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3‰º•”Á‰»ŠÇŠO, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5ã•”Á‰»ŠÇŠO): ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723209. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’°‰ñ“]ˆÙíÇ’†’°Ž²”P“]‚𔺂Á‚½V¶Ž™ˆÝ”j—ô‚̈ê—á. ‘¾“c@—½1, “c’†@Œ‰2,3, ŽR–{—T‹P3, o‰Æ‹œˆê3, ’ǖ؍Gé3, “n•”–õ˜Y3 (1‰º•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29-31), WebŠJÃ.

723210. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å’°ŠàŠÌ“]ˆÚ‚ɑ΂·‚é• o‹¾‰ºŽèp‚Ì“K‰ž‚ÉŠÖ‚·‚錟“¢. “¡ŽR–FŽ÷1, ŠC’ËMŽj2, ’†–{CŽi1, ‰i@Ž ‹³, ¼àVL‹±2, ‹v•Û”CŽj2, “c“‡@O2, ŒGŒ³—Y‰î2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723211. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äXŠà‚ɑ΂·‚é• o‹¾‰ºäX‘Ì”ö•”Øœ‚ÌŽ¡—ЬÑ‚ÆŽèpŽè‹Z‚̍H•v. ¼àVL‹±1, “c“‡@O1, æс@—T—º2, ‰ª–{Œõ‹FŽq1, “¡ŽR–FŽ÷2, ‹v•Û”CŽj1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723212. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) C tube drainage against bile leakage in laparoscopic liver resection. ŠC’ËMŽj1, “c“‡@O1, ¼àVL‹±1, ‹v•Û”CŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ32‰ñ“ú–{ŠÌ’_äXŠO‰ÈŠw‰ïŠwpW‰ï (2021/2/24), WebŠJÃ.

723213. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Standardized of laparoscopic distal pancreatectomy and the ingenuity of the procedure. “c“‡@O1, ŠC’ËMŽj1, ¼àVL‹±1, ‹v•Û”CŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ32‰ñ“ú–{ŠÌ’_äXŠO‰ÈŠw‰ïŠwpW‰ï (2021/2/24), WebŠJÃ.

723214. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Three anatomical landmarks in laparoscopic distal pancreatectomy for pancreatic cancer. ¼àVL‹±1, “c“‡@O1, “¡ŽR–FŽ÷2, ’†–{CŽi2, ‹v•Û”CŽj1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ32‰ñ“ú–{ŠÌ’_äXŠO‰ÈŠw‰ïŠwpW‰ï (2021/2/24), WebŠJÃ.

723215. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A Case of Isolated Abscess after Laparoscopic Hepatectomy. ‹v•Û”CŽj1, ¼àVL‹±1, “c“‡@O1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ32‰ñ“ú–{ŠÌ’_äXŠO‰ÈŠw‰ïŠwpW‰ï (2021/2/24), WebŠJÃ.

723033. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‹}«ŠÌáŠQŒã‚̊̏C•œ‚ɂ̓Šƒ“ƒpŠÇV¶‚ƃ}ƒNƒƒtƒ@[ƒW‚ªŠñ—^‚·‚é. ’†–{CŽi1, ˆÉ“¡‹`–ç2, Œã“¡‘ì–ç1, ×–ì‰Á“ÞŽq2, ”¨’†@Œö2, ”n“ˆ³—²2, “V–ì‰pŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—): ‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ï (2021/3/8-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723216. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹}«äX‰Š‚𔭏ǂµC• o‹¾‰ºäB‘ŸŒÅ’èp‚É“ïa‚µ‚½—V‘–äBEˆÝŽ²”P‚Ì1—á. “c’†@Œ‰1,2, ŽR–{—T‹P2, o‰Æ‹œˆê2, ’ǖ؍Gé2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10-13), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

732012. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) • o‹¾‰ºäX“ª\“ñŽw’°Øœp‚Ì“±“ü‚ƍH•v. “c“‡@O1, ŠC’ËMŽj1, ‰ª–{Œõ‹FŽq1, ¼àVL‹±1, ‹v•Û”CŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ14‰ñŠÌ‘Ÿ“àŽ‹‹¾ŠO‰ÈŒ¤‹†‰ïE‘æ12‰ñäX‘Ÿ“àŽ‹‹¾ŠO‰ÈŒ¤‹†‰ï (2020/10/28), WebŠJÃ.

732013. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) Caudal view‚ð—˜—p‚µ‚½ƒAƒvƒ[ƒ`‚Ì—˜“_‚ÆŒ‡“_‚ðl‚¦‚é. ¼àVL‹±1, “c“‡@O1, ‰ª–{Œõ‹FŽq1, ‹v•Û”CŽj1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ14‰ñŠÌ‘Ÿ“àŽ‹‹¾ŠO‰ÈŒ¤‹†‰ïE‘æ12‰ñäX‘Ÿ“àŽ‹‹¾ŠO‰ÈŒ¤‹†‰ï (2020/10/28), WebŠJÃ.

733046. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ’°ŠÇŒ¸ˆ³—pƒJƒe[ƒeƒ‹’°á‘‚ÌŒoŒ±. “c’†@Œ‰1,2, ŽR–{—T‹P2, o‰Æ‹œˆê2, ’ǖ؍Gé2 (1V¢‹Iˆã—ÁEæ’[’f“Iˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äX): ‘æ34‰ñ“ú–{¬Ž™ƒXƒg[ƒ}E”rŸ•E‘nŠÇ—Œ¤‹†‰ï (2020/6/13), ŽãŠJÃ.

733047. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ƒXƒg[ƒ}‚ð•Û—L‚·‚鏬Ž™‚âŠÔŒ‡“±”A‚ð•K—v‚Æ‚·‚鏬Ž™‚̏A‰€EAŠw‚É‚¨‚¯‚é‰Û‘è‚Ì–¾Šm‰»|ˆã—ÃŽÒ‚ÌŒoŒ±‚ÉŠî‚­ŽÀ‘Ô’²¸: ƒXƒg[ƒ}|. •ÛŠ L‘ã, ‰œ“c—T”ü, ˆ¢•”@ŒO, Š™“c’¼Žq, ‚Œ©àVŽ , “ŒŠÔ–¢—ˆ, ¼–ì‘å•ã, “c’†@Œ‰1,2 (1V¢‹Iˆã—ÁEæ’[’f“Iˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äX): ‘æ34‰ñ“ú–{¬Ž™ƒXƒg[ƒ}E”rŸ•E‘nŠÇ—Œ¤‹†‰ï (2020/6/13), ŽãŠJÃ.

733048. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ƒXƒg[ƒ}‚ð•Û—L‚·‚鏬Ž™‚âŠÔŒ‡“±”A‚ð•K—v‚Æ‚·‚鏬Ž™‚̏A‰€EAŠw‚É‚¨‚¯‚é‰Û‘è‚Ì–¾Šm‰»|ˆã—ÃŽÒ‚ÌŒoŒ±‚ÉŠî‚­ŽÀ‘Ô’²¸: ŠÔŒ‡“±”A|. Š™“c’¼Žq, •ÛŠ L‘ã, ˆ¢•”@ŒO, ‰œ“c—T”ü, ‚Œ©àVŽ , “ŒŠÔ–¢—ˆ, ¼–ì‘å•ã, “c’†@Œ‰1,2 (1V¢‹Iˆã—ÁEæ’[’f“Iˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äX): ‘æ34‰ñ“ú–{¬Ž™ƒXƒg[ƒ}E”rŸ•E‘nŠÇ—Œ¤‹†‰ï (2020/6/13), ŽãŠJÃ.

733049. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) •Ûˆç‰€E—c’t‰€E¬ŠwZ‚É‚¨‚¯‚éƒXƒg[ƒ}ƒPƒAEŽ©ŒÈ“±”AƒPƒAŽÀŽ{‚Ì‚½‚߂̕׋­‰ï‚ÉŽæ‚è“ü‚ê‚é“à—e‚ÌŒŸ“¢‚ƍu‹`Ž‘—¿‚̍쐬. ‰œ“c—T”ü, •ÛŠ L‘ã, ˆ¢•”@ŒO, Š™“c’¼Žq, ‚Œ©àVŽ , “ŒŠÔ–¢—ˆ, ¼–ì‘å•ã, “c’†@Œ‰1,2 (1V¢‹Iˆã—ÁEæ’[’f“Iˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äX): ‘æ34‰ñ“ú–{¬Ž™ƒXƒg[ƒ}E”rŸ•E‘nŠÇ—Œ¤‹†‰ï (2020/6/13), ŽãŠJÃ.

733050. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ’Eo‘ŸŠí‚ÌŠÒ”[‚ª¢“ï‚È‹‘åä`‘уwƒ‹ƒjƒA‚ɑ΂µ‚Ä•Û‘¶“I‚ȉÁ—Âðs‚Á‚½‚ª—\Šú‚µ‚È‚¢Œo‰ß‚ð’H‚Á‚½ˆê—á. o‰Æ‹œˆê1, “c’†@Œ‰1,2, ŽR–{—T‹P1, ’ǖ؍Gé1, ã¼—R¹1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ6‰ñ“ú–{¬Ž™‚Ö‚»Œ¤‹†‰ï (2020/8/14), WebŠJÃ.

733051. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ŠàŠÔŽ¿üˆÛ‰è×–E‚É‚¨‚¯‚éSPARC”­Œ»‚ð‰î‚µ‚½Wnt/ƒÀ-cateninŒo˜HŠˆ«‰»‚Æ‘å’°Šà‰“Šu“]ˆÚ‹@˜‚̉ð–¾. “¡ŽR–FŽ÷1, ’†–{CŽi1, ¼àVL‹±2, æс@—T—º1, “¡–ìŽjD1, Œã“¡‘ì–ç1, ‰¡“cŒõ‰›1, “Y–ìF•¶1, b”ã“c•Žu1, ‰¡“c˜aŽq, ¬›¸Œc‘¾, “à“¡@„3, ŒGŒ³—Y‰î2, ŽR‰ºŒpŽj4,5 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3‰º•”Á‰»ŠÇŠO, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5ã•”Á‰»ŠÇŠO): ‘æ40‰ñ“ú–{•ªŽqŽîᇃ}[ƒJ[Œ¤‹†‰ï (2020/9/30), WebŠJÃ.

733052. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) • o‹¾‰ºŠÌØœ‚É‚¨‚¯‚é‘Ì“àŽ®Pringle–@. ‰ª–{Œõ‹FŽq1, ŠC’ËMŽj1, ¼àVL‹±1, “c“‡@O1, ‹v•Û”CŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ14‰ñŠÌ‘Ÿ“àŽ‹‹¾ŠO‰ÈŒ¤‹†‰ïE‘æ12‰ñäX‘Ÿ“àŽ‹‹¾ŠO‰ÈŒ¤‹†‰ï (2020/10/28), WebŠJÃ.

733053. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) • o‹¾‰ºŠÌS7ES8ˆŸ‹æˆæØœ‚ÌŽèpŽè‹Z‚¨‚æ‚Ñ‚»‚̈À‘S«. ŠC’ËMŽj1, “c“‡@O1, ¼àVL‹±1, ‹v•Û”CŽj1, ‰ª–{Œõ‹FŽq1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ14‰ñŠÌ‘Ÿ“àŽ‹‹¾ŠO‰ÈŒ¤‹†‰ïE‘æ12‰ñäX‘Ÿ“àŽ‹‹¾ŠO‰ÈŒ¤‹†‰ï (2020/10/28), WebŠJÃ.

733054. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “ú—î49C‘̏d950 g‚ÅŠ‹¼Žèp‚ðŽ{s‚µ‚½’´’áo¶‘̏dŽ™’_“¹•Â½Ç‚Ì1—á. ã¼—R¹1, “c’†@Œ‰1,2, o‰Æ‹œˆê1, “n•”–õ˜Y1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ47‰ñ“ú–{’_“¹•Â½ÇŒ¤‹†‰ï (2020/12/5), å‘ä (ƒnƒCƒuƒŠƒbƒhŠJÃ).

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110017. [Œ´’˜] A multicenter prospective registration study on laparoscopic pancreatectomy in Japan: report on the assessment of 1,429 patients. Ohtsuka T, Nagakawa Y, Toyama H, Takeda Y, Maeda A, Kumamoto Y1, Nakamura Y, Hashida K, Honda G, Fukuzawa K, Toyoda E, Tanabe M, Gotohda N, Matsumoto I, Ryu T, Uyama I, Kojima T, Unno M, Ichikawa D, Inoue Y, Matsukawa H, Sudo T, Takaori K, Yamaue H, Eguchi S, Tahara M, Shinzeki M, Eguchi H, Kurata M, Morimoto M, Hayashi H, Marubashi S, Inomata M, Kimura K, Amaya K, Sho M, Yoshida R, Murata A, Yoshitomi H, Hakamada K, Yasunaga M, Abe N, Hioki M, Tsuchiya M, Misawa T, Seyama Y, Noshiro H, Sakamoto E, Hasegawa K, Kawabata Y, Uchida Y, Kameyama S, Ko S, Takao T, Kitahara K, Nakahira S, Baba H, Watanabe M, Yamamoto M, Nakamura M: J Hepatobiliary Pancreat Sci 2020/2; 27 (2): 47-55. (ŒGŒ³—Y‰î1: 1ˆê”ʁE¬Ž™EŠÌ’_äXŠO)


ã•”Á‰»ŠÇŠO‰ÈŠw

[Šwp˜_•¶]

110224. [Œ´’˜] Intraoperative conversion from laparoscopic gastrectomy to an open procedure: a decade of experience in a Japanese high-volume center. Kumagai K, Hiki N1, Nunobe S, Jiang X, Makuuchi R, Ida S, Ohashi M, Yamaguchi T, Sano T: Surg Endosc 2021/4; 35 (4): 1834-42. doi: 10.1007/s00464-020-07584-7. Epub 2020 Apr 30. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

110225. [Œ´’˜] Prevention of intra-thoracic recurrent laryngeal nerve injury with robot-assisted esophagectomy. Hosoda K1, Niihara M1, Ushiku H1, Harada H1, Sakuraya M1, Washio M1, Yamashita K1,2, Hiki N1: Langenbecks Arch Surg 2020/6; 405 (4): 533-40. (×“c@Œj1, VŒ´³‘å1, ‹‹vGŽ÷1, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110226. [Œ´’˜] A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction. Hosoda K1, Azuma M2, Katada C2, Ishido K2, Niihara M1, Ushiku H1, Sakuraya M1, WashioM1, Wada T2, Watanabe A2, Harada H1, Tanabe S2,3, Koizumi W2, Yamashita K1,4, Hiki N1: Int J Clin Oncol 2020/6; 25 (6): 1090-7. (×“c@Œj1, “Œ@’q2, Œ˜“ce—˜2, ÎŒËŒªŽŸ2, VŒ´³‘å1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ˜a“c‘ñ–ç2, “n糍WŽ¯2, Œ´“cG‹P1, “c糁@‘2,3, ¬ò˜aŽO˜Y2, ŽR‰ºŒpŽj1,4, ”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO, 2Á‰»Ší“à, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110227. [Œ´’˜] Delta-shaped anastomosis vs circular stapler anastomosis after laparoscopic distal gastrectomy with Billroth I reconstruction: A randomized controlled trial. Hosoda K1, Mieno H1, Ema A1, Ushiku H1, Washio M1, Song I, Watanabe M2, Yamashita K1,3, Hiki N1: Asian J Endosc Surg 2020/7; 13 (3): 301-10. (×“c@Œj1, ŽOd–ì_˜N1, ]ŠÔ@—æ1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, “n粏¹•F2, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110228. [Œ´’˜] Risk factors and prognosis of gastric stasis, a crucial problem after laparoscopic pylorus-preserving gastrectomy for early middle-third gastric cancer. Takahashi R, Ohashi M, Hiki N1, Makuuchi R, Ida S, Kumagai K, Sano T, Nunobe S: Gastric Cancer 2020/7; 23 (4): 707-15. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

110229. [Œ´’˜] Neoadjuvant chemotherapy plus surgery for high-risk advanced gastric cancer: long-term results of KDOG1001 trial. Hosoda K1, Katada C2, Ishido K2, Niihara M1, Ushiku H1, Sakuraya M1, Washio M1, Wada T2, Watanabe A2, Harada H1, Sato T3, Tajima H1, Kaizu T1, Kosaka Y4, Kato H4, Sengoku N4, Tanaka K5,6, Naito T3, Kumamoto Y6, Sangai T4, Tanabe S2,5, Koizumi W2, Yamashita K1,7, Hiki N1: Langenbecks Arch Surg 2020/9; 40 5 (6): 777-85. (×“c@Œj1, Œ˜“ce—˜2, ÎŒËŒªŽŸ2, VŒ´³‘å1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ˜a“c‘ñ–ç2, “n糍WD2, Œ´“cG‹P1, ²“¡•˜Y3, “c“‡@O1, ŠC’ËMŽj1, ¬â–ùŒ«4, ‰Á“¡@O4, åÎ‹I•F4, “c’†@Œ‰5,6, “à“¡@„3, ŒGŒ³—Y‰î6, ŽOŠK‹MŽj4, “c糁@‘2,5, ŽR‰ºŒpŽj1,7, ¬ò˜aŽO˜Y2, ”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO, 2Á‰»Ší“à, 3‰º•”Á‰»ŠÇŠO, 4“û‘BEbó‘BŠO, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã, 6ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 7V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110230. [Œ´’˜] Patient selection for salvage surgery after definitive chemoradiotherapy in esophageal squamous cell carcinoma. Harada H1, Yamashita K1,2, Katada C3, Ishiyama H4, Soeno T5, Washio M1, Sakuraya M1, Ushiku H1, Niihara M1, Hosoda K1, Hiki N1: Langenbecks Arch Surg 2020/9; 405 (6): 767-76. (Œ´“cG‹P1, ŽR‰ºŒpŽj1,2, Œ˜“ce—˜3, ÎŽR”ŽžŠ4, “Y–ìF•¶5, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3Á‰»Ší“à, 4•úŽËü (Žîá‡), 5‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110231. [Œ´’˜] Therapeutic value of splenectomy to dissect splenic hilar lymph nodes for type 4 gastric cancer involving the greater curvature, compared with other types. Kano Y, Ohashi M, Ida S, Kumagai K, Makuuchi R, Sano T, Hiki N1, Nunobe S: Gastric Cancer 2020/9; 23 (5): 927-36. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

110232. [Œ´’˜] An Unmodulated Very-Low-Voltage Electrosurgical Technology Creates Predictable and Ultimate Tissue Coagulation: From Experimental Data to Clinical Use. Watanabe Y, Fuchshuber P, Homma T, Bilgic E, Madani A, Hiki N1, Cammack I, Noji T, Kurashima Y, Shichinohe T, Hirano S: Surg Innov 2020/10; 27 (5): 492-8. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

110233. [Œ´’˜] Comparison of Postoperative Quality of Life among Three Different Reconstruction Methods After Proximal Gastrectomy: Insights From the PGSAS Study. Yabusaki H, Kodera Y, Fukushima N, Hiki N1, Kinami S, Yoshida M, Aoyagi K, Ota S, Hata H, Noro H, Oshio A, Nakada K: World J Surg 2020/10; 44 (10): 3433-40. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

110234. [Œ´’˜] Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists. Kano Y, Ohashi M, Hiki N1, Takahari D, Chin K, Yamaguchi K, Ida S, Kumagai K, Sano T, Nunobe S: Surg Today 2020/10; 50 (10): 1197-205. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

110235. [Œ´’˜] Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer. Takahashi R, Nunobe S, Osumi H, Takahari D, Yamamoto N, Ida S, Kumagai K, Ohashi M, Sano T, Hiki N1: Surg Today 2020/10; 50 (10): 1240-8. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

110236. [Œ´’˜] Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer. Harada H1, Soeno T2, Yokoi K3, Nishizawa N4, Ushiku H1, Hosoda K1, Hiki N1, Yamashita K1,5: J Surg Res 2020/12; 256: 404-12. (Œ´“cG‹P1, “Y–ìF•¶2, ‰¡ˆäŒ\Œå3, ¼àVL‹±4, ‹‹vGŽ÷1, ×“c@Œj1, ”äŠé’¼Ž÷1, ŽR‰ºŒpŽj1,5: 1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‰º•”Á‰»ŠÇŠO, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110237. [Œ´’˜] Size-dependent differences in the proximal remnant stomach: how much does a small remnant stomach after subtotal gastrectomy work? Yasufuku I, Ohashi M, Eto K, Ida S, Kumagai K, Nunobe S, Sano T, Hiki N1: Surg Endosc 2020/12; 34 (12): 5540-9. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

110238. [Œ´’˜] The incidences of metachronous multiple gastric cancer after various types of gastrectomy: analysis of data from a nationwide Japanese survey. Kinami S, Aizawa M, Yamashita H, Kumagai K, Kamiya S, Toda M, Takahata T, Fujisaki M, Miyamoto H, Kusanagi H, Kobayashi K, Washio M1, Hosoda K1, Kosaka T: Gastric Cancer 2021/1; 24 (1): 22-30. (˜h”ö^—ˆ¤1, ×“c@Œj1: 1ã•”Á‰»ŠÇŠO)

120008. [Œ´’˜] _“ސ쌧‰º‚̍‚—îŽÒˆÝŠàÇ—á‚ɑ΂·‚é• o‹¾ˆÝØœp‚ÌŒ»ó. ²“¡@Â, š èŽåÅ, ‚‹´³ƒ, ‘哇@‹M, ”äŠé’¼Ž÷1, ‘å’Ø‹Bl, ¬àVšáŽ¡, ‰““¡@Ši (1ã•”Á‰»ŠÇŠO): “ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ïŽGŽ 2020/7; 25 (4): 254-62.

320004. [Ç—á•ñ] Nab-PTX + RAM•¹—p—Ö@Œã‚É• o‹¾‰ºŠÌ•”•ªØœp‚ðŽ{s‚µ‚½Ä”­ˆÝŠà‚Ì1—á. ’†”nŠî”Ž1,2, ‚‹´’õl2,3, Žž”C’‘, ŠÛŽR³—T2,3, ç–ìTˆê˜Y2,4, ‹‹vGŽ÷1, ’†‘º˜a“¿2,3, “à“¡³‹K2,4, ‹ß“¡NŽj2,5, ŽRè@“™2,6, ¼@”ªŽk, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4‰º•”Á‰»ŠÇŠO, 5“û‘BEbó‘BŠO, 6•a—): Šà‚Ɖ»Šw—Ö@ 2020/12; 47 (13): 2065-7.

320005. [Ç—á•ñ] ä‚̍‚‚¢”S–Œ‰ºŽîᇗl—²‹N‚ð’悵‚½ˆÝ’ê‘BŒ^ˆÝŠà‚Ì1—á. “y•ûˆê”Í, —R—Y•q”V, ‰Í“à@—m, ‹g…Ëˆê, –x“à—T‰î, ÎŽRW¢Žu, •½àVr–¾, “y“c’mG, ¯Ži‰ÀW, ”äŠé’¼Ž÷1, “¡è‡Žq (1ã•”Á‰»ŠÇŠO): ˆÝ‚Æ’° 2020/9; 55 (10): 1313-22.

510010. [‘à] Robot-assisted minimally invasive esophagectomy for esophageal cancer: Meticulous surgery minimizing postoperative complications. Hosoda K1, Niihara M1, Harada H1, Yamashita K1,2, Hiki N1: Ann Gastroenterol Surg 2020/8; 4 (6): 608-17. (×“c@Œj1, VŒ´³‘å1, Œ´“cG‹P1, ŽR‰ºŒpŽk1,2, ”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

510011. [‘à] Postoperative pancreatic fistula after gastrectomy for gastric cancer. Washio M1, Yamashita K1,2, Niihara M1, Hosoda K1, Hiki N1: Ann Gastroenterol Surg 2020/9; 4 (6): 618-27. (˜h”ö^—ˆ¤1, ŽR‰ºŒpŽk1,2, VŒ´³‘å1, ×“c@Œj1, ”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

510012. [‘à] History and emerging trends in chemotherapy for gastric cancer. Yamashita K1,2, Hosoda K2, Niihara M2, Hiki N2: Ann Gastroenterol Surg 2021/2; 5 (4): 446-56. (ŽR‰ºŒpŽj1,2, ×“c@Œj2, VŒ´³‘å2, ”äŠé’¼Ž÷2: 1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2ã•”Á‰»ŠÇŠO)

520007. [‘à] III. Á‰»Ší“àŽ‹‹¾‚Ì”­“W@• o‹¾Ž¡—Â̐V“WŠJ@• o‹¾E“àŽ‹‹¾‡“¯ˆÝØœ (LECS) ‚ÌŒ»Ý‚Æ–¢—ˆ. ”äŠé’¼Ž÷ (ã•”Á‰»ŠÇŠO): “ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŽGŽ 2020/11; 62 (Suppl.3): 2440-6.

522053. [uÀ]y“ÁW: ŽÀ‘H! Žèp‚ªã’B‚·‚éƒgƒŒ[ƒjƒ“ƒO–@|Off the Job Training‚̍ŐV“®Œüz¡Žèp‚̘r‚𖁂­‚½‚ß‚É•K—v‚ȃrƒfƒI‰æ‘œ‚É‚æ‚éŠwK@Šw‰ï‚âweb‚È‚Ç‚Å’ñ‹Ÿ‚³‚ê‚é–͔͓IƒrƒfƒI‰æ‘œ‚ÌŠˆ—p–@. ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´³‘å1, ×“c@Œj1, ”äŠé’¼Ž÷1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ’†”nŠî”Ž1,2, “Y–ìF•¶3, ŽR‰ºŒpŽj1,4: 1ã•”Á‰»ŠÇŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4V¢‹Iˆã—ÁE‰¡’f“I): —Տ°ŠO‰È 2020/4; 75 (4): 388-92.

522054. [uÀ]y‘æ1“ÁW: ‚ä‚é`‚­, ‚Å‚à‚¿‚á‚ñ‚ÆŠw‚Ñ‚½‚¢ƒi[ƒX‚Ì‚½‚ß‚Ì33‚̏Á‰»ŠíŽ¾Š³&Ž¡—à g‚í‚éh‚«‚á‚ç ‚¸‚©‚ñz2. ˆÝ‚ÌŽ¾Š³&Ž¡—Á@‚í‚é‚«‚á‚炸‚©‚ñ. ŸN’J”ü‹MŽq1, ”äŠé’¼Ž÷1, ×“c@Œj1, VŒ´³‘å1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰ºŒpŽj1,2 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“I): Á‰»Šíƒi[ƒVƒ“ƒO 2020/5; 25 (5): 402-10.

530011. [‚»‚Ì‘¼ (Editorial)] Why minimally invasive surgery for esophageal cancer is minimally invasive? Hiki N1: Ann Gastroenterol Surg 2020/5; 4 (3): 188-9. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

[’˜@‘]

620041. [Šwp‘ (•ª’SŽ·•M)]yƒL[ƒ[ƒh‚Å‚í‚©‚é—Տ°‰h—{ —ߘa”Ł@‰h—{‚ÅŽ¡‚·! Šî‘b‚©‚çŽÀ‘H‚܂Łz‘æ10Í ŠeŽ¾Š³‚̉h—{ŠÇ—@16. ‚ª‚ñ, p.344-54. VŒ´³‘å1, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO), •Ò: ‰ª“cWŒá, —r“yŽÐ, “Œ‹ž, 2020/4”­s.

620042. [Šwp‘ (•ª’SŽ·•M)]yp‘OEpŒãŠÇ—•KŒg2020 (Á‰»ŠíŠO‰È2020”N4ŒŽ‘Š§†)zii. p‘OŒŸ¸@7. ‰h—{ƒAƒZƒXƒƒ“ƒg, p.581-4. VŒ´³‘å1, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO), ‚Ö‚é‚·o”Å, “Œ‹ž, 2020/4”­s.

620043. [Šwp‘ (•ª’SŽ·•M)]y“àŽ‹‹¾ŠO‰ÈŽèp@–𗧂ƒeƒNƒjƒbƒN100 [Web“®‰æ•t] ‘æ1”Łzƒ|[ƒg‚Ì‘}“üˆÊ’u@02ã•”Á‰»ŠÇ‡A (ˆÝ), p.203-5. Œ´“cG‹P1, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO). •Ò: ‹{àVŒõ’j, ˆãŠw‘‰@, “Œ‹ž, 2020/10”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

721011. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ŽüpŠúPatient selection‚É‚æ‚éH“¹ŠàŽ¡—ÍœK‰»‚Ö‚Ì’§í. ŽR‰ºŒpŽj1,2, Œ´“cG‹P2, VŒ´³‘å2, ×“c@Œj2, ‹‹vGŽ÷2, ˜h”ö^—ˆ¤2, ŸN’J”ü‹MŽq2, Œ˜“ce—˜3, ÎŽR”ŽžŠ4, ”äŠé’¼Ž÷2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2ã•”Á‰»ŠÇŠO, 3Á‰»Ší“à, 4•úŽËü (Žîá‡)): ‘æ74‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2020/12/10), “¿“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722053. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) A phase I study of DOS neoadjuvant chemotherapy for esophagogastric junction cancer. ×“c@Œj1, “Œ@’q2, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´³‘å1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2Á‰»Ší“à, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/7/1-31), WebŠJÃ, “ú–{ˆÝŠàŠw‰ï‘‰ï‹LŽ– 2020/3; 92: 199.

722054. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Intrathoracic double flap technique for esophagogastric cancer. VŒ´³‘å1, ‹‹vGŽ÷1, ×“c@Œj1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ìF•¶2, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/7/1-31), WebŠJÃ, “ú–{ˆÝŠàŠw‰ï‘‰ï‹LŽ– 2020/3; 92: 201.

722055. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚“xisˆÝŠà‚ɑ΂·‚é“àŽ‹‹¾ŠO‰ÈŽèp: isH“¹ˆÝÚ‡•”Šà‚ɑ΂·‚é“àŽ‹‹¾ŠO‰ÈŽèp. ×“c@Œj1, VŒ´³‘å1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ²“¡•˜Y2, ŠC’ËMŽj1, ‰Á“¡@O3, “c’†@Œ‰4,5, “à“¡@„2, ŒGŒ³—Y‰î5, ŽOŠK‹MŽj3, ŽR‰ºŒpŽj1,6, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‰º•”Á‰»ŠÇŠO, 3“û‘BEbó‘BŠO, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 6V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/30), WebŠJÃ, “ú–{—Տ°ŠO‰ÈŠw‰ïŽGŽ 2020/10; 81 (‘Š§†): 214.

722056. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒƒ{ƒbƒgŽx‰‡‰ºˆÝØœp‚Ì’èŒ^‰»‚ÆŽ¡—ЬÑ: ƒƒ{ƒbƒgŽx‰‡ˆÝŠàŽèp‚Ì’ZŠú’·Šú¬Ñ. ×“c@Œj1, VŒ´³‘å1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ²“¡•˜Y2, ŠC’ËMŽj3, ‰Á“¡@O4, “c’†@Œ‰3,5, “à“¡@„2, ŒGŒ³—Y‰î3, ŽOŠK‹MŽj4, ŽR‰ºŒpŽj1,6, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‰º•”Á‰»ŠÇŠO, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4“û‘BEbó‘BŠO, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã, 6V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/31), WebŠJÃ, “ú–{—Տ°ŠO‰ÈŠw‰ïŽGŽ 2020/10; 81 (‘Š§†): 237.

722057. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Thoracoscopic double-flap reconstruction for esophagogastric junction cancer. ×“c@Œj1, VŒ´³‘å1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722058. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Feasibility of laparoscopic gastrectomy for gastric cancer in multicenter prospective studies. Etoh E, ”äŠé’¼Ž÷1, Honda M, Shiraishi N, Kitano S, Inomata M (1ã•”Á‰»ŠÇŠO): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722059. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Še—̈æ‚É‚¨‚¯‚郍ƒ{ƒbƒgŽx‰‡Žèp|ˆÝŠà‚ɑ΂·‚郍ƒ{ƒbƒgŽx‰‡Žèp|. ×“c@Œj1, VŒ´³‘å1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ45‰ñ“ú–{ŠO‰ÈŒn˜A‡Šw‰ïŠwpW‰ï (2020/12/23), WebŠJÃ, “ú–{ŠO‰ÈŒn˜A‡‰ïŠw‰ïŠwpW‰ï´˜^W 2020/12; 45 (5): 539.

723217. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îŽÒˆÝŠà‚ÌŠO‰ÈŽ¡—ЬÑ. ˜h”ö^—ˆ¤1, ŽR‰ºŒpŽj1,2, “Y–ìF•¶3, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723218. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V‹KˆÝŠàDNA• …ôò×–Ef‚ÌŠm—§|CDO1ˆâ“`Žqƒƒ`ƒ‹‰»‚ð—p‚¢‚ā| . Œ´“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723219. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÈ•Ö‚È• o‹¾‰ºˆÝØœp‚Ì“ï“x—\‘ªˆöŽq‚Æ‚µ‚Ă̐t•‚—VƒTƒCƒ“. “n•”WŽq1, ×“c@Œj2, VŒ´³‘å2, ‹‹vGŽ÷2, ŸN’J”ü‹MŽq2, ˜h”ö^—ˆ¤2, Œ´“cG‹P2, ŽR‰ºŒpŽj2,3, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723220. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝH“¹‹t—¬‚Ì–hŽ~‚É‚¨‚¯‚éDouble-flap–@ÄŒš‚ÆOrvil–@ÄŒš‚ÌŒŸ“¢. ‹‹vGŽ÷1, ×“c@Œj1, VŒ´³‘å1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ìF•¶2, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723221. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V‚µ‚¢p‘O‰»Šw—Ö@‚É‚æ‚éconversion surgery‚̐¬Ñ. ŸN’J”ü‹MŽq1, ŽR‰ºŒpŽj1,2, “Y–ìF•¶3, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723222. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹‘åˆÝ”S–Œ‰ºŽîᇂɑ΂µ‚ÄŠJ• E“àŽ‹‹¾‡“¯ˆÝ‹ÇŠØœ‚ðs‚¢‘ŸŠíE‹@”\‰·‘¶‚ª‰Â”\‚Å‚ ‚Á‚½ˆê—á. ‘¾“c@—½1, Œ´“cG‹P2, “Y–ìF•¶3, ˜h”ö^—ˆ¤2, ‹‹vGŽ÷2, ŸN’J”ü‹MŽq2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,4, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723223. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Digital droplet PCR‚ð—p‚¢‚½ˆÝŠà• –Œ”dŽí‚ɑ΂µ‚Ă̐V‹Kf’f–@. “Y–ìF•¶1, Œ´“cG‹P2, ŸN’J”ü‹MŽq2, ˜h”ö^—ˆ¤2, ‹‹vGŽ÷2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,3, ”äŠé’¼Ž÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/7/1-31), WebŠJÃ.

723224. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠà‚É‚¨‚¯‚éMutL homolog 1 (MLH1) ˆâ“`ŽqDNAƒƒ`ƒ‹‰»‚̗Տ°“IˆÓ‹`. Œ´“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ106‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2020/8/13), ŽãŠJÃ (ˆê•”WebŠJÃ).

723225. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÇo“àŽ‹‹¾E• o‹¾‡“¯Žèp‚̍őOü@‚—îŽÒˆÝŠàŠ³ŽÒ‚ɑ΂·‚éoptional LECS. ˜h”ö^—ˆ¤1, ”äŠé’¼Ž÷1, “Y–ìF•¶2, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13), WebŠJÃ.

723226. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) DCF‚ðŽ¡—Ãí—ª‚É‘g‚Ý“ü‚ꂽT4‹¹•”H“¹Šà‚ÌŽ¡—ЬÑ‚©‚ç‚Ý‚¦‚鍡Œã‚̉ۑè. VŒ´³‘å1, Œ´“cG‹P1, ×“c@Œj1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13), WebŠJÃ.

723227. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠà‚É‚¨‚¯‚éSSIƒŠƒXƒNƒ‚ƒfƒ‹‚Æ—\ŒãEÄ”­Œ`Ž®‚ɂ‚¢‚Ä. ŸN’J”ü‹MŽq1, ŽR‰ºŒpŽj1,2, “Y–ìF•¶3, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13), WebŠJÃ.

723228. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹¾ˆÝØœ‚É‚¨‚¯‚éäXã‰Šs´Žž‚ÌäX“]‚ª‚µ–@‚̍H•v. “n•”WŽq1, ‹‹vGŽ÷2, ×“c@Œj2, VŒ´³‘å2, ŸN’J”ü‹MŽq2, ˜h”ö^—ˆ¤2, Œ´“cG‹P2, ŽR‰ºŒpŽj2,3, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/14), WebŠJÃ.

723229. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ŠàŽèp‚É‚¨‚¯‚é‰h—{Ž©ŒÈ•]‰¿ƒV[ƒg‚ð—p‚¢‚½ŽüpŠú‰h—{ŠÇ—‚ÌŒŸ“¢. Œ´“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/14), WebŠJÃ.

723230. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ã•”Á‰»ŠÇ‹@”\‰·‘¶pŽ®‚̃Gƒrƒfƒ“ƒX@ˆÝH“¹‹t—¬‚Ì–hŽ~‚É‚¨‚¯‚éDouble-flap–@ÄŒš‚ÆOrvil–@ÄŒš‚ÌŒŸ“¢. ‹‹vGŽ÷1, ×“c@Œj1, VŒ´³‘å1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/15), WebŠJÃ.

723231. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ŠàŽèp‚É‚¨‚¯‚éƒ_ƒrƒ“ƒ`‚ª‚à‚½‚ç‚·—˜“_@º‘Ñ–ƒáƒŒyŒ¸‚̉”\«. ×“c@Œj1, ‹‹vGŽ÷1, VŒ´³‘å1, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/15), WebŠJÃ.

723232. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠà‚É‚¨‚¯‚é‘OŠàƒ}[ƒJ[‚Æ‚µ‚Ä‚ÌKKLC-1‚Ì—L—p«‚ɂ‚¢‚Ä. ’†”nŠî”Ž1,2, •ŸŽR@—²1, ‘å’ˏr˜a3, “ñ“nM], Žs—ˆ‰ÃL, Žž”C’‘4, ŠÛŽR³—T1,5, ’†‘º˜a“¿1,5, “à“¡³‹K1,4, ‹ß“¡NŽj1,6, ¼@”ªŽk1, ‚‹´’õl1,5, ¬—ÑŒ›’‰1, ŽRè@“™1,7, ”äŠé’¼Ž÷2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2ã•”Á‰»ŠÇŠO, 3Á‰»Ší“à, 4‰º•”Á‰»ŠÇŠO, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 6“û‘BEbó‘BŠO, 7•a—): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/15), WebŠJÃ.

723233. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ŠàŠ³ŽÒ‚É‚¨‚¯‚鎡—ÑOŒŒ´CRP’l‚ª¶‘¶—¦‚É—^‚¦‚é‰e‹¿. Œã“¡‘ì–ç1, “Y–ìF•¶1, ×“c@Œj2, ”äŠé’¼Ž÷2, ŽR‰ºŒpŽj2,3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723234. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹G•½ã”çŠà‚É‚¨‚¯‚铯Žžˆâ“`Žq‘•‚̉»Šw—Ö@’ïR«‚Ö‚ÌŠñ—^. “Y–ìF•¶1, Œ´“cG‹P2, ×“c@Œj2, ”äŠé’¼Ž÷2, ŽR‰ºŒpŽj2,3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ79‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2020/10/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723235. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠà‚̐[’B“xf’f‚É‚¨‚¯‚éCT‚Ì—L—p«‚ɂ‚¢‚Ä. ‰œ–ìW‘¾1, Œ´“cG‹P2, ˜h”ö^—ˆ¤2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,3, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723236. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹‘åˆÝ”S–Œ‰ºŽîᇂɑ΂µ‚ÄŠJ• E“àŽ‹‹¾‡“¯ˆÝ‹ÇŠØœ (Open Endoscopic CooperativeSurgery; OECS) ‚ðs‚¢‘ŸŠíE‹@”\‰·‘¶‚ª‰Â”\‚Å‚ ‚Á‚½ˆê—á. ‘¾“c@—½1, Œ´“cG‹P2, “Y–ìF•¶3, ˜h”ö^—ˆ¤2, ‹‹vGŽ÷2, ŸN’J”ü‹MŽq2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,4, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723237. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —H–剺ŒŒŠÇ‚ðTree‚̂悤‚ÉŽ‹–ì“WŠJ‚·‚éV‚µ‚¢No.6ƒŠƒ“ƒpßŠs´–@. ‹‹vGŽ÷1, ×“c@Œj1, VŒ´³‘å1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ìF•¶2, “à“¡@„3, ŒGŒ³—Y‰î4, “c’†@Œ‰4,5, ŽOŠK‹MŽj6, ²“¡•˜Y3, ŠC’ËMŽj1, ŽR‰ºŒpŽj1,7, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‰º•”Á‰»ŠÇŠO, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã, 6“û‘BEbó‘BŠO, 7V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723238. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÌ’_äX—̈æ‚É‚¨‚¯‚éReduced portŽèp‚̍H•v‚Æ“W–]: • o‹¾‰ºŒn““IŠÌØœ‚É‚¨‚¯‚éReduced Port Surgery (RPS) ‚̍H•v. ŠC’ËMŽj1, “c“‡@O1, ¼àVL‹±2, ‰ª–{Œõ‹FŽq2, æс@—T—º3, “¡ŽR–FŽ÷3, ‹v•Û”CŽj2, ²“¡•˜Y4, ×“c@Œj1, ŽR‰ºŒpŽj1,5, “c’†@Œ‰2,6, ”äŠé’¼Ž÷1, “à“¡@„4, ŽOŠK‹MŽj7, ŒGŒ³—Y‰î2 (1ã•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4‰º•”Á‰»ŠÇŠO, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 6V¢‹Iˆã—ÁEæ’[ˆã—Ã, 7“û‘BEbó‘BŠO): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723239. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÌ’_äX—̈æ‚É‚¨‚¯‚éReduced portŽèp‚̍H•v‚Æ“W–]: • o‹¾‰º”ö‘¤äXØœ‚Å‚Ìreduced port surgery. “c“‡@O1, ŠC’ËMŽj1, ‹v•Û”CŽj1, ¼àVL‹±2, ‰ª–{Œõ‹FŽq2, “¡ŽR–FŽ÷3, æс@—T—º3, ²“¡•˜Y4, ×“c@Œj1, ŽR‰ºŒpŽj1,5, “c’†@Œ‰2,6, ”äŠé’¼Ž÷1, “à“¡@„4, ŽOŠK‹MŽj7, ŒGŒ³—Y‰î2 (1ã•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4‰º•”Á‰»ŠÇŠO, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 6V¢‹Iˆã—ÁEæ’[ˆã—Ã, 7“û‘BEbó‘BŠO): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723240. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Minimally invasive surgery‚Ö-ˆÀ‘S‚ÈŽèpŽè‹Z‚ÌŒp³‚Æ‘n‘¢|äX‘Ÿ‚ðG‚ç‚È‚¢• o‹¾‰ºˆÝØœ|. ˜h”ö^—ˆ¤1, ”äŠé’¼Ž÷1, “Y–ìF•¶2, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723241. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Å“K‚ȏpŒãŠÇ—‚ð–ÚŽw‚µ‚½Žæ‚è‘g‚Ý (Á‰»ŠÇ) Stage IˆÝŠàpŒã‚É‚¨‚¯‚鑼•aŽ€—\‘ªˆöŽq‚Ì“¯’è. ŸN’J”ü‹MŽq1, ŽR‰ºŒpŽj1,2, “Y–ìF•¶3, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723242. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • –Œ”dŽí‚ɑ΂·‚鎡—Ð헪: CDO1ˆâ“`ŽqDNAƒƒ`ƒ‹‰»‚ð—p‚¢‚½V‹KˆÝŠàDNA• …ôò×–Ef‚ÌŠm—§. Œ´“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723243. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚“xisˆÝŠàCÄ”­ˆÝŠà‚ɑ΂·‚鎡—Ð헪-–ò•¨—Ö@‚ÆŽèp‚Æ‚Ì—Z‡-Øœ•s”\isˆÝŠà‚ɑ΂·‚éconversionŽèpÇ—á‚Ì’·Šú—\Œã. Œ´“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/31), WebŠJÃ.

723244. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝØœŒã‚̍Čš•û–@‚ðÄl‚·‚é-ˆÀ‘S«‚ÆQOL‚ÌŠÏ“_‚©‚ç-—H–呤ˆÝØœp‚ƈݑS“Ep‚É‚¨‚¯‚é’·Šú—\Œã‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘å–ØŒcŽq1, Œ´“cG‹P2, “Y–ìF•¶3, ˜h”ö^—ˆ¤2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,4, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/31), WebŠJÃ.

723245. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Organ touchless‚ÉŠî‚­ˆÝ‘S“EŒã‚̐H“¹‹ó’°•«‡. VŒ´³‘å1, ×“c@Œj1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ìF•¶2, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/31), WebŠJÃ.

723246. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äXŠà‚ɑ΂·‚é• o‹¾‰ºäX‘Ì”ö•”Øœ: äXŠà‚ɑ΂·‚é• o‹¾‰º”ö‘¤äXØœ‚Ì’èŒ^‰». “c“‡@O1, ŠC’ËMŽj1, ‹v•Û”CŽj1, ¼àVL‹±2, ‰ª–{Œõ‹FŽq2, “¡ŽR–FŽ÷3, æс@—T—º3, ²“¡•˜Y4, ×“c@Œj1, ŽR‰ºŒpŽj1,5, “c’†@Œ‰2,6, ”äŠé’¼Ž÷1, “à“¡@„4, ŽOŠK‹MŽj7, ŒGŒ³—Y‰î2 (1ã•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4‰º•”Á‰»ŠÇŠO, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 6V¢‹Iˆã—ÁEæ’[ˆã—Ã, 7“û‘BEbó‘BŠO): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/31), WebŠJÃ.

723247. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ˆÝÚ‡•”Šà‚ɑ΂·‚é• o‹¾‰ºH“¹•¬–呤ˆÝØœ, ‹¹o‹¾‰ºŠÏ‰¹ŠJ‚«–@ÄŒš. ×“c@Œj1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ28‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔ (2020/11/6), •ºŒÉ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723248. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ªŽ¡“I‰ÈŠw•úŽËüŽ¡—ÃŒã‚̐H“¹ƒTƒ‹ƒx[ƒWŽèp‚É‚¨‚¯‚é—\Œã—\‘ªˆöŽq‚ÌŒŸ“¢. ‹‹vGŽ÷1, Œ´“cG‹P1, ×“c@Œj1, VŒ´³‘å1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, “Y–ìF•¶2, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2020/12/10), “¿“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723249. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹Šàp‘OŒŒ‰tƒKƒXCO-Hb‚Æ–D‡•s‘SC”x‰Š‚Æ‚ÌŠÖ˜A. “Y–ìF•¶1, Œ´“cG‹P2, ŸN’J”ü‹MŽq2, ˜h”ö^—ˆ¤2, ‹‹vGŽ÷2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,3, ”äŠé’¼Ž÷2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2020/12/10), “¿“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723250. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ŠàpŒã‚Ì–D‡•s‘S‰ü‘P‚ð–ÚŽw‚µ‚½ÄŒšˆÝŠÇ‚¨‚æ‚эČšŒo˜Hì¬. VŒ´³‘å1, ×“c@Œj1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ìF•¶2, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2020/12/10), “¿“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723251. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹Šà‚É‚¨‚¯‚é–òÜ‘ϐ«‚ÉŠÖ—^‚·‚郢Np63/SOX2ˆâ“`Žq‚Ì—\‘ªƒ}[ƒJ[‚Æ‚µ‚Ä‚ÌŒŸ“¢. Œ´“cG‹P1, ‘åò—z‰î, “Y–ìF•¶2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2020/12/10), “¿“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723252. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹Œ´”­GIST‚ɑ΂·‚éŽèpí—ª‚ɂ‚¢‚Ä‚ÌŒŸ“¢. “¡”örˆò1, Œ´“cG‹P2, ˜h”ö^—ˆ¤2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,3, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2020/12/10), “¿“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723253. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ŠàØœŒã‡•¹Ç—\–h‚Ì‚½‚ß‚ÌŽèpŽžƒƒ{ƒbƒg—˜—p. ×“c@Œj1, VŒ´³‘å1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ìF•¶2, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2020/12/10), “¿“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723254. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŽüpŠúPatient selection‚É‚æ‚éH“¹ŠàŽ¡—ÍœK‰»‚Ö‚Ì’§í. ŽR‰ºŒpŽj1,2, Œ´“cG‹P2, VŒ´³‘å2, ×“c@Œj2, ‹‹vGŽ÷2, ˜h”ö^—ˆ¤2, ŸN’J”ü‹MŽq2, Œ˜“ce—˜3, ÎŽR”ŽžŠ4, ”äŠé’¼Ž÷2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2ã•”Á‰»ŠÇŠO, 3Á‰»Ší“à, 4•úŽËü (Žîá‡)): ‘æ74‰ñ“ú–{H“°Šw‰ïŠwpW‰ï (2020/12/10-11), “¿“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ), “ú–{H“¹Šw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€E´˜^W 2020/12; 74: 18.

723255. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îŽÒisˆÝŠàŠ³ŽÒ‚ɑ΂·‚éoptional LECS. ˜h”ö^—ˆ¤1, ”äŠé’¼Ž÷1, “Y–ìF•¶2, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723256. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —H–呤ˆÝØœŒã‚ÌRoux-en-YÄŒš‚ÆBillroth-I–@ÄŒš‚Ì’·Šú—\Œã‚ÌŒŸ“¢. ‘å–ØŒcŽq1, Œ´“cG‹P2, “Y–ìF•¶3, ˜h”ö^—ˆ¤2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,4, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723257. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝØœŒã‚ÌŽcˆÝŠg’£‚ð—\‘ª‚·‚é• •”’PƒƒŒƒ“ƒgƒQƒ“‚Ì—L—p‚ÈŽw•W. “n•”WŽq1, Œ´“cG‹P2, “Y–ìF•¶3, ˜h”ö^—ˆ¤2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,4, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723258. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) p‘O‰»Šw—Ö@‚ðŽ{s‚µ‚½ˆÝŠàpŒã‡•¹Ç—á‚Ì—\Œã‚ւ̉e‹¿. Œ´“cG‹P1, ‹‹vGŽ÷1, “Y–ìF•¶2, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723259. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹¾‰ºˆÝØœ‚É‚¨‚¯‚éäXã‰Šs´Žž‚ÌäX“]‚ª‚µ–@‚̍H•v. “¡”örˆò1, ‹‹vGŽ÷2, ×“c@Œj2, VŒ´³‘å2, ŸN’J”ü‹MŽq2, ˜h”ö^—ˆ¤2, Œ´“cG‹P2, “Y–ìF•¶3, ŽR‰ºŒpŽj2,4, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723260. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Øœ•s”\isˆÝŠà‚ɑ΂·‚éC“–‰@‚É‚¨‚¯‚éV‚µ‚¢p‘O‰»Šw—Ö@‚É‚æ‚éConversion surgery‚̐¬Ñ. ŸN’J”ü‹MŽq1, ŽR‰ºŒpŽj1,2, “Y–ìF•¶3, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723261. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ˆÝÚ‡•”Šà‚ɑ΂·‚é• o‹¾‰º•¬–呤ˆÝØœE‹¹o“àãì–@ÄŒš‚Ì—L—p«. ‹‹vGŽ÷1, ×“c@Œj1, VŒ´³‘å1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ìF•¶2, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723262. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡‹¹o‹¾‰ºH“¹Øœp‚̈ʒu‚¯. VŒ´³‘å1, ×“c@Œj1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, Œ´“cG‹P1, “Y–ìF•¶2, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723263. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) âu⃕”Øœ‚É’…–Ú‚µ‚½ˆÝØœ–@•Ê‘̏dEœŠi‹Ø—ÊŒ¸­—¦‚ÌŒŸ“¢|“–‰@‚ÌŒ»ó‚𓥂܂¦‚ā|. ŸN’J”ü‹MŽq1, ”äŠé’¼Ž÷1, “Y–ìF•¶2, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ŠO‰È‘ãŽÓ‰h—{Šw‰ï‘æ57‰ñŠwpW‰ï (2020/12/24-26), WebŠJÃ.

723264. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îŽÒH“¹‚ª‚ñŽèpÇ—á‚É‚¨‚¯‚é‰h—{ÛŽæ—ÊŽ©ŒÈ•]‰¿ƒV[ƒg‚Ì—L—p«‚ÌŒŸ“¢. VŒ´³‘å1, ‹‹vGŽ÷1, Œ´“cG‹P1, ‹e’r“Þ•äŽq2, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‰h—{•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ŠO‰È‘ãŽÓ‰h—{Šw‰ï‘æ57‰ñŠwpW‰ï (2020/12/24-26), WebŠJÃ.

723265. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) âu⃕”Øœ‚É’…–Ú‚µ‚½ˆÝØœ–@•Ê‘̏dEœŠi‹Ø—ÊŒ¸­—¦‚ÌŒŸ“¢. ŸN’J”ü‹MŽq1, ”äŠé’¼Ž÷1, “Y–ìF•¶2, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3), WebŠJÃ.

723266. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹¾‰ºˆÝØœ‚É‚¨‚¯‚éäX‚ðˆ³”r‚µ‚È‚¢“WŠJ. ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3), WebŠJÃ.

723267. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äX‘Ÿ”ñˆ³”räXã‰ƒŠƒ“ƒpßŠs´‚𔺂Á‚½ƒƒ{ƒbƒgŽx‰‡ˆÝØœp. ×“c@Œj1, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´³‘å1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3), WebŠJÃ.

723268. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) QOL‚Ì–Ê‚©‚ç‚Ý‚½ˆÝŠàŽ¡—Â̍H•v|ŒŒ“œ•Ï“®‚É”º‚¤ˆÝØœŒãƒ_ƒ“ƒsƒ“ƒOÇó‚̉ü‘P‚ÌŒoŒ±‚ƌ•ʉ»‰h—{—Ö@‚̉î“ü‚ÌŽŽ‚݁|. VŒ´³‘å1, ‹‹vGŽ÷1, ×“c@Œj1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3), WebŠJÃ.

723269. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠà‚ɑ΂·‚é“àŽ‹‹¾‚ð—˜—p‚µ‚½Ž¡—à (ESD, LECS) ‚ÌŒ»ó‚Æ“W–]|‚—îŽÒˆÝŠàŠ³ŽÒ‚ɑ΂·‚éoptional LECS|. ˜h”ö^—ˆ¤1, ”äŠé’¼Ž÷1, ×“c@Œj1, VŒ´³‘å1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜a“c‘ñ–ç2, Œ´“cG‹P1, “Y–ìF•¶3, “c糁@‘2,4, ŽR‰ºŒpŽj1,5 (1ã•”Á‰»ŠÇŠO, 2Á‰»Ší“à, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3), WebŠJÃ.

723270. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •¬–呤ˆÝØœp‚É‚¨‚¯‚éŽèpŽè‹Z‚̍H•v@•¬–呤ˆÝØœp‚É‚¨‚¯‚éÅ“K‚ȍČš–@‚ɂ‚¢‚Ä‚ÌŒŸ“¢. Œ´“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3), WebŠJÃ.

723271. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠà‰æ‘œf’f‚̐V¢ŠE@ˆÝŠà‚ÌCT‚É‚æ‚é•”ˆÊ•Ê[’B“xf•]‰¿‚ɂ‚¢‚Ä. ‰œ–ìW‘¾1, Œ´“cG‹P2, ˜h”ö^—ˆ¤2, ‹‹vGŽ÷2, ŸN’J”ü‹MŽq2, VŒ´³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,3, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ93‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2021/3/3), WebŠJÃ.

733055. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) H“¹G•½ã”çŠà‚Ì“¯Žžˆâ“`Žq‘•‚É‚æ‚鉻Šw—Ö@’ïR«‚ÌŠl“¾. “Y–ìF•¶1, Œ´“cG‹P2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, ˜h”ö^—ˆ¤2, VŒ´³‘å2, ×“c@Œj2, ”äŠé’¼Ž÷2, ŽR‰ºŒpŽj2,3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ40‰ñ“ú–{•ªŽqŽîᇃ}[ƒJ[Œ¤‹†‰ï (2020/9/30), WebŠJÃ.

733056. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) H“¹Šà‚É‚¨‚¯‚é—\ŒãˆöŽq‚Æ‚µ‚ÄŽ¡—ÑOC-reactive protein’l‚ÌŒŸ“¢. Œã“¡‘ì–ç1, “Y–ìF•¶1, Œ´“cG‹P2, ˜h”ö^—ˆ¤2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, VŒ´³‘å2, ×“c@Œj2, ”äŠé’¼Ž÷2, ŽR‰ºŒpŽj2,3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ40‰ñ“ú–{•ªŽqŽîᇃ}[ƒJ[Œ¤‹†‰ï (2020/9/30), WebŠJÃ.

733057. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘å’°ŠàÇ—á‚É‚¨‚¯‚éAscl2/Wnt2ˆâ“`Žq”­Œ»‚ÉŠÖ‚·‚é—Տ°•a—Šw“IŒŸ“¢. b”ã“c•Žu1, “¡ŽR–FŽ÷1, “Y–ìF•¶1, ‰¡“cŒõ‰›1, Œã“¡‘ì–ç1, æс@—T—º1, “¡–쎍D1, ŽR‰ºŒpŽj2,3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ã•”Á‰»ŠÇŠO): ‘æ40‰ñ“ú–{•ªŽqŽîᇃ}[ƒJ[Œ¤‹†‰ï (2020/9/30), WebŠJÃ.

733058. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) • o‹¾‰º•¬–呤ˆÝØœ‚É‚¨‚¯‚éDouble-flap–@ÄŒš‚ÆOrvil–@ÄŒš‚ÌŒŸ“¢ ”äŠé’¼Ž÷ (ã•”Á‰»ŠÇŠO): ‘æ50‰ñˆÝŠO‰ÈEpŒãáŠQŒ¤‹†‰ï (2020/11/14), WebŠJÃ.

733059. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‚—îŽÒˆÝŠàŠ³ŽÒ‚ɑ΂µŠÉ˜aLECS‚ðŽ{s‚µ‚½4—á‚ÌŒŸ“¢. ˜h”ö^—ˆ¤1, ”äŠé’¼Ž÷1, ˜a“c‘ñ–ç2, VŒ´³‘å1, “c糁@‘2,3 (1ã•”Á‰»ŠÇŠO, 2Á‰»Ší“à, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ111‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/12/19), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110018. [Œ´’˜] Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Yasufuku I, Nunobe S, Ida S, Kumagai K, Manabu Ohashi M1, Hiki N1, Sano T: Gastric Cancer 2020/3; 23 (2): 319-27. (”äŠé’¼Ž÷1: 1ã•”Á‰»ŠÇŠO)

[’˜@‘]

'19-620008. [Šwp‘ (•ª’SŽ·•M)]y—ߘaƒXƒ^ƒCƒ‹ ‹¾Ž‹‰ºˆÝŽèp‚Ì‚·‚ׂāz˜•¶, p.iii. ‘˜_: • o‹¾‰ºŽèp‚ŏoŒŒ‚³‚¹‚È‚¢ƒRƒc, p.2-6. ƒRƒ‰ƒ€: —H–剺“®Ã–¬ŽüˆÍ‚ÌŠs´‚ðŠÈ’P‚É‚·‚éV‚µ‚¢No.6 Šs´, p.92-9. ”äŠé’¼Ž÷ (ã•”Á‰»ŠÇŠO), •Ò: ”äŠé’¼Ž÷, •zŽ{‘n–ç, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/12”­s.

'19-620009. [Šwp‘ (•ª’SŽ·•M)]y—ߘaƒXƒ^ƒCƒ‹ ‹¾Ž‹‰ºˆÝŽèp‚Ì‚·‚ׂāzƒRƒ‰ƒ€: ƒƒ{ƒbƒgŽèp‚Í–{“–‚ɍ‡•¹Ç‚ðŒyŒ¸‚·‚é‚©?, p.157-9. ×“c@Œj (ã•”Á‰»ŠÇŠO), •Ò: ”äŠé’¼Ž÷, •zŽ{‘n–ç, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/12”­s.

'19-620010. [Šwp‘ (•ª’SŽ·•M)]yÁ‰»ŠíŠO‰Èê–åˆã‚̐S“¾ ãŠªz1. Á‰»ŠíŠO‰ÈŠw‘˜_@2. ‰h—{‚Æ‘ãŽÓ@4. ‰h—{ŠÇ—@ŽüpŠú‚̉h—{ŠÇ—, p.12-6. ”äŠé’¼Ž÷ (ã•”Á‰»ŠÇŠO), ˆê”ÊŽÐ’c–@l “ú–{Á‰»ŠíŠO‰ÈŠw‰ï “Œ‹ž, 2020/2”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

'19-723019. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ª‚ñ‰»Šw—Ö@E•úŽËü—Ö@‚É‚¨‚¯‚é‰h—{ŽxŽ—Ö@‚Ì–ðŠ„@ã•”Á‰»ŠÇŽèpŒã‚̉h—{ŽxŽ—Ö@. VŒ´³‘å1, ×“c@Œj1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰ºŒpŽj1,2, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ35‰ñ“ú–{—Տ°‰h—{‘ãŽÓŠw‰ïŠwpW‰ï (2020/2/27), ŽãŠJÃ.

'19-723020. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝØœpŒã‚Ì‘Šú‰h—{‚¨‚æ‚щ^“®‰î“ü‚ÌŒø‰Ê. ˆä“c@’q, ŒF’JŒúŽu, ¼”öG”ü, •z•”‘n–ç, ”äŠé’¼Ž÷1 (1ã•”Á‰»ŠÇŠO): ‘æ35‰ñ“ú–{—Տ°‰h—{‘ãŽÓŠw‰ïŠwpW‰ï (2020/2/27), ŽãŠJÃ.


‰º•”Á‰»ŠÇŠO‰ÈŠw

[Šwp˜_•¶]

110239. [Œ´’˜] The Function and Prognostic Significance of Cripto-1 in Colorectal Cancer. Sato J, Karasawa H, Suzuki T, Nakayama S, Katagiri M, Maeda S, Ohnuma S, Motoi F, Naitoh T1, Unno M: Cancer Invest 2020/4; 38 (4): 214-27. (“à“¡@„1: 1‰º•”Á‰»ŠÇŠO)

110240. [Œ´’˜] Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. Maeda S, Ariake K, Iseki M, Ohtsuka H, Mizuma M, Nakagawa K, Morikawa T, Hayashi H, Motoi F, Kamei T, Naitoh T1, Unno M: Surg Today 2020/5; 50 (5): 490-8. (“à“¡@„1: 1‰º•”Á‰»ŠÇŠO)

110241. [Œ´’˜] Mechanism of Bile Acid Reabsorption in the Biliopancreatic Limb After Duodenal-Jejunal Bypass in Rats. Ueno T, Tanaka N, Imoto H, Maekawa M, Kohyama A, Watanabe K, Motoi F, Kamei T, Unno M, Naitoh T1: Obes Surg 2020/7; 30 (7): 2528-37. (“à“¡@„1: 1‰º•”Á‰»ŠÇŠO)

110242. [Œ´’˜] Influence of chemoradiotherapy on nutritional status in locally advanced rectal cancer: Prospective multicenter study. Yamano T, Tomita N, Sato T1, Hayakawa K, Kamikonya N, Matoba S, Uki A, Baba H, Oya N, Hasegawa H, Shigematsu N, Hiraoka M, Shimada M, Noda M, Sakai Y, Sato H, Saegusa M2, Takeuchi M, Oguchi M, Oya M, Watanabe M1,3: Nutrition 2020/9; 77: 110807. (²“¡•˜Y1, ŽOŽ}@M2, “n粏¹•F1,3: 1‰º•”Á‰»ŠÇŠO, 2•a—, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

110243. [Œ´’˜] Current status of laparoscopic bariatric/metabolic surgery in Japan: The sixth nationwide survey by the Japan Consortium of Obesity and Metabolic Surgery. Ohta M1, Kasama K1, Sasaki A1, Naitoh T1,2, Seki Y1, Inamine S1, Oshiro T1, Doki Y1, Seto Y1, Hayashi H1, Uyama I1, Takiguchi S1, Kojima K1, Mori T1, Inomata M1, Kitagawa Y1, Kitano S1 (1Japan Consortium of Obesity and Metabolic Surgery (JCOMS)): Asian J Endosc Surg 2021/4; 14 (2): 170-7. doi: 10.1111/ases.12836. Epub 2020 Jul 21. (“à“¡@„1,2: 2‰º•”Á‰»ŠÇŠO)

320006. [Ç—á•ñ] äXŠà‰»Šw—Ö@’†‚Éè÷—±‹…ƒRƒƒj[ŽhŒƒˆöŽq»Ü‚É‚æ‚é‘å“®–¬‰Š‚𔭏ǂµ‚½1—á. ‹{èŒ’l, ‚ŠÚ’B”V, Œ³ˆä“~•F, ‹Tˆä@®, “à“¡@„1, ŠC–ì—Ï–¾ (1‰º•”Á‰»ŠÇŠO): Šà‚Ɖ»Šw—Ö@ 2020/5; 47 (5): 851-3.

320007. [Ç—á•ñ] ‹ÇŠ‰º•”is’¼’°Šà‚ɑ΂µp‘O‰»Šw•úŽËü—Ö@‚ÅcCR ‚Æ‚È‚è’·ŠúWatch and Wait‚Ì1—á. ¬›¸Œc‘¾1, ’†‘º—²r1, ²“¡•˜Y1, “n粏¹•F2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): Šà‚Ɖ»Šw—Ö@ 2020/8; 47 (8): 1241-13.

320008. [Ç—á•ñ] ‚“x”ì–ž‚ð‡•¹‚µ‚½SóŒ‹’°ŠàäNã÷ZÇ—á‚ɑ΂µ‰»Šw—Ö@EŒ¸—ʌ㍪Ž¡Øœ‚µ“¾‚½1—á. “cŽR•ä‚, “‚àVG–¾, ŠŒ´‘å‹P, —é–؏GK, ŽR‘º–¾Š°, _ŽR“ÄŽj, “n•Ó˜aG, ‘åÀ@”E, ‹Tˆä@®, “à“¡@„1, ŠC–ì—Ï–¾ (1‰º•”Á‰»ŠÇŠO): Šà‚Ɖ»Šw—Ö@ 2020/12; 47 (13): 2320-2.

320009. [Ç—á•ñ] • •”‘å“®–¬áŽƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}pŒã‚É• o‹¾‰º’¼’°Øœp‚ðŽ{s‚µ‚½ˆê—á. ¬›¸Œc‘¾1, ‰HœAŒ’m2, ŽO‰YŒ[šæ1, ‰Ÿ“c¬•S‡3, ˜m’J”ü“Þ3, —с@‹žŽq3, ’†‘º—²r1, “à“¡@„1, ÎˆäŒ’ˆê˜Y2 (1‰º•”Á‰»ŠÇŠO, 2‘Š–Í–ì•a‰@, 3“û‘BEbó‘BŠO): –k—¢ˆãŠw 2020/12; 50 (2): 125-8.

521007. [‰ðà]y‰ðà4zcolitic cancer. ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, ‰¡ˆäŒ\Œå1, “c’†r“¹1, ”‹Œ´çŒb1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): Á‰»ŠíŠO‰È 2020/7; 43 (8): 1277-80.

522055. [uÀ]y˜AÚ: Ž„‚ÌŽ¡—Ázis‘å’°Šà. Îˆä—ǍK1,2, “n粏¹•F2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): “ú–{ˆãŽ–V•ñ 2020/4; 5007: 39.

522056. [uÀ]y“ÁW: ŽÀ‘H! Žèp‚ªã’B‚·‚éƒgƒŒ[ƒjƒ“ƒO–@|Off the Job Training‚̍ŐV“®Œüz¡Žèp‚̘r‚𖁂­‚½‚ß‚É•K—v‚ȃrƒfƒI‰æ‘œ‚É‚æ‚éŠwK@Žèp“®‰æ‚Ì•Û‘¶ƒVƒXƒeƒ€: “®‰æ‚̉掿‚Æ•Û‘¶•û–@,ŒÂlî•ñ•ÛŒì‚ÌŠÏ“_‚©‚ç. “à“¡@„ (‰º•”Á‰»ŠÇŠO): —Տ°ŠO‰È 2020/4; 75 (4): 397-401.

522057. [uÀ]y“ÁW: “àŽ‹‹¾ŠO‰ÈŽèp‚É•K—v‚ȋǏŠ‰ð–U|Œ‹’°E’¼’°z• o‹¾‰ºŒ‹’°‰E”¼Øœp‚É•K—v‚ȋǏŠ‰ð–U. ŒÃé@Œ›1, ²“¡•˜Y1, ŽO‰YŒ[šæ1, ‰¡ˆäŒ\Œá1, “c’†r“¹1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): Žèp 2020/12; 74 (13): 1805-13.

522058. [uÀ]y“ÁW: ŠÌ“à’_ŠÇŠà‚ð‹É‚ß‚ézII. ŠÌ“à’_ŠÇŠà‚̗Տ°@ŠÌ“à’_ŠÇŠà‚ÌŠO‰È“IŽ¡—Á|Øœ‰Â”\«‚©‚玡–ü‰Â”\«‚Ö: ãk–§‚ÈŽèpí—ª‚Ætransplant oncology‚ª‚à‚½‚ç‚·ƒpƒ‰ƒ_ƒCƒ€ƒVƒtƒg|. ’|‘º—T‰î1, ˆ¢•”—Y‘¾, Îˆä—ǍK1,2, “n粏¹•F1, “ú”ä‘ב¢ (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO): ŠÌ’_äX 2021/2; 82 (2): 215-23.

[’˜@‘]

620044. [Šwp‘ (•ª’SŽ·•M)]yp‘OEpŒãŠÇ—•KŒg2020 (Á‰»ŠíŠO‰È2020”N4ŒŽ‘Š§†)zIII. pŽ®•Êp‘OEpŒãŠÇ—@3. ¬’°E‘å’°@5) ‘å’°Šà’°•ÂÇ, p.651-5. —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, “n粏¹•F1 (1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO), ‚Ö‚é‚·o”Å, “Œ‹ž, 2020/4”­s.

620045. [Šwp‘ (•ª’SŽ·•M)]y•Êû“ú–{—Õଠ—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY No.12@Á‰»ŠÇÇŒóŒQ (‘æ3”Å) IV|‚»‚Ì‘¼‚̏Á‰»ŠÇŽ¾Š³‚ðŠÜ‚߂ā|z3. ’°•ÂÇ@(2) –ü’…«’°•ÂÇ, p.304-10. Îˆä—ǍK1,2, —Ž‡‘åŽ÷2, ”—@—T”V2, “n粏¹•F2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@), “ú–{—Õ଎Ð, “Œ‹ž, 2020/5”­s.

620046. [Šwp‘ (•ª’SŽ·•M)]y‘å’°ŠO‰ÈŽèp‚É‚¨‚¯‚éƒgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO (Žèp2020”N7ŒŽ‘‘卆)zI. p’†oŒŒ@6) • o‹¾‰º’¼’°ŠàŽèp‚É‚¨‚¯‚ép’†oŒŒ‚Ì—\–h‚ƑΏˆ–@, p.1113-20. Îˆä—ǍK1,2, —Ž‡‘åŽ÷2, ”—@—T”V2, “n粏¹•F2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@), ‹àŒ´o”Å, “Œ‹ž, 2020/7”­s.

620047. [Šwp‘ (•ª’SŽ·•M)]y‘å’°ŠO‰ÈŽèp‚É‚¨‚¯‚éƒgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO (Žèp2020”N7ŒŽ‘‘卆)zIII. Á‰»ŠÇ–D‡E•«‡@1) –D‡•s‘S‚ð–h‚®Žè–D‚¢•«‡‚̍H•v‚ƃgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO, p.1185-90. “à“¡@„1, ²“¡•˜Y1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, ‰¡ˆäŒ\Œå1, “c’†r“¹1 (1‰º•”Á‰»ŠÇŠO), ‹àŒ´o”Å, “Œ‹ž, 2020/7”­s.

620048. [Šwp‘ (•ª’SŽ·•M)]y”ì–žÇŠO‰ÈŽ¡—Â̍őOü (BIO Clinica 2020”N11ŒŽ—ÕŽž‘Š§†)zŒ¸—ʁE‘ãŽÓ‰ü‘PŽèp‚Ì•ªŽq‹@\|Á‰»ŠÇ‚É‚æ‚é“œ‘ãŽÓ§Œä|, p.1224-8. “à“¡@„ (‰º•”Á‰»ŠÇŠO), –k—²ŠÙ, “Œ‹ž, 2020/10”­s.

620049. [Šwp‘ (•ª’SŽ·•M)]y‘‚í‚©‚è–D‡E•«‡‚Ì‚·‚×‚Ä (—Տ°ŠO‰È2020”N10ŒŽ‘Š§†)z1Í –D‡E•«‡–@‚ÌŠî–{@Œ‹ãF (Ž…Œ‹‚Ñ) ‚Ì•û–@@“àŽ‹‹¾‰º, p.28-31. “à“¡@„1, ‹‹vGŽ÷2, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, “c’†r“¹1, ŽO‰YŒ[šæ1, “c“‡@O3, ŽR—œ‚L1, ²“¡•˜Y1, ŠC’ËMŽj3, ×“c@Œj2, ŽR‰ºŒpŽj2,4, ŒGŒ³—Y‰î3, ”äŠé’¼Ž÷ (1‰º•”Á‰»ŠÇ, 2ã•”Á‰»ŠÇŠO, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã), ˆãŠw‘‰@, “Œ‹ž, 2020/10”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713035. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Laparoscopic right colectomy with co-axial port setting. Naitoh T1: Elsa 2020 Virtual Congress (2020/9/11), WebŠJÃ. (“à“¡@„1: 1‰º•”Á‰»ŠÇŠO)

722060. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‘ãŽÓ‰ü‘PŽèp‚Æ‚µ‚Ă̏Á‰»ŠÇƒoƒCƒpƒX•t‰ÁŽèp“±“ü‚É‚¨‚¯‚é‰Û‘è. “à“¡@„1, “c’†’¼Ž÷1, ˆä–{”Ž•¶, ‹‹vGŽ÷2, VŒ´³‘å2, ˜h”ö^—ˆ¤2, ‰¡ˆäŒ\Œå1, “c’†r“¹1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, ×“c@Œj2, ŽR‰ºŒpŽj2,3, ”äŠé’¼Ž÷2 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722061. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ”ì–ž2Œ^“œ”A•aŠ³ŽÒ‚ɑ΂·‚錸—ʁE‘ãŽÓ‰ü‘PŽèp‚ÌŠ°‰ð—\‘ªˆöŽq‚ÌŒŸØ “à“¡@„1, Š}ŠÔ˜a“T, ˆîŠ_’¨–ç, “¡‘qƒ“ñ, ¬ì@Â, œA“c—EŽm, ‘¾“c³”V, ¬ŽR‰p‘¥, ‰K–؁@’q, ŽRŒû@’ (1‰º•”Á‰»ŠÇŠO): ‘æ41‰ñ“ú–{”ì–žŠw‰ïE‘æ38‰ñ“ú–{”ì–žÇŽ¡—Êw‰ïŠwpW‰ï (2021/3/21), WebŠJÃ.

723272. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰»Šw—Ö@‚É‚æ‚èŠÌ“]ˆÚ‚ªÁŽ¸‚µ’·Šú¶‘¶‚𓾂½’¼’°Šà“¯Žž«‘½”­ŠÌ“]ˆÚ‚Ì1—á. ”‹Œ´çŒb1, ’†‘º—²r1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ²“¡•˜Y1 (1‰º•”Á‰»ŠÇŠO): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13), WebŠJÃ.

723273. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) BMI‚ÍŒ‹’°ŠàŽèp‚Ì’ZŠú¬Ñ‚ŃŠƒXƒNˆöŽq‚ɂȂ蓾‚é‚©. ‰¡ˆäŒ\Œå1, ’†‘º—²r1, ”‹Œ´çŒb1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1 (1‰º•”Á‰»ŠÇŠO): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/14), WebŠJÃ.

723274. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ÇŠis’¼’°Šà‚ɑ΂·‚ép‘O‰»Šw•úŽËüŽ¡—ÃŒã‚ÌWatch-and-wait approach‚ÆSalvageŽèp. ŒÃé@Œ›1, ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ‰¡ˆäŒ\Œå1, ”‹Œ´çŒb1 (1‰º•”Á‰»ŠÇŠO): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/14), WebŠJÃ.

723275. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ÇŠis’¼’°Šà‚ɑ΂·‚é•úŽËüŠ´Žó«‚𑝋­‚·‚éTS-1‚ð—p‚¢‚½Ž¡—Ð헪‚Ì’·Šú—\Œã. ’†‘º—²r1, ²“¡•˜Y1, “n粏¹•F2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/14), WebŠJÃ.

723276. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠàŽèp‚É‚¨‚¯‚éƒTƒ‹ƒRƒyƒjƒA‚Æ—\Œã‚Æ‚ÌŒŸ“¢. ”—@—T”V1, ‘åì¹‹`1, –k@‰p“T1, ‘O“c“úØŽq1, ‰J‹{—²‰î1, —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, _’J‹I‹P1,3, ŒÜŒŽ—Œbˆê1, ‹e’rŽj˜Y1,4, “n粏¹•F1 (1–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO, 4•a‰@˜AŒg‹³ˆç): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13-15), WebŠJÃ.

723277. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚¨‚¯‚é‹}«’Ž‚‰Š‚ÌŽ¡—Ð헪. ‰J‹{—²‰î1, Îˆä—ǍK1,2, –k@‰p“T1, ‘O“c“úØŽq1, ”—@—T”V1, —Ž‡‘åŽ÷1, ŒÜŒŽ—Œbˆê1, _’J‹I‹P1,3, “n粏¹•F1 (1–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13-15), WebŠJÃ.

723278. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ûŠà¶ŒŸ‘gD‚Ɛ؏œ•W–{‚É‚¨‚¯‚é•a—‘gDŠw“IˆöŽq‚̈ê’v‚ÌŒŸ“¢. ŒÜŒŽ—Œbˆê1, ‘O“c“úØŽq1, ’r“c@³1, –öàV‹MŽq1, –k@‰p“T1, ‰J‹{—²‰î1, ”—@—T”V1, —Ž‡‘åŽ÷1, ‘åì¹‹`1, _’J‹I‹P1,2, Îˆä—ǍK1,3, ‘å•”@½1, ‘O“cˆê˜Y1, “n粏¹•F1 (1–k—¢Œ¤‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰º•”Á‰»ŠÇŠO): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13-15), WebŠJÃ.

723279. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚éHER2—z«“ûŠà‚ÌŽ¡—ЬÑ‚©‚ç‚Ý‚½ŽüpŠúPertuzumab‚Ì“K‰ž‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘O“c“úØŽq1, ’r“c@³1, –k@‰p“T1, ‰J‹{—²‰î1, –öàV‹MŽq1, ”—@—T”V1, —Ž‡‘åŽ÷1, _’J‹I‹P1,2, ŒÜŒŽ—Œbˆê1, ‘åì¹‹`1, Îˆä—ǍK1,3, “n粏¹•F1, ‘å•”@½1, ‘O“cˆê˜Y1,4 (1–k—¢Œ¤‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰º•”Á‰»ŠÇŠO, 4•a—): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13-15), WebŠJÃ.

723280. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHãè–å‘¢Ýp‚ª—LŒø‚¾‚Á‚½–«‹]µ’°•ÂÇ‚̈ê—á. ¬›¸Œc‘¾, ”‹Œ´çŒb1, ²“¡•˜Y1, ’†‘º—²r1 (1‰º•”Á‰»ŠÇŠO): ‘æ56‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2020/10/8), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723281. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã’°•ÂÇ‚ɑ΂µ‚Ä• o‹¾‰ºŽèp‚Í—L—p‚©@ŠJ• ˆÚsÇ—á‚ÌŒŸ“¢. ’†‘º—²r1, ²“¡•˜Y1, ”‹Œ´çŒb1, “n粏¹•F2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ56‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2020/10/8), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723282. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “û“ª‰·‘¶“û–[Øœp+Ž‰–b’“üÄŒšŒã‚ɍĔ­‚ð‚«‚½‚µ‚½1Ç—á. “¡–ìŽjD1, åU•À@Ÿ, ’†‹{‹IŽq, ’|‰º—˜•v, ‰ª–{@—¤1, …–ì–œ—¢, ‘åò—z‰î, “c’†r“¹1, ª–{¹”V, ¬‘q’¼l1 (1‰º•”Á‰»ŠÇŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723283. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ûŠà‚É‚¨‚¯‚éKi67‚̗Տ°•a—Šw“IˆöŽq‚Æ‚ÌŠÖŒW, —\ŒãˆöŽq‚Æ‚µ‚Ă̏d—v«. ŒÜŒŽ—Œbˆê1, ‘O“c“úØŽq1, –öàV‹MŽq1, –k@‰p“T1, ‰J‹{—²‰î1, —Ž‡‘åŽ÷1, ”—@—T”V1, ‘åì¹‹`1, _’J‹I‹P1,2, Îˆä—ǍK1,3, óÀŽjŽ÷1, “n粏¹•F1, ‘O“cˆê˜Y1,4, ’r“c@³1 (1–k—¢Œ¤‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰º•”Á‰»ŠÇŠO, 4•a—): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/9-31), WebŠJÃ.

723284. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) f’f‚É‹ê—¶‚µ‚½‰ºsŒ‹’°Šà’°•ÂÇ‚ÌŒoŒ±. —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, ”—@—T”V1, ‰J‹{—²‰î1, ‘O“c“úØŽq1, –k@‰p“T1, ŒÜŒŽ—Œbˆê1, ‘åì¹‹`1, _’J‹I‹P1,3, “n粏¹•F1 (1–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ56‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2020/10/8-11/2), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723285. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –T_ŒoßŽîᇂƂ̊ӕʂɓïa‚µ‚½¬’°_Œo“à•ª”åŽîᇠ(NET) ‚̈ê—á. ‚‹´@–G1, ŒÃé@Œ›1, ‰¡ˆäŒ\Œå1, “c’†r“¹1, ŽO‰YŒ[šæ1, ²“¡•˜Y1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723286. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ÇŠis’¼’°‚ª‚ñ‚ɑ΂µ‚ďp‘O‰»Šw•úŽËüŽ¡—ÃŒã‚ÌWatch-and wait approach‚Æ‚µ‚½ŒoŒ±. —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, ”—@—T”V1, ‰J‹{—²‰î1, ‘O“c“úØŽq1, ¬‹Ë‰ë¢1, “n粏¹•F1 (1–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO): ‘æ75‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2020/11/13-14), WebŠJÃ.

723287. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Še‰È‚É‚¨‚¯‚郍ƒ{ƒbƒgŽx‰‡‰ºŽèp‚̍H•v: ’¼’°Šà‚ɑ΂·‚é• o‹¾‰ºŽèp‚ƃƒ{ƒbƒgŽx‰‡‰ºŽèp‚Ì”äŠrŒŸ“¢. ŽO‰YŒ[šæ1, ²“¡•˜Y1, “c’†r“¹1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ×“c@Œj2, ŽR‰ºŒpŽj2,3, “c’†@Œ‰4,5, ŽOŠK‹MŽj6, ŒGŒ³—Y‰î5, ”äŠé’¼Ž÷2, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 6“û‘BEbó‘BŠO): ‘æ58‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2020/10/22), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723288. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Stage III‘å’°Šà‚É‚¨‚¯‚éCT‚ð—p‚¢‚½œŠi‹Ø—Ê‘ª’è‚É‚æ‚é’ZŠú‹y‚Ñ’·Šú—\Œã‚Ì—\‘ª. ‰¡ˆäŒ\Œå1, “c’†r“¹1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ‰Á“¡@O2, ŠC’ËMŽj3, ²“¡•˜Y1, ×“c@Œj4, ŽR‰ºŒpŽj4,5, “c’†@Œ‰3,6, ŽOŠK‹MŽj2, ŒGŒ³—Y‰î3, ”äŠé’¼Ž÷4, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO, 2“û‘BEbó‘BŠO, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4ã•”Á‰»ŠÇŠO, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 6V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ58‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2020/10/22), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723289. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å’°Šà‚É‚¨‚¯‚ép‘OCT‚ð—p‚¢‚½œŠi‹Ø—Ê‘ª’è‚É‚æ‚é’ZŠú‹y‚Ñ’·Šú—\Œã‚Ì—\‘ª. ‰¡ˆäŒ\Œå1, “c’†r“¹1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, ×“c@Œj2, ŽR‰ºŒpŽj2,3, “c’†@Œ‰4,5, ŽOŠK‹MŽj6, ŒGŒ³—Y‰î5, ”äŠé’¼Ž÷2, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 6“û‘BEbó‘BŠO): ‘æ82‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2020/10/29), WebŠJÃ.

723290. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ÇŠis’¼’°Šà‚ɑ΂·‚ép‘O‰»Šw•úŽËüŽ¡—ÃŒã‚ÌWatch-and-wait approach‚̉”\«‚Æ–â‘è“_. ŒÃé@Œ›1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ‰¡ˆäŒ\Œå1, “c’†r“¹1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ75‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2020/11/13), WebŠJÃ.

723291. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) is‰¡sŒ‹’°Šà‚ɑ΂·‚é• o‹¾‰ºŽèp‚Ì’ZŠú‹y‚Ñ’·Šú¬Ñ. ŽO‰YŒ[šæ1, ŒÃé@Œ›1, ‰¡ˆäŒ\Œå1, “c’†r“¹1, ²“¡•˜Y1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ75‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2020/11/13), WebŠJÃ.

723292. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚éãsŒ‹’°Šà‚ɑ΂·‚épŽ®‚ÌŒŸ“¢. ‰¡ˆäŒ\Œå1, “à“¡@„1, ²“¡•˜Y1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “c’†r“¹1 (1‰º•”Á‰»ŠÇŠO): ‘æ75‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2020/11/13), WebŠJÃ.

723293. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) is’¼’°Šà‚ɑ΂·‚鉻Šw•úŽËüŽ¡—ÃŒã‚ÌWatch-and-wait approach‚É‚¨‚¯‚éClinical complete response‚Ì”»’è. ŒÃé@Œ›1, ”‹Œ´çŒb1, ‰¡ˆäŒ\Œå1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, ’†‘º—²r1 (1‰º•”Á‰»ŠÇŠO): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723294. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹¾‰ºŒ‹’°Šà‚É‚¨‚¯‚éBMI‚Ì’ZŠú¬Ñ‚ɑ΂·‚é‰e‹¿‚ÌŒŸ“¢. ‰¡ˆäŒ\Œå1, ’†‘º—²r1, ”‹Œ´çŒb1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ²“¡•˜Y1 (1‰º•”Á‰»ŠÇŠO): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723295. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚Ì’¼’°Šà‚ɑ΂·‚郍ƒ{ƒbƒgŽx‰‡‰ºŽèp. ŽO‰YŒ[šæ1, ’†‘º—²r1, ”‹Œ´çŒb1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ²“¡•˜Y1, “à“¡@„1, “n粏¹•F2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723296. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •úŽËüŽ¡—ÃŒã7”N–Ú‚É’°•ÂÇ‚ðŒ_‹@‚ɐf’f‚³‚ꂽ•úŽË«¬’°‰Š‚Ì1—á. –k@‰p“T1, —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, ‰J‹{—²‰î1, ”—@—T”V1, ‘O“c“úØŽq1, ‘åì¹‹`1, ŒÜŒŽ—Œbˆê1, _’J‹I‹P1,3, “n粏¹•F1 (1–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723297. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) p‘O‹Ø“÷—Ê‚ªpŒã•â•‰»Šw—Ö@‚É‹y‚Ú‚·‰e‹¿. ”—@—T”V1, ‘åì¹‹`1, –k@‰p“T1, ‘O“c“úØŽq1, ‰J‹{—²‰î1, —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, _’J‹I‹P1,3, ŒÜŒŽ—Œbˆê1, “n粏¹•F1 (1–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2020/12/15-17), ˜a‰ÌŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723298. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å’°ŠàŠÌ“]ˆÚ‚É‚æ‚é’_“¹oŒŒ‚ɑ΂µ“àŽ‹‹¾, •úŽËüŽ¡—Âɂæ‚è‹~–½‚µ“¾‚½1—á. ‰ª@‘׏B1, ’|‘º—T‰î1, Îˆä—ǍK1,2, ”—@—T”V1, —Ž‡‘åŽ÷1, “n粏¹•F1 (1–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO): ‘æ57‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2021/3/11-12), WebŠJÃ.

723299. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹¾‰ºŽèp‚©‚烍ƒ{ƒbƒgŽx‰‡‰º• o‹¾‰ºŽèp‚ց|’¼’°Šà ŽèpŽè‹Z‚̃Cƒmƒx[ƒVƒ‡ƒ“|. ŽR—œ‚L1, ²“¡•˜Y1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, ‰¡ˆäŒ\Œå1, “c’†r“¹1, ×“c@Œj2, ŠC’ËMŽj3, åÎ‹I•F4, ŽR‰ºŒpŽj2,5, “c’†@Œ‰3,6, ”äŠé’¼Ž÷2, ŒGŒ³—Y‰î3, ŽOŠK‹MŽj4, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO, 2ã•”Á‰»ŠÇŠO, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4“û‘BEbó‘BŠO, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 6V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723300. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Safety and validity of laparoscopic surgery after NCRT for advanced lower rectal cancer. ŒÃé@Œ›1, ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ‰¡ˆäŒ\Œå1, “c’†r“¹1, ”‹Œ´çŒb1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723301. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Surgical and Survival Outcomes of Surgery Alone for pT3-T4 Rectal Cancer. ”‹Œ´çŒb1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ²“¡•˜Y1, ’†‘º—²r1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723302. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) The analysis of short- and long-term prognosis in laparoscopic right-side colectomy in our hospital. ‰¡ˆäŒ\Œå1, ”‹Œ´çŒb1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ²“¡•˜Y1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/12), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723303. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ÇŠis‰º•”’¼’°Šà‚ɑ΂·‚ép‘O‰»Šw•úŽËü—Ö@Œã‚Ì• o‹¾/ƒƒ{ƒbƒgŽx‰‡‰ºŽèp‚Ì—L—p«. ²“¡•˜Y1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, “c’†r“¹1, ‰¡ˆäŒ\Œå1, ŽR—œ‚L1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/12), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723304. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Evaluation of outlet obstruction after ileostomy in our hospital. b”ã“c•Žu1, ŒÃé@Œ›2, Œã“¡‘ì–ç1, ”‹Œ´çŒb2, ‰¡ˆäŒ\Œå2, “c’†r“¹2, ŽO‰YŒ[šæ2, ŽR—œ‚L2, ²“¡•˜Y2, ’†‘º—²r2, “à“¡@„2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‰º•”Á‰»ŠÇŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10-13), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723305. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) The impact of body mass index on short-term outcome in laparoscopic colectomy. Œã“¡‘ì–ç1, ‰¡ˆäŒ\Œå2, ”‹Œ´çŒb2, ŒÃé@Œ›2, ŽO‰YŒ[šæ2, ²“¡•˜Y2, “à“¡@„2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‰º•”Á‰»ŠÇŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10-13), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723306. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A case of cCR after preoperative chemoradiotherapy for rectal cancer with watch and wait approach. ¬›¸Œc‘¾, ’†‘º—²r1, ²“¡•˜Y1, “n粏¹•F2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10-13), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723307. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ischemic necrosis of colorectal anastomosis at oral side after RALS-LAR. “n•”WŽq1, ²“¡•˜Y1, ”‹Œ´çŒb1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ’†‘º—²r1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10-13), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723308. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Rectal Cancer who Received TS1, which Enhances Radiosensitivity. ’†‘º—²r1, ²“¡•˜Y1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10-13), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723309. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Verification of the safety of robot-assisted laparoscopic surgery for rectal cancer. ŽO‰YŒ[šæ1, ²“¡•˜Y1, ”‹Œ´çŒb1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ’†‘º—²r1, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): ‘æ33‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (JSES 2020) (2021/3/10-13), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

733060. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Œ‹’°ŒeŽº‹ß–T‚É‚Å‚«‚½•a•Ï‚ɑ΂·‚é“àŽ‹‹¾Ž¡ŒoŒ±. —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, ”—@—T”V1, ‘O“c“úØŽq1, ’|‘º—T‰î1, ŒÜŒŽ—Œbˆê1, _’J‹I‹P1,3, í¼@—ß1, ¼‘º@Œ«1,4, ’†–ì@‰ë1, “n粏¹•F1 (1–k—¢Œ¤‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO, 4Á‰»Ší“à): ‘æ111‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ï (2020/12/19-20), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-320001. [Ç—á•ñ] Œã• –ŒŽîᇐ؏œŒã’ōœ“®–¬áŽ”j—ô‚É‚æ‚é‹C“¹•ÂÇ‚©‚çS”x’âŽ~‚ð‚«‚½‚µ‚½_ŒoüˆÛŽîÇIŒ^‚Ì1‹~–½—á. ŽO‰YF”V, …ŠÔ³“¹, Œ³ˆä“~•F, “à“¡@„1, ‹Tˆä@ ®, ‚£@Œ\, ŠC–ì—Ï–¾ (1‰º•”Á‰»ŠÇŠO): Japanese Journal of Acute Care Surgery 2019; 9 (2): 254-7.

'19-320002. [Ç—á•ñ] ‹~–½‚µ“¾‚¸–UŒŸ‚ÅCMVŠ´õ‚ª”»–¾‚µ‚½‘½”­¬’°’×ᇂÌ1—á. ˆä–{”Ž•¶, “c’†’¼Ž÷, •ŽÒGº, ‘åÀ@”E, Œ³ˆä“~•F, “à“¡@„1, ‹Tˆä@®, ŠC–ì—Ï–¾ (1‰º•”Á‰»ŠÇŠO): Japanese Journal of Acute Care Surgery 2019; 9 (2): 272-6.


S‘ŸŒŒŠÇŠO‰ÈŠw

[Šwp˜_•¶]

110244. [Œ´’˜] Preoperative skeletal muscle density is associated with postoperative mortality in patients with cardiovascular disease. Yamashita M1, Kamiya K2, Matsunaga A2, Kitamura T3, Hamazaki N4, Matsuzawa R, Nozaki K4, Ichikawa T4, Nakamura T1, Yamamoto S1, Kariya H4, Maekawa E5, Meguro K5, Ogura M2, Yamaoka-Tojo M2, Ako J5, Miyaji K3: Interact Cardiovasc Thorac Surg 2020/4; 30 (4): 515-22. (ŽR‰º^Ži1, _’JŒ’‘¾˜Y2, ¼‰i“Ä•F2, –k‘º@—¥3, à_èL–¾4, –ìèN•½4, Žsì‹M•¶4, ’†‘ºŠxŽj1, ŽR–{®•½1, Š¡’J‰p‹I4, ‘OìŒb”ü5, –ڍ•Œ’‘¾˜Y5, ¬‘q@Ê2, “ŒžŠ”ü“ÞŽq2, ˆ¢ŒÃÆ5, ‹{’n@ŠÓ3: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3S‘ŸŒŒŠÇŠO, 4ƒŠƒnƒrƒŠ•”, 5zŠÂŠí“à)

110245. [Œ´’˜] Risk Factors for Progression of Distal Deep Vein Thrombosis. Fujioka S1, Ohkubo H1, Kitamura T1, Mishima T1, Onishi Y1, Tadokoro Y1, Araki H1, Matsushiro T1, Yakuwa K1, Miyamoto T1, Torii S1,2, Miyaji K1: Circ J 2020/9; 84 (10): 1862-5. (“¡‰ªrˆê˜Y1, ‘å‹v•Û”Ž¢1, –k‘º@—¥1, ”ü“‡—˜º1, ‘吼‹`•F1, “cŠ—S‹I1, r‹Lt“Þ1, ¼‘ã‘ì–ç1, ”ªŒLˆê‹M1, ‹{–{—²Ži1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç)

110246. [Œ´’˜] Risk Factors for Mid-Term Liver Disease After the Fontan Procedure. Oka N1, Miyamoto T1, Tomoyasu T1, Hayashi H1, Miyaji K1: Int Heart J 2020/9; 61 (5): 979-83. (‰ª@“¿•F1, ‹{–{—²Ži1, —F•Û‹M”Ž1, —с@GŒ›1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

110247. [Œ´’˜] Watch-and-wait strategy for type A intramural haematoma and acute aortic dissection with thrombosed false lumen of the ascending aorta: a Japanese single-centre experience. Kitamura T1, Torii S1,2, Miyamoto T1, Mishima T1, Ohkubo H1, Fujioka S1, Yakuwa K1, Araki H1, Kondo S, Tamura Y1, Tadokoro Y1, Onishi Y1, Miyaji K1: Eur J Cardiothorac Surg 2020/9; 58 (3): 590-7. (–k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, “c‘º‰À”ü1, “cŠ—S‹I1, ‘吼‹`•F1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç)

110248. [Œ´’˜] Regional thigh tissue oxygen saturation during cardiopulmonary bypass predicts acute kidney injury after cardiac surgery. Sakaki K, Kitamura T1, Kohira S2, Torii S1,3, Mishima T1, Hanayama N1, Kobayashi K1, Ohkubo H1, Miyaji K1: J Artif Organs 2020/12; 23 (4): 315-20. (–k‘º@—¥1, ¬•½@‘2, ’¹ˆäWŽO1,3, ”ü“‡—˜º1, ‰ØŽR’¼“ñ1, ¬—ÑŒ’‰î1, ‘å‹v•Û”Ž¢1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—Éq¶Šw•”, 3’nˆæˆã—˳ˆç)

110249. [Œ´’˜] Gluteal Blood Flow Monitoring in Endovascular Aneurysm Repair With Internal Iliac Artery Embolization. Fujioka S1, Kitamura T1, Mishima T1, Nakajima R1, Tamura Y1, Horikoshi R1, Araki H1, Yakuwa K1, Tomoyasu T1, Okamura T1, Miyamoto T1, Torii S1,2, Miyaji K1: Circ J 2021/3; 85 (4): 345-50. (“¡‰ªrˆê˜Y1, –k‘º@—¥1, ”ü“‡—˜º1, ’†“‡—Žq1, “c‘º‰À”ü1, –x‰z—m1, r‹Lt“Þ1, ”ªŒLˆê‹M1, —F•Û‹M”Ž1, ‰ª‘º@ç1, ‹{–{—²Ži1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç)

310024. [Ç—á•ñ] Aortic atresia with transposition of the great arteries. Fukunishi T1, Miyaji K1, Miyamoto T1, Inoue N1, Kitamura T1: Gen Thorac Cardiovasc Surg 2020/12; 68 (12): 1492-4. (•Ÿ¼‘ô^1, ‹{’n@ŠÓ1, ‹{–{—²Ži1, ˆäãMK1, –k‘º@—¥1: 1S‘ŸŒŒŠÇŠO)

310025. [Ç—á•ñ] Spontaneous splenic rupture, mesenteric ischemia and spinal infarction after aortic repair for acute type A dissection in a patient with sickle cell trait. Toyoda M1, Kitamura T1, Nakashima K1, Matsunaga Y1, Nie M1, Miyaji K1: Gen Thorac Cardiovasc Surg 2021/3; 69 (3): 560-3. (–L“c^Žõ1, –k‘º@—¥1, ’†“‡Œõ‹M1, ¼‰iŒc—õ1, æс@³Šî1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

320010. [Ç—á•ñ] ‰ºŽˆŒŒ—¬áŠQ‚𔺂¤BŒ^‘å“®–¬‰ð—£‚ɑ΂·‚éEVARŽ¡—ÂÌ1—á. ’†“‡Œõ‹M1, ”g—¢—z‰î1, ‚–ØŽõl, –k‘º@—¥1, ‹{’n@ ŠÓ1 (1S‘ŸŒŒŠÇŠO): “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŽGŽ 2021/1; 50 (1): 69-72.

[Šw‰ïEŒ¤‹†‰ï“™]

723310. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “à’°œ“®–¬Çð‚𕹗p‚µ‚½• •”ƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}p‚É‚¨‚¯‚éä\‹ØŒŒ—¬ƒ‚ƒjƒ^ƒŠƒ“ƒOŽè–@‚ÌŒŸ“¢. “¡‰ªrˆê˜Y1, ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, ’¹ˆäWŽO1,2, ‹{–{—²Ži1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ‘吼‹`•F1, “cŠ—S‹I1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13-15), webŠJÃ, “ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï´˜^W 2020/8; 120: SF-035-2.

723311. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬lŠJSp‚É‚¨‚¯‚é‘gDŽ_‘f–O˜a“x‚ƐlHS”xŠÖ˜A‹}«táŠQ‚ÌŠÖ˜A«. åŒ’Ži˜N1, ŒÃ•½@‘2, –k‘º@—¥1, ’¹ˆäWŽO1,3, ‹{–{—²Ži1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ‘吼‹`•F1, “cŠ—T‹I1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—Éq¶Šw•”, 3’nˆæˆã—˳ˆç): ‘æ120‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/8/13-15), webŠJÃ, “ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï´˜^W 2020/8; 120: SF-070-6.

723312. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) æ“V«SŽ¾Š³ŽèpƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚̗Տ°‰ž—p (4D MRI, 3D) ƒRƒ“ƒsƒ…[ƒ^[ƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚É‚æ‚鉼‘zŽèp‚ÉŠî‚¢‚½”x“®–¬Œ`¬p. ‹{’n@ŠÓ1, ‹{–{—²Ži1, ¼‘ã‘ì–ç1, ‘吼‹`•F1, ’¹ˆäWŽO1,2, –k‘º@—¥1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, “cŠ—T‹I1, ‹{èãĕ½3, ”Â’JŒcˆê4 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4‹ž“s•{—§‘åŠw): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: PD3-2.

723313. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ––½ŒŒD’†‹…/ƒŠƒ“ƒp‹…”ä‚͐æ“V«SŽ¾Š³pŒã‚Ì‘å—Ê‹¹…Ž¡—ÃŒø‰Ê—\‘ªˆöŽq‚ƂȂ肤‚é. ”ªŒLˆê‹M1, •ˆä“N—2, X‰ºŠ°”V2, ‹{’n@ŠÓ1, ‹{–{—²Ži1, –k‘º@—¥1, ‹àŽqK—T2 (1S‘ŸŒŒŠÇŠO, 2“Œ‹ž‘åŠw): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: PR4-4.

723314. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –«‘å“®–¬‰ð—£‚ɑ΂·‚éŠO‰È“IŽ¡—Ð헪`Crawford extent 2‚ɑ΂·‚é“ñŠú“IŽ¡—Á`. “¡‰ªrˆê˜Y1, –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ‘吼‹`•F1, “cŠ—S‹I1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: PR9-5.

723315. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™Šú–¢Ž¡—Ьlæ“V«SŽ¾Š³Š³ŽÒ‚̏pŒãŠëŒ¯—\‘ªˆöŽq‚ÌŒŸ“¢. ‹{–{—²Ži1, ”ªŒLˆê‹M1, “cŠ—S‹I1, ‘吼‹`•F1, “c‘º‰À”ü1, ‹ß“¡@^1, r‹Lt“Þ1, “¡‰ªrˆê˜Y1, ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: PR17-4.

723316. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Iliac Branch Endoprosthesis (IBE) ‚ð—p‚¢‚½EVAR‚ÌŒŸ“¢. ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ü“‡—˜º1, ‘吼‹`•F1, “cŠ—S‹I1, r‹Lt“Þ1, ”ªŒLˆê‹M1, –k‘º@—¥1, ‹{–{—²Ži1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: PR21-4.

723317. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Contegra conduit‚ð—p‚¢‚½‘“®–¬Š²ÇC•œp. ‹{’n@ŠÓ1, ‹{–{—²Ži1, ”ªŒLˆê‹M1, “cŠ—S‹I1, ’¹ˆäWŽO1,2, –k‘º@—¥1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, ‹ß“¡@^1, “c‘º‰À”ü1, ‘吼‹`•F1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: V2-2.

723318. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å“®–¬‹|C•œpŽž‚É—p‚¢‚锽‰ñ_ŒoƒXƒPƒ‹ƒgƒ“‰»–@‚Ì—L—p«‚ɂ‚¢‚Ä. ‹{–{—²Ži1, —F•Û‹M”Ž1, ‘吼‹`•F1, “cŠ—S‹I1, ”ªŒLˆê‹M1, —с@GŒ›1, ‰ª@“¿•F1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: V2-4.

723319. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Š´õ«S“à–Œ‰ŠC‘m–X•Ù•Â½•s‘SÇ‚ɑ΂·‚鎩ŒÈS–Œ‚ð—p‚¢‚½‘m–X•ÙŒ`¬p‚Ì’Z’†Šú¬Ñ. r‹Lt“Þ1, ‘吼‹`•F1, “cŠ—S‹I1, ”ªŒLˆê‹M1, ¼‘ã‘ì–ç1, “¡‰ªrˆê˜Y1, ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, –k‘º@—¥1, ‹{–{—²Ži1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: O21-4.

723320. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ûŽ™’vŽ€«•s®–¬‚ɑ΂·‚éA‚¦ž‚ÝŒ^œ×“®Ší‚Ì—L—p«. “cŠ—S‹I1, ‹{–{—²Ži1, ”ªŒLˆê‹M1, ’¹ˆäWŽO1,2, –k‘º@—¥1, ¼‰º@O1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, ‹ß“¡@^1, “c‘º‰À”ü1, ‘吼‹`•F1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: P3-2.

723321. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) BŒQ—nŒŒ«˜A½‹…‹ÛŠ´õÇ‡•¹‚Ì‘å“®–¬kkó•¡‡‚ɑ΂µ‚ďC•œp‚ðŽ{s‚µ‚½ˆê—á. ”ªŒLˆê‹M1, ‹{–{—²Ži1, “cŠ—S‹I1, ‘吼‹`•F1, “c‘º‰À”ü1, ‹ß“¡@^1, r‹Lt“Þ1, “¡‰ªrˆê˜Y1, ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: P27-5.

723322. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒnƒCƒŠƒXƒNŠ³ŽÒ‚É‚¨‚¯‚鋹• •”‘å“®–¬áŽ‚ɑ΂·‚鎡—Ð헪. ‘吼‹`•F1, “¡‰ªrˆê˜Y1, –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ‹ß“¡@^1, “c‘º‰À”ü1, “cŠ—S‹I1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ50‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/8/17-19), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2020/8; 50: P52-4.

723323. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¶”x“®–¬‹‘剼«áŽ‚ɑ΂µC•œp‚ðŽ{s‚µ‚½ˆê—á. “c‘º‰À”ü1, ‹{’n@ŠÓ1, ‹{–{—²Ži1, ‰ª‘º@’B1, ¼‘ã‘ì–ç1, –x‰z—m1, ’¹ˆäWŽO1,2, –k‘º@—¥1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ’†“‡—Žq1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ73‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/10/29-11/1), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2020/10; suppl: 118.

723324. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’჊ƒXƒN‚—îASŠ³ŽÒ‚É‚¨‚¯‚éTAVI, SAVR‘I‘ð‚ÌŽw•W‚ÉŠÖ‚·‚錟“¢. ’†“‡—Žq1, –k‘º@—¥1, ’¹ˆäWŽO1, ‹{–{—²Ži1, ”ü“‡—˜º1, ‰ª‘º@’B1, ‘å‹v•Û”Ž¢1, —F•Û‹M”Ž1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, –x‰z—m1, “c‘º‰À”ü1 (1S‘ŸŒŒŠÇŠO): ‘æ73‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/10/29-11/1), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2020/10; suppl: 147.

723325. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒtƒ@ƒ[Žl’¥Ç‚É‚¨‚¯‚é‘Ì”x’Z—Žèp‚É‚æ‚é”x“®–¬•Ù—֐¬’·‚ÌŒø‰Ê. “c‘º‰À”ü1, ‹{’n@ŠÓ1, ‹{–{—²Ži1, ‰ª‘º@’B1, —F•Û‹M”Ž1, –k‘º@—¥1, ’¹ˆäWŽO1,2, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, –x‰z—m1, ’†“‡—Žq1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ73‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/10/29-11/1), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2020/10; suppl: 210.

723326. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) FallotŽl’¥ÇpŒã”x“®–¬•Ù’uŠ·p‚É‚¨‚¯‚éŽOë•Ù—ÖŒ`¬p‚Ì’†Šú‰“ŠuŠú¬Ñ. –x‰z—m1, ‹{’n@ŠÓ1, ‹{–{—²Ži1, ‰ª‘º@’B1, —F•Û‹M”Ž1, “c‘º‰À”ü1, –k‘º@—¥1, ’¹ˆäWŽO1,2, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ’†“‡—Žq1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ73‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/10/29-11/1), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2020/10; suppl: 229.

723327. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 65ÎˆÈãS‘ŸŽèpŠ³ŽÒ‚ɑ΂·‚é‘Þ‰@ŒãƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Œp‘±‚ÌŽw•W. –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‰ª‘º@’B1, ‘å‹v•Û”Ž¢1, —F•Û‹M”Ž1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, –x‰z—m1, “c‘º‰À”ü1, ’†“‡—Žq1, à_èL–¾3, ŽR‰º^Ži4, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç, 3ƒŠƒnƒrƒŠ•”, 4‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ73‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/10/29-11/1), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2020/10; suppl: 247.

723328. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬lŠJSpŠ³ŽÒ‚É‚¨‚¯‚ép‘O––½‹ßÔŠOü‘gDŽ_‘f–O˜a“x‚Ì‘ª’è‹@Ží‚É‚æ‚é‘Šˆá|p‘OˆöŽq‚Æ‚ÌŠÖ˜A«|. ŒÃ•½@‘1, ‹{’n@ŠÓ2, –k‘º@—¥2, ’¹ˆäWŽO2,3, “¡‰ªrˆê˜Y2, ‹{–{—²Ži2, ‰ª‘º@’B2, r‹Lt“Þ2, —F•Û‹M”Ž2, –x‰z—m2, “c‘º‰À”ü2, ’†“‡—Žq2 (1ˆã—Éq¶Šw•”, 2S‘ŸŒŒŠÇŠO, 3’nˆæˆã—˳ˆç): ‘æ73‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/10/29-11/1), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2020/10; suppl: 249.

723329. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠO‰ÈŽ¡—Áu‹@”\“I’PSŽº‚ɑ΂·‚éƒVƒƒƒ“ƒgŽèpv‰‰ñŽèp‚É‘Ì”x“®–¬’Z—Žèp‚ð—v‚·‚é‹@”\“I’PSŽº‚ÌŽ¡—Ð헪. ‰ª@“¿•F1, —с@GŒ›1, —F•Û‹M”Ž1, ‹{–{—²Ži1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ56‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2020/11/22-24), ‹ž“s (webŠJÃ), “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2020/11; 36 (Suppl 2): s2-122.

723330. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) bulging sinus•tePTFE mono-cusp patch‚ð—p‚¢‚½RVOTR‚Ì’†Šú‰“Šu¬Ñ. ¼‘ã‘ì–ç1, ‹{’n@ŠÓ1, ‹{–{—²Ži1, ‰ª@“¿•F1, —F•Û‹M”Ž1, —с@GŒ›1, –k‘º@—¥1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ‘吼‹`•F1, “cŠ—T‹I1 (1S‘ŸŒŒŠÇŠO): ‘æ56‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2020/11/22-24), ‹ž“s (webŠJÃ), “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2020/11; 36 (Suppl 2): s2-331.

723331. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V¶Ž™‹y‚Ñ“ûŽ™Šú‘•’…‚̐S‘Ÿƒy[ƒXƒ[ƒJ[‚̉“ŠuŠú¬Ñ‚ɂ‚¢‚Ä. ‹{–{—²Ži1, ¼‘ã‘ì–ç1, ‘吼‹`•F1, [’¬’¼”V2, —F•Û‹M”Ž1, —с@GŒ›1, ‰ª@“¿•F1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ŒQ”nŒ§—§¬Ž™ˆã—ÃZƒ“ƒ^[): ‘æ56‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2020/11/22-24), ‹ž“s (webŠJÃ), “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2020/11; 36 (Suppl 2): s2-400.

723332. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Samurai Cannulation (Direct True Lumen Cannulation) for Acute Stanford Type A AorticDissection. –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‰ª‘º@’B1, —F•Û‹M”Ž1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, “c‘º‰À”ü1, ’†“‡—Žq1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ48‰ñ“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/11/27-29), webŠJÃ, “ú–{ŒŒŠÇŠO‰ÈŠw‰ïŽGŽ 2020/11; 29 (Suppl): 11.

723333. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ª‚ñŠÖ˜AÃ–¬ŒŒðÇ‚ÌŽ¡—ЬÑ. “¡‰ªrˆê˜Y1, ”ü“‡—˜º1, ’†“‡—Žq1, “c‘º‰À”ü1, r‹Lt“Þ1, ”ªŒLˆê‹M1, —F•Û‹M”Ž1, ‰ª‘º@’B1, –k‘º@—¥1, ‹{–{—²Ži1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ48‰ñ“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2020/11/27-29), webŠJÃ, “ú–{ŒŒŠÇŠO‰ÈŠw‰ïŽGŽ 2020/11; 29 (Suppl): 23.

723334. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹}«AŒ^‰ð—£‚ɑ΂·‚é‘S‹|•”’uŠ·{Frozen Elephant Trunk‚Æ‘å“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚ÌŒŸ“¢. “¡‰ªrˆê˜Y1, –k‘º@—¥1, “c‘º‰À”ü1, r‹Lt“Þ1, ”ªŒLˆê‹M1, —F•Û‹M”Ž1, ”ü“‡—˜º1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ51‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2021/2/19-21), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2021/2; 51: 38.

723335. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚é’iŠK“IYasuiŽèp (Norwood-RastelliŽèp) ‚ÌŽ¡—ЬÑ‚ÌŒŸ“¢. “c‘º‰À”ü1, ‹{’n@ŠÓ1, ‹{–{—²Ži1, ‰ª‘º@ç1, ’†“‡—Žq1, ’¹ˆäWŽO1,2, ”ü“‡—˜º1, –k‘º@—¥1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, —F•Û‹M”Ž1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ51‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2021/2/19-21), webŠJÃ, “ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W 2021/2; 51: 64.

733061. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ¶”x“®–¬‹‘剼«áŽ‚ɑ΂µC•œp‚ðŽ{s‚µ‚½ˆê—á. “c‘º‰À”ü1, ‹{’n@ŠÓ1, ‹{–{—²Ži1, ‰ª‘º@’B1, ¼‘ã‘ì–ç1, –x‰z—m1, ’¹ˆäWŽO1,2, –k‘º@—¥1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ’†“‡—Žq1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ183‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/7/16-8/7), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2020/7; 183: 18.

733062. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘å“®–¬•Ù•Â½•s‘SÇp‘O‚É‹ô”­“I‚ɐf’f‚³‚ꂽ‘å“®–¬4ë•Ù‚Ì1—á. ¼‰iŒc—õ1, ¬—ÑŒ’‰î1, “c‘ºK•ä1, ¬Œ´–M‹`, æс@³Šî1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ183‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/7/16-8/7), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2020/7; 183: 28.

733063. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‰ºs‘å“®–¬’uŠ·pŒã‰¼«áŽ|”xú”j‚ɑ΂µ‚Ä, ‹Ù‹}TEVAR‚©‚ç‚Ìbridgesurgery‚Å‹~–½‚µ“¾‚½1—á. ’†“‡—Žq1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, ”ªŒLˆê‹M1, –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ183‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/7/16-8/7), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2020/7; 183: 33.

733064. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‹}«S‹Ø[ÇŒã“û“ª‹Ø’f—ô‚É‚æ‚é‘m–X•Ù•Â½•s‘SÇ‚ɑ΂·‚é‘m–X•ÙŒ`¬p‚̈ê—á. “c‘º‰À”ü1, –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‰ª‘º@’B1, “¡‰ªrˆê˜Y1, —F•Û‹M”Ž1, ”ªŒLˆê‹M1, r‹Lt“Þ1, –x‰z—m1, ’†“‡—Žq1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ184‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/11/28), “Œ‹ž (webŠJÃ) “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2020/11; 184: 13.

733065. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ¬lValsalva“´“®–¬áŽ”j—ô‚ɑ΂·‚éŽèp—á. ’†“‡—Žq1, ‰ª‘º@’B1, “c‘º‰À”ü1, ‹{–{—²Ži1, –x‰z—m1, r‹Lt“Þ1, ”ªŒLˆê‹M1, —F•Û‹M”Ž1, “¡‰ªrˆê˜Y1, ”ü“‡—˜º1, –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ184‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/11/28), “Œ‹ž (webŠJÃ) “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2020/11; 184: 25.

733066. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) S‹Ø[ÇŒã“û“ª‹Ø’f—ô‚ɑ΂·‚é‘m–X•ÙŒ`¬pŒã‚É‘m–X•Ù’uŠ·p‚ðŽ{s‚µ‚½ˆê—á. “c‘º‰À”ü1, –k‘º@—¥1, ’¹ˆäWŽO1,2, ‰ª‘º@’B1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ¼‰iŒc—õ1, ’†“‡—Žq1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ185‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/3/13), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2021/3; 185: 13.

733067. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Œ€ÇŒ^S‹Ø‰ŠŒã‚̐Së•”SŽºáŽ‚ÌŽ¡—ÃŒoŒ±. –L“c^Žõ1, ¼‰iŒc—õ1, “üàV—F•ã1, ¬Œ´–M‹`, æс@³Šî1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ185‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/3/13), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2021/3; 185: 14.

733068. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ŠwZŒ’f‚Å”­Œ©‚³‚ꂽ‰EŽº”S‰tŽî‚ɑ΂µ‚ÄŽîᇐ؏œCryoablation‚É‚æ‚éÄ”­—\–h‚ðs‚È‚Á‚½1—á. ‘ºˆä—C‘¾1, “c’†—C‹M1, ’†“‡Œõ‹M1, –k‘º@—¥1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ185‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/3/13), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2021/3; 185: 32.

733069. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) MACDORV, AS, Hypoarch, PDA‚ɑ΂·‚érapid two staged modified NorwoodŽèp—á. ¼‰iŒc—õ1, ‰ª‘º@’B1, ’†“‡—Žq1, “c‘º‰À”ü1, ”ªŒLˆê‹M1, r‹Lt“Þ1, “¡‰ªrˆê˜Y1, ”ü“‡—˜º1, –k‘º@—¥1, ’¹ˆäWŽO1,2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆæˆã—˳ˆç): ‘æ185‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/3/13), webŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2021/3; 185: 34.


ŒÄ‹zŠíŠO‰ÈŠw

[Šwp˜_•¶]

110250. [Œ´’˜] EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer. Satoh Y1, Matsuo Y2, Kuba T3, Yamashita K3, Sawano M, Tozaka S, Yamazaki H1, Sonoda D4, Mikubo M1, Naito M1, Matsui Y1, Shiomi K1, Yoshida T5, Murakumo Y5: Virchows Arch 2020/5; 476 (5): 753-62. (²“¡”Vr1, ¼”ö—R‹IŽq2, ‹vê@Ž÷3, ŽR‰º˜a–ç3, ŽRèGŒp1, ‰€“c@‘å4, ŽOŒE«Žj1, “à“¡‰ëm1, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, ‹g“c@Œ÷5, ‘º‰_–FŽ÷5: 1ŒÄ‹zŠíŠO, 2•a‘ԁEf—ÃŒn, 3•a—•”, 4‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 5•a—)

110251. [Œ´’˜] Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and Japanese Society of Clinical Cytology: An Interobserver Reproducibility Study and Risk of Malignancy Evaluation on Cytology Specimens. Hiroshima K, Yoshizawa A, Takenaka A, Haba R, Kawahara K, Minami Y, Kakinuma H1, Shibuki Y, Miyake A, Kajio K, Miyamoto K, Nagatomo M, Nishimura S, Mano M, Matsubayashi J, Motoi N, Nagao T, Nakatsuka S, Yoshida T2, Satoh Y3: Acta Cytol 2020/9-10; 64 (5): 452-62. (Š`ÀœA–M1, ‹g“c@Œ÷2, ²“¡”Vr3: 1•a—•”, 2•a—, 3ŒÄ‹zŠíŠO)

110252. [Œ´’˜] Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure. Sonoda D1, Matsuura Y, Kondo Y2, Ichinose J, Nakao M, Ninomiya H, Ishikawa Y, Nishio M, Okumura S, Satoh Y2, Mun M: Thorac Cancer 2020/11; 11 (11): 3280-8. (‰€“c@‘å1, ‹ß“¡‘אl2, ²“¡”Vr2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ŒÄ‹zŠíŠO)

110253. [Œ´’˜] Prognostic impact of preoperative FDG-PET positive lymph nodes in lung cancer. Endoh H, Ichikawa A, Yamamoto R, Shiozawa S, Nishizawa N, Satoh Y1, Oriuchi: Int J Clin Oncol 2021/1; 26 (1): 87-94. (²“¡”Vr1: 1ŒÄ‹zŠíŠO)

110254. [Œ´’˜] Method for preservation of DNA stability of liquid-based cytology specimens from a lung adenocarcinoma cell line. Matsuo Y1, Yamashita K2, Yoshida T3, Satoh Y4: Virchows Arch 2021/3; 478 (3): 507-16. (¼”ö—R‹IŽq1, ŽR‰º˜a–ç2, ‹g“c@Œ÷3, ²“¡”Vr4: 1•a‘ԁEf—ÃŒn, 2•a—•”, 3•a—, 4ŒÄ‹zŠíŠO)

310026. [Ç—á•ñ] Resection of intra-pulmonary endometriosis by video-assisted thoracoscopic surgery under pre-operative CT-guided marking synchronized with menstrual cycle. Matsushima K1, Ono M1, Hayashi S1, Sonoda D2, Matsui Y1, Shiomi K1, Satoh Y1, Ohbu M3: Gen Thorac Cardiovasc Surg 2020/5; 68 (5): 549-53. (¼“‡Œ\Œá1, ¬–쌳Žk1, —с@ËŽq1, ‰€“c@‘å2, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1, ‘å•”@½3: 1ŒÄ‹zŠíŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@)

310027. [Ç—á•ñ] Subxiphoid dual-port thymectomy for thymoma in a patient with post-aortic left brachiocephalic vein. Naito M1, Ono M1, Hayashi S1, Mastui Y1, Shiomi K1, Satoh Y1: Gen Thorac Cardiovasc Surg 2021/1; 69 (1): 151-4. (“à“¡‰ëm1, ¬–쌳Žk1, —с@ËŽq1, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1: 1ŒÄ‹zŠíŠO)

320011. [Ç—á•ñ] –³Š¾«ŠOãó—tŒ`¬•s‘SÇ‚É”º‚¤Š´õ«”xùN–E‚Ì1Øœ—á. ŠÛŽR—ˆ‹P1, ¼“‡Œ\Œá1, ŽOŒE«Žj1, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): “ú–{ŒÄ‹zŠíŠO‰ÈŠw‰ïŽGŽ 2020/5; 34 (4): 275-80.

520008. [‘à] ŒÄ‹zŠí×–Efupdata|f’f‚¨‚æ‚уoƒCƒIƒ}[ƒJ[‚Ö‚ÌŠˆ—p‚Ɖۑè|. ‰€“c@‘å1, ²“¡”Vr2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ŒÄ‹zŠíŠO): ”xŠà 2020/10; 60 (5): 373-8.

522059. [uÀ]y“ÁW: ”xcŠu‚Ì‹¹o‹¾Eƒƒ{ƒbƒgŽx‰‡Žèp‚̐i•àz2. Žè‹ZE‹@Ší@‘OcŠuŽèp‚É‚¨‚¯‚é’áNP«Žèp‚Ì“±“ü‚©‚çl‚¦‚邱‚Ɓ|Œ•ó“Ë‹N‰ºŽè‹Z‚ƃƒ{ƒbƒgŽx‰‡Žèp. ²“¡”Vr1, —с@ËŽq1, “à“¡‰ëm1, ¼ˆäŒ[•v1 (1ŒÄ‹zŠíŠO): ‹¹•”ŠO‰È 2020/4; 73 (4): 274-9.

522060. [uÀ]y“ÁW: ”xE‹¹‘B_Œo“à•ª”åŽîᇂ̎¡—Áz2. _Œo“à•ª”åŽîᇂɂ¨‚¯‚é×–Ef‚Ì–ðŠ„|Ž¡—ÑOf’f‚𒆐S‚Ɂ|. ²“¡”Vr (ŒÄ‹zŠíŠO): “úŠO‰ïŽ 2021/1; 122 (1): 10-7.

[’˜@‘]

620050. [Šwp‘ (•ª’SŽ·•M)]yƒnƒCƒŠƒXƒN‹¹•”ŠO‰ÈŽèp (‹¹•”ŠO‰È2020”N9ŒŽ‘Š§†)zII. ŒÄ‹zŠí—̈æ@26. t•s‘S‡•¹Ç—á‚É‚¨‚¯‚é”xEcŠuŽèp‚ÆŽüpŠúŠÇ—, p. 866-9. “à“¡‰ëm1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO), “ì]“°, “Œ‹ž, 2020/9”­s.

620051. [Šwp‘ (•ª’SŽ·•M)]y”xŠàf—ÃKƒCƒhƒ‰ƒCƒ“|ˆ««‹¹–Œ’†”çŽîE‹¹‘BŽîᇊ܂ށ|2020”N”Å ‘æ6”Łz‘æ1•” ”xŠàf—ÃKƒCƒhƒ‰ƒCƒ“2020”N”Ł@I. ”xŠà‚̐f’f@4. •a—×–Ef’f, p.34-46. ²“¡”Vr (ŒÄ‹zŠíŠO), •Ò: “ú–{”xŠàŠw‰ï, ‹àŒ´o”Å, “Œ‹ž, 2021/1”­s.

620052. [Šwp‘ (•ª’SŽ·•M)]yŒÄ‹zŠíŽ¾Š³ÅV‚ÌŽ¡—Ã2021-2022zXIII æ“V«ˆÙíEŒ`¬•s‘S@2 ”x“®Ã–¬á‘ (”x“®Ã–¬ŠïŒ`), p.405-7. —с@ËŽq1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO), •Ò: –å“c~ˆê, Œ·ŠÔº•F, ¼‰ªˆÀ•F, “ì]“°, “Œ‹ž, 2021/3”­s.

620053. [Šwp‘ (‹¤’˜)]y—Տ°E•a—@”xŠàŽæˆµ‚¢‹K–ñ@‘æ8”Å•â’ù”Łz4. •a—f’f, p68-124. 5. ×–Ef, p.126-48. 8. Œ´”­«”xŽîᇂ̎¡—ÃŒø‰Ê‚Ì‘gDŠw“I”»’èŠî€, p.184-6. ²“¡”Vr (ŒÄ‹zŠíŠO), •Ò: “ú–{”xŠàŠw‰ï, ‹àŒ´o”Å, “Œ‹ž, 2021/3”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

721012. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ×–Ef‚̃mƒuƒŒƒXEƒIƒuƒŠ[ƒWƒ…`Ž„‚½‚¿‚Ì–ÚŽw‚·‚à‚́`. ²“¡”Vr (ŒÄ‹zŠíŠO): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20), WebŠJÃ.

722062. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “ú–{‚É‚¨‚¯‚éŒÄ‹zŠí×–Ef”»’èŠî€: ‘Û‰»‚ð–ÚŽw‚µ‚Ä. ‹gàV–¾•F, œA“‡Œ’ŽO, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20), WebŠJÃ.

722063. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) JSCC-JLCSV•ñ—lŽ®‚É‚¨‚¯‚éatypical cells‚ɂ‚¢‚Ä. ‰ÍŒ´–MŒõ, œA“‡Œ’ŽO, ’|’†–¾”ü, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20), WebŠJÃ.

722064. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒÄ‹zŠí×–Ef‚Ì“W–] `”»’èŠî€‚̍‘Û‰»‚ð–ÚŽw‚µ‚ā`. ²“¡”Vr (ŒÄ‹zŠíŠO): ‘æ59‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2020/11/22), ‰¡•l.

723336. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ´”­«”xŠà‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚½”xZ‚𔺂¤‹¹‘BG•½ã”çŠà‚̈ê—á. ˆäoL–ç, ’†ŽR•üH, Šâ¼O•¶, ’†ŽRŒPŽq, ²“¡Œ›r, ¼—Yˆê‹M, Â–ö‘åŽ÷, ‰–àV@“N, Î‹TœAŽ÷, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20), WebŠJÃ.

723337. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘½Šj‹×–E“à‚ÉAsteroid body‚ð”F‚ß‚½”xŒ´”­«ƒNƒŠƒvƒgƒbƒRƒbƒJƒXÇ‚Ì1—á. Šâ¼O•¶, ’†ŽR•üH, ²“¡Œ›r, ˆäoL–ç, ¼—Yˆê‹M, Î‹TœAŽ÷, rìˆ¤Žq, Â–ö‘åŽ÷, ‰–àV@“N, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20), WebŠJÃ.

723338. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ´”­«”ñ¬×–E”xŠà‚̈â“`Žq‰ðÍ‚É‚¨‚¯‚é‰tó‰»ŒŸ‘̍זEf‚Ì—LŒø«. ¼”ö—R‹IŽq1, ŽR‰º˜a–ç2, ‹g“c@Œ÷3, ‹vê@Ž÷2, àV–ì^—Žq, ‘º‰_–FŽ÷3, ²“¡”Vr4 (1•a‘ԁEf—ÃŒn, 2•a—•”, 3•a—, 4ŒÄ‹zŠíŠO): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20), WebŠJÃ.

723339. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”xŠàp‘O‚É‚¨‚¯‚é‘Ϗp”\ŒŸ¸‚Æ‚µ‚Ä‚Ì•‰‰×S“d}ŒŸ¸“K‰ž‚ÌŒŸ“¢. ‹Êì@’B1, ŽOˆä@ˆ¤1, —с@ËŽq1, “à“¡‰ëm1, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ37‰ñ“ú–{ŒÄ‹zŠíŠO‰ÈŠw‰ïŠwpW‰ï (2020/9/29-10/12), WebŠJÃ.

723340. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒe[ƒvƒ‰[Œã‚ÌŒŒŠÇ’f’[‚̐ؗ£‘€ì‚É‚æ‚è”x“®–¬oŒŒ‚𗈂µ‚½ˆê—á. _’J‹I‹P1,2, –k@‰p“T2, ‘O“c“úØŽq2, ‰J‹{—²‰î2, ”—@—T”V2, —Ž‡‘åŽ÷2, ŒÜŒŽ—Œbˆê2, Îˆä—ǍK1,3 (1ŒÄ‹zŠíŠO, 2–k—¢Œ¤‹†Š•a‰@, 3‰º•”Á‰»ŠÇŠO): ‘æ37‰ñ“ú–{ŒÄ‹zŠíŠO‰ÈŠw‰ïŠwpW‰ï (2020/9/29-10/12), WebŠJÃ.

723341. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚éŠO«ŒŒ‹C‹¹‚ÌŽèpÇ—á‚ÌŒŸ“¢. —с@ËŽq1, ŽOˆä@ˆ¤1, ‹Êì@’B1, ¼“‡Œ\Œá1, “à“¡‰ëm1, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ73‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2020/10/29-11/1), WebŠJÃ.

723342. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰E”x’†—t’áŒ`¬‚É”­¶‚µ‚½’èŒ^ƒJƒ‹ƒ`ƒmƒCƒh3—á‚ÌŒŸ“¢. ŽOˆä@ˆ¤1, ‹Êì@’B1, ¼“‡Œ\Œá1, —с@ËŽq1, “à“¡‰ëm1, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1, ˆêŒË¹–¾2 (1ŒÄ‹zŠíŠO, 2•a—): ‘æ61‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2020/11/12), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723343. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã21”N–Ú‚É‹¹–Œ”dŽíÄ”­‚ð”F‚ß‚½‹¹‘BŒ´”­”S•\”çŠà‚Ì1—á. ¼“‡Œ\Œá1, ŽOˆä@ˆ¤1, ‹Êì@’B1, —с@ËŽq1, “à“¡‰ëm1, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, “È–{¹F2, ˆêŒË¹–¾2,@Ó@¢ˆ®, ²“¡”Vr1 (1ŒÄ‹zŠíŠO, 2•a—): ‘æ61‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2020/11/12), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723344. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”÷¬“û“ªŒ^‘BŠà‚É‚¨‚¯‚é×–EŠ”‚ð—p‚¢‚½ˆ««“x‚ÌŒŸ“¢. ‰€“c@‘å1, ¼”ö—R‹IŽq2, ¼“‡Œ\Œá3, ŽOŒE«Žj3, “à“¡‰ëm3, ²“¡”Vr3 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2•a‘ԁEf—ÃŒn, 3ŒÄ‹zŠíŠO): ‘æ59‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2020/11/22), ‰¡•l.

733070. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “]ˆÚ«‰¡Šu–ŒŽîᇂ̈êØœ—á. ‹Êì@’B1, ŽOˆä@ˆ¤1, ¼“‡Œ\Œá1, —с@ËŽq1, “à“¡‰ëm1, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ184‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/11/28), “Œ‹ž.

733071. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “Á”­«S”X…’™—¯‚ɑ΂µS–ŒŠJ‘‹p‚ðŽ{s‚µ‚½1—á. ŽOˆä@ˆ¤1, ‹Êì@’B1, —с@ËŽq1, “à“¡‰ëm1, ¼ˆäŒ[•v1, ‰–Œ©@˜a1, “¡“c“S•½2, ²“¡”Vr1 (1ŒÄ‹zŠíŠO, 2ŒÄ‹zŠí“à): ‘æ185‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/3/13), WebŠJÃ.


”]_ŒoŠO‰ÈŠw

[Šwp˜_•¶]

110255. [Œ´’˜] Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. Natsume A1, Aoki K1, Ohka F1, Maeda S1, Hirano M1, Adilijiang A1, Motomura K1, Sumi M1, Nishikawa R1, Narita Y1, Muragaki Y1, Maruyama T1, Ito T1, Beppu T1, Nakamura H1, Kayama T1, Sato S1, Nagane M1, Mishima K1, Nakasu Y1, Kurisu K1, Yamasaki F1, Sugiyama K1, Onishi T1, Iwadate Y1, Terasaki M1, Kobayashi H1, Matsumura A1, Ishikawa E1, Sasaki H1, Mukasa A1, Matsuo T1, Hirano H1, Kumabe T1,2, Shinoura N1, Hashimoto N1, Aoki T1, Asai A1, Abe T1, Yoshino A1, Arakawa Y1, Asano K1, Yoshimoto K1, Shibui S1, Okuno Y1, Wakabayashi T1 (1Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG): J Neurooncol 2020/5; 148 (1): 17-27. (ŒG•”rG1,2: 2”]ŠO)

110256. [Œ´’˜] Ergonomics-based Positioning of the Operating Handle of Surgical Microscopes. Shimizu S1, Kuroda H1, Mochizuki T, Kumabe T1: Neurol Med Chir (Tokyo) 2020/6; 60 (6): 313-6. (´…@ú1, •“c”Ž‹I1, –]ŒŽ’O, ŒG•”rG1: 1”]ŠO)

110257. [Œ´’˜] Ribosomal protein S6 promotes stem-like characters in glioma cells. Shirakawa Y, Hide T1, Yamaoka M, Ito Y, Ito N, Ohta K, Shinojima N, Mukasa A, Saito H, Jono H: Cancer Sci 2020/6; 111 (6): 2041-51. (G‘ñˆê˜Y1: 1”]ŠO)

110258. [Œ´’˜] TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma. Kikuchi Z, Shibahara I1, Yamaki T, Yoshioka E, Shofuda T, Ohe R, Matsuda K, Saito R, Kanamori M, Kanemura Y, Kumabe T1, Tominaga T, Sonoda Y: Neurooncol Adv 2020/9; 2 (1): vdaa114. (ŽÄŒ´ˆê—z1, ŒG•”rG1: 1”]ŠO)

110259. [Œ´’˜] H3K27M and TERT promoter mutations are poor prognostic factors in surgical cases of adult thalamic high-grade glioma. Osada Y, Saito R, Shibahara I1, Sasaki K, Shoji T, Kanamori M, Sonoda Y, Kumabe T1, Watanabe M, Tominaga T: Neurooncol Adv 2021/2; 3 (1): vdab038. (ŽÄŒ´ˆê—z1, ŒG•”rG1: 1”]ŠO)

110260. [Œ´’˜] So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma? Kanamori M, Takami H, Yamaguchi S, Sasayama T, Yoshimoto K, Tominaga T, Inoue A, Ikeda N, Kambe A, Kumabe T1, Matsuda M, Tanaka S, Natsumeda M, Matsuda K, Nonaka M, Kurihara J, Yamaoka M, Kagawa N, Shinojima N, Negoto T, Nakahara Y, Arakawa Y, Hatazaki S, Shimizu H, Yoshino A, Abe H, Akimoto J, Kawanishi Y, Suzuki T, Natsume A, Nagane M, Akiyama Y, Keino D, Fukami T, Tomita T, Kanaya K, Tokuyama T, Izumoto S, Nakada M, Kuga D, Yamamoto S, Anei R, Uzuka T, Fukai J, Kijima N, Terashima K, Ichimura K, Nishikawa R: Neuro Oncol 2021/2; 23 (2): 295-303. (ŒG•”rG1: 1”]ŠO)

110261. [Œ´’˜] Electron microscopic study of the median structure of the posterior column of the spinal cord of the adult rat with a special reference to the posterior median septum. Mii K, Yagishita S, Kumabe T1: Anat Rec (Hoboken) 2021/3; 304 (3): 625-30. (ŽOˆäŒö•F, –ö‰ºŽO˜Y, ŒG•”rG1: 1”]ŠO)

310028. [Ç—á•ñ] Frequent Clinical and Radiological Progression of Optic Pathway/Hypothalamic Pilocytic Astrocytoma in Adolescents and Young Adults. Shoji T, Kanamori M, Saito R, Watanabe Y, Watanabe M, Fujimura M, Ogawa Y, Sonoda Y, Kumabe T1, Kure S, Tominaga T: Neurol Med Chir (Tokyo) 2020/6; 60 (6): 277-85. (ŒG•”rG1: 1”]ŠO)

320012. [Ç—á•ñ] •¡”‰ñ‚Ì‘å‘Ú‹Ø–ŒÌŽæ•”‚ɃŠƒ“ƒp˜R‚𐶂¶‚½1—á. ´…@ú1, –]ŒŽ’O1, •“c”Ž‹I1, ªŒ³@[2, ŒG•”rG1 (1”]ŠO, 2Œ`¬E”üŠO): ”]_ŒoŠO‰È 2020/7; 48 (7): 621-5.

320013. [Ç—á•ñ] ”]ŒŒŠÇ‘¢‰e‚Å early venous filling ‚ð’悵‚½”]ƒAƒ~ƒƒCƒhƒAƒ“ƒMƒIƒpƒ`[ŠÖ˜A‰ŠÇ‚Ì1—á. ŽR–{‘å•ã1, ˆä“‡‘å•ã2, Œ¢Ž”@‰~1, m–؁@~1, ‰Oˆä@—É2, ¬òŠ°”V1, ŽOŽ}@M3, ¼ŽR˜a—˜2, ŒG•”rG1 (1”]ŠO, 2”]_Œo“à, 3•a—): ”]_ŒoŠO‰È 2020/7; 48 (7): 641-7.

320014. [Ç—á•ñ] ’†”]³’†•”ŠC–ȏ󌌊ǎî‚ɑ΂µanterior interhemispheric transcallosal transforaminal approach‚ð—p‚¢‚Ä“Eo‚µ‚½1—á. ‰Ž“c˜a‹MŽq1, ŽÄŒ´ˆê—z1, ûŒ´Œõl, ŒG•”rG1 (1”]ŠO) ”]_ŒoŠO‰È 2020/8; 48 (8): 717-23.

320015. [Ç—á•ñ] “ªŠW“àãóŽî•úŽËüŒãŽ¡—Ã’·ŠúŠÏŽ@ŠúŠÔ’†‚É‚¨‚¯‚éƒsƒbƒgƒtƒH[ƒ‹: ‘æ1Œz_Œo_ŒoâŽî‚Ì1f’f’x‰„—á. ˆäã’q•v1, ŽÄŒ´ˆê—z1, Œ¢Ž”@‰~1, ”¼“c@”£1, ²“¡Ÿl1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO) ”]_ŒoŠO‰È‘¬•ñ 2020/9; 30 (9): 1010-5.

320016. [Ç—á•ñ] •êŽw‚Ü‚½‚ÍŽ¦Žw‚Ì‚Ý‚Ì‹ü‹ÈáŠQ‚ð‰ŠúÇó‚Æ‚µ‚½‘OœŠÔ_Œo–ƒáƒ‚Ì2Ç—á. ´…@ú1, –]ŒŽ’O, •“c”Ž‹I1, ‘åàV¬”V, “c’†@—, ª–{@[2, ŒG•”rG1 (1”]ŠO, 2Œ`¬E”üŠO): ”]_ŒoŠO‰È 2021/2; 49 (2): 452-3.

522061. [uÀ]y‹³ŒP“IÇ—á‚ÉŠw‚ÔƒVƒŠ[ƒYz—¼‘¤‘Ώ̐«––½«‘O‘å”]“®–¬áŽ‚ɑ΂µ‚ÄŒŒŠÇ“àŽ¡—Âðs‚Á‚½1—á. ŽR–{‘å•ã1, ¬òŠ°”V1, ˆä“‡‘å•ã2, m–؁@~ 1, ‰Oˆä@—É2, ‹{â˜aO1, ŒG•”rG1 (1”]ŠO, 2”]_Œo“à): ”]_ŒoŠO‰È 2020/4; 48 (4): 349-53.

530012. [‚»‚Ì‘¼ (Comment)] In Reply to the Letter to the Editor Regarding ""A Case of Calcifying Pseudoneoplasms of the Neuraxis Coexisting with Interhemispheric Lipoma and Agenesis of the Corpus Callosum: Involvement of Infiltrating Macrophages"". Inukai M1, Shibahara I1, Kumabe T1: World Neurosurg 2020/7; 139: 670-1. (Œ¢Ž”@‰~1, ŽÄŒ´ˆê—z1, ŒG•”rG1: 1”]ŠO)

530013. [‚»‚Ì‘¼ (Comment)] Letter to the Editor Regarding ""Failure of Surgery in Idiopathic Spinal Cord Herniation: Case Report and Review of the Literature"". Shimizu S1: World Neurosurg 2020/10; 142: 556-7. (´…@ú1: 1”]ŠO)

[’˜@‘]

620054. [Šwp‘ (•ª’SŽ·•M)] yˆ««”]Žîᇂ̂·‚ׂā|Neuro-Oncology‚Ì‹³‰È‘|ˆâ“`Žqf’fŽž‘ã‚̗Տ°ƒŠƒAƒ‹ƒ[ƒ‹ƒh (”]_ŒoŠO‰È‘¬•ñ2020”N‘Š§†)z[VÍ Žèp] 1. äP‰èŽî (GBM) ‚ÌŽèp|‰äX‚Ì—¬‹V1: ‘¤“ª—t“à‘¤äP‰èŽî‚𒆐S‚É, p.74-83. ŽÄŒ´ˆê—z1, ŒG•”rG1 (1”]ŠO), •Ò: ™ŽRˆê•F, ‹´–{’¼Æ, ƒƒfƒBƒJo”Å, ‘åã, 2020/9”­s.

620055. [Šwp‘ (•ª’SŽ·•M)]yˆ««”]Žîᇂ̂·‚ׂā|Neuro-Oncology‚Ì‹³‰È‘|(”]_ŒoŠO‰È‘¬•ñ2020”N‘Š§†)z[VÍ Žèp] 12. ãó×–EŽîᇠ(germ cell tumor) ‚ÌŽèp, p.184-94. ‹àX­”V, ŒG•”rG1, •y‰i’î“ñ (1”]ŠO), •Ò: ™ŽRˆê•F, ‹´–{’¼Æ, ƒƒfƒBƒJo”Å, ‘åã, 2020/9”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722065. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) _ŒoäPŽî‚É‚¨‚¯‚éæ’BŽÒ‚Ì‹³‚¦‚ÆŽ„‚̃AƒŒƒ“ƒW. ŒG•”rG1, ŽÄŒ´ˆê—z1 (1”]ŠO): ‘æ25‰ñ“ú–{”]Žîᇂ̊O‰ÈŠw‰ï (2020/9/11), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722066. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ‰ð–UŠw‚ÉŠî‚¢‚½‘¤“ª—t“à‘¤Œã•û (Œã•ûŠC”n/ŠC”n–T‰ñ) _ŒoäPŽî’ñop: “ª’¸Œã“ªaE¬”]ƒeƒ“ƒgE“à‘å”]Ã–¬‚ðŒ©‚é. ŽÄŒ´ˆê—z1, ²“¡Ÿl1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO): ‘æ25‰ñ“ú–{”]Žîᇂ̊O‰ÈŠw‰ï (2020/9/11), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722067. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ƒgƒ‹ƒRˆÆ‹ß–TŽîᇎèp‚É‚¨‚¯‚鉶Žt‚Ì‹³‚¦‚ÆŽ„‚̃AƒŒƒ“ƒW|‰¶Žt‚͐¢ŠE’†‚É‚¢‚é!|. ‰ª@GG1, ‹v{”ü^—1, ‹ß“¡GŽ¡1, ƒVƒƒƒCƒgƒnƒEƒA[Eƒo[ƒ“ƒh2, ƒƒCƒhEƒŠƒJƒ‹ƒh2, ƒŠƒ…[ƒfƒbƒNEƒ_ƒCƒGƒ^[3, ƒyƒ‹ƒlƒcƒL[EƒAƒNƒZƒ‹4, ƒoƒ‹ƒgƒ‰ƒ“ƒtƒB[Eƒwƒ‹ƒ€ƒ“ƒg5, ˆÒ‘ºŒöˆè1, “¡ˆä´F6 (1”]ŠO, 2ƒƒCƒˆ[ƒNƒŠƒjƒbƒNEƒƒCƒˆ[ˆã‰È‘åŠw•a—, 3ƒnƒ“ƒuƒ‹ƒO‘åŠw”]_ŒoŠO‰È, 4ƒ}ƒCƒ“ƒc‘åŠw”]_ŒoŠO‰È, 5ƒ`ƒ…[ƒŠƒbƒq‘åŠw”]_ŒoŠO‰È, 6•Ÿ‰ª“¿F‰ï•a‰@”]_ŒoŠO‰È): ‘æ25‰ñ“ú–{”]Žîᇂ̊O‰ÈŠw‰ï (2020/9/12), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722068. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Šç–ʐ_Œo‘O“ªŽ}–ƒáƒ‚ðo‚³‚È‚¢Œo‘Ì–@‚̔畆ØŠJ. ‹v{”ü^—1,2, ‰ª@GG1,2, ‹ß“¡GŽ¡1,2, ˆÒ‘ºŒöˆè1,2, ŒG•”rG2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): ‘æ29‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ï (CNTT2020) (2020/9/29), ‰¡•l.

722069. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ‘åŒûŒa‹zˆøƒJƒe[ƒeƒ‹‚̐퍑Žž‘ã`SOFIAFLOW Plus‚ðŽg‚¢‚±‚È‚¹!`. ŽR–{‘å•ã (”]ŠO): ‘æ29‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ï (CNTT2020) (2020/9/30), ‰¡•l.

722070. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒ`ƒ^ƒ“ƒvƒŒ[ƒg‚ðŽg—p‚µ‚È‚¢‚½‚ß‚ÌŠJ“ªH•v: “Á‚É–¢”j—ô”]“®–¬áŽƒNƒŠƒbƒsƒ“ƒOp‚É‚¨‚¢‚Ä. ¬òŠ°”V1,2, ŽR–{‘å•ã2, ”¼“c@”£2, ‹{â˜aO2, ‰Ž“c˜a‹MŽq2, ´…@ú2, ŒG•”rG2 (1‹~–½, 2”]ŠO): ‘æ13‰ñ“ú–{®—e”]_ŒoŠO‰ÈŠw‰ï (JSAN2020) (2020/9/30), ‰¡•l.

722071. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ‘ŠO—¯Šw‚©‚çŠw‚ñ‚¾Žèp‚̐S“¾‚Æ‹¾Ž‹‰ºŽèp‹³ˆç|Š³ŽÒ’†SŽèp‹³ˆç|. ‰ª@GG1, ƒyƒ‹ƒlƒcƒL[EƒAƒNƒZƒ‹2, ƒŠƒ…[ƒfƒNEƒfƒCƒGƒ^[3, ƒoƒ‹ƒgƒ‰ƒ“ƒtƒB[Eƒwƒ‹ƒ€ƒ“ƒg4, ƒƒCƒhEƒŠƒJƒ‹ƒh5, ƒVƒƒƒCƒgƒnƒEƒA[Eƒo[ƒ“ƒh5, “¡ˆä´F6 (1”]ŠO, 2ƒ}ƒCƒ“ƒc‘åŠw”]_ŒoŠO‰È, 3ƒnƒ“ƒuƒ‹ƒO‘åŠw”]_ŒoŠO‰È, 4ƒ`ƒ…[ƒŠƒbƒq‘åŠw”]_ŒoŠO‰È, 5ƒƒCƒˆ[ƒNƒŠƒjƒbƒNEƒƒCƒˆ[ˆã‰È‘åŠw•a—, 6•Ÿ‰ª“¿F‰ï•a‰@”]_ŒoŠO‰È): ‘æ29‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ï (CNTT2020) (2020/9/30), ‰¡•l.

722072. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) “Á”­«EˆãŒ´«Œã“ª_Œo’ɂ̉ð–UŠw“IlŽ@. ´…@ú1, ‰ª@GG1, ŒG•”rG1 (1”]ŠO): ‘æ27‰ñ“ú–{Ò’ŁEÒ‘_ŒoŽèpŽè‹ZŠw‰ïŠwpW‰ï (2020/10/3), webŠJÃ.

722073. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ¶Brodamnn 22, 41, 42–ì‚É‘¶Ý‚·‚é_ŒoäPŽî‚ɑ΂·‚éŠoÁ‰º_Œo¶—Šwƒ‚ƒjƒ^ƒŠƒ“ƒO‚𕹗p‚µ‚½‰Â‹y“I“Eop. ŽÄŒ´ˆê—z1, ã“cˆ»Žq2, “’–{@“µ2, ‹{â˜aO1, ²“¡Ÿl1, G‘ñˆê˜Y1, âV“¡—³‘¾3, Šâè^Ž÷4, ‰i¼Œªˆê3, ‹àX­”V3, ‰€“c‡•F5, —é–Ø‹§Žq6, ’†—¢M˜a7, •y‰i’î“ñ3, ŒG•”rG1 (1”]ŠO, 2ƒŠƒnƒrƒŠ•”, 3“Œ–k‘åŠw”]_ŒoŠO‰È, 4‘—§¸_E_Œoˆã—ÃŒ¤‹†ƒZƒ“ƒ^[”]_ŒoŠO‰È, 5ŽRŒ`‘åŠw”]_ŒoŠO‰È, 6“Œ–k‘åŠw‚ŽŸ‹@”\áŠQŠw•ª–ì, 7“Œ–k‘åŠw‚Ä‚ñ‚©‚ñŠw•ª–ì): ‘æ18‰ñ“ú–{Awake SurgeryŠw‰ï (2020/10/3), webŠJÃ.

722074. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ¬Ž™”]Žîᇂɑ΂·‚鑽Šp“IƒAƒvƒ[ƒ`: ‹ÇŠŽîᇃRƒ“ƒgƒ[ƒ‹‚É‚¨‚¯‚éÄŽèp‚Ì•K—v«. ŒG•”rG (”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï ‘æ79‰ñŠwp‘‰ï (2020/10/16), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722075. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Ä”­ãóŽî‚ɑ΂·‚é’áü—Ê‘S”]EÒ‘ÆŽË. ‹àX­”V, âV“¡—³‘¾, ‰€“c‡•F, ŒG•”rG1, ¼‰º°—Y, •y‰i’î“ñ (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/16), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722076. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ¬Ž™”]Žîᇂɑ΂·‚éÄŽèpŽž‚̏pŒãŠ´õ—\–h–@. ŽÄŒ´ˆê—z1, ”¼“c@”£1, ‹{â˜aO1, ²“¡Ÿl1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO): ‘æ48‰ñ“ú–{¬Ž™_ŒoŠO‰ÈŠw‰ï (2020/11/22-23), webŠJÃ.

722077. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Ä”­ãóŽî‚ɑ΂·‚é‘S”]EÒ‘ÆŽË. ‹àX­”V, âV“¡—³‘¾, ‰€“c‡•F, ŒG•”rG1, •y‰i’î“ñ (1”]ŠO): ‘æ48‰ñ“ú–{¬Ž™_ŒoŠO‰ÈŠw‰ï (2020/11/23), WebŠJÃ.

722078. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) äP‰èŽîŠ²×–Eƒjƒbƒ`‚ł̍זEŠÔƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“. G‘ñˆê˜Y1, ”’ì—T‹M2, é–씎Žj2, ŽÄŒ´ˆê—z1, Œ¢Ž”@‰~1, ŽÂ“‡’¼Ž÷3, •Š}Wä3, ŒG•”rG1 (1”]ŠO, 2ŒF–{‘åŠw¶–½‰ÈŠwŒ¤‹†•”—Տ°–ò•¨“®‘ÔŠw, 3ŒF–{‘åŠw¶–½‰ÈŠwŒ¤‹†•””]_ŒoŠO‰È): ‘æ38‰ñ“ú–{”]Žîᇊw‰ïŠwpW‰ï (2020/11/30), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723345. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šáâ|“à_ŒoâŽî‚ɂĐf’f‚³‚ꂽ‰Æ‘°«schwannomatosis‚Ì1—á. ‹{â˜aO1, ŽÄŒ´ˆê—z1, G‘ñˆê˜Y1, Œ¢Ž”@‰~1, ŽOŽ}@M2, ’†–ì‰ÃŽq, Žs‘ºKˆê, ‚‘Š»Žm3, ŒG•”rG1 (1”]ŠO, 2•a—, 3®ŠO): ‘æ38‰ñ“ú–{”]Žîᇕa—Šw‰ï (2020/8/6), WebŠJÃ.

723346. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Optic hypothalamic pilocytic astrocytoma‚ÌŒoŽž“I•a—ŠŒ©‚̕ω». ‹àX­”V, “n•Ó‚Ý‚©, âV“¡—³‘¾, ŒG•”rG1, •y‰i’î“ñ (1”]ŠO): ‘æ38‰ñ“ú–{”]Žîᇕa—Šw‰ï (2020/8/6), WebŠJÃ.

723347. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž‹°‚ˆ««“x_ŒoäPŽî‚É‚¨‚¯‚éƒqƒXƒgƒ“•ÏˆÙ‚Æ—\Œã‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ’·“c‰À®, âV“¡—³‘¾, ¯Ži‘ñ‘å, ’·“ì‰ëŽu, ŽÄŒ´ˆê—z1, ‹àX­”V, ‰€“c‡•F, ŒG•”rG1, “n•Ó‚Ý‚©, •y‰i’î“ñ (1”]ŠO): ‘æ38‰ñ“ú–{”]Žîᇕa—Šw‰ï (2020/8/7), WebŠJÃ.

723348. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Ž€‚ÉŽŠ‚Á‚½Šáâ|æ’[ÇŒóŒQ‚̈ê—á`NP«ƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ì‹ºˆÐ`. Œ¢Ž”@‰~1, ”¼“c@”£1, G‘ñˆê˜Y1, ‰Ž“c˜a‹MŽq1, ‹{â˜aO1, ‹g“c@Œ÷2, ŽOŽ}@M2, ŒG•”rG1 (1”]ŠO, 2•a—): ‘æ38‰ñ“ú–{”]Žîᇕa—Šw‰ï (2020/8/7), “Œ‹ž.

723349. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”j—ô“®–¬áŽ‚ɑ΂·‚éŠO‰ÈŽ¡—ÃŒã‚É”ñ•ÂÇ«’°ŠÇ‹•ŒŒ‚𔭏ǂµ‚½2—á. ¬òŠ°”V1,2, ŽR–{‘å•ã1, ó—˜@–õ2, ŒG•”rG1 (1”]ŠO, 2‹~–½): ‘æ45‰ñ“ú–{”]‘²’†Šw‰ï‘‰ï (2020/8/23), webŠJÃ.

723350. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “Ý“I“ª•”ŠO‚É‚æ‚è’†‘å”]“®–¬M2‹NŽn•”‚ɉ¼«“®–¬áŽ‚𐶂¶‚½1—á. ´…@ú1, •“c”Ž‹I1, ‰ª@GG1, ŒG•”rG1 (1”]ŠO): ‘æ49‰ñ“ú–{”]‘²’†‚ÌŠO‰ÈŠw‰ï (2020/8/23), webŠJÃ.

723351. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ˆÊŒz“®–¬‚“x‹·óÇ‚ɑ΂·‚鎡—Õûj: high cervical approach‚©‚猟Ø. ‹v{”ü^—1, ˆÒ‘ºŒöˆè1, ‹ß“¡GŽ¡1, ‰ª@GG1 (1”]ŠO): ‘æ49‰ñ“ú–{”]‘²’†‚ÌŠO‰ÈŠw‰ï (2020/8/23), webŠJÃ.

723352. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”]ŒŒŠÇ‘¢‰e‚É‚æ‚éŠOŒz“®–¬•ªŠò—lŽ®‚Ì•ª—Þ‚Æ“Á’¥. ŽR–{‘å•ã1, ŽÄŒ´ˆê—z1, ¬òŠ°”V1,2, “n糁@’3, ˆä“‡‘å•ã4, •“c”Ž‹I1, m–؁@~1, ‹{â˜aO1, ‹ß“¡—³Žj5, ŒG•”rG1 (1”]ŠO, 2‹~–½, 3å‘ä•a‰@‘‡f—ÉÈ, 4”]_Œo“à, 5é‹ÊÎS‰ï•a‰@”]ŒŒŠÇ“àŽ¡—ÉÈ): ‘æ49‰ñ“ú–{”]‘²’†‚ÌŠO‰ÈŠw‰ï (2020/8/23), webŠJÃ.

723353. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰ð–UŠw‚ÉŠî‚¢‚½ŠC”n/ŠC”n–T‰ñŒã•ûäP‰èŽî“Eop: “ª’¸Œã“ªaE¬”]ƒeƒ“ƒgE“à‘å”]Ã–¬EƒKƒŒƒ“‘åÃ–¬‚ðŒ©‚é. ŽÄŒ´ˆê—z1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO): ‘æ29‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ï (CNTT2020) (2020/9/29), ‰¡•l.

723354. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) _ŒoäP‰èŽî’ño‚É‚¨‚¯‚éSonopet҂ƃoƒCƒ|[ƒ‰“¯Žž•¹—p‚Ì—L—p«. ŒG•”rG1, ŽÄŒ´ˆê—z1, G‘ñˆê˜Y1 (1”]ŠO): ‘æ29‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ï (CNTT2020) (2020/9/29), ‰¡•l.

723355. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šç–ʐ_Œo–ƒáƒ‚ðo‚³‚È‚¢¬”]‹´Šp•”Žîᇎèp. ‹v{”ü^—1,2, ‰ª@GG1,2, ‹ß“¡GŽ¡1,2, ŒG•”rG2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): ‘æ43‰ñ“ú–{Šç–ʐ_ŒoŠw‰ï (2020/9/30), ˆ¤•Q.

723356. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •¡”‰ñ‚Ì‘å‘Ú‹Ø–ŒÌŽæ•”‚ɃŠƒ“ƒp˜R‚𐶂¶‚½1—á. ´…@ú1, –]ŒŽ’O, •“c”Ž‹I1, ªŒ³@[2, ŒG•”rG1 (1”]ŠO, 2Œ`¬E”üŠO): ‘æ13‰ñ“ú–{®—e”]_ŒoŠO‰ÈŠw‰ï (JSAN2020) (2020/9/30), ‰¡•l.

723357. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lŠÔHŠw‚ÉŠî‚­ŽèpŒ°”÷‹¾‘€ìƒnƒ“ƒhƒ‹‚̐ݒè: p’†”æ˜J’ጸ‚ÌŽŽ‚Ý. ´…@ú1, •“c”Ž‹I1, –]ŒŽ’O, ŒG•”rG1 (1”]ŠO): ‘æ27‰ñ“ú–{Ò’ŁEÒ‘_ŒoŽèpŽè‹ZŠw‰ïŠwpW‰ï (2020/10/2), webŠJÃ.

723358. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò‘Œã³’†i“ü–@‚̉ð–UŠw“IŒŸ“¢: ƒ‰ƒbƒgŒã³’†’†Šu‚Ì’´”÷×\‘¢‚©‚ç. ŽOˆäŒö•F, –ö‰ºŽO˜Y, ŒG•”rG1 (1”]ŠO): ‘æ27‰ñ“ú–{Ò’ŁEÒ‘_ŒoŽèpŽè‹ZŠw‰ïŠwpW‰ï (2020/10/3), webŠJÃ.

723359. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒxƒoƒWƒYƒ}ƒu“±“üŒã‚ÌäP‰èŽîŽ¡—ЬÑ. âV“¡—³‘¾, ‹àX­”V, ŽÄŒ´ˆê—z1, ’·“c‰À®, ‰€“c‡•F, ŒG•”rG1, “n•Ó‚Ý‚©, •y‰i’î“ñ (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723360. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äP‰èŽî‚É‚¨‚¯‚éTERTp•ÏˆÙ‚̗Տ°“IˆÓ‹`. ‹e’n‘P², ŽR–{@“N, ŽÄŒ´ˆê—z1, ¼“cŒ›ˆê˜N, ‹à‘º•Ä”Ž, ‘å]—Ï‘¾˜Y, ‹àX­”V, ŒG•”rG1, •y‰i’î“ñ, ‰€“c‡•F (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723361. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž‹°‚ˆ««“x_ŒoäPŽî’ño—á‚É‚¨‚¯‚éƒqƒXƒgƒ“•ÏˆÙ‚Æ—\Œã‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ’·“cŒj®, âV“¡—³‘¾, ŽÄŒ´ˆê—z1, ¯Ži‘ñ‘å, ’·“ì‰ëŽu, ‹àX­”V, ‰€“c‡•F, ŒG•”rG1, “n糂݂©, •y‰i’î“ñ (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723362. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’†Œ^‚Ì’®_ŒoŽîᇂɑ΂·‚é’®—͉·‘¶Žèp. ‹v{”ü^—1, ‰ª@GG1, ‹ß“¡GŽ¡1, ˆÒ‘ºŒöˆè1, ŒG•”rG1 (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15-11/30), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723363. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ñ“TŒ^“I‰æ‘œŠŒ©‚ðŽ¦‚·Œ´”­«’†•_ŒoŒnˆ««ƒŠƒ“ƒpŽî‚Ì•a—‘gDŠw“I“Á’¥. Œ¢Ž”@‰~1, ŽÄŒ´ˆê—z1, ”¼“c@”£1, ‰Ž“c˜a‹MŽq1, ²“¡Ÿl1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15-11/30), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723364. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îŽÒ‚Ì‚Ñ‚Ü‚ñ«Ž²õ‘¹‚̗Տ°“I“Á’¥. G‘ñˆê˜Y1, ŽR–{‘å•ã1, ¬òŠ°”V1,2, ²“¡Ÿl1, ó—˜@–õ2, ŒG•”rG1 (1”]ŠO, 2‹~–½): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15-11/30), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723365. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ªŠò—lŽ®‚É’–Ú‚µ‚½”]ŒŒŠÇŽB‰e‚É‚æ‚éŠOèò“®–¬‚Ì“Á’¥‰ðÍ. ŽR–{‘å•ã1, ¬òŠ°”V1,2, ˆä“‡‘å•ã3, •“c”Ž‹I1, ŽÄŒ´ˆê—z1, m–؁@~1, ‹{â˜aO1, “n糁@’4, ‹ß“¡—³Žj5, ŒG•”rG1 (1”]ŠO, 2‹~–½, 3”]_Œo“à, 4JCHOå‘ä•a‰@‘‡f—ÉÈ, 5é‹ÊÎS‰ï•a‰@”]ŒŒŠÇ“àŽ¡—ÉÈ): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15-11/30), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723366. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Ä”­äP‰èŽî‚ɑ΂·‚éBevacizumab‚ÌŽ¡—ЬÑ‚Æ“Á’¥“I‚ȉ摜ŠŒ©‚ÉŠÖ‚·‚錟“¢. ”¼“c@”£1, ŽÄŒ´ˆê—z1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15-11/30), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723367. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‘O“ª“ª’¸•ÙŠW•”_ŒoäPŽî“EoŒã‚̉^“®‹@”\áŠQ‚ÉŠÖ‚·‚éŠëŒ¯ˆöŽq‚ÌŒŸ“¢. ŽÄŒ´ˆê—z1, ²“¡Ÿl1, –؉º@Šw2, “n糁@’3, G‘ñˆê˜Y1, âV“¡—³‘¾4, ‹àX­”V4, ‰€“c‡•F5, •y‰i’î“ñ4, ŒG•”rG1 (1”]ŠO, 2‘åã‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È”]_ŒoŠO‰È, 3JCHOå‘ä•a‰@‘‡f—ÉÈ, 4“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È_ŒoŠO‰ÈŠw•ª–ì, 5ŽRŒ`‘åŠwˆãŠw•””]_ŒoŠO‰È): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15-11/30), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723368. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Ž¥êŽ®ƒiƒrƒQ[ƒVƒ‡ƒ“ƒKƒCƒh‰º“àŽ‹‹¾‰º•”ŒŒŽî“Eop‚ð‘g‚ݍž‚ñ‚¾ŒŒŽî‚𔺂¤”j—ô”]“®Ã–¬ŠïŒ`‚ɑ΂·‚é‹}«ŠúŽ¡—Ð헪. ¬òŠ°”V1,2, ŽR–{‘å•ã2, G‘ñˆê˜Y2, ó—˜@–õ1, ŒG•”rG2 (1‹~–½, 2”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15-11/30), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723369. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) lŠÔHŠw‚ÉŠî‚­ŽèpŒ°”÷‹¾‘€ìƒnƒ“ƒhƒ‹‚̐ݒè: p’†”æ˜J’ጸ‚ÌŽŽ‚Ý. ´…@ú1, •“c”Ž‹I1, –]ŒŽ’O, ŒG•”rG1 (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ79‰ñŠwp‘‰ï (2020/10/15-11/30), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723370. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”ñ“TŒ^“I‰æ‘œŠŒ©‚ðŽ¦‚·Œ´”­«’†•_ŒoŒnˆ««ƒŠƒ“ƒpŽî‚Ì•a—‘gDŠw“I“Á’¥. Œ¢Ž”@‰~1, ŽÄŒ´ˆê—z1, ”¼“c@”£1, ‰Ž“c˜a‹MŽq1, ²“¡Ÿl1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO): ‘æ38‰ñ“ú–{”]Žîᇊw‰ïŠwpW‰ï (2020/11/29), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723371. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Ä”­äP‰èŽî‚ɑ΂·‚éBevacizmab‚ÌŽ¡—ЬÑ‚Æ“Á’¥“I‚ȉ摜ŠŒ©‚ÉŠÖ‚·‚錟“¢. ”¼“c@”£1, ŽÄŒ´ˆê—z1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO): ‘æ38‰ñ“ú–{”]Žîᇊw‰ïŠwpW‰ï (2020/11/29), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723372. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ¬Ž™EAYA¢‘ã‚̍Ĕ­ˆ««”]Žîᇂɑ΂·‚éˆâ“`Žqƒpƒlƒ‹ŒŸ¸‚̗Տ°‰ž—p. ŽÄŒ´ˆê—z1, ŒG•”rG1, G‘ñˆê˜Y1, ù”ö—º‘¾2, ²X–ØŒõ2, ²X–ØŽ¡ˆê˜Y3 (1”]ŠO, 2Œcœä‹`m‘åŠwˆãŠw•””]_ŒoŠO‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ38‰ñ“ú–{”]Žîᇊw‰ïŠwpW‰ï (2020/11/30), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723373. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Extra-parenchymal (Peripheral) Atypical Teratoid/Rhabdoid Tumors. ‰ª@GG1, ‹v{”ü^—1, ˆÒ‘ºŒöˆè1, ‹ß“¡_Ž¡1 (1”]ŠO): ‘æ38‰ñ“ú–{”]Žîᇊw‰ïŠwpW‰ï (2020/12/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723374. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 12p gain‚͍‚ˆ««“x‚Ì”ñƒWƒƒ[ƒ~ƒm[ƒ}«ãó×–EŽî‚ō‚•p“x‚É”F‚ß‚ç‚ê‚é. —¢Œ©‰îŽj, ‚Œ©_”, •Ÿ“‡T‘¾˜Y, ’†—¢—mˆê, “c’†›’‘¾, âV“¡‰„l, ‹àX­”V, ŒG•”rG1, ¬—ÑŒ[ˆê, ‰iªŠî—Y, ˆä“àr•F, aŒû¹O, “c‘º@ˆè, ‘OŒ´Œ’Žõ, ŽðˆäŒ\ˆê, ™ŽRˆê•F, ‰¡ã¹‹M, ’|“‡G—Y, ”W’†³”Ž, ŸÇˆäº—Y, ¼ì@—º, ¼’J­¶, Žs‘ºKˆê (1”]ŠO): ‘æ38‰ñ“ú–{”]Žîᇊw‰ïŠwpW‰ï (2020/12/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723375. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘æŽl”]ŽºãˆßŽî‚̉ð–U•ª—ށE•ªŽq•ª—Þ‚©‚ç‚Ý‚½“Eo“xE‹@”\‰·‘¶EŽîᇐ§Œä. ‹àX­”V, âV“¡—³‘¾, “n•Ó‚Ý‚©, ‰€“c‡•F, ŒG•”rG1, •y‰i’î“ñ (1”]ŠO): ‘æ38‰ñ“ú–{”]Žîᇊw‰ïŠwpW‰ï (2020/12/1), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723376. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”]ŒŒŠÇáŠQŽèp‚É‚¨‚¯‚铪ŠW’êŽè‹Z‚Ì—L—p«. ‹v{”ü^—1, ‹ß“¡GŽ¡1, ˆÒ‘ºŒöˆè1, ‰ª@GG1 (1”]ŠO): ‘æ50‰ñ“ú–{”]‘²’†‚ÌŠO‰ÈŠw‰ïŠwpW‰ï (STROKE 2021) (2021/3/12), •Ÿ‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723377. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) M1-2“®–¬áŽƒgƒ‰ƒbƒsƒ“ƒOp‚É•¹—p‚·‚éƒAƒVƒXƒgƒoƒCƒpƒXp‚É‚¨‚¯‚érecipient artery‘I‘ð‚̍H•v|Ç—á•ñ. •“c”Ž‹I1, ’†‹N“W, –]ŒŽ’O, ´…@ú1, ŒG•”rG1 (1”]ŠO): ‘æ50‰ñ“ú–{”]‘²’†‚ÌŠO‰ÈŠw‰ïŠwpW‰ï (STROKE 2021) (2021/3/11-4/12), •Ÿ‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723378. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’ōœ”]’ê“®–¬paramedian longitudinal axis‚̈âŽc“®–¬‚ɐ¶‚¶‚½‰ð—£«“®–¬áŽ‚Ì1—á. ´…@ú1, •“c”Ž‹I1, ŠÃ—˜˜aŒõ, ’†‹N“W, Œ¢Ž”@‰~1, ŒG•”rG1 (1”]ŠO): ‘æ50‰ñ“ú–{”]‘²’†‚ÌŠO‰ÈŠw‰ïŠwpW‰ï (STROKE 2021) (2021/3/11-4/12), •Ÿ‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

731013. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) eloquent area‚É‚¨‚¯‚éäP‰èŽî‚ÌŽèpí—ª. ŒG•”rG (”]ŠO): MB”]Žîá‡WebƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2020/10/6), webŠJÃ.

731014. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ¬Ž™”]Žîᇂ̑Šúf’f‚É‚¨‚¯‚钍ˆÓŽ–€. ŒG•”rG (”]ŠO): ‘æ230‰ñ“ú–{¬Ž™‰ÈŠw‰ï‹{é’n•û‰ï (2020/11/15), WebŠJÃ.

733072. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ¬”]ˆÙŒ`¬‚ð”wŒi‚É”­¶‚µ‚½¬l‘‰èŽî‚Ì1—á. –L“c䝗œŽq1, ŽÄŒ´ˆê—z1, ”¼“c@”£1, •S•—C—1, Œ¢Ž”@‰~1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO): ‘æ143‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ïŠÖ“ŒŽx•”‰ï (2020/12/12), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

733073. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “ªŠW“àgerminoma‚É‘Sl«sarcoidosis‚ð‡•¹‚µ‚½ˆê—á. •S•—C—1, ŽÄŒ´ˆê—z1, ˆäã’q•v1, ¬òŠ°”V1,2, Žt“cMl1, G‘ñˆê˜Y1, Œ¢Ž”@‰~1, ‹g“c@Œ÷3, ²X–ØŽ¡ˆê˜Y4, ŒG•”rG1 (1”]ŠO, 2‹~–½, 3•a—, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ143‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ïŠÖ“ŒŽx•”‰ï (2020/12/12), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

'19”N“xˆÈ‘O•ª

[’˜@‘]

'19-620011. [Šwp‘ (•ª’SŽ·•M)]yƒCƒ‰ƒXƒg‚Ɖ摜‚ł݂錌ŠÇ“àŽ¡—ÂɕK—v‚È‘SgŒŒŠÇ (ƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒt‚Ì‚½‚ß‚ÌŒŒŠÇ“àŽ¡—ÃVƒŠ[ƒY ƒƒfƒBƒJƒe…B)z1Í “ª•”‚ÌŒŒŠÇ, p.15-56. ŽR–{‘å•ã1, Î“cO‹B2, “¡‰ªrˆê˜Y3, ‘å‹v•Û”Ž¢3, ’r“c—S‹B4, ƒEƒbƒhƒnƒ€ƒX—æŽq5, ¼‰iŒh“ñ5, Œ´@•q«, “¡ˆä@Š]5, ˆ¢ŒÃÆ2 (1”]ŠO, 2zŠÂŠí“à, 3S‘ŸŒŒŠÇŠO, 4‹~–½, 5•úŽËü (‰æ‘œ)) •Ò: ˆ¢ŒÃÆ, ƒƒfƒBƒJo”Å, ‘åã, 2019/10”­s.


¬Ž™‰ÈŠw

[Šwp˜_•¶]

110262. [Œ´’˜] Hypoxic activation of glucose-6-phosphate dehydrogenase controls the expression of genes involved in the pathogenesis of pulmonary hypertension through the regulation of DNA methylation. Joshi SR, Kitagawa A1, Jacob C, Hashimoto R, Dhagia V, Ramesh A, Zheng C, Zhang H, Jordan A, Waddell I, Leopold J, Hu C-J, McMurtry IF, D'Alessandro A, Stenmark KR, Gupte SA: Am J Physiol Lung Cell Mol Physiol 2020/4; 318 (4): L773-86. (–kì“ÄŽj1: 1¬Ž™)

110263. [Œ´’˜] Primary causes of kidney disease and mortality in dialysis-dependent children. Okuda Y1, Soohoo M, Ishikura K1, Tang Y, Obi Y, Laster M, Rhee CM, Streja E, Kalantar-Zadeh K: Pediatr Nephrol 2020/5; 35 (5): 851-60. (‰œ“c—Y‰î1, Î‘qŒ’Ži1: 1¬Ž™)

110264. [Œ´’˜] CRISPR-Mediated Single Nucleotide Polymorphism Modeling in Rats Reveals Insight Into Reduced Cardiovascular Risk Associated With Mediterranean G6PD Variant. Kitagawa A1, Kizub I, Jacob C, Michael K, D'Alessandro A, Reisz JA, Grzybowski M, Geurts AM, Rocic P, Gupte R, Miano JM, Gupte SA: Hypertension 2020/8; 76 (2): 523-32. (–kì“ÄŽj1: 1¬Ž™)

110265. [Œ´’˜] A cross-sectional nationwide survey of congenital and infantile nephrotic syndrome in Japan. Hamasaki Y, Hamada R, Muramatsu M, Matsumoto S, Aya K, Ishikura K1, Kaneko T, Iijima K: BMC Nephrol 2020/8; 21 (1): 363. (Î‘qŒ’Ži1: 1¬Ž™)

110266. [Œ´’˜] A simple, refined approach to diagnosing renovascular hypertension in children: A 10-year study. Saida K, Kamei K, Hamada R, Yoshikawa T, Kano Y, Nagata H, Sato M, Ogura M, Harada R, Hataya H, Miyazaki O, Nosaka S, Ito S, Ishikura K1: Pediatr Int 2020/8; 62 (8): 937-43. (Î‘qŒ’Ži1: 1¬Ž™)

110267. [Œ´’˜] Refractory Hypertension in Infantile-Onset Denys-Drash Syndrome. Nishi K, Kamei K, Ogura M, Sato M, Murakoshi M,Kamae C,Suzuki R , Kanamori T, Nagano C, Nozu K, Ishikura K1, Ito S: Tohoku J Exp Med 2020/9; 252 (1): 45-51. (Î‘qŒ’Ži1: 1¬Ž™)

110268. [Œ´’˜] Prospective study of live attenuated vaccines for patients receiving immunosuppressive agents. Kamei K, Miyairi I, Ishikura K1, Ogura M, Shoji K, Arai K, Ito R, Kawai T, Ito S: PLoS One 2020/10; 15 (10): e0240217. (Î‘qŒ’Ži1: 1¬Ž™)

110269. [Œ´’˜] Dietary Potassium Intake and Mortality in a Prospective Hemodialysis Cohort. Narasaki Y, Okuda Y1, Kalantar SS, You AS, Novoa A, Nguyen T, Streja E, Nakata T, Colman S, Kalantar-Zadeh K, Nguyen DV, Rhee CM: J Ren Nutr 2021/7; 31 (4): 411-20. doi: 10.1053/j.jrn.2020.05.008. Epub 2020 Oct 27. (‰œ“c—Y‰î1: 1¬Ž™)

110270. [Œ´’˜] Perinatal factors contributing to chronic kidney disease in a cohort of Japanese children with very low birth weight. Uemura O, Ishikura K1, Kaneko T, Hirano D, Hamasaki Y, Ogura M, Mikami N, Gotoh Y, Sahashi T, Fujita N, Yamamoto M, Hibino S, Nakano M, Wakano Y, Honda M: Pediatr Nephrol 2021/4; 36 (4): 953-60. doi: 10.1007/s00467-020-04791-1. Epub 2020 Oct 17. (Î‘qŒ’Ži1: 1¬Ž™)

110271. [Œ´’˜] Association of age with risk of first and subsequent allograft failure and mortality among young kidney transplant recipients in the USA - a retrospective cohort study. Okuda Y1, Streja E, Rhee CM, Tantisattamo E, Reddy U, Laster M, Tang Y, Rajpoot D, Molnar MZ, Ichii H, Obi Y, Kalantar-Zadeh K: Transpl Int 2020/11; 33 (11): 1503-15. (‰œ“c—Y‰î1: 1¬Ž™)

110272. [Œ´’˜] Influenza virus vaccination in children with nephrotic syndrome: insignificant risk of relapse. Ishimori S, Kamei K, Ando T, Yoshikawa T, Kano Y, Nagata H, Saida K, Sato M, Ogura M, Ito S, Ishikura K1: Clin Exp Nephrol 2020/11; 24 (11): 1069-76. (Î‘qŒ’Ži1: 1¬Ž™)

110273. [Œ´’˜] Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome. Jia X , Yamamura T , Gbadegesin R, McNulty MT, Song K, Nagano C, Hitomi Y, Lee D, Aiba Y, Khor S-S, Ueno K, Kawai Y, Nagasaki M, Noiri E, Horinouchi T, Kaito H, Hamada R, Okamoto T, Kamei K, Kaku Y, Fujimaru R, Tanaka R , Shima Y, Research Consortium on Genetics of Childhood Idiopathic Nephrotic Syndrome in Japan; Baek J, Kang HG, Ha I-S, Han KH, Yang EM, Korean Consortium of Hereditary Renal Diseases in Children; Abeyagunawardena A, Lane B, Chryst-Stangl M, Esezobor C, Solarin A, Midwest Pediatric Nephrology Consortium (Genetics of nephrotic syndrome study group); Dossier C, Deschnes G, NEPHROVIR; Vivarelli M, Debiec H, Ishikura K1, Matsuo M, Nozu K, Ronco P, Cheong HI, Sampson MG, Tokunaga K, Iijima K: Kidney Int 2020/11; 98 (5): 1308-22. (Î‘qŒ’Ži1: 1¬Ž™)

110274. [Œ´’˜] A faster decline of residual kidney function and erythropoietin stimulating agent hyporesponsiveness in incident hemodialysis patients. Kimura H, Sy J, Okuda Y1, Wenziger C, Hanna R, Obi Y, Rhee CM, Kovesdy CP, Kalantar-Zadeh K, Streja E: Hemodial Int 2021/1; 25 (1): 60-70. (‰œ“c—Y‰î1: 1¬Ž™)

110275. [Œ´’˜] Hyperglycemic Crisis in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS). Toki T1, Shimizu-Motohashi Y, Komaki H, Takeshita E, Ishiyama A, Saito T, Mori-Yoshimura M, Sumitomo N, Hirasawa-Inoue A, Nakagawa E, Nishino I, Goto Y, Sasaki M: Pediatr Neurol 2021/1; 114: 1-4. (“yŠò@•½1: 1¬Ž™)

110276. [Œ´’˜] A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study. Prusakov P1, Goff DA1, Wozniak PS1, Cassim A1, Scipion CEA1, Urzœa S1, Ronchi A1, Zeng L1, Ladipo-Ajayi O1, Aviles-Otero N1, Udeigwe-Okeke CR1, Melamed R1, Silveira RC1, Auriti C1, Beltr‡n-Arroyave C1, Zamora-Flores E1, Sanchez-Codez M1, Donkor ES1, KekomŠki S1, Mainini N1, Trochez RV1, Casey J1, Graus JM1, Muller M1, Singh S1, Loeffen Y1, PŽrez MET1, Ferreyra GI1, Lima-Rogel V1, Perrone B1, Izquierdo G1, Cernada M1, Stoffella S1, Ekenze SO1, de Alba-Romero C1, Tzialla C1, Pham JT1, Hosoi K1, Consuegra MCCC1, Betta P1, Hoyos OA1, Roilides E1, Naranjo-Zu–iga G1, Oshiro M1, Garay V1, Mond“ V1, Mazzeo D1, Stahl JA1, Cantey JB1, Monsalve JGM1, Normann E1, Landgrave LC1, Mazouri A1, Avila CA1, Piersigilli F1, Trujillo M1, Kolman S1, DelgadoV1, Guzman V1, Abdellatif M1, Monterrosa L1, Tina LG1, Yunis K1, Rodriguez MAB1, Le Saux N1, Leonardi V1, Porta A1, Latorre G1, Nakanishi H1,2,3, Meir M1, Manzoni P1, Norero X1, Hoyos A1, Arias D1, S‡nchez RG1, Medoro AK1, S‡nchez PJ1 (1Global NEO-ASP Study Group): EClinicalMedicine 2021/1; 32: 100727. (’†¼G•F1,2,3: 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3¬Ž™)

110277. [Œ´’˜] Race and Ethnicity Predict Bone Markers and Fracture in Pediatric Patients With Chronic Kidney Disease. Laster M, Denburg M, Okuda Y1, Kumar J, Furth S, Warady B, Kalantar-Zadeh K, Norris K, Salusky IB: J Bone Miner Res 2021/2; 36 (2): 298-304. (‰œ“c—Y‰î1: 1¬Ž™)

110278. [Œ´’˜] Prognosis and acute complications at the first onset of idiopathic nephrotic syndrome in children: a nationwide survey in Japan (JP-SHINE study). Sato M1, Ishikura K1,2, Ando T1, Kikunaga K1, Terano C1, Hamada R1, Ishimori S1, Hamasaki Y1, Araki Y1, Gotoh Y1, Nakanishi K1, Nakazato H1, Matsuyama T1, Iijima K1, Yoshikawa N1, Ito S1, Honda M1 (1Japanese Pediatric Survey Holding Information of Nephrotic Syndrome (JP-SHINE) study of the Japanese Study Group of Renal Disease in Children): Nephrol Dial Transplant 2021/2; 36 (3): 475-81. (Î‘qŒ’Ži1,2: 2¬Ž™)

110279. [Œ´’˜] A Retrospective Cohort Study on Mortality and Neurodevelopmental Outcomes of Preterm Very Low Birth Weight Infants Born to Mothers with Hypertensive Disorders of Pregnancy. Kono Y1, Yonemoto N1, Nakanishi H1,2,3, Hosono S1, Hirano S1, Kusuda S1, Fujimura M1 (1Neonatal Research Network Japan): Am J Perinatol 2021/2. doi: 10.1055/s-0041-1722874. Online ahead of print. (’†¼G•F1,2,3: 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3¬Ž™)

110280. [Œ´’˜] Development and validation of a Japanese version of the TRANSITION-Q. Morisaki-Nakamura M, Suzuki S, Kobayashi A, Kita S, Sato I, Iwasaki M, Hirata Y1, Sato A, Oka A, Kamibeppu K: Pediatr Int 2021/3; 63 (3): 270-8. (•½“c—zˆê˜Y1: 1¬Ž™)

110281. [Œ´’˜] G6PD activity contributes to the regulation of histone acetylation and gene expression in smooth muscle cells and to the pathogenesis of vascular diseases. Dhagia V, Kitagawa A1, Jacob C, Zheng C, D'Alessandro A, Edwards JG, Rocic P, Gupte R, Gupte SA: Am J Physiol Heart Circ Physiol 2021/3; 320 (3): H999-1016. (–kì“ÄŽj1: 1¬Ž™)

110282. [Œ´’˜] Prophylactic rituximab administration in children with complicated nephrotic syndrome. Okutsu M, Kamei K, Sato M, Kanamori T, Nishi K, Ishiwa S, Ogura M, Sako M, Ito S, Ishikura K1: Pediatr Nephrol 2021/3; 36 (3): 611-9. (Î‘qŒ’Ži1: 1¬Ž™)

120009. [Œ´’˜] é‹ÊŒ§‚É‚¨‚¯‚éƒ_ƒjƒAƒŒƒ‹ƒM[‚ÉŠÖ‚·‚éˆÓŽ¯’²¸‚ÌŒ‹‰Ê. ‹V“¯´, ²“¡G”ü, ŽO‘î’è–¾, â“Œ—R‹I1,2, ‚‰ª³•q, ‘åêCˆê, ‘º“c@Œõ (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): é‹ÊŒ§‰q¶Œ¤‹†Š•ñ 2021/1; 54: 116-21.

120010. [Œ´’˜] YS1402”牺“Š—^, ‚¨‚æ‚ѐS‹Ø“Š—^‚É‚¨‚¯‚é‹•ŒŒ«S‹ØÇ‚ɑ΂·‚éŒø‰Ê‚ÌŒŸ“¢. •½“c—zˆê˜Y1, ²“c­—² (1¬Ž™): ŒŽŠ§Bio Industry 2020/8; 37 (8): 38-45.

120011. [Œ´’˜] “ûŽ™‘Šú‚ɐAž‚ÝŒ^œ×“®Ší (ICD) Až‚Ý‚ðs‚Á‚½æ“V«QT‰„’·ÇŒóŒQ‚Ì1—á. “yŠò”ü‹v1, ˆÀ“¡@Žõ1, •ô”öŒb—œ1, –Ø‘ºƒl1, ‚—œ@Šw1, –{“c@’1, •½“c—zˆê˜Y1, ‹{’n@ŠÓ2, Î‘qŒ’Ži1 (1¬Ž™, 2S‘ŸŒŒŠÇŠO): “ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2021/2; 20 (1): 39-42.

310029. [Ç—á•ñ] Successful angioplasties using high pressure large balloons in a patient with severe anastomotic pulmonary artery stenosis soon after single-lung transplantation. Shiraga K, Hirata Y1, Saito A, Ozcelik N, Asakai H, Inuzuka R, Soma K, Sato M, Hirata Y, Oka A: J Cardiol Cases 2020/5; 22 (1): 22-5. (•½“c—zˆê˜Y1: 1¬Ž™)

310030. [Ç—á•ñ] Two cases of idiopathic steroid-resistant nephrotic syndrome complicated with thrombotic microangiopathy. Nishi K, Sato M, Ogura M, Okutsu M, Ishikura K1, Kamei K: BMC Nephrol 2020/8; 21 (1): 323. (Î‘qŒ’Ži1: 1¬Ž™)

310031. [Ç—á•ñ] A girl with MIRAGE syndrome who developed steroid-resistant nephrotic syndrome: a case report. Ishiwa S, Koichi Kamei K, Tanase-Nakao K, Shibata S, Matsunami K, Takeuchi I, Sato M, Ishikura K1, Narumi S: BMC Nephrol 2020/8; 21 (1): 340. (Î‘qŒ’Ži1: 1¬Ž™)

310032. [Ç—á•ñ] Poor Myocardial Compaction in a Patient with Recessive MYL2 Myopathy. Monoi-Tamamitsu A, Nakagama Y, Domoto Y, Yoshida K, Ogawa S, Hirono K, Shindo T, Ogawa Y, Nakano K, Asakai H, Hirata Y1, Matsui H, Inuzuka R: Int Heart J 2021/3; 62 (2): 445-7. (•½“c—zˆê˜Y1: 1¬Ž™)

310033. [Ç—á•ñ] Echocardiogram Unmasked Hemodynamic Advantage of Atrial Pacing in Securing Ventricular Preload in a Fontan Patient with Junctional Rhythm. Saiki H, Kawada K1, Kuwata S1, Takanashi M1, Fukunishi T2, Miyaji K2, Senzaki H: Int Heart J 2021/3; 62 (2): 448-52. (ì“cF•½1, øw“c¹Žq1, ‚—œ@Šw1, •Ÿ¼‘ô^2, ‹{’n@ŠÓ2: 1¬Ž™, 2S‘ŸŒŒŠÇŠO)

320017. [Ç—á•ñ] SŽº’†ŠuŒ‡‘¹‚ð‡•¹‚µ‘Šú‚ÉŠO‰È“IŽ¡—Éî“ü‚ð—v‚µ‚½‘½E«ŽOS–[S‚Ì“ûŽ™—á. ì“cF•½1, –Ø‘ºƒl1, •½“c—zˆê˜Y1, –{“c@’1, ‚—œ@Šw1, â“Œ—R
‹I1,2, X@‘PŽ÷, Î‘qŒ’Ži1 (1¬Ž™, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ¬Ž™‰È 2021/2; 62 (2): 193-8.

510013. [‘à] Inherited salt-losing tubulopathy: An old condition but a new category of tubulopathy. Nozu K, Yamamura T, Horinouchi T, Nagano C, Sakakibara N, Ishikura K1, Hamada R, Morisada N, Iijima K: Pediatr Int 2020/4; 62 (4): 428-37. (Î‘qŒ’Ži1: 1¬Ž™)

520009. [‘à] —Տ°ˆã‚ªŽè‚ª‚¯‚é‰uŠwŒ¤‹†. ‰œ“c—Y‰î1, Î‘qŒ’Ži1 (1¬Ž™): –k—¢ˆãŠw 2020/12; 50 82): 93-103.

522062. [uÀ]y“ÁW: ŽüŽYŠú‚ƏzŠÂŠÇ—zV¶Ž™Šú‚̏zŠÂŠÇ—@”ÓŠúzŠÂ•s‘S‚Ì•a‘Ô‚ÆŠÇ—. ’†¼G•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ŽüŽYŠúˆãŠw 2020/7; 50 (7): 1133-8.

522063. [uÀ]y“ÁW: ¬Ž™‚ÌäPŒ´•az[—Տ°—á] ¬Ž™Šú‚É”­Ç‚µ‚½microgeodic disease‚Ì2Ç—á. ]”gŒËF•ã1, ‹àŽq‰ë‹I1, â“Œ—R‹I1, Î‘qŒ’Ži1 (1¬Ž™): ”畆•af—à 2021/3; 43 (3): 260-3.

530014. [‚»‚Ì‘¼ (Letter to the Editor)] Toward co-production of research in 22q11.2 deletion syndrome: Research needs from the caregiver's perspective. Tamune H, Kumakura Y, Morishima R, Kanehara A, Tanaka M, Okochi N, Nakajima N, Hamada J, Ogawa T, Nakahara M, Jinde S, Kano Y, Tanaka K, Hirata Y1, Oka A, Kasai K: Psychiatry Clin Neurosci 2020/11; 74 (11): 626-7. (•½“c—zˆê˜Y1: 1¬Ž™)

540025. [‚»‚Ì‘¼ (ƒ[ƒLƒ“ƒOƒOƒ‹[ƒv•ñ)]y“ú–{¬Ž™‰ÈŠw‰ï“­‚«•û‰üŠvŒŸ“¢ƒ[ƒLƒ“ƒOƒOƒ‹[ƒv•ñz‚±‚ê‚©‚ç‚̏¬Ž™‰Èˆã‚ª–ÚŽw‚·¬Ž™•ÛŒ’Eˆã—Â̕ûŒü«‚ɂ‚¢‚Ä. ‘åŽR¸ˆê1, Ô—ä—zŽq1, •ŸŒ´—¢Œb1, r–xm”ü1, Î–с@’1, Îè—DŽq1, ˆÉ“¡—F–í1, ]Œ´@˜N1, “ú‰º@—²1, ŽíŽsq’ˆ1, à_“c—m’Ê1, •½–{—´Œá1, ˜Ô“cŒõ˜a1, “¹’[L–¾1, â“Œ—R‹I1,2,3, ‹àé‹IŽq1, ¼Œ´’m‘ã1, •½ŽR‰ë_1 (1“ú–{¬Ž™‰ÈŠw‰ï“­‚«•û‰üŠvŒŸ“¢ƒ[ƒLƒ“ƒOƒOƒ‹[ƒv, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3¬Ž™): “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2021/3; 125 (3): 540-4.

[’˜@‘]

610002. [Šwp‘ (•ª’SŽ·•M)]yMolecular Mechanism of Congenital Heart Disease and Pulmonary Hypertensionz11. Morphological Characterization of Pulmonary Microvascular Disease in Bronchopulmonary Dysplasia Caused by Hyperoxia in Newborn Mice, p.91-3. Nakanishi H1,2, Morikawa S, Kitahara S, Yoshii A, Uchiyama A, Kusuda S, Ezaki T, Editors: Nakanishi T, Baldwin HS, Fineman JR, Yamagishi H, Springer, Singapore, 2020/10. (’†¼G•F1,2: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™)

620056. [Šwp‘ (•ª’SŽ·•M)]y¬Ž™Ž¾Š³‚Ì–ò•¨Ž¡—ÃKƒCƒhƒ‰ƒCƒ“‘‚܂Ƃ߁@•W€Ž¡—Âð‚܂邲‚Ɖðà! (ŒŽŠ§–òŽ–2020”N5ŒŽ—ÕŽž‘Š§†)z‘æVÍ tŽ¾Š³@æ“V«t”A˜HˆÙí, p.1388-92. Î‘qŒ’Ži (¬Ž™), •ÒW‘ã•\: ŒÜ\—’—², •Ò: ꎓ¡‡•½, ŽR’J–¾³, ‚¶‚Ù‚¤, “Œ‹ž, 2020/5”­s.

620057. [Šwp‘ (•ª’SŽ·•M)]y¬Ž™ƒŠƒEƒ}ƒ`Šwz‘æI•” ‘˜_@¬Ž™ƒŠƒEƒ}ƒ`«Ž¾Š³‚Ì—‰ð‚É•K—v‚ȖƉuŠw‚ÌŠî‘b’mŽ¯, p.10-4. â“Œ—R‹I1,2, A¼’”V (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™), ŠÄC: ˆÉ“¡Gˆê, X@‰ë—º, •Ò: “ú–{¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï, ’©‘q‘“X, “Œ‹ž, 2020/5”­s.

620058. [Šwp‘ (•ª’SŽ·•M)]y‚ŒŒˆ³Šw@‰º|‚ŒŒˆ³§ˆ³‚ÌŒ»ó‚Æ“W–]|(“ú–{—Õà¬78Šª‘Š§†2)zXIII. ƒ‰ƒCƒtƒXƒe[ƒWEƒ‰ƒCƒtƒCƒxƒ“ƒg‚©‚ç‚Ý‚½‚ŒŒˆ³‚ÌŽ¡—ÂƊǗ2. ¬Ž™‚©‚çŽvtŠú‚̍‚ŒŒˆ³‚̐f’fEŽ¡—ÁE—\Œã, p.244-51. ‰œ“c—Y‰î1, Î‘qŒ’Ži1, ”Ñ“‡ˆê½ (1¬Ž™, “ú–{—Õ଎Ð, “Œ‹ž, 2020/7”­s.

620059. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚̏¬Ž™Ž¡—ÃŽwj ‘æ17”Łz16. tE”å”AŠíŽ¾Š³@––Šút•s‘S, p.594-9. Î‘qŒ’Ži (¬Ž™), ‘•ÒW: …Œû@‰ë, Žs‹´@Œõ, èŽR@O, ˆÉ“¡ Gˆê, ˆãŠw‘‰@, “Œ‹ž, 2020/12”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713036. [Šw‰ï (‘Û)] (ˆê”ÊŒû‰‰) Racial-ethnic differences in bone and mineral outcomes in children with CKD. Marciana Laster, Michelle Denburg, Okuda Y1, Juhi Kumar, Susan Furth, Keith Norris, Kamyar Kalantar-Zadeh, Bradley Warady, Isidro Salusky Pediatric Academic Societies (PAS) Meeting 2020 (2020/4/29-5/6), Philadelphia, USA. (‰œ“c—Y‰î1: 1¬Ž™)

713037. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Kidney Transplant Access Among Children and Young Adults on Dialysis in the United States. Okuda Y1, Ekamol Tantisattamo, Elani Streja, Marciana Laster, Connie M Rhee, Kamyar Kalantar-Zadeh American Society of Nephrology Kidney Week 2020 (2020/10/19-12/4), WebŠJÃ. (‰œ“c—Y‰î1: 1¬Ž™)

713038. [Šw‰ï (‘Û)] (ˆê”ÊŒû‰‰) Secular Trends in the Incidence and Prevalence of Dialysis Therapy among Children and Young Adults in JAPAN Compared with the USA, Europe and Oceania. Okuda Y1, Harada R, Hamada R, Hamasaki Y, Ishikura K1 14th Asian Congress of Pediatric Nephrology (2021/3/29-4/2), Taipei, Taiwan. Asian J Pediatr Nephrol 2021; 4 (Suppl S1): 1-67. (‰œ“c—Y‰î1, Î‘qŒ’Ži1: 1¬Ž™)

713039. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Polyhydramnios as a symptom of antenatal Bartter syndrome. Kawada K1, Okuda Y1, Kon S1,2, Serizawa H, Ishida S, Nozu K, Ishikura K1: 14th Asian Congress of Pediatric Nephrology (2021/3/29-4/2), Taipei, Taiwan. (ì“cF•½1, ‰œ“c—Y‰î1, © L–ç1,2, Î‘qŒ’Ži1: 1¬Ž™, 2‹~–½)

721013. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) Žö“û’†‚Ì•êe‚ɑ΂·‚é–ò•¨Ž¡—Â̍l‚¦•û. ’†¼G•F1,2, ‘º“‡‰·Žq (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2020/8/21), WebŠJÃ.

721014. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ‘ŽYŽ™RSƒEƒCƒ‹ƒXŠ´õ‚̏dÇ‰»—}§‚É‚¨‚¯‚éƒsƒbƒgƒtƒH[ƒ‹`ƒpƒŠƒrƒYƒ}ƒu‚̉¶Œb‚ðŽó‚¯‚é‚ׂ«‘Ώێҁ`. ’†¼G•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‘æ56‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2020/11/28-12/4), WebŠJÃ.

722079. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) ƒlƒtƒƒ“ᔁ|—Տ°Œ^‚ƈâ“`ŽqˆÙí|. ‰œ“c—Y‰î1, Î‘qŒ’Ži1 (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ.

722080. [Šw‰ï (‘S‘)] (ƒL[ƒ|ƒCƒ“ƒgƒŒƒNƒ`ƒƒ[)yƒKƒCƒhƒ‰ƒCƒ“‚©‚çŠw‚ÔCAKUT‚̐f—ÁzCAKUT‚Ì“à‰È“IŠÇ—: ƒKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚¢‚Ä. Î‘qŒ’Ži (¬Ž™): ‘æ29‰ñ“ú–{¬Ž™”å”AŠí‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2021/2/1), WebŠJÃ.

723379. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) TSH’P“ÆŒ‡‘¹Ç‚Ì•ªŽqŠî”Õ: ¬Ž™Š³ŽÒ13—á‚ÌŒn““Iˆâ“`Žq‰ðÍ‚Æ•¶Œ£ƒŒƒrƒ…[. ™àVç•ä, ˆ¢•”´”ü, Žu‰êŒ’‘¾˜Y, ›Œ´G“T, ‘吙NŽi, Žº’J_“ñ, ’©‘q—R”üŽq, ˆÀ’B¹Œ÷, ‘å’ʁ@®, À‘qŽü•F, ¬’r–¾”ü, ’ց@~Žq, ‹k“cˆê‹P1, ¼‰YM•v, ’JŽR¼—Y, ’·’Jì•ò‰„, –ŠCŠoŽu (1¬Ž™): ‘æ93‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï (2020/7/20-8/31), WebŠJÃ, “ú–{¬Ž™t‘Ÿ•aŠw‰ïŽGŽ 2020/12; 33 (Suppl 1): 53.

723380. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “–‰È‚É‚¨‚¯‚鏬Ž™Šú”­Ç‚̃WƒXƒgƒjƒA‚ÉŠÖ‚·‚éf—Ø^’²¸. “yŠò@•½1, ’|‰ºŠG—¢, Z—F“TŽq, –{‹´—TŽq, ÎŽRº•F, âV“¡‹MŽu, ¬–qG•¶, ’†ì‰h“ñ, {ŠLŒ¤Ži, ²X–ؐªs (1¬Ž™): ‘æ62‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠwpW‰ï (2020/8/18-20, 9/1-30), WebŠJÃ.

723381. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŠÌÃ–¬, –å–¬ŒŒðÇ‚𕹔­‚µ‚½‰»”^«ŠÌ”^ᇂÌ4Î—Ž™—á. ì“cF•½1, ‹k“cˆê‹P1, ‰Y“c‰è‹v”ü1, ]”gŒËF•ã1, “¡•‹`l1, ˆÉ“¡®Žu1, â“Œ—R‹I1,2, Î‘qŒ’Ži1 (1¬Ž™, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2020/8/21-23), WebŠJÃ, “ú–{“à•ª”åŠw‰ïŽGŽ 2020; 95 (4): 1333.

723382. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ¬Ž™“§ÍŠ³ŽÒ‚É‚¨‚¯‚é”N—î, Œ´Ž¾Š³‚ƍ‚ŒŒˆ³‚ÌŠÖ˜A. ‰œ“c—Y‰î1, ©@L–ç1,2, Î‘qŒ’Ži1 (1¬Ž™, 2‹~–½): ‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2020/8/21-23), WebŠJÃ, “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2020/2; 124 (2): 225.

723383. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ”sŒŒÇ«ƒVƒ‡ƒbƒN‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚½ClarksonÇŒóŒQ‚ÆŽv‚í‚ê‚鐶Œã7ƒ•ŒŽ‚Ì’jŽ™. ]”gŒËF•ã1, ‹àŽq‰ë‹I1, Î‘qŒ’Ži1 (1¬Ž™): ‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2020/8/21-23), WebŠJÃ,

723384. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‘ŽYEXITÇ—á‚É‚¨‚¯‚é“K³‚ȕ؏oŽžŠú‚ƃŠƒXƒNˆöŽq. ŠÖ’J—¢‰À1, Î“c@Ži1, ŽRŒûˆ»”T1, ‘剪–ƒ—1, çݎ@Šw1, ’†¼G•F1,2, Î‘qŒ’Ži1 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[“Iˆã—Ã): ‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2020/8/21-23), WebŠJÃ.

723385. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “–‰@o¶‚Ì’´‘ŽYŽ™AŠwó‹µƒAƒ“ƒP[ƒg’²¸. çݎ@Šw1, ‘剪–ƒ—1, ŽRŒûˆ»”T1, ‰¡ŠÖ—Sˆê˜Y1, Î“c@Ži1, ’†¼G•F1,2, Î‘qŒ’Ži1 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[“Iˆã—Ã): ‘æ123‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2020/8/21-23), WebŠJÃ.

723386. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™‚É‚¨‚¯‚éæs“I“ñŽŸtˆÚA‚ƈڐAt¶‘¶—¦‚ÌŠÖ˜A. ‰œ“c—Y‰î1, Î‘qŒ’Ži1, Elani Streja, Kamyar Kalantar-Zadeh (1¬Ž™): ‘æ56‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2020/11/5), WebŠJÃ.

723387. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “–‰@‚ÅŽ{s‚µ‚½FontanŽèpŠ³ŽÒ‚Ìfenestration‚ÌŽ©‘R—ð. ‚—œ@Šw1, –{“c@’1, –Ø‘ºƒl1, ‹{–{—²Ži2, ‹{’n@ŠÓ2, •½“c—zˆê˜Y1, Î‘qŒ’Ži1 (1¬Ž™, 2S‘ŸŒŒŠÇŠO): ‘æ56‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2020/11/22-24), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ), “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2020/11; 36 (Suppl 2): s2-326.

723388. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ”ì‘åŒ^S‹ØÇ‚ð‡•¹‚µ‚½æ“V«ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´õÇ‚Ì1—á. “n糗ڔü1, –{“c@’1, ‚—œ@Šw1, –Ø‘ºƒl1, ŽRŒûˆ»”T1, •½“c—zˆê˜Y1, Î‘qŒ’Ži1 (1¬Ž™): ‘æ56‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2020/11/22-24), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723389. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) LoweÇŒóŒQ‚Ì’·Šú“I‚Ȑt—\Œã‚ÉŠÖ‚·‚錟“¢. –÷“à’q˜N, ŽO‰YŒ’ˆê˜Y, ’£“c@–L, Î’ˊ쐢L, _“cËˆê˜Y, ²“¡“ÖŽu, ˆé“‡@‹, à_“c@—¤, Î‘qŒ’Ži1, ŒÜ\—’—², •ž•”Œ³Žj (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ,

723390. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™Šú”­Ç‚̃lƒtƒƒ“ᔊ³Ž™28—á‚̗Տ°‘œ. ˆäŒû’q—m, à_“c@—¤, “ì@—T‰À, ˆÄ”[‚ ‚‚±, “‡‘܁@“n, ”’ª³ˆê˜Y, ”‘@O‹B, Ô•ôŒhŽ¡, Ž›–ìçŽq, Œ´“c—ÁŽq, à_è—SŽq, Î‘qŒ’Ži1, ”¦’J_Žj, –{“c‰ëŒh (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ,

723391. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’PˆêŽ{Ý‚É‚¨‚¯‚éƒlƒtƒƒ“á”16–¼‚̗Տ°‘œ‚ÌŒŸ“¢. Š˜]’q‰ÀŽq, ¬–¸‰ë•v, ‘º‰z–¢Šó, ¼Œ’‘¾˜N, ‹àX@“§, —é–Ø—³‘¾˜Y, ²“¡@•‘, Î‘qŒ’Ži1, ‹TˆäGˆê (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ, “ú–{¬Ž™t‘Ÿ•aŠw‰ïŽGŽ 2020/12; 33 (Suppl 1): 82.

723392. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™t—̈æ‚̊󏭁E“«Ž¾Š³‚Ì”­Œ©ŽžŠú‚¨‚æ‚ÑŒ_‹@‚ÉŠÖ‚·‚é‘S‘’²¸Œ¤‹†. à_“c@—¤, à_è—SŽq, ã‘º@Ž¡, •ž•”Œ³Žj, ’†¼_ˆê, ŠÛŽR²ˆê, ˆÉ“¡Gˆê, X’å’¼Æ, –ì’Ê°‘å, ’£“c@–L, Œ´“c—ÁŽq, ‹àŽq“OŽ¡, –{“c‰ëŒh, Î‘qŒ’Ži1 (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ, “ú–{¬Ž™t‘Ÿ•aŠw‰ïŽGŽ 2020/12; 33 (Suppl 1): 129.

723393. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™tŽ¾Š³‚É‚¨‚¯‚铧Í“±“ü‘O‚̐t‹@”\’ቺ‘¬“x‚ÌŽ¾Š³–ˆ‚Ì”äŠr. ‹àX@“§, ²“¡@•‘, —é–Ø—³‘¾˜Y, ‘º‰z–¢Šó, ¼Œ’‘¾˜N, Š˜]’q‰ÀŽq, ¬–¸‰ë•v, Î‘qŒ’Ži1, ‹TˆäGˆê (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ, “ú–{¬Ž™t‘Ÿ•aŠw‰ïŽGŽ 2020/12; 33 (Suppl 1): 150.

723394. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ£tˆÚA“o˜^‚µ‚Ä‚¢‚½‚ªPDƒ‰ƒXƒg‚ð‘I‘ð‚µ‚½ƒ_ƒEƒ“ÇŒóŒQ‚Ì31Î—«—á. ©@L–ç1,2, ’†‘ºM–ç2, ‚—œ@Šw2, Îˆä‘å•ã3, ‰¡“à‹ÅŽq2, ‰œ“c—Y‰î2, Šâ”g’¼”ü, ‘åŒF_], Žç‰®r‰î, ‰Í¼‹Iº, ‹g“cˆê¬3,4, Î‘qŒ’Ži2 (1‹~–½, 2¬Ž™, 3”å”AŠí, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ, “ú–{¬Ž™t‘Ÿ•aŠw‰ïŽGŽ 2020/12; 33 (Suppl 1): 158.

723395. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –{–M¬Ž™‚Ì’´‰¹”g’f‘w–@‚É‚æ‚ét’·Ž²Œa‚̊’l‚̍쐬. “¡“c’¼–ç, Œã“¡–F[, Œ´“c—ÁŽq, ¼‘ºçŒbŽq, âˆä’qs, à_è—SŽq, ¼Œ’‘¾˜N, ‹àŽq“OŽ¡, ã‘º@Ž¡, Î‘qŒ’Ži1 (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ, “ú–{¬Ž™t‘Ÿ•aŠw‰ïŽGŽ 2020/12; 33 (Suppl 1): 159.

723396. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–ƒZƒ“ƒ^[ŠJÝˆÈ—ˆ‚ÌŒo”ç“It¶ŒŸ1045Œ‚̃Œƒrƒ…[. ‹TˆäGˆê, ¬–¸‰ë•v, ²“¡@•‘, ‘º‰z–¢Šó, —é–Ø—³‘¾˜Y, Š˜]’q‰ÀŽq, ‹àX@“§, ¼Œ’‘¾˜N, ‹`‰ªFŽq, Î‘qŒ’Ži1, ˆÉ“¡Gˆê, ”Ñ“‡ˆê½ (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ, “ú–{¬Ž™t‘Ÿ•aŠw‰ïŽGŽ 2020/12; 33 (Suppl 1): 161.

723397. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™‹}«Ž¾Š³‚²‚Æ‚Ì’áƒiƒgƒŠƒEƒ€ŒŒÇ‚Ì•p“x‚Æ’ö“x. ”’ª³ˆê˜Y, à_“c@—¤, Xì˜a•F, ˆÄ”[‚ ‚‚±, “‡‘܁@“n, ”‘@O‹B, Ô•ôŒhŽ¡, ˆäŒû’q—m, Ž›–ìçŽq, Œ´“c—ÁŽq, à_è—SŽq, Î‘qŒ’Ži1, ”¦’J_Žj, –{“c‰ëŒh (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2021/1/9), WebŠJÃ, “ú–{¬Ž™t‘Ÿ•aŠw‰ïŽGŽ 2020/12; 33 (Suppl 1): 173.

731015. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) I‚‡Y; R‘Ì‚©‚çŠw‚Ԑ¶•¨‚̐i‰»‚ÆŠ´õÇ. â“Œ—R‹I (¬Ž™): ‘æ180‰ñ“ú–{¬Ž™‰ÈŠw‰ïé‹Ê’n•û‰ïŠwpW‰ï (2020/9/13), WebŠJÃ.

731016. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ‘ŽYŽ™‚ɑ΂·‚éˆêŽ_‰»’‚‘f‹z“ü—Ö@‚ÌŽÀÛ. ’†¼G•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ƒ}ƒŠƒ“ƒNƒƒbƒgƒtƒ@[ƒ}WEBƒZƒ~ƒi[ (2020/11/17), “Œ‹ž.

731017. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) Äl: ŒãŠú‘ŽYŽ™ (Late-preterm) ‚ÍNear term‚Å‚Í‚È‚¢`ŽY•wl‰Èf—ÃKƒCƒhƒ‰ƒCƒ“‰ü’èŒã‚ÌRSVŠ´õ‘΍ô‚ɂ‚¢‚čl‚¦‚é`. ’†¼G•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): Japan Experts' Meeting (2021/1/16), “Œ‹ž.

731018. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ‘ϐ«Šl“¾‚ð–ÚŽw‚µ‚½H•¨ƒAƒŒƒ‹ƒM[Ž¡—Â̎ÀÛ. â“Œ—R‹I1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): é‹ÊŒ§‰›ƒAƒŒƒ‹ƒM[ƒtƒH[ƒ‰ƒ€ (2021/1/27), ‚³‚¢‚½‚ÜŽs (Web).

731019. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ¬Ž™“Á”­«ƒlƒtƒ[ƒ[ÇŒóŒQF–{–M‚̗Տ°Œ¤‹†‚ƍŐV‚̃KƒCƒhƒ‰ƒCƒ“. Î‘qŒ’Ži (¬Ž™): ‘æ62‰ñ‘åã¬Ž™tŒ¤‹†‰ï (2021/2/25), ‘åã.

731020. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰)uV¶Ž™‘h¶v`ŽÀÛ‚ÌŒ»ê‚Å‚ÌŒoŒ±‚©‚ç`. ’†¼G•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‘æ9‰ñ–ƒŒ‰Èˆã‚Ì‚½‚ß‚ÌŽY‰È–ƒŒƒvƒƒtƒFƒbƒVƒ‡ƒiƒ‹ƒZƒ~ƒi[ (2021/2/27), WebŠJÃ.

731021. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰)y‚±‚ê‚©‚ç‚̐ؔ—‘ŽYŠÇ—‚ɂ‚¢‚čl‚¦‚ézV¶Ž™‰Èˆã‚©‚ç‚Ý‚½Ø”—‘ŽYŠÇ—`’·Šú—\Œã‚àŒ©˜‚¦‚ā`. ’†¼G•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‚’mŽY‰ÈƒZƒ~ƒi[ (2021/2/28), ‚’m.

731022. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ¬lˆÚsˆã—Á|–{–M‚ɉ—‚¯‚ét‘Ÿ•a—̈æ‚Å‚Ì‚ ‚ä‚݂ƍ¡Œã‚Ì–k—¢‘åŠw•a‰@‚É‚¨‚¯‚éŽæ‚è‘g‚݁|. Î‘qŒ’Ži (¬Ž™): ¬Ž™Šú”­Ç–«tŽ¾Š³‚ð‚à‚Š³ŽÒ‚³‚ñ‚̐¬lˆÚsˆã—Âðl‚¦‚é‰ï (2021/3/25), Œú–Ø.

732014. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (‹³ˆçu‰‰) –k—¢‘åŠw•a‰@¬Ž™‰È‚ÌCOVID-19‚Æ‚Ì“¬‚¢. Î‘qŒ’Ži (¬Ž™): Ã‰ªŒ§—§´…•a‰@¬Ž™‰Èu‰‰‰ï (2020/5/22), Ã‰ª.

732015. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (‹³ˆçu‰‰) ¬Ž™‰È‚©‚çt‘Ÿ“à‰È‚ւ̐tŽ¾Š³Š³ŽÒ‚̈ڍsˆã—Ñ̐§‚̍\’z. ©@L–ç1,2 (1‹~–½, 2¬Ž™): ‘Š–ÍŒ´CKD webƒZƒ~ƒi[ (2020/10/20), ‘Š–ÍŒ´.

732016. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (Žs–¯ŒöŠJuÀ) ¬Ž™Š³ŽÒ‚³‚ñ‚ÌŽ©—§‚Ƃ́`¬lˆÚsŽx‰‡‚ÌŒ»ó‚Ɖۑè`. •½“c—zˆê˜Y (¬Ž™): ‘æ177‰ñŠƒ–è¬Ž™ˆã—ÃZƒ~ƒi\ (2020/10/20), Šƒ–è.

732017. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (‹³ˆçu‰‰) —Տ°Œ¤‹†‚̏‰ŠwŽÒ‚ªŠ×‚è‚â‚·‚¢ƒsƒbƒgƒtƒH[ƒ‹. Î‘qŒ’Ži (¬Ž™): 2020”N“x—Տ°Œ¤‹†ƒZƒ~ƒi[u—Տ°Œ¤‹†Å‰‚̈ê•àv (2021/3/16), _“ސì.

733074. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) –{Ç—á‚͐ìè•a‚¾‚Á‚½‚Ì‚©? ]”gŒËF•ã (¬Ž™): ‘æ15‰ñ_“ސ쌧ìè•aŒ¤‹†‰ï (2020/9/14), WebŠJÃ.

733075. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) S’âŽ~‚̈êˆö‚Æ‚µ‚čRƒqƒXƒ^ƒ~ƒ“–ò‚̉ߗʓŠ—^‚ª‹^‚í‚ꂽ“ûŽ™—á. ì“cF•½1, •ô”öŒb—œ1, ¼“c®Žj1, ˆÀ“¡@Žõ1, çݎ@Šw1, Î‘qŒ’Ži1 (1¬Ž™): ‘æ362‰ñ“ú–{¬Ž™‰ÈŠw‰ï_“ސ쌧’n•û‰ï (2020/11/21), ‰¡•l.

733076. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) ”­ì«Ž¸’²‚ðŽåÇó‚Æ‚·‚éƒOƒ‹ƒR[ƒXƒgƒ‰ƒ“ƒXƒ|[ƒ^[1Œ‡‘¹Ç (GLUT1DS). “yŠò@•½1, âV“¡‹MŽu, Z—F“TŽq, ’|‰ºŠG—¢, –{‹´—TŽq, ÎŽRº•F, ¬–qG•¶, ’†ì‰h“ñ, ¯–ìœAŽ÷, ‹{–{—Yô, Îˆä“ÖŽm, œA£Lˆê, ²X–ؐªs (1¬Ž™): ‘æ74‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠÖ“Œ’n•û‰ï (2021/3/20), “Œ‹ž.

'19”N“xˆÈ‘O•ª

[Šw‰ïEŒ¤‹†‰ï“™]

H29-723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ê‘̃AƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚É‚æ‚èV¶Ž™‰¼Ž€‚ŏo¶‚µ‚½ˆê—á. ‘½“c‹ÓŽi, çݎ@Šw1, ’†‹à˜NŽq2, –]ŒŽƒŽq2, ŽRŒûˆ»”T1, ‘剪–ƒ—¢1, Îˆä³_1 (1¬Ž™, 2ŽY‰È): ‘æ53‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2017/7/17), ‰¡•l.

'19-723021. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) WŠw“IŽ¡—Âɂæ‚è‹~–½‚µ‚¦‚½‹}«’Ž‚‰Š‚Ì1—á. “c‘º—C•½1, •ô”öŒb—œ1, ˆÀ“¡@Žõ1, “c’†@Œ‰2,3, Î‘qŒ’Ži1 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ47‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2020/3/6-8), –¼ŒÃ‰®.

'19-733008. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) Microgeodic disease‚ƍl‚¦‚ç‚ꂽ2Ç—á. ]”gŒËF•ã1, â“Œ—R‹I1,2, Î‘qŒ’Ži1 (1¬Ž™, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ357‰ñ“ú–{¬Ž™‰ÈŠw‰ï_“ސ쌧’n•û‰ï (2019/6/22), ‰¡•l.

'19-733009. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) ìè•a‚ÌŽå—vÇó‚ð’悵‚½–ƒ]‚Ì1’jŽ™—á. “c‘º—C•½1, ²“¡‰Á‘ãŽq1, –Ø‘ºƒl1, –¥‰YŽ‘¥1, ]”gŒËF•ã1 (1¬Ž™): ‘æ358‰ñ“ú–{¬Ž™‰ÈŠw‰ï_“ސ쌧’n•û‰ï (2019/9/21), ‰¡•l.

'19-733010. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) ‰Æ‘°—ð‚æ‚è‹^‚¢, ŒJ‚è•Ô‚·ŒŸ¸‚©‚çf’f‚µ“¾‚½’჊ƒ“ŒŒ«‚­‚é•a‚Ì1Ç—á. ‹k“cˆê‹P1, ‰Y“c‰è‹v”ü1, ‘å’Ь”V, Î‘qŒ’Ži1 (1¬Ž™): ‘æ358‰ñ“ú–{¬Ž™‰ÈŠw‰ï_“ސ쌧’n•û‰ï (2019/9/21) ‰¡•l.

'19-733011. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) V¶Ž™‹Áœ±•a‚Ì2Ç—á. ”’ˆäG’¼1, –ìX“c–L1, Šâèr”V1, çݎ@Šw1, Î‘qŒ’Ži1 (1¬Ž™): ‘æ360‰ñ“ú–{¬Ž™‰ÈŠw‰ï_“ސì’n•û‰ï (2020/2/5), ‰¡•l.


ŽY‰ÈŠw^•wl‰ÈŠw

[Šwp˜_•¶]

110283. [Œ´’˜] Inhibition of autophagy in theca cells induces CYP17A1 and PAI-1 expression via ROS/p38 and JNK signalling during the development of polycystic ovary syndrome. Kobayashi M, Yoshino O1,2, Nakashima A, Ito M, Nishio K, Ono Y, Kusabiraki T, Kunitomi C, Takahashi N, Harada M, Hattori K, Orisaka M, Osuga Y, Saito S: Mol Cell Endocrinol 2020/5; 508: 110792. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110284. [Œ´’˜] Low Bone Mineral Density in Elite Female Athletes With a History of Secondary Amenorrhea in Their Teens. Nose-Ogura S, Yoshino O1,2, Dohi M, Kigawa M, Harada M, Kawahara T, Osuga Y, Saito S: Amenorrhea in Their Teens. Clin J Sport Med 2020/5; 30 (3): 245-50. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110285. [Œ´’˜] Acquired contractile ability in human endometrial stromal cells by passive loading of cyclic tensile stretch. Kim J, Ushida T, Montagne K, Hirota Y, Yoshino O1,2, Hiraoka T2, Osuga Y, Furuakwa KS: Sci Rep 2020/6; 10 (1): 9014. (‹g–ì@C1,2, •½‰ª‹B‘å2: 1ŽY‰È, 2•wl)

110029. [Œ´’˜] Lymphangiogenesis induced by vascular endothelial growth factor receptor 1 signaling contributes to the progression of endometriosis in mice. Hattori K1, Ito Y2, Honda M1, Sekiguchi K3, Hosono K2, Shibuya M, Unno N3, Majima M2: J Pharmacol Sci 2020/8; 143 (4): 255-63. (•ž•”‹¿Žq1, ˆÉ“¡‹`–ç2, –{“c‰ëŽq1, ŠÖŒû˜aŠé3, ×–ì‰Á“ÞŽq2, ŠC–ìM–ç3, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3ŽY‰È)

110286. [Œ´’˜] Effect of transdermal estradiol therapy on bone mineral density of amenorrheic female athletes. Nose-Ogura S, Yoshino O1,2, Kanatani M, Dohi M, Tabei K, Harada M, Hiraike O, Kawahara T, Osuga Y, Fujii T: Scand J Med Sci Sports 2020/8; 30 (8): 1379-86. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110287. [Œ´’˜] Relationship between tartrate-resistant acid phosphatase 5b and stress fractures in female athletes. Nose-Ogura S, Yoshino O1,2, Dohi M, Torii S, Kigawa M, Harada M, Hiraike O, Kawahara T, Osuga Y, Fujii T, Saito S: J Obstet Gynaecol Res 2020/8; 46 (8): 1436-42. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110288. [Œ´’˜] Differential roles of uterine epithelial and stromal STAT3 coordinate uterine receptivity and embryo attachment. Hiraoka T1, Hirota Y, Fukui Y, Gebril M, Kaku T, Aikawa S, Hirata T, Akaeda S, Matsuo M, Haraguchi H, Saito-Kanatani M, Shimizu-Hirota R, Takeda N, Yoshino O1,2, Fujii T, Osuga Y: Sci Rep 2020/9; 10 (1): 15523. (•½‰ª‹B‘å1, ‹g–ì@C1,2: 1•wl, 2ŽY‰È)

110289. [Œ´’˜] Uterine CD11c+ cells induce the development of paternal antigen-specific Tregs via seminal plasma priming. Shima T, Nakashima A, Yasuda I, Ushijima A, Inada K, Tsuda S, Yoshino O1,2, Tomura M, Saito S: J Reprod Immunol 2020/9; 141: 103165. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110290. [Œ´’˜] Relaxin-2 May Suppress Endometriosis by Reducing Fibrosis, Scar Formation, and Inflammation. Yoshino O1,2, Ono Y, Honda M3, Hattori K3, Sato E4, Hiraoka T2, Ito M, Kobayashi M, Arai K, Katayama H, Tsuchida H, Yamada-Nomoto K, Iwahata S1, Fukushi Y, Wada S, Iwase H2, Koga K, Osuga Y, Iwaoka M, Unno N1: Biomedicines 2020/10; 8 (11): 467. (‹g–ì@C1,2, –{“c‰ëŽq3, •ž•”‹¿Žq3, ²“¡ŠG—¢“Þ4, •½‰ª‹B‘å2, Šâ’[r•ã1, Šâ£tŽq2, ŠC–ìM–ç1: 1ŽY‰È, 2•wl, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4•a‘ԁEf—ÃŒn)

110032. [Œ´’˜] Inhibition of receptor activity-modifying protein 1 suppresses the development of endometriosis and the formation of blood and lymphatic vessels. Honda M1, Ito Y2, Hattori K1, Hosono K2, Sekiguchi K3, Unno N3, Majima M2: J Cell Mol Med 2020/10; 24 (20): 11984-97. (–{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq1, ×–ì‰Á“ÞŽq2, ŠÖŒû˜aŠé3, ŠC–ìM–ç3, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3ŽY‰È)

110291. [Œ´’˜] Uterine Epithelial Progesterone Receptor Governs Uterine Receptivity Through Epithelial Cell Differentiation. Gebril M, Hirota Y, Aikawa S, Fukui Y, Kaku T, Matsuo M, Hirata T, Akaeda S, Hiraoka T1, Shimizu-Hirota R, Takeda N, Taha T, Balah OAl , Elnoury MAH, Fujii T, Osuga Y: Endocrinology 2020/12; 161 (12): bqaa195. (•½‰ª‹B‘å1: 1•wl)

110292. [Œ´’˜] CD206+ macrophage is an accelerator of endometriotic-like lesion via promoting angiogenesis in the endometriosis mouse model. Ono Y, Yoshino O1,2, Hiraoka T2, Sato E3, Furue A2, Nawaz A, Hatta H, Fukushi Y, Wada S, Tobe K, Hirota Y, Osuga Y, Unno N1, Saito S: Sci Rep 2021/1; 11 (1): 853. (‹g–ì@C1,2, •½‰ª‹B‘å2, ²“¡ŠG—¢“Þ3, ŒÃ]–¾Žq2, ŠC–ìM–ç1: 1ŽY‰È, 2•wl, 3•a‘ԁEf—ÃŒn)

110293. [Œ´’˜] Retinoblastoma protein promotes uterine epithelial cell cycle arrest and necroptosis for embryo invasion. Akaeda S, Hirota Y, Fukui Y, Aikawa S, Shimizu-Hirota R, Kaku T, Gebril M, Hirata T, Hiraoka T1, Matsuo M, Haraguchi H, Saito-Kanatani M, Takeda N, Fujii T, Osuga Y: EMBO Rep 2021/2; 22 (2): e50927. (•½‰ª‹B‘å1: 1•wl)

110294. [Œ´’˜] Perinatal outcomes associated with the positional relationship between the placenta and the adenomyosis lesion. Ono Y, Ota H, Takimoto K, Tsuzuki Y, Ayako Nakajima A,Yoshino O1,2, Unno N1, Fujino T, Fukushi Y, Shinichiro Wada S: J Gynecol Obstet Hum Reprod 2021/3; 50 (7): 102114. (‹g–ì@C1,2, ŠC–ìM–ç1: 1ŽY‰È, 2•wl)

110295. [Œ´’˜] Surgical margin status and recurrence pattern in invasive vulvar Paget's disease: A Japanese Gynecologic Oncology Group study. Matsuo K, Nishio S, Matsuzaki S, Iwase H1, Kagami S, Soeda S, Usui H, Nishikawa R, Mikami M, Enomoto T: Gynecol Oncol 2021/3; 160 (3): 748-54. (Šâ£tŽq1: 1•wl)

110296. [Œ´’˜] Attitudes toward overtime work and self-training: A survey on obstetricians and gynecologists in Japan. Mayama M, Sekine M, Onodera Y, Suemitsu T, Maeda Y, Nakano K, Sugita Y, Ogura J, Ohsuga T, Kodera C, Murakami T, Kido M, Suzuki Y, Shibata A, Nishijima K, Umazume T, Nakagawa S, Unno N1, Komatsu H, Shozu M, Enomoto T, Watari H: J Obstet Gynaecol Res 2021/5; 47 (5): 1666-74. doi: 10.1111/jog.14735. Epub 2021 Mar 10. (ŠC–ìM–ç1: 1ŽY‰È)

120012. [Œ´’˜] •wl‰Èˆ««Žîᇔ]“]ˆÚÇ—á‚̗Տ°“I“Á’¥‚ɂ‚¢‚Ä‚ÌŒã•ûŽ‹“IŒŸ“¢. ŒÃì³‹`1, Šâ£tŽq1, ‰““¡^ˆê1, ‘吼Œ«l1, “cŽG—L‹I1, ‚“c‹±b1, Vˆä³G1, ‹g–ì@C1,2, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È): “ú–{•wl‰ÈŽîᇊw‰ïŽGŽ 2020/4; 38 (2): 182-92.

310034. [Ç—á•ñ] First report in Japan of a delivery of a woman with the 2019 novel coronavirus disease. Mochizuki J1, Nakamura M2, Iwahata S2, Nishijima J1, Ito T3, Wada T4, Takayama Y5, Unno N1: J Obstet Gynaecol Res 2021/1; 47 (1): 407-10. (–]ŒŽƒŽq1, ’†‘ºŠîŠ°2, Šâ’[r•ã2, ¼“‡ƒˆê1, ˆÉ“¡®Žu3, ˜a“c’B•F4, ‚ŽR—zŽq5, ŠC–ìM–ç1: 1ŽY‰È, 2•wl, 3¬Ž™, 4äPŒ´•aEŠ´õ“à, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

320018. [Ç—á•ñ] Massive ovarian edema‚ɑ΂µ‚Ä• o‹¾‰ºŽèp‚ðŽ{s‚µ‘ΏƓI‚È“]‹@‚ð‚Æ‚Á‚½2Ç—á. ŽRè@—D1, ‹v“ˆ‘¥s2, ª’ÍK•ä1, ’†‘ºŠîŠ°3, HŽRŠG—¢Žq, ÎˆäŠG从q, “‡‰ª‹¶1, ˆÉ“¡ŽÀ1,2, ŒÜ“‡—T”V1, â“Œ—R‹I2,4, ŽO–Ø–¾“¿1,2 (1ŽY‰È, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•wl, 4¬Ž™): é‹ÊŒ§ŽY‰È•wl‰ÈŠw‰ïŽGŽ 2020/9; 50 (2): 107-13.

320019. [Ç—á•ñ] p‘O‚ÌŽîᇓà—eƒhƒŒƒi[ƒWŒãˆÀ‘S‚ÉŽèp‚ðŽ{s‚µ‚¦‚½–ñ75 kg‚Ì‹‘å—‘‘ƒŠà‚̈ê—á. ¼ŽRD1, Vˆä³G1, ã–V•qŽq, ‰““¡^ˆê1, ŒÃì³‹`1, “cŽG—L‹I1, ‚“c‹±b1, Šâ£tŽq1, ‰¶“c‹MŽu1 (1•wl): “ú–{•wl‰ÈŽîᇊw‰ïŽGŽ 2020/10; 38 (4): 348-55.

320020. [Ç—á•ñ] “–‰@‚ÅŒoŒ±‚µ‚½‹H­•”ˆÊ”DP5—á. ’†‘ºŠîŠ°1, ª’ÍK•ä2, ¬“‡@ˆè2, ŽRè@—D2, ŒÜ“‡—T”V2, ˆÉ“¡ŽÀ2,3, ‰““¡^ˆê1, ŒÃì³‹`1, “‡‰ª‹¶2, ‹v“ˆ‘¥s3, ŽO–Ø–¾“¿2,3 (1•wl, 2ŽY‰È, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): é‹ÊŽY‰È•wl‰ÈŠw‰ïŽGŽ 2021/3; 51 (1): 35-40.

320021. [Ç—á•ñ] Š®‘S’†ŠuŽq‹{‚̉E‘¤Žq‹{‚É”­¶‚µ‚½Žq‹{‘ÌŠà‚Ì1—á. ˆ¢•”@‰1, Šâ£tŽq1, “cŽG—L‹I1, ’†‘ºŠîŠ°1, ‰““¡^ˆê1, ŒÃì³‹`1, ‘吼Œ«l1, ‚“c‹±b1, Vˆä³G1, ‹g–ì@C1,2, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È): ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ïŽGŽ 2021/3; 58 (1): 101-8.

522064. [uÀ]y‚ЂƂ­‚¿ƒƒ‚zˆÀ‘SEˆÀS‚È–³’É•ª•Ø‚Í. ŠC–ìM–ç (ŽY‰È) “ú–{ˆãŽt‰ïŽGŽ 2020/4; 149 (1): 68.

522065. [uÀ]y“ÁW: V ŒoäT•ª•Ø‚𐬌÷‚³‚¹‚é29‚Ì’ñŒ¾z‹zˆø•Øop|‹à‘®ƒJƒbƒv, ƒ\ƒtƒgƒJƒbƒv, Žè“®Ž®‹zˆøŠí‚È‚Ç‚ÌŽg‚¢•ª‚¯. ‹àˆä—Y“ñ (ŽY‰È): ŽüŽYŠúˆãŠw 2021/1; 51 (1): 63-8.

522066. [uÀ]y“ÁW: QOL‚ðl‚¦‚éz4. Žq‹{“à–ŒÇ‚ÆQOL. ‹g–ì@C1,2, b‰ê‚©‚ð‚è, —銛‚悵‚Ý, Šâ£tŽq2 (1ŽY‰È, 2•wl): ŽY‰È‚Æ•wl‰È 2021/2; 88 (3): 291-6.

522067. [uÀ]y“ÁW: V‹»EÄ‹»Š´õÇ, —A“üŠ´õÇ‚ÆŽüŽYŠúˆãŠwz[Še˜_] VŒ^ƒRƒƒiƒEƒCƒ‹ƒX@COVID-19‚Æ”DŽY•wŠÇ—. ŠC–ìM–ç (ŽY‰È): ŽüŽYŠúˆãŠw 2021/3; 51 (3): 330-8.

540026. [‚»‚Ì‘¼ (Šw‰ï´˜^)]y‘æ139‰ñ ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï ‘‰ïEŠwpW‰ï ´˜^†zŒãˆâÇ‚È‚­‹~–½‚µ“¾‚½S”x‹•’EŒ^—r…ÇðÇ‚̈ê—á. ŒÜ“‡—T”V1, ‘吼—fŽq1, ‹g‘º‰ÃL1, ’†‹à˜NŽq1, •ž•”‹¿Žq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‹àˆä—Y“ñ1, –]ŒŽ‡Žq1, ŠC–ìM–ç1 (1ŽY‰È): ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‰ïŽ 2020/6; 57 (2): 235.

540027. [‚»‚Ì‘¼ Šˆ“®•ñ)] JALAu–³’É•ª•ØŠÖŒWŠw‰ïE’c‘̘A—‹¦‹c‰ïvŠˆ“®•ñ (2019”N“x). ŠC–ìM–ç (ŽY‰È): •ª•Ø‚Æ–ƒŒ 2020/10; 102: 38-46.

[’˜@‘]

620060. [Šwp‘ (•ª’SŽ·•M)]yŒŸ¸’l‚ð“Ç‚Þ2020 (—Տ°ŽGŽ“à‰È2020”N4ŒŽ‘‘卆)z<17Í ‰ŠÇƒ}[ƒJ[ŒŸ¸>Žq‹{èòŠÇ”S‰t’†è÷—±‹…ƒGƒ‰ƒXƒ^[ƒ[, p.818. ŠC–ìM–ç (ŽY‰È), “ì]“°, “Œ‹ž, 2020/4”­s.

620061. [Šwp‘ (•ª’SŽ·•M)]yŒŸ¸’l‚ð“Ç‚Þ2020 (—Տ°ŽGŽ“à‰È2020”N4ŒŽ‘‘卆)z<17Í ‰ŠÇƒ}[ƒJ[ŒŸ¸> APRƒXƒRƒA, p.819-20. ŠC–ìM–ç (ŽY‰È), “ì]“°, “Œ‹ž, 2020/4”­s.

620062. [Šwp‘ (•ª’SŽ·•M)]yŒŸ¸’l‚ð“Ç‚Þ2020 (—Տ°ŽGŽ“à‰È2020”N4ŒŽ‘‘卆)z<17Í ‰ŠÇƒ}[ƒJ[ŒŸ¸>äT•ª”å‰t’†ƒCƒ“ƒXƒŠƒ“—l¬’·ˆöŽqŒ‹‡’`”’1Œ^ (IGF-BP1), p.821. ŠC–ìM–ç (ŽY‰È), “ì]“°, “Œ‹ž, 2020/4”­s.

620063. [Šwp‘ (•ª’SŽ·•M)]y–ƒŒ‰Èƒvƒ‰ƒNƒeƒBƒX 1@ŽY‰È–ƒŒAll in OnezV. ŒoäT•ª•Ø‚Ì–ƒŒ@2. –³’É•ª•Ø‚̏€”õ@[T] –³’É•ª•ØŽ–ŒÌ‚ðŽó‚¯‚½–³’É•ª•Ø‚̈À‘S«Œüã‚Ì‚½‚߂̑Ήž|JALA: ”­‘«‚ÉŽŠ‚é‚Ü‚Å‚ÌŒo‰ß‚Æ‚»‚ÌŠˆ“®“à—e|, p.119-21. ŠC–ìM–ç (ŽY‰È), •¶Œõ“°, “Œ‹ž, 2020/7”­s.

620064. [Šwp‘ (•ª’SŽ·•M)]yŽY•wl‰Èê–åˆã‚Ì‚½‚ß‚Ì•KC’mŽ¯@2020”N“x”ŁzŽY•wl‰ÈŠÖ˜A‚Ì“Œv, A28-33. ŠC–ìM–ç (ŽY‰È), •ÒWEŠÄC: “ú–{ŽY‰È•wl‰ÈŠw‰ï, “ú–{ŽY‰È•wl‰ÈŠw‰ïŽ––±‹Ç, “Œ‹ž, 2020/12”­s.

620065. [Šwp‘ (•ª’SŽ·•M)]y¡ŒŽ‚̗Տ°@¶Bˆã—Â̊î‘b’mŽ¯ƒAƒbƒvƒf[ƒg@Š³ŽÒà–¾‚ɖ𗧂ŐVƒGƒrƒfƒ“ƒXEÅVƒf[ƒ^ (—Տ°•wl‰ÈŽY‰ÈVol.75 No.1‡•¹‘‘卆)z¡[ˆê”Ê•s”DŽ¡—Ã] •s”DÇ‚ɑ΂·‚éˆê”Ê“I‚ÈŒŸ¸EŽ¡—Á@öÝ«‚ƒvƒƒ‰ƒNƒ`ƒ“ŒŒÇ, p.43-8. ‹g–ì@C1,2, ŒÃ]–¾Žq2, •½‰ª‹B‘å2 (1ŽY‰È, 2•wl): ˆãŠw‘‰@, “Œ‹ž, 2021/1”­s.

620066. [Šwp‘ (•ª’SŽ·•M)]y•W€ŽY‰È•wl‰ÈŠw@‘æ5”ŁzŽY‰È•Ò@‘æ21Í ”DP‚ÌŠÇ—@A ”DP‚ÉŠÖ‚·‚é—pŒê, B ”DP‚Ì’¥Œó‚Ɛf’f, C ”D•wŒ’f (”DŽY•wŒ’Nf¸), D ƒnƒCƒŠƒXƒN”DP, p.483-92. ŠC–ìM–ç (ŽY‰È), •Ò: ˆ»•”‘ôÆ, ”‘q“Ö•v, ˆãŠw‘‰@, “Œ‹ž, 2021/3”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

721015. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ŒŽŒo¢“ïÇEŽq‹{“à–ŒÇ‚ªŠ³ŽÒ‚É—^‚¦‚ég‘Ì“IE¸_“I‰e‹¿ (HR-QOL). ‹g–ì@C1,2 (1ŽY‰È, 2•wl): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/24), WebŠJÃ.

721016. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ‚킪‘‚Ì–³’É•ª•Ø‚Ì‚ ‚è•û|–³’É•ª•ØŠÖŒWŠw‰ïE’c‘̘A—‹¦‹c‰ï‚ÌŽæ‘g|. ŠC–ìM–ç (ŽY‰È): “ú–{‹æˆæ–ƒŒŠw‰ï‘æ7‰ñŠwpW‰ï (2020/8/9-22), WebŠJÃ.

721017. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ‹³ˆçƒvƒƒOƒ‰ƒ€C (C-5) —‘‘ƒŠàE—‘ŠÇŠàE• –ŒŠà‚ÌŽèp—Ö@. Šâ£tŽq (•wl): ‘æ62‰ñ“ú–{•wl‰ÈŽîᇊw‰ïŠwpu‰‰‰ï (2021/1/29-30), WebŠJÃ.

722081. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) Ä”­—‘‘ƒŠàI––Šú‚ÉCART‚ðŽ{s‚µ‚½1—á. “cŽG—L‹I1, ’†‘ºŠîŠ°1, ‰““¡^ˆê1, ŒÃì³‹`1, ‘吼Œ«l1, ‚“c‹±b1, Šâ£tŽq1 (1•wl): ‘æ9‰ñ•wl‰ÈŽîᇂ̊ɘaˆã—Âðl‚¦‚é‰ïŠwpW‰ï (2020/10/10), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722082. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) –³’É•ª•Ø‚̈À‘S«Šm•Û‚ÉŒü‚¯‚½Žæ‘g|–³’É•ª•ØŠÖŒWŠw‰ïE’c‘̘A—‹¦‹c‰ï‚ÌŠˆ“®‚©‚ç|. ŠC–ìM–ç (ŽY‰È): ‘æ56‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2020/11/28-12/4), WebŠJÃ.

722083. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) —‘‘ƒŠàE—‘ŠÇŠàE• –ŒŠà‚ÌŽèp—Ö@. Šâ£tŽq (•wl): ‘æ62‰ñ“ú–{•wl‰ÈŽîᇊw‰ïŠwpu‰‰‰ï (2021/1/29-2/11), WebŠJÃ.

722084. [Šw‰ï (‘S‘)] (“Á•ÊŠé‰æ) ÐŠQŽž¬Ž™ŽüŽYŠúƒŠƒGƒ]ƒ“‚̐¬‚è—§‚¿‚©‚çƒRƒƒi‘Ήž‚Ü‚Å. •ž•”‹¿Žq (‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ26‰ñ“ú–{ÐŠQˆãŠw‰ï‘‰ïEŠwpW‰ï (2021/3/15-17), WebŠJÃ.

723398. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) _“ސ쌧‚É‚¨‚¯‚éÐŠQŽž¬Ž™ŽüŽYŠúƒŠƒGƒ]ƒ“‚Ì‘å‹K–Í’nkŽžˆã—ʈ“®ŒP—ûŽQ‰Á•ñ. •ž•”‹¿Žq1, ‘qàVŒ’‘¾˜Y2, ‰|–{‹I”üŽq3, •½’m—Y4, Î–{lŽm5, ŠC–ìM–ç6 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‰¡•lŽs—§‘啍‘®•a‰@, 3‰¡•lŽs—§‘åƒZƒ“ƒ^[•a‰@, 4¬“cŒ´Žs—§•a‰@, 5“ŒŠC‘å•t‘®•a‰@, 6ŽY‰È): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/23-28), WebŠJÃ.

723399. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Žq‹{‹¾Žèp‘O‚ÉŒoŒûGnRH antagonist (relugolix) ‚ð“Š—^‚µ‚½Ç—á‚ÌŒŸ“¢. ˆÉ“¡ŽÀ1, ‹g–ì@C1,2, Šâ’[r•ã1, •½‰ª‹B‘å1, ‰º“c—²m1, –{“c‰ëŽq3, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/23-28), WebŠJÃ.

723400. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‘ÙŽ™èò•”ŠïŒ`Žî4—á‚ÌŒoŒ±. ‘吼—fŽq1, ‹g‘º‰ÃL1, •ž•”‹¿Žq2, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‹àˆä—Y“ñ1, –]ŒŽƒŽq1, ŠC–ìM–ç1 (1ŽY‰È, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/23-28), WebŠJÃ.

723401. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) äT•Ç‚É”­¶‚µ‚½ƒƒgƒgƒŒƒLƒT[ƒgŠÖ˜AƒŠƒ“ƒp‘B«Ž¾Š³‚̈ê—á. ŒÜ\”¨mŽu1, ‚“c‹±b1, ŒÃì³‹`1, ‘吼Œ«l1, “cŽG—L‹I1, Šâ£tŽq1, ‰¶“c‹MŽu1 (1•wl): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/23-28), WebŠJÃ.

723402. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) pT1‚¨‚æ‚ÑpT2‚̏ã”琫—‘‘ƒŠà‚É‚¨‚¯‚éŒã• –ŒƒŠƒ“ƒpßŠs´‚̈Ӌ`‚ÉŠÖ‚·‚錟“¢. ‘吼Œ«l1, Šâ£tŽq1, ŒÃì³‹`1, “cŽG—L‹I1, ‚“c‹±b1, ‹g–ì@C1,2, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/23-28), WebŠJÃ.

723403. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Žq‹{“à–ŒÇ‚É‚¨‚¯‚錌ŠÇEƒŠƒ“ƒpŠÇV¶‚𐧌䂷‚é_Œoƒyƒvƒ`ƒhCGRP‚Ì–ðŠ„. –{“c‰ëŽq1, •ž•”‹¿Žq1, ŠÖŒû˜aŠé2, ‹g–ì@C2,3, ‰¶“c‹MŽu3, ŠC–ìM–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ŽY‰È, 3•wl): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/23-28), WebŠJÃ.

723404. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Investigation of the functional role of ovarian hormone receptors in the carcinogenic process from ovarian endometrioma to ovarian cancer. •½‰ª‹B‘å1, ‹g–ì@C1,2, Šâ’[r•ã1, ˆÉ“¡ŽÀ1, –{“c‰ëŽq3, Šâ£tŽq1, Žž”CòŒÎ2, ‰¶“c‹MŽu1, Osuga Y (1•wl, 2ŽY‰È, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/23-28), WebŠJÃ.

723405. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’oŠÉoŒŒÇ—á‚̏dÇ‰»‚ð—\‘ª‚·‚éŽw•W‚ÉŠÖ‚·‚錟“¢. ’†‹à˜NŽq1, –]ŒŽƒŽq1, ‘吼—fŽq1, •ž•”‹¿Žq1, ‹g‘º‰ÃL1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‹àˆä—Y“ñ1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/23-28), WebŠJÃ.

723406. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚ŃŠƒXƒN’ጸ—‘ŠÇ—‘‘ƒ“Eop (RRSO) ‚ðs‚Á‚½1Ç—á. —é–Ø—R—œ“Þ, ‘«—§Ž”V, ‰““¡^ˆê1, ¼“‡@–¾, ‹{â˜±Šó, ‹{–{^‹, –x]O“ñ, ‰¡“cŽ¡d (1•wl): ‘æ72‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/4/23-28), WebŠJÃ.

723407. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) • …×–Ef‚ł͐f’f¢“ï‚Å‚ ‚Á‚½—‘‘ƒŒ´”­ˆ««•FŽî‚̈ê—á. ‘吼Œ«l1, Šâ£tŽq1, âŒû@”E2, ŒÃì³‹`1, “cŽG—L‹I1, ‚“c‹±b1, ‰¶“c‹MŽu1 (1•wl, 2•a—•”): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20-7/19), WebŠJÃ.

723024. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒ}ƒEƒXŽq‹{“à–ŒÇ‚É‚¨‚¯‚éRAMP1‚ÌŒŒŠÇEƒŠƒ“ƒpŠÇV¶‘£iì—p. –{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq1, ×–ì‰Á“ÞŽq2, ’†–{CŽi1, ‘卂Žj¹1, ’ׯ¢—¢3, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3–ƒŒ): ‘æ41‰ñ“ú–{‰ŠÇEÄ¶ˆãŠw‰ï (2020/7/8-9), WebŠJÃ.

723027. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒ}ƒEƒXŽq‹{“à–ŒÇ‚É‚¨‚¯‚éRAMP1‚̃Šƒ“ƒpŠÇV¶‘£iì—p. –{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq1, ×–ì‰Á“ÞŽq2, ‘卂Žj¹1, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—): ‘æ44‰ñ“ú–{ƒŠƒ“ƒpŠw‰ï‘‰ï (2020/9/11-12), ‘å‹{.

723408. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) —‘‘ƒ–¢•ª‰»ãó×–EŽî‚Ì• …’†‚ɏoŒ»‚µ‚½ŽîᇍזE‘œ‚Ì“Á’¥. “cŽG—L‹I1, ’†‘ºŠîŠ°1, ‰““¡^ˆê1, ŒÃì³‹`1, ‘吼Œ«l1, ‚“c‹±b1, Šâ£tŽq1 (1•wl): ‘æ59‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2020/11/21-22, 12/11-27), ‰¡•l/WebŠJÃ.

723409. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Žq‹{èòŠà‚É‚¨‚¯‚épŒãÄ”­‚ƒŠƒXƒNŒQÇ—á‚̗Տ°“IŒŸ“¢. ŽRè@—D1, ŒÃì³‹`2, ’†‘ºŠîŠ°2, ‰““¡^ˆê2, ‘吼Œ«l2, “cŽG—L‹I2, ‚“c‹±b2, ‹g–ì@C1,2, Šâ£tŽq2, ‰¶“c‹MŽu2 (1ŽY‰È, 2•wl): ‘æ62‰ñ“ú–{•wl‰ÈŽîᇊw‰ïŠwpu‰‰‰ï (2021/1/29-2/11), WebŠJÃ.

723410. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) —‘‘ƒŒ´”­«ˆ««•FŽî‚ɑ΂µ‚ĖƉuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚ðŽg—p‚µ‚½2—á. ’J@‘ì–ç1, ‘吼Œ«l1, ’†‘ºŠîŠ°1, ŒÃì³‹`1, “cŽG—L‹I1, ‚“c‹±b1, ‹g–ì@C1,2, Šâ£tŽq1, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È): ‘æ62‰ñ“ú–{•wl‰ÈŽîᇊw‰ïŠwpu‰‰‰ï (2021/1/29-2/11), WebŠJÃ.

732018. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (Žw“±ˆãuK‰ï) ŽY•wl‰Èˆã‚̘J“­ŠÂ‹«‚ð‰ü‘P‚³‚¹‚悤. ŠC–ìM–ç (ŽY‰È): ‘æ139‰ñ ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2020/6/23-7/6), WebŠJÃ.

732019. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŒöŠJuÀ) ˆã—Эô‚ÆŒ»ê|ŽY‰ÈEŽüŽYŠúˆã—Õª–ìŠe˜_|. ŠC–ìM–ç (ŽY‰È): “Œ‹ž‘åŠwˆãŠw•”Šw¶E‹³Eˆõ‘ΏۈãŠw˜˜_˜A‘±uÀƒVƒŠ[ƒYXX‘æ2‰ñ (2020/10/1-11/26), WebŠJÃ.

732020. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒZƒ~ƒi[) –³’É•ª•ØŠÖŒWŠw‰ïE’c‘̘A—‹¦‹c‰ï (JALA) ‚ÌŠˆ“®ó‹µ|–³’É•ª•Ø‚̈À‘S«Šm•Û‚Ì‚½‚߂Ɂ|. ŠC–ìM–ç (ŽY‰È): “ú–{ŽY‰È–ƒŒŠw‰ïŽåÃ‘æ1‰ñWEBƒZƒ~ƒi[ (2020/12/14-2021/1/11), WebŠJÃ.

732021. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) ÐŠQŽž‚É‚¨‚¯‚é_“ސ쌧‚̏¬Ž™EŽüŽYŠúˆã—Ñ̐§: ÐŠQŽž‚Ì”DŽY•wE•êŽq‚ðŽç‚邽‚ß‚ÌŽx‰‡•û–@‚ÌŽÀÛ‚Ƒ΍ô‚Ì‚·‚ׂÄ. ŠC–ìM–ç (ŽY‰È): _“ސ쌧•ŽYŽt‰ïŒ¤C‰ï (2021/2/27), WebŠJÃ.

732022. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (Žs–¯ŒöŠJuÀ) ƒŠƒvƒƒ_ƒNƒeƒBƒuƒwƒ‹ƒX: “ú–{‚̎Љ•ø‚¦‚é‰Û‘è@—«‚ÌŒ’NTŠÔ. ŠC–ìM–ç (ŽY‰È): ŠÛ‚Ì“àƒLƒƒƒŠƒAmƒXƒyƒVƒƒƒ‹ƒZƒ~ƒi[@—«‚̃‰ƒCƒtƒfƒUƒCƒ“‚ƃŠƒvƒƒ_ƒNƒeƒBƒuƒwƒ‹ƒX|¡‚±‚»l‚¦‚½‚¢ƒg[ƒ^ƒ‹ƒwƒ‹ƒXƒPƒA| (2021/3/3), WebŠJÃ.

732023. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ|ƒXƒ^[) ŒãˆâÇ‚È‚­‹~–½‚µ“¾‚½S”x‹•’EŒ^—r…ÇðÇ‚̈ê—á. ŒÜ“‡—T”V1, ‘吼—fŽq1, ‹g‘º‰ÃL1, ’†‹à˜NŽq1, •ž•”‹¿Žq2, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‹àˆä—Y“ñ1, –]ŒŽ‡Žq1, ŠC–ìM–ç1 (1ŽY‰È, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ139‰ñ ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2020/6/23-7/6), WebŠJÃ.

733077. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) COVID-19ƒtƒ‹PPE‘•”õ‚őΉž‚µ‚½–¢Žóf”D•w‚Ì1—á. ŒÜ\”¨mŽu1, ‹g‘º‰ÃL1, ¼“‡ƒˆê1, •ž•”‹¿Žq2, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‘吼—fŽq1, ‹àˆä—Y“ñ1, –]ŒŽƒŽq1, ŠC–ìM–ç1 (1ŽY‰È, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ429¥430‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/7/12), WebŠJÃ.

733078. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) Žq‹{‹ØŽî”P“]‚̈ê—á. ‰““¡“ޏ”ü1, ŒÜ\”¨mŽu1, “‡‰ª‹¶1, ’F@‰pŽ÷, Vˆä@“w2 (1ŽY‰È, 2•wl): ‘æ429¥430‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/7/12), WebŠJÃ.

733079. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) ƒyƒ€ƒuƒƒŠƒYƒ}ƒu‚ª’˜Œø‚µ‚½MSIŒŸ¸—z«Žq‹{‘ÌŠà‚̈ê—á. £ŒË¹ŒŽ1, ‚“c‹±b1, ’†‘ºŠîŠ°1, ŒÃì³‹`1, ‘吼Œ«l1, “cŽG—L‹I1, Šâ£tŽq1, ‰¶“c‹MŽu1 (1•wl): ‘æ429¥430‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/7/12), WebŠJÃ.

733080. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) •½¬31”N“x_“ސìŽY‰È•wl‰Èˆã‰ï•wl‰Èˆ««Žîᇓo˜^WŒv•ñ. ˆéè‘¾ˆê, Àè—ߎq, Vˆä@“w1, ƒ‹ƒCƒY‰¡“c“Þ•ü, ‹g“c@_, ™‰Y@Œ«, ‘匴@Ž÷, ‚“c‹±b1, –ؔҍvŽœ, ²X–؍N, •ÄŽR„ˆê, —с@NŽq, •½àV@–Ò, ”ª‘ã—•Žq, “y‰®@‘, ’†“c‚³‚­‚ç, X‰ª@Š², ŽOãŠ²’j, ‰Á“¡‹v·, ’†–ìáÁ²’j, ‹{é‰xŽq, ‚‹´P’j (1•wl): ‘æ429¥430‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/7/12), WebŠJÃ.

733081. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) —¬ŽYˆ’u‚ðŒ_‹@‚Éseptic shock‚𗈂½‚µ‚½ˆê—á. •½“cŠxŽj1, ‹g‘º‰ÃL1, •ž•”‹¿Žq1, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‘吼—fŽq1, ‹àˆä—Y“ñ1, ŠC–ìM–ç1 (1ŽY‰È, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ431‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2020/9/26), WebŠJÃ.

733082. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ|ƒXƒ^[) 13Î‚̏‰Œo‘O‚̏­—‚É”­¶‚µ‚½—‘‘ƒ”S‰t«Šà‚̈ê—á. ‰““¡“ޏ”ü1, ‚“c‹±b1, ’†‘ºŠîŠ°1, ‰““¡^ˆê1, ‘吼Œ«l1, “cŽG—L‹I1, ‹g–ì@C1,2, Šâ£tŽq1 (1•wl, 2ŽY‰È): ‘æ140‰ñŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2020/11/12-18): WebŠJÃ.

733083. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) “–‰@‚̍L”ÄŽq‹{‘S“EpŒã”r”AáŠQ‚ÌŠÇ—. ˆ¢•”@‰1, ‚“c‹±b2, ’†‘ºŠîŠ°2, ‰““¡^ˆê2, ŒÃì³‹`2, ‘吼Œ«l2, “cŽG—L‹I2, ‹g–ì@C1,2, Šâ£tŽq2, ŠC–ìM–ç1 (1ŽY‰È, 2•wl): ‘æ383‰ñŽl…‰ï (2020/11/18), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-110001. [Œ´’˜] HIF2ƒ¿ in the uterine stroma permits embryo invasion and luminal epithelium detachment. Matsumoto L, Hirota Y, Saito-Fujita T, Takeda N, Tanaka T, Hiraoka T1, Akaeda S, Fujita H, Shimizu-Hirota R, Igaue S, Matsuo M, Haraguchi H, Saito-Kanatani M, Fujii T, Osuga Y: J Clin Invest 2018/7; 128 (7): 3186-97. (•½‰ª‹B‘å1: 1•wl)

'18-110002. [Œ´’˜] Mdm2-p53-SF1 pathway in ovarian granulosa cells directs ovulation and fertilization by conditioning oocyte quality. Haraguchi H, Hirota Y, Saito-Fujita T, Tanaka T, Shimizu-Hirota R, Harada M, Akaeda S, Hiraoka T1, Matsuo M, Matsumoto L, Hirata T, Koga K, Wada-Hiraike O, Fujii T, Osuga Y: FASEB J 2019/2; 33 (2): 2610-20. (•½‰ª‹B‘å1: 1•wl)

[Šw‰ïEŒ¤‹†‰ï“™]

H28-723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–Ž{Ý‚É‚¨‚¯‚éŽüŽYŠú—̈æ‚Ì’™ŒŒŽ®Ž©ŒÈŒŒ—AŒŒŽÀŽ{ŠÇ—‘̐§‚ɂ‚¢‚Ä. ŠÖŒû˜aŠé1, –]ŒŽƒŽq1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ30‰ñ“ú–{Ž©ŒÈŒŒ—AŒŒŠw‰ïŠwp‘‰ï (2017/3/10-11), ‰¡•l.

'19-733012. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) Massive ovarian edema‚ɑ΂µ‚Ä• o‹¾‰ºŽèp‚ðŽ{s‚µ‘ΏƓI‚È“]‹@‚ð‚Æ‚Á‚½2Ç—á. ŽRè@—D1, ‹v“ˆ‘¥s2, ’†‘ºŠîŠ°3, HŽRŠG—¢Žq1, ÎˆäŠG从q, ˆÉ“¡ŽÀ1,2, ŒÜ“‡—T”V1, “‡‰ª‹¶1, ª’ÍK•ä, â“Œ—R‹I2,4, ŽO–Ø–¾“¿1,2 (1ŽY‰È, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•wl, 4¬Ž™): ‘æ57‰ñé‹ÊŒ§ˆãŠw‰ï‘‰ï (2020/2/22), é‹Ê.


®Œ`ŠO‰ÈŠw

[Šwp˜_•¶]

110297. [Œ´’˜] A portable pneumatic compression device to prevent venous thromboembolism in orthopedic patients with the highest risks of both venous thrombosis and bleeding: A case series study. Takahashi Y, Takahira N1, Shibuya M, Uchiyama K2, Fukushima K3, Iwase D3, Kawamura T3, Miyagi M3, Higashiyama R3, Moriya M3, Sakai K, Tsuda K, Sakamoto M, Akamine A4, Takaso M3: J Orthop Surg (Hong Kong) 2020/1-4; 28 (1): 2309499020905711. (‚•½®L1, “àŽRŸ•¶2, •Ÿ“‡Œ’‰î3, Šâ£@‘å3, ‰Í‘º@’¼3, ‹{é³s3, “ŒŽR—玡3, X’JŒõr3, Ô—䑏•F4, ‚‘Š»Žm3: 1ˆã—Éq¶Šw•”, 2ˆã—ÈÀ‘SEŠÇ—, 3®ŠO, 4–òÜ•”)

110298. [Œ´’˜] Sequential CCL2 Expression Profile After Disc Injury in Mice. Nakawaki M1, Uchida K1, Miyagi M1, Inoue G1, Kawakubo A1, Kuroda A2, Satoh M3, Takaso M1: J Orthop Res 2020/4; 38 (4): 895-901. (’†˜e[Í1, “à“cŒ’‘¾˜Y1, ‹{é³s1, ˆäã@Œº1, ì‹v•Û•à1, •“cW‹`2, ²“¡@‰ë3, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3–Ɖu)

110299. [Œ´’˜] Increase in Tryptase and Its Role in the Synovial Membrane of Overweight and Obese Patients with Osteoarthritis of the Knee. Takata K1, Uchida K2, Mukai M1, Takano S2, Aikawa J2, Iwase D2, Sekiguchi H2, Miyagi M2, Inoue G2, Takaso M2: Diabetes Metab Syndr Obes 2020/5; 13: 1491-7. (‚“c@Œ¤1, “à“cŒ’‘¾˜Y2, Œ}@@Šw1, ‚–쏸‘¾˜Y2, ‘Šì@~2, Šâ£@‘å2, ŠÖŒû—T”V2, ‹{é³s2, ˆäã@Œº2, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO)

110300. [Œ´’˜] Arthroscopic tenodesis using a bioabsorbable interference screw and soft anchor: A case series of 60 patients. Sasaki Y, Ochiai N, Kenmoku T1, Yamaguchi T Kijima T, Hashimoto E, Ohtori S: J Orthop Sci 2020/5; 25 (3): 410-5. (Œ©–Ú’q‹I1: 1®ŠO)

110301. [Œ´’˜] Risk factors associated with prolonged intensive care unit stay after posterior spinal fusion for Duchenne muscular dystrophy. Saito W1, Inoue G1, Shirasawa E1, Imura T1, Nakazawa T1, Miyagi M1, Uchida K1, Matsuda H2, Akazawa T, Takaso M1: J Orthop Sci 2021/5; 26 (3): 332-6. (âV“¡@˜j1, ˆäã@Œº1, ”’àV‰hŽ÷1, ˆä‘º‹M”V1, ’†àVr”V1, ‹{é³s1, “à“cŒ’‘¾˜Y1, ¼“cO”ü2, ‚‘Š»Žm1: 1®ŠO, 2–ƒŒ)

110302. [Œ´’˜] Arthroscopic tenodesis using a bioabsorbable interference screw and soft anchor: A case series of 60 patients. Sasaki Y, Ochiai N, Kenmoku T1,2, Yamaguchi T, Kijima T, Hashimoto E, Ohtori S: J Orthop Sci 2020/5; 25 (3): 410-5. (“ú•û’qG1,2: 1–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 2®ŠO)

110303. [Œ´’˜] Loop-Mediated Isothermal Amplification Screening for COVID-19 in Asymptomatic Preoperative Orthopedic Patients in a General Hospital in Kanagawa, Japan. Uchida K1, Sekiguchi H1, Higashiyama R1, Endo T, Yokozeki Y2, Inoue G1, Miyagi M1, Fujino S1, Yoshida N, Takaso M1: Cureus 2020/7; 12 (7): e9331. (“à“cŒ’‘¾˜Y1, ŠÖŒû—T”V1, “ŒŽR—玡1, ‰¡ŠÖ—YŽi2, ˆäã@Œº1, ‹{é³s1, “¡–쏯‘¾˜Y1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110304. [Œ´’˜] Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study. Kawabata A, Yoshii T, Hirai T, Ushio S, Kaito T, Yamashita T, Fujiwara H, Nagamoto Y, Matsuoka Y, Suzuki H, Nishimura H, Terai H, Tamai K, Tagami A, Yamada S, Adachi S, Watanabe K, Katsumi K, Ohashi M, Shibuya Y, Harimaya K, Kawaguchi K, Yokoyama N, Oishi H, Doi T, Kimura A, Inoue H, Inoue G1, Miyagi M1, Saito W1, Nakano A, Sakai D, Nukaga T, Ikegami S, Shimizu M, Futatsugi T, Ohtori S, Furuya T, Orita S, Imagama S, Ando K, Kobayashi K, Kiyasu K, Murakami H, Yoshioka K, Seki S, Hongo M, Kakutani K, Yurube T, Aoki Y, Oshima M, Takahata M, Iwata A, Endo H, Abe T, Tsukanishi T, Nakanishi K, Watanabe K, Hikata T, Suzuki S, Isogai N, Okada E, Funao H, Ueda S, Shiono Y, Nojiri K, Hosogane N, Ishii K: BMC Musculoskelet Disord 2020/7; 21 (1): 420. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

110305. [Œ´’˜] Prediction tool for high risk of surgical site infection in spinal surgery. Namba T, Ueno M, Inoue G1, Imura T1, Saito W1, Nakazawa T1, Miyagi M1, Shirasawa E1, Takahashi O, Takaso M1: Infect Control Hosp Epidemiol 2020/7; 41 (7): 799-804. (ˆäã@Œº1, ˆä‘º‹M”V1, âV“¡@˜j1, ’†àVr”V1, ‹{é³s1, ”’àV‰hŽ÷1, ‚‘Š»Žm1: 1®ŠO)

110306. [Œ´’˜] Body Composition in Japanese Girls with Adolescent Idiopathic Scoliosis. Miyagi M1, Saito W1, Imura T1, Nakazawa T1, Shirasawa E1, Kawakubo A1, Uchida K1, Akazawa T, Inage K, Ohtori S, Inoue G1, Takaso M1: Spine Surg Relat Res 2020/8; 5 (2): 68-74. (‹{é³s1, âV“¡@˜j1, ˆä‘º‹M”V1, ’†àVr”V1, ”’àV‰hŽ÷1, ì‹v•Û•à1, “à“cŒ’‘¾˜Y1, ˆäã@Œº1, ‚‘Š»Žm1: 1®ŠO)

110307. [Œ´’˜] Posterior Spinal Correction and Fusion Surgery in Patients with Spinal Muscular Atrophy-Associated Scoliosis for Whom Treatment with Nusinersen Was Planned. Machida S1, Miyagi M1, Saito W1, Matsui A, Imura T1, Inoue G1, Nakazawa T1, Shirasawa E1, Ikeda S1, Kawakubo A1, Kuroda A2, Yokozeki Y2, Mimura Y, Uchida K1, Akazawa T, Takaso M1: Spine Surg Relat Res 2020/8; 5 (2): 109-13. (’¬“cŽü•½1, ‹{é³s1, âV“¡@˜j1, ˆä‘º‹M”V1, ˆäã@Œº1, ’†àVr”V1, ”’àV‰hŽ÷1, ’r“cM‰î1, ì‹v•Û•à1, •“cW‹`2, ‰¡ŠÖ—YŽi2, “à“cŒ’‘¾˜Y1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110308. [Œ´’˜] Acceleration of Bone Healing by In Situ-Forming Dextran-Tyramine Conjugates Containing Basic Fibroblast Growth Factor in Mice. Shoji S1, Uchida K2, Saito W2, Sekiguchi H2, Inoue G2, Miyagi M2, Kuroda A1, Takaso M2: Cureus 2020/8; 12 (8): e10085. (¯Ži^‘¾˜Y1, “à“cŒ’‘¾˜Y2, âV“¡@˜j2, ŠÖŒû—T”V2, ˆäã@Œº2, ‹{é³s2, •“cW‹`1, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO)

110309. [Œ´’˜] Investigation of resident and recruited macrophages following disc injury in mice. Kawakubo A1, Uchida K1, Miyagi M1, Nakawaki M1, Satoh M2, Sekiguchi H1, Yokozeki Y3, Inoue G1, Takaso M1: J Orthop Res 2020/8; 38 (8): 1703-9. (ì‹v•Û•à1, “à“cŒ’‘¾˜Y1, ‹{é³s1, ’†˜e[Í1, ²“¡@‰ë2, ŠÖŒû—T”V1, ‰¡ŠÖ—YŽi3, ˆäã@Œº1, ‚‘Š»Žm1: 1®ŠO, 2–Ɖu, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110310. [Œ´’˜] Short- versus long-segment posterior spinal fusion with vertebroplasty for osteoporotic vertebral collapse with neurological impairment in thoracolumbar spine: a multicenter study. Ishikawa Y, Watanabe K, Katsumi K, Ohashi M, Shibuya Y, Izumi T, Hirano T, Endo N, Kaito T, Yamashita T, Fujiwara H, Nagamoto Y, Matsuoka Y, Suzuki H, Nishimura H, Terai H, Tamai K, Tagami A, Yamada S, Adachi S, Yoshii T, Ushio S, Harimaya K, Kawaguchi K, Yokoyama N, Oishi H, Doi T, Kimura A, Inoue H, Inoue G1, Miyagi M1, Saito W1, Nakano A, Sakai D, Nukaga T, Ikegami S, Shimizu M, Futatsugi T, Ohtori S, Furuya T, Orita S, Imagama S, Ando K, Kobayashi K, Kiyasu K, Murakami H, Yoshioka K, Seki S, Hongo M, Kakutani K, Yurube T, Aoki Y, Oshima M, Takahata M, Iwata A, Endo H, Abe T, Tsukanishi T, Nakanishi K, Watanabe K, Hikata T, Suzuki S, Isogai N, Okada E, Funao H, Ueda S, Shiono Y, Nojiri K, Hosogane N, Ishii K: BMC Musculoskelet Disord 2020/8; 21 (1): 513. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

110311. [Œ´’˜] Pulmonary Function Improves in Patients with Adolescent Idiopathic Scoliosis who Undergo Posterior Spinal Fusion Regardless of Thoracoplasty: A Mid-Term Follow-Up. Akazawa T, Kotani T, Sakuma T, Nakayama K, Iijima Y, Torii Y, Iinuma M, Kuroya S, Asano K, Ueno J, Yoshida A, Murakami K, Minami S, Orita S, Inage K, Shiga Y, Nakamura J, Inoue G1, Miyagi M1, Saito W1, Eguchi Y, Fujimoto K, Takahashi H, Ohtori S, Niki H: Spine Surg Relat Res 2020/8; 5 (1): 22-7. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

110312. [Œ´’˜] Central sensitization inventory scores correlate with pain at rest in patients with hip osteoarthritis: a retrospective study. Ohashi Y1, Fukushima K2, Inoue G2, Uchida K2, Koyama T1, Tsuchiya M2, Uchiyama K3, Takahira N4, Takaso M2: BMC Musculoskelet Disord 2020/9; 21 (1): 595. (‘å‹´Œc‹v1, •Ÿ“‡Œ’‰î2, ˆäã@Œº2, “à“cŒ’‘¾˜Y2, ¬ŽR’q‹v1, “y‰®^•ä2, “àŽRŸ•¶3, ‚•½®L4, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”)

110313. [Œ´’˜] Sports activity participation after curved periacetabular osteotomy for acetabular dysplasia. Takahashi Y1, Takahira N2, Uchiyama K3, Fukushima K4, Moriya M4, Shibuya M1, Tsuda K1, Tozaki K1, Kudo S1, Kaneda H1, Sekita J1, Takaso M4: BMC Musculoskelet Disord 2020/9; 21 (1): 637. (‚‹´‰Àô1, ‚•½®L2, “àŽRŸ•¶3, •Ÿ“‡Œ’‰î4, X’JŒõr4, a’J^1, ’ÓcWŽi1, ŒËè@¸1, H“¡@«1, ‹à“c_–¾1, ŠÖ“c“Õ–ç1, ‚‘Š»Žm4: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3ˆã—ÈÀ‘SEŠÇ—, 4®ŠO)

110314. [Œ´’˜] Short-Term Impact of Staying Home on Bone Health in Patients With Osteoporosis During a State of Emergency Declaration Due to COVID-19 in Kanagawa, Japan. Yokozeki Y1, Uchida K2, Miyagi M2, Murata K1, Koyama T1, Kuroda A1, Kawakubo A2, Nannri Y3, Inoue G2, Takaso M2: Cureus 2020/9; 12 (9): e10278. (‰¡ŠÖ—YŽi1, “à“cŒ’‘¾˜Y2, ‹{é³s2, ‘º“cK—C1, ¬ŽR’q‹v1, •“cW‹`1, ì‹v•Û•à2, “ì—¢—C‘¾3, ˆäã@Œº2, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3ƒŠƒnƒrƒŠ•”)

110315. [Œ´’˜] Acceleration of bone union by in situ-formed hydrogel containing bone morphogenetic protein-2 in a mouse refractory fracture model. Shoji S1, Uchida K2, Saito W2, Sekiguchi H2, Inoue G2, Miyagi M2, Takata K1, Yokozeki Y1, Takaso M2: J Orthop Surg Res 2020/9; 15 (1): 426. (¯Ži^‘¾˜Y1, “à“cŒ’‘¾˜Y2, âV“¡@˜j2, ŠÖŒû—T”V2, ˆäã@Œº2, ‹{é³s2, ‚“c@Œ¤1, ‰¡ŠÖ—YŽi1, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO)

110316. [Œ´’˜] Experience of an Orthopaedic Surgery Department Early During the COVID-19 Outbreak in Japan Including Real-Time Polymerase Chain Reaction Assay Results for SARS-CoV-2. Inoue G1, Uchida K1, Fukushima K1, Uchiyama K2, Nakazawa T1, Aikawa J1, Matsuura T1, Miyagi M1, Takahira N3, Takaso M1: Cureus 2020/10; 12 (10): e11140. (ˆäã@Œº1, “à“cŒ’‘¾˜Y1, •Ÿ“‡Œ’‰î1, “àŽRŸ•¶2, ’†àVr”V1, ‘Šì@~1, ¼‰YW³1, ‹{é³s1, ‚•½®L3, ‚‘Š»Žm1: 1®ŠO, 2ˆã—ÈÀ‘SEŠÇ—, 3ˆã—Éq¶Šw•”)

110317. [Œ´’˜] Poly(POG)n loaded with recombinant human bone morphogenetic protein-2 accelerates new bone formation in a critical-sized bone defect mouse model. Tazawa R1, Uchida K1, Minehra H1, Matsuura T1, Kawamura T1, Sekiguchi H1, Muneshige K2, Inoue S2, Inoue G1, Takaso M1: J Orthop Surg Res 2020/10; 15 (1): 471. (“càV@—È1, “à“cŒ’‘¾˜Y1, •ôŒ´G¹1, ¼‰YW³1, ‰Í‘º@’¼1, ŠÖŒû—T”V1, @d‹¿Žq2, ˆäã@ãÄ2, ˆäã@Œº1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110318. [Œ´’˜] Evaluation of myeloperoxidase in synovial fluid as a biomarker for chronic periprosthetic joint infection. Ikeda S1, Uchiyama K2, Minegishi Y1, Nakamura M3, Takaso M1: Int Orthop 2020/10; 44 (10): 1915-20. (’r“cM‰î1, “àŽRŸ•¶2, •õŠÝ—mŽŸ˜Y1, ’†‘º³Ž÷3, ‚‘Š»Žm1: 1®ŠO, 2ˆã—ÈÀ‘SEŠÇ—, 3ˆã—Éq¶Šw•”)

110319. [Œ´’˜] Unilateral-dominant reduction in muscle volume in female knee osteoarthritis patients: computed tomography-based analysis of bilateral sides. Tsukada A1, Uchida K1, Aikawa J1, Takano S1, Iwase D1, Mukai M2 Miyagi M1, Nanri Y3, Inoue G1, Takaso M1: J Orthop Surg Res 2020/11; 15 (1): 543. (’Ë“cˆŸ—T”ü1, “à“cŒ’‘¾˜Y1, ‘Šì@~1, ‚–쏸‘¾˜Y1, Šâ£@‘å1, Œ}@@Šw2, ‹{é³s1, “ì—¢—C‘¾3, ˆäã@Œº1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ƒŠƒnƒrƒŠ•”)

110320. [Œ´’˜] Effects of Tissue Flossing and Dynamic Stretching on Hamstring Muscles Function. Kaneda H1, Takahira N2, Tsuda K1, Tozaki K1, Kudo S1, Takahashi Y1, Sasaaki S3, Kenmoku T4: J Sports Sci Med 2020/11; 19 (4): 681-9. (‹à“c_–¾1, ‚•½®L2, ’ÓcWŽi1, ŒËè@¸1, H“¡@«1, ‚‹´‰Àô1, ²X–؏Gˆê3, Œ©–Ú’q‹I4: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4®ŠO)

110321. [Œ´’˜] In Vivo Evaluation of the Mechanical Strength of a Slide Lengthening Technique With a Locking Mechanism Using a Rabbit Model. Iwase D1, Uchida K1, Metoki Y1, Sekiguchi H1, Aikawa J1 Matsuo T, Matsuo A, Takaso M1: Cureus 2020/12; 12 (12): e12387. (Šâ£@‘å1, “à“cŒ’‘¾˜Y1, –ÚŽž—LŠóŒb1, ŠÖŒû—T”V1, ‘Šì@~1, ‚‘Š»Žm1: 1®ŠO)

110322. [Œ´’˜] Influence of outer geometry on primary stability for uncemented acetabular shells in developmental dysplasia of the hip. Yoshida K1, Fukushima K2, Sakai R1, Uchiyama K3, Takahira N1, Ujihira M1: Proc Inst Mech Eng H 2021/1; 235 (1): 65-72. (‹g“c˜aO1, •Ÿ“‡Œ’‰î2, Žðˆä—˜“Þ1, “àŽRŸ•¶3, ‚•½®L1, Ž•½­L1: 1ˆã—Éq¶Šw•”, 2®ŠO, 3ˆã—ÈÀ‘SEŠÇ—)

110323. [Œ´’˜] Elevated levels of TNF-ƒ¿, IL-1ƒÀ and IL-6 in the synovial tissue of patients with labral tear: a comparative study with hip osteoarthritis. Koyama T1, Uchida K2, Fukushima K2, Ohashi Y1, Uchiyama K3, Inoue G2, Takahira N4, Takaso M2: BMC Musculoskelet Disord 2021/1; 22 (1): 33. (¬ŽR’q‹v1, “à“cŒ’‘¾˜Y2, •Ÿ“‡Œ’‰î2, ‘å‹´Œc‹v1, “àŽRŸ•¶3, ˆäã@Œº2, ‚•½®L4, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”)

110324. [Œ´’˜] Assessment of the duration and effectiveness of intra-articular lidocaine injections for groin pain in patients with labral tears involving early osteoarthritis. Fukushima K1, Inoue G1, Kawakubo A2, Uchida K1, Koyama T2, Ohashi Y2, Uchiyama K3, Takahira N4, Takaso M1: SICOT J 2021; 7: 4. doi: 10.1051/sicotj/2020049. Epub 2021 Jan 12. (•Ÿ“‡Œ’‰î1, ˆäã@Œº1, ì‹v•Û•à2, “à“cŒ’‘¾˜Y1, ¬ŽR’q‹v2, ‘å‹´Œc‹v2, “àŽRŸ•¶3, ‚•½®L4, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”)

110325. [Œ´’˜] Management of regional bone bank during declaration of a state of emergency concerning the COVID-19 in Japan. Uchida K1, Mukai M2, Miyagi M1, Fukushima K1, Uchiyama K3, Nakayama A1, Matsumoto M1, Takahira N4, Urabe K1, Takaso M1, Inoue G1: Cell Tissue Bank 2021/12; 22 (4): 703-9. doi: 10.1007/s10561-021-09908-w. Epub 2021 Feb 20. (“à“cŒ’‘¾˜Y1, Œ}@@Šw2, ‹{é³s1, •Ÿ“‡Œ’‰î1, “àŽRŸ•¶3, ’†ŽR»Žq1, ¼–{@•‘1, ‚•½®L4, è•”@Œ›1, ‚‘Š»Žm1, ˆäã@Œº1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”)

110326. [Œ´’˜] Limitations of posterior spinal fusion to L5 for flaccid neuromuscular scoliosis focusing on pelvic obliquity. Saito W1, Inoue G1, Shirasawa E1, Imura T1, Nakazawa T1, Miyagi M1, Kawakubo A2, Uchida K1, Kotani T, Akazawa T, Takaso M1: Spine Deform 2021/3; 9 (2): 559-65. (âV“¡@˜j1, ˆäã@Œº1, ”’àV‰hŽ÷1, ˆä‘º‹M”V1, ’†àVr”V1, ‹{é³s1, ì‹v•Û•à2, “à“cŒ’‘¾˜Y1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

120013. [Œ´’˜] –«t‘Ÿ•a‚ªœ‘e頏NJ³ŽÒ‚̗Տ°ŠŒ©‚É‹y‚Ú‚·‰e‹¿. Îˆä‘å•ã1, ‹{é³s1, ¼–{ŒõŒ\1, •ˆä³ˆê˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO): “Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ïŽGŽ 2020/4; 32 (1): 38-44.

120014. [Œ´’˜] ‘gD‚ð–Í‹[‚µ‚½‘å‘ڍœœŠ²•”‚É‚¨‚¯‚éƒ|ƒŠƒGƒ`ƒŒƒ“ƒP[ƒuƒ‹‚ƃ`ƒ^ƒ“ƒP[ƒuƒ‹‚̖ʈ³‚Ì”äŠr. –î“c“¡ô1, Žðˆä—˜“Þ2, ‹g“c˜aO2, Ž•½­L2, “àŽRŸ•¶3, ‚‘Š»Žm4 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3ˆã—ÈÀ‘SEŠÇ—, 4®ŠO): œÜ 2020/5; 42 (3): 981-4.

120015. [Œ´’˜] lHŒÒŠÖß’uŠ·p‚É‚¨‚¯‚éƒnƒ“ƒ}ƒŠƒ“ƒO‰¹‚ÌŽü”g”‰ðÍ‚Æ‘å‘ڍœ‚̉ž—͂̐„’è. Žðˆä—˜“Þ1, ‹g“c˜aO1, Ž•½­L1, –k—¢Ž÷¶2, “àŽRŸ•¶3, ‚•½®L1 (1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—): œÜ 2020/5; 42 (3): 1087-90.

120016. [Œ´’˜] ‚—‘e頏NJ³ŽÒ‚É‚¨‚¯‚錒NŠÖ˜AQOL‚ÌŒŸ“¢. ŽO‘º—I—S1, ‹{é³s1, “c“‡Gˆê˜Y1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, “à“cŒ’‘¾˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): Journal of Spine Research 2020/9; 11 (9): 1114-9.

120017. [Œ´’˜] “ú–{l‚É‚¨‚¯‚éCORAILÒ stem‚ÌŽg—pƒTƒCƒY‚ÌŒXŒü. ˆäãG‰î1, •Ÿ“‡Œ’‰î1, ¬ŽR’q‹v2, ‘å‹´Œc‹v2, “àŽRŸ•¶3, ‚•½®L4, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”): ŠÖßŠO‰È 2020/10; 39 (10): 1135-41.

120018. [Œ´’˜] Š°œ‰PŒ`¬•s‘S‚É‚¨‚¯‚鏉ŠúŒÅ’萫‚ɑ΂·‚锼‘ȉ~‹…Œ^ƒZƒƒ“ƒgƒŒƒXlHŒÒŠÖßƒVƒFƒ‹‚ÌŒø‰Ê. ‹g“c˜aO1, •Ÿ“‡Œ’‰î2, Žðˆä—˜“Þ1, “àŽRŸ•¶3, ‚•½®L1, Ž•½­L1 (1ˆã—Éq¶Šw•”, 2®ŠO, 3ˆã—ÈÀ‘SEŠÇ—): —Տ°ƒoƒCƒIƒƒJƒjƒNƒX 2020/10; 41: 43-8.

120019. [Œ´’˜] ’´‚•ªŽq—ʃ|ƒŠƒGƒ`ƒŒƒ“»ƒP[ƒuƒ‹‚Æ‹à‘®»ƒP[ƒuƒ‹‚Ì‘å‘ڍœœŠ²•”‚É‚¨‚¯‚é–ʈ³‚Ì”äŠr. Žðˆä—˜“Þ1, –î“c“¡ô2, ‹g“c˜aO1, “àŽRŸ•¶3, ‚•½®L1, Ž•½­L1 (1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—): —Տ°ƒoƒCƒIƒƒJƒjƒNƒX 2020/10; 41: 381-4.

120020. [Œ´’˜] ‹Â‰çˆÊƒ|[ƒ^ƒuƒ‹ƒiƒrƒQ[ƒVƒ‡ƒ“HipAlign‚Ì“±“ü‘OŒã‚É‚¨‚¯‚éƒJƒbƒvÝ’u¸“x‚ÌŒŸ“¢. ŽÄ“c’¼–í1, “àŽRŸ•¶2, •Ÿ“‡Œ’‰î1, âV“¡LŽ÷3, X’JŒõr1, ‚•½®L4, ‚‘Š»Žm1 (1®ŠO, 2ˆã—ÈÀ‘SEŠÇ—, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4ˆã—Éq¶Šw•”): Hip joint 2020/8; 46 (1): 404-5.

120021. [Œ´’˜] ‘å‘ڍœ“]Žq•”œÜ‚É‚æ‚鏬“]Žqœ•Ð“]ˆÊ‚ª•àsŒ`‘Ô‚É—^‚¦‚é‰e‹¿. ¬–ö‰À‘ã, •Ÿ“‡Œ’‰î1, Ä“¡Œc‘¾ (1®ŠO): Hip joint 2020/8; 46 (2): S219-22.

310035. [Ç—á•ñ] Cervical Hyperextension Treated by Posterior Spinal Correction and Fusion in A Patient with Ullrich Congenital Muscular Dystrophy: A Case Report. Saito W1, Imura T1, Miyagi M1, Nakazawa T1, Takaso M1, Inoue G1: JBJS Case Connect 2020/4-6; 10 (2): e0392. (âV“¡@˜j1, ˆä‘º‹M”V1, ‹{é³s1, ’†àVr”V1, ‚‘Š»Žm1, ˆäã@Œº1: 1®ŠO)

310036. [Œ´’˜] Impact of Jiggling Exercise as Conservative Treatment for Hip Osteoarthritis: A Report of Two Cases. Teramoto Y1, Fukushima K1, Koyama T2, Ohashi Y2, Uchiyama K3, Takahira N2, Takaso M1: Case Rep Orthop 2020/5; 2020: 2804193. doi: 10.1155/2020/2804193. eCollection 2020. (Ž›–{—m•½1, •Ÿ“‡Œ’‰î1, ¬ŽR’q‹v2, ‘å‹´Œc‹v2, “àŽRŸ•¶3, ‚•½®L2, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—)

310037. [Ç—á•ñ] Bilateral Solitary Osteochondroma of the Bicipital Tuberosity Accompanied with Painful Clicking: A Case Report and Literature Review. Metoki Y1, Sukegawa 1, Onuma K1, Otake Y1, Yokozeki Y2, Miyata T1, Kenmoku T1, Takaso M1: J Hand Surg Asian Pac Vol 2020/6; 25 (2): 245-50. (–ÚŽž—LŠóŒb1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‘å’|—IÆ1, ‰¡ŠÖ—YŽi2, ‹{“c@Ž÷1, Œ©–Ú’qG1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

310038. [Ç—á•ñ] Flexor Tenosynovitis Caused by Mycobacterium arupense: A Case Report and Review of the Literature. Yokozeki Y1, Sukegawa K2, Onuma K2, Otake Y2, Wada T3, Takaso M2: JBJS Case Connect 2020/7-9; 10 (3): e2000033. (‰¡ŠÖ—YŽi1, •ì_Žm2, ¬ÀŒ«Ž¡2, ‘å’|—IÆ2, ˜a“c’B•F3, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3äPŒ´•aEŠ´õ“à)

310039. [Ç—á•ñ] Arthroscopic Superior Capsule Reconstruction for Cuff Tear Arthropathy (Hamada Grade 5): A Case Report. Inoue K1, Kenmoku T1, Nakawaki M1, Tazawa R1, Matsumoto M1, Takaso M1: JBJS Case Connect 2020/12; 10 (4): e20.00511. (ˆäãG‰î1, Œ©–Ú’q‹I1, ’†˜e[Í1, “càV@—È1, ¼–{ŒõŒ\1, ‚‘Š»Žm1: 1®ŠO)

310040. [Ç—á•ñ] A dorsal approach for the distal-to-proximal internal fixation of oblique scaphoid fractures. Tada T1, Onuma K1, Sukegawa K1, Otake Y1, Kenmoku T1, Takaso M1: J Orthop Case Rep 2020/12; 10 (9): 98-101. (‘½“c‘ñ–î1, ¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, Œ©–Ú’qG1, ‚‘Š»Žm1: 1®ŠO)

320022. [Ç—á•ñ] 20”NˆÈã•sˆÀ’萫‚ð—L‚µ‚Ä‚¢‚½’‹Œ«•IŠÖßŒãŠO‘¤‰ñù•sˆÀ’èÇ|’·¶‹ØäF‚Æ•I‹Ø•Ù‚ð—p‚¢‚Ä•IŠÖß‚ðÄŒš‚µ‚½1—á|. ’¬“cŽü•½1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‘å’|—IÆ1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): “ú–{•IŠÖßŠw‰ïŽGŽ 2020; 27 (2): 184-8.

320023. [Ç—á•ñ] èò’Å’E‰PœÜpŒã‚ɐ¶‚¶‚½”]Š²[Ç‚Ì1—á. ’Ë“cˆŸ—T”ü1, ‹{é³s1, ”’àV‰hŽ÷1, âV“¡@˜j1, ˆä‘º‹M”V1, ’†àVr”V1, ˆäã@Œº1, ‚•½®L2, ‚‘Š»Žm1 (1®ŠO, 2ˆã—Éq¶Šw•”): ŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ïŽGŽ 2020/4; 51 (2): 45-9.

320024. [Ç—á•ñ] Ò’ÅŒã‹ü‰^“®‚ðŒ_‹@‚É”­Ç‚µ‚½¬Ž™spinal cord injury without radiographic abnormality‚Ì2—á. ‰¡ŠÖ—YŽi1, ‹{é³s2, ˆäã@Œº2, ’†àVr”V2, ˆä‘º‹M”V2, âV“¡@˜j2, ”’àV‰hŽ÷2, ‚•½®L3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”): ŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ïŽGŽ 2020/6; 51 (3): 138-44.

320025. [Ç—á•ñ] ‘å‘ڍœ“ª‚·‚ׂèÇ‚ÌŒ’‘¤—\–h“IpinningŽž‚̉ߔM‚É‚æ‚荜‰óŽ€‚𐶂¶‚½1—á. ìˆä_•½1, “àŽRŸ•¶2, •Ÿ“‡Œ’‰î1, X’JŒõr1, ‚•½®L3, ‚‘Š»Žm1, ŽR–{‹–¾ (1®ŠO, 2ˆã—ÈÀ‘SEŠÇ—, 3ˆã—Éq¶Šw•”): ŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ïŽGŽ 2020/6; 51 (3): 171-6.

320026. [Ç—á•ñ] Œã•û‹¸³ŒÅ’èpŒã‚ÉŒŒ‹C‹¹‚ð‚«‚½‚µ‚½_Œo‹ØŒ´«‘¤œ]Ç‚Ì1—á. ˆäã@ãÄ1, ‹{é³s2, ’†àVr”V2, ˆäã@Œº2, ˆä‘º‹M”V2, ‚•½®L3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”): ŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ïŽGŽ 2020/6; 51 (3): 234-8.

320027. [Ç—á•ñ] ‘å‘ڍœŠO”½œØ‚èŒã11”NŒo‰ß‚µ‚Ä‚àœ–ü‡‚¹‚¸THAŽ{s‚É“ïa‚µ‚½1—á. ‹´’܍F“T1, “àŽRŸ•¶2, •Ÿ“‡Œ’‰î1, ‘å‹´Œc‹v3, ¬ŽR’q‹v3, X’JŒõr1, ‚•½®L4, ‚‘Š»Žm1 (1®ŠO, 2ˆã—ÈÀ‘SEŠÇ—, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4ˆã—Éq¶Šw•”): Hip Joint 2020/8; 46 (2): 1019-24.

320028. [Ç—á•ñ] ’Å‘Ì‚É’¼ÚZ‚µ‚½”ñ¬×–E”xŠà‚ɑ΂µ•”•ª’ő̐؏œ‚𕹗p‚µŽîᇂðˆê‰ò‚É“Eo‚µ‚¦‚½1—á. •Ä“c¹L1, ”’àV‰hŽ÷1, ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1, ‚‘Š»Žm1 (1®ŠO): “Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ïŽGŽ 2020/8; 32 (2): 221-226.

320029. [Ç—á•ñ] AŒQƒÀ—n˜A‹Û‚É‚æ‚é•êŽw‰óŽ€«“î•”‘gDŠ´õÇ‚Ì1—á. ‹{“c@Ž÷1, •ì_Žm1, ¬ÀŒ«Ž¡1, ì‹v•Û•à2, ‘å’|—IÆ1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ®Œ`ŠO‰È 2020/9; 71 (10): 1087-9.

320030. [Ç—á•ñ] ƒTƒbƒJ[‚̃S[ƒ‹ƒL[ƒp[‚ɐ¶‚¶‚½ã˜rŽO“ª‹Ø”牺’f—ô‚Ì1—á. ŽÄ“c’¼–í1, ¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): ŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ïŽGŽ 2020/10; 51 (5): 420-5.

510014. [‘à] Technical and Conceptual Review on the L5-S1 Oblique Lateral Interbody Fusion Surgery (OLIF51). Orita S, Shiga Y, Inage K, Eguchi Y, Maki S, Furuya T, Aoki Y, Inoue M, Hynes RA, Koda M, Takahashi H, Akazawa T, Nakamura J, Hagiwara S, Inoue G1, Miyagi M1, Fujibayashi S, Iida T, Kotani Y, Tanaka M, Nakajima T, Ohtori S: Spine Surg Relat Res 2020/6; 5 (1): 1-9. (ˆäã@Œº1, ‹{é³s1: 1®ŠO)

520015. [‘à] ’ŊԔ«˜’É‚Ì–«‰»‹@˜‚ÉŠÖ‚·‚élŽ@. ‹{é³s1, “à“cŒ’‘¾˜Y1, ’†˜e[Í1, ì‹v•Û•à2, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): Journal of Spine Research 2020/; 11 (6): 878-82.

522068. [uÀ]y“ÁW: lHŠÖßŽüˆÍŠ´õ‚ÌŒ»ó‚Æ“W–]@‘ÛƒRƒ“ƒZƒ“ƒTƒX‚𓥂܂¦‚āzŽ¡—ÃDebridement, Antibiotics, and Implant Retention (DAIR)|ˆêŠú“IÄ’uŠ·p‚Ü‚½‚Í“ñŠú“IÄ’uŠ·p|. “àŽRŸ•¶1, ’r“cM‰î2, ŽR–{‹–¾, •Ÿ“‡Œ’‰î2, X’JŒõr2, ‚•½®L3, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3ˆã—Éq¶Šw•”): —Տ°®Œ`ŠO‰È 2020/4; 55 (4): 345-51.

522069. [uÀ]y“ÁW: ŒÒŠÖß—̈æ‚̏p‘OEp’†Žx‰‡‹ZpUp to datezII. p’†ŽèpŽx‰‡@ƒ|[ƒ^ƒuƒ‹ƒiƒrƒQ[ƒVƒ‡ƒ“ƒVƒXƒeƒ€‚ð—p‚¢‚½‹Â‰çˆÊTHA. –¥“csG, ˆÉ“¡‰ë”V, ŠâØŒ’‘¾˜Y, “àŽRŸ•¶1, ìè‰ëŽj, _“cÍ’j, _–ì“N–ç, FŠ™@—º, ç—t‘å‰î, ’·’Jì³—T, “¡‘㍂–¾, ‹{•˜a³ (1ˆã—ÈÀ‘SEŠÇ—): ŠÖßŠO‰È 2020/6; 39 (6): 642]51.

522070. [uÀ]y“ÁW: ŒÒŠÖß—̈æ‚̏p‘OEp’†Žx‰‡‹ZpUp to datezII. p’†ŽèpŽx‰‡@HipGridÒ DRONE‚É‚æ‚é‹Â‰çˆÊTHA‚̏p’†Žx‰‡. •Ÿ“‡Œ’‰î1, ‚•½®L2, ‚‘Š»Žm1 (1®ŠO, 2ˆã—Éq¶Šw•”): ŠÖßŠO‰È 2020/6; 39 (6): 652-6.

522071. [uÀ]yŽáŽèˆãŽt‚Ì‚½‚ß‚Ì ŒoŒ±‚·‚ׂ«g—̈æ•ÊhŽèpuÀz[ŒÒŠÖß] (PART 1) ŠÖß‹¾Ž‹‰ºŽèp@ŒÒŠÖßO–D‡p (Œ`¬p). •Ÿ“‡Œ’‰î1, ‚•½®L2, ‚‘Š»Žm1 (1®ŠO, 2ˆã—Éq¶Šw•”): ®Œ`ŠO‰ÈSurgical Technique 2020/6; 10 (3): 328-34.

522072. [uÀ]y“ÁW: ‚—îŽÒ‚Ìáu’ÉŠÇ—‚ƊɘaƒPƒAz2. ˜•”Ò’ŒŠÇ‹·óÇ‚ƍ˜’ÉŠÖ˜AŽ¾Š³. ˆäã@Œº (®ŠO): “ú–{˜V”NˆãŠw‰ïŽGŽ 2020/7; 57 (3): 243-53.

522073. [uÀ]y“ÁW: ƒCƒ“ƒvƒ‰ƒ“ƒgŽüˆÍœÜ‚ÌŽ¡—Ð헪@THAETKAEœÜŒã‚̃vƒŒ[ƒgE‘“à“Bz¡ƒRƒ‰ƒ€@ƒCƒ“ƒvƒ‰ƒ“ƒgŽüˆÍœÜ‚É‚¨‚¯‚é‘å‘ڍœƒXƒeƒ€Ä’uŠ·p‚̃eƒNƒjƒbƒN. “àŽRŸ•¶1, •Ÿ“‡Œ’‰î2, X’JŒõr2, ¬ŽR’q‹v3, ‘å‹´Œc‹v3, ‚•½®L4, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4ˆã—Éq¶Šw•”): —Տ°®Œ`ŠO‰È 2020/9; 55 (9): 1037-46.

522074. [uÀ]y“ÁW: ’áNPŽèp‚É‚¨‚¯‚銴õ‘΍ôƒ}ƒjƒ…ƒAƒ‹zI. Surgical Site Infection (SSI) ‚Ì—\–h@RMRSA–ò‚Ì—\–hR‹Û–ò“Š—^‚ÆŽ¡—ÓŠ—^‚̍l‚¦•û. “àŽRŸ•¶1, •Ÿ“‡Œ’‰î2, X’JŒõr2, ¬ŽR’q‹v3, ‘å‹´Œc‹v3, ‚•½®L4, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4ˆã—Éq¶Šw•”): ®Œ`ŠO‰ÈÅ¬NPŽèpƒWƒƒ[ƒiƒ‹ 2021/2; 98: 44422.

522075. [uÀ]y“ÁW: lHŒÒŠÖßÄ’uŠ·p@Å‘Oü‚©‚ç“ïˆÕ“x‚̍‚‚¢Ç—á‚܂ŁzƒCƒ“ƒvƒ‰ƒ“ƒg”j‘¹‚É‚æ‚élHŒÒŠÖßÄ’uŠ·p. ŽR–{‹–¾, “àŽRŸ•¶1, ‚•½®L2 (1ˆã—ÈÀ‘SEŠÇ—, 2ˆã—Éq¶Šw•”): ŠÖßŠO‰È 2021/2; 40 (2): 175-85.

522076. [uÀ]y“ÁW: lHŒÒŠÖßÄ’uŠ·p@Å‘Oü‚©‚ç“ïˆÕ“x‚̍‚‚¢Ç—á‚܂ŁzœŒ‡‘¹‚ւ̑Ήž|“¯Žíœ‚ð—p‚¢‚½ÄŒš. •Ÿ“‡Œ’‰î1, “àŽRŸ•¶2, ˆäã@Œº1, ‚•½®L3, ‚‘Š»Žm1 (1®ŠO, 2ˆã—ÈÀ‘SEŠÇ—, 3ˆã—Éq¶Šw•”): ŠÖßŠO‰È 2021/2; 40 (2): 205-12.

[’˜@‘]

620067. [Šwp‘ (•ª’SŽ·•M)]ySave the Athlete ŒÒŠÖßƒXƒ|[ƒc‘¹zII@ŒÒŠÖßEœ”Ղ̃Xƒ|[ƒc‘¹@A. Ž¾Š³•Ò@1. ‘å‘ڍœŠ°œ‰PƒCƒ“ƒsƒ“ƒWƒƒ“ƒg (FAI), p.34-44. •Ÿ“‡Œ’‰î (®ŠO), •Ò: ‚•½®L, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/10”­s.

620068. [Šwp‘ (•ª’SŽ·•M)]yƒp[ƒtƒFƒNƒg@‘O\Žšx‘эČšp (ACL)z‘æ4ÍŽ¡—Á@6. “¯ŽíäF‚É‚æ‚éACLÄŒš, p.138-44. “ŒŽR—玡 (®ŠO), •Ò: Î‹´‹±”V, •“c—Ç—S, ‘O@’B—Y, ‹à–F“°, ‹ž“s, 2020/10”­s.

620069. [Šwp‘ (•ª’SŽ·•M)]y®Œ`ŠO‰ÈƒŒƒWƒfƒ“ƒg‚Ì‚½‚߂̐Ғł̃x[ƒVƒbƒNŽèpz1Í‰ð–U, ŒŸ¸–@@2. ˆê”Ê“I‚ÈŒŸ¸–@ (Ò‘o‘¢‰eŒŸ¸, _ŒoªƒuƒƒbƒN, ’ŊԔ’ŽËE‘¢‰eŒŸ¸), p.16. ‹{é³s1, ŽO‘º—I—S1 (1®ŠO), •Ò’˜: ‘D”ö—z¶, “ú–{ˆãŽ–V•ñŽÐ, “Œ‹ž, 2020/12”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

711001. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Bone allograft: What can they offer? Urabe K1: Asia Pacific Association of Surgical Tissue Banking 2021 (2021/3/19), WebŠJÃ. (è•”@Œ›1: 1®ŠO)

711002. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Meniscal allograft. Urabe K1: Asia Pacific Association of Surgical Tissue Banking 2021 (2021/3/19), WebŠJÃ. (è•”@Œ›1: 1®ŠO)

712005. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Curved Periacebular Osteotomy. Fukushima K1, Koyama T2, Ohashi Y2, Uchiyama K3, Takahira N4, Takaso M1: The 2nd Annual Congress of Asia Society of Hip Arthroscopy & Preservation (2020/4/4), WebŠJÃ. (•Ÿ“‡Œ’‰î1, ¬ŽR’q‹v2, ‘å‹´Œc‹v2, “àŽRŸ•¶3, ‚•½®L4, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”)

713040. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Prevalence and characteristics of a spinal sagittal imbalance in patients with osteoporosis. Miyagi M1, Matsunaga T1, Murata K2, Koyama T2, Kawakubo A2, Yokozeki Y2, Uchida K1, Inoue G1, Takaso M1: The World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases 2020 (WCO-IOF-ESCEO 2020) (2020/8/20-22), WebŠJÃ. (‹{é³s1, ¼‰iã”V1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, ‰¡ŠÖ—YŽi2, “à“cŒ’‘¾˜Y1, ˆäã@Œº1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

713041. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Poor general condition, low trunk muscle mass, and spinal sagittal imbalance affect the health-related quality of life in osteoporosis patients. Koyama T1, Miyagi M2, Murata K1, Kuroda A1, Kawakubo A1, Ohtori S, Inage K, Uhida K2, Inoue G2, Takaso M2: The World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases 2020 (WCO-IOF-ESCEO 2020) (2020/8/20-22), WebŠJÃ. (¬ŽR’q‹v1, ‹{é³s2, ‘º“cK—C1, •“cW‹`1, ì‹v•Û•à1, “à“cŒ’‘¾˜Y2, ˆäã@Œº2, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO)

721018. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) Vertebral osteotomy in patients with adult spinal deformity. ˆäã@Œº (®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

721019. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ƒŠƒEƒ}ƒ`«Ž¾Š³‚ɐ¶‚¶‚½lHŒÒŠÖßŽüˆÍŠ´õ‚ÌŽ¡—Ã. “àŽRŸ•¶1, ’r“cM‰î2, X’JŒõr2, •Ÿ“‡Œ’‰î2, ‚•½®L3, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ49‰ñ“ú–{ƒŠƒEƒ}ƒ`‚ÌŠO‰ÈŠw‰ï (2020/9/11), WebŠJÃ.

721020. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) Avenir Complete: Full HA coated stem‚̃fƒUƒCƒ“ƒRƒ“ƒZƒvƒg‚ƗՏ°ŒoŒ±. •Ÿ“‡Œ’‰î (®ŠO): ‘æ47‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2020/10/24), Žl“úŽs (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722085. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) •Û‘¶—Ö@‚ƌҊ֐ߋ¾Ž‹‰ºŽèp. •Ÿ“‡Œ’‰î1, ¬ŽR’q‹v2, ‘å‹´Œc‹v2, “àŽRŸ•¶3, ‚•½®L4, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ.

722086. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “¯Žíœ‚ð—p‚¢‚½lHŒÒŠÖß’uÄ’uŠ·p‚ÌŠî–{Žè‹Z. “àŽRŸ•¶1, •Ÿ“‡Œ’‰î2, X’JŒõr2, ‚•½®L3, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ,“ú–{®Œ`ŠO‰ÈŠw‰ïŽ´˜^W p. S391.

722087. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‘ÛƒRƒ“ƒZƒ“ƒTƒX‚̂킪‘‚ł̉ž—p. ŽR“c_Ži, “c’†Nm, “y‰®Os, ˆî—t@—T, ¬—Ñ’¼ŽÀ, ›Á@Œ«–¯, XˆäŒ’Ži, “àŽRŸ•¶1, ˆäã‘å•ã, ¼‰º˜a•F (1ˆã—ÈÀ‘SEŠÇ—): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ,“ú–{®Œ`ŠO‰ÈŠw‰ïŽ p. S477.

722088. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ŒÒŠÖßPJI‚ÌŽ¡—Â̍H•v. “àŽRŸ•¶1, ’r“cM‰î2, X’JŒõr2, •Ÿ“‡Œ’‰î2, ‚•½®L3, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ,‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï´˜^W‡U p. S602.

722089. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) œØ‚èp‚É‚¨‚¯‚鋸³‘€ì‚Ő¶‚¶‚½_Œo‘¹‚ÌŒŸ“¢. ˆäã@Œº1, ˆä‘º‹M”V1, ‹{é³s1, ꎓ¡@˜j1, ”’àV‰hŽ÷1, ì‹v•Û•à2, ’†àVr”V1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ10‰ñ“ú–{¬lÒ’Œ•ÏŒ`Šw‰ï (2020/8/15), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722090. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ¬lÒ’Œ•ÏŒ`‚É‚¨‚¯‚鍜‘e頏ǎ¡—Â̖¢—ˆ. ‹{é³s (®ŠO): ‘æ10‰ñ“ú–{¬lÒ’Œ•ÏŒ`Šw‰ï (2020/8/15), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722091. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) œ‘e頏NJ³ŽÒ‚Ì""˜‹È‚ª‚è""‚ƍ˜’É. ‹{é³s1, ‚‘Š»Žm1 (1®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722092. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ŒÒŠÖß‚𒆐S‚Æ‚µ‚½ŽOŽŸŒ³ƒAƒ‰ƒCƒƒ“ƒgHip-Spine-Knee. ‹{é³s1, •Ÿ“‡Œ’‰î1, “àŽRŸ•¶2, ˆäã@Œº1, ’†àVr”V1, ˆä‘º‹M”V1, ꎓ¡@˜j1, ”’àV‰hŽ÷1, ‚•½®L3, ‚‘Š»Žm1 (1®ŠO, 2ˆã—ÈÀ‘SEŠÇ—, 3ˆã—Éq¶Šw•”): ‘æ47‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2020/10/23), Žl“úŽs (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722093. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Ò’ÅŽèp‚É‚¨‚¯‚éoŒŒ’ጸ‚̍H•v. ˆäã@Œº (®ŠO): ‘æ29‰ñ“ú–{Ò’ŃCƒ“ƒXƒgƒDƒ‹ƒƒ“ƒe[ƒVƒ‡ƒ“Šw‰ï (2020/11/18), WebŠJÃ.

722094. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Surgical technique and clinical results for patients of Femoroacetabular impingement syndrome (FAIS). •Ÿ“‡Œ’‰î1, ‘å‹´Œc‹v2, ¬ŽR’q‹v2, ‚•½®L3, “àŽRŸ•¶4, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—Éq¶Šw•”, 4ˆã—ÈÀ‘SEŠÇ—): ‘æ12‰ñ“ú–{ŠÖß‹¾E•GEƒXƒ|[ƒc®Œ`ŠO‰ÈŠw‰ï/‘æ46‰ñ“ú–{®Œ`ŠO‰ÈƒXƒ|[ƒcˆãŠw‰ïŠwpW‰ï‡“¯Šw‰ï (JOSKAS-JOSSM 2020) (2020/12/17), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722095. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) lHŠÖßpŒãŠ´õÇ‚Ì‘ŠúŒŸo‚Ì‚½‚߂̃oƒCƒIƒ}[ƒJ[‚ÆPCR–@|MPO‚ÆTm mapping–@|. “àŽRŸ•¶1, ’r“cM‰î2, ŸNˆäŒc‘¢3, mˆäŒ©‰pŽ÷, •õŠÝ—mŽŸ˜Y2, X’JŒõr2, •Ÿ“‡Œ’‰î2, ‚•½®L4, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3—ÕŒŸ•”, 4ˆã—Éq¶Šw•”): ‘æ43‰ñ“ú–{œEŠÖßŠ´õÇŠw‰ï (2020/12/25), WebŠJÃ.

722096. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) œEŠÖßŠ´õÇpŒã SSI—\–h‚Ì‚½‚ß‚ÌŽèp‹@ŠíŽæ‚舵‚¢ã‚Ì’ˆÓ“_. “àŽRŸ•¶1, •Ÿ“‡Œ’‰î2, X’JŒõr2, ’r“cM‰î2, “n糁@“O, ‹àŒ´ƒŽi3, ‚•½®L4, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3ŠÅŒì•”, 4ˆã—Éq¶Šw•”): ‘æ43‰ñ“ú–{œEŠÖßŠ´õÇŠw‰ï (2020/12/26), WebŠJÃ.

723411. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖßƒŠƒEƒ}ƒ`‚ÌŠÓ•Ê‚É‚¨‚­‚ׂ«Žè•””ñŒ‹Šj«RŽ_‹ÛÇ|Ž¡—ÊJŽn‚Ü‚ÅŠúŠÔ‚ð—v‚µ‚½‹³ˆç“I‚È2Ç—á|. ‘å’|—IÆ1, •ì_Žm1, ‰¡ŠÖ—YŽi2, ‹{“c@Ž÷1, ’¬“cŽü•½1, Šâ£@‘å1, Œ©–Ú’q‹I1, ¬ÀŒ«Ž¡1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ.

723412. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •êŽwCMŠÖßÇ‚ɑ΂·‚郍ƒbƒLƒ“ƒOƒvƒŒ[ƒg‚ðŽg—p‚µ‚½•êŽwCMŠÖßŒÅ’èp‚ÌŽ¡—ÃŒoŒ±. ¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ.

723413. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò’Œ–îó–ʃAƒ‰ƒCƒƒ“ƒg‚ɉe‹¿‚ð—^‚¦‚éˆöŽq‚ÌŒŸ“¢@‹Ø—ʁE‹Ø—͒ቺ‚ªÒ’Œ–îó–ʃAƒ‰ƒCƒƒ“ƒgˆÙí‚ÉŠÖ—^‚·‚é. ‹{é³s1, ¯–ì‰ër, ˆî–шêG, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, –x@—I‰î, Ü“cƒ‹v, ˆäã@Œº1, ‘å’¹¸Ži, ’†‘º”Ž—º, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ.

723414. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰Á—‹Ø“÷Œ¸­ÇƒTƒ‹ƒRƒyƒjƒA‚ð‡•¹‚µ‚½Œ´”­«œ‘e頏NJ³ŽÒ‚Ì“Á’¥. –î–씎”V1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ‘å’¹¸Ži, ˆî–шêG, ŠÖŒû—T”V1, “à“cŒ’‘¾˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ.

723415. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îŽÒŒãœ]Ç‚ɑ΂·‚郌ƒWƒXƒ^ƒ“ƒXƒgƒŒ[ƒjƒ“ƒO‚Ì—LŒø«‚ÉŠÖ‚·‚錟“¢. ˆî–шêG, ‹{é³s1, ]Œû@˜a, “n粉pˆê˜Y, –LŒû@“§, ™‰YŽj˜Y, Ü“cƒ‹v, Žu‰êN_, ‘å’¹¸Ži (1®ŠO): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ.

723416. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒÒŠÖßŽèpŠ³ŽÒ‚É‚¨‚¯‚é’†•«Š´ì‚Ì‘¶Ý. ‘å‹´Œc‹v1, •Ÿ“‡Œ’‰î2, ˆäã@Œº2, ‹{é³s2, “à“cŒ’‘¾˜Y2, ¬ŽR’q‹v1, “àŽRŸ•¶3, ‚•½®L4, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ.

723417. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˜•”Ò’ŒŠÇ‹·óÇŽèp‚É‚¨‚¯‚é‹Ø“÷—ʂ̉e‹¿‚ÌŒŸ“¢. ì‹v•Û•à1, ‹{é³s2, ’†àVr”V2, ˆä‘º‹M”V2, âV“¡@˜j2, ”’àV‰hŽ÷2, ‘å’¹¸Ži, ˆî–шêG, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2020/6/11-8/31), WebŠJÃ.

723418. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ñ¶‘Ì“¯Ží’°ãøx‘Ñ‚ð—p‚¢‚½ŠO«‘O˜r‰ñùáŠQ‚ÌŽ¡—ÃŒoŒ±|ŠO«žôŽÚœ–ü‡Ç‚Ì2—á|. ‘å’|—IÆ1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‰¡ŠÖ—YŽi2, ‹{“c@Ž÷1, ’¬“cŽü•½1, Šâ£@‘å1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ63‰ñ“ú–{ŽèŠO‰ÈŠw‰ïŠwpW‰ï (2020/6/25-8/17), WebŠJÃ.

723419. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ã˜r•”žôœ_Œo‚Ì‘–s‚Əã˜rŽO“ª‹ØŠO‘¤“ªäF|ŠO‘¤‹ØŠÔ’†Šu•¡‡‘Ì‚ÌŠÖŒW«. •ì_Žm1, ”Ñ“c仗^, ¬ÀŒ«Ž¡1, ‘å’|—IÆ1, –ÚŽž—LŠóŒb1, ‹Ê–؉p–¾2, ¬ìŒ³”V3, ‚‘Š»Žm1 (1®ŠO, 2—Տ°‰ð–U‹³ˆç, 3‰ð–U): ‘æ63‰ñ“ú–{ŽèŠO‰ÈŠw‰ïŠwpW‰ï (2020/6/25-8/17), WebŠJÃ.

723420. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò’Œ–îó–ʃAƒ‰ƒCƒƒ“ƒgˆÙí, ‘ÌŠ²‹Ø—ʒቺ‚ªœ‘e頏NJ³ŽÒ‚ÌŒ’NŠÖ˜AQOL‚ɉe‹¿‚ð‹y‚Ú‚·. ‹g“c’¼l1, ¬ŽR’q‹v2, ‹{é³s1, ‘º“cK—C2, ì‹v•Û•à2, ‘å’¹¸Ži, ˆî–шêG, ꎓ¡@˜j1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ10‰ñ“ú–{¬lÒ’Œ•ÏŒ`Šw‰ï (2020/8/15), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723421. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Development of general check-up system using smartphone application to detect the adolescent idiopathic scoliosis. ˆäã@Œº1, ‹{é³s1, ꎓ¡@˜j1, ˆä‘º‹M”V1, ¬’Jr–¾, ÔàV@“w, ²‹vŠÔ‹B, ’¹‹—Ǐº, ˆî–шêG, ’†ŽRŒh‘¾, ”Ñ“‡@–õ, ”яÀ‰ë‰›, ‰““¡ˆŸ¹Žq, ”’àV‰hŽ÷1, ’†àVr”V1, ‚‘Š»Žm1 (1®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723422. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Radiological and clinical results of corrective surgery for spinal deformity in patients with Parkinson disease. ˆäã@Œº1, ꎓ¡@˜j1, ‹{é³s1, ˆä‘º‹M”V1, ”’àV‰hŽ÷1, •“cW‹`2, ì‹v•Û•à2, ‰¡ŠÖ—YŽi2, ’†àVr”V1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/8), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723423. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) _Œo‹ØŒ´«Ò’Œ‘¤œ]ÇŽèp‚É‚¨‚¯‚éŽüpŠú‡•¹Ç‚ÌŒŸ“¢ (‘æ2•ñ). ‹{é³s1, ¼–{ŒõŒ\1, âV“¡@˜j1, ˆä‘º‹M”V1, ˆäã@Œº1, ’†àVr”V1, ”’àV‰hŽ÷1, •“cW‹`2, ì‹v•Û•à2, ‰¡ŠÖ—YŽi2, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723424. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) GFPœ‘ƒLƒƒ‰ƒ}ƒEƒX‚ð—p‚¢‚½’ŊԔŠQŒã‚É‘‰Á‚·‚éƒ}ƒNƒƒtƒ@[ƒW‚Ì‹NŒ¹‰ðÍ. ì‹v•Û•à1, “à“cŒ’‘¾˜Y2, ‹{é³s2, ’†˜e[Í2, ’†àVr”V2, ˆä‘º‹M”V2, âV“¡@˜j2, ”’àV‰hŽ÷2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723425. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˜•”Ò’ŒŠÇ‹·óÇŽèp‚É‚¨‚¯‚é‹Ø“÷—ʂ̉e‹¿‚ÌŒŸ“¢. ì‹v•Û•à1, ‹{é³s2, ’†àVr”V2, ˆä‘º‹M”V2, âV“¡@˜j2, ”’àV‰hŽ÷2, ‘å’¹¸Ži, ˆî–шêG, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723426. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™‘¤œ]ÇŽèp‚É‚¨‚¯‚ép’†’á‘̉·Ç‚̃ŠƒXƒNˆöŽq. âV“¡@˜j1, ˆäã@Œº1, ‹{é³s1, ˆä‘º‹M”V1, ”’àV‰hŽ÷1, ’†àVr”V1, ‚‘Š»Žm1 (1®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723427. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™Šú‘¤œ]ÇŽèp‚É‚¨‚¯‚éŠeŽèpŽè‹Z’iŠK‚Å‚ÌŒŒ‰t‘¹Ž¸‚ÌŒŸ“¢. ”’àV‰hŽ÷1, âV“¡@˜j1, ˆäã@Œº1, ‹{é³s1, ˆä‘º‹M”V1, ’†àVr”V1, ‚‘Š»Žm1 (1®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723428. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒNƒ‰ƒXƒ^[‰ðÍ‚ð—p‚¢‚½Ò’Œ–îó–ʃAƒ‰ƒCƒƒ“ƒg‚Ì•ª—Þ: Ò’ÅŠO—ˆŠ³ŽÒ1,378—á‚Å‚ÌŒŸ“¢. –x@—I‰î, –L“cGŒõ, ¯–ì‰ër, ‚‹´^Ž¡, ‘åŽRãĈê˜N, —é–Ø‹œ’¨, ’Ò”ö—B—Y, Ž›ˆäG•x, “°‰€@«, ˆî–шêG, Ü“cƒ‹v, ‹{é³s1, ˆäã@Œº1, ‘å’¹¸Ži, ‚‘Š»Žm1, ’†‘º”Ž—º (1®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723429. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “¯Žíœ’P“Ƃōs‚Á‚½‘¤•ûi“ü˜’Œő̊ԌŒèp‚̍œ–ü‡—¦. ˆä‘º‹M”V1, ˆäã@Œº1, ’†àVr”V1, âV“¡@˜j1, ‹{é³s1, ”’àV‰hŽ÷1, ‚‘Š»Žm1 (1®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723430. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ƒGƒlƒ‹ƒM[ŠO‚É‚æ‚éåœ•sˆÀ’èŒ^œÜ‚ɑ΂·‚é’áNPŒã•ûŒÅ’èp‚Ì—L—p«. ‰¡ŠÖ—YŽi1, ‹{é³s2, ˆä‘º‹M”V2, âV“¡@˜j2, ”’àV‰hŽ÷2, “¡–쏯‘¾˜Y2, ’†àVr”V2, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723431. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒ}[ƒgƒtƒHƒ“ƒAƒvƒŠ‚ð—p‚¢‚½‘¤œ]ÇŒŸfƒVƒXƒeƒ€‚ÌŠJ”­. ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1, ˆä‘º‹M”V1, ¬’Jr–¾, ÔàV@“w, ²‹vŠÔ‹B, ’¹‹—Ǐº, ˆî–шêG, ’†ŽRŒh‘¾, ”Ñ“‡@–õ, ”яÀ‰ë‰›, ‰““¡ˆŸ¹Žq, ”’àV‰hŽ÷1, ’†àVr”V1, ‚‘Š»Žm1 (1®ŠO): ‘æ49‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2020/9/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723432. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚Ì–«˜’ɂɑ΂·‚éƒfƒ…ƒƒLƒZƒ`ƒ“‰–Ž_‰–‚Ì—LŒø«‚ƈÀ‘S«. ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, •“cW‹`2, ì‹v•Û•à2, ‰¡ŠÖ—YŽi2, ŽO‘º—I‰î1, ^•ÇŠîŽ÷1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ22‰ñ“ú–{œ‘e頏NJw‰ï (2020/10/9-11), WebŠJÃ.

723433. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚É‚¨‚¯‚éˆÝH“¹‹t—¬Çó‚ƐҒŒ–îó–ʃAƒ‰ƒCƒƒ“ƒgˆÙí. ‹gàV@‘×1, ¼–{ŒõŒ\1, •ˆä³ˆê˜Y1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, “à“cŒ’‘¾˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ22‰ñ“ú–{œ‘e頏NJw‰ï (2020/10/9-11), WebŠJÃ.

723434. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚É‚¨‚¯‚é‰h—{ó‘ԂƍœŽ¿ƒ}[ƒJ[Eƒyƒ“ƒgƒVƒWƒ“, ƒzƒ‚ƒVƒXƒeƒCƒ“’l‚ÌŠÖŒW. Îˆä‘å•ã1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, •“cW‹`2, ‰¡ŠÖ—YŽi2, ^•ÇŠîŽ÷1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ22‰ñ“ú–{œ‘e頏NJw‰ï (2020/10/9-11), WebŠJÃ.

723435. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚É‚¨‚¯‚é’ő̍œÜ‚̊댯ˆöŽq‚ÌŒŸ“¢@‰ºˆÊ˜’ōœÜ‚É’…–Ú‚µ‚Ä. ‹{“c@Ž÷1, ‹{é³s1, ‰¡ŠÖ—YŽi2, ‘º“cK—C2, ¬ŽR’q‹v2, •“cW‹`2, ì‹v•Û•à2, ^•ÇŠîŽ÷1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ22‰ñ“ú–{œ‘e頏NJw‰ï (2020/10/9-11), WebŠJÃ.

723436. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò’Œ–îó–ʃAƒ‰ƒCƒƒ“ƒgˆÙí‚Æ‘ÌŠ²‹Ø—ʒቺ‚ªœ‘e頏NJ³ŽÒ‚É‚¨‚¯‚鍘’É‚ÉŠÖ—^‚·‚é. ‘ºãᩑ¥1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, ŽO‘º—I—C1, ˆî–шêG, ‘哇¸Ži, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ22‰ñ“ú–{œ‘e頏NJw‰ï (2020/10/9-11), WebŠJÃ.

723437. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) dÇœ‘e頏NJ³ŽÒ‚ɑ΂·‚郍ƒ‚ƒ\ƒYƒ}ƒu“Š—^‚Ì’ZŠú¬Ñ. ‘º“cK—C1, ‹{é³s2, •Ÿ“‡é–¾, ¬—Ñ–¾³, ‚–쏸‘¾˜Y2, ¬ŽR’q‹v1, •“cW‹`1, ì‹v•Û•à1, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ22‰ñ“ú–{œ‘e頏NJw‰ï (2020/10/9-11), WebŠJÃ.

723438. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏ǒŽËÜ‚ªt‹@”\‚É—^‚¦‚é‰e‹¿‚ÉŠÖ‚·‚錟“¢. _•”’q•F1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, •“cW‹`2, ì‹v•Û•à2, ‰¡ŠÖ—YŽi2, ^•ÇŠîŽ÷1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ22‰ñ“ú–{œ‘e頏NJw‰ï (2020/10/9-11), WebŠJÃ.

723439. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHŠÖßŽüˆÍŠ´õ‚É‚¨‚¯‚錴ˆö‹ÛŽí“¯’è‚Ì‚½‚ß‚ÌTm mapping–@‚É‚æ‚é‹Û”’è—Ê–@‚ÌŒŸ“¢. “àŽRŸ•¶1, ŸNˆäŒc‘¢2, mˆäŒ©‰pŽ÷, ’r“cM‰î3, •Ÿ“‡Œ’‰î3, X’JŒõr3, ‚•½®L4, ‚‘Š»Žm3 (1ˆã—ÈÀ‘SEŠÇ—, 2—ÕŒŸ•”, 3®ŠO, 4ˆã—Éq¶Šw•”): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/16), WebŠJÃ,“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï@´˜^Wp.55

723440. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’ŊԔŠQŒã‚ÌM1, M2ƒ}ƒNƒƒtƒ@[ƒW‚Ì‹NŒ¹‚̉ðÍ. ì‹v•Û•à1, “à“cŒ’‘¾˜Y2, ‹{é³s2, ’†˜e[Í2, ˆäã@Œº2, âV“¡ ˜j2, ŠÖŒû—T”V2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723441. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) CD206—z«’ŊԔ“àÝ«ƒ}ƒNƒƒtƒ@[ƒW‚ÍŒ¸­‚·‚é. ì‹v•Û•à1, “à“cŒ’‘¾˜Y2, ‹{é³s2, ’†˜e[Í2, ˆäã@Œº2, âV“¡ ˜j2, ŠÖŒû—T”V2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723442. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ÏŒ`«•GŠÖßÇŠ³ŽÒ‚ÌŠŠ–Œ‘gD‚É‚¨‚¯‚éPeptide Lv‚Ì”­Œ»‚Æáu’É‚Ö‚ÌŠÖ—^‚ÌŒŸ“¢. Œ}@@Šw1, “à“cŒ’‘¾˜Y2, ‚–쏸‘¾˜Y2, ‚“c@Œ¤1, Šâ£@‘å2, ‘Šì@~2, ‘åŠÑ—TŽq3, ŠÖŒû—T”V2, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3•a‘ԁEf—ÃŒn): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723443. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒoƒ“ƒRƒ}ƒCƒVƒ“ŠÜ—LƒŠƒ“Ž_ƒJƒ‹ƒVƒEƒ€ƒZƒƒ“ƒg‚Í–„“üŒã6ƒJŒŽ‚É“n‚萶‘Ì“à‚ł̏™•ú“Á«‚ƍR‹ÛŠˆ«‚ðˆÛŽ‚µ‚Ä‚¢‚é. Œ}@@Šw1, “à“cŒ’‘¾˜Y2, ›¶@Œ’, ’†“‡••F, ‘Šì@~2, Šâ£@‘å2, ‚–쏸‘¾˜Y2, ŠÖŒû—T”V2, ‚‘Š»Žm2, è•”@Œ›2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723444. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) TNF-ƒ¿‚͒ŊԔ‘gD“à‚ÌiNOS”­Œ»‚𐧌䂵‚Ä‚¢‚é. ’†˜e[Í1, “à“cŒ’‘¾˜Y1, ì‹v•Û•à2, ‹{é³s1, ‘å‹v•Û’¼3, ‰¡ŠÖ—YŽi2, ŠÖŒû—T”V1, ˆäã@Œº1, âV“¡@˜j1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ŽÀ“®): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723445. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •›bó‘Bƒzƒ‹ƒ‚ƒ““Š—^‚͍œ‘e頏ǃ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éNGFã¸‚ð—}§‚·‚é. ‘º“cK—C1, “à“cŒ’‘¾˜Y2, ‹{é³s2, “càV@—È2, ˆäã@Œº2, ¬ŽR’q‹v1, ì‹v•Û•à1, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723446. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ì–ž‚𔺂¤•ÏŒ`«•GŠÖßÇŠ³ŽÒ‚ÌŠŠ–Œ‘gD‚Å‚ÍCD5L‚ª‘‰Á‚·‚é. ¯Ži^‘¾˜Y1, “à“cŒ’‘¾˜Y2, ˆäã@Œº2, ‚“c@Œ¤1, Œ}@@Šw1, ‘Šì@~2, Šâ£@‘å2, ‚–쏸‘¾˜Y2, ŠÖŒû—T”V2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723447. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰Á—î‚É”º‚¤‹Ø‘gD‚É‚¨‚¯‚éApelinŽó—e‘Ì”­Œ»‚̒ቺ‚É‚ÍTNF-ƒ¿‚ªŠÖ—^‚·‚é. ¬ŽR’q‹v1, “à“cŒ’‘¾˜Y2, ‹{é³s2, “càV@—È2, ˆäã@Œº2, “¡ŠªŽõŽq, ‘å‹´Œc‹v1, ŠÖŒû—T”V2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723448. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ÏŒ`«ŒÒŠÖßÇŠ³ŽÒ‚É‚¨‚¯‚éCD163‚ƈÀÃŽž’É‚ÌŠÖ˜A. ‘å‹´Œc‹v1, •Ÿ“‡Œ’‰î2, “à“cŒ’‘¾˜Y2, ¬ŽR’q‹v1, “àŽRŸ•¶3, ‚•½®L4, ‘åŠÑ—TŽq5, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”, 5•a‘ԁEf—ÃŒn): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723449. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) iN«_ŒoáŠQƒ‚ƒfƒ‹ƒ‰ƒbƒg‚Ì––½_Œo‚É‚¨‚¯‚éApelin‚Ì”­Œ»“®‘Ô‚ÌŒŸ“¢. ‰¡ŠÖ—YŽi1, “à“cŒ’‘¾˜Y2, ŒüˆäW–±, œAàV’¼–ç, ˆäã@Œº2, ‹{é³s2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723450. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ÏŒ`«•GŠÖßÇ‚ÌŠŠ–Œ‘gD‚É‚¨‚¯‚éAdrenomedullin‚Ɣ얞×–E‚Æ‚ÌŠÖ˜A«‚ÌŒŸ“¢. ‚–쏸‘¾˜Y1, “à“cŒ’‘¾˜Y1, ‚“c@Œ¤2, Œ}@@Šw2, ‘Šì@~1, Šâ£@‘å1, ˆäã@Œº1, ‘åŠÑ—TŽq3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3•a‘ԁEf—ÃŒn): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723451. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’ŊԔ‘gD‚É‚¨‚¯‚é_Œo¬’·ˆöŽq‚Ì”­Œ»§Œä‹@\‚ÌŒŸ“¢. ‰¡ŠÖ—YŽi1, “à“cŒ’‘¾˜Y2, ì‹v•Û•à1, ‹{é³s2, ‘å‹v•Û’¼3, ’†˜e[Í2, ˆäã@Œº2, âV“¡@˜j2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3ŽÀ“®): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723452. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Peptide Lv‚͒ŊԔŠQŒã‚ÌMacrophage polarization‚𐧌䂷‚é. “à“cŒ’‘¾˜Y1, ì‹v•Û•à2, ‘å‹v•Û’¼3, ‹{é³s1, ˆäã@Œº1, ‰¡ŠÖ—YŽi2, Œ}@@Šw2, ŠÖŒû—T”V1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ŽÀ“®): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723453. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖßƒŠƒEƒ}ƒ`Š³ŽÒ‚Å‚ÍŠŠ–ŒüˆÛ‰è×–E‚É‚¨‚¯‚éCŒ^ƒŒƒNƒ`ƒ“Žó—e‘ÌMacrophage inducible C-type lectin‚Ì”­Œ»‚͘´i‚µ‚Ä‚¢‚é. ‚“c @Œ¤1, “à“cŒ’‘¾˜Y2, ‚–쏸‘¾˜Y2, Šâ£@‘å2, ˆäã@Œº2, ‹{é³s2, ‘Šì@~2, ŠÖŒû—T”V2, ‘åŠÑ—TŽq3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3•a‘ԁEf—ÃŒn): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723454. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹‘卜Œ‡‘¹‚ɑ΂·‚éBMP-2ŠÜ—LlHƒRƒ‰[ƒQƒ“ƒQƒ‹‚Ì—LŒø«‚ÌŒŸ“¢. “càV@—È1, “à“cŒ’‘¾˜Y1, •ôŒ´G¹, ¼‰YW³2, ‰Í‘º@’¼1, ˆäã@Œº1, ¯Ži^‘¾˜Y3, âŒûŽµŠC, ‘åŠÑ—TŽq4, ‚‘Š»Žm1 (1®ŠO, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4•a‘ԁEf—ÃŒn): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723455. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) BMP-2ŠÜ—L‹ÇŠd‰»ƒqƒAƒ‹ƒƒ“Ž_ƒQƒ‹‚ð—p‚¢‚½“«œÜŽ¡—Ö@‚Ì—L—p«. ¯Ži^‘¾˜Y1, “à“cŒ’‘¾˜Y2, ŠÖŒû—T”V2, ˆäã@Œº2, âV“¡@˜j2, ‹{é³s2, ‘º“cK—C1, ì‹v•Û•à1, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723456. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽèªŠÇÇŒóŒQŠ³ŽÒ‚ÌŠŠ–Œ‰ºŒ‹‡‘gD‚É‚¨‚¯‚éHIF-1ƒ¿”­Œ»‚ƐüˆÛ‰»ŠÖ˜AˆöŽq‚Æ‚ÌŠÖ˜A«‚ÌŒŸ“¢. ‰¡ŠÖ—YŽi1, “à“cŒ’‘¾˜Y2, ’†˜e[Í2, ¬ÀŒ«Ž¡2, •ì_Žm2, Œ©–Ú’q‹I2, ‘åŠÑ—TŽq3, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3•a‘ԁEf—ÃŒn): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723457. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —«‚Ì•ÏŒ`«•GŠÖßÇŠ³ŽÒ‚ÌŠŠ–Œ‘gD‚Å‚Í’j«‚É”ä‚׃Jƒ‹ƒVƒgƒjƒ“ˆâ“`ŽqŠÖ˜Aƒyƒvƒ`ƒhŽó—e‘ÌRAMP1‚Ì”­Œ»‚ª‚‚¢. “à“cŒ’‘¾˜Y1, ‚–쏸‘¾˜Y1, ‚“c@Œ¤2, Œ}@@Šw2, ‘Šì@~1, Šâ£@‘å1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723458. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —«ŽèªŠÇÇŒóŒQŠ³ŽÒ‚ÌŠŠ–Œ‰ºŒ‹‡‘gD‚Å‚ÍCOL3A1‚Ì”­Œ»‚ª˜´i‚µ‚Ä‚¢‚é. •“cW‹`1, ‰¡ŠÖ—YŽi1, “à“cŒ’‘¾˜Y2, ’†˜e[Í2, ¬ÀŒ«Ž¡2, •ì_Žm2, Œ©–Ú’q‹I2, ‘åŠÑ—TŽq3, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO, 3•a‘ԁEf—ÃŒn): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723459. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ‰ƒbƒg_Œo‘¹ƒ‚ƒfƒ‹‚ɑ΂·‚éplatelet-rich plasma“Y‰ÁƒRƒ‰[ƒQƒ“ƒV[ƒg‚Ì’ÉŠo‰ß•q—}§Œø‰Ê‚Æ‚»‚Ì‹@˜‚ÉŠÖ‚·‚錟“¢. Œüˆä–±W, “à“cŒ’‘¾˜Y1, Žu‰êN_, ˆî–шêG, Ü“cƒ‹v, ¼‰Y—C‰î, ]Œû@˜a, ‹{é³s1, ˆäã@Œº1, ‚‘Š»Žm1, ‘å’¹¸Ži (1®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723460. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ‰ƒbƒg¿œ_Œo‘¹ƒ‚ƒfƒ‹‚ɑ΂·‚é—â“€•Û‘¶‚µ‚½vein ‚É‚æ‚éwrapping‚Ì’ÉŠo‰ß•q—}§Œø‰Ê‚Æheme oxygenase-1 (HO-1) —U“±”\‚ÌŒŸ“¢. Œüˆä–±W, “à“cŒ’‘¾˜Y1, Žu‰êN_, ˆî–шêG, Ü“cƒ‹v, ¼‰Y—C‰î, ]Œû@˜a, ‹{é³s1, ˆäã@Œº1, ‚‘Š»Žm1, ‘å’¹¸Ži (1®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723461. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Chronic constriction injury (CCI) ƒ‚ƒfƒ‹‚ɑ΂·‚鏜ˆ³pŒã‚ÌT×–E‚̕ω»‚ÉŠÖ‚·‚錟“¢. Œüˆä–±W, “à“cŒ’‘¾˜Y1, Žu‰êN_, ˆî–шêG, Ü“cƒ‹v, ¼‰Y—C‰î, ]Œû@˜a, ˆäã@Œº1, ‚‘Š»Žm1, ‘å’¹¸Ži (1®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723462. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —¼‘¤‰ºŽˆCT‰æ‘œ‚ð—p‚¢‚½•ÏŒ`«•GŠÖßÇ‚É‚¨‚¯‚é•Ð‘¤«‚̋ؗʕω»‚ÌŒŸ“¢. Œ}@@Šw1, “à“cŒ’‘¾˜Y2, ’Ë“cˆŸ—S”ü2, ‘Šì@~2, Šâ£@‘å2, ‚–쏸‘¾˜Y2, ‹{é³s2, ŠÖŒû—T”V2, ˆäã Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723463. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏ǂɔº‚¤˜’ɂɑ΂·‚é Weekly PTH»Ü‚Ì—LŒø«. ‘º“cK—C1, ‹{é³s2, ¬ŽR’q‹v1, ì‹v•Û•à1, ¼–{ŒõŒ\2, •Ä“c¹L2, ‚‰ªƒˆê2, “à“cŒ’‘¾˜Y2, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723464. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚É‚¨‚¯‚é‰h—{ó‘Ԃƃyƒ“ƒgƒVƒWƒ“, ƒzƒ‚ƒVƒXƒeƒCƒ“’l‚ÌŠÖŒW. ‹{é³s1, “à“cŒ’‘¾˜Y1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, •“cW‹`2, ‰¡ŠÖ—YŽi2, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723465. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Schwann×–E—R—ˆƒGƒNƒ\ƒ\[ƒ€‚ªTNFƒ¿‚Ì gdecoyh‚Æ‚µ‚čì—p‚·‚é. œAàV’¼–ç, Wendy Campana, Hyojun Kwon, “à“cŒ’‘¾˜Y1, —Ž‡M–õ, ‹´–{‰lŽq, ]Œû@˜a, ‘å’¹¸Ži (1®ŠO): ‘æ35‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/15-16), WebŠJÃ.

723466. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬lÒ’Œ•ÏŒ`Žèp‚É‚¨‚¯‚éLLIFƒP[ƒW‚Ő¶‚¶‚éI”‘¹‚ÉŠÖ‚·‚錟“¢. ˆäã@Œº1, âV“¡@˜j1, ”’àV‰hŽ÷1, ‹{é³s1, ˆä‘º‹M”V1, ŽO‘º—I—S1, ì‹v•Û•à2, •“cW‹`2, ‰¡ŠÖ—YŽi2, ’†àVr”V1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ29‰ñ“ú–{Ò’ŃCƒ“ƒXƒgƒDƒ‹ƒƒ“ƒe[ƒVƒ‡ƒ“Šw‰ï (2020/10/24), WebŠJÃ.

723467. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚Ì–«˜’ɂɑ΂·‚éƒfƒ…ƒƒLƒZƒ`ƒ“‰–Ž_‰–‚ÌŒø‰Ê. ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, •“cW‹`2, ì‹v•Û•à2, ‰¡ŠÖ—YŽi2, ŽO‘º—I‰î1, ^•ÇŠîŽ÷1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ28‰ñ“ú–{˜’ÉŠw‰ï (2020/10/30-11/29), WebŠJÃ.

723468. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽvtŠú“Á”­«‘¤œ^ÇŠ³ŽÒ‚ɑ΂·‚éŒã•û‹¸³ŒÅ’èp‚É‚¨‚¯‚ép’†‘oŒŒ—Ê. ”’àV‰hŽ÷1, ꎓ¡@˜j1, ‹{é³s1, ˆäã@Œº1, ˆä‘º‹M”V1, ’†àVr”V1, •“cW‹`2, ì‹v•Û•à2, ‰¡ŠÖ—YŽi2, ŽO‘º—I—S1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ54‰ñ“ú–{‘¤œ]ÇŠw‰ï (2020/11/6-8), WebŠJÃ.

723469. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Cluster ‰ðÍ‚ð—p‚¢‚½Ò’Œ–îó–ʃAƒ‰ƒCƒƒ“ƒg‚Ì•ª—Þ:Ò’ÅŠO—ˆŠ³ŽÒ1,378—á‚Å‚ÌŒŸ“¢. –x@—I‰î, –L“cGŒõ, ¯–ì‰ër, ‚‹´^Ž¡, ‘åŽRãĈê˜N, —é–Ø‹œ’¨, Ž›ˆäG•x, ˆî–шêG, Ü“cƒ‹v, ‹{é³s1, ˆäã@Œº1, ‘å’¹¸Ži, ‚‘Š»Žm1, ’†‘º”Ž—º (1®ŠO): ‘æ54‰ñ“ú–{‘¤œ]ÇŠw‰ï (2020/11/6-8), WebŠJÃ.

723470. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Type1 AIS‚É‚¨‚¯‚ép‘OCT‚ł̏p’†ƒƒbƒh’·‚̐³Šm‚È—\‘ª•û–@‚ÌŒŸ“¢. ì‹v•Û•à1, âV“¡@˜j2, ’†àVr”V2, ˆä‘º‹M”V2, ‹{é³s2, ”’àV‰hŽ÷2, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2®ŠO): ‘æ54‰ñ“ú–{‘¤œ]ÇŠw‰ï (2020/11/6-8), WebŠJÃ.

731023. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ˜’ŕϐ«Ž¾Š³‚̐f’f‚ÆŽ¡—ÇT. ˆäã@Œº (®ŠO): ‘æ18‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïÒ’ŐҐ‘•aˆãŒ¤C‰ï (2020/8/30), WebŠJÃ.

731024. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ƒXƒ}[ƒgƒtƒHƒ“‚ð—p‚¢‚½ŽvtŠú“Á”­«‘¤œ^ÇƒXƒNƒŠ[ƒjƒ“ƒOƒc[ƒ‹‚ÌŠJ”­. ˆäã@Œº1, ˆä‘º‹M”V1, ¬’Jr–¾, ”Ñ“‡@–õ, ²‹vŠÔ‹B, ’†ŽRŒh‘¾, ÔàV@“w, ‰““¡ˆŸ¹Žq, ’¹‹—Ǐº, ˆî–шêG, ‘å’¹¸Ži, ‚‘Š»Žm1 (1®ŠO): ‘æ69‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2020/9/19), WebŠJÃ.

731025. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ÅV‚̏pŒãŠ´õÇf—Ã. “àŽRŸ•¶1, ’r“cM‰î2, X’JŒõr2, •Ÿ“‡Œ’‰î2, ‚•½®L3, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ69‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2020/9/19), WebŠJÃ.

731026. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) •a‘ÔƒƒJƒjƒYƒ€‚ðl—¶‚µ‚½•ÏŒ`«ŒÒŠÖßÇ‚̐f—Âƃfƒ…ƒƒLƒZƒ`ƒ“‚̈ʒu‚¯. •Ÿ“‡Œ’‰î (®ŠO): ƒVƒIƒmƒMwebƒZƒ~ƒi[ in _“ސì (2020/9/24), WebŠJÃ.

731027. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) lHŒÒŠÖßŽüˆÍŠ´õ‚̐f’fEŽ¡—Â̍ŐVî•ñ. “àŽRŸ•¶ (ˆã—ÈÀ‘SEŠÇ—): Zimmer BiometŽÐ WebƒZƒ~ƒi[ (2020/9/29), WebŠJÃ.

731028. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) •a‘ÔƒƒJƒjƒYƒ€‚ðl—¶‚µ‚½•ÏŒ`«ŒÒŠÖßÇ‚̐f—Âƃfƒ…ƒƒLƒZƒ`ƒ“‚̈ʒu‚¯. •Ÿ“‡Œ’‰î (®ŠO): ‘½–€ŠÖßƒtƒH[ƒ‰ƒ€ (2020/12/10), WebŠJÃ.

731029. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ŒÒŠÖßf—Â̎ÀÛ (f’f). •Ÿ“‡Œ’‰î (®ŠO): S&N webinar ŒÒŠÖß’É‚ðƒTƒˆƒiƒ‰‚·‚邽‚ß‚É (2021/1/29), WebŠJÃ.

731030. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) “úíŠO—ˆ‚É‚¨‚¯‚éꋌa•”’ɂ̐f—Á`g‘̏ŠŒ©‚𒆐S‚Ɂ`. •Ÿ“‡Œ’‰î (®ŠO): Johnson & Johnson HIP Total Solution Seminar (2021/2/20), WebŠJÃ.

731031. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) •ÏŒ`«ŒÒŠÖßÇŽ¡—Âɂ¨‚¯‚éáu’É‚Ì•]‰¿‚Æ‚»‚̑Ώˆ. •Ÿ“‡Œ’‰î (®ŠO): ‘Š–ÍŒ´Pain Forum Online 2021 (2021/3/11), WebŠJÃ.

732024. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) 15ÎˆÈ‰º‚ÌŽá”NŽÒ‚ɑ΂·‚éŒÒŠÖß‹¾Ž‹‰ºŽèp@•½‹Ï3”NˆÈã‚̗Տ°¬Ñ. •Ÿ“‡Œ’‰î1, ‘å‹´Œc‹v2, ¬ŽR’q‹v2, “y‰®^•ä1, ´…Œ’Žj1, “àŽRŸ•¶3, ‚‘Š»Žm, ‚•½®L4 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”): ‘æ69‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2020/9/19), WebŠJÃ.

732025. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) ‹‘卜Œ‡‘¹‚ɑ΂·‚铯Žíœ‚ð—p‚¢‚½‘Ώˆ–@. “àŽRŸ•¶1, •Ÿ“‡Œ’‰î2, X’JŒõr2, ¬ŽR’q‹v3, ‘å‹´Œc‹v3, ‚•½®L4, ‚‘Š»Žm2 (1ˆã—ÈÀ‘SEŠÇ—, 2®ŠO, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4ˆã—Éq¶Šw•”): Johnson & Johnson HIP Total Solution Seminar (2021/2/21), WebŠJÃ.

732026. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) lHŠÖßŽüˆÍŠ´õ‚É‚¨‚¯‚éf’f‚̐i•à|V‹KƒoƒCƒIƒ}[ƒJ[MPO‚ÆTm mapping–@|. “àŽRŸ•¶1, ŸNˆäŒc‘¢2, mˆäŒ©‰pŽ÷, ’r“cM‰î3, •Ÿ“‡Œ’‰î3, X’JŒõr3, ‚•½®L4, ‚‘Š»Žm3 (1ˆã—ÈÀ‘SEŠÇ—, 2—ÕŒŸ•”, 3®ŠO, 4ˆã—Éq¶Šw•”): ‘æ61‰ñŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ï (2021/3/26), WebŠJÃ.

732027. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) Full HA stem (Corail stem) ‚Ì’ZŠúŽ¡—ЬÑ. •Ÿ“‡Œ’‰î1, “y‰®^•ä1, âV“¡LŽ÷1, ¬ŽR’q‹v2, ‘å‹´Œc‹v2, “àŽRŸ•¶3, ‚•½®L4, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”): ‘æ61‰ñŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ï (2021/3/27), WebŠJÃ.

733084. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ƒCƒk™ùŒã‚É”­Ç‚µ‚½Mycobacterium chelonae‚É‚æ‚éŽè•”L‹ØäFäFâŠŠ–Œ‰Š‚̈ê—á. –©²‘ãŽq1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‘å’|—IÆ1, ’¬“cŽü•½1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): ‘æ69‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ïŠwpW‰ï (2020/9/18), webŠJÃ.

733085. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ƒS[ƒ‹ƒL[ƒp[‚ªƒ{[ƒ‹‚ðŽè¶•”‚ŃZ[ƒu‚µ‚½Û‚Ɏ󏝂µ‚½‚ƍl‚¦‚ç‚ꂽMóœœÜ‚Ì2—á. ‘½“c‘ñ–î1, ¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): ‘æ69‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2020/9/19), WebŠJÃ.

733086. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Ò’Œ–îó–ʃAƒ‰ƒCƒƒ“ƒgˆÙí‚Æ‘ÌŠ²‹Ø—ʒቺ‚ªœ‘e頏NJ³ŽÒ‚É‚¨‚¯‚鍘’É‚ÉŠÖ—^‚·‚é. –슡‰Æw1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, ŽO‘º—I‰î1, ˆî–шêG, ‘å’¹¸Ži, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ69‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2020/9/19), WebŠJÃ.

733087. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‹}‘¬is«‚Ì–ƒáƒ‚ð’悵‚½ŠÂ’Ō㓪œ–ü‡Ç‚Ì1—á. ¡–ì—Y‘¾1, ˆä‘º‹M”V1, ˆäã@Œº1, ’†àVr”V1, ‹{é³s1, ꎓ¡@˜j1, ”’àV‰hŽ÷1, ‚‘Š»Žm1 (1®ŠO): ‘æ69‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2020/9/19), WebŠJÃ.

733088. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚É‚¨‚¯‚éáu’É‚Ì—L•a—¦‚Ɛ_ŒoáŠQ«áu’É. ˆêžŠ—FF1, ‹{é³s1, •“cW‹`2, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, ‰¡ŠÖ—YŽi2, ^•ÇŠîŽ÷1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ69‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2020/9/19), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110019. [Œ´’˜] The Surgical Outcomes of Spinal Fusion for Osteoporotic Vertebral Fractures in the Lower Lumbar Spine with a Neurological Deficit. Isogai N, Hosogane N, Funao H, Nojiri K, Suzuki S, Okada E, Ueda S, Hikata T, Shiono Y, Watanabe K, Watanabe K, Kaito T, Yamashita T, Fujiwara H, Nagamoto Y, Terai H, Tamai K, Matsuoka Y, Suzuki H, Nishimura H, Tagami A, Yamada S, Adachi S, Ohtori S, Orita S, Furuya T, Yoshii T, Ushio S, Inoue G1, Miyagi M1, Saito W1, Imagama S, Ando K, Sakai D, Nukaga T, Kiyasu K, Kimura A, Inoue H, Nakano A, Harimaya K, Kawaguchi K, Yokoyama N, Oishi H, Doi T, Ikegami S, Shimizu M, Futatsugi T, Kakutani K, Yurube T, Oshima M, Uei H, Aoki Y, Takahata M, Iwata A, Seki S, Murakami H, Yoshioka K, Endo H, Hongo M, Nakanishi K, Abe T, Tsukanishi T, Ishii K: Spine Surg Relat Res 2020/1; 4 (3): 199-207. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

'19-120002. [Œ´’˜] •sˆÀ’èŒ^‘å‘ڍœ“]Žq•”œÜ‚̏pŒã®•œˆÊ‚É‚¨‚¯‚é—ÍŠw“IŒŸ“¢. ‰Í‘º@’¼1, •ôŒ´G¹1, ¼‰YW³1, ¯Ži^‘¾˜Y1, “càV@—È1, ‚‘Š»Žm1, Žðˆä—˜“Þ2, ‹g“c˜aO2, Ž•½­L2 (1®ŠO, 2ˆã—Éq¶Šw•”): œÜ 2019/4; 41 (2): 522-4.

'19-120003. [Œ´’˜] ƒ]ƒŒƒhƒƒ“Ž_…˜a•¨”N1‰ñ“Š—^»Ü‹}«Šú”½‰ž‚ɑ΂·‚éƒJƒ‹ƒVƒgƒjƒ“»Üæs“Š—^‚ÌŒø‰Ê. “y‰®^•ä1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, ˆäã@Œº1, “à“cŒ’‘¾˜Y1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): _“ސ쐮Œ`ÐŠQŠO‰ÈŒ¤‹†‰ïŽGŽ 2019/11; 32 (4): 121-4.

'19-320003. [Ç—á•ñ] •I‹ü‹ÈˆÊ‚Å‚ÌMRIŽB‘œ‚Å•]‰¿‚µ‚½•IŠÖß‘¤•û’E‰P‚Ì1—á. “c’†ŒcG1, Œ©–Ú’q‹I1, âV“¡LŽ÷1, –¼‘q’¼d, ’†˜e[Í1, “càV@—È1, ¬ÀŒ«Ž¡1, •ì_Žm1, ‚‘Š»Žm1 (1®ŠO): _“ސ쐮Œ`ÐŠQŠO‰ÈŠw‰ïŽ 2019/11; 32 (4): 89-92.

'19-522005. [uÀ]y_Œo‹ØŽ¾Š³, V‚½‚ÈŽ¡—Â̎ž‘ã‚ցzIII. ‡•¹Ç‚ւ̉î“ü@Ò’Œ•ÏŒ`‚ւ̃Aƒvƒ[ƒ` ‚‘Š»Žm1, âV“¡@˜j1, ‹{é³s1, ˆäã@Œº1, ’†àVr”V1, ˆä‘º‹M”V1, ”’àV‰hŽ÷1, ì‹v•Û•à2 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ¬Ž™‰Èf—à 2019/12; 83 (1): 113-22.

[’˜@‘]

H27-620001. [Šwp‘ (•ª’SŽ·•M)]yŠOŠO‰ÈŽèpƒp[ƒtƒFƒNƒg@dÇŠ³ŽÒ‹~–½‚Ì‚½‚߂̃xƒXƒgƒAƒvƒ[ƒ`z‘æ3ÍŠe˜_@4. œ”ՍœÜ, p.2-9. •ôŒ´G¹, ¼‰YW³1, V“¡³‹P (1‹~–½), •Ò: Š‹¼@–Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 2015/8”­s.

H27-620002. [Šwp‘ (•ª’SŽ·•M)]y‰ºŽˆ—Տ°ÇŒó‚̐f‚©‚½El‚¦•ûz‘æ3ÍŒÒŠÖßEœ”Õ•”‚̗Տ°f’fŠe˜_@œŽvtŠúEÂ”NŠú (ƒXƒ|[ƒcáŠQEŠOŠÜ‚Þ)@8. —œó‹ØÇŒóŒQ, 9. œ”ՍœÜEŒÒŠÖß’E‰P, p.70-3. ¼‰YW³1, •ôŒ´G¹, V“¡³‹P (1‹~–½), •Ò: ‹g–îWˆê, ’Ÿ²‰x’j, “c’†Nm, “ìŽR“°, “Œ‹ž, 2015/11”­s.

H29-620001. [Šwp‘ (•ª’SŽ·•M)]yê–åˆã‚̐®Œ`ŠO‰ÈŠO—ˆf—Á@ÅV‚̐f’fEŽ¡—ÁzII. Ž¾Š³Še˜_@5) ƒRƒ“ƒp[ƒgƒƒ“ƒgÇŒóŒQ, p.84-7. •ôŒ´G¹, ¼‰YW³1, V“¡³‹P (1‹~–½), •Ò: •yŽm•Žj, “c•ÓGŽ÷, ‘åì@~, “ì]“°, “Œ‹ž, 2017/4”­s.

'18-620002. [Šwp‘ (•ª’SŽ·•M)]yŒˆ’è”Å!‚à‚¤‹êŽè‚Æ‚ÍŒ¾‚킹‚È‚¢@‚܂邲‚ƍœÜ‚±‚ê1û (®Œ`ŠO‰ÈŠÅŒì2018”Nt‹G‘Š§)z‘æ4Í‰ºŽˆ‚̍œÜ@5. ãøœœŠ²•”œÜ, p.142-5. ¼‰YW³ (‹~–½), •Ò: ‰–“c’¼Žj, ƒƒfƒBƒJo”Å, ‘åã, 2018/5”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

'18-723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •sˆÀ’èŒ^‘å‘ڍœ“]Žq•”œÜ‚É‚¨‚¯‚épŒã®•œ•]‰¿‚Æsliding‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ¼‰YW³1, •ôŒ´G¹, ‰Í‘º@’¼2, “àŽRŸ•¶3, •Ÿ“‡Œ’‰î2, ¯Ži^‘¾˜Y4, “càV@—È2, ‘å’|—IÆ2, ‚•½®L5, ‚‘Š»Žm2 (1‹~–½, 2®ŠO, 3ˆã—ÈÀ‘SEŠÇ—, 4‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 5ˆã—Éq¶Šw•”): ‘æ44‰ñ“ú–{œÜŽ¡—Êw‰ï (2018/7/6-7), ‰ªŽR.

'19-713011. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Stability of internal fixation for distal clavicular fractures. Kawai K1, Matsuura T2, Minehara H, Kawamura T1, Takaso M1: 27th Annual Meeting of the European Orthopaedic Research Society (2019/10/2-5), Maastricht, Netherlands. (ìˆä_•½1, ¼‰YW³2, ‰Í‘º@’¼1, ‚‘Š»Žm1: 1®ŠO, 2‹~–½)

'19-723022. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠO«L”͈͑å‘ڍœœŒ‡‘¹‚ɑ΂µ‚ÄMasquelet –@‚ð—p‚¢‚½Ž¡—ÃŒoŒ±. –©@„Ž÷1, ¼‰YW³2, •ôŒ´G¹, ‰Í‘º@’¼1, ¯Ži^‘¾˜Y3, “càV@—È1, âV“¡LŽ÷1, “¡—R’”V, ‚‘Š»Žm1 (1®ŠO, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ45‰ñ“ú–{œÜŽ¡—Êw‰ï (2019/6/28), •Ÿ‰ª.

'19-723023. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Suicidal jumperfs fracture‚É”º‚¤åœ•”‚ÌŠpó•ÏŒ`‚ɑ΂µ‚ÄŠÏŒŒ“I®•œŒÅ’èp‚ðŽ{s‚µ‚½1—á. •Ä“c¹L1, ‰Í‘º@’¼1, •ôŒ´G¹, ¼‰YW³2, ¯Ži^‘¾˜Y3, “càV@—È1, ŽO‘º—I—C1, ‚‘Š»Žm1 (1®ŠO, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ45‰ñ“ú–{œÜŽ¡—Êw‰ï (2019/6/28), •Ÿ‰ª.

'19-723024. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ƒGƒlƒ‹ƒM[ŠO‚É‚æ‚é•sˆÀ’èŒ^åœœÜ‚ɑ΂·‚é’áNPŒã•ûŒÅ’èp‚Ì—L—p«. ‹{é³s1, ˆä‘º‹M”V1, •ôŒ´G¹, ¼‰YW³2, ‰Í‘º@’¼1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‹~–½): ‘æ45‰ñ“ú–{œÜŽ¡—Êw‰ï (2019/6/29), •Ÿ‰ª.

'19-723025. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘½”­ŠOŠ³ŽÒ‚ɑ΂µ‚ÄEarly Appropriate Care‚ðs‚Á‚½1—á. âV“¡LŽ÷1, ¼‰YW³2, •ôŒ´G¹, ‰Í‘º@’¼1, ¯Ži^‘¾˜Y3, “càV@—È1, ‰¡ŠÖ—YŽi3, ‚‘Š»Žm1 (1®ŠO, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ45‰ñ“ú–{œÜŽ¡—Êw‰ï (2019/6/29), •Ÿ‰ª.

'19-723026. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œˆÚ“®p‚É‚¨‚¯‚鍜ˆÚ“®‘¬“x‚ªdocking site‚̍œ–ü‡‚É‹y‚Ú‚·‰e‹¿. “càV@—È1, •ôŒ´G¹, ¼‰YW³2, ‰Í‘º@’¼1, “à“cŒ’‘¾˜Y1, ˆäã@Œº1, ¯Ži^‘¾˜Y3, ì‹v•Û•à3, ‚‘Š»Žm1 (1®ŠO, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ45‰ñ“ú–{œÜŽ¡—Êw‰ï (2019/6/29), •Ÿ‰ª.

'19-723027. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 20”NˆÈã•sˆÀ’萫‚ð—L‚µ‚Ä‚¢‚½•IŠÖßŒãŠO‘¤‰ñù•sˆÀ’èÇ|’·¶‹ØäF‚Æ•I‹Ø‚ð—p‚¢‚čČš‚µ‚½1—á|. ’¬“cŽü•½1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‘å’|—IÆ1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): ‘æ32‰ñ“ú–{•IŠÖßŠw‰ïŠwpW‰ï (2020/2/7), “Þ—Ç.

'19-723028. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ã˜r•”žôœ_Œo‚Ì‘–s‚Əã˜rŽO“ª‹ØŠO‘¤“ªäF|ŠO‘¤‹ØŠÔ’†Šu•¡‡‘Ì‚ÌŠÖŒW‚ɂ‚¢‚Ẳð–UŠw“IŒ¤‹† (‘æ1•ñ)|. •ì_Žm1, ’¬“cŽü•½1, ¬ÀŒ«Ž¡1, ‘å’|—IÆ1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): ‘æ32‰ñ“ú–{•IŠÖßŠw‰ïŠwpW‰ï (2020/2/7), “Þ—Ç.

'19-733013. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚鍜”՗֍œÜ‚ɑ΂·‚é‘nŠOŒÅ’è–@‚ÌŽ¡—ÃŒoŒ±. Ž›–{—m•½1, •ôŒ´G¹, ¼‰YW³2, ‰Í‘º@’¼1, ¯Ži^‘¾˜Y3, “càV@—È1, Š}Œ´@s2, ó—˜@–õ2, ‚‘Š»Žm1 (1®ŠO, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ68‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2019/9/5-6), “Œ‹ž.

'19-733014. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ŠO«L”͈͍œŒ‡‘¹‚ɑ΂µ‚ÄMasquelet–@‚ð—p‚¢‚½Ž¡—ϬŒoŒ±. –L‘º—fŽi1, ¼‰YW³2, •ôŒ´G¹, ‰Í‘º@’¼1, ¯Ži^‘¾˜Y3, “càV@—È1, âV“¡LŽ÷1, ‚‘Š»Žm1 (1®ŠO, 2‹~–½, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ167‰ñ_“ސ쐮Œ`ÐŠQŠO‰ÈŒ¤‹†‰ï (2019/10/5), ‰¡•l.

'19-733015. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‰ºŽˆ‚̃Cƒ“ƒvƒ‰ƒ“ƒgŽüˆÍœÜ‚ÌŽ¡—Ã: lH•GŠÖß’uŠ·pŒã‚̃Cƒ“ƒvƒ‰ƒ“ƒgŽüˆÍœÜ‚ÌŽ¡—Ã. ‘Šì@~1, Šâ£@‘å1, ‹g“c’¼l1, •ôŒ´G¹, –©²‘ãŽq1, •ˆä³ˆê˜Y1, Œ}@@Šw2, ‚–쏸‘¾˜Y1, ‰Í‘º@’¼1, ¼‰YW³3, ‚‘Š»Žm1, “ŒŽR—玡1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3‹~–½): ‘æ167‰ñ_“ސ쐮Œ`ÐŠQŠO‰ÈŒ¤‹†‰ï (2019/10/5), ‰¡•l.

'19-733016. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) 3ŽŸŒ³‘¢Œ`ƒ‚ƒfƒ‹‚ð—p‚¢‚ďp‘OƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚ðs‚Á‚½Madelung•ÏŒ`‚ÌŽ¡—ÃŒoŒ±. –ÚŽž—LŠóŒb1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‘å’|—IÆ1, ’¬“cŽü•½1, ‚‘Š»Žm1 (1®ŠO): ‘æ34‰ñ“Œ“ú–{ŽèŠO‰ÈŒ¤‹†‰ï (2020/2/1), “Œ‹ž.


Œ`¬ŠO‰ÈE”ü—eŠO‰ÈŠw

[Šwp˜_•¶]

522077. [uÀ] ]—ˆ‚ÌŽ¡—Âʼnü‘P‚É“ïa‚·‚é‘n‚Ö‚ÌŽ¡—Ð헪|‹ÇŠ‰Aˆ³•Â½—Ö@|. ”nêŽq1,2, â“Œ—R‹I1,3 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3¬Ž™): é‹ÊŒ§ˆãŽt‰ïŽ 2020; 839: 36-9.

522078. [uÀ] Œ`¬ŠO‰Èˆã‚ª“`‚¦‚½‚¢‘n‚Ì‚¨˜b‚µ|Œ`¬ŠO‰È‚Ì‚²Ð‰î‚©‚çÅ‹ß‚̃gƒsƒbƒN‚܂Ł|. ”nêŽq1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): –k‘«—§ŒSˆãŽt‰ï‰ï•ñ 2020; 308: 37-41.

540028. [‚»‚Ì‘¼ (‰ÈŒ¤”ï•ñ‘)]y•¶•”‰ÈŠwÈ‰ÈŠwŒ¤‹†”ï•â•‹àŠî”ÕŒ¤‹†C: V‚½‚ȐOŠ{ŒûŠW—ôŽ¡—Ð헪‚ÌŠJ”­‚ÉŒü‚¯‚½ä`‘сEä`‘ÑŒŒ‚ÆŽèp—]è‘gD‚É‚æ‚é‘gDÄ¶z”nêŽq1,2, ŽRèˆÀ°2, •“c@Œ[2, ™–{F”V2, ŒFàVŒ›ˆê2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): •¶•”‰ÈŠwÈ‰ÈŠwŒ¤‹†”ï•â•‹àŠî”ÕŒ¤‹†C: V‚½‚ȐOŠ{ŒûŠW—ôŽ¡—Ð헪‚ÌŠJ”­‚ÉŒü‚¯‚½ä`‘сEä`‘ÑŒŒ‚ÆŽèp—]è‘gD‚É‚æ‚é‘gDÄ¶@Œ¤‹†¬‰Ê•ñ‘ 2020/6; https://kaken.nii.ac.jp/ja/file/KAKENHI-PROJECT-16K11376/16K11376seika.pdf.

540029. [‚»‚Ì‘¼ (‰ÈŒ¤”ï•ñ‘)]y•¶•”‰ÈŠwÈ‰ÈŠwŒ¤‹†”ï•â•‹àŠî”ÕŒ¤‹†C: ”­¶•ê’n‚Ɉˑ¶‚·‚鍜‘gD—R—ˆŠÔ—tŒn×–E‚Ì‘½•ª‰»”\‚̉𖾂Ƃ»‚̗Տ°“IˆÓ‹`zŽRèˆÀ°1, ™–{F”V1, ”nêŽq1,2, ™–{‰À1, XŽR˜a‚Ì1 (1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): •¶•”‰ÈŠwÈ‰ÈŠwŒ¤‹†”ï•â•‹àŠî”ÕŒ¤‹†C: ”­¶•ê’n‚Ɉˑ¶‚·‚鍜‘gD—R—ˆŠÔ—tŒn×–E‚Ì‘½•ª‰»”\‚̉𖾂Ƃ»‚̗Տ°“IˆÓ‹`@Œ¤‹†¬‰Ê•ñ‘ 2020/5; https://kaken.nii.ac.jp/ja/file/KAKENHI-PROJECT-17K11852/17K11852seika.pdf.

[Šw‰ïEŒ¤‹†‰ï“™]

713042. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Co-culture of Umbilical Cord derived Mesenchymal Stem Cells (UCMSCs) and Chondrocytes improved Chondrogenic differentiation. Baba K1,2, Yamazaki Y2, Sone Y3, Sugimoto Y2, Moriyama K2, Sugimoto T2, Kumazawa K2, Takeda A2: 11th WORLD BIOMATERIALS CONGRESS (2020/12/11-15), WEBŠJÃ. (”nêŽq1,2, ŽRèˆÀ°2, ‘]ª—R”üŽq3, ™–{‰À2, XŽR˜a‚Ì2, ™–{F”V2, ŒFàVŒ›ˆê2, •“c@Œ[2: 1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3•a‘ԁEf—ÃŒn)

713043. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Differentiation and proliferation potencies of human bone tissue-derived mesenchymal stromal cells (hBT-MSCs) after long-term cryopreservation -Comparison among cells stored for 1, 5, 10, 15, and 20 years-. Sugimoto Y1, Yamazaki Y1, Moriyama K1, Sugimoto T1, Kumazawa K1, Baba K1,2, Sone Y3, Takeda A1: 11th WORLD BIOMATERIALS CONGRESS (2020/12/11-15), WEBŠJÃ. (™–{‰À1, ŽRèˆÀ°1, XŽR˜a‚Ì1, ™–{F”V1, ŒFàVŒ›ˆê1, ”nêŽq1,2, ‘]ª—R”üŽq3, •“c@Œ[1: 1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•a‘ԁEf—ÃŒn)

713044. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The bone differenciation inducibility by exosome of the mescenchymal cells from human ilium bone (hBMCs). Yamazaki Y1, Sone Y2, Sugimoto Y1, Baba K1,3, Moriyama K1: 11th WORLD BIOMATERIALS CONGRESS (2020/12/11-15), WEBŠJÃ. (ŽRèˆÀ°1, ‘]ª—R”üŽq2, ™–{‰À1, ”nêŽq1,3, XŽR˜a‚Ì1: 1Œ`¬E”üŠO, 2•a‘ԁEf—ÃŒn, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

713045. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Differences in pluripotency of jawbone- and iliac bone-derived mesenchymal cells. Moriyama K1, Yamazaki Y1, Sugimoto Y1, Sugimoto T1, Kumazawa K1, Baba K1,2, Sone Y3, Takeda A1F11th WORLD BIOMATERIALS CONGRESS (2020/12/11-15), WEBŠJÃ. (XŽR˜a‚Ì1, ŽRèˆÀ°1, ™–{‰À1, ™–{F”V1, ŒFàVŒ›ˆê1, ”nêŽq1,2, ‘]ª—R”üŽq3, •“c@Œ[1: 1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•a‘ԁEf—ÃŒn)

723471. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒVƒ…ƒƒ“×–E‚Æ‚Ì‹¤”|—{‚É‚æ‚éƒqƒgä`‘Ñ—R—ˆŠÔ—tŒn×–E‚Ì•ª‰»”\‚ÌŒŸ“¢. ”nêŽq1,2, ŽRèˆÀ°2, ‘]ª—R”üŽq3, ™–{‰À2, XŽR˜a‚Ì2, ŒFàVŒ›ˆê2,4, ™–{F”V2, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3•a‘ԁEf—ÃŒn, 4‹~–½): ‘æ19‰ñ“ú–{Ä¶ˆã—Êw‰ï‘‰ï (2020/5/18-29), WEBŠJÃ.

723472. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 20”N’·Šú“€Œ‹•Û‘¶‚µ‚½œ—R—ˆŠÔ—tŒn×–E‚Ì•ª‰»”\‹y‚Ñ’·ŠúŒp‘ã‚ðŒJ‚è•Ô‚µ‚½×–E‚Ƃ̘V‰»õF‚ÌŒŸ“¢. ™–{‰À1, ŽRèˆÀ°1, XŽR˜a‚Ì1, ™–{F”V1, ŒFàVŒ›ˆê1,2, ”nêŽq1,3, ‘]ª—R”üŽq4, •“c@Œ[1 (1Œ`¬E”üŠO, 2‹~–½, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4•a‘ԁEf—ÃŒn): ‘æ19‰ñ“ú–{Ä¶ˆã—Êw‰ï‘‰ï (2020/5/18-29), WEBŠJÃ.

723473. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠO—ˆf—Âɂ¨‚¯‚é“«’×ᇂƒሟ‰”ŒŒÇ. ”nêŽq1,2, ‘åŒGÊ‰Á2, ‹àŽq—F‹I2, •º“ª“O–ç, ª–{@[2, Î•‹§Žj, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ63‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2020/8/26-28), –¼ŒÃ‰® (WEBŠJÃ).

723474. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • –Œ“§ÍƒJƒe[ƒeƒ‹oŒû•””^ᇂɑ΂µ‚čs‚Á‚½Ž‘±Ÿó—¬•¹—p‹ÇŠ‰Aˆ³•Â½—Ö@ (NPWTi-d) ‚ÌŽ¡—ÃŒoŒ±. ‘åŒGÊ‰Á1, ”nêŽq1,2, ª–{@[1, •º“ª“O–ç, •“c@Œ[1 (1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ63‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2020/8/26-28), –¼ŒÃ‰® (WEBŠJÃ).

723475. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”MŠ³ŽÒ‚É‚¨‚¯‚éÁ‰»Ší‡•¹Ç‚ÌŒŸ“¢. ŒFàVŒ›ˆê1, ª–{@[1, ”–ؐT–ç1, Šâì‚³‚¨‚è2, ˜a“‚ƒ•½1, V”ü—Y‘å1, •“c@Œ[1, ŠÛ‹´Fº2, ‘“c’q¬2, ‰Ô“‡@Ž‘2, •Ð‰ª—Sˆê2, ó—˜@–õ2 (1Œ`¬E”üŠO, 2‹~–½): ‘æ46‰ñ“ú–{”MŠw‰ï‘‰ïEŠwpW‰ï (2020/9/2-3), ‘åã.

723476. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) dÇ”M‚ɍ‡•¹‚µ‚½–³Î«‰óás«’_ùN‰Š‚ɑ΂µ, ”M‘n‚©‚çŠJ• Žèp‚ðŽ{s‚µ‚½ˆê—á. V”ü—Y‘å1, ŒFàVŒ›ˆê1, Šâì‚³‚¨‚è2, ”–ؐT–ç1, ª–{@[1, •“c@Œ[1, ŠÛ‹´Fº2, ó—˜@–õ2 (1Œ`¬E”üŠO, 2‹~–½): ‘æ46‰ñ“ú–{”MŠw‰ï‘‰ïEŠwpW‰ï (2020/9/2-3), ‘åã.

723477. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒVƒ…ƒƒ“×–E‚Æ‚Ì”ñÚGŒ^‹¤”|—{‚É‚¨‚¯‚éä`‘Ñ—R—ˆŠÔ—tŒn×–E‚̃OƒŠƒAŒn×–E‚Ö‚Ì•ª‰»”\‚ÌŒŸ“¢. ”nêŽq1,2, ŽRèˆÀ°2, ™–{‰À2, XŽR˜a‚Ì2, ŒFàVŒ›ˆê2, ™–{F”V2, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ29‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/8-9), ‰¡•l (WEBŠJÃ).

723478. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) micrograft‚Ì’S‘Ì‚Æ‚µ‚Ä—p‚¢‚½lH^”ç‚Ì‘gDŠw“IŒŸ“¢. V”ü—Y‘å1, ”nêŽq1,2, ª–{@[1, •“c@Œ[1 (1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ29‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2020/10/8-9), ‰¡•l (WEBŠJÃ).

723479. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ—¬sŠú‚ɉ„ŠúE’†Ž~‚µ‚½Œ`¬ŠO‰ÈŽèpÇ—á‚ÌŒŸ“¢. ”nêŽq1,2, V”ü—Y‘å2, “c’†Šó2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ68‰ñ“ú–{E‹ÆEÐŠQˆãŠw‰ïŠwp‘å‰ï (2020/12/5), •l¼ (ŽãŠJÃ).

723480. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • –Œ“§ÍƒJƒe[ƒeƒ‹oŒû•””^ᇂɑ΂·‚é, ƒJƒe[ƒeƒ‹‚ð‰·‘¶‚µ‚½Žèp•û–@‹y‚яpŒãŠÇ—‚ɂ‚¢‚Ä. “c’†Šó1, ”nêŽq1,2, V”ü—Y‘å1 (1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ68‰ñ“ú–{E‹ÆEÐŠQˆãŠw‰ïŠwp‘å‰ï (2020/12/5), •l¼ (ŽãŠJÃ).

723481. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚icrograft‚ð—p‚¢‚½“«’×ᇂɑ΂·‚éV‚½‚ÈŽ¡—Ð헪-Š´õÇ—¬sŠú‚̐§ŒÀ‰º‚ÅŽ¡—µ‚½4Ç—á‚Ì•ñ. V”ü—Y‘å1, ”nêŽq1,2, “c’†Šó1 (1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ68‰ñ“ú–{E‹ÆEÐŠQˆãŠw‰ïŠwp‘å‰ï (2020/12/5), •l¼ (ŽãŠJÃ).

723482. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒVƒ…ƒƒ“×–E‚Æ‚Ì”ñÚGŒ^‹¤”|—{‚É‚æ‚éƒqƒgä`‘Ñ—R—ˆŠÔ—tŒn×–E‚̐_ŒoŒn×–E‚Ö‚Ì•ª‰»”\‚ÌŒŸ“¢. ”nêŽq1,2, ŽRèˆÀ°2, ‘]ª—R”üŽq3, ™–{‰À2, ŒFàVŒ›ˆê2, ™–{F”V2, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3•a‘ԁEf—ÃŒn): ‘æ20‰ñ“ú–{Ä¶ˆã—Êw‰ï‘‰ï (2021/3/11-13), WEBŠJÃ.

723483. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒGƒNƒ\ƒ\[ƒ€‚É‚æ‚Á‚ăqƒgœ‘gD—R—ˆŠÔ—tŒn×–E‚͍œ•ª‰»—U“±‚³‚ê‚é‚©H ŽRèˆÀ°1, ™–{‰À1, ŒFàVŒ›ˆê1, ”nêŽq1,2, ™–{F”V1, ‘]ª—R”üŽq3, •“c@Œ[1 (1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•a‘ԁEf—ÃŒn): ‘æ20‰ñ“ú–{Ä¶ˆã—Êw‰ï‘‰ï (2021/3/11-13), WEBŠJÃ.

733089. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “–‰È‚ÅŽ¡—Éî“ü‚µ‚½Š¥“®–¬ƒXƒeƒ“ƒgžôœ“®–¬Žc—¯‚̈ê—á. “y“c—Žq1, V”ü—Y‘å1, ”nêŽq1,2 (1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ23‰ñ–k—¢Œ`¬ŠO‰ÈƒtƒH[ƒ‰ƒ€ (2020/10/18-24), WEBŠJÃ.

733090. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ä`•”–Ñ‘ƒ“´‚Ì1—á. ‘åŠÖ—º‰î1,2, “y“c—Žq2, ”nêŽq1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ŠÖ“ŒŒ`¬ŠO‰ÈŠw‰ï‘æ299‰ñ“Œ‹ž’n•û‰ï (2021/3/6), WEBŠJÃ.


”畆‰ÈŠw

[Šwp˜_•¶]

110327. [Œ´’˜] Inhibition of Endoglin Exerts Antitumor Effects through the Regulation of Non-Smad TGF-ƒÀ Signaling in Angiosarcoma. Sakamoto R, Kajihara I, Miyauchi H, Maeda-Otsuka S, Yamada-Kanazawa S, Sawamura S, Kanemaru H, Makino K, Aoi J, Makino T, Fukushima S, Masuzawa M1, Masuzawa M, Amoh Y1, Hoshina D, Abe R, Ihn H: J Invest Dermatol 2020/10; 140 (10): 2060-72.e6. (‘àV^ŽÀŽq1, “V‰HN”V1: 1”畆)

320031. [Ç—á•ñ] ”^áv«Š£á‚ÆŠÓ•Ê‚ð—v‚µ‚½‹}«”Ä”­«”­]«”^ávÇ‚ƍl‚¦‚ç‚ꂽ1—á. ŠFì‘å•ã1, ‘å‹v•ÛŽu‚¸‚©1, ”’ˆä‹ž”ü1, ˆÀåY—Ljê1, “V‰HN”V1 (1”畆): ”畆‰È‚̗Տ° 2020/11; 62 (12): 1703-7.

522079. [uÀ]y“ÁW: ŠÔ—tŒnŽîᇁz“ª•”’P”­Žîᎂ©‚çf’f‚ÉŽŠ‚Á‚½‹}«’P‹…«”’ŒŒ•a. Ž”ÀŽÀ—D1, ‘àV^ŽÀŽq1, –x•Ä—Sˆê, “V‰HN”V1 (1”畆): ”畆‰È‚̗Տ° 2020/5; 62 (5): 583-6.

522080. [uÀ]y“ÁW: “÷‰èŽîÇz‚¨‚Þ‚ÂŽüˆÍ‚ɐH•i•Û‘¶—p‚̃‰ƒbƒv‚ðŠª‚¢‚Ä‚¢‚½Diaper Area Granuloma of the Age‚Ì1—á. ²X–؈²1, Œj@—F—1, ”’ˆä‹ž”ü1, ã“c‹ªŽm1 (1”畆: ”畆‰È‚̗Տ° 2020/8; 62 (9): 1294-5.

[Šw‰ïEŒ¤‹†‰ï“™]

723484. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰º‘Ú’×ᇂð’悵‚½–¢•ª‰»‘½Œ`“÷Žî‚Ì1—á. ¬ŽR”ü•ä1, ‘àV^ŽÀŽq1, ‚‰ª“ޓߎq, âV“¡‹±Žq1, ”’ˆä‹ž”ü1, •l“c—SŽq2, ˜a“‚ƒ•½3, —§Î—D”üŠG, “V‰HN”V1 (1”畆, 2•a‘ԁEf—ÃŒn, 3Œ`¬E”üŠO): ‘æ119‰ñ“ú–{”畆‰ÈŠw‰ï‘‰ï (2020/6/4), WebŠJÃ.

723485. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”畆•a•Ï‚©‚猩‹É‚ß‚é‘ãŽÓˆÙíŽ¾Š³@‘ãŽÓˆÙíÇ‚É”º‚¤”畆•a•Ï@–³‹@•¨Ž¿Cƒrƒ^ƒ~ƒ“, ƒ€ƒ`ƒ““™. ”’ˆä‹ž”ü (”畆): ‘æ119‰ñ“ú–{”畆‰ÈŠw‰ï‘‰ï (2020/6/4-7), WebŠJÃ.

723486. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ª•”ŒŒŠÇ“÷Žî‚Ì”–•Ç‹ó“´Œ^”x“]ˆÚ‚É‚æ‚éÄ”­«‹C‹¹‚ɑ΂µ‚ăpƒ]ƒpƒjƒu‚Æ”x•”•ªØœ‚ª‘tŒ÷‚µ‚½1—á. ‘àV^ŽÀŽq1, —с@ËŽq2, ‰–Œ©@˜a2, ‹à•£—DŽ÷1, ‚‰ª“ޓߎq, ”’ˆä‹ž”ü1, “V‰HN”V1 (1”畆, 2ŒÄ‹zŠíŠO): ‘æ119‰ñ“ú–{”畆‰ÈŠw‰ï‘‰ï (2020/6/4-7), WebŠJÃ.

723487. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ámᝃgƒ“ƒlƒ‹‚É‚Ý‚ç‚ê‚錮u•‰vŠŒ©‚ɂ‚¢‚Ä‚ÌŒŸ“¢ V‹Kƒ_[ƒ‚ƒXƒRƒs[ŠŒ©‚Ì’ñˆÄ. ã“c‹ªŽm1, ²X–؈²1, Œj@—F—1, ”’ˆä‹ž”ü1 (1”畆): ‘æ119‰ñ“ú–{”畆‰ÈŠw‰ï‘‰ï (2020/6/4-7), WebŠJÃ.

723488. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ª•”ŒŒŠÇ“÷Žî‚ɑ΂µƒhƒLƒ\ƒ‹ƒrƒVƒ““Š—^‚ªˆêŽž‘tŒ÷‚µ‚½1—á. Ž”ÀŽÀ—D1, ‘àV^ŽÀŽq1, ‚‰ª“ޓߎq, ”’ˆä‹ž”ü1, ‘“c@Ši2, –öàVGl, “V‰HN”V1 (1”畆, 2•úŽËü (Žîá‡)): ‘æ36‰ñ“ú–{”畆ˆ««Žîᇊw‰ïŠwp‘å‰ï (2021/1/8-9), ‰¡•l.

733091. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‰E‘lŒa•”‚É–Iâ|D‰Š—l‚̗Տ°‚ð’悵‚½ALK‰A«–¢•ª‰»‘å×–EŒ^ƒŠƒ“ƒpŽî‚Ì1—á. Ž”ÀŽÀ—D1, ‘àV^ŽÀŽq1, ‹à•£—DŽ÷1, ”’ˆä‹ž”ü1, “V‰HN”V1, ™–{‰À2 (1”畆, 2Œ`¬E”üŠO): “ú–{”畆‰ÈŠw‰ï‘æ891‰ñ“Œ‹ž’n•û‰ï (2020/9/5), WebŠJÃ.

733092. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) –«ƒŠƒ“ƒp«”’ŒŒ•a‚ɍ‡•¹‚µ‚½…áv«—Þ“VávጂÌ1—á. ‹àŽR‚Ü‚è‚©1, ‹à•£—DŽ÷1, ˆÀåY—Ljê1, ”’ˆä‹ž”ü1, Š™“c_–«2, ŽOˆäƒá1, “V‰HN”V1 (1”畆, 2ŒŒ‰t“à): ‘æ84‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹žŽx•”Šwp‘å‰ï (2020/11/21-22), WebŠJÃ.

733093. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) –ѕ×–E‚ð—p‚¢‚½ƒh[ƒpƒ~ƒ“ŽY¶×–E‚Ì—U“±. ŽRª”ü’qŽq, ‚‰ª“ޓߎq, ¬Œ´GÆ1, ”’ˆä‹ž”ü1, ˆÀåY—Ljê1, •l“c—SŽq2, rìLŽq, Robert M Hoffman, “V‰HN”V1 (1”畆, 2•a‘ԁEf—ÃŒn): ‘æ28‰ñ–Ñ”¯‰ÈŠwŒ¤‹†‰ï (2020/12/5), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

733094. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘å’°ŒeŽºúE‚ð‡•¹‚µ‚½‰óás«”^”çÇ‚Ì1—á. …Œû—³”V‰î1, ”’ˆä‹ž”ü1, ‚–ì“N˜Y1, ‹à•£—DŽ÷1, ²X–؈²1, “V‰HN”V1, “n•”WŽq2, ”óŒû“¹¶ (1”畆, 2‰º•”Á‰»ŠÇŠO): “ú–{”畆‰ÈŠw‰ï‘æ893‰ñ“Œ‹ž’n•û‰ï (2020/12/19), WebŠJÃ.

733095. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) èò•”‚É‘½”­ùN–E«ƒŠƒ“ƒpß“]ˆÚ‚ð‚«‚½‚µ‚½èò•”ƒŠƒ“ƒpŠÇ“÷Žî‚Ì1—á. ”ä—¯ŠÔ‰À“Þ1, ‘àV^ŽÀŽq1, ²X–؈²1, ”’ˆä‹ž”ü1, “V‰HN”V1, ¼–؁@’2, “cY‹ïŽ‹ (1”畆, 2Ž¨•@ˆôAE“ªèòŠO): “ú–{”畆‰ÈŠw‰ï‘æ893‰ñ“Œ‹ž’n•û‰ï (2020/12/19), WebŠJÃ.

733096. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) IgG/IgA“VávጂÌ1—á. ‹àŽR‚Ü‚è‚©1, ‹à•£—DŽ÷1, ‘àV^ŽÀŽq1, ”’ˆä‹ž”ü1, “V‰HN”V1, “yˆäŠó•¶, ÎˆäŽjl (1”畆): “ú–{”畆‰ÈŠw‰ï‘æ894‰ñ“Œ‹ž’n•û‰ï (2021/1/16), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šw‰ïEŒ¤‹†‰ï“™]

'19-733017. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) œ‘ˆÙŒ`¬ÇŒóŒQ‚ÌŒo‰ß’†‚É”­Ç‚µ‚½‰óás«”^”çÇ‚Ì1—á. ¬ŽR”ü•ä1, ‚‰ª“ޓߎq, ‚–ì“N˜Y1, ”’ˆä‹ž”ü1, “V‰HN”V1, Š™“c_–«2, ‰®‘㐳W (1”畆, 2ŒŒ‰t“à): “ú–{”畆‰ÈŠw‰ï‘æ886‰ñ“Œ‹ž’n•û‰ï (2019/10/19), _“ސì.

'19-733018. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) HPV16Œ^‚ªŒŸo‚³‚ꂽQueyratgF”ìŒúÇ‚Ì1—á. ŠFì‘å•ã1, ¬Œ´GÆ1, ”’ˆä‹ž”ü1, “V‰HN”V1, “c•ÓŒ’ˆê (1”畆): “ú–{”畆‰ÈŠw‰ï‘æ889‰ñ“Œ‹ž’n•û‰ï (2020/2/15), _“ސì.


”å”AŠí‰ÈŠw

[Šwp˜_•¶]

110328. [Œ´’˜] Electronic nose to distinguish bladder cancer by urinary odour feature: A pilot study. Matsumoto K1, Murakami Y1, Shimizu Y, Hirayama T1, Ishikawa W, Iwamura M1: Cancer Biomark 2020/4; 28 (1): 33-9. (¼–{˜a«1, ‘ºã‘א´1, •½ŽR‹M”Ž1, Šâ‘º³Žk1: 1”å”AŠí)

110329. [Œ´’˜] Cefaclor as a first-line treatment for acute uncomplicated cystitis: a retrospective single-center study. Koguchi D1, Murakami Y1, Ikeda M1, Dobashi M, Ishii J: BMC Urol 2020/4; 20 (1): 38. (‚Œû@‘å1, ‘ºã‘א´1, ’r“cŸb1: 1”å”AŠí)

110330. [Œ´’˜] The third national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from complicated urinary tract infection patients. Kobayashi K, Yamamoto S2, Takahashi S, Ishikawa K, Yasuda M, Wada K, Hamasuna R, Hayami H, Minamitani S, Matsumoto T, Kiyota H, Tateda K, SatoJ, Hanaki H1, Masumori N, Hiyama Y, Yamada H, Egawa S, Kimura T, Nishiyama H, Miyazaki J, Matsumoto K2, Homma Y, Kamei J, Fujimoto K, Torimoto K, Tanaka K, Togo Y, Uehara S, Matsubara A, Shoji K, Goto H, Komeda H, Ito T, Katsuhisa K, Mita K, Kato M, Fujimoto Y, Masue T, Inatomi H, Takahashi Y, Ishihara S, Nishimura K, Mitsumori K, Ito N, Kanamaru S, Yamada D, Maeda H, Yamashita M, Tsugawa M, Takenaka T, Takahashi K, Oka Y, Yasufuku T, Watanabe S, Chihara Y, Okumura K, Kawanishi H, Matsukawa M, Shigeta M, Koda S: J Infect Chemother 2020/5; 26 (5): 418-28. (‰Ô–؏G–¾1, ¼–{˜a«2: 1–k—¢‘åŠw‘呺’q‹L”OŒ¤‹†Š, 2”å”AŠí)

110331. [Œ´’˜] Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Noguchi M, Arai G, Egawa S, Ohyama C, Naito S, Matsumoto K1, Uemura H, Nakagawa M, Nasu Y, Eto M, Suekane S, Sasada T, Shichijo S, Yamada A, Kakuma T, Itoh K: Cancer Immunol Immunother 2020/5; 69 (5): 847-57. (¼–{˜a«1: 1”å”AŠí)

110332. [Œ´’˜] Renal functional outcome after laparoscopic partial nephrectomy using dynamic renal scintigraphy. Fujita T1, Nishi M1, Ishii D1, Matsumoto K1, Yoshida K2, Iwamura M1: Can J Urol 2020/10; 27 (5): 10402-6. (“¡“c“N•v1, ¼@·G1, Îˆä‘å•ã1, ¼–{˜a«1, ‹g“cˆê¬2, Šâ‘º³Žk1: 1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110333. [Œ´’˜] Efficacy of Exercise Therapy Initiated in the Early Phase After Kidney Transplantation: A Pilot Study. Yamamoto S1, Matsuzawa R, Kamitani T, Hoshi K2, Ishii D3, Noguchi F4, Hamazaki N5, Nozaki K5, Ichikawa T5, Maekawa E6, Matsunaga A7, Yoshida K8: J Ren Nutr 2020/11; 30 (6): 518-25. (ŽR–{®•½1, ¯@‰À–F2, Îˆä‘å•ã3, –ìŒû•¶”T4, à_èL–¾5, –ìèN•½5, Žsì‘¸•¶5, ‘OìŒb”ü6, ¼‰i“Ä•F7, ‹g“cˆê¬8: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2‰q¶, 3”å”AŠí, 4ŠÅŒì•”, 5ƒŠƒnƒrƒŠ•”, 6zŠÂŠí“à, 7ˆã—Éq¶Šw•”, 8V¢‹Iˆã—ÁEæ’[’f“Iˆã—Ã)

110334. [Œ´’˜] Prognostic impact of preoperative renal function in patients treated with radical cystectomy: a multi-institutional retrospective study. Koguchi D, Matsumoto K1, Ikeda M1, Taoka Y1, Hirayama T1, Murakami Y1, Utsunomiya T, Matsuda D, Okuno N, Irie A, Iwamura M1: Int J Clin Oncol 2020/11; 25 (11): 1969-76. (‚Œû@‘å1, ¼–{˜a«1, ’r“cŸb1, “c‰ª‰ÀŒ›1, •½ŽR‹M”Ž1, ‘ºã‘א´1, Šâ‘º³Žk1: 1”å”AŠí)

110335. [Œ´’˜] The usefulness of ultrasound examination in detecting testicular nubbin in Japanese boys with non-palpable testes. Mori K1, Hamano A, Yamamoto S, Kawamura H, Koyama M, Fujishita M: J Pediatr Urol 2020/12; 16 (6): 816.e1-e4. (X@˜j•½1: 1”å”AŠí)

110336. [Œ´’˜] PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. Murakami Y1, Matsumoto K1, Shimizu Y, Ikeda M1, Amano N2, Shimura S1, Ishii D1, Sato Y3, Iwamura M1: Urol Oncol 2021/3; 39 (3): 195.e15-e23. (‘ºã‘א´1, ¼–{˜a«1, ’r“cŸb1, “V–쓝”V2, Žu‘º‘sˆê˜N1, Îˆä‘å•ã1, ²“¡—Yˆê3, Šâ‘º³Žk1: 1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—Éq¶Šw•”)

110337. [Œ´’˜] Impact of maintenance therapy using a half dose of the bacillus Calmette-Gu?rin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study. single-center stud Koguchi D1, Matsumoto K1, Hirayama T1, Moroo S1, Kobayashi M1, Katsumata H2, Ikeda M1, Iwamura M1: BMC Urol 2020/12; 20 (1): 194. (‚Œû@‘å1, ¼–{˜a«1, •½ŽR‹M”Ž1, Žt”ö”ɍF1, ¬—Ñ“Žq1, Ÿ–”—mŽ÷2, ’r“cŸb1, Šâ‘º³Žk1: 1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110338. [Œ´’˜] Oncologic Outcomes of Salvage Chemotherapy in Patients with Recurrent or Metastatic Lesions after Radical Nephroureterectomy: A Multi-Institutional Retrospective Study. Ikeda M1, Matsumoto K1, Hirayama T1, Koguchi D1, Murakami Y1, Matsuda D, Okuno N, Utsunomiya T, Taoka Y1, Irie A, Iwamura M1: Chemotherapy 2020; 65 (5-6): 134-40. (’r“cŸb1, ¼–{˜a«1, •½ŽR‹M”Ž1, ‚Œû@‘å1, ‘ºã‘א´1, “c‰ª‰ÀŒ›1, Šâ‘º³Žk1: 1”å”AŠí)

110339. [Œ´’˜] Non-maintenance intravesical Bacillus Calmette-Gu?rin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. Miyake M1, Iida K1, Nishimura N1, Miyamoto T1, Fujimoto K1, Tomida R1, Matsumoto K1,2, Numakura K1, Inokuchi J1, Morizane S1, Yoneyama T1, Matsumura Y1, Abe T1, Inoue M1, Yamada T1, Terada N1, Hirao S1, Uemura M1, Matsushita Y1, Taoka R1, Kobayashi T1, Kojima T1, Matsui Y1, Kitamura H1, Nishiyama H1 (1Japanese Urological Oncology Group): BMC Cancer 2021/3; 21 (1): 266. (¼–{˜a«1,2: 2”å”AŠí)

110340. [Œ´’˜] High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy. Amano N1, Matsumoto K2, Shimizu Y, Nakamura M2, Tsumura H2, Ishii D2, Sato Y3, Iwamura M2: Urol Oncol 2021/3; 39 (3): 196.e1-e7. (“V–쓝”V1, ¼–{˜a«2, ’†‘º^—˜]2, ’ѺGN2, Îˆä‘å•ã2, ²“¡—Yˆê3, Šâ‘º³Žk2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2”å”AŠí, 3ˆã—Éq¶Šw•”)

310041. [Ç—á•ñ] Complete biochemical response following metastasis-directed radiotherapy for oligometastatic prostate cancer: A case report. Okuda S1, Tabata K1, Shimura S1, Harano T1, Shiba I1, Iwamura M1: Urol Case Rep 2020/6; 33: 101315. (‰œ“c’mŽj1, “c”¨Œ’ˆê1, Žu‘º‘sˆê˜N1, Œ´–ì‹MO1, Ži”n@o1, Šâ‘º³Žk1: 1”å”AŠí)

520010. [‘à] Ý—¯E–K“úŠO‘l‘Ήž‚̈ã—Ã`[ƒ€. ’r“c¬]1, “c‘ºƒl, Îˆä‘å•ã1, Šâ‘º³Žk1, ‹g“cˆê¬2 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ðæ’[): “ú–{—Տ°tˆÚAŠw‰ïŽGŽ 2020/5; 8 (1): 26-32.

520011. [‘à] t×–EŠà‚ÆC”½‰ž«’`”’. “¡“c“N•v1, Šâ‘º³Žk1 (1”å”AŠí): –k—¢ˆãŠw 2020/12; 50 (2): 87-91.

522081. [uÀ]y“ÁW: ƒIƒŠƒS“]ˆÚEƒIƒŠƒSÄ”­‘O—§‘BŠà‚ð„‚é”–â‘èz“]ˆÚ‘ƒ•W“I‹ÇŠŽ¡—Ã. “c”¨Œ’ˆê1, Šâ‘º³Žk1, ’ѺGN1 (1”å”AŠí): ”å”AŠíŠO‰È 2020/7; 33 (7): 953-8.

522082. [uÀ]yÀ’k‰ï: ‘O—§‘BŠàf—ÂɊւ·‚éÅVƒRƒ“ƒZƒ“ƒTƒX|APCCC 2019‚ðŽó‚¯‚ā|z —é–ØŒ[‰x, “c”¨Œ’ˆê1, Ô¼G•ã, ã‘º”ŽŽi (1”å”AŠí): ESPOIR 2020/8; 3 (1): 44391.

522083. [uÀ]y“ÁW: Žn‚߂悤! V‚½‚É2020”N•ÛŒ¯ŽûÚ‚³‚ꂽŽèpEŒŸ¸EŠÇ—Žw“±zƒƒ{ƒbƒgŽx‰‡t᱌`¬p|ƒƒ{ƒbƒg‚͑̍o“à–D‡‚̃n[ƒhƒ‹‚ð‰º‚°‚ç‚ê‚é‚©|. Šâ‘º³Žk (”å”AŠí): ”å”AŠíŠO‰È 2020/10; 33 (10): 1267-73.

540030. [‚»‚Ì‘¼ (Šw‰ï´˜^)]y‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï‹L˜^WzƒVƒ“ƒ|ƒWƒEƒ€5: “]ˆÚ«”A˜Hã”çŠà‚̈ꎟ‰»Šw—Ö@Œã‚ÌŽ¡—ÃŽwj@“ñŽŸŽ¡—ÂƂµ‚Ẳ»Šw—Ö@. ¼–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ”å”AŠíŠO‰È 2020/6; 33 (—ÕŽž‘Š§): 728.

540031. [‚»‚Ì‘¼ (V•·‹LŽ–)] ”]Ž€tˆÚAƒnƒCƒy[ƒX. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): “Œ‰œ“ú•ñ 2020/7; p.7.

[’˜@‘]

620070. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ1Í tˆÚA‚ƖƉu—}§–ò@1. tˆÚA‚Æ‹‘â”½‰ž|‹‘â”½‰ž‚Ì‚µ‚­‚݁|, p.2-6. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí), •Ò: ‹g“cˆê¬, ¬—я¹G, ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620071. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ1Í tˆÚA‚ƖƉu—}§–ò@3. –Ɖu—}§–ò‚ɂ‚¢‚Ä‚­‚킵‚­’m‚낤 (ƒAƒUƒ`ƒIƒvƒŠƒ“), p.25-6. Îˆä‘å•ã1 (1”å”AŠí), •Ò: ‹g“cˆê¬, ¬—я¹G (2V¢‹Iˆã—ÁEæ’[ˆã—Ã), ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620072. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ1Í tˆÚA‚ƖƉu—}§–ò@3. –Ɖu—}§–ò‚ɂ‚¢‚Ä‚­‚킵‚­’m‚낤 (ƒƒ`ƒ‹ƒvƒŒƒhƒjƒ]ƒƒ“, ƒvƒŒƒhƒjƒ]ƒƒ“), p.29-31. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí), •Ò: ‹g“cˆê¬1,2, ¬—я¹G, ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620073. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ1Í tˆÚA‚ƖƉu—}§–ò@4. –Ɖu—}§–ò‚Ì•ž—p’†‚É‹C‚ð•t‚¯‚邱‚Æ (Š´õÇ‚ÌŽ¡—Öò), p.48-50. –k“‡˜aŽ÷1 (1”å”AŠí), •Ò: ‹g“cˆê¬1,2, ¬—я¹G (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí), ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620074. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ1Í tˆÚA‚ƖƉu—}§–ò@4. –Ɖu—}§–ò‚Ì•ž—p’†‚É‹C‚ð•t‚¯‚邱‚Æ (Column tˆÚAŽÒ‚ƐVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ), p.50. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí), •Ò: ‹g“cˆê¬1,2, ¬—я¹G, ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620075. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ1Í tˆÚA‚ƖƉu—}§–ò@4. –Ɖu—}§–ò‚Ì•ž—p’†‚É‹C‚ð•t‚¯‚邱‚Æ (‚”AŽ_ŒŒÇ), p.66-7. Îˆä‘å•ã1 (1”å”AŠí), •Ò: ‹g“cˆê¬1,2, ¬—я¹G (2V¢‹Iˆã—ÁEæ’[ˆã—Ã), ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620076. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ2Í –ò‚𐳂µ‚­ˆù‚Ý‘±‚¯‚邽‚߂Ɂ@–Ɖu—}§–ò@ˆù‚ݍ‡‚킹‚Ì’ˆÓ“_yHŽ–z(‚¨Žð‚ðˆù‚Þ‚Æ‚«‚É‚Í, ‚ǂ̃^ƒCƒ~ƒ“ƒO‚Å•ž—p‚·‚ê‚΂悢‚Å‚·‚©?), p.132. Îˆä‘å•ã1 (1”å”AŠí), •Ò: ‹g“cˆê¬1,2, ¬—я¹G (2V¢‹Iˆã—ÁEæ’[ˆã—Ã), ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620077. [Šwp‘ (•ª’SŽ·•M)]y¬Ž™”å”AŠí‰ÈŠwzII¬Ž™”å”AŠí‰ÈŠw‘˜_@BŽ¡—э˜_@3. ¬Ž™‚Ì• o‹¾Žèp, p.84-7. Šâ‘º³Žk (”å”AŠí), •Ò: “ú–{¬Ž™”å”AŠí‰ÈŠw‰ï, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 2021/2”­s.

621001. [Šwp‘ (ŠÄCE•ÒWE‚»‚Ì‘¼)]ytˆÚA‚Æ‚­‚·‚èz‚Í‚¶‚ß‚É, p.1. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí), •Ò: ‹g“cˆê¬1,2, ¬—я¹G, ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722097. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) tˆÚAŒã“§ÍÄ“±“üŽž‚̃PƒA‚Æ—\Œã. Îˆä‘å•ã1, –ìŒû•¶”T2 (1”å”AŠí, 2ŠÅŒì•”): ‘æ56‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2020/11/1-30), webŠJÃ, ˆÚA 2020/10; 55 (‘‰ï—ÕŽž): 301.

722098. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) tˆÚAŒã‚Ì“§ÍƒAƒNƒZƒX‚ɂ‚¢‚Ä: ˆÚAŽž`Ä“±“ü‚Ö‚Þ‚¯‚Ä. Îˆä‘å•ã1, –k“‡˜aŽ÷1, ‹g“cˆê¬1,2 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ24‰ñ“ú–{“§ÍƒAƒNƒZƒXˆãŠw‰ïŠwpW‰ïE‘‰ï (2020/11/28), ‘åã (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722099. [Šw‰ï (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) ‰Ç•ªŠ„ÆŽË‚É‚¨‚¯‚é SpaceOARTM‚Ì–ðŠ„. ’ѺGN (”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722100. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹ÇŠ‘O—§‘BŠà‚ɑ΂·‚éHDR brachytherapy‚ð—p‚¢‚½Ž¡—Ð헪`‚»‚ÌŒÀŠE‚ƍ¡Œã‚Ì“W–]`. ’ѺGN1, “c”¨Œ’ˆê1, ²“¡ˆÐ•¶, –k–ì‰ëŽj, ÎŽR”ŽžŠ2, Šâ‘º³Žk1 (1”å”AŠí, 2•úŽËü (Žîá‡)): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722101. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒAƒbƒvƒtƒƒ“ƒgEƒhƒZƒ^ƒLƒZƒ‹+ADT. “c”¨Œ’ˆê (”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/24), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722102. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‚—îŽÒ‚ÌŒ£tˆÚA“o˜^. Îˆä‘å•ã1, ‹g“cˆê¬1,2 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ54‰ñ“ú–{—Տ°tˆÚAŠw‰ï (2021/2/18), WebŠJÃ.

723489. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž¡—Âɋꗶ‚µ‚½Mycobacterium abscessus‚É‚æ‚è• –Œ“§ÍƒJƒe[ƒeƒ‹ƒgƒ“ƒlƒ‹Š´õ‚̈ê—á. Ÿ–”—mŽ÷1, Îˆä‘å•ã1, ‰œ“c’mŽj1, Žt”ö”ɍF1, Žu‘º‘sˆê˜N1, Šâ‘º³Žk1, ‹g“cˆê¬1,2 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ26‰ñ“ú–{• –Œ“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2020/9/19), Vh.

723490. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’†ŠÔƒŠƒXƒNŒQ‚É‚¨‚¯‚郈ƒE‘f125–§••¬üŒ¹—Ö@’P“Æ‚ÆŠOÆŽË•¹—p–§••¬üŒ¹—Ö@‚Ì”äŠr. ’ѺGN1, “c’†é“¹2, ¬Œû’q•F3, ”ö’£‘ñ–ç, ’†ˆä@–õ2, óì—E—Y4, ”Ñ“‡˜a–F5, ‰Á“¡°˜N5, ‹´“c@ŠÞ5, “c”¨Œ’ˆê1, ²“¡ˆÐ•¶, ÎŽR”ŽžŠ6, Šâ‘º³Žk1 (1”å”AŠí, 2“Þ—ÇŒ§—§ˆã‰È‘åŠw, 3‚ª‚ñŒ¤—L–¾•a‰@, 4“Þ—ÇŒ§—§ˆã‰È‘å•úŽËüŽ¡—ÉÈ, 5’·–ìŽs–¯•a‰@, 6•úŽËü (Žîá‡)): ‘æ58‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2020/10/22-24), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ), “ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï´˜^W58‰ñ 2020; 58: O66-2.

723491. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’†ŠÔƒŠƒXƒNŒQ‚É‚¨‚¯‚郈ƒE‘f125–§••¬üŒ¹—Ö@’P“Æ‚ÆŠOÆŽË•¹—p–§••¬üŒ¹—Ö@‚Ì”äŠr. ’ѺGN1, “c’†é“¹, ¬Œû’q•F, ”ö’£‘ñ–ç, ’†ˆä@–õ, óì—E—Y, ”Ñ“‡˜a–F, ‰Á“¡°˜N, ‹´“c@ŠÞ, “c”¨Œ’ˆê1, ²“¡ˆÐ•¶, ÎŽR”ŽžŠ2, Šâ‘º³Žk1 (1”å”AŠí, 2•úŽËü (Žîá‡)): ‘æ58‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2020/10/24), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723492. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘O—§‘B‘S“Eœp‚É‚¨‚¢‚Đ_Œo‰·‘¶Žèp‚ªØœ’f’[‚É—^‚¦‚é‰e‹¿‚ÉŠÖ‚·‚錟“¢. Žu‘º‘sˆê˜N1, “c”¨Œ’ˆê1, ’ѺGN1, ’r“cŸb1, –k“‡˜aŽ÷1, X@˜j•½1, •½–ìC•½1, Îˆä‘å•ã1, ¼–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ34‰ñ“ú–{”å”AŠí“àŽ‹‹¾Šw‰ï‘‰ï (2020/11/19), WebŠJÃ.

723493. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚¨‚¯‚郍ƒ{ƒbƒgŽx‰‡t᱌`¬p‚̏‰Šú¬Ñ‚Æ• o‹¾‰ºt᱌`¬p‚Æ‚Ì”äŠrŒŸ“¢. X@˜j•½1, ¼@·G, ’r“cŸb1, Šâ‘º³Žk1, Îˆä‘å•ã1 (1”å”AŠí): ‘æ34‰ñ“ú–{”å”AŠí“àŽ‹‹¾Šw‰ï‘‰ï (2020/11/19), WebŠJÃ.

723494. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) The usefulness of ultrasound examination in detecting testicular nubbin in Japanese boys with nonpalpable testes. X@˜j•½1, Hamano A, Yamamoto S, Kawamura H, Koyama M, Fujishita M (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723495. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒvƒ‰ƒ`ƒi»Ü‘ϐ«Ä”­”A˜Hã”çŠà‚ɑ΂·‚égemcitabine/paclitaxel—Ö@‚ÌŽ¡—ЬÑ. ’r“cŸb1, ¼–{˜a«1, “V–쓝”V2, Žu‘º‘sˆê˜N1, •½–ìC•½1, “c”¨Œ’ˆê1, “¡“c“N•v1, ‹g“cˆê¬1,3, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723496. [Šw‰ï (‘S‘)] (‘‰ïÜƒ|ƒXƒ^[) ƒŠƒXƒN‚̍‚‚¢“]ˆÚ«‹Ž¨’ïR«‘O—§‘BŠà‚ɑ΂·‚é’€ŽŸ—Ö@‚ŃhƒZƒ^ƒLƒZƒ‹‚ðæs‚³‚¹‚éˆÓ‹`‚͏­‚È‚¢: ‘½Ž{Ý‹¤“¯Œã‚ëŒü‚«Œ¤‹†. –î–쏻‘å, ìã@—, ’ѺGN1, “c”¨Œ’ˆê1, _’J’¼l, —é–ØŒ[‰x, ‰ÍŒ´’Ži, ã‘º”ŽŽi, “¡–{—S–¢, ¼Œ´LW (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723497. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Œo”A“¹“I‘O—§‘BƒŒ[ƒU[Šjop (HoLEP) Œã‚Ì‹ô”­‘O—§‘BŠà‚ÌŒŸ“¢. –]ŒŽN•½1, â“c—T‰î1, ‚Œû@‘å1, “y‹´³l, Îˆä~ˆê˜Y (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723498. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ªŽ¡Ž¡—ÃŒã‚Ì“]ˆÚ«‘O—§‘BŠà‚ɑ΂·‚é“]ˆÚ•”ÆŽË‚̏‰ŠúŽ¡—ÃŒoŒ±. “c”¨Œ’ˆê1, ’ѺGN1, ‘ºã‘א´1, –k“‡˜aŽ÷1, Žu‘º‘sˆê˜N1, •½–ìC•½1, ’r“cŸb1, Îˆä‘å•ã1, ¼–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723499. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ã•””A˜HŠà‚ɑ΂·‚ét᱔AŠÇ‘S“EœpEäNã÷•”•ªØœpŒã‚ÌäNã÷Ä”­‚É‚¨‚¯‚é—Տ°•a—Šw“IˆöŽq‚ÌŒŸ“¢. Žu‘º‘sˆê˜N1, ¼–{˜a«1, ’r“cŸb1, ‚Œû@‘å1, “c‰ª‰ÀŒ›1, •½ŽR‹M”Ž1, ‘ºã‘א´1, ‰F“s‹{‘ñŽ¡, ¼“c‘å‰î1, ‰œ–ì‹I•F, “ü]@Œ[, Šâ‘º³Žk1 (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723500. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŒÀ‹Ç‘O—§‘BŠàŽ¡—Á`ƒGƒrƒfƒ“ƒX‚ÆŽ„‚Ì‚±‚¾‚í‚è`‹ÇŠ‘O—§‘BŠà‚ɑ΂·‚éHDR brachytherapy‚ð—p‚¢‚½Ž¡—Ð헪: ‚»‚ÌŒÀŠE‚ƍ¡Œã‚Ì“W–]. ’ѺGN1, “c”¨Œ’ˆê1, ²“¡ˆÐ•¶1, –k–ì‰ëŽj2, ÎŽR”ŽžŠ3, Šâ‘º³Žk1 (1”å”AŠí, 2‘—§•a‰@‹@\‘Š–ÍŒ´•a‰@, 3•úŽËü (Žîá‡)): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ), “ú–{”å”AŠí‰ÈŠw‰ï‘‰ï108‰ñ 2020; 108: 308.

723501. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’†ŠÔƒŠƒXƒNŒQ‚É‚¨‚¯‚é‘O—§‘B‘S“Eœp‚ÆLow-dose-rate brachytherapy‚ÌŽ¡—ЬÑ”äŠr: ‘½Ž{Ý‹¤“¯ŒãŒü‚«Œ¤‹†. ’ѺGN1, “c’†é“¹2, ¬Œû’q•F3, ’†ˆä@–õ2, ”ö’£‘ñ–ç, óì—E—Y4, ”Ñ“‡˜a–F5, ‰Á“¡°˜N5, ‹´“c@ŠÞ5, “c”¨Œ’ˆê1, ²“¡ˆÐ•¶1, ÎŽR”ŽžŠ6 (1”å”AŠí, 2“Þ—ÇŒ§—§ˆã‰È‘åŠw, 3‚ª‚ñŒ¤—L–¾•a‰@, 4“Þ—ÇŒ§—§ˆã‰È‘å•úŽËüŽ¡—ÉÈ, 5’·–ìŽs–¯•a‰@, 6•úŽËü (Žîá‡)): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ), “ú–{”å”AŠí‰ÈŠw‰ï‘‰ï108‰ñ 2020; 108: 869.

723502. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V‹K—\Œã—\‘ªƒ‚ƒfƒ‹‚©‚猩‚½ƒIƒŠƒSƒƒ^‘O—§‘BŠà‚Ì—\Œã. ˆÀˆä«l, ŽODNG, •ÄŽRãùŽq, ‰ÍŒ´’Ži, ’†_‹`O, ‘å–ì–F³, ”ђˏ~•½, ‹´–{‹±L, ’ѺGN1, “c”¨Œ’ˆê1, ã‘º”ŽŽi (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/23), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723503. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‘O—§‘B‘S“Eœp‚É‚¨‚¯‚é_Œo‰·‘¶Žèp‚ªØœ’f’[‚É—^‚¦‚é‰e‹¿‚ÉŠÖ‚·‚錟“¢. Œ´–ì‹MO1, “c”¨Œ’ˆê1, ’ѺGN1, ‘ºã‘א´1, Ži”n@o1, ‰œ“c’mŽj1, –Ȋс@ãÄ1, Žt”ö”ɍF1, “¡“c“N•v1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723504. [Šw‰ï (‘S‘)] (‘‰ïÜƒ|ƒXƒ^[) ’†ŠÔƒŠƒXƒNŒQ‚É‚¨‚¯‚é‘O—§‘B‘S“Eœp‚ÆLow-dose-rate brachytherapy‚ÌŽ¡—ЬÑ”äŠr: ‘½Ž{Ý‹¤“¯ŒãŒü‚«Œ¤‹†. ’ѺGN1, “c’†é“¹, ¬Œû’q•F, ’†ˆä@–õ, ”ö’£‘ñ–ç, óì—E—Y, ”Ñ“‡˜a–F, ‰Á“¡°˜N, ‹´“c@ŠÞ, “c”¨Œ’ˆê1, ²“¡ˆÐ•¶, ÎŽR”ŽžŠ2 (1”å”AŠí, 2•úŽËü (Žîá‡)): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723505. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “]ˆÚ«tŠà‚ɑ΂µƒjƒ{ƒ‹ƒ}ƒu‚ðŠÜ‚ޏWŠw“IŽ¡—ÂðŽ{s‚µ’·Šú¶‘¶‚𓾂½1—á. ‰––ì@—T1, “ì“c@—@, —§‰Ô‹MŽj1, “c‰ª‰ÀŒ›1 (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723506. [Šw‰ï (‘S‘)] (‘‰ïÜƒ|ƒXƒ^[) “ñ•ªÒ’ŏNJ³ŽÒ‚É‚¨‚¯‚étፍ­‚ÌŒoŽž“I„ˆÚ‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‰º–ØŒ´q‘¾, ¬—Ñ“Žq1, ‹½Œ´ˆºŽq, ¼@·G, ŽRè—Yˆê˜Y (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723507. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”A“¹‰º—ôpŒã‚ÌŠ¥óa•””A“¹”畆ᑂɑ΂µ‚ÄPATIO (gpreserve the tract and turn it inside outh) –@‚Í—LŒø‚©? ¬—Ñ“Žq1, ‰º–ØŒ´q‘¾, ‹½Œ´ˆºŽq, ¼@·G, ŽRè—Yˆê˜Y, Šâ‘º³Žk1 (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723508. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”A˜HŒ‹Î“™‚̏Ǐó‚ðŽófŒ_‹@‚Æ‚µ‚ďÁ‰»Ší‰ŠÇ«Ž¾Š³‚ªÅIf’f‚Æ‚È‚Á‚½Ç—á‚̗Տ°“IŒŸ“¢. ˆ¢•”‹I”V, ŽRŒû@‘, ‘åŽR“N•½1, “¿Œõ³s, ‘ˆä‘¥º, Î“c—T‘¥, ŠC˜VàV—Ǐº, …‰iŒõ”Ž, ‹àì‹§ˆê (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/24), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723509. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) –k—¢‘åŠw•a‰@‚É‚¨‚¯‚éPembrolizumab‚̏‰ŠúŽg—pŒoŒ±. “V–쓝”V1, ¼–{˜a«2, –Ȋс@ãÄ2, â“c—T‰î2, ‘ºã‘א´2, •½ŽR‹M”Ž2, ’ѺGN2, Îˆä‘å•ã2, Šâ‘º³Žk2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723510. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äNã÷Šà‚É‚¨‚¯‚éPD-L1”­Œ»‚Æ—\Œã‚ÉŠÖ‚·‚錟“¢. ‘ºã‘א´1, ¼–{˜a«1, Žu‘º‘sˆê˜N1, ’ѺGN1, “c”¨Œ’ˆê1, Îˆä‘å•ã1, “¡“c“N•v1, ²“¡—Yˆê, Šâ‘º³Žk1 (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/24), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723511. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) äNã÷ŠàŠ³ŽÒ‚É‚¨‚¯‚錌´’†DJƒ^ƒ“ƒpƒNŽ¿”­Œ»ƒŒƒxƒ‹‚ÌŒŸ“¢. •½–ìC•½1, ¼–{˜a«1, “c’†@Œ\, “V–쓝”V2, ’ѺGN1, “c”¨Œ’ˆê1, Îˆä‘å•ã1, ’·‰–@—º3, ²“¡—Yˆê3, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—Éq¶Šw•”): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723512. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) äNã÷‘S“EÇ—á‚É‚¨‚¯‚é”A˜H•ÏŒüp‚¨‚æ‚яp‘Ot‹@”\‚Æ—\Œã‚ÉŠÖ‚·‚錟“¢. ‚Œû@‘å1, ¼–{˜a«1, ’r“cŸb1, “c‰ª‰ÀŒ›1, •½ŽR‹M”Ž1, ‘ºã‘א´1, ‰F“s‹{‘ñŽ¡, ¼“c‘å‰î1, ‰œ–ì‹I•F, “ü]@Œ[, Šâ‘º³Žk1 (1”å”AŠí): ‘æ108‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (JUA2020) (2020/12/22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723513. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚¨‚¯‚郍ƒ{ƒbƒgŽx‰‡t᱌`¬p‚̏‰Šú¬Ñ‚Æ• o‹¾‰ºt᱌`¬p‚Æ‚Ì”äŠrŒŸ“¢. X@˜j•½1, •½–ìC•½1, –k“‡˜aŽ÷1, ¼@·G, ’r“cŸb1, Îˆä‘å•ã1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ13‰ñ“ú–{ƒƒ{ƒbƒgŠO‰ÈŠw‰ïŠwpW‰ï (2021/1/23), WebŠJÃ.

723514. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) —¼‘¤ÁŽ¸¸‘ƒ‚Ì1—á. X@˜j•½1, ŽR–{Í‘¾˜Y, à_–ì@“Ö (1”å”AŠí): ‘æ29‰ñ“ú–{¬Ž™”å”AŠí‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2021/1/31), WebŠJÃ.

723515. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚¯‚étˆÚAŒãƒŠƒ“ƒp‘B«Ž¾Š³ (PTLD) ‚ÌŒŸ“¢. ’†‘º^—˜]1, Îˆä‘å•ã1, ¬—Ñ“Žq1, –k“‡˜aŽ÷1, ˆä‘º—[•P2, –ìŒû•¶”T2, Šâ‘º³Žk1, ‹g“cˆê¬1,3 (1”å”AŠí, 2ŠÅŒì•”, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ54‰ñ“ú–{—Տ°tˆÚAŠw‰ï (2021/2/18), WebŠJÃ.

723516. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) –k—¢‘åŠw‚Ì‘ƒóŽ…‹…‘̍d‰»Ç‚ðŒ´Ž¾Š³‚Æ‚·‚郌ƒVƒsƒGƒ“ƒg16—á. –k“‡˜aŽ÷1, Îˆä‘å•ã1, ˆ¢•”“N–ç2, ’†‘º^—˜]1, ¬—Ñ“Žq1, –ìŒû•¶”T3, ˆä‘º—[•P3, ‹g“cˆê¬1,4, Šâ‘º³Žk1 (1”å”AŠí, 2t‘Ÿ“à, 3ŠÅŒì•”, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ54‰ñ“ú–{—Տ°tˆÚAŠw‰ï (2021/2/19), WebŠJÃ.

731032. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ‹ŽŸŽ¡—Âɂ¨‚¯‚鉻Šw—Ö@‚̈ʒu•t‚¯|•›ì—pŠÇ—‚ÅŒø‰Ê‚ðÅ‘å‚É!|. “c”¨Œ’ˆê (”å”AŠí): WEBƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2020/8/5), WebŠJÃ.

731033. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) “–‰È‚É‚¨‚¯‚éCRPCŽ¡—Õûj. “c”¨Œ’ˆê (”å”AŠí): JEVTANA Interactive Webinar (2020/8/6), WebŠJÃ.

731034. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ˆÚAˆã—Âɂ¨‚¯‚éCOVID-19‘΍ô. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): Novartis Pharma Web Symposium (2020/8/6), Vh (ƒnƒCƒuƒŠƒbƒhŠJÃ).

731035. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ‰“Šu“]ˆÚ‚ð—L‚·‚é‘O—§‘BŠàŽ¡—Ẫpƒ‰ƒ_ƒCƒ€ƒVƒtƒg`–òÜ—Ö@‚ƋǏŠŽ¡—Â̎g‚¢‚Ç‚±‚ë`. “c”¨Œ’ˆê (”å”AŠí): Prostate Cancer Skype Symposium in Sagamihara (2020/9/2), WebŠJÃ.

731036. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) •úŽËüŽ¡—©‚çl‚¦‚éLow Vol. (Oligo) mCSPC‚ÌŽ¡—Ð헪. ’ѺGN (”å”AŠí): Prostate Cancer Academy WebƒZƒ~ƒi[ (2020/9/7), WebŠJÃ.

731037. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) M1HSPC‚̍ŐV–ò•¨Ž¡—Ã. “c”¨Œ’ˆê (”å”AŠí): —Տ°”å”AŠíƒZƒ~ƒi[ (2020/11/6), WebŠJÃ.

731038. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) Low volume and high volume mCSPC@–ò•¨—Ö@‚Æ•úŽËü—Ö@: ‚»‚ꂼ‚ê‚©‚ç‚Ý‚½Ž¡—Ð헪. ’ѺGN (”å”AŠí): ‘O—§‘BWEBƒZƒ~ƒi[ (2020/11/12), WebŠJÃ.

731039. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) mCSPCŽ¡—Â̍ŐV’ª—¬‚ɑ΂·‚éClinical question. “c”¨Œ’ˆê (”å”AŠí): ‘O—§‘BŠàÅVCQ WebƒZƒ~ƒi[ (2020/11/18), WebŠJÃ.

731040. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) CRPC‚É‚¨‚¯‚éƒ^ƒLƒTƒ“Œn–òÜ‚ÌFNƒ}ƒlƒWƒƒ“ƒg “c”¨Œ’ˆê (”å”AŠí): WEBƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2020/12/11), WebŠJÃ.

731041. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ‰“Šu“]ˆÚ‚ð—L‚·‚é‘O—§‘BŠà‚̃pƒ‰ƒ_ƒCƒ€ƒVƒtƒg. “c”¨Œ’ˆê (”å”AŠí): Niigata Urology Seminar 2020 (2020/12/12), VŠƒ.

731042. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ARAMISŽŽŒ±“ñŒ¾ƒf[ƒ^‚©‚ç–{–M‚É‚¨‚¯‚éMOCRPCŽ¡—Âðl‚¦‚é. “c”¨Œ’ˆê (”å”AŠí): ƒjƒ…ƒxƒNƒIWEB conference (2021/1/28), WebŠJÃ.

731043. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) mCRPC‚É‚¨‚¯‚郊ƒ€ƒp[ƒU‚ÌŽg—pŒoŒ±. “c”¨Œ’ˆê (”å”AŠí): CRPC Precision Medicine Online Seminar (2021/2/3), WebŠJÃ.

731044. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) Ý‘îˆã—ÂƂµ‚Ă̐t•s‘SŽ¡—Âɂ¨‚¯‚é“à‰ÈŽ¡—Â̏d—v«. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): “Œ‘å˜aŽsˆãŽt‰ïŠwpu‰‰‰ïWeb”zM (2021/2/26), WebŠJÃ.

731045. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) umCSPC‚Ì•W€Ž¡—Áv`–ò•¨—Ö@‚Æ•úŽËüŽ¡—ẪGƒrƒfƒ“ƒX‚ƍ¡Œã‚Ì“W–]`. ’ѺGN (”å”AŠí): ‘O—§‘B‚ª‚ñWebƒZƒ~ƒi[ in KANAGAWA (2021/3/11), WebŠJÃ.

732028. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) æs“ItˆÚA‚ÌŒ»ó. Îˆä‘å•ã1, –k“‡˜aŽ÷1, ‹g“cˆê¬1,2 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ85‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2020/9/25), WebŠJÃ.

732029. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (‹¤ÃƒZƒ~ƒi[) is«‘O—§‘BŠàŽ¡—Â̍őOü`ÅVƒGƒrƒfƒ“ƒX‚ðŽó‚¯‚Ä‚Ç‚¤•Ï‚í‚é‚Ì‚©?`. “c”¨Œ’ˆê (”å”AŠí): ‘æ85‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2020/10/10), WebŠJÃ.

732030. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (‹¤ÃƒZƒ~ƒi[) mCSPCŽ¡—ÂðlŽ@‚·‚é. “c”¨Œ’ˆê (”å”AŠí): ‘æ3‰ñ‘Š–ÍŒ´E¼ŒÎƒGƒŠƒACSPCu‰‰‰ï (2020/11/12), WebŠJÃ.

733097. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚é‘O—§‘BŠà‚̃uƒ‰ƒLƒZƒ‰ƒs[`ƒuƒ‰ƒL (“àÆŽË) ‚Ì—LŒø«‚ɂ‚¢‚ā`. ’ѺGN (”å”AŠí): ‘æ2‰ñ_“ސ쌧¼•”Urology Web Seminar (2020/9/1), ŠC˜V–¼.

733098. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‰º•””A˜HÇó‚¨‚æ‚ÑŒŒ”A‚ð‡•¹‚µ‚½äNã÷ƒwƒ‹ƒjƒA‚Ì2—á. ‹e’n‘åŽ÷, ŽRŒû@‘, ‘åŽR“N•½1, “¿Œõ³s, ‘ˆä‘¥º, Î“c—T‘¥ (1”å”AŠí): ‘æ410‰ñ“ú–{”å”AŠí‰ÈŠw‰ï–kŠC“¹’n•û‰ï (2020/9/12), ŽD–y.

733099. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ|ƒXƒ^[) ‘O—§‘BŠà‚̃IƒŠƒS“]ˆÚ‚ɑ΂·‚é“]ˆÚ•”ˆÊ•úŽËüŽ¡—à (MDRT) ‚ÌŒŸ“¢. “c”¨Œ’ˆê1, ’ѺGN1, ‘ºã‘א´1, “V–ìh”V2, Žu‘º‘sˆê˜N1, •½–ìC•½1, –k“‡˜aŽ÷1, ’r“cŸb1, X@˜j•½1, ¼–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ85‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2020/9/25), WebŠJÃ.

733100. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ|ƒXƒ^[) is«”A˜Hã”çŠà‚ɑ΂·‚éPembrolizumab‚ÌŽg—pŒoŒ±. “V–ìh”V1, ¼–{˜a«2, ’r“cŸb2, •½–ìC•½2, X@˜j•½2, ’ѺGN2, “c”¨Œ’ˆê2, Îˆä‘å•ã2, Šâ‘º³Žk2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2”å”AŠí): ‘æ85‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2020/9/25), WebŠJÃ.

733101. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) äNã÷Šà‚Å‚ÌPD-L1”­Œ»•”ˆÊ‚Æ‚»‚Ì—\Œã—\‘ªˆöŽq‚Æ‚µ‚Ä‚Ì–ðŠ„‚É‚Â‚¢‚Ä. ‘ºã‘א´1, ¼–{˜a«1, ’r“cŸb1, •½–ìC•½1, –k“‡˜aŽ÷1, Îˆä‘å•ã1, ²“¡—Yˆê2, Šâ‘º³Žk1 (1”å”AŠí, 2ˆã—Éq¶Šw•”): ‘æ85‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2020/9/25), WebŠJÃ.

733102. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ”A˜Hã”çŠà‚ɑ΂·‚égemcitabine/paclitaxel 2ŽŸ‰»Šw—Ö@‚ÌŽ¡—ЬÑ. ’r“cŸb1, ¼–{˜a«1, “V–ìh”V2, Žu‘º‘sˆê˜N1, ’ѺGN1, “c”¨Œ’ˆê1, ‹g“cˆê¬1,3, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ85‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2020/9/25), WebŠJÃ.

733103. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ|ƒXƒ^[) ŠÌE”]“]ˆÚtŠàÇ—á‚ɑ΂·‚éƒCƒsƒŠƒ€ƒ}ƒu{ƒjƒ{ƒ‹ƒ}ƒu (Ipi{Nivo) •¹—p—Ö@‚ÌŒoŒ±. –k“‡˜aŽ÷1, Îˆä‘å•ã1, “¡“c“N•v1, ‰œ“c’mŽj1, Ži”n@o1, ’†‘º^—˜]1, Ÿ–”—mŽ÷1, Žt”ö”ɍF1, Žu‘º‘sˆê˜N1, “V–ìh”V2, ‘ºã‘א´1, •½–ìC•½1, ’r“cŸb1, ¼–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ85‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2020/9/25), WebŠJÃ.

733104. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) t᱔AŠÇ‘S“EopŒã‚ÌäNã÷Ä”­‚É‚¨‚¯‚é—Տ°•a—Šw“IˆöŽq‚ÌŒŸ“¢. Žu‘º‘sˆê˜N1, ¼–{˜a«1, ’r“cŸb1, Žt”ö”ɍF1, ‚Œû@‘å1, “c‰ª‰ÀŒ›1, •½ŽR‹M”Ž1, ‘ºã‘א´1, ‰F“s‹{‘ñŽ¡, ¼“c‘å‰î1, ‰œ–ì‹I•F, “ü]@Œ[, Šâ‘º³Žk1 (1”å”AŠí): ‘æ85‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2020/9/25), WebŠJÃ.

733105. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘O—§‘B‘S“EŒã‚É”AŠÇ“]ˆÚ‚𗈂µ‚½ˆê—á. ‚Œû@‘å1, ’r“cŸb1, ‰©@‰p–Î (1”å”AŠí): ‘æ72‰ñ¼“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2020/11/7), WebŠJÃ.

733106. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) B«äNã÷‰Š‚ƍœ”ÕŽ‰–bÇ‚ð‡•¹‚µ‚½—¼‘¤…tÇ‚ð’悵‚½1—á. –]ŒŽN•½1, â“c—T‰î1, ‚Œû@‘å1, Îˆäƒˆê˜Y, ’r“cŸb1 (1”å”AŠí): ‘æ72‰ñ¼“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2020/11/7), WebŠJÃ.

733107. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘B«äNã÷‰Š‚ƍœ”ÕŽ‰–bŽîÇ‚ð‡•¹‚µ—¼‘¤…tÇ‚ð’悵‚½1—á. –]ŒŽN•½1, â“c—T‰î1, ‹àj—F–ØŽq, Îˆä~ˆê˜Y (1”å”AŠí): ‘æ72‰ñ¼“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2020/11/7), WebŠJÃ.

733108. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) OLEP‚É‚¨‚¯‚é‰ßŠˆ“®äNã÷‰ü‘PŒø‰Ê. â“c—T‰î1, –]ŒŽN•½1, ‚Œû@‘å1, “y‹´³l, Îˆäƒˆê˜Y (1”å”AŠí): ‘æ70‰ñ“ú–{”å”AŠí‰ÈŠw‰ï’†•”‘‰ï (2020/11/12-14), Îì (ƒnƒCƒuƒŠƒbƒhŠJÃ).

733109. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘O—§‘BŠàEtŠà‚̃ƒ{ƒbƒgŽèp‚ÉŠú‘Ò‚³‚ê‚邱‚Æ. –k“‡˜aŽ÷ (”å”AŠí): SKYT2021 WEB Conference (2021/2/4), WebŠJÃ.

733110. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‰Et᱊àp’¼Œã‚ÉŒŒ´ŠÌy‘fCäXy‘f‚ª‹}‘¬‚É‘ˆ«‚µ‚½ˆê—á. Œ´–ì‹MO1, Žá“c•”—zŽi1, ‰œ–ì‹I•F, Šâ‘º³Žk1 (1”å”AŠí): ‘æ62‰ñ“ú–{”å”AŠí‰ÈŠw‰ï_“ސì’n•û‰ï (2021/2/25), WebŠJÃ,”å”AŠíŠO‰È 2021; 34 (8): 1013.

733111. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ˆ««•FŽî‚Ì—¼‘¤•›t“]ˆÚ‚ɑ΂µ‚Ä—¼‘¤•›t“Eœp‚ðŽ{s‚µ‚½ˆê—á. –L“c¹”ü1, ’r“cŸb1, ŸNˆä@—v1, ‘º–Ø•q˜Y1, ‘åXŽé˜a”T1, ’†‘º^—˜]1, ¬—Ñ“Žq1, Ÿ–”—mŽ÷1, ¼–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ62‰ñ“ú–{”å”AŠí‰ÈŠw‰ï_“ސì’n•û‰ï (2021/2/25), WebŠJÃ,”å”AŠíŠO‰È 2021; 34 (8): 1015.


Šá‰ÈŠw

[Šwp˜_•¶]

110341. [Œ´’˜] Relationship between novel intraocular pressure measurement from Corvis ST and central corneal thickness and corneal hysteresis. Matsuura M1, Murata H, Fujino Y2, Yanagisawa M, Nakao Y, Tokumo K, Nakakura S, Kiuchi Y, Asaoka R: Br J Ophthalmol 2020/4; 104 (4): 563-8. (¼‰Y«l1, “¡–ì—F—¢2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Šá‰È)

110342. [Œ´’˜] Validating the efficacy of the binomial pointwise linear regression method to detect glaucoma progression with multicentral database. Asano S, Murata H, Matsuura M1, Fujino Y2, Miki A, Tanito M, Mizoue S, Mori K, Suzuki K, Yamashita T, Kashiwagi K, Shoji N2, Zangwill LM, Asaoka R: Br J Ophthalmol 2020/4; 104 (4): 569-74. (¼‰Y«l1, “¡–ì—F—¢2, ¯ŽiMs2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Šá‰È)

110343. [Œ´’˜] Effect of corneal cross-linking on endothelial cell density and morphology in the peripheral cornea. Goukon H1, Kamiya K2, Takahashi M1, Shoji N1: BMC Ophthalmol 2020/4; 20 (1): 139. (‹½‰E‹ß”ŽN1, _’J˜aF2, ‚‹´³‰p1, ¯ŽiMs1: 1Šá‰È, 2ˆã—Éq¶Šw•”)

110344. [Œ´’˜] Comparison of Conventional Keratometry and Total Keratometry in Normal Eyes. Hoshikawa R1, Kamiya K1, Fujimura F1, Shoji N2: Biomed Res Int 2020/4; 2020: 8075924. (Š±ì—¢ŠG1, _’J˜aF1, “¡‘º•‡²Žq1, ¯ŽiMs2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

110345. [Œ´’˜] The usefulness of the Deep Learning method of variational autoencoder to reduce measurement noise in glaucomatous visual fields. Asaoka R, Murata H, Asano S, Matsuura M, Fujino Y, Miki A, Tanito M, Mizoue S, Mori K, Suzuki K, Yamashita T, Kashiwagi K, Shoji N1: Sci Rep 2020/5; 10 (1): 7893. (¯ŽiMs1: 1Šá‰È)

110346. [Œ´’˜] Comparison of angle-to-angle distance using three devices in normal eyes. Saito A1, Kamiya K2, Fujimura F2, Takahashi M1, Shoji N1: Eye (Lond) 2020/6; 34 (6): 1116-20. (âV“¡@Ê1, _’J˜aF2, “¡‘º•‡²Žq2, ‚‹´³‰p1, ¯ŽiMs1: 1Šá‰È, 2ˆã—Éq¶Šw•”)

110347. [Œ´’˜] Comparison of Predictability Using Barrett Universal II and SRK/T Formulas according to Keratometry. Iijima K1, Kamiya K2, Iida Y1, Shoji N1: J Ophthalmol 2020/6; 2020: 7625725. (”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, ¯ŽiMs1: 1Šá‰È, 2ˆã—Éq¶Šw•”)

110348. [Œ´’˜] Effect of Angle Opening Parameters on Corneal Endothelial Cell Density and Intraocular Pressure after Posterior Chamber Phakic Intraocular Lens Implantation. Kamiya K1, Ando W2, Tsujisawa T2, Takahashi M2, Shoji N2: J Clin Med 2020/8; 9 (9): 2704. (_’J˜aF1, ˆÀ“¡˜a‰ÌŽq2, ’Ò‘ò’C•F2, ‚‹´³‰p2, ¯ŽiMs2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

110349. [Œ´’˜] Standard coronal orbital magnetic resonance imaging is an effective technique for diagnosing sagging eye syndrome. Kawai M1, Goseki T2, Ishikawa H1, Tatsui S2, Shoji N2: Graefes Arch Clin Exp Ophthalmol 2020/9; 258 (9): 1983-9. (‰Í‡ˆ¤ŽÀ1, ŒãŠÖ—˜–¾2, Îì@‹Ï1, —´ˆä‰‘Žq2, ¯ŽiMs2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

110350. [Œ´’˜] Visual and Topographic Improvement with Epithelium-On, Oxygen-Supplemented, Customized Corneal Cross-Linking for Progressive Keratoconus. Kamiya K1, Kanayama S2, Takahashi M2, Shoji N2: J Clin Med 2020/10; 9 (10): 3222.
(_’J˜aF1, ‹àŽRr‰î2, ‚‹´³‰p2, ¯ŽiMs2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

110351. [Œ´’˜] Objective measurement of nine gaze-directions using an eye-tracking device. Iwata Y1, Handa T1, Ishikawa H1: J Eye Mov Res 2020/10; 13 (6): 10.16910/jemr.13.6.4. (Šâ“c@—y1, ”¼“c’m–ç1, Îì@‹Ï1: 1ˆã—Éq¶Šw•”)

110352. [Œ´’˜] The Effects of Chewing Gum in Preventing Eyestrain. Asakawa K1, Kanno S, Ando T, Osawa K, Ishikawa H1: Biomed Res Int 2020/11; 2020: 2470473. (óì@Œ«1, Îì@‹Ï1: 1ˆã—Éq¶Šw•”)

110353. [Œ´’˜] Long-term clinical results of trabectome surgery in patients with open-angle glaucoma. Kono Y1, Kasahara M2, Hirasawa K2, Tsujisawa T1, Kanayama S1, Matsumura K2, Morita T, Shoji N2: Graefes Arch Clin Exp Ophthalmol 2020/11; 258 (11): 2467-76. (‰Í–ì—Y—º1, Š}Œ´³s2, •½àVˆê–@2, ’Ò‘ò’C•F1, ‹àŽRr‰î1, ¼‘ºˆêO2, ¯ŽiMs2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Šá‰È)

110354. [Œ´’˜] Usefulness of data augmentation for visual field trend analyses in patients with glaucoma. Asaoka R, Murata H, Matsuura M1, Fujino Y2, Miki A, Tanito M, Mizoue S, Mori K, Suzuki K, Yamashita T, Kashiwagi K, Shoji N2: Br J Ophthalmol 2020/12; 104 (12): 1697-703. (¼‰Y«l1, “¡–ì—F—¢2, ¯ŽiMs2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Šá‰È)

110355. [Œ´’˜] Comparison of Phakic Intraocular Lens Vault Using Conventional Nomogram and Prediction Formulas. Ando W1, Kamiya K2, Hayakawa H1, Takahashi M1, Shoji N1: J Clin Med 2020/12; 9 (12): 4090. (ˆÀ“¡˜a‰ÌŽq1, _’J˜aF2, ‘ìG‹P1, ‚‹´³‰p1, ¯ŽiMs1: 1Šá‰È, 2ˆã—Éq¶Šw•”)

110356. [Œ´’˜] Etiology and outcomes of current posterior chamber phakic intraocular lens extraction. Hayakawa H1, Kamiya K2, Ando W1, Takahashi M1, Shoji N1: Sci Rep 2020/12; 10 (1): 21686. (‘ìG‹P1, _’J˜aF2, ˆÀ“¡˜a‰ÌŽq1, ‚‹´³‰p1, ¯ŽiMs1: 1Šá‰È, 2ˆã—Éq¶Šw•”)

110357. [Œ´’˜] Discrepancy in Loss of Macular Perfusion Density and Ganglion Cell Layer Thickness in Early Glaucoma. Hirasawa K1, Smith CA, West ME, Sharpe GP, Shuba LM, Rafuse PE, Nicolela MT, Vianna JR, Chauhan BC: Am J Ophthalmol 2021/1; 221: 39-47. (•½àVˆê–@1: 1Šá‰È)

110358. [Œ´’˜] Characteristics of Japanese patients with Leber's hereditary optic neuropathy and idebenone trial: a prospective, interventional, non-comparative study. Ishikawa H, Masuda Y, Ishikawa H1, Shikisima K, Goseki T2, Kezuka T, Terao M, Miyazaki A, Matsumoto K, Nishikawa H, Gomi F, Mimura O: Jpn J Ophthalmol 2021/1; 65 (1): 133-142. (Îì@‹Ï1, ŒãŠÖ—˜–¾2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

110359. [Œ´’˜] Ocular and Systemic Factors Affecting Laser Speckle Flowgraphy Measurements in the Optic Nerve Head. Anraku A, Enomoto N, Tomita G, Iwase A, Sato T, Shoji N1, Shiba T, Nakazawa T, Sugiyama K, Nitta K, Araie M: Transl Vis Sci Technol 2021/1; 10 (1): 13. (¯ŽiMs1: 1Šá‰È)

110360. [Œ´’˜] Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study. Mimura O, Ishikawa H1, Kezuka T, Shikishima K, Suzuki T, Nakamura M, Chuman H, Inoue K, Kimura A, Yamagami A, Mihoya M, Nakao Y: Jpn J Ophthalmol 2021/1; 65 (1): 122-32. ( Îì@‹Ï1: 1ˆã—Éq¶Šw•”)

110361. [Œ´’˜] Strabismus After Ahmed Glaucoma Valve Implantation. Robbins L, Goseki T1, Law SK, Nouri-Mahdavi K, Caprioli J, Coleman AL, Giaconi JA, Demer JL, Velez FG, Pineles SL: Am J Ophthalmol 2021/2; 222: 1-5. (ŒãŠÖ—˜–¾1: 1Šá‰È)

110362. [Œ´’˜] Prediction of distance visual acuity in presbyopic astigmatic subjects. Hoshikawa R1, Kamiya K1, Fujimura F1, Shoji N2: Sci Rep 2021/3; 11 (1): 6958. (Š±ì—¢ŠG1, _’J˜aF1, “¡‘º•‡²Žq1, ¯ŽiMs2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

110363. [Œ´’˜] Characterization of the position of the extraocular muscles and orbit in acquired esotropia both at distance and near using orbital magnetic resonance imaging. Kawai M1, Goseki T2, Ishikawa H3, Tatsui S2, Li H, Ukisu R4, Shoji N2: PLoS One 2021/3; 16 (3): e0248497. (‰Í‡ˆ¤ŽÀ1, ŒãŠÖ—˜–¾2, Îì@‹Ï3, —´ˆä‰‘Žq2, •‚F—´‘¾˜Y4, ¯ŽiMs2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Šá‰È, 3ˆã—Éq¶Šw•”, 4•úŽËü (‰æ‘œ))

120022. [Œ´’˜]yŠw‰ïŒ´’˜: ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ïu‰‰W [3]zu‰‰21-1 ŠááÙáz¹Š³ŽÒ‚Ì“úí¶Šˆ‚Ì•sŽ©—R“x‚Ɗ댯“x. ‰Í–{‚Ђë”ü1, Šâ²^‹|1, ŽRã–¾Žq1,2, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1 (1ˆäãŠá‰È•a‰@, 2Šá‰È): —Տ°Šá‰È2020/5; 74 (5): 577-81.

120023. [Œ´’˜]yŠw‰ïŒ´’˜: ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ïu‰‰W [4]z“WŽ¦6-037 …»‘̍ČšpŒã‚ÌŠá“àƒŒƒ“ƒYŒõŠw•”‚ÌŒXŽÎ•ûŒü‚Æ’ö“x‚ðŠÏŽ@‚·‚éV‚µ‚¢•û–@. ”n“ˆ´”@1, Žsì@Œc2, ŽðˆäKO3, “à“¡®‹v3, ˆé’J®‹P4, •Ð‰ª“”Ž4, ’†‘º—Fº4, ‹Ê’u–¾–ì5, Žsìˆê•v3,6 (1Šá‰È–¾Šá‰@, 2‘‡ÂŽR•a‰@Šá‰È, 3’†‹žŠá‰È, 4–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 5’nˆæˆã—Ë@”\„i‹@\’†‹ž•a‰@Šá‰È, 6Šá‰È): —Տ°Šá‰È 2020/6; 74 (6): 735-45.

120024. [Œ´’˜]y‘æ58‰ñ“ú–{”’“àáŠw‰ïŠwpÜŽóÜ‹L”O˜_•¶|—Տ°|z”’“àáŠá‚É‚¨‚¯‚鑼Šo‘O•ûŽU—‚ÌŠÖ˜AˆöŽq‚ÆŽèp‘OŒã‚É‚¨‚¯‚é•Ï‰». _’J˜aF (ˆã—Éq¶Šw•”): “ú–{”’“àáŠw‰ïŽ 2020/6; 32: 11-5.

120025. [Œ´’˜] 3D Visual Function Trainer-ORTe‚Æ‘åŒ^ŽãŽ‹‹¾‚̉ñù—Z‘œˆæ‚Ì”äŠr. ŒË’˘aŽq1,2, ŒãŠÖ—˜–¾1, Îì@‹Ï3, ”¼“c’m–ç3, •û’qŒbŽq2, ¯ŽiMs1 (1Šá‰È, 2•ûˆã‰@, 3ˆã—Éq¶Šw•”): _ŒoŠá‰È 2020/6; 37 (2): 154-9.

120026. [Œ´’˜] ƒAƒoƒ“ƒVƒBÒ1P‚ÌùN“àŒÅ’èó‘Ô‚Ì•]‰¿. ”Ñ“c‰Ã•F1, ´…Œö–ç2, ¯ŽiMs1 (1Šá‰È, 2ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[): IOL&RS 2020/9; 34 (3): 475-80.

120027. [Œ´’˜]yŠw‰ïŒ´’˜: ‘æ60‰ñ“ú–{Ž‹”\‹¸³Šw‰ïƒVƒ“ƒ|ƒWƒEƒ€I@ƒNƒ[ƒYƒAƒbƒv`‹ßŽ‹`zŠwZŒ’Nf’f‚Ə¬Ž™‚̋ߎ‹ “¡‘º•‡²Žq (ˆã—Éq¶Šw•”): “ú–{Ž‹”\ŒP—ûŽm‹¦‰ïŽ 2020/12; 49: 1-6.

120028. [Œ´’˜]yŠw‰ïŒ´’˜: ‘æ60‰ñ“ú–{Ž‹”\‹¸³Šw‰ïˆê”ʍu‰‰zÅ“_[“xŠg’£Œ^3Å“_Šá“àƒŒƒ“ƒY‚Æ’á‰Á“ü‰ñÜŒ^2Å“_Šá“àƒŒƒ“ƒY‚̏pŒã¬Ñ‚Ì”äŠr. Š–ìãČå1, ¬“‡—²Ži2, ‰F‘ÉŒbŽq1, ŽðˆäKO1, ‰Á“¡Km1, ŽO“c‘º–ƒ—¢1, “à“¡®‹v1, ‹Ê’u–¾–ì3, Žsìˆê•v1,4 (1’†‹žŠá‰È, 2Œc‰ž‹`m‘åŠw, 3JCHO’†‹ž•a‰@, 4Šá‰È): “ú–{Ž‹”\ŒP—ûŽm‹¦‰ïŽ 2020/12; 49: 21-30.

120029. [Œ´’˜]yŠw‰ïŒ´’˜: ‘æ60‰ñ“ú–{Ž‹”\‹¸³Šw‰ïˆê”ʍu‰‰zŒõŠwŽ®¶‘ÌŒv‘ª‘•’u‚Æ‘OŠá•”OCT‚É‚æ‚éƒg[ƒŠƒbƒNŠá“àƒŒƒ“ƒY‚Ì—Ž‹‹¸³Œø‰Ê‚Ì”äŠr. —]“cçŒb1, ŽðˆäKO1, ¬“‡—²Ži2, ‹Ê’u–¾–ì3, ‰Á“¡Km1, ‰F‘ÉŒbŽq1, Š–ìãČå1, ŽR–{^Ø3, “à“¡®‹v1, Žsìˆê•v1,4 (1’†‹žŠá‰È, 2Œc‰ž‹`m‘åŠw, 3JCHO’†‹ž•a‰@, 4Šá‰È): “ú–{Ž‹”\ŒP—ûŽm‹¦‰ïŽ 2020/12; 49: 31-8.

120030. [Œ´’˜]yŠw‰ïŒ´’˜: ‘æ60‰ñ“ú–{Ž‹”\‹¸³Šw‰ïˆê”ʍu‰‰z¬Šw4E5”N¶‚É‚¨‚¯‚銿Žš‘Žš‚ɉe‹¿‚·‚鎋Šo“I—vˆö‚ÌŒŸ“¢. ‰ª–ì^‹|1, “àì‹`˜a1, “c‘ºÈŒå2, âV“¡^”V‰î2, Vˆä“cF—T1,3 (1‘Ûˆã—ÕŸŽƒ‘åŠw•ÛŒ’ˆã—Êw•”Ž‹‹@”\—Ö@Šw‰È, 2‹ãB•ÛŒ’•ŸŽƒ‘åŠw•ÛŒ’‰ÈŠw•”Ž‹‹@”\—Ö@Šw‰È, 3Šá‰È): “ú–{Ž‹”\ŒP—ûŽm‹¦‰ïŽ 2020/12; 49: 119-25.

120031. [Œ´’˜]yŠw‰ïŒ´’˜: ‘æ60‰ñ“ú–{Ž‹”\‹¸³Šw‰ïˆê”ʍu‰‰zÕ“®«Šá‹…‰^“®‚¨‚æ‚ÑŠŠ“®«’Ǐ]‰^“®‚ªÃ“I—§ˆÊŽž‚̏dS“®—h‚É‹y‚Ú‚·‰e‹¿. “àì‹`˜a1, ‰ªŽÀ”T—¢1, Ö“¡ç—T1, ’†“c仓Þ1, ‘º‰ªŽµŠC1, ‰ª–ì^‹|1, Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw•ÛŒ’ˆã—Êw•”Ž‹‹@”\—Ö@Šw‰È, 2Šá‰È): “ú–{Ž‹”\ŒP—ûŽm‹¦‰ïŽ 2020/12; 49: 147-54.

120032. [Œ´’˜] ‘OŠá•”ŒõŠ±Â’f‘wŒv‚ð—p‚¢‚½Šp–ŒŒú‚Ì•”ˆÊ•Ê”äŠr‚Æ”N—î•Ï‰». âV“¡ˆÇ“Þ1, ˆÉ“¡”ü¹ŠG1, ’r“c“N–ç1,2, ŒÜ\—’ÍŽj1,2, ´…Œö–ç1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‚ ‚½‚炵‚¢Šá‰È 2021/2; 38 (2): 197-201.

120033. [Œ´’˜] ‚ŽŸ”]‹@”\‚ÌŠÖ—^‚ª‹^‚í‚ê‚é㵖¾EŠá’É. Žá‘q‰ë“o1, ‘]‰ä•”—R2, Œ´@’¼l3, ŽRã–¾Žq1,4, ‰Á–ΏƒŽq5, •Ÿ‘º”ü”¿6, ‰œ@‰pO7, ’‡”‘@‘8, ŽO‘º@Ž¡9 (1ˆäãŠá‰È•a‰@, 2ŽO–L‘‡•a‰@, 3‘Ûˆã—ÕŸŽƒ‘åŠw•ÛŒ’ˆã—Êw•”Ž‹‹@”\—Ö@Šw, 4Šá‰È, 5b•{‹¤—§•a‰@, 6‰ºŠÖˆã—ÃZƒ“ƒ^[, 7‘åãˆã‰È‘åŠw, 8—‰»ŠwŒ¤‹†Š, 9•ºŒÉˆã‰È‘åŠw): _ŒoŠá‰È 2021/3; 38 (1): 7-13.

310042. [Ç—á•ñ] Two cases of epithelial ingrowth after small incision lenticule extraction. Kamiya K1, Takahashi M2, Shoji N2, Naruse S: Am J Ophthalmol Case Rep 2020/7; 19: 100819. (_’J˜aF1, ‚‹´³‰p2, ¯ŽiMs2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

320032. [Ç—á•ñ] ‹­“x‹ßŽ‹‚𔺂í‚È‚¢ŒÅ’è“àŽÎŽ‹‚ɑ΂µ, ãŠO’¼‹ØŒ‹‡p‚ª—L—p‚Å‚ ‚Á‚½ˆê—á. Œ´“c—DŽq1, ŒãŠÖ—˜–¾2, ‹à“c˜a–L1, Îì@‹Ï3, ’†èG“ñ1 (1‹{è’†‰›Šá‰È•a‰@, 2Šá‰È, 3ˆã—Éq¶Šw•”): _ŒoŠá‰È 2020/6; 37 (2): 160-4.

320033. [Ç—á•ñ] Šá‹…‰^“®áŠQ‚𔺂Á‚½Ž‹—͉ñ•œ•s—ǂ̍RMOGR‘Ì—z«Ž‹_Œo‰Š‚Ì1—á. Îì‘å‹N1, Îì@‹Ï2, —´ˆä‰‘Žq1, ŒãŠÖ—˜–¾1, ‹àŽRr‰î3, ”Ñ“c‰Ã•F1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): _ŒoŠá‰È 2020/12; 37 (4): 413-7.

320034. [Ç—á•ñ] ƒXƒeƒƒCƒhƒpƒ‹ƒX‚¨‚æ‚ÑŒŒŸ÷ŒðŠ·—Ö@‚É–³”½‰ž‚Å‚ ‚Á‚½ƒ~ƒgƒRƒ“ƒhƒŠƒAˆâ“`Žq•ÏˆÙ‚ð—L‚·‚鎋_Œo‰Š‚Ì1—á. —´ˆä‰‘Žq1, ‹àŽRr‰î2, ŒãŠÖ—˜–¾1, Îì@‹Ï3, ¯ŽiMs1 (1Šá‰È, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—Éq¶Šw•”): _ŒoŠá‰È 2020/12; 37 (4): 418-22.

320035. [Ç—á•ñ] ƒrƒ^ƒ~ƒ“AŒ‡–RÇ‚ªŒ´ˆö‚ƍl‚¦‚ç‚ê‚édŠp–ŒŠ´õÇ‚𐶂¶‚½¬Ž™Ž©•ÂÇƒXƒyƒNƒgƒ‰ƒ€áŠQ‚Ì1—á. ‚‹´‰ØŽq1, _’J˜aF2, ‚‹´³‰p1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): Šá‰È 2021/3; 63 (3): 267-73.

510016. [‘à] Effectiveness and limitations of minimally invasive glaucoma surgery targeting Schlemm's canal. Kasahara M1, Shoji N1: Jpn J Ophthalmol 2021/1; 65 (1): 6-22. (Š}Œ´³s1, ¯ŽiMs1: 1Šá‰È)

520012. [‘à] Sagging Eye Syndrome. ŒãŠÖ—˜–¾ (Šá‰È): “ú–{‚ÌŠá‰È 2020/6; 91 (6): 60-5.

520013. [‘à] 2020JSCRS Clinical Survey. ²“¡³Ž÷1, _’J˜aF1,2, ¬“‡—²Ži1, Œã“¡Œ›m1, “c•£mŽu1, ‰â“Þ’ÃŽq1, —с@@Œ¤1 (1JSCRSƒf[ƒ^‰ðÍˆÏˆõ‰ï, 2ˆã—Éq¶Šw•”): IOL&RS 2020/9; 34 (3): 412-32.

520014. [‘à] JSCRS COVID-19‹Ù‹}ƒAƒ“ƒP[ƒg. _’J˜aF1,2, ²“¡³Ž÷1, —с@@Œ¤1, ¬“‡—²Ži1, Œã“¡Œ›m1, “c•£mŽu1, ‰â“Þ’ÃŽq1 (1JSCRSƒf[ƒ^‰ðÍˆÏˆõ‰ï, 2ˆã—Éq¶Šw•”): IOL&RS 2020/9; 34 (3): 441-6.

521008. [‰ðà]y‹@ŠíE–òÜÐ‰îzŽèp‚̃Rƒc‚ƃgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO: —Γàá•Ò1. ‘@ˆÛ’Œ‘ѐ؏œp. ¯ŽiMs (Šá‰È): Šá‰È 2020/4; 62 (4): 383-9.

521009. [‰ðà]y‹@ŠíE–òÜÐ‰îz46. ‘¼Šo“IŽ‹‹@”\ŒŸ¸‘•’uORTe EYENAC. ”¼“c’m–ç (ˆã—Éq¶Šw•”): Šá‰È 2020/5; 62 (5): 482-8.

521010. [‰ðà]yƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“ƒR[ƒi[zƒGƒLƒXƒp[ƒg‚É•·‚­ (˜b‘è’ñ‹ŸŽÒ). ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): IOL&RS 2020/6; 34 (2): 329-36.

521011. [‰ðà]yŠá‰Èˆã‚ÌŽèˆø <967>zŽÎŽ‹‚ւ̃{ƒcƒŠƒkƒX“Å‘fŽ¡—Ã. ŒãŠÖ—˜–¾ (Šá‰È): “ú–{‚ÌŠá‰È 2020/9; 91 (9): 1322-3.

521012. [‰ðà]yClinical ChallengezŽ‹_Œo“û“ª”­ÔEŽî’¯‚©‚çl‚¦‚éŠÓ•Êf’f. Îì@‹Ï1, —´ˆä‰‘Žq2 (1ˆã—Éq¶Šw•”, 2Šá‰È): —Տ°Šá‰È 2020/10; 74 (10): 1182-5.

521013. [‰ðà]y–Ú‚ÅŒ©‚éƒVƒŠ[ƒY ‰æ‘œ‚ÅŒ©‚é—Γàá‚Ì•a‘Ô ‘æ15‰ñz–[…Ã–¬‚É’–Ú‚µ‚½—¬o˜HÄŒšp. •ÄŽR@—È1, Š}Œ´³s1 (1Šá‰È): Frontiers in Glaucoma 2020/10; 60: 1-6.

521014. [‰ðà]y‚±‚¾‚í‚è‚̐f—Êí‹ïzŽsìŽ®ƒ_ƒuƒ‹ƒGƒ“ƒhƒ}ƒjƒsƒ…ƒŒ[ƒ^[. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): IOL&RS 2021/3; 35 (1): 166-8.

522084. [uÀ]y“ÁW (1): V‚µ‚¢Šp–ŒŽèpzƒtƒFƒ€ƒgƒZƒJƒ“ƒhƒŒ[ƒU[Šp–ŒŽèp. _’J˜aF (ˆã—Éq¶Šw•”): Šá‰ÈƒOƒ‰ƒtƒBƒbƒN 2020/4; 9 (2): 124-30.

522085. [uÀ]y“ÁW: ‚æ‚­‚í‚©‚é‹üÜ‹¸³ŽèpzƒŒ[ƒVƒbƒN, •\–ʏƎ˂̏pŒãfŽ@‚Æ’·ŠúŒo‰ß. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): OCULISTA 2020/4; 85: 59-66.

522086. [uÀ]y“ÁW: Šá‰È‚É‚¨‚¯‚郊ƒXƒNƒ}ƒlƒWƒƒ“ƒg‚̃|ƒCƒ“ƒgz“œ”A•a–Ô–ŒÇ, ‚ŒŒˆ³«Šá’êf—ẪŠƒXƒNƒ}ƒlƒWƒƒ“ƒg. Žs糋`Í1,2 (1_“ސ쎕‰È‘åŠw•t‘®‰¡•lƒNƒŠƒjƒbƒN, 2Šá‰È): OCULISTA 2020/5; 86: 47-56.

522087. [uÀ]y“ÁW…A: ‰~Šp–Œf—Â̐i•àz‰~Šp–Œ‚ɑ΂·‚éŠÏŒŒ“IŽ‹—Í‹¸³–@. _’J˜aF (ˆã—Éq¶Šw•”): Šá‰ÈƒOƒ‰ƒtƒBƒbƒN 2020/6; 9 (3): 307-13.

522088. [uÀ]y“ÁW: ‰~Šp–ŒŽ¡—Â̏pŒã•]‰¿zƒJƒXƒ^ƒ€Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚̏pŒãŽ‹‹@”\. ‚‹´³‰p (Šá‰È): Šá‰ÈŽèp 2020/4; 33 (2): 198-206.

522089. [uÀ]y‚í‚©‚è‚â‚·‚¢—Տ°uÀz”’“àáŽèp‚É‚¨‚¯‚郂ƒmƒrƒWƒ‡ƒ“. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): “ú–{‚ÌŠá‰È 2020/8; 91 (8): 1187-92.

522090. [uÀ]y¡ŒŽ‚̘b‘èzAI‚ÌŠp–ŒŒ`ó‰ðÍ‚ւ̉ž—p. _’J˜aF (ˆã—Éq¶Šw•”): —Տ°Šá‰È 2020/9; 74 (9): 1077-83.

522091. [uÀ]yNEWS&TOPICS¡ŒŽ‚̈ê˜bzRŽîᇖò‚É‚æ‚éŠá•›ì—p. ”–؍LÆ1,2 (1Ã‰ªŒ§—§Ã‰ª‚ª‚ñƒZƒ“ƒ^[Šá‰È, 2Šá‰È): “ú–{‚ÌŠá‰È 2020/9; 91 (9): 1282-3.

522092. [uÀ]y‚í‚©‚è‚â‚·‚¢—Տ°uÀzFƒRƒ“ƒgƒ‰ƒXƒg‚ÆŽ‹”F«. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): “ú–{‚ÌŠá‰È 2020/9; 91 (9): 1298-302.

522093. [uÀ]y“ÁW: ‹üÜ‹¸³Žèp‚̃gƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒOzŒã–[Œ^—L…»‘ÌŠá“àƒŒƒ“ƒY‚̃gƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): IOL&RS 2020/9; 34 (3): 400-6.

522094. [uÀ]y“ÁW: E‹Æ«ŠááŠQ‚̃}ƒl[ƒWƒƒ“ƒgzð¡‚̃‚ƒoƒCƒ‹ƒfƒoƒCƒXŽg—p‚É‚æ‚鎋‹@”\‚ւ̉e‹¿. Šâ“c@—y1, Îì@‹Ï1 (1ˆã—Éq¶Šw•”): OCULISTA 2020/10; 91: 69-76.

522095. [uÀ]yŠá‰ÈƒŒƒ“ƒYƒZƒ~ƒi[ 407zƒwƒbƒYƒAƒbƒv (heads-up) ”’“àáŽèp. Žsìˆê•v1,2, Žsì@Œc1 (1’†‹žŠá‰È, 2Šá‰È): ‚ ‚½‚炵‚¢Šá‰È 2020/10; 37 (10): 1269-70.

522096. [uÀ]y—ΓàáƒZƒ~ƒi[ ˜AÚ245z—ΓàáŽèpMIGS‚Ì“®Œü. ¯ŽiMs (Šá‰È): ‚ ‚½‚炵‚¢Šá‰È 2020/11; 37 (11): 1425-6.

522097. [uÀ]y“ÁW: ŽÎŽ‹|Šî–{‚©‚çŽÀ‘H‚܂ŁzSagging eye syndrome. ŒãŠÖ—˜–¾ (Šá‰È): OCULISTA 2020/12; 93: 52-8.

522098. [uÀ]y“ÁW: Šáâ|Ž¾Š³‚Ɛ_ŒoŠá‰ÈzŠáâ|ˆ««ŽîᇂƐ_ŒoŠá‰È. ”–؍LÆ1,2 (1Ã‰ªŒ§—§Ã‰ª‚ª‚ñƒZƒ“ƒ^[, 2Šá‰È): _ŒoŠá‰È 2020/12; 37 (4): 362-9.

522099. [uÀ]yŠá“àƒŒƒ“ƒYƒZƒ~ƒi[ ˜AÚ410zƒ‚ƒ‹ƒK[ƒj”’“àá‚É‚¨‚¯‚é‘OùNØŠJViscoexpansion Technique. ”Ñ“c‰Ã•F (Šá‰È): ‚ ‚½‚炵‚¢Šá‰È 2021/1; 38 (1): 71-2.

522100. [uÀ]yˆã‰ïPick Up@‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï@“ú–{Šá‰ÈŽÐ‰ï•ÛŒ¯‰ï‹cƒVƒ“ƒ|ƒWƒEƒ€uV‚µ‚¢Šá‰Èˆãpvz2. MIGS‚̍וª‰»‚ƗΓàáŽèp‚ÌŠvV. ¯ŽiMs (Šá‰È): “ú–{‚ÌŠá‰È 2021/2; 92 (2): 54-5.

522101. [uÀ]y“ÁW: ‘OŠá•”ŒŸ¸‚̃Rƒc‹³‚¦‚Ü‚·z‘OŠá•”OCT‚ÌŽg‚¢•û. _’J˜aF (ˆã—Éq¶Šw•”): —Տ°Šá‰È 2021/2; 75 (2): 163-70.

522102. [uÀ]y“ÁW: Šm‚©‚߂悤! —Ž‹‚ÌŠî‘b@Œ©’¼‚»‚¤! —Ž‹‚̐f—Áz—L…»‘ÌŠá“àƒŒƒ“ƒY‚É‚æ‚闐Ž‹‹¸³. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): OCULISTA 2021/2; 95: 25-32.

522103. [uÀ]y“ÁW: V‚µ‚¢Žž‘ã‚ÌIOL“x”ŒvŽZzHill-RBF–@‚Ì—\‘ª«. ”Ñ“‡@Œh (Šá‰È): IOL&RS 2021/3; 35 (1): 10-4.

530015. [‚»‚Ì‘¼ (Letter)] Crosslinking of near responses in healthy young subjects. Asakawa K1, Tomioka M, Nakayama J, Hayama M, Hinata M, Ishikawa H1: Acta Ophthalmol 2020/9; 98 (6): e791-3. (óì@Œ«1, Îì@‹Ï1: 1ˆã—Éq¶Šw•”)

530016. [‚»‚Ì‘¼ (Erratum)] Correction to: Characteristics of Japanese patients with Leber's hereditary optic neuropathy and idebenone trial: a prospective, interventional, non-comparative study. Ishikawa H, Masuda Y, Ishikawa H1, Shikisima K, Goseki T2, Kezuka T, Terao M, Miyazaki A, Matsumoto K, Nishikawa H, Gomi F, Mimura O: Jpn J Ophthalmol 2021/1; 65 (1): 143. (Îì@‹Ï1, ŒãŠÖ—˜–¾2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

530017. [‚»‚Ì‘¼ (Comment)] Reply to: Comment on Prevalence of Sagging Eye Syndrome in Adults with Binocular Diplopia. Goseki T1, Suh SY, Robbins L, Pineles SL, Demer JL, Velez FG: Am J Ophthalmol 2021/1; 221: 324-5. (ŒãŠÖ—˜–¾1: 1Šá‰È)

530018. [‚»‚Ì‘¼ (Letter to the Editor)] Pupil fields in patients with Leber hereditary optic neuropathy. Asakawa K1, Matsuno M2, Ishikawa H1, Shoji N2: Graefes Arch Clin Exp Ophthalmol 2021/3; 259 (3): 791-3. (óì@Œ«1, ¼–ì–Gˆß2, Îì@‹Ï1, ¯ŽiMs2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

540032. [‚»‚Ì‘¼ (¡ŒŽ‚Ì•\Ž†)]y¡ŒŽ‚Ì•\Ž†zŠO«“øÊ—£’f. ‰i–ìKˆê1, ˆäãKŽŸ2 (1Šá‰È, 2’¹Žæ‘åŠw): —Տ°Šá‰È 2020/4; 74 (4): 374.

540033. [‚»‚Ì‘¼ (ƒgƒsƒbƒNƒX)] ‹üÜ‹¸³Žèp‚̃KƒCƒhƒ‰ƒCƒ“‰ü³. _’J˜aF (ˆã—Éq¶Šw•”): Šá‰ÈŽèp 2020/4; 33 (2): 229-32.

540034. [‚»‚Ì‘¼] “ÁW‚É‚ ‚½‚Á‚Ä. _’J˜aF1, ’†‘º—Fº2 (1ˆã—Éq¶Šw•”, 2–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN): IOL&RS 2020/6; 34 (2): 220.

540035. [‚»‚Ì‘¼ (–@l‚©‚ç‚Ì‚¨’m‚点)] ƒRƒƒi—¬s‰º‚ÌŠá‰Èf—Ã. Žsìˆê•v1,2,3 (1JSCRS•›—Ž–’·, 2’†‹žŠá‰È, 3Šá‰È): IOL&RS 2020/6; 34 (2): 347.

540036. [‚»‚Ì‘¼ (ŠCŠOˆãŠwî•ñ)]yŠCŠOˆãŠwî•ñzHeavy eye syndrome‚ÆSagging eye syndrome‚̉º’¼‹ØˆÊ’u•Ï‰». ŒãŠÖ—˜–¾ (Šá‰È): “ú–{‚ÌŠá‰È 2020/7; 91 (7): 994-5.

540037. [‚»‚Ì‘¼ (˜˜_)]y“ÁW: Imaging‚̐i•à‚Ɛ_ŒoŠá‰ÈŽ¾Š³z˜˜_. Îì@‹Ï (ˆã—Éq¶Šw•”): Šá‰È 2020/8; 62 (8): 731.

540038. [‚»‚Ì‘¼ (–@l‚©‚ç‚Ì‚¨’m‚点)] —Ž–’·A”C‚ɂ悹‚Ä. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): IOL&RS 2020/9; 34 (3): 548-9.

540039. [‚»‚Ì‘¼ (V•·‹LŽ–)]u2‚‚Ɍ©‚¦‚é?v•¡Ž‹‚ÌŒ´ˆö‚ÆŽ¡—Ã. ŒãŠÖ—˜–¾ (Šá‰È): ”MŠCV•· 2020/10; p.3.

540040. [‚»‚Ì‘¼ (˜˜_)]y“ÁW: •¡Ž‹z˜˜_. Îì@‹Ï (ˆã—Éq¶Šw•”): Šá‰È 2021/2; 63 (2): 105.

540041. [‚»‚Ì‘¼ (ŠÄC)] 40Î‰ß‚¬‚½‚璍ˆÓ‚ª•K—v! Ž¸–¾Œ´ˆö‘æ1ˆÊ‚́u—Γàáv. ¯ŽiMs (Šá‰È): ‚·‚±‚â‚©Œ’•Û 2021/3; 3 (868): 2.

540042. [‚»‚Ì‘¼] “ÁW‚É‚ ‚½‚Á‚Ä. _’J˜aF1, ¬“‡—²Ži2 (1ˆã—Éq¶Šw•”, 2Œcœä‹`m‘åŠw): IOL&RS 2021/3; 35 (1): 2.

540043. [‚»‚Ì‘¼ (•ÒWŽÒ‚ւ̎莆)] ‹­“x‹ßŽ‹‚É”º‚¤“àŽÎŽ‹‚Ì—pŒê‚̍¬—‚ɂ‚¢‚Ä. ŽRã–¾Žq1,2, Šâ²^‹|1, Žá‘q‰ë“o1, A–Ø’qŽu3, “c‘òˆ»Žq3, ´‰Í@Žœ3, ‰H“ü‹MŽq3, ”¨£“N®3, •Ÿ’nŒ’˜Y3 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3VŠƒ‘åŠw‘åŠw‰@ˆãŽ•Šw‘‡Œ¤‹†‰ÈŠá‰ÈŠw•ª–ì): _ŒoŠá‰È 2021/3; 38 (1): 65-7.

[’˜@‘]

620078. [Šwp‘ (•ª’SŽ·•M)]yŠá‰ÈƒXƒS‹Z —Γàá‚̐f’fEŽ¡—ÁEŽèp (Šá‰ÈƒOƒ‰ƒtƒBƒbƒN2020”N•Êû)z5Í —Γàá‚ÌŽ¡—à (Žèp)@2 ‚Ç‚±‚ÅŽèp‚É“¥‚Ý‚«‚é? •ÂÇ‹÷Šp—Γàá, p.175-80. ¯ŽiMs (Šá‰È), ŠÄC: ’†àV@“O, ƒƒfƒBƒJo”Å, ‘åã, 2020/5”­s.

620079. [Šwp‘ (•ª’SŽ·•M)]yŠá‰ÈŠw ‘æ3”ŁzI. \‘¢‚Æ‚»‚Ì•a‘ԁ@K. Ž‹_Œo@3. Ž‹_Œo‚Ì•a‘ԁ@2) Ž‹_Œo‚̉ŠÇ@…CŽ‹_Œo–Ô–Œ‰Š, …DŽ©ŒÈ–Ɖu«Ž‹_Œo‰Š, p.494-5. ŒãŠÖ—˜–¾ (Šá‰È), •ÒWŽåŠ²: ‘厭“N˜Y, •¶Œõ“°, “Œ‹ž, 2020/4”­s.

620080. [Šwp‘ (•ª’SŽ·•M)]yŠá‰ÈŠw ‘æ3”ŁzI. \‘¢‚Æ‚»‚Ì•a‘ԁ@K. Ž‹_Œo@3. Ž‹_Œo‚Ì•a‘ԁ@3) Ž‹_ŒoÇ@…Dˆ³”—Ž‹_ŒoÇ, p.500-2. ŒãŠÖ—˜–¾ (Šá‰È), •ÒWŽåŠ²: ‘厭“N˜Y, •¶Œõ“°, “Œ‹ž, 2020/4”­s.

620081. [Šwp‘ (•ª’SŽ·•M)]yŠá‰ÈŠw ‘æ3”ŁzI. \‘¢‚Æ‚»‚Ì•a‘ԁ@K. Ž‹_Œo@3. Ž‹_Œo‚Ì•a‘ԁ@3) Ž‹_ŒoÇ@…E’†“Ő«Ž‹_ŒoÇ, p.502-4. ŽRã–¾Žq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È), •ÒWŽåŠ²: ‘厭“N˜Y, •¶Œõ“°, “Œ‹ž, 2020/4”­s.

620082. [Šwp‘ (•ª’SŽ·•M)]yŠá‰ÈŠw ‘æ3”ŁzII. ‹@”\‚Æ‚»‚Ì•a‘ԁ@E. Šá‹…‰^“®EŽÎŽ‹@2. ŒŸ¸@4) —¼ŠáŽ‹‹@”\ŒŸ¸@…@BagoliniŽŽŒ±, …AWorth4“”ŒŸ¸, …B‘åŒ^ŽãŽ‹‹¾, …Cafterimage test, …DŽÀ—p—§‘ÌŽ‹ŒŸ¸, …ELang stereo test, …FTitmus stereo test (TST), …GTNO stereo test, …HFrisby stereo test, …IŽOžW–@, …J3D Visual Function Trainer-ORTe, 5) ‰æ‘œŒŸ¸, p.750-8. ŒãŠÖ—˜–¾ (Šá‰È), •ÒWŽåŠ²: ‘厭“N˜Y, •¶Œõ“°, “Œ‹ž, 2020/4”­s.

620083. [Šwp‘ (•ª’SŽ·•M)]y‘ŽŽ114 ‘æ114‰ñˆãŽt‘‰ÆŽŽŒ±–â‘è‰ðà‘zA-27. ’²ß«“àŽÎŽ‹‚ÌŽ¡—Õûj, p.35-6. B-12. •¡Ž‹‚ƈ«S‚ð‚«‚½‚·Šç–ʍœÜ•”ˆÊ, p.144-5. B-29. ŠáŠO«Ž‹_ŒoÇ‚̏áŠQ•”ˆÊ, p.165-6. ŒãŠÖ—˜–¾ (Šá‰È), •Ò: ˆãŽt‘‰ÆŽŽŒ±–â‘è‰ðà‘•ÒWˆÏˆõ‰ï, ƒeƒRƒ€o”ÅŽ–‹Æ–{•”, “Œ‹ž, 2020/4”­s.

620084. [Šwp‘ (•ª’SŽ·•M)]yŠá‰Èf—ÃrƒWƒ…ƒAƒ‹ƒ‰[ƒjƒ“ƒO 4@…»‘Ì‚Æ‹üÜz3. f—Õҁ@Šá“àƒŒƒ“ƒY‚É‚æ‚郂ƒmƒrƒWƒ‡ƒ“@”’“àáŽèpŽž‚ɕЊቓ•û‹¸³, —»Šá‹ß•û‹¸³‚ðs‚¢, —ǍD‚È‘S‹——£Ž‹—Í‚ª“¾‚ç‚ꂽÇ—á, p.194-7. _’J˜aF (ˆã—Éq¶Šw•”), •Ò: ‘厭“N˜Y, ’†ŽR‘“X, “Œ‹ž, 2020/5”­s.

620085. [Šwp‘ (•ª’SŽ·•M)]yŠá‰Èf—ÃrƒWƒ…ƒAƒ‹ƒ‰[ƒjƒ“ƒO 4@…»‘Ì‚Æ‹üÜz3. f—Õҁ@Šá“àƒŒƒ“ƒY“x”‚¸‚ê‚ɑ΂·‚épiggyback–@@”’“àáŽèpŒã‚Ì‹üÜŒë·‚ɑ΂µ‚Äsecondary piggyback‚ðŽ{s‚µ‚½Ç—á, p.198-201. ”Ñ“c‰Ã•F (Šá‰È), •Ò: ‘厭“N˜Y, ’†ŽR‘“X, “Œ‹ž, 2020/5”­s.

620086. [Šwp‘ (•ª’SŽ·•M)]yŠá‰È‹~‹}Ž¾Š³2020 (Šá‰È2020”N10ŒŽ—ÕŽž‘Š§†)zŠª“ªŒ¾, p.1029. Îì@‹Ï1 (1ˆã—Éq¶Šw•”), •Ò: •x“c„Ži, ’Ø“cˆê’j, Œã“¡@_, ”Ñ“c’mO, ŽG‰êŽiŽì–ç, –å”V‰€ˆê–¾, Îì@‹Ï1, ‹àŒ´o”Å, “Œ‹ž, 2020/10”­s.

620087. [Šwp‘ (•ª’SŽ·•M)]yŠá‰È‹~‹}Ž¾Š³2020 (Šá‰È2020”N10ŒŽ—ÕŽž‘Š§†)zV —Γàá@4. …»‘Ì‚É‹Nˆö‚·‚鍂Šáˆ³, p.1183-8. ¯ŽiMs1 (1Šá‰È), •Ò: •x“c„Ži, ’Ø“cˆê’j, Œã“¡@_, ”Ñ“c’mO, ŽG‰êŽiŽì–ç, –å”V‰€ˆê–¾, Îì@‹Ï2 (2ˆã—Éq¶Šw•”), ‹àŒ´o”Å, “Œ‹ž, 2020/10”­s.

620088. [Šwp‘ (•ª’SŽ·•M)]yŠá‰È‹~‹}Ž¾Š³2020 (Šá‰È2020”N10ŒŽ—ÕŽž‘Š§†)zVI _ŒoŠá‰È@6. Šáâ|‹Ø‰Š, p.1215-9. Šâ²^‹|1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È), •Ò: •x“c„Ži, ’Ø“cˆê’j, Œã“¡@_, ”Ñ“c’mO, ŽG‰êŽiŽì–ç, –å”V‰€ˆê–¾, Îì@‹Ï3 (3ˆã—Éq¶Šw•”), ‹àŒ´o”Å, “Œ‹ž, 2020/10”­s.

620089. [Šwp‘ (•ª’SŽ·•M)]y“ÁW: ‚·‚ׂČ©‚¹‚Ü‚·!@Š³ŽÒà–¾E“¯ˆÓ‘ƒ}ƒjƒ…ƒAƒ‹ (—Տ°Šá‰È2020”N10ŒŽ‘Š§†)z7 ‹üÜ‹¸³@ICL (’ʏíŒ^), 112-3. íœAr‘¾˜Y1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È), ˆãŠw‘‰@, “Œ‹ž, 2020/10”­s.

620090. [Šwp‘ (•ª’SŽ·•M)]y“ÁW: ‚·‚ׂČ©‚¹‚Ü‚·!@Š³ŽÒà–¾E“¯ˆÓ‘ƒ}ƒjƒ…ƒAƒ‹ (—Տ°Šá‰È2020”N10ŒŽ‘Š§†)z8 Šp–Œ@DMEK, p.131-3. eì@Ši1, —с@F•F2,3 (1ƒn[ƒgƒ‰ƒCƒt•a‰@, 2‰¡•l“실Ï•a‰@, 3Šá‰È), ˆãŠw‘‰@, “Œ‹ž, 2020/10”­s.

620091. [Šwp‘ (•ª’SŽ·•M)]yŠá‰ÈƒCƒ[ƒWƒ“ƒO2020Q&A (‚ ‚½‚炵‚¢Šá‰ÈVol.37—ÕŽž‘Š§†)z1. Šp–Œ@Q9 ƒEƒF[ƒuƒtƒƒ“ƒgƒAƒiƒ‰ƒCƒU[‚É‚æ‚éŠp–ŒŽû·‚Æ‘SŠá‹…Žû·‚̉ðÍ‚ɂ‚¢‚Ä‹³‚¦‚Ä‚­‚¾‚³‚¢, p.46-51. _’J˜aF (ˆã—Éq¶Šw•”), ƒƒfƒBƒJƒ‹ˆ¨o”Å, “Œ‹ž, 2020/11”­s.

620092. [Šwp‘ (•ª’SŽ·•M)]yŠá‰ÈƒCƒ[ƒWƒ“ƒO2020Q&A (‚ ‚½‚炵‚¢Šá‰ÈVol.37—ÕŽž‘Š§†)z5. ŽãŽ‹ŽÎŽ‹@Q2 Sagging eye Syndrome‚Ƌߎ‹«ŽÎŽ‹‚ÌMRI‰æ‘œf’f‚ð‹³‚¦‚Ä‚­‚¾‚³‚¢, p.406-9. ‰Í‡ˆ¤ŽÀ1, ŒãŠÖ—˜–¾2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Šá‰È), ƒƒfƒBƒJƒ‹ˆ¨o”Å, “Œ‹ž, 2020/11”­s.

620093. [Šwp‘ (•ª’SŽ·•M)]y‚¨ˆãŽÒ‚³‚ñƒIƒ“ƒ‰ƒCƒ“z—Ž‹: Œ©‚¦•û‚Í? Œ´ˆö‚Í? ƒƒKƒl‚âƒRƒ“ƒ^ƒNƒg‚Å‹¸³‚Å‚«‚é? Ž¡—Â͂ ‚é‚Ì?, webƒy[ƒW. _’J˜aF (ˆã—Éq¶Šw•”), ƒvƒŒƒVƒWƒ‡ƒ“, “Œ‹ž, 2021/1.

620094. [Šwp‘ (•ª’SŽ·•M)]y‚¨ˆãŽÒ‚³‚ñƒIƒ“ƒ‰ƒCƒ“z‰“Ž‹: ‹ßŽ‹‚â˜VŠá‚Ƃ̈Ⴂ‚Í? Œ´ˆö‚Í? ‹¸³‚⎡—Â̕û–@‚Í?, webƒy[ƒW. _’J˜aF (ˆã—Éq¶Šw•”), ƒvƒŒƒVƒWƒ‡ƒ“, “Œ‹ž, 2021/1.

620095. [Šwp‘ (•ª’SŽ·•M)]y‚¨ˆãŽÒ‚³‚ñƒIƒ“ƒ‰ƒCƒ“z‹ßŽ‹: Œ´ˆö‚Í? ˆâ“`‚␶ŠˆKŠµ‚Æ‚ÌŠÖŒW‚Í? ‹¸³‚⎡—Â̕û–@‚Í?, webƒy[ƒW. _’J˜aF (ˆã—Éq¶Šw•”), ƒvƒŒƒVƒWƒ‡ƒ“, “Œ‹ž, 2021/1.

621002. [Šwp‘ (•ÒW)]yŠá‰È‹~‹}Ž¾Š³2020 (Šá‰È2020”N10ŒŽ—ÕŽž‘Š§†)z•Ò: •x“c„Ži, ’Ø“cˆê’j, Œã“¡@_, ”Ñ“c’mO, ŽG‰êŽiŽì–ç, –å”V‰€ˆê–¾, Îì@‹Ï1 (1ˆã—Éq¶Šw•”), ‹àŒ´o”Å, “Œ‹ž, 2020/10”­s.

621003. [Šwp‘ (•ÒW)]y“ú–{Šá‰ÈŠw‰ïê–åˆã§“x@Šá‰ÈŒ¤CˆãƒKƒCƒhƒ‰ƒCƒ“@—ߘa2”N“x”Łz•Ò: “ú–{Šá‰ÈŠw‰ïê–åˆã§“xˆÏˆõ‰ï (ˆÏˆõ’·: ¯ŽiMs (Šá‰È)), “Œ‹ž, “ú–{Šá‰ÈŠw‰ï, 2020/12”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

712006. [Šw‰ï (‘Û)] (µ‘ҍu‰‰) Micro-incisional : Trabectome and Kahook Dual Blade. Shoji N1: WGA Global Webinars (2020/10/10), WebŠJÃ. (¯ŽiMs1: 1Šá‰È)

713046. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Morphological change and possible mechanism of intraocular pressure reduction after MP-TSCPC in rabbits. Tsujisawa T1, Shoji N1, Ishikawa H2, Asakawa K2, Uga S1: World Ophthalmology Congress (WOC 2020) (2020/6/26), WebŠJÃ. (’Ò‘ò’C•F1, ¯ŽiMs1, Îì@‹Ï2, óì@Œ«2, ‰F‰ê–ÎŽO1: 1Šá‰È, 2ˆã—Éq¶Šw•”)

721021. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ’†‹žƒOƒ‹[ƒv‚ÌŠCŠOˆã—ÍvŒ£. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

721022. [Šw‰ï (‘S‘)] (“Á•Êu‰‰)yÀ’·z“Á•Êu‰‰. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722103. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[)yƒI[ƒKƒiƒCƒU[zŠááÙáz¹‚̐f’fEŽ¡—ÁE•a‘Ԑ¶—. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722104. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ‚í‚©‚è‚É‚­‚¢ŠááÙáz¹Ç—á Cases of blepharospasm that is difficult to diagnose. ŽRã–¾Žq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722105. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ŠááÙáz¹‚ÌŽ¡—Ö@ How to treat blepharospasm. ŒãŠÖ—˜–¾ (Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722106. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[)yƒI[ƒKƒiƒCƒU[z‰ü‚ß‚ÄŠw‚ÔŽ‹‹@”\ŒŸ¸–@`‘½Šp“I‚É•]‰¿‚·‚邽‚߂Ɂ`. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722107. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ‹üÜ‚ÆŽ‹—ÍŒŸ¸ refraction and visual acuity test. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722108. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) Šp–Œ“à”ç×–EŒ¸­—á‚ɑ΂·‚é”’“àáŽèp Cataract surgery in patients with corneal endothelial cell loss. ”Ñ“c‰Ã•F (Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722109. [Šw‰ï (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[)yƒfƒBƒŒƒNƒ^[zŽ‹_ŒoŽ¾Š³‚ƊԈႦ‚â‚·‚¢Šá•a•Ï. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722110. [Šw‰ï (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[) Ž‹_ŒoŽ¾Š³‚ÉŽ—‚½Šá’ꎾŠ³ Fundus Diseases Resembling Optic Neuropathy Žs粋`Í1,2 (1_“ސ쎕‰È‘åŠw‰¡•lƒNƒŠƒjƒbƒN, 2Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722111. [Šw‰ï (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[)yƒfƒBƒŒƒNƒ^[zÅV‚̗Γàáf’f (The latest diagnosis methods of glaucoma). Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722112. [Šw‰ï (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[)yƒfƒBƒŒƒNƒ^[zŠeŽí—ΓàáŽ¡—Â̓K‰ž (Indication of various glaucoma therapies). Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722113. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·zACUVUEgŒ©‚¦‚éh‚ð’Ç‹‚·‚é. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722114. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ACUVUEgŒ©‚¦‚éh‚ð’Ç‹‚·‚é. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

722115. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒI[ƒKƒiƒCƒU[zŽ‹–ìŒv2020. ¯ŽiMs (Šá‰È): ‘æ9‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2020/6/17), WebŠJÃ.

722116. [Šw‰ï (‘S‘)] (‰ï’·Šé‰æ) ŠJŠáŽèp‚©‚ç‹üÜ‹¸³Žèp‚Ö. ´…Œö–ç1,2,3 (1ŽR‰¤•a‰@, 2‘Ûˆã—ÕŸŽƒ‘å, 3Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722117. [Šw‰ï (‘S‘)] (“Á•Ê•ñ) JSCRS@COVID-19 ‹Ù‹}ƒAƒ“ƒP[ƒg. _’J˜aF1, —с@@Œ¤2, ²“¡³Ž÷3, ¬“‡—²Ži4, Œã“¡Œ›m5, ‰â“Þ’ÃŽq6, “c•£mŽu7,8 (1ˆã—Éq¶Šw•”, 2—ÑŠá‰È•a‰@, 3ƒTƒgƒEŠá‰È, 4Œc‰ž‘å, 5ŒË“c‚²‚Æ‚¤Šá‰È, 6‹à‘òˆã‘å, 7L“‡‘åŠñ•uÀDTM, 8ƒcƒJƒUƒL•a‰@): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722118. [Šw‰ï (‘S‘)] (“Á•Ê•ñ) 2020 JSCRS clinical survey. ²“¡³Ž÷1, _’J˜aF2, ¬“‡—²Ži3, Œã“¡Œ›m4, “c•£mŽu5,6, ‰â“Þ’ÃŽq7, —с@@Œ¤8 (1ƒTƒgƒEŠá‰È, 2ˆã—Éq¶Šw•”, 3Œc‰ž‘å, 4ŒË“c‚²‚Æ‚¤Šá‰È, 5L“‡‘åŠñ•uÀDTM, 6ƒcƒJƒUƒL•a‰@, 7‹à‘òˆã‘å, 8—ÑŠá‰È•a‰@): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722119. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·z˜VŽ‹‹¸³Šá“àƒŒƒ“ƒY‚ÌŽ‹‹@”\. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722120. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zICL¡’m‚Á‚Ä‚¨‚­‚ׂ«ÅVî•ñ. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722121. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’†‚”NŽÒ‚ւ̑Ήž. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@, 2Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722122. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) AI‚ð—p‚¢‚½—L…»‘ÌŠá“àƒŒƒ“ƒY‚̍œK‰». _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722123. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zV‚µ‚¢Žž‘ã‚ÌIOL“x”ŒvŽZ`SRK/TKŽ®‚ÌŒ÷ß‚ðl‚¦‚é`. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722124. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Hill-RBF–@‚Ì—\‘ª«. ”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722125. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) MIGS“K‰ž‚Ì’ˆÓ“_. ¯ŽiMs (Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722126. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šp–ŒŒ`ó‰ðÍAIƒAƒbƒvƒf[ƒg. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722127. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) 3DƒrƒWƒ…ƒAƒ‹ƒVƒXƒeƒ€‚Ì‹³ˆçŒø‰Ê‚©‚猩‚½—˜“_‚ÆŒ‡“_. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722128. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ƒg[ƒŠƒbƒNŠá“àƒŒƒ“ƒYŽèp‚ÌŽÀÛ. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722129. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) pŒã‡•¹Ç‚ւ̑Ήž. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722130. [Šw‰ï (‘S‘)] (Ž‹”\ŒP—ûŽmƒvƒƒOƒ‰ƒ€)yƒI[ƒKƒiƒCƒU[zŽ‹”\ŒP—ûŽm‚ª’m‚Á‚Ä‚¨‚­‚ׂ«”’“àáE‹üÜ‹¸³Žèp‚Ì•L‚¢’mŽ¯`pŽ®, ŠáŒõŠw, ŒvŽZŽ®, Šá“àƒŒƒ“ƒY‚Ì’mŽ¯`. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722131. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yuŽtz‰~Šp–ŒƒAƒbƒvƒf[ƒg. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722132. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yƒI[ƒKƒiƒCƒU[z¢ŠE‚̍ŐVƒgƒŒƒ“ƒh‚ð’m‚낤! ""What's New in 2022"". _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722133. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yƒI[ƒKƒiƒCƒU[zyORT‚É‚æ‚éORT‚Ì‚½‚ß‚ÌICz’š”J‚É‘¬‚­ŒŸ¸‚ðs‚¤‚½‚ß‚ÌŽ„‚̍H•v. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722134. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yuŽtzyORT‚É‚æ‚éORT‚Ì‚½‚ß‚ÌICz’š”J‚É‘¬‚­ŒŸ¸‚ðs‚¤‚½‚ß‚ÌŽ„‚̍H•v. ˆÀ“¡˜a‰ÌŽq (Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722135. [Šw‰ï (‘S‘)] (ƒP[ƒXƒŒƒ|[ƒg) ƒ‚ƒ‹ƒKƒj”’“àá‚É‚¨‚¯‚é‘OùNØŠJ`viscoexpansion technique. ”Ñ“c‰Ã•F1, ¯ŽiMs1 (1Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722136. [Šw‰ï (‘S‘)] (‹¤ÃƒZƒ~ƒi[)yÀ’·z‚±‚±‚Ü‚Å‚«‚½‚©! ”’“àáŽèp. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722137. [Šw‰ï (‘S‘)] (‹¤ÃƒZƒ~ƒi[) Šá“àƒŒƒ“ƒY“Á«‚𐪂·‚éŽÒ‚́EEE. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722138. [Šw‰ï (‘S‘)] (‹¤ÃƒZƒ~ƒi[) NGENUITY҂̉”\«‚ð’T‚é. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722139. [Šw‰ï (‘S‘)] (‹¤ÃƒZƒ~ƒi[)yÀ’·zQOL‚ð‚‚Ȃ®‘½Å“_SCL‚̉”\«‚ÆŒÀŠE`’PÅ“_IOL‘}“üŒã‚Ɂ`. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722140. [Šw‰ï (‘S‘)] (‹¤ÃƒZƒ~ƒi[) QOL‚ð‚‚Ȃ®‘½Å“_SCL‚̉”\«‚ÆŒÀŠE. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722141. [Šw‰ï (‘S‘)] (‹¤ÃƒZƒ~ƒi[) ‘½Å“_SCL‚̗Տ°Žg—p. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

722142. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒI[ƒKƒiƒCƒU[zŽ‹‹@”\Œ¤‹†‚̐V“WŠJ. Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw, 2Šá‰È): ‘æ76‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ45‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï‡“¯Šw‰ï (2020/7/3), WebŠJÃ.

722143. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zVŒ^ƒRƒƒiƒEƒCƒ‹ƒX‚Æ“¬‚¤ŒõŠw‚ƈãŠw. ¯ŽiMs (Šá‰È): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722144. [Šw‰ï (‘S‘)] (‹L”Ou‰‰)yÀ’·zŠwp§—ãÜŽóÜ‹L”Ou‰‰. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722145. [Šw‰ï (‘S‘)] (‹L”Ou‰‰)yÀ’·zŠwp˜_•¶ÜŽóÜ‹L”Ou‰‰. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722146. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zINTERSECT OF VISION. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722147. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Žq‚Ç‚à‚ÌŠá‚ðŽç‚éŠwZŒ’f. “¡‘º•‡²Žq (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722148. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zŠá‰ÈŽèp‚ÌPriority. ´…Œö–ç1,2 (1ŽR‰¤•a‰@, 2Šá‰È): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722149. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zŠá‰ÈŽèp‚ÌPriority. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722150. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ”’“àáŽèp‚ÌPriority ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@, 2Šá‰È): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722151. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒg[ƒŠƒbƒNŠá“àƒŒƒ“ƒY‚ÌPriority Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722152. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·z—¼ŠáŽ‹‹¸³‚ÌŠáŒõŠw. ”¼“c’m–ç (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722153. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹üÜ‹¸³‚Æ—¼ŠáŽ‹‚ðVEP‚Å‘¼Šo“I‚É‘¨‚¦‚é. ²“¡@Ži1, Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘å, 2Šá‰È): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722154. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Œ©‚¦•û•]‰¿‚Ì’Ç‹. ”¼“c’m–ç (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722155. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) VlˆãŽt‚⌤Cˆã, Šw¶‚Ì‚½‚߂̗Տ°ŠÏŽ@Šá. ”Ñ“c‰Ã•F (Šá‰È): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722156. [Šw‰ï (‘S‘)] (ƒZƒ~ƒi[)yÀ’·zŽŸ¢‘ã‚ÌCataract Refractive Surgery‚ð’T‚é. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722157. [Šw‰ï (‘S‘)] (ƒZƒ~ƒi[) PanOptix҂̌õŠw“Á«‚Æ’†ŠÔ‹——£‚ªŒ©‚¦‚邱‚Ƃ̏d—v«. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722158. [Šw‰ï (‘S‘)] (ƒZƒ~ƒi[)yÀ’·z‚Ü‚à‚È‚­! ƒŒƒ“ƒeƒBƒXƒRƒ“ƒtƒH[ƒgƒg[ƒŠƒbƒNҔ­”„! ŠáŒõŠw‚©‚çf‚½Šá“àƒŒƒ“ƒY‘I‘ð. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722159. [Šw‰ï (‘S‘)] (ƒZƒ~ƒi[) —Ž‹‚ð—L‚·‚éŠá‚ɑ΂·‚é”’“àáŽèpí—ª. ”Ñ“c‰Ã•F (Šá‰È): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722160. [Šw‰ï (‘S‘)] (ƒZƒ~ƒi[) ƒg[ƒŠƒbƒNŠá“àƒŒƒ“ƒY‚𐬌÷‚É“±‚­ƒ|ƒCƒ“ƒg‚Æ’ˆÓ‚·‚ׂ«Ç—á. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722161. [Šw‰ï (‘S‘)] (ƒZƒ~ƒi[)yÀ’·z‰“‹ß—¼—pƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY`ŒõŠw“Á«‚Æ”N‘ã•Êˆ•û‚ÌŽÀÛ`. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722162. [Šw‰ï (‘S‘)] (ƒZƒ~ƒi[) Œõ‚Ì’†‚Ő¶‚«‚é`㵖¾‚̗Տ°Œ»ê, “úí¶Šˆ‚Å‚ÌŒ©‚¦•û‚ւ̉e‹¿`ƒAƒLƒ…ƒrƒ…[҃IƒAƒVƒX҃gƒ‰ƒ“ƒWƒVƒ‡ƒ“ƒY ƒXƒ}[ƒg’²ŒõTM. ”¼“c’m–ç (ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

722163. [Šw‰ï (‘S‘)] (“Á•ÊƒZƒbƒVƒ‡ƒ“) Annual report from blood flow study groupŒŒ—¬”ÇŠˆ“®•ñ. ¯ŽiMs (Šá‰È): ‘æ31‰ñ“ú–{—ΓàáŠw‰ï (2020/10/2), WebŠJÃ.

722164. [Šw‰ï (‘S‘)] (“Á•ÊƒZƒbƒVƒ‡ƒ“) Multicenter study evaluating non-inferiority of microhook ab interno trabeculotomy to Trabectome Microhook (üˆÛ’Œ‘ѐ؊JpŠá“à–@‚ÆTrabectome‚Ì”ñ—ò«‚ðŒŸ“¢‚·‚鑽Ž{Ý—Տ°Œ¤‹†). ’†‘º@½1, aãŽu˜N2, “Œo•ü–¤3, ¯ŽiMs4, Ô–Ø’‰“¹5, ¯Ži‘ñ•½6, ‰¡ŽR@—I7, A“cr•F8, âV“¡—Y‘¾9, ’JŒË³Ž÷10, ˆäãŒ«Ž¡11 (1_ŒË‘å, 2ˆ¤•Q‘å, 3‹à‘ò‘å, 4Šá‰È, 5‹ž“s‘å, 6é‹Êˆã‘å, 7“Œ–k‘å, 8“ñ–{¼Šá‰È•a‰@, 9º˜a‘å, 10“‡ª‘å, 11ˆäãŠá‰È•a‰@): ‘æ31‰ñ“ú–{—ΓàáŠw‰ï (2020/10/2), WebŠJÃ.

722165. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zŽèpŽ¡—Â̐i•à‚Æ•]‰¿. ¯ŽiMs (Šá‰È): ‘æ31‰ñ“ú–{—ΓàáŠw‰ï (2020/10/2), WebŠJÃ.

722166. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Complication management and drug management after outoflow reconstructive surgery (—¬o˜HÄŒšpŒã‚̍‡•¹ÇŠÇ—‚Æ–ò•¨ŠÇ—). Š}Œ´³s (Šá‰È): ‘æ31‰ñ“ú–{—ΓàáŠw‰ï (2020/10/2), WebŠJÃ.

722167. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) —ΓàáƒgƒŠƒrƒA. ¯ŽiMs (Šá‰È): ‘æ31‰ñ“ú–{—ΓàáŠw‰ï (2020/10/2), WebŠJÃ.

722168. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) ŽÎŽ‹Žèp‚̃Oƒ[ƒoƒ‹ƒXƒ^ƒ“ƒ_[ƒh‚ðl‚¦‚é@‚»‚Ì2. ’·’J•”‘1, ªŠÝ‹MŽu2, ŒãŠÖ—˜–¾3,4, —с@F—Y5, –îƒPè’îŽi6 (1ìèˆã‘å, 2‡“V‘å, 3‘Ûˆã—ÕŸŽƒ‘å, 4Šá‰È, 5’é‹ž‘åEˆã—ËZp, 6Šá‰È‚₪‚³‚«ˆã‰@): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722169. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·z‘½Å“_Šá“àƒŒƒ“ƒY‚Ì“K³Žg—p. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722170. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚̐i‰» (Evolution of Corneal Cross-linking). _’J˜aF (ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722171. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) MIGS‚̍וª‰»‚ƗΓàáŽèp‚ÌŠvV (Subdivision of MIGS and innovations in glaucoma surgery). ¯ŽiMs (Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722172. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) Šp–Œ“à”çˆÚAp (DSAEK/DMEK): Šî–{‚Ɖž—p. ¬—с@Œ°1, “V–ìŽj˜Y2, ˆî•x@•×3, Y‘ºdl4, —с@F•F5,6, ¼“cK“ñ7, –å“c@—V8 (1‹à‘ò‘å, 2ˆäãŠá‰È, 3‘—§’·Žõˆã—ÃZƒ“ƒ^[, 4Œcœä‘å, 5‰¡•l“실Ï•a‰@, 6Šá‰È, 7‘åã‘å, 8‹v—¯•Ä‘å): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722173. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) FŠoˆÙí‚̐f’f‚ÆŽw“±, ‰Á—î‚É‚æ‚éFŠoˆÙí‚àŠÜ‚Þ. Žsìˆê•v1,2, ’†‘º‚©‚¨‚é3, ‘º–Ø‘•c4, –Û–ì‹v”üŽq5, Šâ²^‹I6, ’†‘º‰pŽ÷7, ”ˆä^—Žq8 (1’†‹žŠá‰È, 2Šá‰È, 3—Žqˆã‘å, 4‚Þ‚ç‚«Šá‰È, 5Š ’J–L“c‘‡•a‰@, 6Ž ‰êˆã‰È‘å, 7–¼“ŒŠá‰È, 8Šá‰È”ˆäˆã‰@): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722174. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) ŽÀ‘H‚©‚çŠw‚Ô—L…»‘ÌŠá“àƒŒƒ“ƒY. ´…Œö–ç1,2, _’J˜aF3, Žsìˆê•v2,4, ’†‘º—Fº5, –kàV¢Žu”Ž6, ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 1,2Šá‰È, 3ˆã—Éq¶Šw•”, 4’†‹žŠá‰È, 5–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 6ƒTƒsƒAƒ^ƒ[ƒAƒCƒNƒŠƒjƒbƒN“Œ‹ž): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722175. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šáâ|ƒvƒŠ[ˆÙí‚ªˆø‚«‹N‚±‚·•¡Ž‹Diplopia caused by orbital pulley disorder. ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 2Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722176. [Šw‰ï (‘S‘)] (Šwp“WŽ¦ƒVƒ‡[ƒgƒg[ƒN) ŠááÙáz¹Ç—á‚̃{ƒcƒŠƒkƒXŽ¡—ÃŒã‚ÌBUT, u–ÚƒXƒRƒA, Ž©ŠoÇó‚ÌŒŸ“¢. ’©”ä“Þ—T”ü1, Šâ²^‹|1,2, ŽRã–¾Žq1,2, “V–ìŽj˜Y1, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722177. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ƒXƒ}[ƒg’²ŒõƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚ÌŽÀÛ‚Ɖ”\«, Šî‘b‚ƗՏ°‚©‚ç. ”¼“c’m–ç (ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722178. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·zƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[27. ¯ŽiMs (Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722179. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ‘½ŒŒ¬”ÂŒŒŸ÷ (Platelet-rich plasma: PRP) ‚ÌŽ¡—Â̌»ó‚Æ–¢—ˆ. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722180. [Šw‰ï (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) ƒIƒ“ƒ‰ƒCƒ“f—Âɂ‚¢‚Ä’m‚Á‚Ä‚¨‚­‚ׂ«‚±‚Æ‚Í? ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722181. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ƒNƒ[ƒWƒ“ƒOƒŠƒ}[ƒNƒX. ´…Œö–ç1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722182. [Šw‰ï (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) ”’“àá‚̃Gƒrƒfƒ“ƒX ‹­“x‹ßŽ‹‚Ö‚ÌŠp–Œ—Ž‹‹¸³. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722183. [Šw‰ï (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[)yƒg[ƒŠƒbƒNIOLˆÓŒ©ŒðŠ·‰ïz—Ž‹‚ð‚Ç‚¤Žc‚·‚©, Žc‚³‚È‚¢‚©`—Ž‹‚Í‘P‚©ˆ«‚©`. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

722184. [Šw‰ï (‘S‘)] (ŽÀ‘HƒZƒ~ƒi[)yÀ’·zŽÀ‘HƒZƒ~ƒi[1. ŽRã–¾Žq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

722185. [Šw‰ï (‘S‘)] (ŽÀ‘HƒZƒ~ƒi[) ‚₳‚µ‚¢ŽÎŽ‹Ž¡—Âƃ{ƒgƒbƒNƒX‚̉ž—p|‘Î’k•Ò|. ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 2Šá‰È): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

722186. [Šw‰ï (‘S‘)] (“¢˜_‰ï) Nationwide epidemiological and clinical survey of optic neuritis in Japan. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

722187. [Šw‰ï (‘S‘)] (Ç—ጟ“¢‰ï) ‚¤‚ÁŒŒ“û“ª‚ð‚«‚½‚µ‚½Camurati-EngelmannÇŒóŒQ‚Ì1—á ‰¡ŽRˆ¢Žq1,2, ŒãŠÖ—˜–¾1,3, —´ˆä‰‘Žq1, Îì@‹Ï4, ¯ŽiMs1 (1Šá‰È, 2ŠC˜V–¼‘‡•a‰@, 3‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 4ˆã—Éq¶Šw•”): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

722188. [Šw‰ï (‘S‘)] (Ç—ጟ“¢‰ï) MRI‚É‚Ä‘å”]”’Ž¿‚ɍL”Ăȍ‚M†—̈æ‚ð”F‚ß‚½m11778“_•ÏˆÙ—z«Ž‹_ŒoÇ‚̈ê—á. ‹àŽRr‰î1, Îì@‹Ï2, ŒãŠÖ—˜–¾1,3, —´ˆä‰‘Žq1, HŽR‹v®4, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”, 3‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 4¹ƒ}ƒŠƒAƒ“ƒiˆã‰È‘åŠw”]_Œo“à‰È): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

722189. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·zŽ‹_Œo‰Šf—Â̍őOü. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

722190. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·zƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[2. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

723517. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —LF‰Æ“e‚É‚¨‚¯‚éMP-TSCPCÆŽËŒã‚Ì‘gD•Ï‰»‚Ɗሳ‰º~‚̍ì—p‹@˜‚ÌŒŸ“¢. ’Ò‘ò’C•F1, ¯ŽiMs1, óì@Œ«2, ‰Í–ì—Y—º1, Îì@‹Ï2 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723518. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Variational Bayes‚ð—p‚¢‚½Ž‹–쑪’èƒAƒ‹ƒSƒŠƒYƒ€. ‘º“c”ŽŽj1, “¡–ì—F—¢1,2, ¼‰Y«l1,2, “‡“c@Œ«3, ’©‰ª@—º1 (1“Œ‹ž‘å, 2Šá‰È, 3‹»˜a): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723519. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’PÅ“_Šá“àƒŒƒ“ƒY‘}“üpŒã‚Ì‘½Å“_ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚ÌŽ‹‹@”\‚Æ–ž‘«“x‚ÌŒŸ“¢. _’J˜aF1, “¡‘º•‡²Žq1, ˆÀ“¡˜a‰ÌŽq2, ”Ñ“‡@Œh2, ¯ŽiMs2 (1ˆã—Éq¶Šw•”, 2Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723520. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒqƒg…»‘̂̐ԓ¹•”‚ðŒŸo‚·‚éV‚µ‚¢‰æ‘œ‰ðÍ–@. ”n“ˆ´”@1, Žsì@Œc2, “à“¡®‹v3, ŽðˆäKO3, •Ð‰ª“”Ž4, ˆé’J®Ž÷4, ’†‘º—Fº4, ‹Ê’u–¾–ì5, Žsìˆê•v3,6 (1Šá‰È–¾Šá‰@, 2Šò•ŒÔ\Žš•a‰@, 3’†‹žŠá‰È, 4–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 5JCHO’†‹ž•a‰@, 6Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723521. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Hill-RBF–@Version1.0‚ÆVersion2.0‚Ì—\‘ª«‚Ì”äŠr. ”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723522. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒJƒXƒ^ƒ}ƒCƒYƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚É‚æ‚éŠp–Œ‘OŒã–Ê‹üÜ—͕ω». ‚‹´³‰p (Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723523. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·z’áNP—ΓàáŽèp. ¯ŽiMs (Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723524. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒgƒ‰ƒxƒNƒg[ƒ€ŽèpŠù‰Šá‚ɑ΂·‚é’ljÁƒÊƒtƒbƒNƒgƒ‰ƒxƒNƒƒgƒ~[‚̐¬Ñ. ‰Í–ì—Y—º1, Š}Œ´³s1, ’Ò‘ò’C•F1, •ÄŽR@—È1, ‰¡ŽRˆ¢Žq1, ¯ŽiMs1 (1Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723525. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒgƒ‰ƒxƒNƒg[ƒ€ŽèpŒã‚̍R—Γàá“_Šá–òŽg—p•Ê‚̐¬Ñ. Š}Œ´³s1, ‰Í–ì—Y—º1, ’Ò‘ò’C•F1, •ÄŽR@—È1, ‰¡ŽRˆ¢Žq1, ¯ŽiMs1 (1Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723526. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·z¶‘ÌŒv‘ª. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723527. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”’“àáŽèp‘OŒã‚É‚¨‚¯‚éŠáˆÊ‚ÌŒŸ“¢. ˆÉ“¡”ü¹ŠG1, ’r“c“N–ç1, âV“¡ˆÇ“Þ1, ŒÜ\—’ÍŽj1,2, ´…Œö–ç1,2 (1ŽR‰¤•a‰@, 2Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723528. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Vault—\‘ª‰ñ‹A‚Ì3Ž®ƒŒƒ“ƒYƒTƒCƒY•Ê”äŠr. ˆÀ“¡˜a‰ÌŽq1, _’J˜aF2, ‚‹´³‰p1, ‹àŽRr‰î1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723529. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ªŒõ“§‰ß—¦‚̈قȂ鉩F’…FƒŒƒ“ƒY‚ªƒRƒ“ƒgƒ‰ƒXƒgŠ´“x‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢. “¡‘º•‡²Žq1, _’J˜aF1, Œ´Œûãđ¾2, ìŽç“c‘ñŽu1, ”Ñ“c‰Ã•F2, Š±ì—¢ŠG1, ¯ŽiMs2 (1ˆã—Éq¶Šw•”, 2Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723530. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) RƒqƒXƒ^ƒ~ƒ““_Šá–ò (ƒGƒsƒiƒXƒ`ƒ“‰–Ž_‰–) ‚Ì“µE‚ɑ΂·‚éì—p. —´ˆä‰‘Žq1, Îì@‹Ï2, áÁ‰º‹I”ü‘ã1, óì@Œ«2, ‹g•xŒ’Žu3, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”, 3•Ÿ‰ª‘Ûˆã—ÕŸŽƒ‘åŠw): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723531. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘OŠá•”ŽOŽŸŒ³‰æ‘œ‰ðÍ‘•’u‚ð—p‚¢‚½Œ’íŠá‚É‚¨‚¯‚é‹÷ŠpŒ`ó‰ðÍ. •½–ìTˆê˜Y1, ŒÜ\—’ÍŽj1,2,3, ŽRìç‰À2, ´…Œö–ç1,2,3, ‰Pˆä’q•F1 (1‘Ûˆã—ÕŸŽƒ‘å, 2ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 3Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723532. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lH’m”\‚ð—p‚¢‚½Hessƒ`ƒƒ[ƒg‚ÌŽ©“®f’f. ŒãŠÖ—˜–¾1, “c•£mŽu3,4, ¡–{_‹I3, Î”ò’¼Žj3, ‰Í‡ˆ¤ŽÀ1, ¯ŽiMs1, Žs粋`Í1,2, ‹{“c˜a“T5, ’†àV—S‘¥6, —с@@Œ¤7, –Ø“à—Ç–¾4, ‰«–{‘Žu8 (1Šá‰È, 2_“ސ쎕‰È‘åE‰¡•lƒNƒŠƒjƒbƒN, 3ƒcƒJƒUƒL•a‰@, 4L“‡‘å, 5‹{“cŠá‰È•a‰@, 6Ž­Ž™“‡‘å, 7—ÑŠá‰È•a‰@, 8L“‡Ô\ŽšEŒ´”š•a‰@): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723533. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠááÙáz¹Š³ŽÒ‚É‚¨‚¯‚éƒhƒ‰ƒCƒAƒCf’fŠî€‚É‚æ‚錟“¢. ’†–´“c‘uŽj1, Šâ²^‹|1,2, ŽRã–¾Žq1,2, “V–ìŽj˜Y1, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723534. [Šw‰ï (‘S‘)] (Šwp“WŽ¦) ”z‡Üƒ‰ƒ^ƒmƒvƒƒXƒg/ƒ`ƒ‚ƒ[ƒ‹‚ðƒ‰ƒ^ƒmƒvƒƒXƒg/ƒJƒ‹ƒeƒIƒ[ƒ‹‚Ö12ƒ•ŒŽŠÔ•ÏX. ‹àŒ´¶‹ž1,2, ˆäãŒ«Ž¡1, Šâ²^‹|1,3, š ¼Žu•Û4, Î“c‹±Žq5, •x“c„Ži5 (1ˆäãŠá‰È•a‰@, 2‡“V‘åE‰YˆÀ, 3Šá‰È, 4¼Š‹¼EˆäãŠá‰È•a‰@, 5“Œ–M‘åE‘å‹´): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723535. [Šw‰ï (‘S‘)] (Šwp“WŽ¦) ƒSƒjƒIƒXƒR[ƒvuGS-1v‚Ì—L—p«‹y‚шÀ‘S«‚ÌŒŸ“¢. ‚–Ø—E‹M1,2, “n糎OŒP2, ŽðˆäKO2, ‚–Ø–FŒb2, —]“cçŒb2, Žsìˆê•v2,3 (1”Ñ“cŽs—§•a‰@, 2’†‹žŠá‰È, 3Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723536. [Šw‰ï (‘S‘)] (Šwp“WŽ¦) ã•ûŠp–ŒØŠJ, ‚’¼ŒÅ’è‚ð‚µ‚½ŠÑ’ʍE•t‚«—L…»‘ÌŒã–[ƒŒƒ“ƒY‚̗Տ°¬Ñ. ŒÜ\—’ÍŽj1,2, ´…Œö–ç1,2, ‰Á“¡ŽÑ–1 (1ŽR‰¤•a‰@, 2Šá‰È): ‘æ124‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2020/4/27), WebŠJÃ.

723537. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰“‹ß—¼—pƒ\ƒtƒgƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‘•—p—L–³‚É‚æ‚éOCT‰ðÍŒ‹‰Ê‚Ì”äŠrŒŸ“¢. “¡‘º•‡²Žq1, Œ‹‘©‰p—˜“Þ1, “‡’Õ‡—D1, –ìè‰Ø–ë1, ˆÀ“c‘Šó1, Îì@‹Ï1, ¯ŽiMs2 (1ˆã—Éq¶Šw•”, 2Šá‰È): ‘æ9‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2020/6/17), WebŠJÃ.

723538. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Discrepancy between patterns of deterioration in macular perfusion density and ganglion cell thickness in early glaucoma. •½àVˆê–@1,2, Corey A Smith1, Michael E West1, Jayme R Vianna1, Lesya M Shuba1, Paul E Rafuse1, Marcelo T Nicolela1, Balwantray C Chauhan1 (1Dalhousie University, 2Šá‰È): ‘æ9‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2020/6/17), WebŠJÃ.

723539. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Corvis ST‚É‚æ‚鐶‘Ì—ÍŠw“I—ΓàáˆöŽq‚̗ΓàáŽ¯•Ê”\‚¨‚æ‚ÑŽ‹–ìis‚Æ‚ÌŠÖ˜A. Â–؏Cˆê˜Y1, –Ø“à—Ç–¾2, “¿–щԍØ2, “¡–ì—F—¢3,4, ¼‰Y«l3,4, ‘º“c”ŽŽj3, ’†‘qr—S5, ’©‰ª@—º3 (1Žs—§ŽD–y•a‰@, 2L“‡‘å, 3“Œ‹ž‘å, 4Šá‰È, 5ŽO‰h‰ïƒcƒJƒUƒL•a‰@): ‘æ9‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2020/6/17), WebŠJÃ.

723540. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A deep learning model to predict visual field in central 10 degrees from optical coherence tomography measurement in glaucoma. Fujino Y1, Hashimoto Y1, Asaoka R1, Kiwaki T2, Sugiura H2, Asano S1, Murata H1, ¼‰Y«l1,3, Miki A4, Mori K5, Ikeda Y5,6, Kanamoto T7, Yamagami J8, Inoue K9, Tanito M10, Yamanishi K2 (1“Œ‹ž‘å, 2“Œ‹ž‘åŠwî•ñ—HŠw, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4‘åã‘å, 5‹ž“s•{ˆã‘å, 6Œä’rŠá‰È, 7L“‡‹L”O•a‰@, 8JR“Œ‹ž‘‡•a‰@, 9ˆäãŠá‰È, 10“‡ª‘å): ‘æ9‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2020/6/17), WebŠJÃ.

723541. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒŒ[ƒxƒ‹ˆâ“`«Ž‹_ŒoÇ‚É‚¨‚¯‚éƒwƒbƒhƒ}ƒEƒ“ƒgŒ^Ž‹–ìŒv‚É‚æ‚铵EŽ‹–쑪’è. ¼–ì–Gˆß1, ˆÉ“¡Žé—1, ŒË’ˁ@Œå1, óì@Œ«2, Îì@‹Ï2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ9‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2020/6/17), WebŠJÃ.

723542. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·z‘½Å“_Eƒg[ƒŠƒbƒN2. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723543. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·z¶‘ÌŒv‘ª. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723544. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘OŠá•”ŒõŠ±Â’f‘wŒv‚ðŽg—p‚µ‚½ƒqƒg…»‘ÌŠj‚̐V‚µ‚¢•ª—Þ. ”n“ˆ´”@1, Žsì@Œc2, ŽðˆäKO3, ‰Á“¡Km3, “à“¡®‹v3, ‹Ê’u–¾–ì4, Žsìˆê•v3,5 (1Šá‰È–¾Šá‰@, 2‘‡ÂŽR•a‰@, 3’†‹žŠá‰È, 4JCHO’†‹ž•a‰@, 5Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723545. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘OŠá•”OCT Anterion҂ÆIOL-Master700҂̊eŽí‘ª’è’l‚Ì”äŠr. Žsì@Œc1,2, ¬“‡—²Ži2,3, “c‘ºŒ«¶2, ŽðˆäKO2, ‰Á“¡Km2, Žsì—æŽq2, àV–؈»Žq4, ‹Ê’u–¾–ì4, Žsìˆê•v2,4,5 (1‘‡ÂŽR•a‰@, 2’†‹žŠá‰È, 3Œcœä‘å, 4’†‹ž•a‰@, 5Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723546. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’†‚”NŽÒ‚É‚¨‚¯‚闐Ž‹—Ê‚ªŽ‹—Í‚É—^‚¦‚é‰e‹¿. Š±ì—¢ŠG1, _’J˜aF1, ”Ñ“c‰Ã•F2, ‰¡ŠÖ—S‰ÀŽq2, ‹àŽRr‰î2, ¯ŽiMs2 (1ˆã—Éq¶Šw•”, 2Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723547. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šááىº‚‚ɑ΂·‚éãŠááَèp‘OŒã‚ÌŠp–ŒŒ`ó•Ï‰»‚ÌŒŸ“¢. ÎìŒb—¢1, ŒÜ\—’ÍŽj2,3, ¬àV’‰•F1 (1¬‘òŠá‰È“à‰È•a‰@, 2ŽR‰¤•a‰@, 3Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723548. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒŒ[ƒVƒbƒN’·ŠúŒo‰ßŒã‚ÌŠO«ƒtƒ‰ƒbƒv•ÎˆÊ‚ɑ΂µ‚Đ®•œ‚ð—v‚µ‚½4Ç—á. ŸNˆä—•Žq1, ‚‹´³‰p1, _’J˜aF2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723549. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰~Šp–ŒŠá‚É‚¨‚¯‚éƒJƒXƒ^ƒ€Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‘OŒã‚Ìstress-strain index‚Ì”äŠr. àV–؈»Žq1, ’·’JìˆŸ—¢1, ¬“‡—²Ži2, ¼“c’m–ç3, ’†‘º—Fº3, Žsìˆê•v4,5 (1JCHO’†‹ž•a‰@, 2Œcœä‘å, 3–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 4’†‹žŠá‰È, 5Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723550. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒyƒ‹[ƒVƒhŠp–Œ•Ó‰•Ï«‚ɑ΂·‚éƒJƒXƒ^ƒ}ƒCƒYƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚Ì‘Šú—Տ°¬Ñ. ‚‹´³‰p1, _’J˜aF2, ‹àŽRr‰î1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723551. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) is«‰~Šp–Œ‚ɑ΂·‚éƒJƒXƒ^ƒ}ƒCƒYƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚̏pŒã1”N¬Ñ‚ÌŒŸ“¢. ‹àŽRr‰î1, _’J˜aF2, ‚‹´³‰p1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723552. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚̃JƒXƒ^ƒ€–@‚Æ”ñƒJƒXƒ^ƒ€–@‚Ì”äŠr. ¬“‡—²Ži1,2, ¼“c’m–ç1, ’†‘º—Fº1, “n•”@ŠÂ3, ”’ˆä—D‘¾3, ²“¡—T–ç3, Žsìˆê•v4,5 (1–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 2Œcœä‘å, 3²“¡—T–çŠá‰Èˆã‰@, 4’†‹žŠá‰È, 5Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723553. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) NX70CH‚ð—p‚¢‚½ƒ_ƒuƒ‹ƒz[ƒ‹ƒj[ƒhƒ‹‚É‚æ‚éƒ_ƒuƒ‹ƒj[ƒhƒ‹–@. ‹g“c‘¥•F1, Žsìˆê•v2,3 (1Šò•ŒÔ\Žš•a‰@, 2’†‹žŠá‰È, 3Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723554. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zICL. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723555. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘OŠá•”3ŽŸŒ³ŒõŠ±Â’f‘wŒv‚É‚¨‚¯‚é‰ÁŽZ•½‹Ï‰æ‘œ‚ð—p‚¢‚½‹÷ŠpŠÔ‹——£‚̍Č»«. ‰Á“¡ŽÑ–1, ´…Œö–ç1,2, ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@, 2Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723556. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ICLƒTƒCƒY‚Ì—\‘ªŽ®NK2Ž®‚̉ü—Ç. ’†‘º—Fº1, ‹g“c—zŽq1, …–ì‘׎q1, ˆé’J®‹P1, ¼“c’m–ç1, ™ŽRN—Y1, ¬“‡—²Ži1,2, Žsìˆê•v3,4 (1–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 2Œcœä‘å, 3’†‹žŠá‰È, 4Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723557. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —L…»‘ÌŠá“àƒŒƒ“ƒY‚̍œKƒTƒCƒY—\‘ª‚Ì•sˆê’v—¦‚Æ‚»‚ÌŒ´ˆö‚ÌŒŸ“¢. ˆÀ“¡˜a‰ÌŽq1, _’J˜aF2, ‚‹´³‰p1, ‹àŽRr‰î1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723558. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —L…»‘ÌŠá“àƒŒƒ“ƒY‚̐‚’¼ŒÅ’è‚É‚æ‚évault‚ÌŒoŽž•Ï‰». ‚Œ´—Rˆß1, _’J˜aF2, ˆÀ“¡˜a‰ÌŽq1, ‚‹´³‰p1, ‹àŽRr‰î1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723559. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œã–[Œ^ƒtƒFƒCƒLƒbƒNŠá“àƒŒƒ“ƒY (ICL) ‘}“üpŒã‘Šú‚ÌIrido-Trabecular Contact (ITC) ‚Ì”­¶—¦‚Æ‚»‚Ì—vˆö‚ÌŒŸ“¢. ‚–Ø—E‹M1, ¼“c’m–ç2, ¬“‡—²Ži2,3, “c’†–FŽ÷4, ’†‘º—Fº2, Žsìˆê•v4,5 (1”Ñ“cŽs—§•a‰@, 2–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 3Œc‰ž‘å, 4’†‹žŠá‰È, 5Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723560. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —L…»‘ÌŠá“àƒŒƒ“ƒY‚̏pŒãƒnƒ[‚Ì•]‰¿. ]”gŒË”ü˜a1, ŒÜ\—’ÍŽj2,3, ‰Á“¡ŽÑ–2, ¬àV’‰•F1 (1¬‘òŠá‰È“à‰È•a‰@, 2ŽR‰¤•a‰@, 3Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723561. [Šw‰ï (‘S‘)] (Šwp“WŽ¦) ‰“Ž‹E‰“Ž‹«—Ž‹‚ɑ΂·‚éImplantable Collamer Lens (ICH) ‚̏pŒã¬Ñ. ‹g“c—zŽq1, ¼“c’m–ç1, ˆé’J®‹P1, “´ˆä—¢ŠG1,2, …–ì‘׎q1, ¬“‡—²Ži1,3, ’†‘º—Fº1, ²“¡—T–ç4, Žsìˆê•v2,5 (1–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 2’†‹žŠá‰È, 3Œcœä‘å, 4²“¡—T–çŠá‰Èˆã‰@, 5Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723562. [Šw‰ï (‘S‘)] (Šwp“WŽ¦) ]—ˆ‚ÌŒ°”÷‹¾”’“àáŽèp‚ƃfƒWƒ^ƒ‹Œ°”÷‹¾‚ð—p‚¢‚½Heads-up cataract surgery‚̏‰Šú¬Ñ‚ÌŒŸ“¢. ŒÃì—F‘å1, Žsì@Œc2, ‰¡ŽR@ãÄ3, ¬“‡—²Ži4, “c’†–FŽ÷5, í”Ր¹Ži5, “´ˆä—¢ŠG5, Žsìˆê•v5,6 (1‘å—Y‰ï‘æˆê•a‰@, 2‘‡ÂŽR•a‰@, 3JCHO’†‹ž•a‰@, 4Œc‰ž‘å, 5’†‹žŠá‰È, 6Šá‰È): ‘æ35‰ñJSCRSŠwp‘‰ï (2020/7/1), WebŠJÃ.

723563. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Virtual RealityƒVƒ…[ƒeƒBƒ“ƒOƒQ[ƒ€‚É‚æ‚éŠáˆÊE’²ß‹@”\‚¨‚æ‚щf‘œŒ‚¢‚ւ̉e‹¿. Œ´@’¼l1, Š™“c‘׏²1, Œã“¡Œ\—S1, ‚–Û”ü]1, ‘O“c^Šó1, ŽRè‹I1, Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘åE•ÛŒ’ˆã—Êw•”Ž‹‹@”\—Ö@Šw‰È, 2Šá‰È): ‘æ76‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ45‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï‡“¯Šw‰ï (2020/7/3), WebŠJÃ.

723564. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Spot vision screener‚ð—p‚¢‚½ŠÔŒ‡«ŠOŽÎŽ‹‚Ì—¼ŠáŠJ•ú‰º‚ƕЊáŽÕ•Â‰º‚Å‚Ì‹üÜ’l•Ï‰». ÀàV—E‹P1, ŒãŠÖ—˜–¾2, ŒË’ˁ@Œå1, —´ˆä‰‘Žq2, Îì@‹Ï3, ¯ŽiMs2 (1ORT, 2Šá‰È, 3ˆã—Éq¶Šw•”): ‘æ76‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ45‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï‡“¯Šw‰ï (2020/7/3), WebŠJÃ.

723565. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰)yÀ’·z‰æ‘œ‰ðÍ. ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åE”MŠC, 2Šá‰È): ‘æ76‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ45‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï‡“¯Šw‰ï (2020/7/3), WebŠJÃ.

723566. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŽãŽ‹Šá‚É‚¨‚¯‚éLSFG‚ÆSS-OCT‚ð—p‚¢‚½ŒŒ—¬“®‘Ô‚Æ–¬—–ŒŒú‚Ì•]‰¿. ŒË’ˁ@Œå1, ŒãŠÖ—˜–¾2, Îì@‹Ï3, —´ˆä‰‘Žq2, ¯ŽiMs2 (1ORT, 2Šá‰È, 3ˆã—Éq¶Šw•”): ‘æ76‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ45‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï‡“¯Šw‰ï (2020/7/3), WebŠJÃ.

723567. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒfƒWƒ^ƒ‹ƒfƒoƒCƒX‚É‚æ‚Á‚悶‚éŒã“V‹¤“¯«“àŽÎŽ‹‚Ì“Á’¥‚ÆŽ¡—ЬÑ. Îì‘å‹N1, ŒãŠÖ—˜–¾1, —´ˆä‰‘Žq1, Îì@‹Ï2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ76‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ45‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï‡“¯Šw‰ï (2020/7/3), WebŠJÃ.

723568. [Šw‰ï (‘S‘)] (Šwp“WŽ¦) Ž‹ü‰ðÍ‘•’u‚É‚æ‚éASDŽ™‚̏Փ®«Šá‹…‰^“®‚ÉŠÖ‚·‚錟“¢. Žl”V‹{—C”n1, —é–ØŒ«Ž¡1, ¬–ì‹|ŠG2, Œlã‹±•F1, ²“¡–­Žq1, ŽOXçŽí1, Vˆä“cF—T1,3 (1‘Ûˆã—ÕŸŽƒ‘å, 2–¾Ž¡‘å, 3Šá‰È): ‘æ76‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ45‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï‡“¯Šw‰ï (2020/7/3), WebŠJÃ.

723569. [Šw‰ï (‘S‘)] (Šwp“WŽ¦) Šáâ|MRI‚É‚æ‚éŒã“V“àŽÎŽ‹‚ÌŠOŠá‹ØˆÊ’u•]‰¿. ‰Í‡ˆ¤ŽÀ1, ŒãŠÖ—˜–¾2, Îì@‹Ï3, —´ˆä‰‘Žq2, ¯ŽiMs2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2Šá‰È, 3ˆã—Éq¶Šw•”): ‘æ76‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ45‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï‡“¯Šw‰ï (2020/7/3), WebŠJÃ.

723570. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) FŠoˆÙíŽÒ‚É‚¨‚¯‚é”–•é‰º‚ÌŽ‹”F«‚É‹y‚Ú‚·F‚̉e‹¿. ”Ñ’Ë’B–ç1, ìŽç“c‘ñŽu2, ’|’†@’¼3, ’ҁ@@‘n4, ‹àˆä”ŽK5, •½ˆä—˜”Ž6, —é–Ø—T¶7, ”¼“c’m–ç2, Îì@‹Ï2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒjƒbƒZƒ“ƒPƒ“•iŽ¿•]‰¿ƒZƒ“ƒ^[, 4ƒJƒPƒ“ƒeƒXƒgƒZƒ“ƒ^[, 5MB‘å‘@ˆÛŠw•”, 6MB‘å, 7ƒAƒ[ƒAƒX (Š”)): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

723571. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ÐŠá«‚̐Sˆö«Ž‹—͏áŠQ‚ɑ΂·‚éOcclu-pad‚ð—p‚¢‚½—¼ŠáŠJ•ú‰º‚É‚¨‚¯‚é’PŠáŽ‹—ÍŒŸ¸. Šâ“c@—y1, ”¼“c’m–ç1, Îì@‹Ï1, ¯ŽiMs2 (1ˆã—Éq¶Šw•”, 2Šá‰È): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

723572. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Waterclefts‚̋Ǎ݂̈Ⴂ‚ªŽ‹‹@”\‚Ö‹y‚Ú‚·‰e‹¿|ŒõŠwƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚É‚æ‚é‰ðÍ|. ŠÖ@—S‰î1, ìŽç“c‘ñŽu2, ŽO“c“N‘å1, ‹v•Û]—1, ²X–Ø—m1 (1‹à‘òˆã‘å, 2ˆã—Éq¶Šw•”): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

723573. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ªŒõ“§‰ß—¦‚̈قȂ鉩F’…FƒŒƒ“ƒY‚̃OƒŒƒA‰º‚É‚¨‚¯‚éƒRƒ“ƒgƒ‰ƒXƒgŠ´“x‚ւ̉e‹¿. Œ´Œûãđ¾1, ìŽç“c‘ñŽu2, “¡‘º•‡²Žq2, ¯ŽiMs3 (1“Œ–k•¶‰»Šw‰€‘å, 2ˆã—Éq¶Šw•”, 3Šá‰È): ‘æ56‰ñ“ú–{ŠáŒõŠwŠw‰ï‘‰ï`FOCUS 2020` (2020/9/5), WebŠJÃ.

723574. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·z—ΓàáŽèp. ¯ŽiMs (Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723575. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹}«Œ´”­•ÂÇ‹÷ŠpÇ‚ɑ΂·‚鎡—Â̗Տ°¬Ñ. ”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723576. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÑ’ʍE•t‚«—L…»‘ÌŠá“àƒŒƒ“ƒY“Eo‚ÉŽŠ‚Á‚½Ç—á‚ÌŒ´ˆö‚Æ—\Œã‚ÌŒŸ“¢. ‘ìG‹P1, _’J˜aF2, ‚‹´³‰p1, ˆÀ“¡˜a‰ÌŽq1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723577. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ[ƒJ[ƒmƒ‚ƒOƒ‰ƒ€‚Æ—\‘ªŽ®‚ð—p‚¢‚½—L…»‘ÌŠá“àƒŒƒ“ƒYpŒãVault‚Ì”äŠr. ˆÀ“¡˜a‰ÌŽq1, _’J˜aF2, ‚‹´³‰p1, ‘ìG‹P1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723578. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒJƒXƒ^ƒ}ƒCƒYƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚̃R[ƒ“Œ`ó•Ê‚̏pŒã¬Ñ. ‚‹´³‰p1, _’J˜aF2, ‘ìG‹P1, ˆÀ“¡˜a‰ÌŽq1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723579. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Corneal Cross-Linking for Pediatric Keratoconus: A Meta-Analysis. ¬‹´‰p’·1,2, •B“c@–q1,3, Ž…ˆä‘fŒ[1,3, _’J˜aF1,4, ‰Á“¡’¼Žq1,2, ’Ø“cˆê’j2, “‡ú±@1,5 (1‰~Šp–ŒŒ¤‹†‰ï, 2Œcœä‘å, 3‹ž“s•{ˆã‘å, 4ˆã—Éq¶Šw•”, 5“Œ‹žŽ•‘åEŽsì): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723580. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zŠá“àƒŒƒ“ƒY“x”ŒvŽZE¶‘ÌŒv‘ª. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723581. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘OŠá•”OCT‚ð—p‚¢‚½V‚µ‚¢Šá“àƒŒƒ“ƒY“x”ŒvŽZŽ®‚Ì‘OŒü‚«ŒŸØ. ²“¡@Ži1,2, ´…Œö–ç1,2,3, íœAr‘¾˜Y1,2,3, ŒÜ\—’ÍŽj1,2,3, ‰Á“¡ŽÑ–2, ‰i£x‹K2, —`…@Šw1,2,3, Vˆä“cF—T1,3 (1‘Ûˆã—ÕŸŽƒ‘åŠw, 2ŽR‰¤•a‰@, 3Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723582. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒqƒg”’“àá…»‘̂̐ԓ¹•”‚ðŒŸo‚·‚éV‚µ‚¢‰æ‘œ‰ðÍ–@. ”n“ˆ´”@1, Žsì@Œc2, ŽðˆäKO2, •Ð‰ª“”Ž3, ˆé’J®Ž÷3, ’†‘º—Fº3, ‹Ê’u–¾–ì4, Žsìˆê•v2,5 (1Šá‰È–¾Šá‰@, 2’†‹žŠá‰È, 3–¼ŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 4JCHO’†‹ž•a‰@, 5Šá‰È) ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723583. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”’“àáŽèp‚É‚¨‚¯‚éŠp–Œ“à”ç×–E–§“xŒ¸­‚ɉe‹¿‚·‚éˆöŽq‚ÌŒŸ“¢. àV–؈»Žq1, ¬“‡—²Ži2, “à“¡ˆ¤—3, “´ˆä—¢ŠG4, –{‹´F•F5, Žsìˆê•v4,6 (1JCHO’†‹ž•a‰@Šá‰È, 2Œcœä‘å, 3’†‹žƒƒfƒBƒJƒ‹, 4’†‹žŠá‰È, 5–{‹´Šá‰ÈƒNƒŠƒjƒbƒN, 6Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723584. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —Γàá«Ž‹–ìˆÙí‚ª”’“àáŽèpŒã‚̃Rƒ“ƒgƒ‰ƒXƒgŠ´“x‚É‹y‚Ú‚·‰e‹¿ˆöŽq‚ÌŒŸ“¢. Š±ì—¢ŠG1, _’J˜aF1, ”Ñ“c‰Ã•F2, “¡‘º•‡²Žq1, ”Ñ“‡@Œh2, Š}Œ´³s2, ¯ŽiMs2 (1ˆã—Éq¶Šw•”, 2Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723585. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·z_ŒoŠá‰È1. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723586. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’†•«ãµ–¾‚ƍl‚¦‚ç‚ê‚é9Ç—á. ‰Í–{‚Ђë”ü1, Šâ²^‹|1,2, ŽRã–¾Žq1,2, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ74‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2020/11/5), WebŠJÃ.

723587. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) LSFG‚ɂĊጌ—¬Œo‰ß‚ðŠÏŽ@‚Å‚«‚½Ž‹_Œo“û“ªŒŒŠÇ‰Š‚Ì2—á. •š‰®ˆêŽ÷1, •x“c‹§•F1, ¼–{@’¼1, Xì—tŒŽ1, ‰Á“¡ŒjŽq1, •½–ìK¢1, –x—Tˆê1, Îì@‹Ï2 (1“Œ–M‘åŠwˆã—ÃZƒ“ƒ^[‘åX•a‰@, 2ˆã—Éq¶Šw•”): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

723588. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —«‚É”­Ç‚µ‚½ƒŒ[ƒxƒ‹ˆâ“`‚µŽ‹_ŒoÇ27Ç—á‚ÌŒŸ“¢. ³ˆä’qŽq1,2,3, Šâ²^‹|1,4, ŽRã–¾Žq1,4, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1, Îì@‹Ï2, ˆÀ–{—´”n3, ŸNˆäŒc‘¢3 (1ˆäãŠá‰È•a‰@, 2ˆã—Éq¶Šw•”, 3—ÕŒŸ•”, 4Šá‰È): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

723589. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ñ“TŒ^“I‚ÈŒo‰ß‚Å”­Ç‚µ‚½¬Ž™‚̃Œ[ƒxƒ‹ˆâ“`ŽqŽ‹_ŒoÇ‚̈ê—á. Šâ²^‹|1,2, ŽRã–¾Žq1,2, ’߉ªŽOœ¨Žq1, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1, ˆÀ–{—´”n3, ŸNˆäŒc‘¢3, Îì@‹Ï4 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3—ÕŒŸ•”, 4ˆã—Éq¶Šw•”): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

723590. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒrƒmƒŒƒ‹ƒrƒ“‚É‚æ‚é’†“Ő«Ž‹_ŒoÇ‚ª‹^‚í‚ꂽˆê—á. ¬¼—uŽq1, Šâ²^‹|1,2, ŽRã–¾Žq1,2, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

723591. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —Γàá¸¸‚Å‹ô”­“I‚É”­Œ©‚³‚ꂽæ“V«1/4“¯–¼”¼–ӂƍl‚¦‚ç‚ꂽ1—á. Œã“¡“c’m–M1, ¬¼“N–ç1, ¼–{@’¼1, •x“c‹§•F1, Xì—tŒŽ1, ‰Á“¡˜Ð—¢1, –x@—Tˆê1, Îì@‹Ï2 (1“Œ–M‘åŠwˆã—ÃZƒ“ƒ^[‘åX•a‰@, 2ˆã—Éq¶Šw•”): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

723592. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·z¬Ž™_ŒoŠá‰È. ŽRã–¾Žq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

723593. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ÐŠá«‚ÌŠá‹…“ˏo‚ðŒ_‹@‚É”­Œ©‚³‚ê, f’f‚É‹ê—¶‚µ‚½anterior condylar confluence‚Ì‹ß–T‚̍d–Œ“®Ã–¬á‘‚Ì1—á. ‚–ØŒ˜‘¾˜Y1, ŒãŠÖ—˜–¾1,2, ‰Í–ì—Y—º1, —´ˆä‰‘Žq1, Îì@‹Ï3, ¯ŽiMs1, ŽR–{‘å•ã4 (1Šá‰È, 2‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 3ˆã—Éq¶Šw•”, 4”]ŠO): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

723594. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) FŠoˆÙíŽÒ‚É‚¨‚¯‚鐍‘̃Rƒ“ƒgƒ‰ƒXƒgŠ´“x. ”Ñ’Ë’B–ç1, ìŽç“c‘ñŽu2, ”¼“c’m–ç2, Œ´Œûãđ¾3, ¯ŽiMs4, Îì@‹Ï2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3“Œ–k•¶‰»Šw‰€‘åŠw, 4Šá‰È): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

723595. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ÂFŒõ‚ðŽhŒƒ‚Æ‚µ‚½‘ÎŒõ”½ŽË‚©‚ç‚Ý‚½•Î“ª’É—U”­ˆöŽq‚ÌŒ¤‹†. HŒ³”ü—D1, Œ´@’¼l2, Š™“c‘׏²2, ˆÉ“¡@—I2, ²X–؈è2, Žá”~¹D2, Vˆä“cF—T2,3 (1‘Ûˆã—ÕŸŽƒ‘åŠw, 2‘Ûˆã—ÕŸŽƒ‘åŠw•ÛŒ’ˆã—Êw•”Ž‹‹@”\—Ö@Šw‰È, 3Šá‰È): ‘æ58‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2020/11/6), WebŠJÃ.

731046. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) Šá‰Èˆã‚©‚ç‚Ý‚½Ž‹_Œo‰Š|f’fEŽ¡—Â̓‚³|. Îì@‹Ï (ˆã—Éq¶Šw•”): Ž‹_Œo‰ŠƒZƒ~ƒi[inå‘ä (2020/7/29), ‹{é (ƒnƒCƒuƒŠƒbƒhŠJÃ).

731047. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ŽÀ‘H, ‚—îŽÒ‚Ì•¡Ž‹. ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 2Šá‰È): ‘æ211‰ñ‹{éŒ§Šá‰ÈW’k‰ï (2020/10/10), WebŠJÃ.

731048. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) —ΓàáŽ¡—Â̓±“ü‚Æ‹­‰». ¯ŽiMs (Šá‰È): ‘æ5‰ñGlaucoma Frontire Conference in Chiba (2020/10/22), WebŠJÃ.

731049. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) MIGS‚ÌŒø‰Ê‚ÆŒÀŠE. ¯ŽiMs (Šá‰È): ‘æ37‰ñ“‡ª—ΓàáŒ¤‹†‰ï (2020/11/1), “‡ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

731050. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) —ΓàáŽ¡—Â̑I‘ð. ¯ŽiMs (Šá‰È): ‘æŽl‰ñ’†‰z—Տ°Šá‰ÈŒ¤‹†‰ï (2020/11/11), WebŠJÃ.

731051. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰)yÀ’·z“Á•Êu‰‰. ¯ŽiMs (Šá‰È): ‘æ18‰ñ–k—¢Šá‰È•af˜AŒg‰ï (2021/1/21), WebŠJÃ.

731052. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ”’“àáŽ¡—Ð헪ƒAƒbƒvƒf[ƒg. ”Ñ“c‰Ã•F (Šá‰È): ‘æ18‰ñ–k—¢Šá‰È•af˜AŒg‰ï (2021/1/21), WebŠJÃ.

731053. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰)yÀ’·z“Á•Êu‰‰I. ¯ŽiMs (Šá‰È): ‘æ2‰ñSENJU Glaucoma Seminar (2021/2/16), WebŠJÃ.

731054. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) MIGS‚ɂ‚¢‚ÄŽv‚¤‚±‚Æ. ¯ŽiMs (Šá‰È): ‘æ27‰ñŽR—œ—ΓàáŒ¤‹†‰ï (2021/3/4), WebŠJÃ.

731055. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) Ž‹_Œo‰Š‚Æ‚»‚ÌŠÓ•ÊŽ¾Š³|ð¡‚ÌŽ¡—Ö@‚ÆŠe‰È‚Ì–ðŠ„|. Îì@‹Ï (ˆã—Éq¶Šw•”): Ž‹_Œo‰Š˜AŒgƒZƒ~ƒi[ in2021 (2021/3/25), H“c (ƒnƒCƒuƒŠƒbƒhŠJÃ).

732031. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“)yƒRƒƒ“ƒe[ƒ^[zŽ‹_Œo‰Š‚Ì‹}«ŠúŽ¡—Âɂ‚¢‚Ä. Îì@‹Ï (ˆã—Éq¶Šw•”): Ž‹_Œo‰ŠƒZƒ~ƒi[inå‘ä (2020/7/29), ‹{é (ƒnƒCƒuƒŠƒbƒhŠJÃ).

732032. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (Œ’NuÀ) ‚¦‚Á! Ž„, ”’“àá‚Å‚·‚©? ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 2Šá‰È): ‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@‘æ69‰ñŒ’NuÀ (2020/8/28), Ã‰ª.

732033. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) —ΓàáŽèp‚̏Љîƒ^ƒCƒ~ƒ“ƒO. Š}Œ´³s (Šá‰È): —ΓàáWEBƒZƒ~ƒi[ (2020/10/13), WebŠJÃ.

732034. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŽÐ“àŒ¤C‰ï) Ž‹_Œo‰Š. ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 2Šá‰È): ’†ŠO»–òŽÐ“àu‰‰‰ï (2020/10/22), Ã‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

732035. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŽÐ“àu‰‰‰ï) ÉŽq‘ÌŽèp‚ÌŠî‘b. t–ؐ’G (Šá‰È): ƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}‡ŠŽÐ“àu‰‰‰ï (2020/10/28), WebŠJÃ.

732036. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰I. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ11‰ñÃ¼Šá‰ÈƒAƒJƒfƒ~[ (2020/10/29), _“ސì.

732037. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰II. ¯ŽiMs (Šá‰È): ‘æ11‰ñÃ¼Šá‰ÈƒAƒJƒfƒ~[ (2020/10/29), _“ސì.

732038. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŽÐ“àŒ¤C‰ï) ”’“àáŽèp‚̓Ç—á‚ɂ‚¢‚Ä. ‘ŠàV‘å•ã1,2 (1ŠC˜V–¼‘‡•a‰@, 2Šá‰È): ‹»˜aŽÐ“àŒ¤C‰ï (2020/11/11), _“ސì.

732039. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŽÐ“àŒ¤C‰ï) ‚—îŽÒ‚Ì•¡Ž‹|Sagging Eye Syndrome‚ð—‰ð‚·‚é|. ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 2Šá‰È): ‚í‚©‚à‚Ɛ»–òŽÐ“àu‰‰‰ï (2020/11/12), Ã‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

732040. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŽÐ“àŒ¤C‰ï) ‹üÜ‹¸³Žèp‚ƃhƒ‰ƒCƒAƒC‚ɂ‚¢‚Ä. _’J˜aF (ˆã—Éq¶Šw•”): ‘å’ː»–òŽÐ“àŒ¤C‰ï (2020/11/20), WebŠJÃ.

732041. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰III. ¯ŽiMs (Šá‰È): SENJU Ophthalmic Seminar 2020 in Tokyo (2020/11/21), WebŠJÃ.

732042. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“¢˜_‰ï) Œ´”­•ÂÇ‹÷ŠpÇ‚Ì‹}«”­ì‚ɑ΂·‚鎡—ЬÑ‚ÌŒŸ“¢. ”Ñ“‡@Œh (Šá‰È): ‘æ15‰ñƒvƒƒOƒŒƒXƒŒƒ|[ƒg‰ï‹c (–k—¢‘åŠwˆãŠw•”ŽáŽèŒ¤‹†ŽÒ”­•\E“¢˜_‰ï) (2020/11/25), _“ސì.

732043. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) ŠááÙáz¹‚É‚¨‚¯‚éƒ{ƒcƒŠƒkƒX—Ö@‚ÌŽÀ‘H. ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 2Šá‰È): Blepharospasm Webinar (2020/11/26), WebŠJÃ.

732044. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŽÐ“àŒ¤C‰ï) —ΓàáŽèpEŽ¡—Âɂ‚¢‚Ä. Š}Œ´³s (Šá‰È): ‘å’ː»–ò‡ŠŽÐ“àŒ¤C‰ï (2020/11/26), WebŠJÃ.

732045. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰1. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ64‰ñÃ¼Šá‰È—Տ°ƒtƒH[ƒ‰ƒ€ (2020/12/10), WebŠJÃ.

732046. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰2. ¯ŽiMs (Šá‰È): ‘æ64‰ñÃ¼Šá‰È—Տ°ƒtƒH[ƒ‰ƒ€ (2020/12/10), WebŠJÃ.

732047. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŽÐ“àŒ¤C‰ï) ‚—îŽÒ‚Ì•¡Ž‹|Sagging Eye Syndrome‚ð—‰ð‚·‚é|. ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 2Šá‰È): çŽõ»–òŽÐ“àu‰‰‰ï (2020/12/11), Ã‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

732048. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŽÐ“àŒ¤C‰ï) ”’“àáŽèp, ŽüpŠú‚̃hƒ‰ƒCƒAƒC‚ɂ‚¢‚Ä. ”Ñ“c‰Ã•F (Šá‰È): ‘å’ː»–ò‡ŠŽÐ“àŒ¤C‰ï (2020/12/14), WebŠJÃ.

732049. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŽÐ“àŒ¤C‰ï) Ž‹_Œo‰Š‚Ì•a‘Ô‚ÆŽ¡—Ã. Îì@‹Ï (ˆã—Éq¶Šw•”): ’élƒwƒ‹ƒXƒPƒAŠ”Ž®‰ïŽÐŽÐ“àŒ¤C‰ï (2021/1/26), WebŠJÃ.

732050. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (Ç—á’ñŽ¦)y‰ðàz…B‹·‹÷ŠpŠá‚Ì”’“àáŽèp. ¯ŽiMs (Šá‰È): —΂ÌãJ2021 (2021/2/2), WebŠJÃ.

732051. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰2. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ8‰ñ_“ސ쏬Ž™Šá‰ÈE_ŒoŠá‰ÈƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/2/4), WebŠJÃ.

732052. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) _ŒoŠá‰È‚ÆŒ©ŠÔˆá‚¤‘¼Ž¾Š³. Žs糋`Í1,2 (1_“ސ쎕‰È‘åŠw, 2Šá‰È): ‘æ8‰ñ_“ސ쏬Ž™Šá‰ÈE_ŒoŠá‰ÈƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/2/4), WebŠJÃ.

732053. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒpƒlƒŠƒXƒg) Ž‹_Œo‰Šf—Âɂ¨‚¯‚éŠá‰È‚Æ”]_Œo“à‰È‚̘AŒg`‹}«Šú‚É‚¨‚¯‚éIVIG‚̈ʒu‚¯‚ðŠÜ‚߂ā`. ŽRã–¾Žq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): Ž‹_Œo‰ŠƒZƒ~ƒi[in“Œ‹ž (2021/2/17), WebŠJÃ.

732054. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) ð¡‚ÌŽ‹_Œo‰Š‚̐f’f–@EŽ¡—Ö@‚Æ’ˆÓ‚·‚ׂ«ŠÓ•ÊŽ¾Š³. Îì@‹Ï (ˆã—Éq¶Šw•”): ŽRŒ`Ž‹_Œo‰ŠƒZƒ~ƒi[ (2021/2/18), WebŠJÃ.

732055. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) À’·. ´…Œö–ç1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ƒŒƒ“ƒeƒBƒXƒRƒ“ƒtƒH[ƒgƒg[ƒŠƒbƒN?”­”„‹L”Ou‰‰‰ï (2021/2/18), WebŠJÃ.

732056. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) Š³ŽÒ–ž‘«“xŒüã‚ð–ÚŽw‚µ‚½Šá“àƒŒƒ“ƒY‘I‘ð. ”Ñ“c‰Ã•F (Šá‰È): ƒŒƒ“ƒeƒBƒXƒRƒ“ƒtƒH[ƒgƒg[ƒŠƒbƒNҔ­”„‹L”Ou‰‰‰ï (2021/2/18), WebŠJÃ.

732057. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (Ç—á•ñ) ”ñŠ´õ«Šp–ŒúE‚ɑ΂µƒVƒAƒmƒAƒNƒŠƒŒ[ƒg‚ʼnÁ—µ‚½2—á. ‚‹´³‰p (Šá‰È): ‘æ13‰ñ_“ސìƒNƒƒXƒI[ƒo[ƒVƒ“ƒ|ƒWƒEƒ€ (2021/2/20), WebŠJÃ.

732058. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) À’·. ¯ŽiMs (Šá‰È): ‘æ6‰ñŽ‹Šo¶—ŠwŠî‘bƒZƒ~ƒi[ (2021/2/21), WebŠJÃ.

732059. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) ‚—îŽÒ‚Ì•¡Ž‹`Sagging Eye Syndrome‚ð—‰ð‚·‚é`. ŒãŠÖ—˜–¾1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw”MŠC•a‰@, 2Šá‰È): ƒOƒ‰ƒiƒeƒbƒNWebƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/2/26), WebŠJÃ.

732060. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰1. ¯ŽiMs (Šá‰È): ‘æ65‰ñÃ¼Šá‰È—Տ°ƒtƒH[ƒ‰ƒ€ (2021/3/11), WebŠJÃ.

732061. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰2. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ65‰ñÃ¼Šá‰È—Տ°ƒtƒH[ƒ‰ƒ€ (2021/3/11), WebŠJÃ.

732062. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) NMOSD‚ɂ‚¢‚ā@`Šá‰Èˆã‚Ì—§ê‚©‚ç`. Îì@‹Ï (ˆã—Éq¶Šw•”): ŠÖ“ŒNMOSDƒXƒvƒŠƒ“ƒOƒZƒ~ƒi[ (2021/3/13), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

733112. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʉ‰‘è. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ18‰ñ–k—¢Šá‰È•af˜AŒg‰ï (2021/1/21), WebŠJÃ.

733113. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ˜AŒg•a‰@EŠÖ˜A•a‰@‚̏Љî. ‘ŠàV‘å•ã1,2 (1ŠC˜V–¼‘‡•a‰@, 2Šá‰È): ‘æ18‰ñ–k—¢Šá‰È•af˜AŒg‰ï (2021/1/21), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110020. [Œ´’˜] Investigation of Stress and Distress Experienced by Guardians of Children with Strabismus and/or Amblyopia. Kitasato M, Iwamitsu Y1, Iwata Y2, Ueta T, Fukaya E, Ishikawa H2: J Binocul Vis Ocul Motil 2020/1-3; 70 (1): 21-8. (Šâ–ž—D”ü1, Šâ“c@—y2, Îì@‹Ï2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”)


Ž¨•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠw

[Šwp˜_•¶]

110364. [Œ´’˜] Effects of the Conductive Component of Hearing Loss on Speech Discrimination Ability. Kurioka T1, Sano H2, Furuki S1, Yamashita T1: J Int Adv Otol 2020/4; 16 (1): 93-7. (ŒI‰ª—²b1, ²–ì@”£2, ŒÃ–؏Ȍá1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”)

110365. [Œ´’˜] Transient Conductive Hearing Loss Regulates Cross-Modal VGLUT Expression in the Cochlear Nucleus of C57BL/6 Mice. Kurioka T1, Mogi S2, Yamashita T1: Brain Sci 2020/4; 10 (5): 260. (ŒI‰ª—²b1, –Ζ؍¹’m‘ã2, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO, 2¶•¨•¨—Œn)

110366. [Œ´’˜] Resection of Parapharyngeal Space Tumors Located in the Prestyloid Compartment: Efficacy of the Cervical Approach. Matsuki T1, Okamoto I, Tada Y, Masubuchi T, Fushimi C, Kamata S, Miyamoto S1, Yamashita T1, Miura K: Ann Surg Oncol 2021/6; 28 (6): 3066-72. (¼–؁@’1, ‹{–{r•ã1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

110367. [Œ´’˜] Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. Matsuki T1, Okamoto I, Fushimi C, Sawabe M, Kawakita D, Sato H, Tsukahara K, Kondo T, Okada T, Tada Y, Miura K, Omura G, Yamashita T1: Cancer Med 2020/7; 9 (14): 5015-24. (¼–؁@’1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

110368. [Œ´’˜] Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan. Saito Y, Hayashi R, Iida Y, Mizumachi T, Fujii T, Matsumoto F, Beppu T, Yoshida M, Shinomiya H, Kamiyama R, Kitano M, Yokoshima K, Fujimoto Y, Hama T, Yamashita T1, Okami K, Miura K, Fujisawa T, Sano D, Kato H, Minami S, Sugasawa M, Masuda M, Ota I, Iwae S, Kawata R, Monden N, Imai T, Asakage T, Okada M, Yoshikawa T, Tanioka K, Kitayama M, Doi M, Fujii S, Fujii M, Oridate N, Nakamizo M, Yoshimoto S, Homma A, Nibu K, Yane K: Cancer 2020/9; 126 (18): 4177-87. (ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

110369. [Œ´’˜] Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma. Fushimi C, Okamoto I, Matsuki T1, Masubuchi T, Okada T, Sato H, Tsukahara K, Kondo T, Yamashita T1, Hanyu K, Omura G, Takahashi H, Tada Y, Miura K: Anticancer Res 2020/9; 40 (9): 5277-83. (¼–؁@’1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

110370. [Œ´’˜] Investigation of varicella-zoster virus immunoglobulin G levels in general health checkup subjects and patients with the Ramsay Hunt syndrome for a diagnosis of zoster sine herpete. Yamaguchi T1, Sano H2, Shibaki S, Yamashita S, Kobayashi S, Okamoto M1: Kitasato Med J 2020/9; 50 (2): 138-45. (ŽRŒû’mŽq1, ²–ì@”£2, ‰ª–{–ql1: 1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”)

110371. [Œ´’˜] Cerebellopontine angle tumor patients with and without sudden hearing loss. Ochiai A1: Kitasato Med J 2020/9; 50 (2): 145-51. (—Ž‡@“Ö1: 1Ž¨•@ˆôAE“ªèòŠO)

110372. [Œ´’˜] Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma. Sato H, Fushimi C, Okada T, Matsuki T1, Kondo T, Omura G, Miura K, Yamashita T1, Okamoto I, Tsukahara K: In Vivo 2020/9-10; 34 (5): 2967-72. (¼–؁@’1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

110373. [Œ´’˜] Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Niwa K, Kawakita D, Nagao T, Takahashi H, Saotome T, Okazaki M, Yamazaki K, Okamoto I, Hirai H, Saigusa N, Fushimi C, Masubuchi T, Miura K, Okazaki S, Matsui H, Okada T, Iwaki S, Matsuki T1, Hanyu K, Tsukahara K, Oridate N, Tada Y: Sci Rep 2020/10; 10 (1): 16988. (¼–؁@’1: 1Ž¨•@ˆôAE“ªèòŠO)

110374. [Œ´’˜] Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Matsuki T1, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T, Sato H, Ito T, Tokashiki K, Tsukahara K, Hanyu K, Masubuchi T, Tada Y, Miura K, Omura G, Sawabe M, Kawakita D, Yamashita T1: Cancers (Basel) 2020/11; 12 (11): 3427. (¼–؁@’1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

110375. [Œ´’˜] Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study. Kondo T, Okamoto I, Sato H, Koyama N, Fushimi C, Okada T, Masubuchi T, Miura K, Matsuki T1, Yamashita T1, Omura G, Takahashi H, Tsukahara K: Asia Pac J Clin Oncol 2020/12; 16 (6): 340-7. (¼–؁@’1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

110376. [Œ´’˜] Long-term administration of vitamin B12 and adenosine triphosphate for idiopathic sudden sensorineural hearing loss: a retrospective study. Kurioka T1, Sano H2, Furuki S1, Yamashita T1: PeerJ 2020/12; 8: e10406. (ŒI‰ª—²b1, ²–ì@”£2, ŒÃ–؏Ȍá1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”)

110377. [Œ´’˜] A kinematic analysis of swallow gestures and timing using video fluoroscopic study after supracricoid laryngectomy. Seino Y1, Miayamoto S1, Nakayama M, Yamashita T1: Radiol Diagn Imaging 2020; 4: 1-7. (´–ì—R”y1, ‹{–{r•ã1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

110378. [Œ´’˜] A Study of Factors that Contribute to the Severe Progression of Peritonsillar Abscess. Fujikawa N1, Yamashita T1: Int J Pract Otolaryngol 2020; 03 (01): e1-5. (“¡ì’¼–ç1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

110379. [Œ´’˜] Speech discrimination impairment of the worse-hearing ear in asymmetric hearing loss. Kurioka T1, Sano H2, Furuki S1, Yamashita T1: Int J Audiol 2021/1; 60 (1): 54-9. (ŒI‰ª—²b1, ²–ì@”£2, ŒÃ–؏Ȍá1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”)

110380. [Œ´’˜] Comparison of real-ear insertion gains in Japanese-speaking individuals wearing hearing aids with DSLv5 and NAL-NL2. Furuki S1, Sano H2, Kurioka T1, Ogiwara A, Nakagawa T1, Inoue R3, Umehara S3, Hara Y2, Suzuki K, Yamashita T1: Auris Nasus Larynx 2021/2; 48 (1): 75-81. (ŒÃ–؏Ȍá1, ²–ì@”£2, ŒI‰ª—²b1, ’†ì‹Mm1, ˆäã—ŠG3, ”~Œ´KŒb3, Œ´@—R‹I2, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”)

120034. [Œ´’˜] •â’®ŠíƒtƒBƒbƒeƒBƒ“ƒOƒ\ƒtƒg‚Å‚ÌNAL-NL, DSL–@‚̏‰ŠúÝ’è’l‚̑Ó–«. ŒÃ–؏Ȍá1, ²–ì@”£2, ŒI‰ª—²b1, ˆäã—ŠG3, ”~Œ´KŒb3, Œ´@—R‹I2, —é–ØŒbŽq2, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”): Audiology Japan 2020/7; 63 (4): 256-62.

120035. [Œ´’˜] ’nˆæƒOƒ‹[ƒvŠˆ“®ŽQ‰Á‚—îŽÒ‚Ì’®Šo•]‰¿‚Æ•â’®ŠíŽŽ’®. —é–ØŒbŽq1, ˆäã—ŠG2, ”~Œ´KŒb2, `@ŽáØ1, ´…@•½, ²–ì@”£1, ’†ì‹Mm3, ‰ª–{–ql3, ŽR‰º@‘ñ3 (1ˆã—Éq¶Šw•”, 2ƒŠƒnƒrƒŠ•”, 3Ž¨•@ˆôAE“ªèòŠO): Audiology Japan 2020/7; 63 (4): 263-71.

120036. [Œ´’˜] G“ŽüˆÍ”^ᇂ̏dÇ‰»‚ÉŠÖ—^‚·‚éˆöŽq‚ÌŒŸ“¢. “¡ì’¼–ç1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): Ž¨•@—Տ° 2020/7; 113 (7): 461-5.

310043. [Ç—á•ñ] Cryptococcal osteomyelitis of the Zygomatic bone: a case report. Matsuki T1, Miyamoto S1, Yamashita T1: BMC Infect Dis 2020/6; 20 (1): 399. (¼–؁@’1, ‹{–{r•ã1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

310044. [Ç—á•ñ] Transoral endoscopic surgical approach to venous malformation of the parapharyngeal space. Kimura A1, Seino Y1, Yamashita T1: SAGE Open Med Case Rep 2020/7; 8: 2050313X20938248. (–Ø‘ºŽé—¢1, ´–ì—R”y1, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO)

320036. [Ç—á•ñ] ŠOèò“®–¬‚Ì‘–sˆÙí‚𔺂Á‚½Ž¨‰º‘B‘½Œ`‘BŽî‚Ì1ŽèpÇ—á. ‹{“‡—æŽq, ¼–؁@’1, ´–ì—R”y1, Îˆä–L‘¾1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): “ªèò•”ŠO‰È 2020/5; 30 (2): 223-7.

320037. [Ç—á•ñ] Sistrunk–@‚Ő؏œ‚µ‚½bóãŠÇŠà‚Ì1—á. –àŽR•Û1, ¼–؁@’1, ‹{–{r•ã1, ‰Á”[Fˆê1, ’ç@ãĕ½, ŒÃ–؈»Žq1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): “ªèò•”ŠO‰È 2020/9; 30 (3): 427-31.

320038. [Ç—á•ñ] ‹CŠÇãA“ªˆŸ‘S“Eop‚ðŽ{s‚µ‚½º–剺i“WÄ”­A“ªŠà‚Ì2—á. ‹{–{r•ã1, ´–ì—R”y1, ¼–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕ½, —é–؈»Žq, –àŽR•Û1, Œ´“c—YŠî1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): “ªèò•”Šà 2020/11; 46 (3): 302-10.

320039. [Ç—á•ñ] ‹~ÏŒoŒû“IŽèpŒã‚ɏd“Ä‚È’x”­«oŒŒ‚𐶂¶‚½Ä”­’†ˆô“ªŠà‚Ì1—á. Œ´“c—YŠî1, ‹{–{r•ã1, ´–ì—R”y1, ¼–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕ½, ŒÃ–؈»Žq1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): “ªèò•”Šà 2020/12; 46 (4): 401-5.

521015. [‰ðà]y“ÁW: ‘æ7‰ñŠw‰ïƒGƒAƒƒ]ƒ‹ƒVƒ“ƒ|ƒWƒEƒ€uŽ¨•@ˆôA‰È—̈æ‚É‚¨‚¯‚éƒAƒŒƒ‹ƒM[Ž¾Š³‚ւ̋ǏŠE‹z“ü—Ö@vzƒAƒŒƒ‹ƒM[«•@‰Š‚É‚¨‚¯‚éƒlƒuƒ‰ƒCƒU[—Ö@. ‘å–ØŠ²•¶ (–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{Ž¨•@ˆôA‰ÈŠ´õÇEƒGƒAƒƒ]ƒ‹Šw‰ï‰ïŽ 2020/11; 8 (3): 176-9.

522104. [uÀ]yClinical Academic TopicszƒXƒM‰Ô•²ÇŠ³ŽÒ‚É‚¨‚¯‚éã‰º–Ɖu—Ö@‚ÆŒo”çRƒqƒXƒ^ƒ~ƒ“–ò•¹—p‚ÌŒø‰Ê. ‘å–ØŠ²•¶1, ‘å‹´Œ’‘¾˜Y1,2, “ߐ{–ì’qŒõ1,2, ”g‘½–ì‰l‘¾2, —é–Ø—§r2, ’†‘º‹g¬2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Ž¨•@ˆôAE“ªèòŠO): ƒAƒŒƒ‹ƒM[‚̗Տ° 2020/4; 40 (4): 290-3.

522105. [uÀ]y“ÁW: ‚—îŽÒ‚Ì‚ß‚Ü‚¢‚ðŽ¡‚·z‚—î‚ß‚Ü‚¢Š³ŽÒ‚ւ̃ŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“. ’·À‰p–¾1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2Ž¨•@ˆôAE“ªèò•”ŠO): Ž¨•@ˆôA‰ÈE“ªèò•”ŠO‰È 2020/5; 92 (6): 427-36.

522106. [uÀ]y“ÁW: •@‚Ƃ̂ǂ̋ǏŠŽ¡—Ázƒlƒuƒ‰ƒCƒU[‚ɂ‚¢‚Ä. ‘å–ØŠ²•¶ (–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): JOHNS 2020/6; 36 (6): 677-80.

522107. [uÀ]yClinical Academic Topicsz•@Ž¾Š³Ž¡—Âɂ¨‚¯‚鎩“®•@oôòŠíŽg—p‚Ì“K³‚ɂ‚¢‚Ä. ‘å–ØŠ²•¶1, ”g‘½–ì‰l‘¾2, ‘å‹´Œ’‘¾˜Y1,2, ‹{‰ºŒ\ˆê2, “ߐ{–ì’qŒõ1,2, ŽR–{Œ«Œá1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Ž¨•@ˆôAE“ªèòŠO): ƒAƒŒƒ‹ƒM[‚̗Տ° 2020/7; 40 (7); 556-9.

522108. [uÀ]y“ÁW: Š¿•ûˆãŠw“ü–å@Ž¨•@ˆôA‰È‚ÅŠ¿•û–ò‚ðŽg‚¢‚±‚È‚·zŽ„‚̐„§|‘ã•\“I‚ÈŠ¿•û–ò‚ÌŽg‚¢•û@•âÜ‚ð‚ª‚ñŽxŽ—Ö@‚É—p‚¢‚é. –àŽR•Û1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): Ž¨•@ˆôA‰ÈE“ªèò•”ŠO‰È 2020/11; 92 (12): 1010-3.

522109. [uÀ]y“ÁW: ƒJƒ‰[p’†ŽÊ^‚Å‚æ‚­‚í‚©‚é@’Bl‚É‚æ‚铪èò•”‚ª‚ñŠg‘åØœzA“ªEˆô“ªŽèp@A“ªˆŸ‘S“Ep|Šî–{“I‚ÈŽè‹Z‚Æ—¯ˆÓ‚·‚ׂ«“_‚Æ‚Í? ‹{–{r•ã (Ž¨•@ˆôAE“ªèòŠO): Ž¨•@ˆôA‰ÈE“ªèò•”ŠO‰È 2020/12; 92 (13): 1094-9.

522110. [uÀ]y“ÁW: ’®ŠoŒŸ¸‚̃|ƒCƒ“ƒg|‘Šú”­Œ©‚Æ“KØ‚ÈŽw“±|zœ“±’l‚ÌŒ©•û, ‚±‚̍œ“±’l‚͐³‚µ‚¢‚©. ²–ì @”£ (ˆã—Éq¶Šw•”): ENTONI 2021/1; 253: 5-10.

522111. [uÀ]yŒ¤Cƒm[ƒgzŽ¨•@ˆôA‰Èˆã‚É•K—v‚È•â’®Ší‚Ì’mŽ¯. ²–ì @”£ (ˆã—Éq¶Šw•”): Ž¨•@—Տ° 2021/2; 114 (2): 168-9.

530019. [‚»‚Ì‘¼ (ASO Author Reflections)] ASO Author Reflections: What is the Best Surgical Approach for Benign Tumors Arising from the Prestyloid Compartment in the Parapharyngeal Space? Matsuki T1: Ann Surg Oncol 2021/6; 28 (6): 3073-4. (¼–؁@’1: 1Ž¨•@ˆôAE“ªèòŠO)

[’˜@‘]

620096. [Šwp‘ (•ª’SŽ·•M)]yŽ¨•@ˆôA‰Èf—ÃQ&A (JOHNS 9ŒŽ‘‘卆)z[•@‰È—̈æ] 3. nasal cycle‚ÌŠT”O‚͍¡‚Ç‚¤‚È‚Á‚Ä‚¢‚Ü‚·‚©? —Տ°‚Æ‚ÌŠÖ˜A‚Í‚Ç‚¤‚Å‚µ‚傤‚©?, p.1148-50. ‘å–ØŠ²•¶ (–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/9”­s.

62097. [Šwp‘ (•ª’SŽ·•M)]yŽ¨•@ˆôA‰Èf—ÃQ&A (JOHNS 9ŒŽ‘‘卆)z[èò•”—̈æ, “ªèò•”Žîá‡] 7. Ä”­«‚̐º‘Ñ”’”ǂɂǂ̂悤‚ɑΉž‚µ‚Ü‚·‚©?, p.1288-90. ŽR‰º@‘ñ (Ž¨•@ˆôAE“ªèòŠO), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/9”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722191. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰)yƒlƒuƒ‰ƒCƒU[—Ö@‚̈À‘S«‚ÆŠ´õ‘΍ô|VŒ^ƒRƒƒiƒEƒCƒ‹ƒX‚ւ̑Ήž‚ÉŠw‚ԁ|zƒlƒuƒ‰ƒCƒU[—Ö@‚̈À‘S«‚ÆŠ´õ‘΍ô|“K‰ž‚ƈÀ‘S«. ‘å–ØŠ²•¶1 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ8‰ñ“ú–{Ž¨•@ˆôA‰ÈŠ´õÇEƒGƒAƒƒ]ƒ‹Šw‰ï‘‰ïEŠwpu‰‰‰ï (2020/9/25-26, 10/3-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

722192. [Šw‰ï (‘S‘)] (Žå‘è)y1-1: ’®Šo‚̉‘Y«|Šî‘bŒ¤‹†‚©‚ç—Տ°ŠŒ©‚܂Łz1. “`‰¹“ï’®‚ªå—‹_Œo‚É‹y‚Ú‚·‰e‹¿‚Ɛ_Œo‰Â‘Y«‚ɂ‚¢‚Ä. ŒI‰ª—²b1, ²–ì@”£2, ŒÃ–؏Ȍá1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ65‰ñ“ú–{’®ŠoˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/10/7-9), –¼ŒÃ‰® (ƒnƒCƒuƒŠƒbƒhŠJÃ), Audiology Japan 2020/9; 63 (5): 300.

722193. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‰¹‹¿«’®ŠoáŠQ‚É‚¨‚¯‚é嗋_Œo‚ÆŠC”n‚̏áŠQƒƒJƒjƒYƒ€‚ɂ‚¢‚Ä. ŒI‰ª—²b (Ž¨•@ˆôAE“ªèò•”ŠO): ‘æ30‰ñ“ú–{Ž¨‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/12), •Ÿ‰ª.

723596. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) èò’Å‘OcèՑэœ‰»Ç‚É‚æ‚éš‹‰ºáŠQ‚ɑ΂µœ‰»‘ƒØœ‚ðs‚¢ˆÙ‚È‚éŒoˆÜ‚ð‚½‚Ç‚Á‚½2Ç—á. ´–ì—R”y1, “¡ì’¼–ç1, ’†‘º‹g¬1, —é–Ø—§r1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): ‘æ43‰ñ“ú–{š‹‰ºˆãŠw‰ïŠwpu‰‰‰ï (2020/7/12), WebŠJÃ.

723597. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆô“ªH“¹•\ÝŠà‚ɑ΂·‚éŒoŒû“IŽèpŒã‚É”­¶‚µ‚½ˆÙŽž«‘¼‘ŸŠíŠà‚ÌŒŸ“¢. ‰Á”[Fˆê1, Œ˜“ce—˜2, ˆêŒË¹–¾3, ÎŒËŒªŽŸ2, ‹{–{r•ã1, ¼–؁@’1, ’ç@ãĕ½4, ŒÃ–؈»Žq1, –àŽR•Û1, Œ´“c—YŠî1, “c糁@‘2,5, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2Á‰»Ší“à, 3•a—, 4‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ44‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2020/7/17-27), WebŠJÃ.

723598. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒjƒ{ƒ‹ƒ}ƒu‚ð“Š—^‚µ‚½Ä”­E“]ˆÚ“ªèò•”G•½ã”çŠàÇ—á‚Ì”N—î•Ê‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢|‘½Ž{Ý‹¤“¯Œ¤‹†|. ‹ß“¡‹Mm, ‰ª–{ˆÉì, ²“¡GŽ÷, ‰ª“c‘ñ˜N, •šŒ©ç’ˆ, ‘•£’B•v, ŽO‰YO‹K, ¼–؁@’1, ŽR‰º@‘ñ1, ¬‘º@‹, ‚‹´G‘, ’ËŒ´´² (1Ž¨•@ˆôAE“ªèòŠO): ‘æ44‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2020/7/17-27), WebŠJÃ.

723599. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •úŽËüŽ¡—ÃŒã‚Ì‹~ÏA“ª‘S“Ep ˆô“ª”畆ᑗ\–h‚É‚¨‚¯‚éPIG‚Ì—LŒø«‚ÌŒŸ“¢|‘½Ž{Ý‹¤“¯Œ¤‹†|. ‰ª–{ˆÉì, ²“¡GŽ÷, ‰ª“c‘ñ˜N, ’ËŒ´´², ‹ß“¡‹Mm, •šŒ©ç’ˆ, ŽO‰YO‹K, ¼–؁@’1, ŽR‰º@‘ñ1, ¬‘º@‹ (1Ž¨•@ˆôAE“ªèòŠO): ‘æ44‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2020/7/17-27), WebŠJÃ.

723600. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ä”­“]ˆÚ‘Á‰t‘BŠà‚ɑ΂·‚éƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“, ƒhƒZƒ^ƒLƒZƒ‹•¹—p—Ö@‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢. ‰ª“c‘ñ˜N, ŒÜŒŽ——², ’·”örF, ‘•£’B•v, •šŒ©ç’ˆ, ¼–؁@’1, ‚‹´G‘, ŽO‰YO‹K, ’ËŒ´´², ‘½“c—Yˆê˜Y (1Ž¨•@ˆôAE“ªèòŠO): ‘æ44‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2020/7/17-27), WebŠJÃ.

723601. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚¨‚¢‚Ä“ªèò•”ŠO‰Èˆã‚ªŽ{s‚µ‚½—V—£”ç•ÙE‹ó’°‚É‚æ‚铪èò•”ÄŒšŽèp40—á‚ÌŒŸ“¢. ¼–؁@’1, ‹{–{r•ã1, ‰Á”[Fˆê1, ’ç@ãĕ½2, ŒÃ–؈»Žq1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ44‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2020/7/17-27), WebŠJÃ.

723602. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A“ªˆŸ‘S“Eop‚É‚¨‚¯‚鎡—ÊúŠÔ’Zk‚ÌŽŽ‚Ý. ‹{–{r•ã1, ¼–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕ½2, ŒÃ–؈»Žq1, –àŽR•Û1, Œ´“c—YŠî1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ44‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2020/7/17-27), WebŠJÃ.

723603. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) (Under 40 session—DG‰‰‘èÜŽóÜ) “ªèò•”•\ÝŠà‘S‘“o˜^’²¸@“àŽ‹‹¾f’f‚ÌŒŸ“¢. ‰Á”[Fˆê1, •@‰ª@¸, Œ˜“ce—˜2, “¡ˆä½Žu, ‹½“cŒ›ˆê, ÎŒ´@—§, –å”n‹v”üŽq, ‘åX@‘×, •“¡@Šw, —с@—²ˆê (1Ž¨•@ˆôAE“ªèòŠO, 2Á‰»Ší“à): ‘æ44‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2020/7/17-27), WebŠJÃ.

723604. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ã‰º–Ɖu—Ö@Ž{s’†‚̃XƒM‰Ô•²ÇŠ³ŽÒ‚É‚¨‚¯‚éŒo”çRƒqƒXƒ^ƒ~ƒ“–ò•¹—p‚Ì—L‰v«. ‘å–ØŠ²•¶1, —é–Ø—§r2, ’†‘º‹g¬2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Ž¨•@ˆôAE“ªèòŠO): ‘æ38‰ñ“ú–{Ž¨•@ˆôA‰È–ƉuƒAƒŒƒ‹ƒM[Šw‰ï (2020/9/15-16, 10/1-7), ‰¡•l (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723605. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —¿“ü‚èö‹Cƒ}ƒXƒN‘•’…‚Ì•@o¶—Šw“IˆÓ‹`‚ÌŒŸ“¢. ‘å–ØŠ²•¶1, ŽR–{Œ«Œá1,2, —é–Ø—§r2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Ž¨•@ˆôAE“ªèòŠO): ‘æ8‰ñ“ú–{Ž¨•@ˆôA‰ÈŠ´õÇEƒGƒAƒƒ]ƒ‹Šw‰ï‘‰ïEŠwpu‰‰‰ï (2020/9/25-26, 10/3-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723606. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆô“ª’ɂ𔺂¢d“Ä‚È‘SgÇó‚𗈂µ‚½Pasteurella Š´õÇ‚̈ê—á. ŽR–{Œ«Œá1,2, ×–ì_Žj2, ‘å–ØŠ²•¶1, ŽR‰º@‘ñ2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Ž¨•@ˆôAE“ªèòŠO): ‘æ8‰ñ“ú–{Ž¨•@ˆôA‰ÈŠ´õÇEƒGƒAƒƒ]ƒ‹Šw‰ï‘‰ïEŠwpu‰‰‰ï (2020/9/25-26, 10/3-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723607. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ý‘îŠÉ˜aƒPƒA‚É—p‚¢‚鐸–û‚É‚¨‚¯‚éh-CLAT ‚ð—p‚¢‚½”畆Š´ì«‚ÌŒŸ“¢. ‹gŽR—F“ñ, ‘å–ØŠ²•¶1 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ8‰ñ“ú–{Ž¨•@ˆôA‰ÈŠ´õÇEƒGƒAƒƒ]ƒ‹Šw‰ï‘‰ïEŠwpu‰‰‰ï (2020/9/25-26, 10/3-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723608. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŒ‰t“§ÍŠ³ŽÒ‚ɍ‡•¹‚µ‚½‹}«Š´‰¹“ï’®‚ÌŒŸ“¢. ŽR–{Œ«Œá1, ŒI‰ª—²b1, ŒÃ–؏Ȍá1, ²–ì@”£2, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ121‰ñ“ú–{Ž¨•@ˆôA‰ÈŠw‰ïŠwpu‰‰‰ï (2020/10/6), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723609. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Extracellular signal-regulated kinaseŒo˜H‘jŠQ‚É‚æ‚é‹CŠÇ‹·óƒ}ƒEƒXƒ‚ƒfƒ‹‚Ì‹·ó—\–hŒø‰Ê. –Ø‘ºŽé—¢1, r–؍Km, ²“¡‘׎i, –Ζ؍¹ç‘ã2, ŒI‰ª—²b1, ‰F–ìŒõ—S, aã‘å•ã, ‰–’J²_, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2¶•¨•¨—Œn): ‘æ121‰ñ“ú–{Ž¨•@ˆôA‰ÈŠw‰ïŠwpu‰‰‰ï (2020/10/6), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723610. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ï’®‚ªŠC”n‚̐_ŒoV¶‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚Ä. ŒI‰ª—²b1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): ‘æ121‰ñ“ú–{Ž¨•@ˆôA‰ÈŠw‰ïŠwpu‰‰‰ï (2020/10/6), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723611. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚鐺–剺ˆÙ•¨12Ç—á‚ÌŒŸ“¢. “¡ì’¼–ç1, ‘匴‘ìÆ1, ´–ì—R”y1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): ‘æ121‰ñ“ú–{Ž¨•@ˆôA‰ÈŠw‰ïŠwpu‰‰‰ï (2020/10/7), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723612. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —¿“ü‚èö‹Cƒ}ƒXƒN‚É‚æ‚é•@Çó‰ü‘PŒø‰Ê‚ÌŒŸ“¢. ‘å–ØŠ²•¶1, ‘å‹´Œ’‘¾˜Y1,2, “ߐ{–ì’qŒõ1,2, ”g‘½–ì‰l‘¾2, —é–؉떾 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Ž¨•@ˆôAE“ªèòŠO): ‘æ121‰ñ“ú–{Ž¨•@ˆôA‰ÈŠw‰ïŠwpu‰‰‰ï (2020/10/6-26), ‰ªŽR (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723613. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “`‰¹“ï’®‚ªå—‹_Œo‚É‹y‚Ú‚·‰e‹¿‚Ɛ_Œo‰Â‘Y«‚ɂ‚¢‚Ä. ŒI‰ª—²b1, ²–ì@”£2, ŒÃ–؏Ȍá1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ65‰ñ“ú–{’®ŠoˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/10/7), ˆ¤’m (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723614. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) NAL-NL–@EDSL–@‚É‚¨‚¯‚éƒtƒ@ƒ“ƒNƒVƒ‡ƒiƒ‹ƒQƒCƒ“‚ÌŒŸ“¢. ŒÃ–؏Ȍá1, ²–ì@”£2, ŒI‰ª—²b1, ”~Œ´KŒb, Œ´@—R‹I2, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ65‰ñ“ú–{’®ŠoˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/10/8), ˆ¤’m (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723615. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˜Vl«“ï’®ƒ^ƒCƒv•ª—Þ‚ÌŽŽ‚Ý. ¼è‘”ü1, ²–ì@”£2 (1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”): ‘æ65‰ñ“ú–{’®ŠoˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/10/9), ˆ¤’m (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723616. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆãŒ´«‘‰t•@˜R‚ð‹^‚Á‚½’x”­«”­Ç×‹Û«‘–Œ‰Š‚Ì2—á. óŒÃ—L‹IŽq1, —é–Ø—§r1, ”g‘½–ì‰l‘¾1,2, ‘å–ØŠ²•¶2, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ59‰ñ“ú–{•@‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/10/10), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723617. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Retrofacial approach‚ð—p‚¢‚½lH“àŽ¨–„‚ߍž‚ݏp‚̈ê—á. ŒÃ–؏Ȍá1, ŒI‰ª—²b1, ²–ì@”£2, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ30‰ñ“ú–{Ž¨‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/12), •Ÿ‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723618. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¶‰E”ñ‘Ώ̐«“ï’®‚É‚¨‚¯‚鈫’®Ž¨‚̌ꉹ’®Žæ”\’ቺ‚ɂ‚¢‚Ä. ŒI‰ª—²b1, ²–ì@”£2, ŒÃ–؏Ȍá1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ30‰ñ“ú–{Ž¨‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/12), •Ÿ‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723619. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) GJB 2ˆâ“`Žqc.235delC•ÏˆÙ‚ðhomo‚Å—L‚·‚é‹H‚ÈŒy“x“ï’®‚Ì1—á. r–؏®”ü1, –]ŒŽƒŽq2, ÎìˆŸŠóŽq, ìŒû仉À1, ‹g‘º‰ÃL2, ŒÃ–؏Ȍá3, ²–ì@”£4, ‚“cŽj’j1,5 (1ˆâ“`f—Õ”, 2ŽY‰È, 3Ž¨•@ˆôAE“ªèòŠO, 4ˆã—Éq¶Šw•”, 5‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È), “ú–{l—Þˆâ“`Šw‰ï‘æ65‰ñ‘å‰ï (2020/11/20), WebŠJÃ.

723620. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰Á—•½táŠQ‚ɑ΂·‚镽t‹Ø—̓gƒŒ[ƒjƒ“ƒO. —Ž‡@“Ö (Ž¨•@ˆôAE“ªèòŠO): ‘æ79‰ñ“ú–{‚ß‚Ü‚¢•½tˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/25), ‰¡•l.

723621. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’·ŠúˆùŽð‚É‚æ‚éƒAƒ‹ƒR[ƒ‹«¬”]•Ï«Ç‚Ì1—á. ’†ì‹M”V1, —Ž‡@“Ö1, ’·À‰p–¾1,2 (1Ž¨•@ˆôAE“ªèòŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ79‰ñ“ú–{‚ß‚Ü‚¢•½tˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/11/27), ‰¡•l.

723622. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‰ß‹Ž30”NŠÔ‚É‚¨‚¯‚鏬Ž™‹CŠÇØŠJÇ—á‚ÌŒŸ“¢. ‘匴‘ìÆ1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): ‘æ15‰ñ“ú–{¬Ž™Ž¨•@ˆôA‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2020/12/1), ‚’m (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723623. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒƒŒƒ“ƒxƒ‹ƒOÇŒóŒQ‚É‚æ‚é•@ˆôo•Â½•s‘S‚ɑ΂µˆô“ª•ÙŽèp‚ðŽ{s‚µ‚½ˆê—á. ´–ì—R”y (Ž¨•@ˆôAE“ªèòŠO): ‘æ44‰ñ“ú–{š‹‰ºˆãŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2021/3/6), WebŠJÃ.

723624. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚ÅŽ{s‚µ‚½‚—îŽÒ‚ɑ΂·‚鎭–쎮º–å•Â½p‚ÌŒoŒ±. ´–ì—R”y1, –àŽR•Û1, ’ç@ãĕ½2, ‹{–{r•ã1, —é–Ø—§r1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ33‰ñ“ú–{A“ª‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2021/3/6), WebŠJÃ.

731056. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ˆôA“ª‚ª‚ñ‚ɑ΂·‚éŒoŒû“IŽèp. ŽR‰º@‘ñ (Ž¨•@ˆôAE“ªèò•”ŠO): ‹ãB‘åŠw Head and Neck Cancer Expert Web Meeting (2020/9/17), WebŠJÃ.

731057. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) “ªèò•”‚ª‚ñ‚Ì’áNPŽ¡—ÂƊ¿•û–ò‚Ì–ðŠ„. ŽR‰º@‘ñ (Ž¨•@ˆôAE“ªèò•”ŠO): H“cŒ§Ž¨•@ˆôA‰ÈŠwpu‰‰‰ï (2021/3/28), WebŠJÃ.

732063. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒ[ƒNƒVƒ‡ƒbƒv)‚Ñ‚Ü‚ñ«H“¹áz¹‚ð’悵‚½ƒp[ƒLƒ“ƒ\ƒ“•aÇ—áE‘æ“ñ•ñ`Žèp‰î“ü‚É‚æ‚é•Ï‰»`. ’rŽR‡Žq, “c‘º¹–ç1, “¿“c@ãÄ, Œö•¶@Ê, ’r’†’B‰›, ‘“cŒö’j, ’·’JìˆêŽq (1Ž¨•@ˆôAE“ªèò•”ŠO): ‘æ19‰ñ‹ú˜Hƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒ[ƒNƒVƒ‡ƒbƒv (2020/8/21-22), ‹ú˜H.

732064. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (Šî’²u‰‰) Ä”­“ªèò•”Šà‚É‚¨‚¯‚éIOãŽsŒã‚ÌŽ¡—Õûj‚ɂ‚¢‚Ä. ‹{–{r•ã (Ž¨•@ˆôAE“ªèò•”ŠO): Head & Neck Expert Meeting (2020/11/19), WebŠJÃ.

732065. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒZƒ~ƒi[) dÇSgáŠQŽ™EŽÒ‚̈ã—à (‹CŠÇØŠJ‚ɂ‚¢‚Ä). ‘匴‘ìÆ (Ž¨•@ˆôAE“ªèò•”ŠO): —ߘa2”N“x‘Š–ÍŽsdÇSgáŠQŽ™ (ŽÒ) ŠÅŒìŒ¤CŽ–‹Æ (2020/12/12), WebŠJÃ.

733114. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Ž¨•@ˆôA‰È‚ÌŽ‹“_‚©‚çl‚¦‚éƒ}ƒXƒN‘•—p‚ÌŒ÷ß. ŽR–{Œ«Œá1,2, ‘å–ØŠ²•¶1, ‘å‹´Œ’‘¾˜Y1,2, “ߐ{–ì’qŒõ1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Ž¨•@ˆôAE“ªèòŠO): ‘æ135‰ñ“úŽ¨•@é‹ÊŒ§’n•û•”‰ïŠwpu‰‰‰ï (2020/10/4), ‰Y˜a.

733115. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Ä”­E“]ˆÚ“ªèò•”Šà‚ɑ΂·‚é ƒjƒ{ƒ‹ƒ}ƒu‚̈ʒu•t‚¯ ƒvƒ‰ƒ`ƒiŠ´Žó«Ç—á‚É‚¨‚¯‚錟“¢. ‹{–{r•ã1, ¼–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕ½2, –àŽR•Û1, Œ´“c—YŠî1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): Head and Neck Immuno-Oncology web Live Seminar in Kanagawa (2020/10/15), ‰¡•l.

733116. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) NCCNƒKƒCƒhƒ‰ƒCƒ“‚©‚ç‚Ý‚½Ä”­“ªèò•”Šà‚É‚¨‚¯‚éIOãŽsŒã‚ÌŽ¡—Õûj‚ɂ‚¢‚Ä. ‹{–{r•ã (Ž¨•@ˆôAE“ªèò•”ŠO): Head & Neck Expert Meeting (2020/11/20), WebŠJÃ.

733117. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ãˆô“ª‘½Œ`‘BŽî‚Ì1—á. ’†‘º‹g¬1, ‹{–{r•ã1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): “ú–{Ž¨•@ˆôA‰ÈŠw‰ï_“ސ쌧’n•û•”‰ï‘æ193‰ñŽ¨•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠwpu‰‰‰ï (2020/11/28), WebŠJÃ.

733118. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “îŒûŠWEãˆô“ª‚̍‡•¹Øœ‚ðs‚Á‚½‰ºˆô“ªŠàÄ”­‚Ì1—á. ˜’ˏ[Œb1, ‹{–{r•ã1, ¼–؁@’1, Œ´“c—YŠî1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): “ú–{Ž¨•@ˆôA‰ÈŠw‰ï_“ސ쌧’n•û•”‰ï‘æ194‰ñŽ¨•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠwpu‰‰‰ï (2021/3/27), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110021. [Œ´’˜] Activity-Dependent Neurodegeneration and Neuroplasticity of Auditory Neurons Following Conductive Hearing Loss in Adult Mice. Kurioka T1, Mogi S2, Tanaka M3, Yamashita T1: Cell Mol Neurobiol 2021/1; 41 (1): 31-42. (ŒI‰ª—²b1, –Ζ؍¹ç‘ã2, “c’†@Šw3, ŽR‰º@‘ñ1: 1Ž¨•@ˆôAE“ªèòŠO, 2¶•¨•¨—Œn, 3ƒoƒCƒIƒCƒ[ƒWŒ¤‹†ƒZ)

'19-120004. [Œ´’˜] A“ªˆŸ‘S“Eop (supracricoid laryngectomy) ‚Ì“K‰ž‚ÆŒÀŠE|Øœü‚ÌŠÏ“_‚©‚ç‚Ý‚½ŒŸ“¢|. ‹{–{r•ã1, ´–ì—R”y1, ¼–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕ½, —é–؈»Žq, –àŽR•Û1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): A“ª 2019/12; 31 (2): 84-91.

'19-320004. [Ç—á•ñ] ’·ŠúŒo‰ß‚µ‚½ˆâŽcƒK[ƒ[‚ðŠj‚Æ‚µ‚½•@ÎÇ‚Ì1—á. ŽR–{Œ«Œá1, ¼–؁@’1, Îˆä–L‘¾1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO): Ž¨•@‚ƗՏ° 2020/3; 66 (2): 47-51.

'19-522006. [uÀ]y“ÁW: ƒƒjƒG[ƒ‹•a\‰Ÿ‚³‚¦‚Ä‚¨‚«‚½‚¢f’fEŽ¡—ẪRƒc\z…‘ãŽÓ‚Ɛ…•ªÛŽæ—Ö@ (hydration thrapy). ’·À‰p–¾1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2Ž¨•@ˆôAE“ªèò•”ŠO): ENTONI 2019/7; 234: 89-9.

'19-540005. [‚»‚Ì‘¼ (uK‰ï´˜^)] ‚ß‚Ü‚¢‚̃ŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“. ’·À‰p–¾1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2Ž¨•@ˆôAE“ªèò•”ŠO): ‘æ36‰ñ“ú–{‚ß‚Ü‚¢•½tˆãŠw‰ïˆãŽtuK‰ï´˜^W 2019-7.

[’˜@‘]

'19-620012. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj2020”N”Ł@Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚éz‘æ25ÍŽ¨•@ˆôA‰ÈŽ¾Š³@ˆôA“ªˆÙíŠ´Ç, p.1606-7. ŽR‰º@‘ñ (Ž¨•@ˆôAE“ªèò•”ŠO), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@½, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2020/1”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

'19-722005. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ˆÀ‘S‚É”z—¶‚µ‚½Šà–ò•¨—Ö@@Š¿•û—Ö@. ŽR‰º@‘ñ (Ž¨•@ˆôAE“ªèòŠO): ‘æ30‰ñ“ú–{‹CŠÇH“¹‰ÈŠw‰ï”F’è‹CŠÇH“¹‰Èê–åˆã‘å‰ï (2020/2/16), ‰¡•l.

'19-723029. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚¨‚¯‚éŠç–ʐ_Œo–ƒáƒÇ—á‚Ì”N—î•ÊŽ¡—×\Œã‚ÌŒŸ“¢. ŒI‰ª—²b (Ž¨•@ˆôAE“ªèòŠO): ‘æ29‰ñ“ú–{Ž¨‰ÈŠw‰ï ‘‰ïEŠwpu‰‰‰ï (2019/10/10), ŽRŒ`.

'19-723030. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒIƒgƒKƒC‰º”ç•Ù‚É‚æ‚èŠg‘åA“ª‘S“EoŒã‚̈ô“ªÄŒš‚ðs‚Á‚½‚—–åãŠà‚Ì2—á. ‹{–{r•ã1, ´–ì—R”y1, ¼–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕ½2, —é–؈»Žq1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Ž¨•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ30‰ñ“ú–{“ªèò•”ŠO‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2020/1/30), ‰«“ê.


¸_‰ÈŠw

[Šwp˜_•¶]

110381. [Œ´’˜] Stroking a Real Horse Versus Stroking a Toy Horse: Effects on the Frontopolar Area of the Human Brain. Matsuura A, Aiba N, Yamamoto H1,2, Takahashi M2,3, Kido H, Suzuki T, Bando Y1,4: Anthrozošs 2020/7; 33 (5): 673-83. (ŽR–{G–¾1,2, ‚‹´@Œb2,3, â“Œ—R‹I1,4 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¸_, 3–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@, 4¬Ž™)

110382. [Œ´’˜] A reliable method to reduce electrode impedances during electroconvulsive therapy. Shimano T1, Sawayama E1, Oishi S1, Natsuyama T1, Takizawa T1, Saito M1, Tanaka K2, Miyaoka H1: Kitasato Med J 2021/3; 51 (1): 19-23. (“‡–ì•ü–ç1, àVŽRŒb”g1, ‘åÎ@’q1, ‰ÄŽR@‘ì1, ‘êàV‹B–î1, âV“¡³”Í1, “c’†Žr2, ‹{‰ª@“™1: 1¸_, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

220002. [€Œ´’˜] ”F’mÇ‚Ì‚ ‚él‚̉Ƒ°‰îŒìŽÒ‚ɑ΂·‚éS—‹³ˆçƒvƒƒOƒ‰ƒ€‚Ì—LŒø«‚ÌŒŸ“¢. ›I@‘P‹M1, ‘åÎ@’q1, ‘êàV‹B–î1, ‹{‰ª@“™1 (1¸_): ¸_‰ÈŽ¡—Êw 2021/3; 36 (3): 357-62.

320040. [Ç—á•ñ] Ž¡—Èæ‚Æ‚³‚ê‚錌’†”Z“x‚Å‚ ‚é‚É‚à‚©‚©‚í‚炸ƒŠƒ`ƒEƒ€’†“ŏǏó‚ð’悵‚½ˆê—á. —é–Ø—´‘¾˜Y1, ›I@‘P‹M1, ‘åÎ@’q1, ‘êàV‹B–î1, ŽRŠp@Œ\1, ŸNˆäGŽ÷1, ’©‘q’•¶1, “‡–ì•ü–ç1, ˆäã•üŽq1, ¡áG’1, âV“¡³”Í1, ‹{‰ª@“™1 (1¸_): ¸_‰ÈŽ¡—Êw 2020/7; 35 (7): 771-6.

320041. [Ç—á•ñ] Ž©‚çuŽ„‚̃gƒŠƒZƒcv‚ðì¬‚µ‚½Ž©•ÂƒXƒyƒNƒgƒ‰ƒ€Ç‚Z¶Ç—á‚©‚ç‚̗Տ°“I‹³ŒP. ˆäãŸ•v1, ‹{‰ª@“™1 (1¸_): Ž™“¶Â”N¸_ˆãŠw‚Æ‚»‚̋ߐڗ̈æ 2020/8; 61 (4): 453-66.

522112. [uÀ] “ÁW: ‚È‚º¸_‰Èˆã‚̓ƒfƒBƒA‚ɏî•ñ‚𔭐M‚µ, •\Œ»‚·‚é‚Ì‚©?z‚È‚ºƒ}ƒXƒƒfƒBƒA‚ð’Ê‚µ‚Ä”­Œ¾‚·‚é‚©. ‹{‰ª@“™ (¸_): ¸_‰ÈŽ¡—Êw 2020/7; 35 (7): 723-5.

522113. [uÀ]y“ÁW:u‘ål‚Ì”­’BáŠQv‚ð‚ß‚®‚éÅ‹ß‚Ì“®Œüz¬lŒã‚É”­’BáŠQ‚ª‹^‚í‚ꂽŽ–—á‚ւ̑Ήž. ‹{‰ª@“™ (¸_): ¸_ˆãŠw 2020/7; 62 (7): 1011-7.

522114. [uÀ] ˆê”ʐ¸_‰ÈŠO—ˆ‚É‚¨‚¯‚鎩•ÂƒXƒyƒNƒgƒ‰ƒ€Ç‚̐S—¸’è. ˆäãŸ•v1, ’ÍèS–ç2 (1¸_, 2—Տ°S—Žº): ‘‡•a‰@¸_ˆãŠw 2020/7; 32 (3): 309-16.

522115. [uÀ]y“ÁW: ”­’BáŠQ‚ƐEˆæ‚É‚¨‚¯‚éƒTƒ|[ƒg‚ðl‚¦‚éz1. ”­’BáŠQ‚ð’m‚é. ‹{‰ª@“™ (¸_): ŽY‹ÆˆãŠwƒWƒƒ[ƒiƒ‹ 2020/9; 43 (5): 4-8.

522116. [uÀ] Œü¸_–ò‚Ì•›ì—p‘΍ô: ‚Ó‚ç‚‚«E‚ß‚Ü‚¢E–°‹C. ¬ì—zŽq1, ‹{’n‰p—Y1, ‹{‰ª@“™1 (1¸_): ƒyƒCƒ“ƒNƒŠƒjƒbƒN 2020/12; 41 (12): 1665-70.

522117. [uÀ]yƒVƒŠ[ƒY21¢‹I‚ÌŒ’N‚Æ‚Í? 9z“ú–{‚̈ˑ¶Ç‘΍ô. Š—¶—TŽi1, ‹{‰ª@“™1 (1¸_): ‚ ‚¢‚Ý‚Á‚­ 2020/12; 41 (4): 94-8.

522118. [uÀ]y“Á•ÊŠé‰æ: SgˆãŠw‚ðê–å‚Æ‚·‚éˆãŽt‚É’m‚Á‚Ä‚à‚ç‚¢‚½‚¢‚±‚Ɓz¸_‰Èˆã‚Ì—§ê‚©‚ç. ‹{‰ª@“™ (¸_): SgˆãŠw 2020/12; 60 (8): 703-6.

522119. [uÀ]y“ÁW: ˜F•ÓŠÕ˜bz‚¤‚•a‚̓XƒgƒŒƒX‚È‚µ‚É‹N‚±‚Á‚ÄŽ©‘R‚ÉŽ¡‚é. ‹{‰ª@“™ (¸_): “ú–{ˆãŽ–V•ñ 2021/1; 5045: 28-9.

522120. [uÀ]y“ÁW: u•W€“I¸_‰Èˆãv‚Ö‚Ì‚·‚·‚߁|ƒvƒ‚ƌĂ΂ê‚邽‚ß‚ÉŽ„‚½‚¿‚͉½‚ðK“¾‚·‚ê‚΂悢‚©|Iz¬l‚Ì”­’BáŠQ‚ð‚݂邽‚ß‚Ì•W€“I’mŽ¯‚Æ‹Z”\|Ž©•ÂƒXƒyƒNƒgƒ‰ƒ€Ç‚𒆐S‚Ɂ|. ‹{‰ª@“™1, ‘åÎ@’q1, ‹{’n‰p—Y1 (1¸_): ¸_‰ÈŽ¡—Êw 2021/2; 36 (2): 189-93.

540044. [‚»‚Ì‘¼ (ƒRƒƒ“ƒg)] Œ´’˜˜_•¶u¸_•ªÍ“IƒAƒZƒXƒƒ“ƒg‚Ɛ¸_ˆãŠw“IƒAƒZƒXƒƒ“ƒgv(”¼“c‘) ‚ւ̃Rƒƒ“ƒg. ˆäãŸ•v (¸_): Â”NŠú¸_—Ö@ 2020/12; 16 (1): 118-9.

[’˜@‘]

620098. [Šwp‘ (•ª’SŽ·•M)]ySgˆãŠw—pŒêŽ–“T@‘æ3”Å (e-Book)z“V•Û‰p–¾1, ˆ¾¶CŽi, Â–؈ºŽq, Â–ì“N•F, ‘¼ (1¸_), •Ò: “ú–{SgˆãŠw‰ï—pŒêˆÏˆõ‰ï, “ú–{S—Óà‰ÈŠw‰ïŠwpŠé‰æˆÏˆõ‰ï, ŽO—֏‘“X, “Œ‹ž, 2020/11”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722194. [Šw‰ï (‘S‘)] (‰ï’·Šé‰æƒVƒ“ƒ|ƒWƒEƒ€) ¡“ú‚̐¸_ˆãŠw‚ÌŒŸØ|ƒoƒCƒIƒ}[ƒJ[‚ðŽ‚½‚È‚¢¸_ˆãŠw‚Ì–]‚Ü‚µ‚¢q˜H‚Ƃ́|PS1-4u¸_ˆã—Â̎ç”õ”͈́v. ‹{‰ª@“™ (¸_): ‘æ116‰ñ“ú–{¸__ŒoŠw‰ïŠwp‘‰ï (2020/9/28), WebŠJÃ.

722195. [Šw‰ï (‘S‘)] (ˆÏˆõ‰ïƒVƒ“ƒ|ƒWƒEƒ€) ˆã—Öʐڂ©‚琸_—Ö@‚Ö: ¸_—Ö@ˆÏˆõ‰ï. ‚‹´@Œb (¸_): ‘æ116‰ñ“ú–{¸__ŒoŠw‰ïŠwp‘‰ï (2020/9/29), WebŠJÃ.

722196. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) ¬lŒã‚ÉŽ©•ÂƒXƒyƒNƒgƒ‰ƒ€Ç‚ð‹^‚í‚ꂽŽ–—á‚ւ̑Ήž. ‹{‰ª@“™ (¸_): ‘æ36‰ñ“ú–{ƒXƒgƒŒƒXŠw‰ïŠwp‘‰ï (2020/10/25), WebŠJÃ.

722197. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) ¸_—Ö@‚Ì•›ì—p‚ƃCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg. ‹{‰ª@“™ (¸_): “ú–{¸_•ªÍŠw‰ï‘æ18‰ñE‘æ19‰ñ‡“¯‘å‰ï (2021/3/20), WebŠJÃ.

722198. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·z‘åŠw•a‰@¸_‰È‚É‚¨‚¯‚鐬lŠúADHDf—Á|’ʏíŠO—ˆu‘Ήžˆãv‚É‚æ‚éf—Â̎ÀÛ|. ˆäãŸ•v1, ¼‰ªF—T (1¸_): ‘æ33‰ñ“ú–{‘‡•a‰@¸_ˆãŠw‰ï‘‰ï (2020/12/13), WebŠJÃ.

731058. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) Žq‚Ç‚à‚̃Q[ƒ€Ç‚Ì—‰ð‚ƑΉž. ˆäãŸ•v (¸_): ‹ž“s‹³ˆç‘åŠw“Á•ÊŽx‰‡‹³ˆçƒZƒ~ƒi[ (2020/12/12), WebŠJÃ.


•úŽËü‰ÈŠw (‰æ‘œf’fŠw)

[Šwp˜_•¶]

110383. [Œ´’˜] Suboptimal modulation of radiation dose in the computed tomography component of whole-body positron emission tomography/computed tomography. Inoue Y1, Adachi M1, Shimizu H1, Nagahara K2, Itoh H2, Takano M2, Jinguji K2: Radiat Prot Dosimetry 2020/12; 192 (1): 69-74. (ˆäã—D‰î1, ˆÀ’B‚Ý‚¸‚Ù1, ´…Gˆê1, ‰iŒ´˜aŒ›2, ˆÉ“¡Š°‘×2, ‚–쐽l2, _‹{Ž›Œö“ñ2: 1•úŽËü (‰æ‘œ), 2•úŽËü•”)

110384. [Œ´’˜] Predictive factors of truncation artifacts in the arterial phase of Gd-EOB-DTPA-enhanced MRI: a nationwide multicenter study. Tsurusaki M, Sofue K, Onishi H, Goshima S, Higaki A, Isoda H, Haradome H1,2, Ishii K, Murakami T: Jpn J Radiol 2021/2; 39 (2): 165-77. (Œ´—¯OŽ÷1,2: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2•úŽËü (‰æ‘œ))

110385. [Œ´’˜] Estimation of radiation dose in CT venography of the lower extremities: phantom experiments using different automatic exposure control settings and scan ranges. Inoue Y1, Itoh H2, Nagahara K2, Takahashi Y2: Radiat Prot Dosimetry. 2020/6; 188 (1): 109-16. (ˆäã—D‰î1, ˆÉ“¡Š°‘×2, ‰iŒ´˜aŒ›2, ‚‹´—R‰À2: 1•úŽËü (‰æ‘œ), 2•úŽËü•”)

110386. [Œ´’˜] Pulmonary Artery-Bronchus Fistula Treated with a Combination of Bare Metal Stent, Metallic Coil, and N-Butyl Cyanoacrylate. Woodhams R1, Fujii K1, Takigawa M, Inoue Y1: J Vasc Interv Radiol 2021/1; 32 (1): 152-5. (ƒEƒbƒhƒnƒ€ƒX—æŽq1, “¡ˆä@Š]1, ˆäã—D‰î1: 1•úŽËü (‰æ‘œ))

110387. [Œ´’˜] Voice, rhythm, and beep stimuli differently affect the right hemisphere preponderance and components of stimulus-preceding negativity. Ohgami Y, Kotani Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: Biol Psychol 2021/3; 160: 108048. (ˆäã—D‰î1: 1•úŽËü (‰æ‘œ))

520015. [‘à] ˆã—ÃŒ»ê‚É‚¨‚¯‚é–@—߉ü³‚É”º‚¤‹ï‘Ì“I‚Ȉã—ÕúŽËüˆÀ‘SŠÇ—‘̐§‚̑Ήž‚ƈã—ÕúŽËüˆÀ‘SŠÇ—ŽÒ‚Ì–ðŠ„|–k—¢‘åŠw‚̏ꍇ|. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ˆã—ÕúŽËü–hŒì 2020/9; 83: 31-2.

522121. [uÀ]y“ÁW1: ˆê‹“Ð‰î! IVRƒKƒCƒhƒ‰ƒCƒ“zŽY‰ÈŠë‹@“IoŒŒ‚ɑ΂·‚éIVRŽ{sˆãƒKƒCƒhƒ‰ƒCƒ“‚Ì—v“_. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ)): Rad Fan 2020/4; 18 (5): 35-9.

522122. [uÀ]y“ÁW: ’N‚É‚à•·‚¯‚È‚¢IVR‚ÌŠî–{FŠî–{Žè‹Z|•”ˆÊ•ÊŒŒŠÇƒJƒe[ƒeƒ‹‚Ì‘I‘ð‚Æ‘}“ü–@|z•”ˆÊ•ÊŒŒŠÇƒJƒe[ƒeƒ‹‚Ì‘I‘ð, ‘}“ü‚̃Rƒc‚Æ‘¢‰e–@@‹¹•”“®–¬‘¢‰e‚ƍǐðp@‹CŠÇŽxE˜]ŠÔ“®–¬‘¢‰e‚ƍǐðp. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ)): —Տ°‰æ‘œ 2020/7; 36 (7): 737-47.

522123. [uÀ]y“ÁW: ƒrƒMƒi[‚Ì‚½‚ß‚Ì“ªŒz•”‰æ‘œf’f|Q&AƒAƒvƒ[ƒ`|z5. Çó‚©‚ç‚̃Aƒvƒ[ƒ`@Q3Šáâ|•”‚̍œÜ‚ÅŒ©“¦‚µ‚Ä‚Í‚¢‚¯‚È‚¢‡•¹Ç‚ð‹³‚¦‚Ä‚­‚¾‚³‚¢. •‚F—´‘¾˜Y (•úŽËü (‰æ‘œ): ‰æ‘œf’f 2020/7; 40 (9): 986-7.

522124. [uÀ]y“ÁW: ƒrƒMƒi[‚Ì‚½‚ß‚Ì“ªŒz•”‰æ‘œf’f|Q&AƒAƒvƒ[ƒ`|z5. Çó‚©‚ç‚̃Aƒvƒ[ƒ`@Q4 Le FortœÜ‚̃^ƒCƒv‚Ɠlje‚̃|ƒCƒ“ƒg‚ð‹³‚¦‚Ä‚­‚¾‚³‚¢. •‚F—´‘¾˜Y (•úŽËü (‰æ‘œ): ‰æ‘œf’f 2020/7; 40 (9): 988-9.

522125. [uÀ]y“ÁW: ƒjƒ…[ƒm[ƒ}ƒ‹Žž‘ã‚̐f—ÕúŽËü‹ZŽt‚ð‚ß‚´‚µ‚ā|ê–å‹ZŽt”F’萧“xE‹Æ–±Šg‘åE“lje‚̕⏕‚É‚¨‚¯‚éŠú‘Ò‚³‚ê‚é–ðŠ„‚Æ’S‚¤‚ׂ«Žg–½|zIV. Ž¿‚̍‚‚¢ƒ`[ƒ€ˆã—Â̎ÀŒ»‚ÉŒü‚¯‚½“lje‚̕⏕‚Ö‚ÌŠú‘ҁ@1.•úŽËü‰Èˆã‚ª‹‚ß‚é“lje‚̕⏕‹Æ–±. ˆäã—D‰î (•úŽËü (‰æ‘œ)): INNERVISION 2020/12; 35 (12): 54-5.

522126. [uÀ]y“ÁW: ŠÌ’_äX‚̐VWHO•ª—ÞŠ®‘S‰ðàz—ǐ«ŠÌŽîᇁ|ŒÀ‹Ç«Œ‹ß«‰ßŒ`¬ (FNH), ŠÌ×–E‘BŽî (HCA)|. Œ´—¯OŽ÷1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2•úŽËü (‰æ‘œ)): ‰æ‘œf’f 2021/2; 41 (3): 268-84.

[’˜@‘]

620099. [Šwp‘ (•ª’SŽ·•M)]y“ªèò•”‰æ‘œf’f‚ÌŠ¨ƒhƒRƒNEOz¡Ž¾Š³•Ò@08 •@•›•@o@³í‰ð–U‚Ɖ摜‰ð–U, p.116-55. •‚F—´‘¾˜Y1 (1•úŽËü (‰æ‘œ), •Ò: •‚F—´‘¾˜Y1, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/12”­s.

621004. [Šwp‘ (•ÒW)]y“ªèò•”‰æ‘œf’f‚ÌŠ¨ƒhƒRƒNEOz•Ò: •‚F—´‘¾˜Y1 (1•úŽËü (‰æ‘œ), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/12”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713047. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Functional Connectivity of Amygdala in a Simple and Short Picture Viewing Task. Kotani Y, Yoshida N, Ohgami Y, Kunimatsu A, Kiryu S, Inoue Y1: Annual Meeting of the Organization of Human Brain Mapping (2020/6/23-7/3), WebŠJÃ, Abstract Listings 2020/6; p.144. (ˆäã—D‰î1: 1•úŽËü (‰æ‘œ))

713048. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Connectivity Dynamics of the Right Anterior Insula Revealed by EEG Source Analysis. Ohgami Y, Kotani Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: Annual Meeting of the Organization of Human Brain Mapping (2020/6/23-7/3), WebŠJÃ, Abstract Listings 2020/6; p.144. (ˆäã—D‰î1: 1•úŽËü (‰æ‘œ))

713049. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The Effect of Task Length on Functional Connectivity of the Amygdala in a Picture Viewing Task. Kotani Y, Ohgami Y, Yoshida N, Kunimatsu A, SKiryu S, Inoue Y1: 2020 Virtual Annual Meeting of Society for Psychophysiological Research (2020/10/4-11), WebŠJÃ, Psychophysiology 2020/10; 57 (Supplement1): S20. (ˆäã—D‰î1: 1•úŽËü (‰æ‘œ))

713050. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Information Flow of the Right Anterior Insula Revealed by fMRI-Constrained EEG Source Analysis. Ohgami Y, Kotani Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: 2020 Virtual Annual Meeting of Society for Psychophysiological Research (2020/10/4-11), WebŠJÃ, Psychophysiology 2020/10; 57 (Supplement1): S35. (ˆäã—D‰î1: 1•úŽËü (‰æ‘œ))

721023. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ˆã—ÕúŽËü”í‚΂­‚Æ‚»‚Ì–hŒì. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ20‰ñ“ú–{ŠjˆãŠw‰ït‹G‘å‰ï (2020/5/14), WebŠJÃ.

721024. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ŠjˆãŠw‚É‚¨‚¯‚éˆã—ÈÀ‘SEŠÖ˜A–@‹KE—Ï— ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ20‰ñ“ú–{ŠjˆãŠw‰ït‹G‘å‰ï (2020/5/14), WebŠJÃ.

721025. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ˆã—ÈÀ‘SE•úŽËü–hŒì2u‰ü³ˆã—Ö@‚̏…Žç (Ž©Ž{Ý‚Å‚ÌŽ–—áÐ‰î)v. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ79‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï‘‰ï (2020/5/15), WebŠJÃ.

721026. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ü—ÊŠÇ—‚ÌŽÀ‘H: ˆã—ÕúŽËü‚̈À‘S—˜—p‚ÉŒü‚¯‚Ä. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ79‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï‘‰ï (2020/5/15), WebŠJÃ.

722199. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Œ»ê‚É‚¨‚¯‚éf—×p•úŽËü‚̈À‘SŠÇ—‘̐§‚̍\’zuˆã—ÕúŽËüˆÀ‘SŠÇ—Ó”CŽÒ‚ªs‚¤‚ׂ«‹Æ–±v. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ79‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï‘‰ï (2020/5/15), WebŠJÃ.

722200. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y‰t‘̍ǐ𕨎¿ (NBCA) ‚ð‹É‚ß‚é!@ƒGƒLƒXƒp[ƒg‚Ö‚Ì“¹zŽY‰ÈoŒŒ‚É‚¨‚¯‚éNBCA‚ð—p‚¢‚½“®–¬Çðp‚Ì•K—v«. ƒEƒbƒhƒnƒ€ƒX—æŽq1, “¡ˆä@Š]1, ¼‰iŒh“ñ1, ŒIŒ´—S‘¾˜N2 (1•úŽËü (‰æ‘œ), 2‹~–½): ‘æ49‰ñ“ú–{IVRŠw‰ï‘‰ï (2020/8/25), _ŒË, “ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ïŽGŽ 2020/8; 35 (Suppl): p.123.

723625. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰¹ºŽhŒƒ‚Ì—\Šú‚ÍŽhŒƒæs‰A«“dˆÊiSPNj‚Ì‘OŠú¬•ª‚ð•ŠŠˆ‚³‚¹‚é. ‘åãi”ü, ¬’J‘ב¥, ‹g“c‹X´, š ¼@‘, ‹Ë¶@–Î, ˆäã—D‰î1 (1•úŽËü (‰æ‘œ)): ‘æ38‰ñ“ú–{¶—S—Šw‰ï‘å‰ï (2020/5/23`24), WebŠJÃEL“‡, ‘æ38‰ñ“ú–{¶—S—Šw‰ï‘å‰ïƒvƒƒOƒ‰ƒ€ 2020; p.7.

723626. [Šw‰ï (‘S‘)] (“dŽqƒ|ƒXƒ^[) S‘ŸMRI‚Őt×–EŠà‚ð”­Œ©‚³‚ꂽ1—á. ˆÀ’B‚Ý‚¸‚Ù1, ’r“crº2, ŽOˆäN•½1, ¼‰iŒh“ñ1, •‚F—´‘¾˜Y1, ˆäã—D‰î1 (1•úŽËü (‰æ‘œ), 2ˆîéŽs—§•a‰@•úŽËü‰È): ‘æ40‰ñ“ú–{‰æ‘œˆãŠw‰ïŠwpW‰ï (2021/2/25-5/25), WebŠJÃ (2021/2/20‘S‘Šw‰ï“dŽqƒ|ƒXƒ^[), JJDI 2021/2/20; 39: p.91.

731059. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ˆã—Ö@Ž{s‹K‘¥‰ü³Œã‚̈ã—ÃŒ»ê‚É‚¨‚¯‚é‘Ήž‚ÌŽÀÛ. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ69‰ñˆã—ÕúŽËüˆÀ‘SŠÇ—uK‰ï (2020/10/25), WebŠJÃ.

731060. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ˆã—Ö@Ž{s‹K‘¥‰ü³Œã‚̈ã—ÃŒ»ê‚É‚¨‚¯‚é‘Ήž‚ÌŽÀÛ. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ70‰ñˆã—ÕúŽËüˆÀ‘SŠÇ—uK‰ï (2020/11/15), WebŠJÃ.

731061. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) f—×p•úŽËü‚̈À‘SŠÇ—‚Ì–@§‰»: ˆã—Ôí‚΂­‚Ì“K³‰»‚ÉŒü‚¯‚Ä. ˆäã—D‰î (•úŽËü (‰æ‘œ)): •úŽËüáŠQ–hŽ~’†‰›‹¦‹c‰ï—ߘa2”N“x (tŠú) •úŽËüˆÀ‘SŠÇ—Œ¤C‰ï (2021/2/22), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJÃ).

732066. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰) f—ÕúŽËü‚̈À‘S—˜—p‚Ì‚½‚ß‚Ì•K{Ž–€Fˆã—Ö@Ž{s‹K‘¥‰ü³‚ðŽó‚¯‚Ä. ˆäã—D‰î (•úŽËü (‰æ‘œ): “Æ—§s­–@l ‘—§•a‰@‹@\ ‰¡•lˆã—ÃZƒ“ƒ^[@‰@“àŒ¤C (2020/10/5), ‰¡•l.

732067. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰) 2020”Nf—×p•úŽËü‚̈À‘S—˜—p‚Ì‚½‚ß‚ÌŒ¤C‰ï|ˆã—Ö@Ž{s‹K‘¥‰ü³‚ð‚¤‚¯‚ā|. ˆäã—D‰î (•úŽËü (‰æ‘œ): ‘Š–ÍŒ´ŽsˆãŽt‰ï@ˆã—ÈÀ‘SuK‰ï (2020/10/20), ‘Š–ÍŒ´.

732068. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰) •@•›•@o‚ÌCTEMRI|ˆË—Šˆã‚Í‚±‚±‚ª’m‚肽‚¢|. •‚F—´‘¾˜Y (•úŽËü (‰æ‘œ): ‘æ61‰ñRadiology UpdateŠwpu‰‰‰ï (2020/11/7), WebŠJÃ.

732069. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰) f—×p•úŽËü‚̈À‘S—˜—p‚Ì‚½‚ß‚ÌŒ¤C‚ƈã—Ë@ŠÖ‚Å‚ÌCOVID-19‘Ήž. ˆäã—D‰î (•úŽËü (‰æ‘œ): —ߘa2”N“x’ZŠúŒ¤C@ˆã—ÕúŽËü‚Ì“K³ŠÇ—‚ÉŠÖ‚·‚錤C (2020/11/27), ˜aŒõ.

732070. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰) ‚½‚©‚ª? ‚³‚ê‚Ç?|•›•@o‰Š‚ÌCTEMRI|. •‚F—´‘¾˜Y (•úŽËü (‰æ‘œ): ‘æ566‰ñNR§˜b‰ï (2021/1/9), WebŠJÃ.

732071. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰) f—×p•úŽËü‚̈À‘SŠÇ—‚Ì–@§‰»: ˆã—Ôí‚΂­‚Ì“K³‰»‚ÉŒü‚¯‚Ä. ˆäã—D‰î (•úŽËü (‰æ‘œ): •úŽËüáŠQ–hŽ~’†‰›‹¦‹c‰ï@—ߘa2”N“x (tŠú)u•úŽËüˆÀ‘SŠÇ—Œ¤C‰ïv(2021/2/22), “Œ‹ž.

733119. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘¤èò•”‚Ì‘½Œ`Œ^Ž‰–b“÷Žî. Šâø“仉l1, •‚F—´‘¾˜Y1, ¼‰i’m”ü1, ŽOˆäN•½1, ˆäã—D‰î1, ‹{–{r•ã2, ŽR‰º@‘ñ2, “È–{¹F3 (1•úŽËü (‰æ‘œ), 2Ž¨•@ˆôAE“ªèòŠO, 3•a—): ‘æ49‰ñ“ªèò•”E‹¹•”‰æ‘œŒ¤‹†‰ï (2020/12/12), WebŠJÃ.

733120. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“dŽqƒ|ƒXƒ^[) èò•”‚Ì‹‘å‚Èspindle cell lipoma. ˆÀ’B‚Ý‚¸‚Ù1, •‚F—´‘¾˜Y1, Šâø“仉l1, ŽOˆäN•½1, ˆäã—D‰î1, ¼–؁@’2, ŽR‰º@‘ñ2, H’J¹Žj3 (1•úŽËü (‰æ‘œ), 2Ž¨•@ˆôAE“ªèòŠO, 3•a—): ‘æ457‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïŠÖ“Œ’n•û‰ï (2021/3/22-31), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-522001. [uÀ]y“ÁW: ‘åŒ^E’†Œ^ŒŒŠÇ‰Š‚̉摜f’fz‚±‚±‚ª‚µ‚肽‚¢!|ŠÌ‚̉摜f’f update|. Œ´—¯OŽ÷1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2•úŽËü (‰æ‘œ)): ‰æ‘œf’f 2019/2; 39 (2): 217-8.

[Šw‰ïEŒ¤‹†‰ï“™]

'19-731001. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) Next 10 years|“W–]‚Ɖۑè|ŠjˆãŠw. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ60‰ñRadiology UpdateŠwpu‰‰‰ï (2019/11/16), “Œ‹ž.


•úŽËü‰ÈŠw (•úŽËüŽîᇊw)

[Šwp˜_•¶]

110388. [Œ´’˜] Clinical outcomes and prognostic factors of limited-stage small cell lung cancer patients treated with chemoradiotherapy: a single-institutional study. Hayakawa T1, Hayakawa K, Soda I1, Sekiguchi A1, Kawakami S1, Sasaki J2,3, Naoki K3, Ishiyama H1: Kitasato Med J 2020/9; 50 (2): 130-7. (‘ì–L˜a1, ‘“c@Ši1, ŠÖŒûˆ©ˆß1, ìã³Œå1, ²X–ØŽ¡ˆê˜Y2,3, —P–؍Ž•F3, ÎŽR”ŽžŠ1: 1•úŽËü (Žîá‡), 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ŒÄ‹zŠí“à)

110389. [Œ´’˜] Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients. Hayakawa T1, Tabata K2, Tsumura H2, Kawakami S3, Katakura T, Hashimoto M4, Watanabe Y3, Iwamura M2, Hasegawa T4, Ishiyama H3: Jpn J Radiol 2020/10; 38 (10): 993-6. (‘ì–L˜a1, “c”¨Œ’ˆê2, ’ѺGN2, ìã³Œå3, ‹´–{¬¢4, “n糗S‰î4, Šâ‘º³Žk2, ’·’Jì’q”V4, ÎŽR”ŽžŠ3: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2”å”AŠí, 3•úŽËü (Žîá‡), 4ˆã—Éq¶Šw•”)

520016. [‘à] ŠàŽ¡—Âɂ¨‚¯‚éƒpƒ‰ƒ_ƒCƒ€‚Ì•Ï‘J|“ûŠà‚𒆐S‚Æ‚µ‚½ˆãŠwŽj“IlŽ@|. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): –k—¢ˆãŠw 2020/6; 50 (1): 9-18.

530020. [‚»‚Ì‘¼ (Erratum)] Corrigendum to: Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease. Hagiwara Y1, Nakayama Y1, Kudo S1, Hayakawa T1,2, Nakamura N1, Kitamoto Y1, Takahashi S1, Tsujino K1, Kubo N1, Tamaki Y1, Nagata Y1 (1Japan Radiation Oncology Study Group (JROSG) Working Subgroup for Lung and Mediastinal Tumors): J Radiat Res 2020/9; 61 (5): 817. (‘ì–L˜a1,2: 2•úŽËü (Žîá‡))

[Šw‰ïEŒ¤‹†‰ï“™]

713051. [Šw‰ï (‘Û)] (ˆê”ÊŒû‰‰) A Phase II Trial of Stereotactic Body Radiotherapy Using 4 Fractions for Patiants with Localized Prostate Cancer. Kawakami S1, Hayakawa T1, Kainuma T1, Tsumura H2, Satoh T2, Tabata K2, Iwamura M2, Ishiyama H1: 2020 Astro Annual Meeting (2020/10/25-28), WebŠJÃ. (ìã³Œå1, ‘ì–L˜a1, Ž”À‘ì˜N1, ’ѺGN2, ²“¡ˆÐ•¶2, “c”¨Œ’ˆê2, Šâ‘º³Žk2, ÎŽR”ŽžŠ1: 1•úŽËü (Žîá‡), 2”å”AŠí)

723627. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‘O—§‘BŠà‰i‹v‘}“ü–§••¬üŒ¹Ž¡—Âɂ¨‚¯‚ép’†CT‰ºcold spot•â³–@‚̐üŒ¹’ljÁ•”ˆÊ‚ÉŠÖ‚·‚錟“¢. ìã³Œå1, Ž”À‘ì˜N1, ‘ì–L˜a1, ’ѺGN2, Šâ‘º³Žk2, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2”å”AŠí): ¬üŒ¹Ž¡—Õ”‰ï‘æ22‰ñŠwp‘å‰ï (2020/5/29), ŽãŠJÃ, ¬üŒ¹Ž¡—Õ”‰ï‘æ22‰ñŠwp‘å‰ï ƒvƒƒOƒ‰ƒ€E´˜^W 2020; p.36.

723628. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “ªèò•”Šà•úŽËüŽ¡—Â̗\Œã—\‘ªˆöŽq‚Æ‚µ‚Ä‚ÌŽ¡—ÑOQOLƒXƒRƒA. ‘ì–L˜a1, ìã³Œå1, ‘“c@Ši2, ŠÖŒûˆ©ˆß1, –ìàVää»‰Ô1, Ž”À‘ì˜N1, ‹{–{r•ã3, ‰Á”[Fˆê3, –àŽR•Û3, ŒÃ–؈»Žq3, ŽR‰º@‘ñ3, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2•½’ËŽs–¯•a‰@•úŽËüŽ¡—ÉÈ, 3Ž¨•@ˆôAE“ªèòŠO): ‘æ44‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2020/7/17-27), WebŠJÃ, “ªèò•”Šà 2020; 46 (2): 161.

723629. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “ªèò•”Šà•úŽËüŽ¡—Â̗\Œã—\‘ªˆöŽq‚Æ‚µ‚Ä‚ÌŽ¡—ÑOQOLƒXƒRƒA. ‘ì–L˜a1, ìã³Œå1, ‘“c@Ši2, ŠÖŒûˆ©ˆß1, –ìàVää»‰Ô1, Ž”À‘ì˜N1, ‹{–{r•ã3, ‰Á”[Fˆê3, –àŽR•Û3, ŒÃ–؈»Žq3, ŽR‰º@‘ñ3, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2•½’ËŽs–¯•a‰@•úŽËüŽ¡—ÉÈ, 3Ž¨•@ˆôAE“ªèòŠO): “ú–{•úŽËüŽîᇊw‰ï‘æ33‰ñŠwp‘å‰ï (2020/10/1-3), WebŠJÃ, “ú–{•úŽËüŽîᇊw‰ï‘æ33‰ñŠwp‘å‰ï•ñ•¶W 2020; p.216.

723630. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‘O—§‘BŠàSeedŽ¡—Âł̏p’†CT‰ºcold spot•â³–@‚̐üŒ¹’ljÁ•”ˆÊ‚ÉŠÖ‚·‚錟“¢. ìã³Œå1, ‘ì–L˜a1, ’ѺGN2, Šâ‘º³Žk2, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2”å”AŠí): “ú–{•úŽËüŽîᇊw‰ï‘æ33‰ñŠwp‘å‰ï (2020/10/1-3), WebŠJÃ, “ú–{•úŽËüŽîᇊw‰ï‘æ33‰ñŠwp‘å‰ï•ñ•¶W 2020; p.248.


–ƒŒ‰ÈŠw

[Šwp˜_•¶]

110390. [Œ´’˜] Preoperative sepsis is a predictive factor for 30-day mortality after major lower limb amputation among patients with arteriosclerosis obliterans and diabetes. Otsuka T1, Arai M2, Sugimura K1, Sakai M1, Nishizawa Y1, Suzuki Y1, Okamoto H1, Kuroiwa M1: J Orthop Sci 2020/5; 25 (3): 441-5. (‘å’Ë’q‹v1, Vˆä³N2, ™‘ºŒ›—º1, ãˆä䝗LŽq1, ¼àV‹`”V1, —é–Ø—D‘¾˜Y1, ‰ª–{_Žk1, •Šâ­”V1: 1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110028. [Œ´’˜] RAMP1 signaling in immune cells regulates inflammation-associated lymphangiogenesis. Tsuru S1, Ito Y2, Matsuda H3, Hosono K2, Inoue T4, Nakamoto S1, Kurashige C3, Mishima T5, Tsujikawa K, Okamoto H3, Majima M2: Lab Invest 2020/5; 100 (5): 738-50. (’ׯ¢—¢1, ˆÉ“¡‹`–ç2, ¼“cO”ü3, ×–ì‰Á“ÞŽq2, ˆäã’qm4, ’†–{CŽi1, åUdçŠG3, ”ü“‡—˜º5, ‰ª–{_Žk3, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2–ò—, 3–ƒŒ, 4Á‰»Ší“à, 5S‘ŸŒŒŠÇŠO)

110391. [Œ´’˜] The concordance rate of L3/4 intervertebral lumbar level estimated by palpation and ultrasonography in Japanese parturients. Hosokawa Y1, Okutomi T1, Hyuga S1, Kato R2, Kuczkowski KM: J Matern Fetal Neonatal Med 2020/7; 33 (14): 2354-8. (×ìKŠó1, ‰œ•xr”V1, “úŒür•ã1, ‰Á“¡—¢ŠG2: 1–ƒŒ, 2V¢‹Iˆã—ÁEæ’[“Iˆã—Ã)

120037. [Œ´’˜] ŒoƒJƒe[ƒeƒ‹“I‘å“®–¬•Ù’uŠ·p (TEVA) pŒã‚É”ñS‘ŸŽèp‚ðŽ{s‚³‚ꂽ5—á‚ÌŒŸ“¢. ŽR‰º@“Ö1, —é–Ø›’Žk1, ˆÀ“¡ŽõŒb1, ¼“cO”ü1, ™‘ºŒ›—º1, ŒË“c‰ë–ç1, ‰ª–{_Žk1 (1–ƒŒ): Cardiovascular Anesthesia 2020/8; 24 (1): 55-60.

310045. [Ç—á•ñ] Venoarterial extracorporeal membrane oxygenation as an early treatment for amniotic fluid embolism with cardiac arrest: A case report. Adachi M1, Adachi T1, Fujita T1, Hyuga S1, Onishi Y2, Okutomi T1: J Obstet Gynaecol Res 2021/9; 47 (9): 3374-8. (ˆÀ’B^—œŽq1, ˆÀ’B@Œ’1, “¡“c“ߌb1, “úŒür•ã1, ‘吼—fŽq2, ‰œ•xr”V1: 1–ƒŒ, 2ŽY‰È)

310046. [Ç—á•ñ] First Report of Spinal Anesthesia for Cesarean Delivery in a Parturient With Jeune Syndrome: A Case Report. Kondo H1, Hyuga S1, Fujita T1, Adachi M1, Mochizuki J2, Okutomi T1: A A Pract 2021/2; 15 (2): e01400. (‹ß“¡OW1, “úŒür•ã1, “¡“c“ߌb1, ˆÀ’B^—œŽq1, –]ŒŽƒŽq2, ‰œ•xr”V1: 1–ƒŒ, 2ŽY‰È)

320042. [Ç—á•ñ] ˆô“ª‚ª‚ñ‚ɑ΂·‚éŒoŒû“I“àŽ‹‹¾ŽèpŽ{sŒã‚É—\Šú‚¹‚¸‹CŠÇØŠJ‚ðŽ{s‚µ‚½2Ç—á. ãˆä䝗LŽq1, ’|˜Q–¯]1, ˆÀ“¡ŽõŒb1, ‰Á”[Fˆê2, Œ˜“ce—˜3, ´–ì—R”y2, ŽR‰º@“Ö1, ‰ª–{_Žk1 (1–ƒŒ, 2Ž¨•@ˆôAE“ªèòŠO, 3Á‰»Ší“à): –ƒŒ 2021/1; 70 (1): 81-3.

320043. [Ç—á•ñ] Ž‘±˜•”d–ŒŠOƒuƒƒbƒN‚É‚æ‚荘‰ºŽˆ’É‚ª‰ü‘P‚µ‚½stiff-personÇŒóŒQ‚Ì1—á. ‰Í‘º’¼Ž÷1, ‹àˆäº•¶2, —с@Œol1, r@«’q1, ‚‹´—Cˆê˜N1, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ïŽ 2021/3; 28 (3): 39-42.

530021. [‚»‚Ì‘¼ (Comment)] Author's response to the comments on ""Preoperative sepsis is a predictive factor for 30-day mortality after major lower limb amputation among patients with arteriosclerosis obliterans and diabetes"". Otsuka T1, Ushiwata A, Okamoto H1, Arai M2, Kuroiwa M1: J Orthop Sci 2020/11; 25 (6): 1133-4. (‘å’Ë’q‹v1, ‰ª–{_Žk1, Vˆä³N2, •Šâ­”V1: 1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

540045. [‚»‚Ì‘¼ (Šª“ªŒ¾)]y“ú–{—Տ°–ƒŒŠw‰ï‘æ39‰ñ‘å‰ïƒVƒ“ƒ|ƒWƒEƒ€zuƒJƒeƒSƒŠ[1 ‹Ù‹}’鉤ØŠJpv‚ɂ悹‚Ä. ‰œ•xr”V1, “c’†@Šî (1–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ïŽ 2021/1; 41 (1): 65.

[’˜@‘]

620100. [Šwp‘ (•ª’SŽ·•M)]y“ú–{‚Ì”DŽY•w‚ð‹~‚¤‚½‚ß‚É2020zƒVƒXƒeƒ€•Ò@ŽüŽYŠúˆã—ÂɖƒŒ‰Èˆã‚ªÏ‹É“I‚É‚©‚©‚í‚ê‚é‚悤‚Ȋ‹«®”õ, p.169-74. ‰œ•xr”V (–ƒŒ), ŠÄC: “ú–{ŽY•wl‰Èˆã‰ïˆã—ÈÀ‘S•”‰ï, ”DŽY•wŽ€–SÇ—ጟ“¢•]‰¿ˆÏˆõ‰ï, •Ò: ŠÖ‘ò–¾•F, ’·’Jìˆê, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2020/4”­s.

620101. [Šwp‘ (•ª’SŽ·•M)]y–ƒŒ‰Èˆã‚Ì‚½‚ß‚ÌŽüpŠú‚̐f—ÃKƒCƒhƒ‰ƒCƒ“Šˆ—ppz3Í@Ç—á‚ÅŠw‚Ԑf—ÃKƒCƒhƒ‰ƒCƒ“‚ÌŽÀ‘H^p’†ŠÇ—@3-6. zŠÂì“®–ò, p.146-56. ¼àV‹`”V1, ‰ª–{_Žk1 (1–ƒŒ), •Ò: ‰¡ŽR³®, ŠÄC: X“c@Œ‰, ’†ŽR‘“X, “Œ‹ž, 2020/6”­s.

620102. [Šwp‘ (•ª’SŽ·•M)]yŽY‰È–ƒŒ@All in OnezV. ŒoäT•ª•Ø‚Ì–ƒŒ@3. d–ŒŠO–ƒŒ, Ò‘‚­‚à–Œ‰º–ƒŒ@1) •û–@, p.122-7. ‰œ•xr”V (–ƒŒ), •Ò: ‰Á“¡—¢ŠG, Ó”C•Ò: ŽR–{’B˜Y, …–{ˆêO, Š_‰Ô@Šw, ‰Á“¡—¢ŠG, ²“¡’¨ˆê, •¶Œõ“°, “Œ‹ž, 2020/7”­s.

620103. [Šwp‘ (•ª’SŽ·•M)]yŽY‰È–ƒŒ@All in OnezV. ŒoäT•ª•Ø‚Ì–ƒŒ@3. d–ŒŠO–ƒŒ, Ò‘‚­‚à–Œ‰º–ƒŒ@mOPAnlH”DP’†â‚ÆŽq‹{“à‘ÙŽ™Ž€–S‚Ì•ª•Ø, p.140. ‰œ•xr”V (–ƒŒ), •Ò: ‰Á“¡—¢ŠG, Ó”C•Ò: ŽR–{’B˜Y, …–{ˆêO, Š_‰Ô@Šw, ‰Á“¡—¢ŠG, ²“¡’¨ˆê, •¶Œõ“°, “Œ‹ž, 2020/7”­s.

620104. [Šwp‘ (•ª’SŽ·•M)]yŽY‰È–ƒŒ@All in OnezV. ŒoäT•ª•Ø‚Ì–ƒŒ@3. d–ŒŠO–ƒŒ, Ò‘‚­‚à–Œ‰º–ƒŒ@mOPAnTOLAC‚Ì–³’É•ª•Ø, p.141. ‰œ•xr”V (–ƒŒ), •Ò: ‰Á“¡—¢ŠG, Ó”C•Ò: ŽR–{’B˜Y, …–{ˆêO, Š_‰Ô@Šw, ‰Á“¡—¢ŠG, ²“¡’¨ˆê, •¶Œõ“°, “Œ‹ž, 2020/7”­s.

620105. [Šwp‘ (•ª’SŽ·•M)]yŽY‰È–ƒŒ@All in OnezV. ŒoäT•ª•Ø‚Ì–ƒŒ@3. d–ŒŠO–ƒŒ, Ò‘‚­‚à–Œ‰º–ƒŒ@mOPAn‘o‘Ù‚Ì–³’É•ª•Ø, p.142. ‰œ•xr”V (–ƒŒ), •Ò: ‰Á“¡—¢ŠG, Ó”C•Ò: ŽR–{’B˜Y, …–{ˆêO, Š_‰Ô@Šw, ‰Á“¡—¢ŠG, ²“¡’¨ˆê, •¶Œõ“°, “Œ‹ž, 2020/7”­s.

620106. [Šwp‘ (•ª’SŽ·•M)]yŽY‰È–ƒŒ@All in OnezVI.’鉤ØŠJp‚Ì–ƒŒ@1. ’鉤ØŠJp‚Ì–ƒŒ@2) p‘O•]‰¿, p.154-8. ˆÀ’B^—œŽq, ‰œ•xr”V1 (1–ƒŒ), •Ò: ‰Á“¡—¢ŠG, Ó”C•Ò: ŽR–{’B˜Y, …–{ˆêO, Š_‰Ô@Šw, ‰Á“¡—¢ŠG, ²“¡’¨ˆê, •¶Œõ“°, “Œ‹ž, 2020/7”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

721027. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ’ɂ݂̍\‘¢‚ōl‚¦‚鐮Œ`ŠO‰ÈŠ³ŽÒ‚Ìáu’ÉŠÇ—. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ53‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïœE“î•”ŽîᇊwpW‰ï (2020/9/17), WebŠJÃ.

721028. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) áu’ɊɘaŽ¡—Öò‚ÉŠÖ‚·‚é’mŽ¯‚̐®—|–«áu’ɂɑ΂·‚éƒIƒsƒIƒCƒh’Á’É–ò‚Ì“K³Žg—p‹³ˆç|–{–M‚ÅŽg—p‰Â”\‚ÈŠeŽí–òÜ‚Æ–ò—Šw“Iì—p. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ54‰ñŠwpW‰ï (2020/11/14-15), WebŠJÃ.

721029. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) –{–M‚É‚¨‚¯‚閝«áu’É‹³ˆç„ŸƒIƒsƒIƒCƒh’Á’É–ò‚Ì“K³Žg—p‚ɂ‚¢‚ÄŠw‚Ú‚¤!! –{–M‚ÅŽg—p‰Â”\‚ÈŠeŽí–òÜ‚Æ–ò—Šw“Iì—p. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ42‰ñ“ú–{áu’ÉŠw‰ï (2020/12/5), WebŠJÃ.

722201. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‹æˆæ–ƒŒ‚ª‚È‚º–«áu’É‚ÉŒø‚­‚Ì‚©? ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): “ú–{‹æˆæ–ƒŒŠw‰ï‘æ7‰ñŠwpW‰ï (2020/8/9), WebŠJÃ.

722202. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‹}«pŒã’É‚©‚疝«pŒã’É‚Ì—\–h: ¡‰½‚ª, –ƒŒ‰Èˆã‚É‹‚ß‚ç‚ê‚Ä‚¢‚é‚Ì‚©? Neuropathic pain‚©‚çpŒã–«’É‚ðl‚¦‚é. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ54‰ñŠwpW‰ï (2020/11/14-15), WebŠJÃ.

723631. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ª‚ñáu’ÉŠ³ŽÒ‚É‚¨‚¯‚é“d—¬’mŠo臒l‚Ì’²¸. ‹àˆäº•¶1,2, –x]ÊD2, r@«’q2, ‰Í‘º’¼Ž÷2, —с@Œol2, ‰ª–{_Žk2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): “ú–{–ƒŒ‰ÈŠw‰ï‘æ67‰ñŠwpW‰ï (2020/7/1-8/31), WebŠJÃ.

723632. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒp[ƒLƒ“ƒ\ƒ“•a‡•¹‘¤œ^ÇŽèp‚̏TpŠúŠÇ—‚ÌŒŸ“¢. ˆÀ•”—D—¢1, ¼àV‹`”V1, ŽR˜H—TO1, ’·“céŽq1, ŒË“c‰ë–ç1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ÈŠw‰ï‘æ67‰ñŠwpW‰ï (2020/7/1-8/31), WebŠJÃ.

723633. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’鉤ØŠJp‚É‚¨‚¯‚éÒ‘‚­‚à–Œ‰º–ƒŒŒã’ጌˆ³‚ɑ΂·ƒtƒFƒjƒŒƒtƒŠƒ“—\–h“IŽ‘±“Š—^‚ÌŒø‰Ê. ˆÀ’B^—œŽq1, “¡“c“ߌb1, “úŒür•ã1, ‰œ•xr”V1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{‹æˆæ–ƒŒŠw‰ï‘æ7‰ñŠwpW‰ï (2020/8/9), WebŠJÃ.

723634. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Zoom cloud meetings‚ð—p‚¢‚½COVID-19œëŠ³”D•w‚ÌŽüpŠúŠÇ—‚ÉŠÖ‚·‚é“ú•ÄŠÔwebinar‚ÌŠJÃ. –{“c’h1, “úŒür•ã1, ˆÀ’B^—œŽq1, ‰œ•xr”V1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ï‘æ40‰ñ‘å‰ï (2020/11/14), WebŠJÃ.

723635. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —L’ɐ«‹Øáz¹‚ð‡•¹‚µ‚½ŠJ‹¹pŒãáu’ɏnjóŒQ‚ɑ΂µÒ‘ŽhŒƒ—Ö@‚ª—L—p‚Å‚ ‚Á‚½1Ç—á. ‰Í‘º’¼Ž÷1, —с@Œol1, ‹àˆäº•¶1,2, r@«’q1, –x]ÊD1, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ54‰ñŠwpW‰ï (2020/11/14-15), WebŠJÃ.

723636. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘‚­‚à–Œ‰º’Á’É‚É‚æ‚è•úŽËüŽ¡—Âðs‚¦‚½ˆ««’°˜‹ØÇŒóŒQ‚ō‚“x”ì–ž‚Ì1Ç—á. —с@Œol1, ‹àˆäº•¶1,2, ‰Í‘º’¼Ž÷1, r@«’q1, –x]ÊD1, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ54‰ñŠwpW‰ï (2020/11/14-15), WebŠJÃ.

723637. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò‘ŽhŒƒ“d‹É‚Ì—¯’u•”ˆÊ‚É“ïa‚µ‚½, d“x‘¤œ^Ç‚Ì1Ç—á. —с@Œol1, ‹àˆäº•¶1,2, ‰Í‘º’¼Ž÷1, r@«’q1, –x]ÊD1, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ54‰ñŠwpW‰ï (2020/11/14-15), WebŠJÃ.

731062. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ŠO«_ŒoáŠQ«áu’É‚ÌŽ¡—à |áu’ÉŠwEBM‚Å—L—pŽ¡—Ã‚ðŒŸØ|. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ1‰ñ“Œ‹žE“ìŠÖ“ŒŽx•”ŠwpW‰ï (2021/1/30), WebŠJÃ.

731063. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ƒIƒsƒIƒCƒh’Á’É–ò‚Ì“K—p|ƒRƒc‚Æ—Ž‚Æ‚µŒŠ|. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ61‰ñŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ï (2021/3/27), WebŠJÃ.

732072. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) ICU‚É‚¨‚¯‚ézŠÂ•s‘S‚Ì•]‰¿‚ƏW’†Ž¡—Èã‚Ì–ðŠ„. ¼àV‹`”V1, ãˆä䝗LŽq1, ˆÀ’B@Œ’1, ‘å’Ë’q‹v1, ‰iˆäˆŸˆË1, ™‘ºŒ›—º1, •Šâ­”V1, Vˆä³N1,2, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{W’†Ž¡—ÈãŠw‰ï‘æ4‰ñŠÖ“ŒbM‰zŽx•”ŠwpW‰ï (2020/9/6), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

H29-510001. [‘à] A systematic review of massive transfusion protocol in obstetrics. Tanaka H, Matsunaga S, Yamashita T, Okutomi T1, Sakurai A, Sekizawa A, Hasegawa J, Terui K, Miyake Y, Murotsuki J, Ikeda T: Taiwan J Obstet Gynecol 2017/12; 56 (6): 715-8. (‰œ•xr”V1: 1–ƒŒ)

H29-522002. [uÀ]yuÀzzŠÂŠíŒn‡•¹Ç”D•w‚̍d–ŒŠO–³’É•ª•Ø‚ð„‚Á‚Ä. ‰Á“¡—¢ŠG1, ‰œ•xr”V2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2–ƒŒ: —Տ°–ƒŒ 2017/11; 41 (11): 1511-7.

'18-120001. [Œ´’˜] ’´‹Ù‹}’鉤ØŠJpƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚̐U‚è•Ô‚è‚É‚¨‚¯‚é4‰æ–Ê“®‰æÄ¶‚Ì—L—p«‚ÌŒŸ“¢. —é–Ø›’Žk1, ×ìKŠó1, “¡“c“ߌb1, ‰Á“¡—¢ŠG2, ‰œ•xr”V1 (1–ƒŒ, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): •ª•Ø‚Æ–ƒŒ 2018; 100: 8-14.

'18-120002. [Œ´’˜] •ª•ØŽº‚É‚¨‚¯‚éPPHƒJ[ƒg“±“üŒø‰Ê‚ÌŒŸ“¢|ˆã—Î҂̃Aƒ“ƒP[ƒg’²¸‚æ‚è|. ¬ŽRˆ¤”ü, ×ìKŠó1, ‰Á“¡—¢ŠG2, ‰œ•xr”V1 (1–ƒŒ, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): •ª•Ø‚Æ–ƒŒ 2018; 100: 15-21.

'18-522002. [uÀ]y“ú–{‚Ì–³’É•ª•Ø‚̏«—ˆ‚Í? Dr. William Camann‚É•·‚­…@zŠ³ŽÒ‚ɃŠƒXƒN‚ð”FŽ¯‚µ‚Ä‚à‚ç‚¢W–ñ‰»‚ð. ’·âˆÀŽq, ‰œ•xr”V1, ÆˆäŽ¶, Œã“¡—²‹v, Šp‘qOs (1–ƒŒ): LiSA 2018/4; 25 (4): 361-70.

'18-522003. [uÀ]y“ú–{‚Ì–³’É•ª•Ø‚̏«—ˆ‚Í? Dr. William Camann‚É•·‚­…Az‰½‚ð‹³‚¦, ’N‚ª‚»‚ÌŽ‘Ši‚ð—^‚¦‚é‚Ì‚©. ’·âˆÀŽq, ‰œ•xr”V1, ÆˆäŽ¶, Œã“¡—²‹v, Šp‘qOs (1–ƒŒ): LiSA 2018/5; 25 (5): 483-9.

'18-522004. [uÀ]y“ÁW: –³’É•ª•Ø‚ƃgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO@•ŽYŽtEŽY‰Èˆã‚ª‰Ÿ‚³‚¦‚Ä‚¨‚«‚½‚¢‘Ήž‚ƃAƒZƒXƒƒ“ƒgz01 –³’É•ª•Ø‚Ì‚¢‚Ü: ‘“àEŠCŠO‚ÌŒ»ó. ‰œ•xr”V (–ƒŒ): ƒyƒŠƒlƒCƒ^ƒ‹ƒPƒA 2018/5; 37 (6): 516-21.

'18-522005. [uÀ]y“ú–{‚Ì–³’É•ª•Ø‚̏«—ˆ‚Í? Dr. William Camann‚É•·‚­…Az—ðŽj‚ðŠw‚Ñ, –¢—ˆ‚ÉŒü‚©‚¨‚¤. ’·âˆÀŽq, ‰œ•xr”V1, ÆˆäŽ¶, Œã“¡—²‹v, Šp‘qOs (1–ƒŒ): LiSA 2018/6; 25 (6): 593-602.

'18-522006. [uÀ]y“ÁW: ŽY‰È–ƒŒ (‘æ2‰ñ)z‡•¹Ç‚ð—L‚·‚é”D•w‚ÌŽY‰È“I, ”ñŽY‰È“IŽèp‚Ì–ƒŒŠÇ—|”DP‚ŒŒˆ³ÇŒóŒQ, HELLPÇŒóŒQ, Žqᒁ|. “¡“c“ߌb1, ‰œ•xr”V1 (1–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ïŽ 2018/9; 38 (5): 678-81.

'18-522007. [uÀ]y“ÁW: ŽY‰È–ƒŒ (‘æ2‰ñ)z‡•¹Ç‚ð—L‚·‚é”D•w‚ÌŽY‰È“I, ”ñŽY‰È“IŽèp‚Ì–ƒŒŠÇ—|SŽ¾Š³EŒÄ‹zŠíŽ¾Š³|. “¡“c“ߌb1, ‰œ•xr”V1 (1–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ïŽ 2018/9; 38 (5): 682-4.

'18-522008. [uÀ]y“ÁW: ŽY‰È–ƒŒ (‘æ2‰ñ)z‡•¹Ç‚ð—L‚·‚é”D•w‚ÌŽY‰È“I, ”ñŽY‰È“IŽèp‚Ì–ƒŒŠÇ—|_Œo‹ØŽ¾Š³, ƒŠƒEƒ}ƒ`, œŽ¾Š³|. “¡“c“ߌb1, ‰œ•xr”V1 (1–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ïŽ 2018/9; 38 (5): 685-7.

'18-522009. [uÀ]y“ÁW: ŽY‰È–ƒŒ (‘æ2‰ñ)zV¶Ž™‚̃PƒA‚Æ‘h¶–@. ×ìKŠó1, ‰œ•xr”V1 (1–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ïŽ 2018/9; 38 (5): 726-31.

'18-522010. [uÀ]y“ÁW: ŽèpŽºŠë‹@ŠÇ—z3. ŽY‰ÈŠë‹@“IoŒŒ‚ƑΉžƒKƒCƒhƒ‰ƒCƒ“2017. ’†‘ºŠG”ü, ‰œ•xr”V1 (1–ƒŒ): —Տ°–ƒŒ 2019/3; 43 (3): 421-8.

'19-522011. [uÀ]y“ÁW: –³’É•ª•ØEŽY‰È–ƒŒUpdatez3. –³’É•ª•Ø. ‰œ•xr”V (–ƒŒ): ŽY‰È‚Æ•wl‰È 2019/5; 86 (5): 545-9.

'19-522012. [uÀ]y“ÁW: Äl! ¬Ž™ŠÅŒìê–åŠÅŒìŽt‚ÌŽÀ‘H‚Æ–ðŠ„z[uŠÅŒìŠO—ˆv‚âuê–å•”–åv‚ÅŠˆ–ô‚·‚鏬Ž™ŠÅŒìê–åŠÅŒìŽt]@…D¬Ž™ŠÖ˜A•a“‚É‚¨‚¯‚éƒvƒƒAƒNƒeƒBƒuƒ‰ƒEƒ“ƒh‚ÌŠˆ“®. ‘å’J®–ç1, ¬’r•üF2, XˆÀŒbŽÀ1, ˆÉ“¡FŽq1, ˆÀ“¡@Žõ3, •Šâ­”V4, Vˆä³N5 (1ŠÅŒì•”, 2W’†Ž¡—ÃZƒ“ƒ^[, 3¬Ž™, 4–ƒŒ, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ¬Ž™ŠÅŒì 2019/6; 42 (6): 669-73.

'19-522013. [uÀ]y“ÁW: ŽüŽYŠú‚̒ɂ݂̃PƒAz<Še˜_@ŠÇ—‚ÌŽÀÛ> d–ŒŠO–ƒŒ‚É‚æ‚é–³’É•ª•Ø@d–ŒŠO–ƒŒEÒ‘‚­‚à–Œ‰º–ƒŒ. ‰œ•xr”V (–ƒŒ): ŽüŽYŠúˆãŠw 2019/8; 49 (8): 1051-4.

'19-522014. [uÀ]y“ÁW: ‹ô”­Ç: ‚»‚ÌŽž, Q‚Ä‚È‚¢‚½‚߂Ɂcz1. p’†”xŒŒðÇðÇ. ˆÀ’B@Œ’1, •Šâ­”V1 (1–ƒŒ: —Տ°–ƒŒ 2020/3; 44 (3): 403-10.

[’˜@‘]

H28-620001. [Šwp‘ (•ª’SŽ·•M)]yVE–ƒŒ‰ÈŒ¤C‚Ì‘f–p‚È‹^–â‚É“š‚¦‚Ü‚·zIIIzŠÂŠÇ—E‘ŸŠízŠÂŠÇ—@051. ”D•w’ጌˆ³Žž‚É‚È‚ºŽq‹{¶•ûˆ³”r‚ðs‚¤‚Ì‚©H, p.156-60. ‰œ•xr”V (–ƒŒ), •Ò: ˆî“c‰pˆê ƒƒfƒBƒJƒ‹EƒTƒCƒGƒ“ƒXEƒCƒ“ƒ^[ƒiƒVƒ‡ƒiƒ‹ “Œ‹ž, 2016/9”­s.

H29-620002. [Šwp‘ (•ª’SŽ·•M)]yƒƒ“ƒ‰ƒ“ƒNã‚ÌŽY‰È–ƒŒ‚É•K—v‚ȃGƒrƒfƒ“ƒXz‘æ1Í@’鉤ØŠJ‚Ì–ƒŒ@6. d–ŒúŽhŒã“ª’É, p.91-9. ‰œ•xr”V (–ƒŒ), ŠÄC: ÆˆäŽ¶, •Ò: ¼“c—S“T, “c’†@Šî, Ž½“°o”Å, “Œ‹ž, 2017/6”­s.

H29-620003. [Šwp‘ (’P’˜)]y–³’É•ª•Ø‚̋ɈӁz‰œ•xr”V (–ƒŒ), Ž½“°o”Å, “Œ‹ž, 2017/11”­s.

'18-610001. [Šwp‘ (•ª’SŽ·•M)]yObstetric Anesthesia for Co-morbid ConditionszChapter 6: Anesthesia for the Pregnant Patient with Autoimmune Disorders, p.87-97. Kato R, Okutomi T1, Editors: Gunaydin B, Ismail S, Springer Nature, Switzerland, 2018/10. (‰œ•xr”V1: 1–ƒŒ)

'18-620003. [Šwp‘ (•ª’SŽ·•M)]yŽY‰Èˆã‚Ì‚½‚ß‚Ì–³’É•ª•ØuÀz‘æ4Í d–ŒŠO’Á’É–@@y2zŽè‹Z‚ÌŽÀÛ, p.27-37. ‰œ•xr”V (–ƒŒ), •Ò: “V–ì@Š®, Ž½“°o”Å, “Œ‹ž, 2018/5”­s.

'18-620004. [Šwp‘ (•ª’SŽ·•M)]yŽY‰Èˆã‚Ì‚½‚ß‚Ì–³’É•ª•ØuÀz‘æ5Í Ò‘‚­‚à–Œ‰ºd–ŒŠO•¹—p’Á’É–@ (CSEA), p.67-72. ‰œ•xr”V (–ƒŒ), •Ò: “V–ì@Š®, Ž½“°o”Å, “Œ‹ž, 2018/5”­s.

'18-620005. [Šwp‘ (•ª’SŽ·•M)]y—Տ°–ƒŒŽÀ‘HƒVƒŠ[ƒY10 ŽY‰È–ƒŒz‘æ7Í‡•¹Ç‚ð—L‚·‚é”D•w‚ÌŽY‰È“I, ”ñŽY‰È“IŽèp‚Ì–ƒŒŠÇ—@[1] ”DP‚ŒŒˆ³ÇŒóŒQ, HELLPÇŒóŒQ, Žqá’, p.58-63. “¡“c“ߌb1, ‰œ•xr”V1 (1–ƒŒ), •Ò: “ú–{—Տ°–ƒŒŠw‰ï, ˆîŠ_ŠìŽO, ꎓ¡—mŽi, ƒ‰ƒCƒtƒƒfƒBƒRƒ€, –¼ŒÃ‰®, 2018”­s.

'18-620006. [Šwp‘ (•ª’SŽ·•M)]y—Տ°–ƒŒŽÀ‘HƒVƒŠ[ƒY10 ŽY‰È–ƒŒz‘æ7Í‡•¹Ç‚ð—L‚·‚é”D•w‚ÌŽY‰È“I, ”ñŽY‰È“IŽèp‚Ì–ƒŒŠÇ—@[2] SŽ¾Š³EŒÄ‹zŠíŽ¾Š³, p.64-7. “¡“c“ߌb1, ‰œ•xr”V1 (1–ƒŒ), •Ò: “ú–{—Տ°–ƒŒŠw‰ï, ˆîŠ_ŠìŽO, ꎓ¡—mŽi, ƒ‰ƒCƒtƒƒfƒBƒRƒ€, –¼ŒÃ‰®, 2018”­s.

'18-620007. [Šwp‘ (•ª’SŽ·•M)]y—Տ°–ƒŒŽÀ‘HƒVƒŠ[ƒY10 ŽY‰È–ƒŒz‘æ7Í‡•¹Ç‚ð—L‚·‚é”D•w‚ÌŽY‰È“I, ”ñŽY‰È“IŽèp‚Ì–ƒŒŠÇ—@[3] _Œo‹ØŽ¾Š³, ƒŠƒEƒ}ƒ`, œŽ¾Š³, p.68-70. “¡“c“ߌb1, ‰œ•xr”V1 (1–ƒŒ), •Ò: “ú–{—Տ°–ƒŒŠw‰ï, ˆîŠ_ŠìŽO, ꎓ¡—mŽi, ƒ‰ƒCƒtƒƒfƒBƒRƒ€, –¼ŒÃ‰®, 2018”­s.

'18-620008. [Šwp‘ (•ª’SŽ·•M)]y—Տ°–ƒŒŽÀ‘HƒVƒŠ[ƒY10 ŽY‰È–ƒŒz‘æ11ÍV¶Ž™‚̃PƒA‚Æ‘h¶–@, p.137-44. ×ìKŠó, ‰œ•xr”V1 (1–ƒŒ), •Ò: “ú–{—Տ°–ƒŒŠw‰ï, ˆîŠ_ŠìŽO, ꎓ¡—mŽi, ƒ‰ƒCƒtƒƒfƒBƒRƒ€, –¼ŒÃ‰®, 2018”­s.

'19-620013. [Šwp‘ (•ª’SŽ·•M)]yŽY‰È–ƒŒ‚Ì‹^–âQ&A 60zIn Chapter 1: ”D•w‚Ì–ƒŒ‘O•]‰¿, p.1-3. ‰œ•xr”V (–ƒŒ), ŠÄC: ‘å›Ô_Ži, •Ò: ã“ˆ_‡, ‰Á“¡—¢ŠG, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2019/11”­s.

'19-620014. [Šwp‘ (•ª’SŽ·•M)]yŽY‰È–ƒŒ‚Ì‹^–âQ&A 60zIn Chapter 1: ”D•w‚Ì–ƒŒ‘O•]‰¿, p.27-9. ‰œ•xr”V (–ƒŒ), ŠÄC: ‘å›Ô_Ži, •Ò: ã“ˆ_‡, ‰Á“¡—¢ŠG, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2019/11”­s.

'19-620015. [Šwp‘ (•ÒW)]y‹Ù‹}ŽY‰ÈŽèp‚Ì–ƒŒ‚É”õ‚¦‚é@‰ü’ù‘æ2”Łz•Ò: ‰œ•xr”V1, ‰Á“¡—¢ŠG, “V–ì@Š®, (1–ƒŒ), Ž½“°o”Å, “Œ‹ž, 2019/11”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

'18-723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Arf6Šˆ«‰»§ŒäˆöŽqcytohesin 2‚̋Ǎ݉ðÍ‚Æáu’ɐ§Œä‹@\‚É‚¨‚¯‚é–ðŠ„. ˆÉ“¡—@Žq1, [’J¹O2, ‰ª–{_Žk1, ãã—ms2 (1–ƒŒ, 2‰ð–U): ‘æ124‰ñ“ú–{‰ð–UŠw‰ï‘S‘ŠwpW‰ï (2019/3/27), VŠƒ.


—Տ°ŒŸ¸f’fŠw

[Šwp˜_•¶]

110207. [Œ´’˜] Short-term Change in Resting Energy Expenditure and Body Compositions in Therapeutic Process for Graves' Disease. Hayashi A1, Takano K1, Kawakami Y2, Hitomi M2, Ohata Y1, Suzuki A1, Kamata Y1, Shichiri M1: Intern Med 2020/8; 59 (15): 1827-33. (—с@“N”Í1, ‚–ìK˜H1, ìã—IŽq2, lŒ©–ƒ”üŽq2, ‘唩NG1, —é–؍V–¼1, Š™“c—T“ñ1, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à, 2‰h—{•”)

110208. [Œ´’˜] Comparison of accuracy between flash glucose monitoring and continuous glucose monitoring in patients with type 2 diabetes mellitus undergoing hemodialysis. Matoba K1,2, Hayashi A1, Shimizu N1, Moriguchi I, Kobayashi N, Shichiri M1: J Diabetes Complications 2020/11; 34 (11): 107680. (“IêŒ’‘¾1,2, —с@“N”Í1, ´…‡–ç1, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à, 2—ÕŒŸŠw)

110392. [Œ´’˜] Use of Noncontact Infrared Skin Thermometer for Peripheral Arterial Disease Screening in Patients With and Without Diabetes. Hayashi A1, Shichiri M2: Angiology 2020/8; 71 (7): 650-7. (—с@“N”Í1, Žµ—¢áÁ‹`2: 1—ÕŒŸŠw, 2“à•ª”å‘ãŽÓ“à)

110095. [Œ´’˜] Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study. Hidaka H1, Uojima H1, Nakazawa T1, Shao X, Hara Y1, Iwasaki S1, Wada N1, Kubota K1, Tanaka Y1, Shibuya A1, Kanoh Y2, Kokubu S1, Koizumi W1: Hepatol Res 2020/9; 50 (9): 1083-90. (“ú‚@‰›1, ‹›“ˆ°‹I1, ’†àV‹MG1, Œ´@—E•ã1, ŠâèGˆê˜Y1, ˜a“c®‹v1, ŒE“cK‰î1, “c’†Œ«–¾1, a’J–¾—²1, Žë–ì—Lì2, š •ª–ΔŽ1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2—ÕŒŸŠw)

110209. [Œ´’˜] The effectiveness of growth hormone replacement on energy expenditure and body composition in patients with adult growth hormone deficiency. Momozono A1, Hayashi A2, Takano K1, Shichiri M1: Endocr J 2021/4; 68 (4): 469-75. doi: 10.1507/endocrj.EJ20-0644. Epub 2020 Dec 22. (“‰€@–¾1, —с@“N”Í2, ‚–ìK˜H1, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à‰ÈŠw, 2—ÕŒŸŠw)

110393. [Œ´’˜] Assessment of the accuracy of an intermittent-scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study. Toyoda M, Murata T, Saito N, Kimura M, Takahashi H, Ishida N, Kitamura M, Hida M, Hayashi A1, Moriguchi I, Kobayashi N, Tsuriya D, Sakao Y, Matsushita T, Ito Y, Suzuki S, Kasama S, Kasahara M, Yamakawa T, Mori K, Kuroda A, Miura J, Hirota Y, Abe M, Fukagawa M, Sakane N, Hosoda K: Ther Apher Dial 2021/10; 25 (5): 586-94. doi: 10.1111/1744-9987.13618. Epub 2021 Feb 2. (—с@“N”Í1: 1—ÕŒŸŠw)

120049. [Œ´’˜] “œ”A•aƒJƒ“ƒoƒZ[ƒVƒ‡ƒ“Eƒ}ƒbƒvTM‚É‚æ‚銴î•‰’S‹y‚ÑŒŒ“œŠÇ—‚Ö‚ÌŒø‰Ê‚ÌŒŸ“¢. ìã—IŽq1, —с@“N”Í2, lŒ©–ƒ”üŽq1, Î–{–]”ü3, ‘åŠÑŒbŽq3, Žç‰®’B”ü4, Žµ—¢áÁ‹`5, ²“¡ÆŽq1 (1‰h—{•”, 2—ÕŒŸŠw, 3ŠÅŒì•”, 4Œ’NŠÇ—ƒZ, 5“à•ª”å‘ãŽÓ“à): “ú–{•a‘Ô‰h—{Šw‰ïŽ 2020; 23 (2): 159-65.

120043. [Œ´’˜] ƒhƒ‰ƒbƒOƒiƒC[ƒu2Œ^“œ”A•aŠ³ŽÒ‚ɑ΂·‚é’ZŠú“I–òÜ”ïŒyŒ¸‚ðŠÓ‚Ý‚½‘æˆê‘I‘ð–òƒtƒ[ƒ`ƒƒ[ƒg‚ÌŒø‰Ê. ŠâàV^‹IŽq1, –xˆä„Žj2, ”–؍ʉØ1, —é–؈ºŠG, ¬ìŒ°Žj3, —с@“N”Í4, Œú“cKˆê˜Y1,2 (1–òŠw•”, 2–òÜ•”, 3“à•ª”å‘ãŽÓ“à, 4—ÕŒŸŠw): “œ”A•a 2020/10; 63 (10): 701-10.

[’˜@‘]

620107. [Šwp‘ (•ª’SŽ·•M)]yŒŸ¸’l‚ð“Ç‚Þ2020 (“à‰È Vol.125 No.4 2020”N4ŒŽ‘‘卆)z19ÍŽ©ŒÈ–ƉuŒŸ¸@RƒŒƒ`ƒNƒŠƒ“R‘Ì, p.872. Žë–ì—Lì (—ÕŒŸŠw), “ì]“°, “Œ‹ž, 2020/4”­s.

620108. [Šwp‘ (•ª’SŽ·•M)]yŒŸ¸’l‚ð“Ç‚Þ2020 (“à‰È Vol.125 No.4 2020”N4ŒŽ‘‘卆)z20Í×–E«–ƉuŒŸ¸@ƒŠƒ“ƒp‹…—cŽá‰»ŒŸ¸, p.886. Žë–ì—Lì (—ÕŒŸŠw), “ì]“°, “Œ‹ž, 2020/4”­s.

620109. [Šwp‘ (•ª’SŽ·•M)]yŒŸ¸’l‚ð“Ç‚Þ2020 (“à‰È Vol.125 No.4 2020”N4ŒŽ‘‘卆)z20Í×–E«–ƉuŒŸ¸@RŒ´“ÁˆÙ“I×–EŠQ«T×–E‰ðÍ (MHC (HLA) ƒeƒgƒ‰ƒ}[), p.889. Žë–ì—Lì (—ÕŒŸŠw), “ì]“°, “Œ‹ž, 2020/4”­s.

620110. [Šwp‘ (•ª’SŽ·•M)]yŒŸ¸’l‚ð“Ç‚Þ2020 (“à‰È Vol.125 No.4 2020”N4ŒŽ‘‘卆)z32ÍúŽh‰tŒŸ¸@ŠÖß‰tŒŸ¸ (IIŒ^ƒRƒ‰[ƒQƒ“[C|ƒyƒvƒ`ƒh), p.1117. Žë–ì—Lì (—ÕŒŸŠw), “ì]“°, “Œ‹ž, 2020/4”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

723638. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 2Œ^“œ”A•aŒŒ‰t“§Í (DMHD) Š³ŽÒ2—á‚É‚¨‚¯‚éƒfƒOƒ‹ƒfƒN (D) /ƒŠƒ‰ƒOƒ‹ƒ`ƒh (L) ”z‡’ (D/L) ‚ÌŽg—pŒoŒ±. XŒû‚¢‚Ô‚«, ¬—Ñ’¼”V, ’|’†@½, ‘å‹v•Û[l, —с@“N”Í1, Žç‰®—˜‰À2, Žç‰®’B”ü3, ’|“àN—Y4 (1—ÕŒŸŠw, 2ˆãŠw‹³ˆç, 3Œ’NŠÇ—ƒZ, 4t‘Ÿ“à): ‘æ65‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2020/11/2-24), WebŠJÃ.

731064. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) Žîᇃ}[ƒJ[. Žë–ì—Lì (—ÕŒŸŠw): “ú–{—Տ°ŒŸ¸ê–åŠw‰@ (‘æ45Šú–ƉuŒŒ´ƒR[ƒX) (2020/10/18), “Œ‹ž.


—AŒŒE×–EˆÚAŠw

[Šwp˜_•¶]

110394. [Œ´’˜] Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption. Izumida E, Suzawa T, Miyamoto Y, Yamada A, Otsu M1, Saito T, Yamaguchi T, Nishimura K, Ohtaka M,. Nakanishi M, Yoshimura K, Sasa K, Takimoto R, Uyama R, Shirota T, Maki K,. Kamijo R: J Dent Res 2020/4; 99 (4): 429-36. (‘å’Á@^1: 1—AŒŒE×–EˆÚA)

110395. [Œ´’˜] Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Paciullo F, Bury L, Noris P, Falcinelli E, Melazzini F, Orsini S, Zaninetti C, Abdul-Kadir R, Obeng-Tuudah D, Heller PG, Glembotsky AC, Fabris F, Rivera J, Lozano ML, Butta N, Favier R, Cid AR, Fouassier M, Podda GM, Santoro C, Grandone E, Henskens Y, Nurden P, Zieger B, Cuker A, Devreese K, Tosetto A, De Candia E, Dupuis A, Miyazaki K1, Othman M, Gresele P: Haematologica 2020/7; 105 (7): 1948-56. (‹{ø“_“ñ1: 1—AŒŒE×–EˆÚA)

110396. [Œ´’˜] Differences among hemoglobin thresholds for red blood cell transfusions in patients with hematological diseases in teaching hospitals: a real world data in Japan. Yokohama A, Okuyama Y, Ueda Y, Itoh M, Fujiwara S, Hasegawa Y, Nagai K, Arakawa K, Miyazaki K1, Makita M, Watanabe M, Ikeda K, Tanaka A, Fujino K, Matsumoto M, Makino S, Kino S, Takeshita A, Muroi K: Int J Hematol 2020/10t ;112 (4): 535-43. (‹{ø“_“ñ1: 1—AŒŒE×–EˆÚA)

522127. [uÀ]y“ÁW: ”’ŒŒ•aEƒŠƒ“ƒpŽîz<Ž¡—Á^ŽÀ’nˆã‰Æ‚É•K—v‚È’mŽ¯> —AŒŒ—Ö@‚Ì’ˆÓ“_. ‹{ø“_“ñ (—AŒŒE×–EˆÚA): Medical Practice 2020/9; 37 (9): 1437-42.

522128. [uÀ]y“ÁW: ŒŒŽZ‚ð‹É‚ß‚éz ŒŒ¬”Š֘AŒŸ¸’l‚̈Ӌ`. ‹{ø“_“ñ (—AŒŒE×–EˆÚA): “à‰È 2020/10; 126 (4): 689-92.

[Šw‰ïEŒ¤‹†‰ï“™]

713052. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A five-year review of the revised institutional workflow of massive transfusion protocol in our institute. Miyazaki K1, Tanabe Y, Komoto M, Arima K, Iwakiri F, Yamabe H, Ohtani S1: The 36th International ISBT Congress (2020/12/12), WebŠJÃ. (‹{ø“_“ñ1, ‘å’JTˆê1: 1—AŒŒE×–EˆÚA)

722203. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) •a‰@î•ñƒVƒXƒeƒ€7”NŠÔ‚Ì•à‚Ý. ‘å’JTˆê (—AŒŒE×–EˆÚA): ‘æ68‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïŠwp‘‰ï (2020/5/29), ŽãŠJÃ.

722204. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ŒŒ‰t»Ü”­’ƒVƒXƒeƒ€‚̍č\’z. ˆäã³O, ‘å’JTˆê1, à_“c‰ër, ‘ëì³O, ‚‹´lŠì (1—AŒŒE×–EˆÚA): ‘æ68‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïŠwp‘‰ï (2020/5/29), ŽãŠJÃ.

723639. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘¢ŒŒŠíŽ¾Š³‚ð‚à‚‘å—ʐԌŒ‹…—AŒŒŠ³ŽÒ‚ɑ΂·‚é“SƒLƒŒ[ƒg—Ö@‚ÌŒ»ó. ‰¡à_Í•F, ‰œŽR”üŽ÷, ã“c‹±“T, ˆÉ“¡^Ÿ, “¡Œ´Tˆê˜Y, ’·ˆäˆê_, rìm, –q“c‰ë“T, ‹{ø“_“ñ1, ’r“c˜a•F, ‹I–ìCˆê, “c’†’©Žu, ’·’Jì—Yˆê, “¡–율ŽO, –q–ì–΋`, ¼–{^‹|, ’|‰º–¾—T, Žºˆäˆê’j (1—AŒŒE×–EˆÚA): ‘æ68‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïŠwp‘‰ï (2020/5/30), ŽãŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110022. [Œ´’˜] Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Gresele P, Orsini S, Noris P, Falcinelli E, Alessi MC, Bury L, Borhany M, Santoro C, Glembotsky AC, Cid AR, Tosetto A, De Candia E, Fontana P, Guglielmini G, Pecci A; BAT-VAL study investigators (Miyazaki K1, et al): J Thromb Haemost 2020/3; 18 (3): 732-9. (‹{ø“_“ñ1: 1—AŒŒE×–EˆÚA)

[’˜@‘]

'19-620016. [Šwp‘ (•ª’SŽ·•M)]yV—Տ°“à‰ÈŠw@‘æ10”Łz‘æ8Í ŒŒ‰tE‘¢ŒŒŠíŽ¾Š³@ŒŒ¬””‚ُ̈í‚𐶂¶‚鎾Š³ (‘¢ŒŒŠíŽîá‡‚ðœ‚­)@[4] ŒŒð«ŒŒ¬”ÂŒ¸­«Ž‡”Á•a, —nŒŒ«”A“ŏǏnjóŒQ, p.1016-8. ‹{ø“_“ñ (—AŒŒE×–EˆÚA), ŠÄC: –îè‹`—Y, ˆãŠw‘‰@, “Œ‹ž, 2020/3”­s.

'19-620017. [Šwp‘ (•ª’SŽ·•M)]yV—Տ°“à‰ÈŠw@‘æ10”Łz‘æ8Í ŒŒ‰tE‘¢ŒŒŠíŽ¾Š³@ŒŒ¬””‚ُ̈í‚𐶂¶‚鎾Š³ (‘¢ŒŒŠíŽîá‡‚ðœ‚­)@[6] ŒŒ¬”‚̕ª•zE’™—¯‚ُ̈í, p.1021-2. ‹{ø“_“ñ (—AŒŒE×–EˆÚA), ŠÄC: –îè‹`—Y, ˆãŠw‘‰@, “Œ‹ž, 2020/3”­s.

'19-620018. [Šwp‘ (•ª’SŽ·•M)]yV—Տ°“à‰ÈŠw@‘æ10”Łz‘æ8Í ŒŒ‰tE‘¢ŒŒŠíŽ¾Š³@ŒŒ¬””‚ُ̈í‚𐶂¶‚鎾Š³ (‘¢ŒŒŠíŽîá‡‚ðœ‚­)@[7] ‹U«ŒŒ¬”ÂŒ¸­, p.1022-3. ‹{ø“_“ñ (—AŒŒE×–EˆÚA), ŠÄC: –îè‹`—Y, ˆãŠw‘‰@, “Œ‹ž, 2020/3”­s.

'19-620019. [Šwp‘ (•ª’SŽ·•M)]y—Տ°HŠwuÀ —Տ°ˆãŠw‘˜_ ‘æ2”Łz‘æ10Í ŒŒ‰t•aŠw@2. ÔŒŒ‹…‚ÌŽ¾Š³, p.245-50. ‹{ø“_“ñ (—AŒŒE×–EˆÚA), ŠÄC: “ú–{—Տ°HŠw‹ZŽm‹³ˆçŽ{Ý‹¦‹c‰ï, •Ò: ŽÂŒ´ˆê•F, ¬’J@“§, ˆãŽ•–òo”Å, “Œ‹ž, 2020/3”­s.


‹~–½‹~‹}ˆãŠw

[Šwp˜_•¶]

110397. [Œ´’˜] Clinical Utility of Coil in Plug Method (CIP) for Internal Iliac Artery Embolization during Endovascular Aortic Aneurysm Repair. Kotoku A, Ogawa Y, Chiba K, Maruhashi T1, Mimura H, Miyairi T, Nishimaki H: Ann Vasc Dis 2020/9; 13 (3): 269-72. (ŠÛ‹´Fº1: 1‹~–½)

110398. [Œ´’˜] Novel transcatheter arterial embolization method for hemodynamically unstable pelvic fractures to prevent complications of gluteal necrosis. Maruhashi T1, Kashimi F1, Kotoh R1, Kasahara S1, Minehara H, Kataoka Y1, Nishimaki H, Asari Y1: Eur J Trauma Emerg Surg 2020/10; 46 (5): 1129-36. (ŠÛ‹´Fº1, Š~Œ©•¶Ž}1, ŒÃ“¡—¢‰À1, Š}Œ´@s1, •Ð‰ª—Sˆê1, ó—˜@–õ1: 1‹~–½)

110399. [Œ´’˜] Safety of arterial catheterization using the distal radial approach in intensive care unit management: A pilot study. Oi M1, Maruhashi T1, Ishikura A2, Kurihara Y1, Yaguchi Y2, Masuda K, Asari Y1: J Vasc Access 2021/3; 11297298211003374. (‘åˆä^—¢“Þ1, ŠÛ‹´Fº1, Î‘q@ˆ¤2, ŒIŒ´—S‘¾˜N1, –îŒûKŽq2, ó—˜@–õ1: 1‹~–½, 2ŠÅŒì•”)

310047. [Ç—á•ñ] Intravascular treatment for ruptured facial artery aneurysm via percutaneous cardiopulmonary support device: A case report. Oi M1, Maruhashi T1, Yamamoto D2, Kurihara Y1, Koizumi H1,2, Asari Y1: Clin Case Rep 2020/4; 8 (7): 1202-5. (‘åˆä^—“Þ1, ŠÛ‹´Fº1, ŽR–{‘å•ã2, ŒIŒ´—S‘¾˜N1, ¬òŠ°”V1,2, ó—˜@–õ1: 1‹~–½, 2”]ŠO)

310048. [Ç—á•ñ] Pancreatitis in a Patient with Severe Coronavirus Disease Pneumonia Treated with Veno-venous Extracorporeal Membrane Oxygenation. Kurihara Y1, Maruhashi T1, Wada T2, Osada M1, Oi M1, Yamaoka K2, Asari Y1: Intern Med 2020/11; 59 (22): 2903-6. (ŒIŒ´—S‘¾˜N1, ŠÛ‹´Fº1, ˜a“c’B•F2, ’·“c^—RŽq1, ‘åˆä^—“Þ1, ŽR‰ª–MG2, ó—˜@–õ1: 1‹~–½, 2äPŒ´•aEŠ´õ“à)

310049. [Ç—á•ñ] Life-threatening traumatic epistaxis due to massive bleeding into the maxillary sinus. Kotoh R1, Maruhashi T1, Tamura S1, Yamamoto D2, Koizumi H2, Kurihara Y1, Osada M1, Oi M1, Asari Y1: Trauma Case Rep 2021/2; 32: 100434. (ŒÃ“¡—¢‰À1, ŠÛ‹´Fº1, “c‘º@’q1, ŽR–{‘å•ã2, ¬òŠ°”V2, ŒIŒ´—S‘¾˜N1, ’·“c^—RŽq1, ‘åˆä^—¢“Þ1, ó—˜@–õ1: 1‹~–½, 2”]ŠO)

320044. [Ç—á•ñ] ’Ëvˆä‚â‚Ü‚ä‚艀‘½”•aŽÒŽ–ˆÄ‚©‚çƒeƒƒŠƒYƒ€‚̑Ήž‚ðl‚¦‚é|ƒhƒNƒ^[ƒJ[‚É‚æ‚錻êŠˆ“®‚ð’Ê‚¶‚ā|. •ž•”@1, ŠÛ‹´Fº1, •Ð‰ª—Sˆê1, ó—˜@–õ1: 1‹~–½): “ú–{—Տ°‹~‹}ˆãŠw‰ïŽGŽ 2020/6; 23 (2): 179-85.

320045. [Ç—á•ñ] Œëˆù‚µ‚½‹`Ž•‚É‚æ‚è‹}«ˆÝ–Iâ|D‰Š‚𔭏ǂµ‚½1—á. ‰Á“¡’q”V1, ‘åˆä^—¢“Þ1, ŠÛ‹´Fº1, ’†’JŒ¤“l1, ŒIŒ´—S‘¾˜N1, •Ð‰ª—Sˆê1, ó—˜@–õ1 (1‹~–½): “ú–{‹~‹}ˆãŠw‰ïŠÖ“Œ’n•û‰ïŽGŽ 2020/12; 41 (4): 496-9.

522129. [uÀ]y“ÁW: Ç—á‚©‚çl‚¦‚édÇŠOf—Á@‚ ‚È‚½‚È‚ç‚Ç‚¤‚·‚é!?zIII. ŠJ• Žž‚̏oŒŒƒRƒ“ƒgƒ[ƒ‹@REBOA. ŒIŒ´—S‘¾˜N1, ŠÛ‹´Fº1 (1‹~–½): ‹~‹}ˆãŠw 2020/9; 44 (10): 1282-90.

522130. [uÀ]y“ÁW: ŒŒŠÇ“àŽ¡—Âɂ¨‚¯‚錻óE–â‘è“_E«—ˆ“W–]z7. • •”ƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}p (EVAR) ‚ÌŒ»ó‚Ə«—ˆ“W–]. ¬ì•‹v, ¼Šª@”Ž, ç—t@´, ¬“¿‹Å¶, ”ª–Ø‹´‘”Ž, ŠÛ‹´Fº1, ŽO‘ºG•¶, ‹{“ü@„ (1‹~–½): “ú–{ŒŒŠÇ“àŽ¡—Êw‰ïŽ 2020/11; 21: 44-52.

530022. [‚»‚Ì‘¼ (Letter to the Editor)] Preloading Coil in Plug Technique for Internal Iliac Artery Embolization During Endovascular Abdominal Aortic Aneurysm Repair. Maruhashi T1, Nishimaki H, Ogawa Y4, Chiba K, Kotoku A, Miyairi T: Cardiovasc Intervent Radiol 2021/1; 44 (1): 179-81. (ŠÛ‹´Fº1: 1‹~–½)

540046. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]yŒú¶˜J“­s­„i’²¸Ž–‹Æ”ï•â•‹à (’nˆæˆã—Êî”ÕŠJ”­„iŒ¤‹†Ž–‹Æ) ‹~‹}ˆã—Ñ̐§‚̐„i‚ÉŠÖ‚·‚錤‹†z“ñŽŸ‹~‹}ˆã—Ë@ŠÖ‚ÌŒ»ó‚Æ•]‰¿‚ɂ‚¢‚Ä. ó—˜@–õ1, ŠÛ‹´Fº1, ŒÃ“¡—¢‰À1, rˆäN•v2, rˆä—L”ü3, •ž•”@1 (1‹~–½, 2f—Ïî•ñŠÇ—Žº, 3ˆã—Â̎¿EˆÀ‘S„iŽº): ‹~‹}ˆã—Ñ̐§‚̐„i‚ÉŠÖ‚·‚錤‹†@—ߘa2”N“x•ª’SŒ¤‹†•ñ‘ 2020.

[’˜@‘]

620111. [Šwp‘ (•ª’SŽ·•M)]yÐŠQˆã—Ã2020|‘å‹K–̓Cƒxƒ“ƒg, ƒeƒ‘Ήž‚ðŠÜ‚ß‚Ä (“ú–{ˆãŽt‰ïŽGŽ‘æ149Šª“Á•Ê† (1))zVIIIÍ. “ÁŽêÐŠQECBRNE‘Ήž@‰Šú‘Ήž, p. 294-8. ŠÛ‹´Fº1, ó—˜@–õ1 (1‹~–½), ŠÄCE•Ò: ‰¡“c—Ts, “ú–{ˆãŽt‰ï, “Œ‹ž, 2020/6”­s.

620112. [Šwp‘ (•ª’SŽ·•M)]yDIRECT REBOAƒZƒ~ƒi[ŒöŽ®ƒeƒLƒXƒg REBOAƒnƒ“ƒhƒuƒbƒNzIIIÍ ŠÇ—, p.55-74. Â–؁@½, Î“cŒ’ˆê˜Y, ‰ÕŒ´—²”V, ŒIŒ´—S‘¾˜N1, ©@—S—, ‹ß“¡_Žj, ŽÂ’ˁ@Œ’, ™ŽR‘ñ–ç, –…”ö‘”ü, •x“cŒ[‰î, ‰i“ˆ@‘¾, lŒ©@G, ‘D‰g’mO, ¼‘º—m•ã, ¼–{ƒˆê, ŠÛ‹´Fº1 (‹~–½1), ŠÄC: DIRECTŒ¤‹†‰ï, •Ò: DIRECTŒ¤‹†‰ïREBOAƒ[ƒLƒ“ƒOƒOƒ‹[ƒv ‚Ö‚é‚·o”Å, “Œ‹ž, 2021/3”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722205. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ¬Œ^Ž²—¬Ž®•â•zŠÂƒ|ƒ“ƒv‚É‚æ‚éV‚½‚ȐS”x‘h¶–@‚̉”\«. ŠÛ‹´Fº1, ñ@Œ[‘¾, ¼ì‘ñ–ç, ŒÃ“¡—¢‰À1, ŒIŒ´—S‘¾˜N1, ‘åˆä^—¢“Þ1, ó—˜@–õ1 (1‹~–½): ‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/11/18-20), Šò•Œ.

722206. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y‘½”­ŠO‚É‚¨‚¯‚éŽ~ŒŒí—ª‚ÆŽ~ŒŒípz‚Ç‚±‚©‚ç‹l‚ß‚é‚©? ‚Ç‚±‚Ü‚Å‹l‚ß‚é‚©? ƒoƒ‹[ƒ“ƒvƒƒeƒNƒVƒ‡ƒ“‚É‚æ‚é‘I‘ð“IÇð. “c‘º@’q1, ŠÛ‹´Fº1, ŒIŒ´—S‘¾˜N1, Š~Œ©•¶Ž}1, ó—˜@–õ1 (1‹~–½): ‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/11/18-20), Šò•Œ.

722207. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) œ”ÕŠO‚É‚¨‚¯‚éREBOA‚Ì—LŒø«‚𑽖ʓI‚É•]‰¿‚·‚é. ŠÛ‹´Fº1, Š~Œ©•¶Ž}1, ñ@Œ[‘¾, ¼ì‘ñ–ç, ŒIŒ´—S‘¾˜N1, ‘åˆä^—¢“Þ1, ŒÃ“¡—¢‰À1, “c‘º@’q1, ¼Šª@”Ž, ó—˜@–õ1 (1‹~–½): ‘æ34‰ñ“ú–{ŠOŠw‰ï‘‰ïEŠwpW‰ï (2020/12/7-8), å‘ä(webŠJÃ).

723640. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹}«ã’°ŠÔ–Œ“®–¬•ÂÇÇ‚ɑ΂µ‚Ä”]“®–¬ƒXƒeƒ“ƒgƒŠƒgƒŠ[ƒo[‚É‚æ‚鎡—Âɐ¬Œ÷‚µ‚½2—á. “c‘º@’q1, Š~Œ©•¶Ž}1, ŠÛ‹´Fº1, ŒIŒ´—S‘¾˜N1, ó—˜@–õ1 (1‹~–½): ‘æ49‰ñ“ú–{IVRŠw‰ï‘‰ï (2020/8/25-27), _ŒË.

723641. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Using intracerebral Stent retriever for acute superior mesenteric artery occlusion: three case reports. “c‘º@’q1, ŠÛ‹´Fº1, ŒIŒ´—S‘¾˜N1, Š~Œ©•¶Ž}1, ó—˜@–õ1 (1‹~–½): ‘æ49‰ñ“ú–{IVRŠw‰ï‘‰ï (2020/8/25-27), _ŒË.

723642. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) The Utility of carbon dioxide angiography for detecting bleeding from the IMA at vaginal hematoma. ŒIŒ´—S‘¾˜N1, ƒEƒbƒhƒnƒ€ƒX—æŽq2, ŽOˆäN•½2, “¡ˆä@Š]2, ¼‰iŒh“ñ2, ˆäã—D‰î2 (1‹~–½, 2•úŽËü (‰æ‘œ)): ‘æ49‰ñ“ú–{IVRŠw‰ï‘‰ï (2020/8/25-27), _ŒË.

723643. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’_”X“EopŒã‚ɐ¶‚¶‚½’_ùN‰¼«“®–¬áŽ‚ɑ΂µTAE‚ðŽ{s‚µ‚½1—á. ’·“c^—RŽq1, Š~Œ©•¶Ž}1, ŒIŒ´—S‘¾˜N1, ŠÛ‹´Fº1, “c‘º@’q1, •ž•”@1, ó—˜@–õ1 (1‹~–½): ‘æ56‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2020/10/8), –¼ŒÃ‰® (webŠJÃ), “ú–{• •”‹~‹}ˆãŠw‰ïŽGŽ 2020; 40: 321.

723644. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŽ¡—ÃŒoŒ±|ƒCƒxƒ‹ƒƒNƒ`ƒ“‚©‚çVV-ECMO‚܂Ł|. ŒIŒ´—S‘¾˜N1, ŠÛ‹´Fº1, ˜a“c’B•F2, ‘åˆä^—¢“Þ1, ‹à@@I1, ŽR‰ª–MG2, ó—˜@–õ1 (1‹~–½, 2äPŒ´•aEŠ´õ“à): ‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/11/18-20), Šò•Œ.

723645. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ßÔŠOü•ªŒõ‚ð—p‚¢‚ÄŠÓ•Ê‚µ‚½“î•”‘gDŠ´õÇ‚Ì2—á. ‘åˆä^—¢“Þ1, ŠÛ‹´Fº1, ŒFàVŒ›ˆê2, ŒIŒ´—S‘¾˜N1, Šâì‚³‚¨‚è1, ó—˜@–õ1 (1‹~–½, 2Œ`¬E”üŠO): ‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/11/18-20), Šò•Œ.

723646. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹}«ã’°ŠÔ–Œ“®–¬•ÂÇÇ‚ɑ΂µ‚Ä”]“®–¬ƒXƒeƒ“ƒgƒŠƒgƒŠ[ƒo[‚É‚æ‚鎡—Âɐ¬Œ÷‚µ‚½3—á. ŒÃ“¡—¢‰À1, “c‘º@’q1, ŠÛ‹´Fº1, ŒIŒ´—S‘¾˜N1, Š~Œ©•¶Ž}1, ó—˜@–õ1 (1‹~–½): ‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/11/18-20), Šò•Œ.

723647. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŒ—F•aAŠ³ŽÒ‚̏oŒŒ«ƒVƒ‡ƒbƒN‚𔺂¤äB‘¹‚ɑ΂·‚錌ŠÇ“àŽ¡—Ã. ’·“c^—RŽq1, ŠÛ‹´Fº1, ŒIŒ´—S‘¾˜N1, “c‘º@’q1, Š~Œ©•¶Ž}1, ó—˜@–õ1 (1‹~–½): ‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/11/18-20), Šò•Œ.

723648. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ”ՍœÜ‚ɑ΂·‚錌ŠÇ“àŽ¡—Âɂ¨‚¯‚é’YŽ_ƒKƒX‚Ì—L—p«. ‹à@@I1, ŠÛ‹´Fº1, ŒIŒ´—S‘¾˜N1, “c‘º@’q1, Š~Œ©•¶Ž}1, ‘åˆä^—¢“Þ1, ó—˜@–õ1 (1‹~–½): ‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/11/18-20), Šò•Œ.

723649. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹~–½‚µ‚¦‚½–ؐ»”¢‚É‚æ‚é‰s“IIIIaS‘¹‚Ì1—á. Žs糉ԓÞ, ŒÃ“¡—¢‰À1, “c‘º@’q1, “c‘º‰À”ü2, ŠÛ‹´Fº1, –k‘º@—¥2, ó—˜@–õ1 (1‹~–½, 2S‘ŸŒŒŠÇŠO): ‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/11/18-20), Šò•Œ.

723650. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ãŠ{“´“à‚ւ̏oŒŒ‚Ì’vŽ€“I‚Æ‚È‚Á‚½ŠO«•@oŒŒ‚̈ê—á. ‹à“cŽµd, ŒÃ“¡—¢‰À1, ŠÛ‹´Fº1, “c‘º@’q1, ŽR–{‘å•ã2, ¬òŠ°”V1,2, ŒIŒ´—S‘¾˜Y1, ’·“c^—RŽq1, ó—˜@–õ1 (1‹~–½, 2”]ŠO): ‘æ48‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/11/18-20), Šò•Œ.

723651. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘h¶“IŠJ‹¹p‚É‚Ä‹~–½‚µTEVAR‚ðŽ{s‚µ‚½‹¹•”‘½”­Žh‘n‚̈ê—á. ‘“c’q¬ (‹~–½): ‘æ34‰ñ“ú–{ŠOŠw‰ï‘‰ïEŠwpW‰ï (2020/12/7-8), webŠJÃ, “ú–{ŠOŠw‰ïŽGŽ 2020; 34 (5): 188.

732073. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€“™) ‘Š–ÍŒ´Žs‚Ì‹~‹}ˆã—Ñ̐§‚ÆŽ{Ý‹~‹}. ’©ŒG’õ—² (‹~–½): —ߘa2”N“x@‘Š–ÍŒ´Žs’nˆæˆã—ØAŒg‹Æ–±ŠÖŒWEˆõ‡“¯‰ï‹c@u‰‰ (2020/10/30), ‘Š–ÍŒ´.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-310004. [Ç—á•ñ] Use of Multimodal Interventional Radiology with an Intracerebral Artery Stent Retriever for Acute Superior Mesenteric Artery Thrombosis: A Case Report. Tamura S1, Maruhashi T1, Kashimi F1, Kurihara Y1, Oi M1, Hanajima T1, Kataoka Y1, Asari Y1: Ann Vasc Surg 2020/2; 63: 457.e13-457.e18. (“c‘º@’q1, ŠÛ‹´Fº1, Š~Œ©•¶Ž}1, ŒIŒ´—S‘¾˜N1, ‘åˆä^—“Þ1, ‰Ô“‡@Ž‘1, •Ð‰ª—Sˆê1, ó—˜@–õ1: 1‹~–½)

[’˜@‘]

'19-620020. [Šwp‘ (•ª’SŽ·•M)]y¬Ž™‚̐f—ÃŽè‹Z (¬Ž™‰Èf—Ã82Šª‘Š§†)zIII. ‹~‹}@‹}«’†“łɑ΂·‚éÁ‰»ŠÇœõ, p. 110-5. ©@L–ç (‹~–½), •Ò: ¯–ì@’¼, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 2019/4”­s.

'19-620021. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚̐f’fŽwj ‘æ8”ŁzII Ž¾Š³•Ò@14. ’†“Ő«Ž¾Š³@—L‹@ƒŠƒ“EƒTƒŠƒ“’†“Å, p. 1431-3. ŠÛ‹´Fº (‹~–½), ‘•ÒW: ‰iˆä—ÇŽO, ˆãŠw‘‰@, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

H29-723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”nŒ–Ø’†“ł̈ê—á. ’·“c^—RŽq1, ŠÛ‹´Fº1, Š}Œ´@s1, •ž•”@1, •Ð‰ª—Sˆê1, ó—˜@–õ1 (1‹~–½): ‘æ45‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2017/10/24-26), ‘åã, “ú–{‹~‹}ˆãŠw‰ïŽGŽ 2017; 28: 573.

'18-723003. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚NaŒŒÇ‚É‚æ‚èZ“§ˆ³«’E‘ÇŒóŒQ‚ð‚«‚½‚µ‚½1—á. ’·“c^—RŽq1, ŠÛ‹´Fº1, ‘åˆä^—¢“Þ1, ŠÛ–؉p—Y1, ŒIŒ´—S‘¾˜N1, •Ð‰ª—Sˆê1, ó—˜@–õ1 (1‹~–½): ‘æ46‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2018/11/19-21), ‰¡•l, “ú–{‹~‹}ˆãŠw‰ïŽGŽ 2018; 29: 631.

'19-723031. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™ŠO‚ɑ΂·‚é‰æ‘œ‰ºŽ¡—Âɂ¨‚¯‚ép’†ŠÇ—–@‚ªŽè‹Z‚É‹y‚Ú‚·‰e‹¿. ‘åˆä^—¢“Þ1, ŠÛ‹´Fº1, Š~Œ©•¶Ž}1, ŒIŒ´—S‘¾˜N1, “c‘º@’q1, ©@L–ç1, ó—˜@–õ1 (1‹~–½): ‘æ47‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2019/10/2-4), “Œ‹ž, “ú–{‹~‹}ˆãŠw‰ïŽGŽ 2019; 30 (9): 688.

'19-732002. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ŒŒŠÇ“àŽ¡—ÂðŽåŽ²‚Æ‚µ‚½‰@ŠO‚©‚çŽn‚Ü‚éŠO‰Šúf—Á`Comprehensive IR strategy in Trauma (CIST)`. “c‘º@’q1, ŠÛ‹´Fº1, ŒIŒ´—S‘¾˜N1, Š~Œ©•¶Ž}1, ‘åˆä^—¢“Þ1, •Ð‰ª—Sˆê1, ó—˜@–õ1 (1‹~–½): ‘æ70‰ñ“ú–{‹~‹}ˆãŠw‰ïŠÖ“Œ’n•û‰ïŠwpW‰ï (2020/1/18), ‘O‹´.

'19-732003. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) Ý‘î‹~‹}‚Æ‹~‹}ˆã—Â̘AŒg@MC ‚É‚¨‚¯‚é‰@ŠOS’âŽ~Š³ŽÒ‚Ì‘h¶‚ɑ΂·‚鎖‘OˆÓŽv•\Ž¦‚â–K–âEÝ‘îˆã—ÂƂ̘AŒg‚ÉŠÖ‚·‚éŽÀ‘Ô’²¸EƒVƒ“ƒ|ƒWƒEƒ€‚©‚猩‚¦‚½‚à‚Ì. ’©ŒG’õ—² (‹~–½): ‘æ70‰ñ“ú–{‹~‹}ˆãŠw‰ïŠÖ“Œ’n•û‰ïŠwpW‰ï (2020/1/18), ‘O‹´.


‘‡f—ÈãŠw

[Šwp˜_•¶]

320046. [Ç—á•ñ]y–k—¢“ŒˆãŒ¤f—Ø^‚©‚ç (193)z‹Gß«‚ÌŠPšu‚ÉŽ ‰AŽŠ•ó“’‚ª—LŒø‚Å‚ ‚Á‚½1Ç—á. ŒÜ–ì—R‰À—1, ¬“cŒû_2,3, ‰Ô—Öšæ•F3 (1‘‡f—Ã, 2“Œ—mˆãŠw‹³ˆç, 3“Œ—mˆãŠw‘‡Œ¤‹†Š): Š¿•û‚̗Տ° 2020/6; 67 (6): 597-601.

320047. [Ç—á•ñ]y–k—¢“ŒˆãŒ¤f—Ø^‚©‚ç (200)z”ñ’èŒ^Ž•’É‚É—§ŒøŽU—¿‚ª—LŒø‚Å‚ ‚Á‚½1—á. ‹yì“N˜Y, ––F‰p, “n糏G—T, ˆÉ“¡³—T, •½ŽR—zŽ¦, ˆÀ“c‘ìŽj, ŒÜ–ì—R‰À—1, X—T‹IŽq2, ‰Ô—Öšæ•F2, ¬“cŒû_2,3 (1‘‡f—Ã, 2“Œ—mˆãŠw‘‡Œ¤‹†Š, 3“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2021/1; 68 (1): 95-99.

521016. [‰ðà] Š³ŽÒ‚É‹}«Š¥ÇŒóŒQ‚ð‹^‚킹‚éÇó‚ª‚ ‚Á‚½‚Ì‚É, 12—U“±S“d}‚ðŽÀŽ{‚µ‚È‚©‚Á‚½‚±‚Æ‚©‚玀–S‚ÉŽŠ‚Á‚½‚Æ‚µ‚Ä‘¹ŠQ”…ž‚ð‹‚ß‚½Ž–—á. ÂŽR’¼‘P (‘‡f—Ã): ˆã—Ô»—á‰ðà 2020/4; 85: 67-86.


ˆãŠw•”•‘®ˆãŠw‹³ˆçŒ¤‹†ŠJ”­ƒZƒ“ƒ^[

ˆãŠw‹³ˆçŒ¤‹†•”–å


ˆãŠwŒ´˜_Œ¤‹†•”–å

[Šwp˜_•¶]

540047. [‚»‚Ì‘¼ (ƒjƒ…[ƒXƒŒƒ^[)] ”D•wŒŒ‰t‚É‚æ‚éo¶‘OŒŸ¸‚Ì20”N‚Æ‚±‚ê‚©‚ç: ƒKƒCƒhƒ‰ƒCƒ“‚ªŽç‚Á‚½‚±‚Æ, §ŒÀ‚µ‚½‚±‚Æ. âV“¡—L‹IŽq (ˆãŠwŒ´˜_): ˆê”ÊŽÐ’c–@l «‚ÆŒ’N‚ðl‚¦‚鏗«ê–å‰Æ‚̉ïƒjƒ…[ƒYƒŒƒ^[ 2020/11; 79: 1.

540048. [‚»‚Ì‘¼ (V•·‹LŽ–)] PGT-AŒ¤‹†‚ÉŠÖ‚·‚éƒRƒƒ“ƒg. âV“¡—L‹IŽq (ˆãŠwŒ´˜_): “Ç”„V•· 2020/12/12.

540049. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]yŒú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹à“«Ž¾Š³­ôŒ¤‹†Ž–‹Æu_Œo•Ï«Ž¾Š³—̈æ‚ÌŠî”Õ“I’²¸Œ¤‹†vzˆÚs: Transitionˆã—Á`Œ»ê‚©‚ç`. ’·’JìˆêŽq, âV“¡—L‹IŽq1 (1ˆãŠwŒ´˜_): _Œo•Ï«Ž¾Š³—̈æ‚ÌŠî”Õ“I’²¸Œ¤‹†”ÇŒ¤‹†•ñ‘ 2021/3; p.42-4.

540050. [‚»‚Ì‘¼ (Œ¤‹†•ñ‘)]yŒú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹à“«Ž¾Š³­ôŒ¤‹†Ž–‹Æu_Œo•Ï«Ž¾Š³—̈æ‚ÌŠî”Õ“I’²¸Œ¤‹†vzˆâ“`Žq‚ÉŠÖ‚·‚é–â‘è‚ðl‚¦‚é. ’·’JìˆêŽq, Ÿ–ì‰ë‰›, ŠÖ“‡—ÇŽ÷, “V–ì’¼“ñ, âV“¡—L‹IŽq1, ’†“‡Œ’“ñ (1ˆãŠwŒ´˜_): _Œo•Ï«Ž¾Š³—̈æ‚ÌŠî”Õ“I’²¸Œ¤‹†”ÇŒ¤‹†•ñ‘ 2021/3; p.45-8.

[Šw‰ïEŒ¤‹†‰ï“™]

731065. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) —D¶•ÛŒì–@‚©‚ç•ê‘Ì•ÛŒì–@‚Ö ƒŠƒvƒƒ_ƒNƒVƒ‡ƒ“‚Ɛ¶–½—Ï—. âV“¡—L‹IŽq (ˆãŠwŒ´˜_): Ã‰ªŒ§•ê‘Ì•ÛŒì–@Žw’èˆãŽtŒ¤C‰ï (2020/9/27), Ã‰ª.

732074. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™) ”D•wŒŒ‰t‚É‚æ‚éo¶‘OŒŸ¸‚Ì20”N‚Æ‚±‚ê‚©‚ç: ƒKƒCƒhƒ‰ƒCƒ“‚ªŽç‚Á‚½‚±‚ƁC§ŒÀ‚µ‚½‚±‚Æ. âV“¡—L‹IŽq (ˆãŠwŒ´˜_): 2020”N“xˆê”ÊŽÐ’c–@l«‚ÆŒ’N‚ðl‚¦‚鏗«ê–å‰Æ‚̉‰ïƒVƒ“ƒ|ƒWƒEƒ€ (2020/10/10), WebŠJÃ.

733121. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ’†â‚ð‚ß‚®‚鏗«‚Ö‚Ì‚Ü‚È‚´‚µ. âV“¡—L‹IŽq (ˆãŠwŒ´˜_): —ߘa2”N“x‘S‘•ŽYŽt‹³ˆç‹¦‹c‰ïŠÖ“ŒbM‰z’n‹æŒ¤C‰ï (2020/11/28), WebŠJÃ.

733122. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) transitionˆã—Ã: Œ»ê‚©‚ç. ’·’JìˆêŽq, âV“¡—L‹IŽq1 (1ˆãŠwŒ´˜_): —ߘa2”N“xŒú˜J‰ÈŒ¤­ôŒ¤‹†”ǐ_Œo•Ï«Ž¾Š³—̈æ‚É‚¨‚¯‚éŠî”Õ“I’²¸Œ¤‹†”Ç (2020/12/11), WebŠJÃ.

733123. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ’…°‘Of’f (PGT-M) “K‰žŠg‘å‚ð‚ß‚®‚éÅ‹ß‚Ì–â‘è. âV“¡—L‹IŽq (ˆãŠwŒ´˜_): _Œo•Ï«Ž¾Š³—̈æ‚É‚¨‚¯‚éŠî”Õ“I’²¸Œ¤‹†”Ljâ“`ŽqŒŸ¸‚ÉŠÖ‚í‚鏔–â‘è‚ðl‚¦‚é‰ï (2020/12/21), WebŠJÃ.

733124. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) —r…ŒŸ¸‚Ì•‹y‚©‚ç50”N“ú–{‚É‚¨‚¯‚éo¶‘OŒŸ¸‚Ì‹c˜_‚ƍ¡Œã‚̉ۑè. âV“¡—L‹IŽq (ˆãŠwŒ´˜_): eŽq‚Ì–¢—ˆ‚ðŽx‚¦‚é‰ï‘ÙŽ™ƒzƒbƒgƒ‰ƒCƒ“‘Š’kˆõ•åWˆç¬Ž–‹Æ”DPŠ‹“¡‘Š’kƒEƒFƒrƒi[ (2021/1/16), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šw‰ïEŒ¤‹†‰ï“™]

'19-733019. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ƒOƒ[ƒoƒ‹lŒ ‚Å‚È‚¢“ú–{‚̃Šƒvƒƒ_ƒNƒVƒ‡ƒ“‚ÉŠÖ‚·‚é–@§“x. âV“¡—L‹IŽq (ˆãŠwŒ´˜_): –¾Ž¡‘åŠwƒOƒ[ƒoƒ‹lŒ Œ¤‹†‰ï (2020/3/18), WebŠJÃ.


ˆã—ÈÀ‘SEŠÇ—ŠwŒ¤‹†•”–å

¦u®Œ`ŠO‰ÈŠwv‚ðŽQÆ


ˆã—ËZp‹³ˆçŒ¤‹†•”–å

¦ut‘Ÿ“à‰ÈŠwv‚ðŽQÆ


ŠwKŽx‰‡Œ¤‹†•”–å


ˆã—Ïî•ñ‹³ˆçŒ¤‹†•”–å

[Šw‰ïEŒ¤‹†‰ï“™]

723652. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒAƒ~ƒƒCƒh‰»ŒXŒü‚ð—L‚·‚éƒ^ƒ“ƒpƒNŽ¿Eƒyƒvƒ`ƒh‚̋ÏW–hŽ~. •ì—D, Š‹ŠÑŠG—œ“Þ, “ú”䌒l, ‰Í–ìr”V1, Ž›˜eTˆê, Žá¼@Š] (1ˆã—Ïî•ñ‹³ˆç): ‘æ59‰ñNMR“¢˜_‰ï (2020/11/17), ‚è.

723653. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒAƒhƒŒƒiƒŠƒ“Žó—e‘̍זE“à‘æŽOƒ‹[ƒv‚ÆGPCR ƒ‚ƒWƒ…ƒŒ[ƒ^[Spinophilin‚Ƃ̐V‚µ‚¢—Z‡ƒ^ƒ“ƒpƒNŽ¿‚ð—p‚¢‚½‘ŠŒÝì—p‰ðÍ. Š‹ŠÑŠG—œ“Þ, “Å“‡‚¢‚Ô‚«, •ì—D, ‰Y–ì’qŽq, “‡èˆÀŠóŽq, ‰Í–ìr”V1, ×“c˜a’j, Ž›˜eTˆê, Žá¼@Š] (1ˆã—Ïî•ñ‹³ˆç): ‘æ59‰ñNMR“¢˜_‰ï (2020/11/17), ‚è.


“Œ—mˆãŠw‹³ˆçŒ¤‹†•”–å

[Šwp˜_•¶]

110400. [Œ´’˜] Effect of Ephedra Herb on Erlotinib Resistance in c-Met-Overexpressing Non-Small-Cell Lung Cancer Cell Line, H1993, through Promotion of Endocytosis and Degradation of c-Met. Hyuga S1, Hyuga M, Amakura Y, Yang J, Mori E1, Hakamatsuka T, Goda Y, Odaguchi H1,2, Hanawa T1: Evidence-Based Complementary and Alternative Medicine 2020/5; 2020: 1-14. Article ID 7184129. (“úŒü{”üŽq1, X@‰lŽq1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1: 1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç)

110401. [Œ´’˜] Emotional Impairments and Neuroinflammation are Induced in Male Mice Invulnerable to Repeated Social Defeat Stress. Ito N1, Sasaki K, Takemoto H2, Kobayashi Y1, Isoda H, Odaguchi H1,3: Neuroscience 2020/9; 443: 148-63. (ˆÉ“¡’¼Ž÷1, ’|Œ³—T–¾2, ¬—Ñ‹`“T1, ¬“cŒû_1,3: 1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2–òŠw•”, 3“Œ—mˆãŠw‹³ˆç)

110402. [Œ´’˜] Hochuekkito comprising Atractylodis lanceae rhizoma prevents pulmonary infection of Streptococcus pneumoniae in cyclophosphamide-treated mice through acceleration of anti-bacterial protein production. Ideno S, Tanaka Y, Sasou K, Hosaka H, Matsui H1, Maruyama H, Tonooka M, Endo M2, Nagai T2, Seki H, Hanawa T2, Ito G, Odaguchi H2,3, Morisaki H, Hiroaki Kiyohara H2: TRADITIONAL & KAMPO MEDICINE 2020/12; 7 (3): 166-79. (¼ˆä‰p‘¥1, ‰““¡^—2, ‰iˆä—²”V2, ‰Ô—Öšæ•F2, ¬“cŒû_2,3, ´Œ´Š°Í2: 1‘呺’q‹L”OŒ¤‹†Š, 2“Œ—mˆãŠw‘‡Œ¤‹†Š, 3“Œ—mˆãŠw‹³ˆç)

320048. [Ç—á•ñ] ŒŒ‚Ì“¹Ç‚ɑ΂µ, —_ŽU‚ª—LŒø‚ƍl‚¦‚ç‚ꂽ10Ç—á‚̗Տ°“IŒŸ“¢. X@‰lŽq1, ‹yì“N˜Y1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): “ú–{“Œ—mˆãŠw‰ïŽGŽ 2020/4; 71 (2): 121-6.

320049. [Ç—á•ñ]y–k—¢“ŒˆãŒ¤f—Ø^‚©‚ç (195)z_Œø“’‚ª—LŒø‚¾‚Á‚½Žq‹{“à–ŒÇ‚É‚æ‚é“«–«‰º• •”’É. X—T‹IŽq1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2020/8; 67 (8): 805-10.

320050. [Ç—á•ñ]y–k—¢“ŒˆãŒ¤f—Ø^‚©‚ç (196)z•s–°‚É”’ŒÕ‰Á‰©˜A“’‚ª—L—p‚Å‚ ‚Á‚½1—á. Î–Ñ’B–ç1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2020/9; 67 (9): 919-22.

320051. [Ç—á•ñ]y–k—¢“ŒˆãŒ¤f—Ø^‚©‚ç (197)z‹@”\«ˆÝ’°áŠQ‚ÉŒ[äB“’, ‹Aãˌš’†“’‚ª‘tŒø‚µ‚½‚P—á. ¯–ì‘ì”V1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2020/10; 67 (10): 1005-8.

320052. [Ç—á•ñ]y–k—¢“ŒˆãŒ¤f—Ø^‚©‚ç (198)zŒ[äB“’‚ÆŽQ—è”’žQŽU‚ÌŠÓ•Ê‚ª–â‘è‚Æ‚È‚Á‚½1—á. ¬“cŒû_1,2, ‰Ô—Öšæ•F2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ¤‹†Š): Š¿•û‚̗Տ° 2020/11; 67 (11): 1095-9.

[Šw‰ïEŒ¤‹†‰ï“™]

713053. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Proposalon Kampo (Traditional Japanese Medicine) treatment for COVID-19. Odaguchi H1,2: 5th Conference for Trilateral Communication between East Asian Pharmacopoeia Committees on Natural Medicines (TEAPN) (2020/12/18), WEBŠJÃ. (¬“cŒû_1,2: 1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ¤‹†Š)

722208. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) —«‚ÌŒ’NŽx‰‡‚ÉŠ¿•ûˆãŠw‚Ì—Í‚ðŠˆ—p‚·‚é. ¬“cŒû_1,2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ¤‹†Š): ‘æ22‰ñ“ú–{•ê«ŠÅŒìŠw‰ïŠwpW‰ï (2020/7/3-16), webŠJÃ.

722209. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‚—îŽÒ‚ɑ΂·‚銿•ûŽ¡—Á`l‚¦•û‚ÆŽÀ‘H`. ¬“cŒû_1,2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ¤‹†Š): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/30), webŠJÃ.

723654. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Relevance between age-related psychological symptoms and neuroinflammaging in SAMP8 mice - a validation of presymptomatic or pre-frailty animal model for pathological senescence. ˆÉ“¡’¼Ž÷1, ’|Œ³—T–¾2, ’·’Jìˆ»“ß1, ™ŽRç‰À1, –{ŠÔŒ’Œå1, ‰iˆä—²”V, ¬—Ñ‹`“T2, ¬“cŒû_1,3 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2–òŠw•”, 3“Œ—mˆãŠw‹³ˆç): ‘æ43‰ñ“ú–{_Œo‰ÈŠw‘å‰ï (2020/7/29), webŠJÃ.

723655. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã’°ŠÇ–ƒáƒƒ‚ƒfƒ‹ƒ}ƒEƒX‚Å‚Ì‹Ø‘w•”‰ŠÇ‚ɑ΂·‚锼‰ÄŒú–p“’÷Ü‚̍ì—p‚̉ðÍ. “a‰ªŽÀŽ÷1, ŽRŒû˜a‹P1, ‰““¡^—1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1, ´Œ´Š°Í1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/29), webŠJÃ.

723656. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã’°ŠÇ–ƒáƒƒ‚ƒfƒ‹ƒ}ƒEƒX‚ɑ΂·‚锼‰ÄŒú–p“’÷Ü‚̍D’†‹…Z—}§ì—p‚Ì‹@˜‚̉ðÍ. ŽRŒû˜a‹P1, “a‰ªŽÀŽ÷1, ‰““¡^—1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1, ´Œ´Š°Í1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/29), webŠJÃ.

723657. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •â’†‰v‹C“’WãË-”’žQ”z‡Ü‚̏¬’°”S–Œ‰ŠÇ‚ɑ΂·‚é‰ü‘Pì—p‚Ì‹@˜‚̉ð–¾. ‰ÌìŽD1, ‰““¡^—1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1, ´Œ´Š°Í1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/29), webŠJÃ.

723658. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) RCD3R‘Ì“Š—^ƒ‚ƒfƒ‹ƒ}ƒEƒX‚̖Ɖu‰ž“š‚ɑ΂·‚é”’žQ”z‡•â’†‰v‹C“’‚̐WãˁE‰©ã˔z‡Ü‚̍ì—p‚Ì”äŠrŒŸ“¢. ‰““¡^—1, ‰ÌìŽD1, ´Œ´Š°Í1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/29), webŠJÃ.

723659. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) COX-2y‘fŠˆ«‚ɑ΂·‚é–ƒ‰©ƒGƒLƒX, EFE, ƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒh‚Ì‘jŠQì—p. “ì@‰ÂŒb1, “úŒü{”üŽq2, ’|“à@ƒ1, ’†Xr•ã1, ‹{“ˆ’¼‹I1, —k@‹àˆÜ, “àŽR“Þ•äŽq, “úŒü¹Ži, ‘哈’¼_, “V‘q‹gÍ, ŒÑ’ˍ‚Žu, ‡“cKL, ¬“cŒû_2,3, ‰Ô—Öšæ•F3, ¬—Ñ‹`“T1 (1–òŠw•”, 2“Œ—mˆãŠw‹³ˆç, 3“Œ—mˆãŠw‘‡Œ¤‹†Š): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/29), webŠJÃ.

723660. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –ƒ‰©‚ÉŠÜ‚Ü‚ê‚éƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒh‚̐‡–°‹y‚щ^“®‹@”\‚ɑ΂·‚éì—p‚̉ðÍ. ’JŠ_•A”T‰î1, ‰©@á’O1, ”ö–ìéDÆ1, “n•”_•½1, “úŒü{”üŽq2, ’|Œ³—T–¾2, ŽR‰º’‰r, —k@‹àˆÜ, “àŽR“Þ•äŽq, “úŒü¹Ži, ‘哈’¼_, “V‘q‹gÍ, ŒÑ’ˍ‚Žu, ‡“cKL, ¬“cŒû_2,3, ‰Ô—Öšæ•F2, ¬—Ñ‹`“T1 (1–òŠw•”, 2“Œ—mˆãŠw‘‡Œ¤‹†Š, 3“Œ—mˆãŠw‹³ˆç): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/29), webŠJÃ.

723661. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EFE‚Ì’P‰ñ‹y‚Ñ2‰ñ“Š—^‚É‚æ‚é’Á’ɍì—p‚Ì”äŠr‚ÆEFE‚ÌŠˆ«¬•ª‚Ì’Tõ. ’†Xr•ã1, ‹{“ˆ’¼‹I1, “úŒü{”üŽq2, D‘ºŽç¶, “V‘q‹gÍ, —k@‹àˆÜ, “àŽR“Þ•äŽq, “úŒü¹Ži, ‘哈’¼_, ŒÑ’ˍ‚Žu, ‡“cKL, ¬“cŒû_2,3, ‰Ô—Öšæ•F3, ¬—Ñ‹`“T1 (1–òŠw•”, 2“Œ—mˆãŠw‹³ˆç, 3“Œ—mˆãŠw‘‡Œ¤‹†Š): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/29), webŠJÃ.

723662. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒAƒNƒ`ƒrƒ“Eƒvƒƒ‚[ƒ^[Šˆ«‚ðã¸‚³‚¹‚鐶–ò‚Ì’Tõ. ‹´–{@“, “úŒü{”üŽq1, ´…N°, –x@‘Žq, –x@@Œú, ‰Ô—Öšæ•F1, ¬“cŒû_1,2 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/29), webŠJÃ.

723663. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EGFRŠˆ«Œ^•ÏˆÙ‚ð—L‚·‚镪Žq•W“IŽ¡—Öò‘ϐ«”ñ¬×–E”x‚ª‚ñ—R—ˆH1975×–E‚ɑ΂·‚é–ƒ‰©‚ÌŒø‰Ê. X@‰lŽq1, “úŒü{”üŽq1, ‰Ô—Öšæ•F1, ¬“cŒû_1,2 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ37‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2020/8/29), webŠJÃ.

723664. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘ºˆä‹ÕŽRw•û‹É™ˆ’èx‚ɑ΂·‚é”á”»‚Æ‚»‚ÌŒ»‘ã“IˆÓ‹`\ICD-11u–ò•û‚̏؁v‹Lq‚ÉŒü‚¯‚Ä. ¯–ì‘ì”V1,2, ¬“cŒû_1,2, ‰Ô—Öšæ•F2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ¤‹†Š): ‘æ121‰ñ“ú–{ˆãŽjŠw‰ï‘‰ïEŠwp‘å‰ï (2020/12/19), webŠJÃ.

723665. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ÎìŒ³¬ïw‹„ŒŠ}‰ðx‚ÉŒ©‚銿—–Ü’. ‰Á”¨‘Žq1, ¯–ì‘ì”V1,2, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ121‰ñ“ú–{ˆãŽjŠw‰ï‘‰ïEŠwp‘å‰ï (2020/12/19-28), webŠJÃ, “ú–{ˆãŽjŠwŽGŽ 2020/6; 66 (2): 232.

723666. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –ƒ‰©ƒGƒLƒX‹y‚уGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒh‚É‚æ‚è—U“±‚³‚ê‚鎩”­‰^“®—ʒቺ‚̍ì—p‹@˜‚̉ð–¾. ˆÉ“¡Ž”T1, ’JŠ_•A”V‰î1, ‰©@á’O1, “úŒü{”üŽq2, “àŽR“Þ•äŽq, “úŒü¹Ži, ‘哈’¼_, “V‘q‹gÍ, ŒÑ’ˍ‚Žu, ‡“cKL, ¬“cŒû_2,3, ‰Ô—Öšæ•F2, ¬—Ñ‹`“T1 (1–òŠw•”, 2“Œ—mˆãŠw‘‡Œ¤‹†Š, 3“Œ—mˆãŠw‹³ˆç): “ú–{–òŠw‰ï‘æ141”N‰ï (2021/3/27), webŠJÃ.

723667. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰©ƒGƒLƒX”z‡Š¿•û–ò‚Ì•iŽ¿ŠÇ—‚É‚¨‚¯‚éŽw•W¬•ª‚ÌŒŸ“¢. ’†Xr•ã1, ’|“à@ƒ1, “úŒü{”üŽq2, “àŽR“Þ•äŽq, ’Ò–{@‹±, ‹{“ˆ’¼‹I, —k@‹àˆÜ, ‘哈’¼_, “V‘q‹gÍ, “úŒü¹Ži, ŒÑ’ˍ‚Žu, ‡“cKL, ¬“cŒû_2,3, ‰Ô—Öšæ•F2, ¬—Ñ‹`“T1 (1–òŠw•”, 2“Œ—mˆãŠw‘‡Œ¤‹†Š, 3“Œ—mˆãŠw‹³ˆç): “ú–{–òŠw‰ï‘æ141”N‰ï (2021/3/28), webŠJÃ.

723668. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EFE”z‡–ƒˆÇŠÃÎ“’‹Ž–ƒ‰©ƒGƒLƒX‚Ì’Á’ɍì—p‚̉ðÍ. ’|“à@ƒ1, ’†Xr•ã1, “úŒü{”üŽq2, ‹{“ˆ’¼‹I, —k@‹àˆÜ, “àŽR“Þ•äŽq, “úŒü¹Ži, ‘哈’¼_, “V‘q‹gÍ, ŒÑ’ˍ‚Žu, ‡“cKL, ¬“cŒû_2,3, ‰Ô—Öšæ•F2, ¬—Ñ‹`“T1 (1–òŠw•”, 2“Œ—mˆãŠw‘‡Œ¤‹†Š, 3“Œ—mˆãŠw‹³ˆç): “ú–{–òŠw‰ï‘æ141”N‰ï (2021/3/28), webŠJÃ.

732075. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (µ‘ҍu‰‰“™)yŠ¿•ûˆãŠw‚Ì‘½—l«|’†ˆãŠw‚Ƃ̈Ⴂ‚ð’m‚é|zII •\”ME•\Š¦‚Ì’è‹`. ¯–ì‘ì”V1,2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ¤‹†Š): ‘æ30‰ñŠ¿•ûŽ¡—ÃŒ¤‹†‰ï (2020/9/27), ç—t.

733125. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) •sˆÀ_ŒoÇ‚̏”Çó‚É—èŒjŠÃž¥“’‰Ág‰Ô‚ª—LŒø‚Å‚ ‚Á‚½ˆêÇ—á. ’†”öŒjŽq1, ¯–ì‘ì”V1,2, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ¤‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ30‰ñŠ¿•ûŽ¡—ÃŒ¤‹†‰ï (2020/9/27), ç—t.


•a‰@˜AŒg‹³ˆçŒ¤‹†•”–å

¦u‰º•”Á‰»ŠÇŠO‰ÈŠwv‚ðŽQÆ


—Տ°‰ð–U‹³ˆç‹†•”–å

¦u‰ð–UŠwi¬ì’PˆÊjv‚ðŽQÆ


’nˆæˆã—Êw‹³ˆçŒ¤‹†•”–å

¦uS‘ŸŒŒŠÇŠO‰ÈŠwv‚ðŽQÆ


ˆãŠw•”•‘®—Տ°Œ¤‹†ƒZƒ“ƒ^[

Šé‰æŠJ”­•”–å

[’˜@‘]

620113. [Šwp‘ (•ª’SŽ·•M)]y–òŠwl‚Ì‚½‚ß‚ÌŽ–—á‚ÅŠw‚Ô—Ï—Šwz‘æIV•”@—Տ°Œ»ê‚Å’¼–Ê‚·‚é—Ï—“I–â‘è, p.228-30. “n糒B–ç (—Տ°Œ¤‹†EŠé‰æ), •Ò: —L“c‰xŽq, ‘«—§’ql, “ì]“°, “Œ‹ž, 2020/4”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722210. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “ú–{•a‰@–òÜŽt‰ï‚É‚æ‚éCRCEŽ––±‹ÇƒXƒ^ƒbƒt‹³ˆçŒ¤C‚ɂ‚¢‚Ä. Žðˆäûé_, ‹ß“¡’¼Ž÷, –Ø–“”ü’Õv, Ž›Œ³@„, ˜V–{–¼’ÃŽq, •“c@’q, “n糒B–ç1, …ˆä‹MŽŒ, ’ߊۉëŽq, “cè‰Ãˆê (1—Տ°Œ¤‹†EŠé‰æ): ‘æ20‰ñCRC‚ƗՏ°ŽŽŒ±‚Ì‚ ‚è•û‚ðl‚¦‚é‰ï‹c 2020 in ’·è (2020/11/3), WebŠJÃ.

722211. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) —Տ°Œ¤‹†ƒR[ƒfƒBƒl[ƒ^[‚©‚猤‹†—Ï—ƒRƒ“ƒTƒ‹ƒ^ƒ“ƒg (‘Š’kˆõ) ‚ð–ÚŽw‚µ‚Ä. “n糒B–ç (—Տ°Œ¤‹†EŠé‰æ): ‘æ41‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2020/12/3), •Ÿ‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723669. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆãŽt‚ÌŒ¤‹†—Ï—‚Ì‘¨‚¦•û‚ÉŠÖ‚·‚鎿“IŒ¤‹†`‚æ‚è“KØ‚ÈŒ¤‹†—Ï—‹³ˆç‚Ì‚½‚߂Ɂ`. “n糒B–ç1, ¬‘q–¢—ˆ, ’|•½—ŒbŽq, —L“c‰xŽq (1—Տ°Œ¤‹†EŠé‰æ): ‘æ14‰ñ“ú–{ƒtƒ@[ƒ}ƒVƒ…[ƒeƒBƒJƒ‹ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“Šw‰ï‘å‰ï (2020/6/28), WebŠJÃ.

723670. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž¡Œ±“¯ˆÓƒ[ƒ‹ƒvƒŒƒCŽÀK‚É‚¨‚¯‚éŠw¶‚̈ӎ¯•Ï‰»‚ÌŽ¿“IŒ¤‹†. ‰ª“cˆ»‰À, —L“c‰xŽq, –{‹´—¹, ã”VŒ´—R‰À, ™‰Y–ƒˆß, ¼‘º‹MŽq, ŽR‘º½Žq, ¼˜e^ŽÀŽq, “n糒B–ç1, ŽŒ´@~ (1—Տ°Œ¤‹†EŠé‰æ): ‘æ14‰ñ“ú–{ƒtƒ@[ƒ}ƒVƒ…[ƒeƒBƒJƒ‹ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“Šw‰ï‘å‰ï (2020/6/28), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šw‰ïEŒ¤‹†‰ï“™]

'19-723032. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –ò‹Ç–òÜŽt‚ÌŒ¤‹†—Ï—‚Ì‘¨‚¦•û‚ÉŠÖ‚·‚鎿“IŒ¤‹†`‚æ‚è“KØ‚ÈŒ¤‹†—Ï—‹³ˆç‚Ì‚½‚߂Ɂ`. ¬‘q–¢—ˆ, ’|•½—ŒbŽq, “n糒B–ç1, —L“c‰xŽq (1—Տ°Œ¤‹†EŠé‰æ): “ú–{–òŠw‰ï‘æ140”N‰ï (2020/3/25), Šw‰ï’†Ž~ (Web—vŽ|‚É‚ÄŽQ‰Á¬—§).


ƒvƒƒWƒFƒNƒgŽÀŽ{•”–å

[Šwp˜_•¶]

110403. [Œ´’˜] A 3-Part Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DSP-6952 in Healthy Japanese Subjects and Those With £3 Spontaneous Bowel Movements per Week. Yumizaki T, Maeda M1, Fujita T, Kakuyama H, Kumagai Y2: Clin Pharmacol Drug Dev 2020/4; 9 (3): 353-65. (‘O“cŽÀ‰Ô1, ŒF’J—YŽ¡2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2—Տ°Œ¤‹† (ƒvƒƒWƒFƒNƒg))

110404. [Œ´’˜] A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver. Kumagai Y1, Fujita T, Maeda M2, Sasaki Y3, Nagaoka M, Huang J, Takenaka T, Kawai M: J Clin Pharmacol 2020/6; 60 (6): 702-10. (ŒF’J—YŽ¡1, ‘O“cŽÀ‰Ô2, ²X–Ø‘PM3: 1—Տ°Œ¤‹† (ƒvƒƒWƒFƒNƒg), 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3–òÜ•”)

110405. [Œ´’˜] Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study. Fujishima H, Hasunuma T1, Kawakita T, Sekiya T, Gomes P, Hollander DA: Ocul Immunol Inflamm 2020/6; 1-6. (˜@À’qŽq1: 1—Տ°Œ¤‹† (ƒvƒƒWƒFƒNƒg))

110406. [Œ´’˜] Hepatic Adaptation to Therapeutic Doses of Acetaminophen: An Exploratory Study in Healthy Individuals. Maeda M1, Tanaka R, Aso M, Sakamoto Y, Song I, Ochiai M, Saito Y, Maekawa K, Arakawa N, Ohno Y, Kumagai Y2: Clin Ther 2020/7; 42 (7): 1276-91.e1. (‘O“cŽÀ‰Ô1, ŒF’J—YŽ¡2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2—Տ°Œ¤‹† (ƒvƒƒWƒFƒNƒg))

110407. [Œ´’˜] Novel concentration-QTc models for early clinical studies with parallel placebo controls: A simulation study. Orihashi Y, Kumagai Y1, Shiosakai K: Pharm Stat 2021/3; 20 (2): 375-89. (ŒF’J—YŽ¡1: 1—Տ°Œ¤‹† (ƒvƒƒWƒFƒNƒg))

530023. [‚»‚Ì‘¼ (Šw‰ï´˜^)] ELOBIXIBAT, ILEAL BILE ACID TRANSPORTER INHIBITOR, INCREASES FECAL BILE ACIDS IN PATIENTS WITH CHRONIC CONSTIPATION. Nakajima A, Ishizaki S, Kurosu S, Taniguchi S, Gillberg P-G, Mattsson JP, Hasunuma T1, Camilleri M: Gastroenterology 2020/5; 158 (6, Suppl 1): S-394-5. (˜@À’qŽq1: 1—Տ°Œ¤‹† (ƒvƒƒWƒFƒNƒg))

[’˜@‘]

620114. [Šwp‘ (ŠÄC)]y‰ü’ù ƒJƒ‹ƒe¸‘I—pŒêWzŠÄC: ŒF’J—YŽ¡1, •Ò: ²X–Ø‘PM2, –F“c@v3, –k“‡_”ü4, (1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg, 2–òÜ•”, 3—ÕŒŸ•”, 4ŠÅŒì•”), ƒnƒCƒTƒ€‹ZŒ¤, ‘åã, 2020/8”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

712007. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Japan-Korea Clinical Pharmacology Collaborative Trials. Kumagai Y1: 2020 KoNECT-MOHW-MFDF International Conference Virtual (2020/9/11), WebŠJÃ. (ŒF’J—YŽ¡1: 1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg)

712008. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Sharing Experiences on FIH Clinical Trials. Kumagai Y1: PMDA-ATC Pharmaceuticals Review Webinar 2020 for NPRA, Malaysia (2020/11/6), WebŠJÃ. (ŒF’J—YŽ¡1: 1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg)

722212. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒgƒLƒVƒRƒƒWƒXƒg‚𓧎‹‚·‚é -ŠO‚©‚猩‚½Šú‘Ò- ‘Šú—Տ°ŽŽŒ±ŽÀŽ{’S“–ˆãŽt‚©‚ç‚ÌŠú‘Ò. ŒF’J—YŽ¡ (—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg): ‘æ47‰ñ“ú–{“Ő«Šw‰ïŠwp”N‰ï (2020/7/1), WebŠJÃ.

722213. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Œ¤‹†ŽÒEŠw‰ï—Ž–‚Ì—§ê‚©‚ç”F’èCRC‚É–]‚Þ‚±‚Æ. ŒF’J—YŽ¡ (—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg): ‘æ41‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2020/12/5), •Ÿ‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723671. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠØ‘‚Ƃ̍‘Û‹¤“¯“Á’è—Տ°Œ¤‹†‚ðŒoŒ±‚µ‚Ä. ŒK–”^—R”ü, ã”VŒ´—R‰À, ¼‘º‹MŽq, ¼˜e^ŽÀŽq, ›–ì”ÍŽq, ‘v@ˆê‘å, ¬‘ì‰ë’j, ŒF’J—YŽ¡1, ˜@À’qŽq1 (1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg): ‘æ41‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2020/12/5), •Ÿ‰ª (ƒnƒCƒuƒŠƒbƒhŠJÃ).


ƒoƒCƒIƒGƒVƒbƒNƒX•”–å


‘n–òƒV[ƒYŒ¤‹†ŠJ”­•”–å


ˆãŠw•”•‘®V¢‹Iˆã—ÊJ”­ƒZƒ“ƒ^[

æ’[ˆã—×̈æŠJ”­•”–å

(‹g“cˆê¬)
¦u”å”AŠí‰ÈŠwv‚ðŽQÆ

(“c糁@‘)
¦uÁ‰»Ší“à‰ÈŠwv‚ðŽQÆ

(’·À‰p–¾)
¦uŽ¨•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠwv‚ðŽQÆ

(“c’†@Œ‰)
¦uˆê”ʁE¬Ž™EŠÌ’_äXŠO‰ÈŠwv‚ðŽQÆ

(Œ´—¯OŽ÷)
¦u•úŽËü‰ÈŠwi‰æ‘œf’fŠwjv‚ðŽQÆ

(æèG–¾)
¦u¬Ž™‰ÈŠwv‚ðŽQÆ

(’†¼G•F)
¦u¬Ž™‰ÈŠwv‚ðŽQÆ


‰¡’f“Iˆã—×̈æŠJ”­•”–å

(‹àˆäº•¶)
¦u–ƒŒ‰ÈŠwv‚ðŽQÆ

(ŽR‰ºŒpŽj)
¦uã•”Á‰»ŠÇŠO‰ÈŠwv‚ðŽQÆ

(Vˆä³N)
¦u–ƒŒ‰ÈŠwv‚ðŽQÆ

(²X–ØŽ¡ˆê˜Y)
¦uŒÄ‹zŠí“à‰ÈŠwv‚ðŽQÆ

(¬—ѐ´“T)
¦uÁ‰»Ší“à‰ÈŠwv‚ðŽQÆ

(‚ŽR—zŽq)
¦u–k—¢‘åŠw•a‰@Š´õŠÇ—Žºv‚àŽQÆ

[Šwp˜_•¶]

110408. [Œ´’˜] Trends and molecular characteristics of carbapenemase-producing Enterobacteriaceae in Japanese hospital from 2006 to 2015. Eda R1, Nakamura M2, Takayama Y3, Maehana S2, Nakano R, Yano H, Kitasato H2: J Infect Chemother 2020/7; 26 (7): 667-71. (]“c—È‘¾˜Y1, ’†‘º³Ž÷2, ‚ŽR—zŽq3, ‘O‰ÔË‘¾˜Y2, –k—¢‰p˜Y2: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

[Šw‰ïEŒ¤‹†‰ï“™]

722214. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) •a‰@Š´õ‘΍ô‚ÌŽÀÛ. ‚ŽR—zŽq (V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20-7/19), WebŠJÃ.

723672. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰º•”Á‰»ŠÇŽèp‚É‚¨‚¯‚éŽüpŠú—\–h-R‹Û–ò‚ÌŒŒ’†‚¨‚æ‚Ñ‘gD“à”Z“x‚ÌŠÖŒW«. ‚ŽR—zŽq1,2, ¬¼•q²2,3, “ñ–{–öL2, ˜a“c’B•F2,4, Œú“cKˆê˜Y3, ‰Ô–؏G–¾5 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Š´õŠÇ—Žº, 3–òÜ•”, 4äPŒ´•aEŠ´õ“à, 5–k—¢¶–½Œ¤‹†Š): ‘æ68‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘‰ï (2020/9/14), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

H14-110001. [Œ´’˜] Apoptosis of intestinal crypt epithelium after Cryptosporidium parvum infection. Sasahara T1, Maruyama H, Aoki M, Kikuno R, Sekiguchi T, Takahashi A, Satoh Y, Kitasato H2, Takayama Y3, Inoue M: J Infect Chemother 2003/9; 9 (3): 278-81. (ùŒ´•Žu1, –k—¢‰p˜Y2, ‚ŽR—zŽq3: 1”÷¶•¨, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

H14-110002. [Œ´’˜] Pretreatment of Pseudomonas aeruginosa with a sub-MIC of imipenem enhances bactericidal activity of neutrophils. Sasahara T1, Satoh Y, Sekiguchi T, Suzuki K, Irinoda K, Takayama Y2, Sakamoto A, Kitasato H3, Okamoto R, Inoue M: J Infect Chemother 2003/12; 9 (4): 297-303. (ùŒ´•Žu1, ‚ŽR—zŽq2, –k—¢‰p˜Y3: 1”÷¶•¨, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ˆã—Éq¶Šw•”)


ˆãŠw•”‹³ˆçŒn‹ZpEˆõ

Œ`‘ÔŒn


¶•¨•¨—Œn


•a‘ԁEf—ÃŒn

[Šwp˜_•¶]

110254. [Œ´’˜] Method for preservation of DNA stability of liquid-based cytology specimens from a lung adenocarcinoma cell line. Matsuo Y1, Yamashita K2, Yoshida T3, Satoh Y4: Virchows Arch 2021/3; 478 (3): 507-16. (¼”ö—R‹IŽq1, ŽR‰º˜a–ç2, ‹g“c@Œ÷3, ²“¡”Vr4: 1•a‘ԁEf—ÃŒn, 2•a—•”, 3•a—, 4ŒÄ‹zŠíŠO)

[Šw‰ïEŒ¤‹†‰ï“™]

723338. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ´”­«”ñ¬×–E”xŠà‚̈â“`Žq‰ðÍ‚É‚¨‚¯‚é‰tó‰»ŒŸ‘̍זEf‚Ì—LŒø«. ¼”ö—R‹IŽq1, ŽR‰º˜a–ç2, ‹g“c@Œ÷3, ‹vê@Ž÷2, àV–ì^—Žq, ‘º‰_–FŽ÷3, ²“¡”Vr4 (1•a‘ԁEf—ÃŒn, 2•a—•”, 3•a—, 4ŒÄ‹zŠíŠO): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20), WebŠJÃ.


—\–hˆãŠwŒn


•ªŽqˆã‰ÈŠwE§ŒäŒn


“Œ•a‰@Œ¤‹†Œn


‘gD”|—{ƒZƒ“ƒ^[


DNAŽÀŒ±ƒZƒ“ƒ^[


ƒoƒCƒIƒCƒ[ƒWƒ“ƒOŒ¤‹†ƒZƒ“ƒ^[


ˆâ“`Žq‚ŽŸ‹@”\‰ðÍƒZƒ“ƒ^[


Œ’NŠÇ—ƒZƒ“ƒ^[

[Šwp˜_•¶]

110409. [Œ´’˜] Association between Low Protein Intake and Mortality in Patients with Type 2 Diabetes. Yamaoka T, Araki A, Tamura Y, Tanaka S, Fujihara K, Horikawa C, Aida R, Kamada C, Yoshimura Y, Moriya T1, Ohashi Y, Akanuma Y, Ito H, Sone H: Nutrients 2020/6; 12 (6): 1629. (Žç‰®’B”ü1: 1Œ’NŠÇ—ƒZ)

110410. [Œ´’˜] Vitamin B6 intake and incidence of diabetic retinopathy in Japanese patients with type 2 diabetes: analysis of data from the Japan Diabetes Complications Study (JDCS). Horikawa C1, Aida R1, Kamada C1, Fujihara K1, Tanaka S1, Tanaka S1, Araki A1, Yoshimura Y1, Moriya T1,2, Akanuma Y1, Sone H1 (1Japan Diabetes Complications Study Group); Eur J Nutr 2020/6; 59 (4): 1585-94. (Žç‰®’B”ü1,2: 2Œ’NŠÇ—ƒZ)

110411. [Œ´’˜] Development of glomerular hyperfiltration, a multiphasic phenomenon. Shimada Y, Nakasone Y, Hirabayashi K, Sakuma T, Koike H, Oguchi T, Yamashita K, Uchimido R, Moriya T1, Komatsu M, Aizawa T: Am J Physiol Renal Physiol 2020/12; 319 (6): F1037-41. (Žç‰®’B”ü1: 1Œ’NŠÇ—ƒZ)

520017. [‘à]wŒûLÇx‚̐¸_ˆãŠw“I‘¤–Ê. ‹{’n‰p—Y (Œ’NŠÇ—ƒZ): “ú–{ŒûLŠw‰ï‰ïŽ 2020/4; 11 (1): 5-10.

522131. [uÀ]y“ÁW: ƒŠƒGƒ]ƒ“¸_ˆãŠw‚É‚¨‚¯‚éf—§‚ĂƑΉž…@zƒŠƒGƒ]ƒ“¸_ˆãŠw‚É‚¨‚¯‚ég‘̏ǏóÇ. ‹{’n‰p—Y (Œ’NŠÇ—ƒZ): —Տ°¸_ˆãŠw 2021/2; 50 (2): 143-7.

540051. [‚»‚Ì‘¼ (—á‰ï•ñ)] ˜b‘è’ñ‹Ÿ‚ð‚³‚¹‚Ä‚¢‚½‚¾‚¢‚Ä. ŽR“c—TŽq (Œ’NŠÇ—ƒZ): ‘æ102‰ñŠÖ“Œ’n‹æŠw¶‘Š’kŒ¤‹†‰ï—á‰ï•ñ 2020. https://www.kantogakuso.jp/member/reikai_houkoku/102houkoku_yamada.pdf.

540052. [‚»‚Ì‘¼ (”N•ñ)] 2019”N“x‚ðU‚è•Ô‚Á‚Ä. ŽR“c—TŽq (Œ’NŠÇ—ƒZ): –k—¢‘åŠwŒ’NŠÇ—ƒZƒ“ƒ^[”N•ñ 2020; ‘æ4†: 17-20.

540053. [‚»‚Ì‘¼ (ŽÀŽ{•ñ‘)]y‰ÈŒ¤”ïuƒAƒNƒeƒBƒuƒ‰[ƒjƒ“ƒO‚ÉŠñ—^‚·‚éƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒXƒLƒ‹ŒüãƒvƒƒOƒ‰ƒ€‚̍\’z‚ÆŒŸØvzŒ¤‹†‘ã•\ŽÒ: Î’ˏ¹•Û (Œ’NŠÇ—ƒZ):uƒAƒNƒeƒBƒuƒ‰[ƒjƒ“ƒO‚ÉŠñ—^‚·‚éƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒXƒLƒ‹ŒüãƒvƒƒOƒ‰ƒ€‚̍\’z‚ÆŒŸØvŽÀŽ{•ñ‘ 2021/3. https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-20K14036/20K140362020hokoku/.

[’˜@‘]

620115. [Šwp‘ (•ª’SŽ·•M)]yŽ™“¶S—Šw‚̐i•à (2020”N”Å)z‚VÍ ‚“™‹³ˆç‚É‚¨‚¯‚é”­’BáŠQ, p.151-74. ‘å’¬’m‹v (Œ’NŠÇ—ƒZ), ŠÄC: “ú–{Ž™“¶Œ¤‹†Š, ‹àŽq‘–[, “Œ‹ž, 2020/6”­s.

620116. [Šwp‘ (•ª’SŽ·•M)]y‰Æ‘°S—Šw”N•ñ38z[Še˜_] ‹³ˆç•ª–ì‚É‚¨‚¯‚éŒÂ‚ƉƑ°Žx‰‡‚ÌŽÀ‘H@‘åŠw‚É‚¨‚¯‚éŽq‚Ç‚à‚ƉƑ°‚Ö‚ÌŽx‰‡, p.44-52. ‘å’¬’m‹v (Œ’NŠÇ—ƒZ), •Ò: “ú–{‰Æ‘°S—Šw‰ï, ‹àŽq‘–[, “Œ‹ž, 2020/8”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

722215. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “«áu’Ɂ|g‘Ì•”ˆÊ•Ê‚ÉŒ©‚½‘Ήž‚̍·‚Æ‹¤’Ê“_|uŒûo—̈æ‚Ìáu’Ɂv. ‹{’n‰p—Y (Œ’NŠÇ—ƒZ): ‘æ116‰ñ“ú–{¸__ŒoŠw‰ïŠwp‘‰ï (2020/9/28), WebŠJÃ.

722216. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ¸_‰Èˆã‚©‚ç‚Ý‚½Œûo—̈æ‚̐g‘̏Ǐó|“‚­”ð‚¯‚ç‚ꂪ‚¿‚È•a‘Ô‚É—§‚¿Œü‚©‚¤uŽ•‰ÈˆãŽt‚Ƃ̘AŒgv. ‹{’n‰p—Y (Œ’NŠÇ—ƒZ): ‘æ116‰ñ“ú–{¸__ŒoŠw‰ïŠwp‘‰ï (2020/9/30), WebŠJÃ.

722217. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “œ”A•a«tÇ‚̐t‹@”\’ቺ‚ð—\‘ª‚·‚é‚Ì‚ÍŽÀ‚Í“œ”A•a–Ô–ŒÇ? Žç‰®’B”ü (Œ’NŠÇ—ƒZ): ‘æ35‰ñ“ú–{“œ”A•a‡•¹ÇŠw‰ïE‘æ26‰ñ“ú–{“œ”A•aŠáŠw‰ï‘‰ï (2020/12/7-21), WebŠJÃ.

723673. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[)yÀ’·z’nˆæˆã—ÁEˆã—Ïî•ñ2 ƒ|ƒXƒ^[149. ¼Œ´‚Ü‚Ç‚© (Œ’NŠÇ—ƒZ): ‘æ63‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï (2020/10/5-16) WebŠJÃ.

723674. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒRƒƒi‰Ð‚ł̃Iƒ“ƒ‰ƒCƒ“‚É‚æ‚éw‚±‚±‚ë‚ÌŒ’N’²¸x‚ƃAƒEƒgƒŠ[ƒ`Œ^Žx‰‡‚ÌŽÀ‘H•ñ. ŽR“c—TŽq1, Î’ˏ¹•Û1, ‘å’¬’m‹v1, ‰ÍŒ´‹v”üŽq, “c’†‚ ‚ä‚Ý, —§‰Ô@•X, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): ‘æ58‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ¤‹†W‰ï (2020/11/25), WebŠJÃ, Campus Health 2021; 58 (1): 309.

723675. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) COVID-19‰Ð‚É‚¨‚¯‚é‘åŠw•a‰@Eˆõ‚̃ƒ“ƒ^ƒ‹ƒwƒ‹ƒX‚Ö‚ÌŽæ‚è‘g‚Ý. ‹{’n‰p—Y1, ŽR‰º^—R1, ìã”ü’q‘ã1,2, ‘Oì‰ÀŽq1,2, ‘“cçH1,2, …Œû@e1,2, “‰€@”E1,2, ‹g“c—F‹I1, ¼Œ´‚Ü‚Ç‚©1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ, 2ŠÅŒì•”): ‘æ58‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ¤‹†W‰ï (2020/11/25-26), WebŠJÃ.

723676. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) COVID-19‰Ð‚É‚¨‚¯‚錒NŠÇ—ƒZƒ“ƒ^[‚Ì–ðŠ„‚Í‘½Šò‚ɂ킽‚é. Žç‰®’B”ü1, ìã”ü’q‘ã1,2, ‘Oì‰ÀŽq1,2, ‘“cçH1,2, …Œû@e1,2, “‰€@”E1,2, ‹g“c—F‹I1, ‹{’n‰p—Y1, ŽR‰º^—R1, ŽR“c—TŽq1, ¼Œ´‚Ü‚Ç‚©1 (1Œ’NŠÇ—ƒZ, 2ŠÅŒì•”): ‘æ58‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ¤‹†W‰ï (2020/11/25-26), WebŠJÃ.

723677. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ñŽå‘Ì“I—ˆ’kŠw¶‚ɑ΂·‚éƒJƒEƒ“ƒZƒ‰[‚Ì—‰ð‚ƑΉž‚ÉŠÖ‚·‚éƒCƒ“ƒ^ƒrƒ…[’²¸|”ñŽå‘Ì“I‚ȏó‘Ô‚Å—ˆ’k‚µ‚½Šw¶‚ªŽå‘Ì“I‚È‘Š’kŽÒ‚Æ‚È‚Á‚Ä‚¢‚­‚Ü‚Å‚ÌŽx‰‡‚ɂ‚¢‚ā|. ‘å’¬’m‹v1, ŽR“c—TŽq1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): “ú–{S——Տ°Šw‰ï‘æ39‰ñ‘å‰ï (2020/11/20-26), WebŠJÃ.

723678. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘Š’k‚·‚鎖‚É”ñŽå‘Ì“I‚ȏó‘Ô‚Å—ˆ’k‚·‚éŠw¶‚ɑ΂·‚éƒJƒEƒ“ƒZƒ‰[‚Ì—‰ð‚ƑΉž|Šw¶‘Š’k‹@ŠÖ‚ɋ΂߂éƒJƒEƒ“ƒZƒ‰[‚ւ̃Cƒ“ƒ^ƒrƒ…[’²¸‚É‚æ‚鎿“IŒŸ“¢|. ‘å’¬’m‹v1, ŽR“c—TŽq1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): “ú–{S——Տ°Šw‰ï‘æ39‰ñ‘å‰ï (2020/11/20-26), WebŠJÃ.

732076. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) VŒ^ƒRƒƒiƒEƒBƒ‹ƒX‰e‹¿‰º‚Å‚Ì–k—¢‘åŠw‚ÌŽæ‘g‚Ý. ŽR“c—TŽq (Œ’NŠÇ—ƒZ): “ú–{Šw¶‘Š’kŠw‰ï‘æ51‰ñŠw¶‘Š’kƒZƒ~ƒi[ (2020/8/2), WebŠJÃ.

733126. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘ΖʑŠ’k, ƒIƒ“ƒ‰ƒCƒ“‘Š’k, “d˜b‘Š’k‚ðŒoŒ±‚µ‚čl‚¦‚½‚±‚Æ. ŽR“c—TŽq (Œ’NŠÇ—ƒZ): ŠÖ“Œ’n‹æŠw¶‘Š’kŒ¤‹†‰ï‘æ102‰ñ—á‰ï (2020/12/6), WebŠJÃ.

733127. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) ’·ŠúŒo‰ß‚Å“œ”A•a–«‡•¹Ç‚ªoŒ»‚µ‚½‚ªŽ¡—Âɂæ‚芰‰ð/‘ޏk‚µ‚½1—á. ¼Œ´‚Ü‚Ç‚© (Œ’NŠÇ—ƒZ): ‘æ58‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2021/1/30), WebŠJÃ.

'19”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-110023. [Œ´’˜] Serial renal biopsies in normo- and microalbuminuric patients with type 2 diabetes demonstrate that loss of renal function is associated with a reduction in glomerular filtration surface secondary to mesangial expansion. Moriya T1, Yamagishi T, Matsubara M1, Ouchi M: J Diabetes Complications 2019/5; 33 (5): 368-73. (Žç‰®’B”ü1, ¼Œ´‚Ü‚Ç‚©1: 1Œ’NŠÇ—ƒZ)

'19-120005. [Œ´’˜] ”ì–ž‘åŠw¶‚Ì‘Ì‘g¬‘ª’è‚Ɖü‘P‚Ö‚ÌŽæ‚è‘g‚Ý. ¼Œ´‚Ü‚Ç‚©1, ‹g“c—F‹I1, ‹{’n‰p—Y1, “‰€@”E1,2, ìã”ü’q‘ã1,2, ‘“cçH1,2, …Œû@e1,2, ‘Oì‰ÀŽq1,2, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ, 2ŠÅŒì•”): CAMPUS HEALTH 2020/3; 57 (1): 130-2.


–k—¢‘åŠw•a‰@

ŠÅŒì•”

[Šwp˜_•¶]

110412. [Œ´’˜] Exploring the components of the quality of death in Japanese emergency departments: A qualitative study. Ito Y, Tsubaki M1, Fujimoto M, Sakaguchi Y: Appl Nurs Res 2020/12; 56: 151371. (’Ö”ü’q”Ž1: 1ŠÅŒì•”)

120038. [Œ´’˜] ’†Œ˜ŠÅŒìŽt‚ÌŠÅŒìŽÀ‘H”\—͂ƃŒƒWƒŠƒGƒ“ƒX‚¨‚æ‚у`[ƒ€ƒAƒvƒ[ƒ`‚Æ‚ÌŠÖ˜A|ŠÅŒìŽÀ‘H”\—ÍŒüã‚ÉŒü‚¯‚Ä‚Ì‘²ŒãŠÅŒìŽt‹³ˆç‚Ì‚ ‚è•û|. “c’†@L1, ‰ºŽi‰fˆê1, ˆÀ•”‘Žq1, ‰|“c‚ß‚®‚Ý1, •Ÿ’n–{°”ü1, ’Ö”ü’q”Ž2, “¡ŒãG•ã1, ’·“ˆk•½1, ”’ŒËMs1 (1º˜a‘åŠw, 2ŠÅŒì•”): º˜aŠwŽm‰ïŽGŽ 2020/7; 80 (2): 131-43.

120039. [Œ´’˜] ¬Ž™Šú‚ɐ¶‘̊̈ڐA‚ðŽó‚¯‚½Š³ŽÒ‚ª‘¨‚¦‚Ä‚¢‚é‰Æ‘°‚Ì—l‘Š|—×{¶Šˆ‚ɂ‚¢‚Ä‚ÌŒê‚è‚©‚ç|. ¼“à‰ÀŽq1, ’†“‡ßŽq1 (1ŠÅŒì•”): “ú–{ˆÚAEÄ¶ˆã—ÊŌìŠw‰ïŽ 2020/7; 15: 1-13.

120040. [Œ´’˜] ‹~–½‹~‹}ƒZƒ“ƒ^[‚É‚¨‚¯‚ég‘ŸŠíE‘gD’ñ‹Ÿ‚̈ӎv‚ɑ΂·‚éƒAƒ“ƒP[ƒgh‚ðŽg—p‚µ‚½‘I‘ðŽˆ’ñŽ¦‚ª‰Æ‘°‚Ì‘ŸŠí’ñ‹Ÿ‚ÉŠÖ˜A‚·‚és“®‚𑣂·Œø‰Ê. ’Ö”ü’q”Ž1, ‰ºŽi‰fˆê2, “¡ŒãG•ã2, ŒF‘ò^‹|2, “c’†@L2 (1ŠÅŒì•”, 2º˜a‘åŠw): º˜aŠwŽm‰ïŽGŽ 2021/3; 80 (6): 546-56.

120041. [Œ´’˜] isäX‚ª‚ñŠ³ŽÒE‰Æ‘°‚Æ‚ª‚ñŠÅŒìê–åŠÅŒìŽt‚Ƃ̃p[ƒgƒi[ƒVƒbƒv‚ÉŠî‚­ŠÅŒì–Ê’k‚Ì•]‰¿. çú±”ü“oŽq1, Ž™‹Ê”ü—R‹I1, ŒK–¼Žõ”ü1, ¬ŽRK‘ã2 (1ŠÅŒì•”, 2ŠÅŒìŠw•”): –Ø‘ºŠÅŒì‹³ˆçU‹»à’cŠÅŒìŒ¤‹†W˜^ 2020/9; 27: 61-99.

220003. [€Œ´’˜] ƒPƒA’ñ‹ŸŽÒ‚ð‘ΏۂƂµ‚½u”F’mÇ‚̐l‚Ƃ̃Rƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒXƒLƒ‹ƒAƒbƒvƒZƒ~ƒi[v‚ÌŽÀŽ{‚Æ‚»‚Ì•]‰¿. ¬ŽRK‘ã1, •Ðˆä”üØŽq2, 傖¼—R‰Á—¢3, sr‰Âˆ¤3, ˜a“c“Þ”üŽq4 (1ŠÅŒìŠw•”, 2’¬“cŽs‚—îŽÒ•ŸŽƒƒZƒ“ƒ^[, 3ŠÅŒì•”, 4–k—¢‘åŠw–k—¢Œ¤‹†Š•a‰@): “ú–{‘Šú”F’mÇŠw‰ïŽ 2020/6; 13 (1): 75-80.

520018. [‘à] (Secondary Publication) ŠÅŒìŠw¶‚Ì‘ŸŠí’ñ‹Ÿ‚Ö‚Ì‘Ô“x‚ÉŠÖ‚·‚éƒiƒ‰ƒeƒBƒuƒŒƒrƒ…[. ’Ö”ü’q”Ž1, “¡ŒãG•ã2, ¬—ÑŠ²h3, rì@‘1, ‹g“cˆê¬4 (1ŠÅŒì•”, 2º˜a‘åŠw“¡‚ª‹u•a‰@, 3‘åŠw‰@ŠÅŒìŠwŒ¤‹†‰È, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã) ˆÚA 2020/7; 55 (2): 109-18.

522132. [uÀ]y¬Ž™ŠÅŒì‚É‚¨‚¯‚éŒp‘±‹³ˆç|2”N–ڈȍ~‚ÌŠÅŒìŽt‚ð‘ΏۂɁ|z[‘˜_] …@2”N–ڈȍ~‚ÌŒp‘±‹³ˆç‚̈Ӌ`E‰Û‘è; ‘åŠw•a‰@‚Ì—§ê‚©‚ç. –Ø‘º‚ä‚ÝŽq (ŠÅŒì•”): ¬Ž™ŠÅŒì 2020/7; 43 (7): 778-83.

522133. [uÀ]yƒf[ƒ^‚ð—p‚¢‚½Œ»ê‚̉Ž‹‰»‚Å, ‘gD‚ÌŽ¿‚ð‚‚ß‚é! –k—¢‘åŠw•a‰@‚̏î•ñƒ}ƒlƒWƒƒ“ƒgzî•ñ’S“–ŠÅŒìŽt‚Ì–ðŠ„‚ÆŽÀ‘H. ´…›’“ (ŠÅŒì•”): ŠÅŒìŠÇ— 2020/8; 30 (8): 708-16.

522134. [uÀ]yƒf[ƒ^‚ð—p‚¢‚½Œ»ê‚̉Ž‹‰»‚Å, ‘gD‚ÌŽ¿‚ð‚‚ß‚é! –k—¢‘åŠw•a‰@‚̏î•ñƒ}ƒlƒWƒƒ“ƒgz–Ú•WŠÇ—‚É‚¨‚¯‚éƒCƒ“ƒfƒBƒP[ƒ^‚ÌŠˆ—p@î•ñ’S“–ŠÅŒìŽt‚É‚æ‚éŠÅŒìŠÇ—ŽÒ‚ÌŽx‰‡. ´…›’“ (ŠÅŒì•”): ŠÅŒìŠÇ— 2020/8; 30 (8): 717-25.

522135. [uÀ]yƒf[ƒ^‚ð—p‚¢‚½Œ»ê‚̉Ž‹‰»‚Å, ‘gD‚ÌŽ¿‚ð‚‚ß‚é! –k—¢‘åŠw•a‰@‚̏î•ñƒ}ƒlƒWƒƒ“ƒgzŽÀ‘H•ñ [•”‚̃f[ƒ^Šˆ—p2] dÇ“x, ˆã—ÁEŠÅŒì•K—v“xƒf[ƒ^‚ÌŠˆ—p. H“¡‹v”üŽq (ŠÅŒì•”): ŠÅŒìŠÇ— 2020/8; 30 (8): 732-5.

522136. [uÀ]yƒf[ƒ^‚ð—p‚¢‚½Œ»ê‚̉Ž‹‰»‚Å, ‘gD‚ÌŽ¿‚ð‚‚ß‚é! –k—¢‘åŠw•a‰@‚̏î•ñƒ}ƒlƒWƒƒ“ƒgzŽÀ‘H•ñ [•”‚̃f[ƒ^Šˆ—p3] ŠÅŒì•â•ŽÒ‚Ì”NŽŸ—L‹‹‹x‰ÉŽæ“¾@u‹Î–±ŽžŠÔŠÈˆÕŒvŽZ•\v‚ð—p‚¢‚½, •a“‚ð‰z‚¦‚½‹Î–±•\ì¬. ‰Í“c‘½‰Á (ŠÅŒì•”): ŠÅŒìŠÇ— 2020/8; 30 (8): 736-40.

522137. [uÀ]yƒf[ƒ^‚ð—p‚¢‚½Œ»ê‚̉Ž‹‰»‚Å, ‘gD‚ÌŽ¿‚ð‚‚ß‚é! –k—¢‘åŠw•a‰@‚̏î•ñƒ}ƒlƒWƒƒ“ƒgzŽÀ‘H•ñ [•”‚̃f[ƒ^Šˆ—p5] ˜J–±ŠÇ—: ŽžŠÔŠO‹Î–±‚̍팸.@ “‰€@”E (ŠÅŒì•”): ŠÅŒìŠÇ— 2020/8; 30 (8): 747-53.

522138. [uÀ]y“ÁW: S‘ŸŒŒŠÇŠO‰È‚̃n[ƒgƒ`[ƒ€‚É‚¨‚¯‚éŠÅŒìŽt‚Ì–ðŠ„z‘¼EŽí‚Æ‹¦“­‚µ‚ÄŽÀ‘H‚·‚éS‘ŸŒŒŠÇŠO‰ÈŽüpŠú‚̃PƒA. “à“¡ˆŸŽ÷ (ŠÅŒì•”): “ú–{zŠÂŠíŠÅŒìŠw‰ïŽ 2020/8; 16 (1): 29-30.

522139. [uÀ]y“Á•ÊŠé‰æ: ƒRƒƒi‚ª•Ï‚¦‚éŽÐ‰ï‚Æ‚±‚±‚ëz–k—¢‘åŠw•a‰@‚É‚¨‚¯‚éVŒ^ƒRƒƒiƒEƒBƒ‹ƒX‘Ήž|ŠÅŒì‚ƃƒ“ƒ^ƒ‹ƒwƒ‹ƒXŽx‰‡‚𒆐S‚Ɂ|. ”’ˆä‹³Žq (ŠÅŒì•”): ‚±‚±‚ë‚̉Ȋw 2020/12; 215: 70-4.

522140. [uÀ]yŠÉ˜aƒPƒAŠÅŒì‹Zp11zŠÉ˜aƒPƒA‚É‚¨‚¯‚éÇóƒ}ƒlƒWƒƒ“ƒg: áu’É. ŒK–¼Žõ”ü (ŠÅŒì•”): “ú–{”ÅNursing Skill‚“ (ƒIƒ“ƒ‰ƒCƒ“‹³ˆçƒc[ƒ‹) 2020/12.

522141. [uÀ]y˜AÚ: ƒIƒsƒIƒCƒh—U”­«•Ö”éÇ (OIC) ‚̃AƒZƒXƒƒ“ƒg‚ÆŽ¡—Öò‚ÌŽg‚¢•ûz‘æ4‰ñ [Ž–—áÐ‰î] ƒIƒsƒIƒCƒh—U”­«•Ö”éÇ (OIC) ‚ւ̃PƒA‚ÌŽÀÛ. ¼Œ´N”ü1, ¼Œ´’mŽ}2, ‰ª“cŒb2 (1ŠÅŒìŠw•”, 2ŠÅŒì•”): ƒi[ƒXê‰È 2021/1; https://knowledge.nurse-senka.jp/500003.

522142. [uÀ]y˜AÚ: ƒjƒ…[ƒ}ƒ“—˜_EŒ¤‹†EŽÀ‘HŒ¤‹†‰ï‚̍LêzCOVID°19ƒpƒ“ƒfƒ~ƒbƒN‚©‚ç‚ÌŠw‚Ñ: ƒ}[ƒKƒŒƒbƒgEƒjƒ…[ƒ}ƒ“—˜_‚ÉŠî‚¢‚½Ž©ŒÈ‚Ì‘ÌŒ±‚̈Ӗ¡‚̕ω»@COVID°19– ‰„‚Ì’†‚ŁAŽ©ŒÈ‚̃pƒ^[ƒ“‚Ö‚Ì‹C‚«. _’J–FŠG (ŠÅŒì•”): ŠÅŒìŽÀ‘H‚̉Ȋw 2021/2; 46 (3): 73°5.

540054. [‚»‚Ì‘¼ (L•ñŽ)] ’j«ŠÅŒìŽt‚̈玙‹x‹ÆŽæ“¾‚Ö‚ÌŽæ‚è‘g‚Ý. ’Ö”ü’q”Ž (ŠÅŒì•”): ‚©‚È‚ª‚íŠÅŒì˜A–¿’ʐM 2020/8; No.73: 7.

[’˜@‘]

620117. [Šwp‘ (•ª’SŽ·•M)]yŠÉ˜aƒPƒA‚É‚¨‚¯‚é‰Æ‘°ƒPƒAƒxƒXƒgƒvƒ‰ƒNƒeƒBƒX (ŠÉ˜aƒPƒA30Šª‘Š§†)z‘æII•” ƒVƒ`ƒ…ƒG[ƒVƒ‡ƒ“‚ɉˆ‚Á‚½Šeê–å‰Æ‚̉Ƒ°ƒPƒAƒxƒXƒgƒvƒ‰ƒNƒeƒBƒX@II-26. –ʉï‚É—ˆ‚È‚­‚È‚Á‚½ŽvtŠú‚ÌŽq‚Ç‚à‚ª‚¢‚é‚Æ‚«|¬Ž™ŠÅŒì‚Ì—§ê‚©‚ç|, p.161-5. ‘å’ˁ@ (ŠÅŒì•”), ÂŠCŽÐ, “Œ‹ž, 2020/6”­s.

620118. [Šwp‘ (•ª’SŽ·•M)]yŒ©‚Ä‚Å‚«‚é—Տ°ƒPƒA}ŠÓ@¬Ž™ŠÅŒìƒrƒWƒ…ƒAƒ‹ƒi[ƒVƒ“ƒOz‘æ2Í ¬Ž™‚Ì“Á’¥@Œ©‚ďo—ˆ‚é—Տ°ƒPƒA, ‚.14-34. ‘å’ˁ@1 (1ŠÅŒì•”), •Ò: ‘å’ˁ@1, ”¼“c_”ü2 (2_ŒËŽsŠÅŒì‘åŠw), ŠwŒ¤ƒƒfƒBƒJƒ‹GŽÐ, “Œ‹ž, 2020/6”­s.

620119. [Šwp‘ (•ª’SŽ·•M)]yŒ©‚Ä‚Å‚«‚é—Տ°ƒPƒA}ŠÓ@¬Ž™ŠÅŒìƒrƒWƒ…ƒAƒ‹ƒi[ƒVƒ“ƒOz‘æ7Í ¬Ž™‰È‚ÌŒŸ¸‚ƃPƒA@1. ŒŸ‘̍̎æ, p.157-60. –Ø‘º‚ä‚ÝŽq1 (1ŠÅŒì•”), •Ò: ‘å’ˁ@1, ”¼“c_”ü2 (2_ŒËŽsŠÅŒì‘åŠw), ŠwŒ¤ƒƒfƒBƒJƒ‹GŽÐ, “Œ‹ž, 2020/6”­s.

620120. [Šwp‘ (•ª’SŽ·•M)]yŒ©‚Ä‚Å‚«‚é—Տ°ƒPƒA}ŠÓ@¬Ž™ŠÅŒìƒrƒWƒ…ƒAƒ‹ƒi[ƒVƒ“ƒOz‘æ7Í ¬Ž™‰È‚ÌŒŸ¸‚ƃPƒA@2. ¬Ž™‚ÌŠÏŽ@@…@g‘Ì‚ÌŒv‘ª, …AƒoƒCƒ^ƒ‹ƒTƒCƒ“‘ª’è, …Bƒ‚ƒjƒ^[‚ÌŒv‘ª, p.161-87. ¼“à‰ÀŽq1 (1ŠÅŒì•”), •Ò: ‘å’ˁ@1, ”¼“c_”ü2 (2_ŒËŽsŠÅŒì‘åŠw), ŠwŒ¤ƒƒfƒBƒJƒ‹GŽÐ, “Œ‹ž, 2020/6”­s.

620121. [Šwp‘ (•ª’SŽ·•M)]yŒ©‚Ä‚Å‚«‚é—Տ°ƒPƒA}ŠÓ@¬Ž™ŠÅŒìƒrƒWƒ…ƒAƒ‹ƒi[ƒVƒ“ƒOz‘æ8Í ¬Ž™‰È‚ÌŽ¡—ÁEˆ’u‚ƃPƒA@4. ˆ’u, p.276-9. –Ø‘º‚ä‚ÝŽq1 (1ŠÅŒì•”), •Ò: ‘å’ˁ@1, ”¼“c_”ü2 (2_ŒËŽsŠÅŒì‘åŠw), ŠwŒ¤ƒƒfƒBƒJƒ‹GŽÐ, “Œ‹ž, 2020/6”­s.

620122. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ2Í –ò‚𐳂µ‚­ˆù‚Ý‘±‚¯‚邽‚߂Ɂ@–ò‚ÌŠÇ—‚ƈù‚Ý–Y‚ê‚È‚¢H•v, ÐŠQ‚É”õ‚¦‚Ä, p.119. –ìŒû•¶”T1, ‹g“cˆê¬2, ¬—я¹G3 (1ŠÅŒì•”, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3–òŠw•”), ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620123. [Šwp‘ (•ª’SŽ·•M)]yŠÅŒìŠwƒeƒLƒXƒgNiCE@‚ª‚ñŠÅŒì@—lX‚È”­’B’iŠKEŽ¡—ÃŒo‰ß‚É‚ ‚邪‚ñŠ³ŽÒ‚ðŽx‚¦‚éz‘æVIÍ ŠÉ˜aƒPƒA@3.ŠeÇó‚̃}ƒlƒWƒƒ“ƒg@C. ˆ«‰tŽ¿, p.214-7. çú±”ü“oŽq (ŠÅŒì•”), •Ò: —é–Ø‹v”ü, —с@’¼Žq, ²“¡‚Ü‚ä‚Ý, “ì]“°, “Œ‹ž, 2021/1”­s.

620124. [Šwp‘ (•ª’SŽ·•M)]yVŒ^ƒRƒƒiƒEƒBƒ‹ƒX ƒi[ƒX‚½‚¿‚ÌŒ»êƒŒƒ|[ƒgz•ª•ØŽæ‚舵‚¢ˆã—Ë@ŠÖ@file #026 COVID-19”D•w‚̒鉤ØŠJ‚ðŒoŒ±‚µ‚Ä, p.229-37. ¬ìŠì”üŽq (ŠÅŒì•”), •Ò: “ú–{ŠÅŒì‹¦‰ïo”ʼnï•ÒW•”, “Œ‹ž, 2021/2”­s.

620125. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER 1 ŠÉ˜aƒPƒA‚ÆŠÅŒìŽt‚Ì–ðŠ„@‚S ŠÉ˜aƒPƒA‚É‚¨‚¯‚éƒ`[ƒ€ˆã—Â̕‹y‚ÆŠÅŒìŽt‚Ì–ðŠ„, p.26-34. ²“¡”ü‹I1, çú±”ü“oŽq1 (1ŠÅŒì•”), •Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620126. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER 2 ÇóƒAƒZƒXƒƒ“ƒg‚Æ•W€“IƒPƒA@1 áu’É, p.36-45 ¬ŽR—F—¢]1, çú±”ü“oŽq2 (1ŠÅŒìŠw•”, 2ŠÅŒì•”), •Ò: çú±”ü“oŽq2, ¬ŽRK‘ã1, ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620127. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER 2 ÇóƒAƒZƒXƒƒ“ƒg‚Æ•W€“IƒPƒA@5 ˆ«‰tŽ¿, p.62-8. çú±”ü“oŽq1 (1ŠÅŒì•”), •Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620128. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER ‚R —×{‰ß’ö‚ÆŽ–—á‚©‚çŠw‚ԊɘaƒPƒA‚ÌŽÀÛ@1 is‚ª‚ñ@(1) —×{‰ß’ö‚ƊɘaƒPƒA‚Ì“Á’¥, p.82-4. çú±”ü“oŽq1 (1ŠÅŒì•”), •Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620129. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER ‚R —×{‰ß’ö‚ÆŽ–—á‚©‚çŠw‚ԊɘaƒPƒA‚ÌŽÀÛ@1 is‚ª‚ñ@(2) Ž–—á|f’f‰Šú‚©‚çŠÉ˜aƒPƒA‚ðŠó–]‚³‚ꂽA‚³‚ñ, p.85-9. …–ì‰À“s”ü1, çú±”ü“oŽq1 (1ŠÅŒì•”), •Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620130. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER ‚R —×{‰ß’ö‚ÆŽ–—á‚©‚çŠw‚ԊɘaƒPƒA‚ÌŽÀÛ@2 S•s‘S, p.98-112. 傖¼—R‰Á—¢1 (1ŠÅŒì•”), •Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620131. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER ‚R —×{‰ß’ö‚ÆŽ–—á‚©‚çŠw‚ԊɘaƒPƒA‚ÌŽÀÛ@3 –«•ÂÇ«”xŽ¾Š³ (COPD)@(1) —×{‰ß’ö‚ƊɘaƒPƒA‚Ì“Á’¥, p.113-6. …–ì‰À“s”ü1 (1ŠÅŒì•”), •Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620132. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER ‚R —×{‰ß’ö‚ÆŽ–—á‚©‚çŠw‚ԊɘaƒPƒA‚ÌŽÀÛ@3 –«•ÂÇ«”xŽ¾Š³ (COPD)@(2) Ž–—á|ŒÄ‹z•â•—Ö@‚É‚æ‚é‹ê’É‚ð•ø‚¦‚éE‚³‚ñ, p.117-21. ŽR–{–¢Ø1 (1ŠÅŒì•”), •Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620133. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER ‚R —×{‰ß’ö‚ÆŽ–—á‚©‚çŠw‚ԊɘaƒPƒA‚ÌŽÀÛ@3 –«•ÂÇ«”xŽ¾Š³ (COPD)@(3) Ž–—á|Çó‚̐is‚É”º‚¢•sˆÀ‚ª‘‹­‚µ‚½F‚³‚ñ, p.122-7. ŒºŠC‘׎q1 (1ŠÅŒì•”), •Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620134. [Šwp‘ (•ª’SŽ·•M)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAzCHAPTER ‚R —×{‰ß’ö‚ÆŽ–—á‚©‚çŠw‚ԊɘaƒPƒA‚ÌŽÀÛ@4 ‹ØˆÞk«‘¤õd‰»Ç (ALS), p.128-42. ‘å‰i—¢”ü1 (1ŠÅŒì•”), •Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

620135. [Šwp‘ (•ª’SŽ·•M)]yƒPƒA‚ð‰ÂŽ‹‰»! ’†”͈͗˜_EŠÅŒìƒ‚ƒfƒ‹@Ž–—á‚ð“Ç‚Ý‰ð‚­Œ^Ž†z¢“—á‚𗝘_‚Å“Ç‚Ý‰ð‚¢‚Ä‚Ý‚æ‚¤@1. ƒjƒ…[ƒ}ƒ“—˜_: ––Šú‚·‚¢‘Ÿ‚ª‚ñ‚̍’m‚ðŽó‚¯‚ăXƒsƒŠƒ`ƒ…ƒAƒ‹ƒyƒCƒ“‚ð‘ÌŒ±‚µ‚Ä‚¢‚é‘s”NŠú‚ÌA‚³‚ñ, p.2-15. çú±”ü“oŽq1, ŽOŽŸ^—2 (1ŠÅŒì•”, 2•‘ –ì‘åŠwŠÅŒìŠw•”), •Ò: r”ö°Œb, “ì]“°, “Œ‹ž, 2021/3”­s.

621005. [Šwp‘ (•ÒW)]yŒ©‚Ä‚Å‚«‚é—Տ°ƒPƒA}ŠÓ@¬Ž™ŠÅŒìƒrƒWƒ…ƒAƒ‹ƒi[ƒVƒ“ƒOz•Ò: ‘å’ˁ@1 (1ŠÅŒì•”), ”¼“c_”ü2 (2_ŒËŽsŠÅŒì‘åŠw), ŠwŒ¤ƒƒfƒBƒJƒ‹GŽÐ, “Œ‹ž, 2020/6”­s.

621006. [Šwp‘ (•ÒW)]y—×{‰ß’ö‚ðŽx‚¦‚邪‚ñE”ñ‚ª‚ñŠ³ŽÒ‚̊ɘaƒPƒAz•Ò: çú±”ü“oŽq1, ¬ŽRK‘ã2 (1ŠÅŒì•”, 2ŠÅŒìŠw•”), ˆãŽ•–òo”Å, “Œ‹ž, 2021/3”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

721030. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ˆÚAˆã‚ÆRTC‚ªŽæ‚è‘g‚ñ‚¾VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ‘΍ô. ˆä‘º—[•P1, Âú刟”ü1, X‰ª—DŽq2, ŽR–{—IŽ÷3, ‹g“c•üŽq2, –ìŒû•¶”T1, –k“‡˜aŽ÷4, Îˆä‘å•ã4, ‹g“cˆê¬4,5 (1ŠÅŒì•”, 2‰h—{•”, 3–òÜ•”, 4”å”AŠí, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ54‰ñ“ú–{—Տ°tˆÚAŠw‰ï (2021/2/17), webŠJÃ, ‘æ54‰ñ“ú–{—Տ°tˆÚAŠw‰ïƒvƒƒOƒ‰ƒ€´˜^W 2021/1; p.63.

722218. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠÅŒì‚Ì•]‰¿‚Ì‚½‚߂̃f[ƒ^Šˆ—p@ŠÅŒìŠÇ—ŽÒ‚ªuŽè’iv‚Æ‚µ‚ăf[ƒ^‚ðŠˆ—p‚Å‚«‚é‚悤‚É‚·‚邽‚߂̏î•ñ’S“–ŠÅŒìŽt‚É‚æ‚éŽx‰‡‚ÌŽÀÛ. ´…›’“ (ŠÅŒì•”): ‘æ24‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2020/8/28), webŠJÃ, ‘æ24‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï´˜^W 2020/7; p.117.

722219. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) VlŠÅŒìŽt‚ÌŽžŠú‚ðU‚è•Ô‚Á‚Ä. •x“c“Þ (ŠÅŒì•”): ‘æ36‰ñ“ú–{ƒXƒgƒŒƒXŠw‰ïŠwp‘‰ï (2020/10/24), webŠJÃ, ƒXƒgƒŒƒX‰ÈŠw 2020/10; 35 (2): 124.

722220. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Žqˆç‚Đ¢‘ã‚Ì—§ê‚©‚ç. ŒÜ\—’ˆŸŠóŽq (ŠÅŒì•”): ‘æ36‰ñ“ú–{ƒXƒgƒŒƒXŠw‰ïŠwp‘‰ï (2020/10/24), webŠJÃ, ƒXƒgƒŒƒX‰ÈŠw 2020/10; 35 (2): 125.

722221. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’j«ŠÅŒìŽt‚Æ‚µ‚ẴLƒƒƒŠƒAŠJ”­. ‰i‰ª@–õ (ŠÅŒì•”): ‘æ36‰ñ“ú–{ƒXƒgƒŒƒXŠw‰ïŠwp‘‰ï (2020/10/24), webŠJÃ, ƒXƒgƒŒƒX‰ÈŠw 2020/10; 35 (2): 126.

722222. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠÅŒìŽt’·‚̃XƒgƒŒƒXƒ}ƒlƒWƒƒ“ƒg`ŠÅŒìŠÇ—‚ðŠy‚µ‚ݐ¶‚«¶‚«‚Æ“­‚­‚½‚߂Ɂ`. ’–ˆäÍŽq (ŠÅŒì•”): ‘æ36‰ñ“ú–{ƒXƒgƒŒƒXŠw‰ïŠwp‘‰ï (2020/10/24), webŠJÃ, ƒXƒgƒŒƒX‰ÈŠw 2020/10; 35 (2): 127.

722223. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠÅŒì•”‚É‚¨‚¯‚éƒXƒgƒŒƒX‘΍ô. ’JŒû—zŽq (ŠÅŒì•”): ‘æ36‰ñ“ú–{ƒXƒgƒŒƒXŠw‰ïŠwp‘‰ï (2020/10/24), webŠJÃ, ƒXƒgƒŒƒX‰ÈŠw 2020/10; 35 (2): 128.

722224. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) I––Šúˆã—ẨƑ°ƒPƒA@‹~‹}EW’†Ž¡—×̈æ‚É‚¨‚¯‚éI––ŠúŠ³ŽÒ‰Æ‘°ƒPƒA‚ðl‚¦‚é. ‚‹´@Œb1,2 (1ŠÅŒì•”, 2ˆÚAˆã—ÃŽx‰‡Žº): ‘æ56‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2020/11/1-30), webŠJÃ, ˆÚA 2020/10; 55 (‘‰ï—ÕŽž): 325.

722225. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv)y‘ŸŠí’ñ‹Ÿ‚ƈڐAˆã—ÁEŠÅŒì‚̍¡`COVID-19Žž‘ã‚ÌŒ£tˆÚA`z“d˜b‚ª—ˆ‚é‚Ì‚Í–¾“ú‚©‚à’m‚ê‚È‚¢. –ìŒû•¶”T (ŠÅŒì•”): ‘æ23‰ñ“ú–{t•s‘SŠÅŒìŠw‰ïŠwpW‰ïE‘‰ï (2020/11/22), webŠJÃ, ‘æ23‰ñ“ú–{t•s‘SŠÅŒìŠw‰ïŠwpW‰ïE‘‰ï´˜^W 2020/10; p.126.

722226. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)ySSI‚¾‚¯‚¶‚á‚È‚¢!ŽüpŠú‚É‚¨‚¯‚éƒfƒoƒCƒXƒT[ƒxƒCƒ‰ƒ“ƒX‚ÌŠˆ—pzŽüpŠúEICU‚É‚¨‚¯‚éVAEƒT[ƒxƒCƒ‰ƒ“ƒX‚ÌŠˆ—p`VAEƒT[ƒxƒCƒ‰ƒ“ƒX‚ÌŠî–{`. ²X–ØŒ°Žq (ŠÅŒì•”): ‘æ33‰ñ“ú–{ŠO‰ÈŠ´õÇŠw‰ï‘‰ïŠwpW‰ï (2020/11/27), webŠJÃ, “ú–{ŠO‰ÈŠ´õÇŠw‰ïŽGŽ 2020/10; 17 (5): 333.

722227. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) COVID-19‚ƍЊQEŒ’NŠë‹@ŠÇ—. ŠŽR˜a”ü (ŠÅŒì•”): ‘æ40‰ñ“ú–{ŠÅŒì‰ÈŠwŠw‰ïŠwpW‰ï (2020/12/13), webŠJÃ.

722228. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y‘ÌŠOzŠÂƒVƒXƒeƒ€‚Ì–¢—ˆ—\‘z}|30”NŒã‚Í‚±‚¤‚È‚Á‚Ä‚¢‚é!zŠÅŒì‚ÌŽ‹“_‚©‚çl‚¦‚é•â•zŠÂŽ¡—Â̖¢—ˆ. “à“¡ˆŸŽ÷ (ŠÅŒì•”): ‘æ49‰ñlHS‘Ÿ‚ƕ⏕zŠÂ§˜b‰ïŠwpW‰ï (2021/2/7), webŠJÃ.

722229. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) Œ£tˆÚA‚Ì’·Šú‘Ò‹@‚ðŽx‚¦‚éS‚̃PƒA. –ìŒû•¶”T1, ˆä‘º—[•P1, –k“‡˜aŽ÷2, Îˆä‘å•ã2, ‹g“cˆê¬2,3 (1ŠÅŒì•”, 2”å”AŠí, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ31‰ñ“ú–{ƒTƒCƒRƒlƒtƒƒƒW[Šw‰ïŠwpW‰ïE‘‰ï (2021/2/13), webŠJÃ, ‘æ31‰ñ“ú–{ƒTƒCƒRƒlƒtƒƒƒW[Šw‰ïŠwpW‰ïE‘‰ï@ƒvƒƒOƒ‰ƒ€E´˜^W 2021/1; p.49.

722230. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ˆÚAˆã‚ÆRTC‚ªŽæ‚è‘g‚ñ‚¾VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ‘΍ô. ˆä‘º—[•P2, Â–öˆŸ”ü2, X‰ª—DŽq2, ŽR–{—IŽ÷3, ‹g“c•üŽq2, –ìŒû•¶”T2, –k“‡˜aŽ÷4, Îˆä‘å•ã4, ‹g“cˆê¬4,5 (2ŠÅŒì•”, 2‰h—{•”, 3–òÜ•”, 4”å”AŠí, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ54‰ñ“ú–{—Տ°tˆÚAŠw‰ï (2021/2/17), WebŠJÃ.

722231. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ‘ŸŠí’ñ‹Ÿ‚ÉŠÖ‚·‚éˆÓŽvŒˆ’èŽx‰‡‚ÌŒ»ó‚ƃRƒƒi‰Ð‚ł̉ۑè‚ðl‚¦‚é. ‚‹´@Œb1,2 (1ŠÅŒì•”, 2ˆÚAˆã—ÃŽx‰‡Žº): ‘æ54‰ñ“ú–{—Տ°tˆÚAŠw‰ï (2021/2/18), webŠJÃ, “ú–{—Տ°tˆÚAŠw‰ïƒvƒƒOƒ‰ƒ€E´˜^W 2021/2; 54: 97.

723679. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒXƒLƒ“ƒPƒAŠO—ˆ‚ŃPƒA‚ðŽó‚¯‚½”r”AáŠQ‚ð—L‚·‚銳ŽÒ‚̃PƒA‰î“ü‘OŒã‚Å‚ÌQOL•]‰¿. ŒÑ“c«Žk1, ´‹{”ü‰r1, ¼Œ´N”ü2, •½ŽR‹M”Ž3 (1ŠÅŒì•”, 2ŠÅŒìŠw•”, 3”å”AŠí): ‘æ29‰ñ“ú–{‘nEƒIƒXƒgƒ~[EŽ¸‹ÖŠÇ—Šw‰ïŠwpW‰ï (2020/7/23), webŠJÃ, “ú–{‘nEƒIƒXƒgƒ~[EŽ¸‹ÖŠÇ—Šw‰ïŽ 2020/7; 24 (2): 184.

723680. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”]‘²’†‹}«Šú‚̃CƒŒƒEƒX—\–h‚Æ‚µ‚Ä‚Ì”r•ÖƒvƒƒgƒRƒ‹‚Ì—L—p«. —é–Ø’B–ç1, ‹TÎ—çŽq1, ‚‹´‚©‚¨‚è1, ¼“cŒb”ü1, ¼ŽR˜a—˜2, –k‘º‰p“ñ2, ˆ¢‹v’Óñ•v2 (1ŠÅŒì•”, 2”]_Œo“à): ‘æ45‰ñ“ú–{”]‘²’†Šw‰ï‘‰ï (2020/8/23-25), webŠJÃ.

723681. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Šw¶Žw“±‚É‚æ‚éŽáŽèŠÅŒìŽt‚̐¬’·. —Ž‡–ƒ‹M1, ‹g•”Œb—Žq1, ‰¡“cçŒb1, ŒÜ“¡—zŽq1 (1ŠÅŒì•”): ‘æ24‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2020/8/28), webŠJÃ, ‘æ24‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï´˜^W 2020/7; p.268.

723682. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) •a“ŠÅŒìŽt‚̋Ζ±‘уŠ[ƒ_[–ðŠ„Ž©ŒÈ•]‰¿‚ƐE–±ƒGƒ“ƒpƒƒƒ“ƒg‚ÌŠÖ˜A. ‰¡ŽR—˜1, “c’†KŽq2 (1ŠÅŒì•”, 2“Œ‹žŽœŒb‰ïˆã‰È‘åŠwˆãŠw•”ŠÅŒìŠw‰È): ‘æ24‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2020/8/28), webŠJÃ, ‘æ24‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï´˜^W 2020/7; p.280.

723683. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Šë‹@ŠÇ—‚̃Š[ƒ_[ƒVƒbƒvŽ©ŒÈŒø—ÍŠ´‚ÌŠÖ˜A—vˆö|ŠÅŒìŽt’·‚ɏœ_‚𓖂Ăā|. ’–Žë—ÉŽq (ŠÅŒì•”): ‘æ24‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2020/8/28), webŠJÃ, ‘æ24‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï´˜^W 2020/7; p.342.

723684. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ’†Œ˜ŠÅŒìŽt‚ւ̏¬Ž™ŠÅŒìŒp‘±‹³ˆç‚ɂ‚¢‚čl‚¦‚悤. –Ø‘º‚ä‚ÝŽq (ŠÅŒì•”): “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ30‰ñŠwpW‰ï (2020/9/19-30), webŠJÃ, “ú–{¬Ž™ŠÅŒìŠw‰ïŠwpW‰ïu‰‰W 2020/8; 30th: 55.

723685. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ®Œ`ŠO‰ÈŽØ—p‹@Šíƒƒjƒ…[•\@Š£‘‡•s—Ç‚ÉŒW‚錟Ø. ‹àŒ´ƒŽi1, “c’†@Œ‰2,3, “n糁@“O (1ŠÅŒì•”, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ95‰ñ“ú–{ˆã—Ë@ŠíŠw‰ï‘å‰ï (2020/9/20-10/19), WebŠJÃ.

723686. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) lˆõŠm•Û‚É‚¨‚¯‚éÐŠQŽžŽ–‹ÆŒp‘±Œv‰æ (BCP) ‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ìã‘å•ã1, ŠŽR˜a”ü1, ã‘º—RŽ—1 (1ŠÅŒì•”): “ú–{ÐŠQŠÅŒìŠw‰ï‘æ22‰ñ”NŽŸ‘å‰ï (2020/9/28-10/11), webŠJÃ, “ú–{ÐŠQŠÅŒìŠw‰ïŽ 2020/9; 22 (1): 118.

723687. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ÐŠQ‘΍ôƒŠƒ“ƒNƒi[ƒX‰ï‚É‚¨‚¯‚é3”NŠÔ‚ÌŠˆ“®•ñ. ã‘º—RŽ—1, ’J@Kˆê1, ŠŽR˜a”ü1 (1ŠÅŒì•”): “ú–{ÐŠQŠÅŒìŠw‰ï‘æ22‰ñ”NŽŸ‘å‰ï (2020/9/28-10/11), webŠJÃ, “ú–{ÐŠQŠÅŒìŠw‰ïŽ 2020/9; 22 (1): 119.

723688. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŠÅŒìƒPƒA‚É‚¨‚¯‚éÐŠQŽžŽ–‹ÆŒp‘±Œv‰æ‚ÌŽæ‚è‘g‚Ý: ÐŠQƒ‚[ƒhŠÅŒìƒPƒA—\’è•\‚̍쐬. ¯–쐳—T1, ŒÃŽs‘¥Œõ1, ã‘º—RŽ—1 (1ŠÅŒì•”): “ú–{ÐŠQŠÅŒìŠw‰ï‘æ22‰ñ”NŽŸ‘å‰ï (2020/9/28-10/11), webŠJÃ, “ú–{ÐŠQŠÅŒìŠw‰ïŽ 2020/9; 22 (1): 119.

723689. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ¶–½‚ÌŠë‹@“Ió‹µ‚É‚¨‚¢‚ďW’†ŠÇ—‰º‚É‚ ‚é•ê‘̂̉Ƒ°‚ւ̉î“üŽ–—á‚ÌŒŸ“¢. ”öŠÖ‹vŽq1, Vˆä—zŽq2 (1ŠÅŒì•”, 2ŠÅŒìŠw•”): ‘æ61‰ñ“ú–{•ê«‰q¶Šw‰ï‘‰ïEŠwpW‰ï (2020/10/9-10), webŠJÃ, •ê«‰q¶ŠwpW‰ï´˜^W 2020/9; 61 (3): 206.

723690. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‘å“®–¬•Ù‹·óÇ‚̍‚—î”F’mÇŠ³ŽÒ‚ɑ΂·‚éQOL‚𑸏d‚µ‚½ˆÓŽvŒˆ’èŽx‰‡. 傖¼—R‰Á—¢ (ŠÅŒì•”): ‘æ17‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ï (2020/10/10), webŠJÃ, ‘æ17‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ï´˜^ (ƒIƒ“ƒfƒ}ƒ“ƒh”zM) WEB p.41.

723691. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) A•a‰@‚É‚¨‚¯‚郊ƒ“ƒp•‚Žî•¡‡“IŽ¡—ÉȂ̐f—Ó±“ü‚ÌŽÀÛ‚ƍ¡Œã‚Ì“W–]. £ŒË–qŽq1, Ä“¡‘Žq1, “y•M—R”ü1, “ŒŠC—Ñ‚¿‚¦‚Ý1, åÎ‹I•F2, ¬â–ùŒ«2, ¼‹{—mŽj2, ‹e’r^—Žq2 (1ŠÅŒì•”, 2“û‘BEbó‘BŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/12), webŠJÃ, “ú–{“ûŠàŠw‰ï‘‰ïƒvƒƒOƒ‰ƒ€´˜^W 2020/10; 28: 115.

723692. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) PSTŠJŽnŒã, ‘Šú‚ÉŽ¡—ª‘tŒø‚µQOL‚ª‰ü‘P‚³‚ꂽ1—á. ˆÉ“¡°1, ‚”ö^‹I1, HŽR’qŽu1, Ä“¡‘Žq1, £ŒË–qŽq1, “y•M—R”ü1, åÎ‹I•F2, ¬â–ùŒ«2, ¼‹{—mŽj2, ‹e’r^—Žq2 (1ŠÅŒì•”, 2“û‘BEbó‘BŠO): ‘æ28‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2020/10/12), webŠJÃ, “ú–{“ûŠàŠw‰ï‘‰ïƒvƒƒOƒ‰ƒ€´˜^W 2020/10; 28: 349.

723693. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Š³ŽÒ‰Æ‘°Žx‰‡‚ð–Ú“I‚Æ‚µ‚½ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚©‚猩‚¦‚½, ‹~‹}ŠO—ˆŠÅŒìŽt‚Æ•a“ŠÅŒìŽt‚ÌŽ‹“_‚Ì‘Šˆá. ¯–쐳—T1, ]ãç»1 (1ŠÅŒì•”): ‘æ22‰ñ“ú–{‹~‹}ŠÅŒìŠw‰ïŠwpW‰ï (2020/12/1-31), webŠJÃ, “ú–{‹~‹}ŠÅŒìŠw‰ïŽGŽ 2020/12; 22 (supple): 121.

723694. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Ý‘îŽx‰‡ƒZƒ“ƒ^[‚É‚¨‚¯‚ég‘̍S‘©‰ðœ‚ÌŽÀ‘Ô’²¸. •Ÿ–{“Þ‰›1, ‘å‰i—¢”ü2, “Þ—Ç’¼”ü2, “¡Ž}@K2, âV“¡˜a”ü2, –Ñ’Ë—R”üŽq2 (1“ì’¬“c–K–âŠÅŒìƒXƒe[ƒVƒ‡ƒ“ ƒyƒ“ƒMƒ“, 2ŠÅŒì•”): ‘æ51‰ñ2020”N“x“ú–{ŠÅŒìŠw‰ïŠwpW‰ï (2020/11/1-30), webŠJÃ, ‘æ51‰ñ“ú–{ŠÅŒìŠw‰ïŠwpW‰ï´˜^W 2020/10; p.175.

723695. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) COVID|19•a“‚Å‚Ì‹}•Ï‘ΉžƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚Ì—L—p«. ‹{–{‹M”V1, ‘å’J®–ç1, ‘¾“c²’mŽq1, ²“¡²“s”ü1 (1ŠÅŒì•”): ‘æ48‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2021/2/12), webŠJÃ, ƒEƒFƒu´˜^ 2021/2; p.GP-NE1-3.

723696. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒXƒg[ƒ}‚ɋߐڂµ‚½‘nŠÇ—‚É“Á’èsˆ×Œ¤C‚ðC—¹‚µ‚½”畆E”rŸ•ƒPƒA”F’èŠÅŒìŽt‚ª‰î“ü‚µ‚½1Ž–—á. “n•Ó¹D (ŠÅŒì•”): ‘æ38‰ñ“ú–{ƒXƒg[ƒ}E”rŸ•ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï‘‰ï (JSSCR) (2021/2/27), •Ÿ‰ª (webŠJÃ), “ú–{ƒXƒg[ƒ}E”rŸ•ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŽ 2021/1; 37 (1): 141.

723697. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) isäX‚ª‚ñŠ³ŽÒE‰Æ‘°‚Æ‚ª‚ñŠÅŒìê–åŠÅŒìŽt‚Ƃ̃p[ƒgƒi[ƒVƒbƒv‚ÉŠî‚­ŠÅŒì–Ê’k‚Ì•]‰¿. çú±”ü“oŽq1, Ž™‹Ê”ü—R‹I1, ŒK–¼Žõ”ü1, ¬ŽRK‘ã2 (1ŠÅŒì•”, 2ŠÅŒìŠw•”): ‘æ35‰ñ“ú–{‚ª‚ñŠÅŒìŠw‰ïŠwpW‰ï (2021/2/27-4/30), webŠJÃ, ‘æ35‰ñ“ú–{‚ª‚ñŠÅŒìŠw‰ïŠwpW‰ïu‰‰W WEB; p.P9-139.

723698. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) H—~•sU‚ð—L‚·‚éŠO—ˆ‰»Šw—Ö@Š³ŽÒ‚Ì‹‚ß‚éŠÅŒìŽx‰‡‚ÉŠÖ‚·‚鎿“IŒ¤‹†. æѓc—¢“Þ1, ”ª–öçt1, ’·“c^—R”ü1, [‘ò²ŒbŽq2, ²X–ØŽ¡ˆê˜Y3 (1ŠÅŒì•”, 2‰h—{•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ18‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï (2021/3/1-31), webŠJÃ, ‘æ18‰ñ—Տ°Žîᇊw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€´˜^ Web; p.P35-5.

731066. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) • –Œ“§Í‚̃oƒbƒOŒðŠ·. ¬‘q—¯”ü1, “‰€@”E1 (1ŠÅŒì•”): –K–âŠÅŒìWebƒZƒ~ƒi[ (2021/2/6, 2/20), _“ސì.

732077. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒCƒ“ƒVƒfƒ“ƒg•ñ‚©‚çl‚¦‚é—AŒŒ—Ö@‚̈À‘SŠm•Û: ŽèpŽº‚Ì—§ê‚©‚ç. ‚–ì@‘ (ŠÅŒì•”): ‘æ151‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïŠÖ“ŒbM‰zŽx•”—á‰ï (2021/2/20), webŠJÃ, ‘æ151‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïŠÖ“ŒbM‰zŽx•”—á‰ïƒvƒƒOƒ‰ƒ€W 2021/2; p.8-9.

733128. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) ‘ÙŽ™Ž¾Š³‚ð—L‚·‚é”D•w‚Ö‚ÌŽüŽYŠúƒ`[ƒ€‚Æ‚µ‚Ä‚ÌŠÖ‚í‚è. ŠC˜VàV‰lŽq1, ’†“à¹’m1, ÎŒ´¹D1, ”‹—FŽq1, ¬ìŠì”üŽq1, •½—Ñ“Þ•c1 (1ŠÅŒì•”): ‘æ34‰ñ_“ސì•ê«‰q¶Šw‰ï (2021/2/6), _“ސì (webŠJÃ), _“ސì•ê«‰q¶Šw‰ïŽ 2021/3; 24 (1): 65.

733129. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) Ò‘‘¹”D•w‚̏oŽY‚Ü‚Å‚ÌŠÇ—`‚»‚̐l‚炵‚³‚ðŠˆ‚©‚µ‚½ƒPƒA`. ŽO‰Y^‹I1, ì’[–[ŠG1 (1ŠÅŒì•”): ‘æ34‰ñ_“ސì•ê«‰q¶Šw‰ï (2021/2/6), _“ސì (webŠJÃ), _“ސì•ê«‰q¶Šw‰ïŽ 2021/3; 24 (1): 70.

733130. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) V¶Ž™‘h¶–@‚Ì‹³ˆçEŽx‰‡ƒVƒXƒeƒ€‚ÉŒü‚¯‚½Žæ‚è‘g‚Ý. ¬’J–ì‚Ý‚Ç‚è1, ì‰º‰è¶1, ›Œ´@‹Õ1, ¬ìŠì”üŽq1, ’†¼G•F2,3, …ã‚¢‚ÂÝ1 (1ŠÅŒì•”, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3¬Ž™): ‘æ34‰ñ_“ސì•ê«‰q¶Šw‰ï (2021/2/6), _“ސì (webŠJÃ), _“ސì•ê«‰q¶Šw‰ïŽ 2021/3; 24 (1): 76.

733131. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ÊŒû‰‰) COVID-19ŒyÇ`’†“™Ç‚ÌŠÅŒìŽÀ‘H‚ÅŠÅŒìŽt‚ªŠ´‚¶‚½¢“ï‚⊋“¡‚Æ•sˆÀ`. ‘¾“ìˆŸ‹I1, Îì”üá1, ²“¡²“s”ü1 (1ŠÅŒì•”): “ú–{ˆã—Ã}ƒlƒWƒƒ“ƒgŠw‰ï‘æ20‰ñ_“ސìŽx•”ŠwpW‰ï (2021/3/13), webŠJÃ.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'19-320005. [Ç—á•ñ] ‘ÌŠOŽ®–ŒŒ^lH”x‚ð‘•’…‚µ‚½_Œo«‚₹ÇŠ³ŽÒ‚̐¶—“I—~‹‚̏[‘«‚ÉŒü‚¯‚½ƒAƒvƒ[ƒ`‚Ì1—á. •Ÿ“ˆ¹D1, ¼“cGˆê1, Î‘q@ˆ¤1, ‘“c³˜a1, ŠÛ‹´Fº2, ‘åˆä^—¢“Þ2, ó—˜@–õ2 (1ŠÅŒì•”, 2‹~–½): “ú–{‹~‹}ˆãŠw‰ïŠÖ“Œ’n•û‰ïŽGŽ 2020/3; 41 (2): 352-5.

[’˜@‘]

'19-620022. [Šwp‘ (•ª’SŽ·•M)]yV‘ÌŒnŠÅŒìŠw‘S‘@ŠÅŒì‚Ì“‡‚ÆŽÀ‘H…A@ÐŠQŠÅŒìŠw@‘æ3”Łz‘æ2Í ’´‹}«ŠúE‹}«Šú‚̍ЊQ•ÛŒ’ˆã—ÂƊŌìŽÀ‘H, p.38-73. ŠŽR˜a”ü (ŠÅŒì•”), •Ò: ¬ˆä“y—Yˆê, Îˆä”üŒbŽq, ƒƒaƒJƒ‹ƒtƒŒƒ“ƒhŽÐ, “Œ‹ž, 2020/2”­s.


—Տ°ŒŸ¸•”

[Šwp˜_•¶]

320053. [Ç—á•ñ] AIDS‚ɍ‡•¹‚µ‚½”dŽí«ƒqƒXƒgƒvƒ‰ƒXƒ}Ç‚̈ê—á. ˆÀ’B@÷1, “ñ–{–öL1,2, ˜a“c’B•F2,3, ‹à–؁@—y1, Š}ˆäˆÇŽq1, ¬ŠÑ’q¢1, ’†èM•F1, ŸNˆäŒc‘¢1, “•ûLˆê1, ‚ŽR—zŽq2,4, ‹v•Ä@Œõ, ‹TˆäŽ•F, Žë–ì—Lì5 (1—ÕŒŸ•”, 2Š´õŠÇ—Žº, 3äPŒ´•aEŠ´õ“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5—ÕŒŸŠw): “ú–{—Տ°”÷¶•¨Šw‰ïŽGŽ 2021/3; 31 (2): 87-91.

522143. [uÀ]y’®ŠoŒŸ¸ƒnƒ“ƒYƒIƒ“ƒZƒ~ƒi[ zŽ©M‚ð‚à‚Á‚ÄŒŸ¸‚ð‚µ‚Ä‚¢‚Ü‚·‚©? ¬”¦@i (—ÕŒŸ•”): “Œ‹ž“sˆãŠwŒŸ¸ 2020/6; 48 (2): 121-3.

522144. [uÀ]y“ÁW: —Տ°‰»ŠwŒŸ¸‚ŃsƒbƒgƒtƒH[ƒ‹‚É—Ž‚¿‚È‚¢‚½‚߂Ɂz3. ŒŸ¸Œã@2) ’ljÁ‘ª’èˆË—ŠŽž (Žæ‚èˆá‚¢, •Û‘¶ˆÀ’萫‚Ì’á‚¢€–Ú‚È‚Ç). “¡‘º‘Ps (—ÕŒŸ•”): Medical Technology 2020/6; 48 (6): 619-21.

522145. [uÀ]y‹ZpuÀz‚æ‚­‚í‚©‚é! •wl‰ÈƒGƒR[‚ÌŠî–{‚Æ‹Zp. ‰FŽ¡‹´‘PŸ (—ÕŒŸ•”): Medical Technology 2020/7; 48 (7): 798-804.

[’˜@‘]

620136. [Šwp‘ (•ª’SŽ·•M)]y‚±‚ê‚Å–œ‘S! ‹Ù‹}‚ð—v‚·‚éƒGƒR[ŠŒ© (—Տ°ŒŸ¸2020”N 4ŒŽ‘Š§†)z¡4Í •wl‰ÈƒGƒR[@ˆÙŠ«”DP (”DP), p.470-3. ‰FŽ¡‹´‘PŸ1, “•ûLˆê1, Žë–ì—Lì2 (1—ÕŒŸ•”, 2—ÕŒŸŠw), •Ò: ‹àŒ´@r, ˆãŠw‘‰@, “Œ‹ž, 2020/4”­s.

620137. [Šwp‘ (•ª’SŽ·•M)]y•iŽ¿•ÛØE¸“xŠÇ—‹³–{z3Í —Տ°‰»ŠwE–Ɖu‰»ŠwŒŸ¸@3.6 ŽŽ–òŠÇ—‘ä’ , p.66-72. “y•M’q» (—ÕŒŸ•”), ŠÄC: “ú–{—Տ°‰q¶ŒŸ¸‹ZŽt‰ï, ‚¶‚Ù‚¤, “Œ‹ž, 2020/11”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

723699. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚é‹Ù‹}—AŒŒ‚ÌŒ»ó‚ɂ‚¢‚Ä. “c•”—T“ñ1,2, ¬–{”ü“Þ1,2, —L”n˜a“Þ1,2, ŠâØ•¶Žq1,2, ŽR•Ó°”ü1,2, ŽR–{–ž—¢“Þ1,2, ‹{ú±_“ñ3, ‘å’JTˆê3 (1—ÕŒŸ•”, 2—AŒŒ•”, 3—AŒŒE×–EˆÚA): ‘æ68‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïŠwp‘‰ï (2020/5/28), ŽãŠJÃ, “ú–{—AŒŒ×–EŽ¡—Êw‰ïŽ 2020/5; 66 (2): 311.

723700. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) CP3000‚É‚¨‚¯‚éƒtƒ@ƒNƒ^[ƒI[ƒg: P-FDPEDƒ_ƒCƒ}[ŽŽ–ò‚̐«”\•]‰¿. ˆ¢•”—L1, ˆäããYØ1, —é–Ø‘‹I1, ¬–ì—Ç‘¾1, ²‹vŠÔ“ÖŽq1, ãŒ´—R‰À—1, ’†¼@ŒO1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ21‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŠwpW‰ï (2020/7/11-12, 7/23-9/30), WebŠJÃ, “ú–{ŒŸ¸ŒŒ‰tŠw‰ïŽGŽ ŒŸ¸‚ÆŒŒ‰t 2020/6; 21: 155.

723701. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒzƒ‹ƒ^[S“d}‚̃pƒjƒbƒN’l•ñ‚Ì—L—p«‚ɂ‚¢‚Ä. ŠFì@•à1, ¬–ìŽRŽuD1, ²‹´‹v”üŽq1, ‹{“à˜a”ü1, ‰FŽ¡‹´‘PŸ1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ69‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï (2020/9/5-6, 10/1-31), ç—t/WebŠJÃ, ‘æ69‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï@ƒvƒƒOƒ‰ƒ€W 2020/4; 69: 78.

723702. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒeƒƒCƒhÜŽg—pŠ³ŽÒ‚ÉŒ©‚ç‚ꂽ•³ü’ŽÇ‚Ì1Ç—á. ˆÉ“¡ˆŸ–퍁1, “y•M’q»1, ”ђˍ‚¶1, ꠓc˜a•ä1, ŽO‰Y–F“T1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ69‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï (2020/9/5-6, 10/1-31), ç—t/WebŠJÃ, ‘æ69‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï´˜^W 2020/9; 69: 359.

723703. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Žá”N—«‚É‚¨‚¯‚錌´ˆŸ‰””Z“x‚¨‚æ‚ѐHKŠµ‚Æ‚ÌŠÖ˜A«‚ɂ‚¢‚Ä. “y•M’q»1, ‹ß“¡—¯”üŽq2, Žç‰®’B”ü3, “•ûLˆê1, Žë–ì—Lì1,4 (1—ÕŒŸ•”, 2–òÜ•”, 3Œ’NŠÇ—ƒZ, 4—ÕŒŸŠw): ‘æ42‰ñ“ú–{—Տ°‰h—{Šw‰ï‘‰ïE‘æ41‰ñ“ú–{—Տ°‰h—{‹¦‰ï‘‰ïE‘æ18‰ñ‘å˜A‡‘å‰ï (2020/10/19-11/2), WebŠJÃ, New Diet Therapy 2020/9; 36 (2): 131.

723704. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –k—¢‘åŠw•a‰@‚É‚¨‚¯‚éˆâ“`ŽqŒŸ¸‘̐§‚̍\’z. Š}ˆäˆÇŽq1, ˆÀ–{—´”n1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ67‰ñ“ú–{—Տ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï (2020/11/19-22), ŠâŽè (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723705. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å“®–¬•Ù’uŠ·pŒã‚ÉäFõ’f—ô‚𐶂¶‚½Š´õ«S“à–Œ‰Š‚Ì1—á. ꠓcŠì”V1, ‘OìŒb”ü2, ‰““¡—¯”üŽq1, Î“c—T”ü1, –öŒ´”ü’qŽq1, ”’J“ߌŽ1, ‰FŽ¡‹´‘PŸ1, ¬”‹´r”ü2, ˆ¢ŒÃ–ç2, Žë–ì—Lì1,3 (1—ÕŒŸ•”, 2zŠÂŠí“à, 3—ÕŒŸŠw): “ú–{’´‰¹”gˆãŠw‰ï‘æ93‰ñŠwpW‰ï (2020/12/1-2021/1/14), WebŠJÃ, ’´‰¹”gˆãŠw 2020/11; 47 (Suppl): S247.

723706. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Cartinoma with neuroendocrine features‚Ì1—á. “n•Ó‚ ‚·‚Í1, —é–ؐ­Žq1, ’†¼‹vK1, ‰FŽ¡‹´‘PŸ1, ꠓcŠì”V1, “•ûLˆê1, åÎ‹I•F2, Š“cç”ü”T3, Žë–ì—Lì1,4 (1—ÕŒŸ•”, 2“û‘BEbó‘BŠO, 3•a—, 4—ÕŒŸŠw): ‘æ45‰ñ“ú–{’´‰¹”gŒŸ¸Šw‰ïŠwpW‰ï (2020/12/19-2021/1/31), WebŠJÃ, ’´‰¹”gŒŸ¸‹Zp 2020; 45 (Suppl): S202.

723707. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) tÇ”­Ç‘O“œ”A•aƒ‰ƒbƒg‚̐t”玿‚É‚¨‚¯‚éƒ~ƒgƒRƒ“ƒhƒŠƒA‚Ì•iŽ¿ŠÇ—‹@\‚ɂ‚¢‚Ä. Îˆä’¼m1, •èËŽj1, ˆä–{–¾”ü1, ’r‰iGŽ÷2, “y•M’q»3, ¬”¦@i3, —é–؉p–¾4, ‰¡ê³“T1, ’|’†P•v5 (1ˆã—Éq¶Šw•”, 2ˆã—Ö@l¹ˆã‰ï, 3—ÕŒŸ•”, 4•Ÿ“‡Œ§—§ˆã‰È‘åŠw•ÛŒ’‰ÈŠw•”, 5‘Ûˆã—ÕŸŽƒ‘åŠwˆãŠw•”t‘Ÿ“à‰ÈŠw): ‘æ60‰ñ“ú–{—Տ°‰»Šw‰ï”NŽŸŠwpW‰ï (2020/10/30-11/1), WebŠJÃ, —Տ°‰»Šw 2020/10; 49 (suppl 1): 180.

731067. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (“Á•Êu‰‰) ŒŸ¸ƒf[ƒ^‚ð“ǂ݉ð‚­. “y•M’q» (—ÕŒŸ•”): ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ïƒvƒƒOƒ‰ƒ€W 2020/12; p.10.

733132. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) Šî‘b’mŽ¯‚Æ‘ã•\“I‚ÈŽ¾Š³‚̐f’f•û–@@‘æ3•”ubó‘Bv@‘æ4•”uŒz“®–¬v. ’†¼‹vK (—ÕŒŸ•”): ‘æ137‰ñˆã—p’´‰¹”gu‹`uK‰ï (2020/12/25-2021/3/24), WebŠJÃ.

733133. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰)  ‚Ì‚±‚¾‚í‚è@bó‘B—̈æ. ’†¼‹vK (—ÕŒŸ•”): JSSŽl‘‘æ39‰ñ’n•û‰ïŒ¤C‰ï (2021/2/21), WebŠJÃ.

733134. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‚ß‚Ü‚¢ŠO—ˆ‚æ‚èˆË—Š‚³‚ꂽ“d‹CŠáU}ŒŸ¸‚É‚¨‚¯‚钍Ž‹ŠáU‚ÌŒŸoó‹µ. ¬”¦@i1, Šâ|‹Ô‰›1, –³‘¾˜Y1, ‘ºŽR^‹|1, ‘ì—R—˜1, ¬—ѐ^”ü1, ‰Í“‡]”ü1, —é–؏~Žq1, ‰FŽ¡‹´‘PŸ1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ïƒvƒƒOƒ‰ƒ€W 2020/12; p.15.

733135. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) –k—¢‘åŠw•a‰@‚É‚¨‚¯‚éALP‚¨‚æ‚ÑLDŒŸ¸‚ÌIFCC–@“±“ü‚ÉŠÖ‚·‚éŽæ‚è‘g‚Ý. “¡‘º‘Ps1, VéhŽq1, ‰ª“c—R‹I1, ’†èLŽq1, ŸNˆäŒc‘¢1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ïƒvƒƒOƒ‰ƒ€W 2020/12; p.15.

733136. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‘å“®–¬•Ù’uŠ·pŒã‚ÉäFõ’f—ô‚𐶂¶‚½Š´õ«S“à–Œ‰Š‚Ì1—á. ꠓcŠì”V1, ‰““¡—¯”üŽq1, Î“c—T”ü1, Î‹½‰ª”ü‰ÁŽq1, –ØŒ´ƒŽq1, ”’J“ߌŽ1, ‘“ãç»1, ‰FŽ¡‹´‘PŸ1, “•ûLˆê1, ‘OìŒb”ü2, ¬”‹´r”ü2, Žë–ì—Lì1,3 (1—ÕŒŸ•”, 2zŠÂŠí“à, 3—ÕŒŸŠw): ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ïƒvƒƒOƒ‰ƒ€W 2020/12; p.15.

733137. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚éƒzƒ‹ƒ^[S“d}‚̃pƒjƒbƒN’l•ñ‚ÌŠT—v‚¨‚æ‚Ñ‘ŠúŽ¡—Âւƌq‚ª‚Á‚½1—á. ŠFì@•à1, ¬–ìŽRŽuD1, ²‹´‹v”üŽq1, ‹{“à˜a”ü1, ‰FŽ¡‹´‘PŸ1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï@ƒvƒƒOƒ‰ƒ€W 2020/12; p.15.

733138. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) –k—¢‘åŠw•a‰@‚É‚¨‚¯‚éHCVR‘ÌŒŸ¸‚Ì—z«‘¬•ñ‚ÌŽæ‚è‘g‚Ý‚ÆŒø‰Ê‚ɂ‚¢‚Ä. ŽÂŒ´—º‘¾1, “¡‘º‘Ps1, “y•M’q»1, ’†èLŽq1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï@ƒvƒƒOƒ‰ƒ€W 2020/12; p.15.

733139. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) –k—¢‘åŠw•a‰@‚É‚¨‚¯‚éˆâ“`ŽqŒŸ¸‘̐§‚̍\’z. Š}ˆäˆÇŽq (—ÕŒŸ•”): ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï@ƒvƒƒOƒ‰ƒ€W 2020/12; p.16.

733140. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) lHŠÖßŠ´õÇ‚É‚¨‚¯‚é×‹Ûˆâ“`ŽqŒŸ¸Tm@mapping’è—Ê‘ª’è‚ð—p‚¢‚½‹N‰Š‹Û”»’è‚ÌŽŽ‚Ý. ŸNˆäŒc‘¢ (—ÕŒŸ•”): ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï@ƒvƒƒOƒ‰ƒ€W 2020/12; p.16.

733141. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) –k—¢‘åŠw•a‰@‚É‚¨‚¯‚錌‰t”|—{ŒŸ¸‚©‚番—£‚µ‚½y•ê—l^‹Û‚ÌŒŸoó‹µ. ‹à–؁@—y1, “ñ–{–öL1,2, ˆÀ’B@÷1, ’†èM•F1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,3 (1—ÕŒŸ•”, 2Š´õŠÇ—Žº, 3—ÕŒŸŠw): ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï@ƒvƒƒOƒ‰ƒ€W 2020/12; p.16.

733142. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ŒŒ‰t”|—{‚©‚猟o‚³‚ꂽPrototheca wickerhamii‚̈ê—á. ˆÉàVh‹P1, ˆÀ’B@÷1, ’†èM•F1, “à“cˆêO1, “•ûLˆê1, ‰ºŽèŒö‰î2, ˜a“c’B•F2, Žë–ì—Lì1,3 (1—ÕŒŸ•”, 2äPŒ´•aEŠ´õ“à, 3—ÕŒŸŠw): ‘æ69‰ñ_“ސ쌧—Տ°ŒŸ¸‹ZŽt‰ï (2021/1/1-11), WebŠJÃ, ‘æ69‰ñ_“ސ쌧ˆãŠwŒŸ¸Šw‰ï@ƒvƒƒOƒ‰ƒ€W 2020/12; p.16.

'19”N“xˆÈ‘O•ª

[Šw‰ïEŒ¤‹†‰ï“™]

'19-723033. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’·Šú“I‚ÉŒo‰ß‚ðŠÏŽ@‚µ“¾‚½ƒNƒƒCƒcƒtƒFƒ‹ƒgEƒ„ƒRƒu•a‚Ì1Ç—á. ‰Á“¡KŽq1, ¬–ìàV—T–ç1, ‰Ÿ“cD”ü1, •P“c‹v”ü1, ‘ì—R—˜1, ‰Í“‡]”ü1, —é–؏~Žq1, “•ûLˆê1 (1—ÕŒŸ•”): ‘æ68‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï (2019/5/18-19), ŽRŒû, “ú–{ˆãŠwŒŸ¸Šw‰ï´˜^W 2019/5; 68: 75.


•úŽËü•”

[Šwp˜_•¶]

110413. [Œ´’˜] Traceable point-like 68Ge/68Ga source with a spherically symmetric positron absorber for PET scanners. Hasegawa T1, Okamoto M, Yamada T, Ishizu H, Mikamoto T, Sato Y, Miyatake H2, Kikuchi K2, Inoue Y3: Radiol Phys Technol 2020/6; 13 (2): 170-6. (’·’Jì’q”V1, ‹{•”ä˜CŽ÷2, ‹e’r@Œh2, ˆäã—D‰î3: 1ˆã—Éq¶Šw•”, 2•úŽËü•”, 3•úŽËü (‰æ‘œ))

[Šw‰ïEŒ¤‹†‰ï“™]

723708. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) XüCT‚É‚¨‚¯‚é2Ží—Þ‚ÌOrgan Dose Modulationƒ\ƒtƒgƒEƒGƒA‚Ì”äŠr. ˆÉ“¡Š°‘×1, ˆäã—D‰î2, `@”Ž•¶1 (1•úŽËü•”, 2•úŽËü (‰æ‘œ)): ‘æ76‰ñ“ú–{•úŽËü‹ZpŠw‰ï‘‰ïŠwp‘å‰ï (2020/5/15-6/14), webŠJÃ, “ú–{•úŽËü‹ZpŠw‰ï‘æ75‰ñ‘‡Šwp‘å‰ï—\eW 2020; p.155.

723709. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹¹•”CT‚É‚¨‚¯‚éƒXƒJƒEƒg‰æ‘œ‚ÌŽB‰eðŒ‚ªŠÇ“d—¬•Ï’²‚É—^‚¦‚é‰e‹¿. ˆÉ“¡Š°‘×1, ˆäã—D‰î2, ––œA’¼Ž÷1 (1•úŽËü•”, 2•úŽËü (‰æ‘œ)): ‘æ76‰ñ“ú–{•úŽËü‹ZpŠw‰ï‘‰ïŠwp‘å‰ï (2020/5/15-6/14), webŠJÃ, “ú–{•úŽËü‹ZpŠw‰ï‘æ75‰ñ‘‡Šwp‘å‰ï—\eW 2020; p.156.


–òÜ•”

[Šwp˜_•¶]

110414. [Œ´’˜] The Population Pharmacokinetics of Rifampicin in Japanese Pulmonary Tuberculosis Patients. Nishimura T, Kohno H, Nagai H, Maruoka D, Koike Y, Kobayashi M1,2, Atsuda K1,2: Drug Res (Stuttg) 2020/5; 70 (5): 199-205. (¬—я¹G1,2, Œú“cKˆê˜Y1,2: 1–òŠw•”, 2–òÜ•”)

110415. [Œ´’˜] Pharmacokinetic Analysis, Analgesic Effects, and Adverse Effects of Tapentadol in Cancer Patients with Pain. Homma M1, Kokubun H2, Okuwaki K3, Katada C3, Hayashi N4, Kanai A5, Koizumi W3, Atsuda K1,6: Biol Pharm Bull 2020/6; 43 (6): 1000-6. (–{ŠÔ‰ëŽm1, ‘•ªG–ç2, ‰œ˜e‹»‰î3, Œ˜“ce—˜3, —с@Œol4, ‹àˆäº•¶5, ¬ò˜aŽO˜Y3, Œú“cKˆê˜Y1,6: 1–òÜ•”, 2“Œ‹ž–ò‰È‘åŠw–òŠw•”ŽÀ–±ŽÀK‹³ˆçƒZƒ“ƒ^[, 3Á‰»Ší“à, 4–ƒŒ, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 6–òŠw•”)

110416. [Œ´’˜] Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Azuma S1, Uojima H2, Chuma M, Shao X2, Hidaka H2, Nakazawa T2, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W2, Atsuda K1,3: Sci Rep 2020/10; 10 (1): 17054. (“ŒM‘¾˜N1, ‹›“ˆ°‹I2, Xue Shao2, “ú‚@‰›2, ’†àV‹MG2, ¬ò˜aŽO˜Y2, Œú“cKˆê˜Y1,3: 1–òÜ•”, 2Á‰»Ší“à, 3–òŠw•”)

110417. [Œ´’˜] Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Azuma S1, Uojima H2, Chuma M, Shao X, Hidaka H2, Nakazawa T2, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W2, Atsuda K1: Sci Rep 2020; 10 (1): 17054. (“ŒM‘¾˜N1, ‹›“ˆ°‹I2, “ú‚@‰›2, ’†àV‹MG2, ¬ò˜aŽO˜Y2, Œú“cKˆê˜Y1: 1–òÜ•”, 2Á‰»Ší“à)

110418. [Œ´’˜] Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy. Minatogawa H, Izawa N, Kawaguchi T, Miyaji T, Shimomura K, Honda K, Iihara H, Ohno Y, Inada Y, Arioka H, Morita H, Hida N, Sugawara M1, Katada C2, Nawata S, Ishida H, Tsuboya A, Tsuda T, Yamaguchi T, Eguchi-Nakajima T: BMJ Open 2020/12; 10 (12): e041737. (›Œ´[L1, Œ˜“ce—˜2: 1–òÜ•”, 2Á‰»Ší“à)

110419. [Œ´’˜] The Japan Society for Surgical Infection: guidelines for the prevention, detection, and management of gastroenterological surgical site infection, 2018. Ohge H1, Mayumi T1, Haji S1, Kitagawa Y1, Kobayashi M1,2,3, Kobayashi M1, Mizuguchi T1, Mohri Y1, Sakamoto F1, Shimizu J1, Suzuki K1, Uchino M1, Yamashita C1, Yoshida M1, Hirata K1, Sumiyama Y1, Kusachi S1 (1Committee for Gastroenterological Surgical Site Infection Guidelines, the Japan Society for Surgical Infection): Surg Today 2021/1; 51 (1): 1-31. (¬—я¹G1,2,3: 2–òŠw•”, 3–òÜ•”)

110420. [Œ´’˜] Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis. Uchino M, Ikeuchi H, Shimizu J, Ohge H, Haji S, Mizuguchi T, Mohri Y, Yamashita C, Kitagawa Y, Suzuki K, Kobayashi M, Kobayashi M1,2, Sakamoto F, Yoshida M, Mayumi T, Hirata K, Takesue Y: Surg Today 2021/1; 51 (1): 32-43. (¬—я¹G1,2: 1–òŠw•”, 2–òÜ•”)

110421. [Œ´’˜] On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes. Horii T1, Oikawa Y, Atsuda K1,2, Shimada A: J Diabetes Investig 2021/1. doi: 10.1111/jdi.13506. Online ahead of print. (–xˆä„Žj1, Œú“cKˆê˜Y1,2: 1–òŠw•”, 2–òÜ•”)

110422. [Œ´’˜] Effects of intermittent pneumatic compression on femoral vein peak venous velocity during active ankle exercise. Sakai K, Takahira N1, Tsuda K, Akamine A2,3: J Orthop Surg (Hong Kong) 2021/1-4; 29 (1): 2309499021998105. (‚•½®L1, Ô—䑏•F2,3: 1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3–òÜ•”)

110423. [Œ´’˜] Population Pharmacokinetic and Pharmacodynamic Target Attainment Analysis of Cefazolin in the Serum and Hip Joint Capsule of Patients Undergoing Total Hip Arthroplasty. Komatsu T1, Natsume Y, Uchiyama K2,3, Ikeda S3, Tomoda Y4, Takayama Y5, Takaso M3, Hanaki H6, Atsuda K1,4: Antimicrob Agents Chemother 2021/3; 65 (4): e02114-20. (¬¼•q²1, “àŽRŸ•¶2,3, ’r“cM‰î3, —F“c‹g‘¥4, ‚ŽR—zŽq5, ‚‘Š»Žm3, ‰Ô–؏G–¾6, Œú“cKˆê˜Y1,4: 1–òÜ•”, 2ˆã—ÈÀ‘SEŠÇ—, 3®ŠO, 4–òŠw•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 6‘呺Œ¤)

120042. [Œ´’˜] ‚ª‚ñ‰»Šw—Ö@Š³ŽÒ‚̐§“fŽ¡—Âɂ¨‚¯‚éƒIƒ‰ƒ“ƒUƒsƒ“‚ÌŽg—pŽÀ‘Ô‚ÉŠÖ‚·‚é’²¸. â‘q’qŽq1, ŠâàV^‹IŽq2, –öàV—D—¢2, £ŒË—Ç‹³1, ’Ł@@’1, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): “ú–{•a‰@–òÜŽt‰ïŽGŽ 2020/10; 56 (10): 1137-42.

120043. [Œ´’˜] ƒhƒ‰ƒbƒOƒiƒC[ƒu2Œ^“œ”A•aŠ³ŽÒ‚ɑ΂·‚é’ZŠú“I–òÜ”ïŒyŒ¸‚ðŠÓ‚Ý‚½‘æˆê‘I‘ð–òƒtƒ[ƒ`ƒƒ[ƒg‚ÌŒø‰Ê. ŠâàV^‹IŽq1, –xˆä„Žj2, ”–؍ʉØ, —é–؈ºŠG, ¬ìŒ°Žj3, —с@“N”Í3, Œú“c Kˆê˜Y1,2 (1–òŠw•”, 2–òÜ•”, 3“à•ª”å‘ãŽÓ“à): “œ”A•a 2020/10; 63 (10): 701-10.

120044. [Œ´’˜] Š¿•û»Ü‚̐¬•ª•ªÍ|äPˆ¹‚¨‚æ‚ё匚’†“’‚Ì“œ—Þ•ªÍ‚Æ‚»‚ê‚ç‚ÌŒŒ“œ’l‚ւ̉e‹¿|. ’Ł@@’1,2, •“c–¾•½1, •Ä‘q–GÎ1, ¼”ö˜ÐŠóŽq1, ˆî—t“ñ˜N1, ŽOŠªË_1 (1“Œ‹ž–ò‰È‘åŠw–òŠw•”, 2–òÜ•”): ‰ž—p–ò— 2020/11; 99 (3/4): 79-84.

120045. [Œ´’˜] Žèp‘O‚̍RŒŒð–ò•ž—pŠ³ŽÒ‚É‚¨‚¯‚é“ü‰@‘O–òÜŽt–Ê’k‚ÌŽÀ‘Ô’²¸. •yàV@~1, Ô—䑏•F1, XˆŸ¹”ü1, ’Ł@@’1, ‹ß“¡—¯”üŽq1, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): “ú–{•a‰@–òÜŽt‰ïŽGŽ 2021/1; 57 (1): 86-92.

521017. [‰ðà]yŽ¿‹^‰ž“š: –ò•iz“\•t•”ˆÊ‚É‚æ‚é“\•t–ò‚ÌŒø‰Ê‚̈Ⴂ. ì–ìçq1, Œú“cKˆê˜Y1,2 (1–òŠw•”, 2–òÜ•”): “ú–{ˆãŽ–V•ñ 2020/4; 5007: 52-3.

522146. [uÀ]yƒVƒŠ[ƒYu‚ ‚̂ЂƂ̔w’†vzˆãŽt~–òÜŽtƒNƒƒXƒg[ƒN ’nˆæ‚É“`‚¦‚½‚¢‚±‚ê‚©‚ç‚Ì“œ”A•aŽ¡—Á|•a‰@–òÜŽt•Ò|. Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): THINK CUBE 2020/8; 15: 12-5.

522147. [uÀ]y˜AÚ: Œ»ê‚̍¢‚Á‚½!@‚ɃGƒLƒXƒp[ƒg‚ª“š‚¦‚é Q&AŠÈˆÕŒœ‘÷–@zŒoŒûƒJƒŠƒEƒ€»Ü‚ÌL-ƒAƒXƒpƒ‰ƒMƒ“Ž_ƒJƒŠƒEƒ€ŽUEù‚ÌŒoŠÇ“Š—^‚ɍ¢‚Á‚Ä‚¢‚Ü‚·. —Ç‚¢•û–@‚Í‚ ‚è‚Ü‚·‚©. ‘q“c‚È‚¨‚Ý, ‹{â—Dl1, Â–ØŠwˆê, HŽRŽ ’j (1–òÜ•”): ’²Ü‚Əî•ñ 2021/1; 27 (1): 103-6.

522148. [uÀ]y“ÁW: ƒ`[ƒ€ˆã—Âɂæ‚é“œ”A•aŠ³ŽÒ‚ÌŽx‰‡`‚±‚ê‚Ü‚Å‚Æ‚±‚ê‚©‚ç`zII. ê–åE‚Ì—§ê‚©‚ç@4. –òÜŽt. ˆî–ì@Š°1, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): ŒŽŠ§“œ”A•a 2021/3; 13 (4): 33-9.

[’˜@‘]

620138. [Šwp‘ (•ª’SŽ·•M)]yƒXƒyƒVƒƒƒ‹Eƒ|ƒsƒ…ƒŒ[ƒVƒ‡ƒ“‚̍R‹Û–ò“Š—^ÝŒv@–ò•¨“®‘ԁE–ò•¨‘ŠŒÝì—pE–ò•¨ƒAƒŒƒ‹ƒM[‚©‚çÅ“K‰» (ŒŽŠ§–òŽ–2020”N7ŒŽ‘Š§†)zIII. “ÁŽê•a‘Ô‚ÌŠ³ŽÒ@2. ”MŠ³ŽÒ, p.2028-36. ¬—я¹G (–òŠw•”), •Ò: ‘º–Ø—Dˆê, ‚‹´‰ÀŽq, ‚¶‚Ù‚¤, “Œ‹ž, 2020/7”­s.

620139. [Šwp‘ (•ª’SŽ·•M)]y•a‹C‚Æ‚­‚·‚è2021@Šî‘b‚ÆŽÀ‘H Expert's Guide (–ò‹Ç2021”N‘Š§Vol.72 No.4)z10. –òŠw“IŠÇ—@Ž¡—Öò‚Ì–ò—‚Æ–òŠwŠÇ—ã‚Ì’ˆÓ“_, p.918-33. Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”), “ìŽR“°, “Œ‹ž, 2020/4”­s.

620140. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ2Í –ò‚𐳂µ‚­ˆù‚Ý‘±‚¯‚邽‚߂Ɂ@3. –Ɖu—}§–ò@ˆù‚ݍ‡‚킹‚Ì’ˆÓ“_ [–òÜ]@”畆‰È, p.111-2. 4. ‰Æ‘°‚ÅŽæ‚è‘g‚Þ•ž–òŠÇ—@‚—îŽÒ‚Ì•ž–òŠÇ—, p.123-4. ˆî–ì@Š°1 (1–òÜ•”), •Ò: ‹g“cˆê¬2,3, ¬—я¹G4 (2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3”å”AŠí, 4–òŠw•”), ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620141. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ2Í –ò‚𐳂µ‚­ˆù‚Ý‘±‚¯‚邽‚߂Ɂ@3. –Ɖu—}§–ò@ˆù‚ݍ‡‚킹‚Ì’ˆÓ“_ [–òÜ]@Ž¨•@ˆôA‰È, p.113-4. ‘æ3Í ‚­‚·‚è‚ÉŠÖ‚·‚éQ&A@–Ɖu—}§–ò, ‚­‚·‚è‘S”ʁ@ˆê•”, p.131, p.137. ‹{â—Dl1 (1–òÜ•”), •Ò: ‹g“cˆê¬2,3, ¬—я¹G4 (2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3”å”AŠí, 4–òŠw•”), ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620142. [Šwp‘ (•ª’SŽ·•M)]ytˆÚA‚Æ‚­‚·‚èz‘æ2Í –ò‚𐳂µ‚­ˆù‚Ý‘±‚¯‚邽‚߂Ɂ@4. ‰Æ‘°‚ÅŽæ‚è‘g‚Þ•ž–òŠÇ—@¬Ž™‚Ì•ž–òŠÇ—, p.125-7. ‘æ3Í ‚­‚·‚è‚ÉŠÖ‚·‚éQ&A@–Ɖu—}§–ò, ‚­‚·‚è‘S”ʁ@ˆê•” p.138. ¬–쎛‚Ý‚³‚«1 (1–òÜ•”), •Ò: ‹g“cˆê¬2,3, ¬—я¹G4 (2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3”å”AŠí, 4–òŠw•”), ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

620143. [Šwp‘ (‹¤’˜)]y‰ü’ù ƒJƒ‹ƒe¸‘I—pŒêWz²X–Ø‘PM1, –F“c@v2, –k“‡_”ü3, ŒF’J—YŽ¡4 (1–òÜ•”, 2—ÕŒŸ•”, 3ŠÅŒì•”, 4—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg), ƒnƒCƒTƒ€‹ZŒ¤, “Œ‹ž, 2020/8”­s.

620144. [Šwp‘ (•ª’SŽ·•M)]y–òÜŽt‚̗Տ°ƒZƒ“ƒX‚𖁂­ƒgƒŒ[ƒjƒ“ƒOƒuƒbƒN@–òƒgƒŒ ŠÌEtzBŒ^ŠÌ‰Š, p.13-4, p.21-4. CŒ^ŠÌ‰Š, p.35-6, p.47-50. Ž©ŒÈ–Ɖu«ŠÌ‰Š, p.79-82. ŠÌd•Ï: –å–¬ˆ³˜´iÇ, p.159-60. ”ñ‘㏞«ŠÌd•Ï: –å–¬ˆ³˜´iÇ, p.161-2. ŠÌd•Ï‚É‚¨‚¯‚é‰h—{ŠÇ—, p.173-4. ‘¾“c’q”Ž1 (1–òÜ•”), •Ò: ‘å–ì”\”V2, ²‘º@—D3, ŽO¯@’m4, ‰Y“cŒ³Ž÷5 (2“Œ‹ž‘åŠwˆãŠw•”•t‘®•a‰@–òÜ•”, 3‰¡•l‘‡•a‰@–òÜ•”, 4‰º‰z•a‰@–òÜ‰Û, 5‘å–ì‹L”O•a‰@–òÜ•”), “ìŽR“°, “Œ‹ž, 2020/12”­s.

620145. [Šwp‘ (•ª’SŽ·•M)]yŽ¡—ÃåZƒnƒ“ƒhƒuƒbƒN2021z“œ”A•aŽ¡—ÖòEŽ‰Ž¿ˆÙíÇŽ¡—ÖòE‚”AŽ_ŒŒÇ, ’É•—Ž¡—Öò, p.633-721. Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”), ŠÄC: ‚‹vŽj–›, •Ò: –x@³“ñ, ›–쌒‘¾˜Y, –å˜eF, Š£@Œ«ˆê, —с@¹—m, ‚¶‚Ù‚¤, “Œ‹ž, 2021/1”­s.

620146. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj2021@Ž„‚Í‚±‚¤Ž¡—µ‚Ä‚¢‚éz‘˜_@11. ‘ãŽÓŽ¾Š³@2Œ^“œ”A•a (•ž–òŽw“±E–òÜî•ñ), p.754, p.758. ¬Ž™‚Ì“œ”A•a (•ž–òŽw“±E–òÜî•ñ), p.771. Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”), ‘•ÒW: •ŸˆäŽŸ–î, ˆãŠw‘‰@, “Œ‹ž, 2021/1”­s.

620147. [Šwp‘ (•ª’SŽ·•M)]yƒi[ƒVƒ“ƒOƒOƒ‰ƒtƒBƒJ@Ž¾•a‚̐¬‚è—§‚¿ (2): —Տ°–ò—Šw ‘æ5”Łz‘æ2Í, p.65-70. ‘æ4Í, p.93-128. Šª––Ž‘—¿, p.264-5. _@ˆê–²1 (1–òÜ•”), •Ò: ŒÃì—T”V, Ô£’qŽq, —ѐ³Œ’“ñ, ‘吼O‚, ƒƒfƒBƒJo”Å, ‘åã, 2021/1”­s.

620148. [Šwp‘ (•ª’SŽ·•M)]y¸_‰È–ò•¨—Ö@ƒKƒCƒh ‰ü’ù”Å (’²Ü‚Əî•ñ2021”N1ŒŽ—ÕŽž‘Š§†)zIV ¸_‰È‚Ì–òŠw“IŠÇ—@ƒNƒŠƒjƒJƒ‹ƒNƒGƒXƒ`ƒ‡ƒ“, p.210-2. ’Ł@@’1 (1–òÜ•”), ŠÄC: ‹g”ö@—²2 (2“Œ–M‘åŠw), •ÒW‘ã•\: ŽO—֍‚Žs3 (3—鎭ˆã—ÉȊw‘åŠw), •Ò: “ú–{¸_–òŠw‰ï, ‚¶‚Ù‚¤, “Œ‹ž, 2021/1”­s.

620149. [Šwp‘ (•ª’SŽ·•M)]yPocket Drugs 2021zŠàŽ¡—Ê֘A–ò@64. ‘ãŽÓhR–ò, p.483-97. ‰ª–{Œb”üŽq1, ¬ò˜aŽO˜Y2 (1–òÜ•”, 2Á‰»Ší“à), ŠÄC: •ŸˆäŽŸ–î3 (3¹˜H‰Á‘Û•a‰@), •Ò: ¬¼NG3, “n糗TŽi4 (4•l¼ˆã‰È‘åŠw), ˆãŠw‘‰@, “Œ‹ž, 2021/1”­s.

621007. [Šwp‘ (•ÒW)]ytˆÚA‚Æ‚­‚·‚èz•Ò: ‹g“cˆê¬1,2, ¬—я¹G3 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí, 3–òŠw•”), ƒoƒŠƒ…[ƒvƒƒ‚[ƒVƒ‡ƒ“, “Œ‹ž, 2020/7”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713054. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) The Reality of Diabetic Ketoacidosis in Patients with Type 2 Diabetes Using SGLT2 Inhibitors Revealed by a Nationwide Claim-Based Database in Japan. Horii T1, Oikawa Y2, Higashiyama T1, Atsuda K1,3, Shimada A2: ADA 80th Scientific Session 2020 (‘æ80‰ñ•Ä‘“œ”A•aŠw‰ï‹c) (2020/6/12-16), WebŠJÃ. (–xˆä„Žj1, “ŒŽR—ÏŽq1, Œú“cKˆê˜Y1,3: 1–òŠw•”, 2é‹Êˆã‰È‘åŠw“œ”A•aE“à•ª”å“à‰È, 3–òÜ•”)

713055. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Investigating the Risk of Severe Hypoglycemia in Elderly Patients with Type 2 Diabetes Mellitus. Horii T1, Atsuda K1,2: ADA 80th Scientific Session 2020 (‘æ80‰ñ•Ä‘“œ”A•aŠw‰ï‹c) (2020/6/12-16), WebŠJÃ. (–xˆä„Žj1, Œú“cKˆê˜Y1,2: 1–òŠw•”, 2–òÜ•”)

722232. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –{Šw‰ïƒKƒCƒhƒ‰ƒCƒ“ì¬‚Ü‚Å‚Ì•à‚Ý. ‘å–эGŠì1, ^‹|r•F1, “à–ì@Šî1, –kì—Yˆê1, ¬—я¹G1,2,3, ¬—с@‹1, â–{Žjˆß1, ´…ŽO1, —é–؍Ž“T1, “yŽt½“ñ1, …Œû@“O1, –Ñ—˜–õ•F1, ŽR‰ºç’ß1, ‹g“c‰ë”Ž1, ŽRŒû’¼”äŒÃ1, •½“cŒöˆê1 (1Á‰»ŠíŠO‰ÈSSI—\–h‚Ì‚½‚ß‚ÌŽüpŠúŠÇ—ƒKƒCƒhƒ‰ƒCƒ“ì¬ˆÏˆõ‰ï, 2–òÜ•”, 3–òŠw•”): ‘æ33‰ñ“ú–{ŠO‰ÈŠ´õÇŠw‰ï‘‰ïŠwpW‰ï (2020/11/27), WebŠJÃ, “ú–{ŠO‰ÈŠ´õÇŠw‰ïŽGŽ 2020/10; 17 (5): 317.

723710. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒŒƒ“ƒoƒ`ƒjƒu—Ö@‚É‚¨‚¯‚éŒø‰Ê—\‘ªˆöŽq‚¨‚æ‚Ñ—\ŒãˆöŽq‚ÉŠÖ‚·‚錤‹†. “ŒM‘¾˜N1, ‹›“ˆ°‹I2, ’†”n@½3 (1–òÜ•”, 2Á‰»Ší“à, 3‰¡•lŽs—§‘åŠw•‘®Žs–¯‘‡ˆã—ÃZƒ“ƒ^[Á‰»Ší•aƒZƒ“ƒ^[): ‘æ56‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ï (2020/8/28-29), ‘åã (ƒnƒCƒuƒŠƒbƒhŠJÃ), ŠÌ‘Ÿ 2020; 61 (suppl 1): A336.

723711. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒJƒ‹ƒoƒyƒlƒ€ŒnR‹Û–ò‚Ì“K³Žg—p‚ÉŒü‚¯‚½Žæ‚è‘g‚Ý. ¬¼•q²1,2, “ñ–{–öL1, ˜a“c’B•F3, ‚ŽR—zŽq1,4, Œú“cKˆê˜Y2,5 (1Š´õŠÇ—Žº, 2–òÜ•”, 3äPŒ´•aEŠ´õ“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5–òŠw•”): ‘æ68‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘‰ï (2020/9/12-14), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJÃ).

723712. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Thrombocytopenia associated with obinutuzumab in patients with CD20-positive follicular lymphoma. ‹{“‡—¥Žq1, Š™“c_–«2, —é–Ø—²_2, Œú“cKˆê˜Y1,3 (1–òÜ•”, 2ŒŒ‰t“à, 3–òŠw•”): ‘æ82‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2020/10/10-11/8), WebŠJÃ.

723713. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) 2Œ^“œ”A•a‚É‚¨‚¯‚éƒ|ƒŠƒtƒ@[ƒ}ƒV[‚ƏdÇ’ጌ“œ”­ÇƒŠƒXƒN‚ÌŠÖ˜A. –xˆä„Žj1, Œú“cKˆê˜Y1,2 (1–òŠw•”, 2–òÜ•”): ‘æ63‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï (2020/10/16), WebŠJÃ.

723714. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ŒoÏ«‚ðl—¶‚µ‚½R‚ª‚ñÜ“Š—^—ʐݒè‚ÌŽÀ‘Ô’²¸. ˆî–ì@Š°1, A“c䝗œŠG1, ›Œ´[L1, ²X–ØŽ¡ˆê˜Y2, Œú“cKˆê˜Y1,3 (1–òÜ•”, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3–òŠw•”): ‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2020/10/24-11/1), WebŠJÃ.

723715. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) –Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚Ì”ñ¬×–E”xŠà‚Ö‚Ì“K‰ž’ljÁ‚ªŠO—ˆ‚ª‚ñ‰»Šw—Ö@’²»‹Æ–±‚É—^‚¦‚é‰e‹¿: –{–M4Ž{Ý‚É‚æ‚鋤“¯’²¸. XŒ³”\m1, ˆî–ì@Š°2, ÎŠÛ”Ž‰ë3, ‰Í‡—S•ã4, ’·àV’m“¿5, ”öè³—²5, ‰Pˆä_–¾5, “c‘ºŸ•F5, ‹g“c@³5, ‹g¬´Žu5, ŽÂŒ´‚—Y5, “n•”ˆêG5, œAŒ´³‹X5 (1º˜a–ò‰È‘åŠw—Տ°–òŠw‹³ˆçŒ¤‹†ƒZƒ“ƒ^[, 2–òÜ•”, 3¹˜H‰Á‘Û•a‰@–òÜ•”, 4»ìŽs—§•a‰@–òÜ•”, 5ˆÇ—Ñ‘åŠwˆãŠw•”•t‘®•a‰@–òÜ•”): ‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2020/10/24-11/1), WebŠJÃ.

723716. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ’áƒAƒ‹ƒuƒ~ƒ“ŒŒÇŠ³ŽÒ‚É‚¨‚¯‚éƒeƒCƒRƒvƒ‰ƒjƒ“‚ÌŽŠ“K•‰‰×“Š—^—Ê‚Ì’Tõ. ‹g£ŠG—1, ¬¼•q²1, ‹{â—Dl1, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): ‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2020/10/24-11/1), WebŠJÃ.

723717. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‰@“à»Ü0.5%ƒfƒmƒVƒ““_Šá‰t‚Ì6‚©ŒŽŠÔˆÀ’萫ŽŽŒ±. —é–Ø–ƒ•¶1, ˆø’n@•¶1, —F“c‹g‘¥2, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): ‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2020/10/24-11/1), WebŠJÃ.

723718. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒoƒ“ƒRƒ}ƒCƒVƒ“‚ÌTDM‚É‚¨‚¯‚é‰@“àƒAƒ‹ƒSƒŠƒYƒ€‚̏…Žçó‹µ‚Æ•]‰¿. £ŒË—Ç‹³1, ‰œ˜e’B–ç2, ¬¼•q²2, ‚ŽR—zŽq1,3, Œú“cKˆê˜Y2,4 (1Š´õŠÇ—Žº, 2–òÜ•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4–òŠw•”): ‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2020/10/24-11/1), WebŠJÃ.

723719. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) –òŠw•”‚Æ‚Ì‹¦“­‚É‚æ‚é•a‰@–òÜŽt‚Ì‘²Œã‹³ˆçŒ¤C‚ÌŽŽ‚Ý. â‘q’qŽq1, ˆî–ì@Š°1, ¬ŽRˆè”ü1, •wì‹M”Ž2, –Ñ—˜‡ˆê2, ŠâàV^‹IŽq2, –xˆä„Žj2, “ŒŽR—ÏŽq2, £ŒË—Ç‹³1, Ž›¼—m”ü1, ŽR–{—IŽ÷1, ‹ß“¡—¯”üŽq1, •½ŽR•Ži1,2, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): ‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2020/10/24-11/1), WebŠJÃ.

723720. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) •a‰@–òÜŽtEˆõ‹³ˆçƒVƒXƒeƒ€‚̍\’z (‘æˆê•ñ)|ƒRƒ“ƒsƒeƒ“ƒV[—˜_‚ð—Z‡‚µ‚½ƒNƒŠƒjƒJƒ‹ƒ‰ƒ_[ì¬‚ÌŽæ‘g‚݁|. ¬ŽRˆè”ü1, ˆî–ì@Š°1, â‘q’qŽq1, ‹ß“¡—¯”üŽq1, •wì‹M”Ž1,2, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): ‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2020/10/24-11/1), WebŠJÃ.

723721. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) R¸_•a–ò’PÜŽg—pŠ³ŽÒ‚É‚¨‚¯‚éŒëš‹«”x‰Š”­Ç‚̊댯ˆöŽq‚ÉŠÖ‚·‚錤‹†. ì–ìçq1,2, ‘º“c@‰Ø2, ¬Œ´”ü]1, •½ŽR•Ži1,2, ‘êàV‹B–î3, ‘åÎ@’q3, ‹{‰ª@“™3, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”, 3¸_): ‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2020/10/24-11/1), WebŠJÃ.

723722. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŠÌ×–EŠàÇ—á‚É‚¨‚¯‚郌ƒ“ƒoƒ`ƒjƒu—Ö@‚ɑ΂·‚éŽîᇌŒŠÇV¶ŠÖ˜Aˆâ“`Žq‚̉e‹¿. “ŒM‘¾˜N1, ‹›“ˆ°‹I2, ’†”n@½3 (1–òÜ•”, 2Á‰»Ší“à, 3‰¡•lŽs—§‘åŠw•‘®Žs–¯‘‡ˆã—ÃZƒ“ƒ^[ Á‰»Ší•aƒZƒ“ƒ^[): ‘æ28‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔ (JDDW 2020 KOBE) (2020/11/5), _ŒË, ŠÌ‘Ÿ 2020; 61 (suppl 2): 65.

723723. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) –òÜŽtEˆã—Ïî•ñ‹ZŽt (HIT-Pharmacist) ‚ɑ΂·‚錻ó’²¸ 2020|‘æ1Í –òÜŽtEˆã—Ïî•ñ‹ZŽt‚Ì”wŒi, ‹Æ–±‚¨‚æ‚ÑŠˆ“®‚ɂ‚¢‚ā|. ¬’rŒ’‘¾1, ‘å’뗝Š°2, ’JŒû”ü—I3, r@‹`º4, ‚‹´³–¾5, ã‘º’‰¹6, {“¡’q‹v7, £ŒË—Ç‹³8, ²“¡ON9 (1ˆã—Ö@lŽÐ’c½Š]‰ï‘ò•a‰@–òÜ•”, 2JA_“ސ쌧Œú¶˜AˆÉ¨Œ´‹¦“¯•a‰@–ò‹Ç, 3–òÜŽtEˆã—Ïî•ñ‹ZŽt‰ï, 4‘—§•a‰@‹@\MBã“cˆã—ÃZƒ“ƒ^[–òÜ•”, 5ŽÐ‰ïˆã—Ö@lŽá’|‰ï‚‚­‚΃Zƒ“ƒgƒ‰ƒ‹•a‰@–òÜ•”, 6ˆê”ʍà’c–@l_“ސ쌧Œx—F‰ï‚¯‚¢‚䂤•a‰@–òÜ•”, 7‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[ ‚ª‚ñƒQƒmƒ€î•ñŠÇ—ƒZƒ“ƒ^[, 8–òÜ•”, 9JA–kŠC“¹Œú¶˜A‘эLŒú¶•a‰@–òÜ•”): ‘æ40‰ñˆã—Ïî•ñŠw˜A‡‘å‰ïE‘æ21‰ñ“ú–{ˆã—Ïî•ñŠw‰ïŠwp‘å‰ï (2020/11/18-22), •l¼, ‘æ40‰ñˆã—Ïî•ñŠw‰ï˜A‡‘å‰ï@´˜^W 2020; p.324.

723724. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) –òÜŽtEˆã—Ïî•ñ‹ZŽt (HIT-Pharmacist) ‚ɑ΂·‚錻ó’²¸ 2020|‘æ2Í Š‘®ˆã—Ë@ŠÖ‚Ì–òÜ•”–åƒVƒXƒeƒ€‚ɂ‚¢‚ā|. ’JŒû”ü—I1, ‘å’뗝Š°2, ¬’rŒ’‘¾3, ’JŒû”ü—I3, r@‹`º4, ‚‹´³–¾5, ã‘º’‰¹6, {“¡’q‹v7, £ŒË—Ç‹³8, ²“¡ON9 (1–òÜŽtEˆã—Ïî•ñ‹ZŽt‰ï, 2JA_“ސ쌧Œú¶˜AˆÉ¨Œ´‹¦“¯•a‰@–ò‹Ç, 3ˆã—Ö@lŽÐ’c½Š]‰ï‘ò•a‰@–òÜ•”, 4‘—§•a‰@‹@\MBã“cˆã—ÃZƒ“ƒ^[–òÜ•”, 5ŽÐ‰ïˆã—Ö@lŽá’|‰ï‚‚­‚΃Zƒ“ƒgƒ‰ƒ‹•a‰@–òÜ•”, 6ˆê”ʍà’c–@l_“ސ쌧Œx—F‰ï‚¯‚¢‚䂤•a‰@–òÜ•”, 7‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[‚ª‚ñƒQƒmƒ€î•ñŠÇ—ƒZƒ“ƒ^[, 8–òÜ•”, 9JA–kŠC“¹Œú¶˜A‘эLŒú¶•a‰@–òÜ•”): ‘æ40‰ñˆã—Ïî•ñŠw˜A‡‘å‰ïE‘æ21‰ñ“ú–{ˆã—Ïî•ñŠw‰ïŠwp‘å‰ï (2020/11/18-22), •l¼, ‘æ40‰ñˆã—Ïî•ñŠw‰ï˜A‡‘å‰ï@´˜^W 2020; p.325.

723725. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) –òÜŽtEˆã—Ïî•ñ‹ZŽt (HIT-Pharmacist) ‚ɑ΂·‚錻ó’²¸ 2020|‘æ3Í •a‰@î•ñƒVƒXƒeƒ€‚ɂ‚¢‚ā|. ‘å’뗝Š°1, ’JŒû”ü—I2, ¬’rŒ’‘¾3, ’JŒû”ü—I3, r@‹`º4, ‚‹´³–¾5, ã‘º’‰¹6, {“¡’q‹v7, £ŒË—Ç‹³8, ²“¡ON9 (1JA_“ސ쌧Œú¶˜AˆÉ¨Œ´‹¦“¯•a‰@–ò‹Ç, 2–òÜŽtEˆã—Ïî•ñ‹ZŽt‰ï, 3ˆã—Ö@lŽÐ’c½Š]‰ï‘ò•a‰@–òÜ•”, 4‘—§•a‰@‹@\MBã“cˆã—ÃZƒ“ƒ^[ –òÜ•”, 5ŽÐ‰ïˆã—Ö@lŽá’|‰ï‚‚­‚΃Zƒ“ƒgƒ‰ƒ‹•a‰@–òÜ•”, 6ˆê”ʍà’c–@l_“ސ쌧Œx—F‰ï‚¯‚¢‚䂤•a‰@–òÜ•”, 7‘—§‚ª‚ñŒ¤‹†ƒZƒ“ƒ^[‚ª‚ñƒQƒmƒ€î•ñŠÇ—ƒZƒ“ƒ^[, 8–òÜ•”, 9JA–kŠC“¹Œú¶˜A‘эLŒú¶•a‰@–òÜ•”): ‘æ40‰ñˆã—Ïî•ñŠw˜A‡‘å‰ïE‘æ21‰ñ“ú–{ˆã—Ïî•ñŠw‰ïŠwp‘å‰ï (2020/11/18-22), •l¼, ‘æ40‰ñˆã—Ïî•ñŠw‰ï˜A‡‘å‰ï@´˜^W 2020; p.325.

723726. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) p‘O‹x–ò‚̈À‘S‚ȉ^—p‚ÉŒü‚¯‚½Žæ‚è‘g‚Ý (‘æ1•ñ)|ƒAƒXƒsƒŠƒ“ƒXƒCƒbƒ`‚ðŽæ‚è“ü‚ꂽV‚½‚ȏp‘O‹x–ò‰^—pƒtƒ[‚̍\’z|. _@ˆê–²1,2, ’ѺGN3, ‰º•lF˜Y4, ¬ò–ƒ”ü5, •yàV@~2, rˆä—L”ü1, “àŽRŸ•¶1,6, ˆ¢ŒÃÆ4 (1ˆã—Â̎¿EˆÀ‘S„iŽº, 2–òÜ•”, 3”å”AŠí, 4zŠÂŠí“à, 5f—Ïî•ñŠÇ—Žº, 6ˆã—ÈÀ‘SEŠÇ—): ‘æ15‰ñˆã—Â̎¿EˆÀ‘SŠw‰ïŠwpW‰ï (2020/11/22), WebŠJÃ, ˆã—Â̎¿EˆÀ‘SŠw‰ïŽ 2020/11; 15 (1): 234.

723727. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒhƒ‹ƒeƒOƒ‰ƒrƒ‹/ƒŠƒ‹ƒsƒrƒŠƒ“‚É‚ÄŠÇ—‚µ“¾‚½HIV—z«tˆÚAƒŒƒVƒsƒGƒ“ƒg‚Ì1—á. Ž“cr–ç1, —F“c‹g‘¥2, •“¹—Á•½1, ˜a“c’B•F3, Îˆä‘å•ã4, Vˆä–œ—Žq1, Æ‰®ŸŽ¡5, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”, 3äPŒ´•aEŠ´õ“à, 4”å”AŠí, 5‘—§‘Ûˆã—ÃŒ¤‹†ƒZƒ“ƒ^[EƒGƒCƒYŽ¡—ÁEŒ¤‹†ŠJ”­ƒZƒ“ƒ^[): ‘æ34‰ñ“ú–{ƒGƒCƒYŠw‰ïŠwpW‰ïE‘‰ï (2020/11/27-12/25), WebŠJÃ, “ú–{ƒGƒCƒYŠw‰ïŽ 2020/11; 22 (4): 451.

723728. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) pŽ®•ÊŽüpŠúŠ´õ‘΍ô‚ÌŒ»ó‚Æ–â‘è“_|SSI—\–h‚ÌŽüpŠúŠÇ—ƒKƒCƒhƒ‰ƒCƒ“‚Ì”­Š§‘O’²¸: Œ»ó‚Ì–â‘è“_|. …Œû@“O1, ÎŠÑ’q—T1, ‹v–ì–F‰À1, ‘å–эGŠì1, “à–ì@Šî1, –kì—Yˆê1, ¬—я¹G1,2,3, ¬—с@‹1, ´…ŽO1, —é–؍Ž“T1, “yŽt½“ñ1, –Ñ—˜–õ•F1, ŽR‰ºç’ß1, ‹g“c‰ë”Ž1, ^‹|r•F1 (1Á‰»ŠíŠO‰ÈSSI—\–h‚Ì‚½‚ß‚ÌŽüpŠúŠÇ—ƒKƒCƒhƒ‰ƒCƒ“ì¬ˆÏˆõ‰ï, 2–òÜ•”, 3–òŠw•”): ‘æ45‰ñ“ú–{ŠO‰ÈŒn˜A‡Šw‰ïŠwpW‰ï (2020/12/22), WebŠJÃ, “ú–{ŠO‰ÈŒn˜A‡Šw‰ïŽ 2020/12; 45 (5): 514.

723729. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Ã–¬ŒŒðÇðÇ‚ɑ΂·‚é—\–h“IR‹ÃŒÅ–ò‚̐VBleeding Risk Score•\‚̍\’z. a’J‰fl1, •yàV@~1, Ô—䑏•F1, ŠÛ‹´Fº2, •Šâ­”V3, Œú“cKˆê˜Y1,4 (1–òÜ•”, 2‹~–½, 3–ƒŒ, 4–òŠw•”): ‘æ10‰ñ“ú–{–òÜŽtƒŒƒWƒfƒ“ƒgƒtƒH[ƒ‰ƒ€ (2021/3/14), WebŠJÃ.

723730. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Mueller Hinton”|’n‚É‚¨‚¯‚郊ƒtƒ@ƒ“ƒsƒVƒ“‚Ì•ª‰ð”½‰ž‚Æ‚»‚Ì—}§‚ÉŠÖ‚·‚錟“¢. –öàV—D—¢1, —F“c‹g‘¥2, ¬—я¹G2, ’†‘º³Ž÷3, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”, 3ˆã—Éq¶Šw•”): “ú–{–òŠw‰ï‘æ141”N‰ï (L“‡) (2021/3/28), WebŠJÃ. “ú–{–òŠw‰ï”N‰ï—vŽ|W (“dŽq—vŽ|W) 2021/3.

'19”N“xˆÈ‘O•ª

[’˜@‘]

'19-620023. [Šwp‘ (•ª’SŽ·•M)]y•a‹C‚Æ–ò•¨—Ö@ ¸_Ž¾Š³@_ŒoE‹ØŽ¾Š³•Ò@‰ü’ù‘æ2”Łz_ŒoE‹ØŽ¾Š³ •Ò@Charpter3 ”F’mÇ, p.147-61. Chapter5 ‚Ä‚ñ‚©‚ñ, p.175-88. Chapter6 ‚»‚Ì‘¼‚̐_ŒoE‹ØŽ¾Š³@2. ƒMƒ‰ƒ“EƒoƒŒ[ÇŒóŒQ, p.192-3. ì–ìçq1 (1–òŠw•”), ŠÄC: Œú“cKˆê˜Y1,2 (2–òÜ•”), •Ò: ¤ú±@žÄ3, •ŽR­ˆê1, ’|“à—T‹I3, •½ŽR•Ži1 (3“Œ‹ž–ò‰È‘åŠw), ƒI[ƒ€ŽÐ, “Œ‹ž, 2019/4”­s.


ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•”

[Šwp˜_•¶]

110424. [Œ´’˜] Preoperative skeletal muscle density is associated with postoperative mortality in patients with cardiovascular disease. Yamashita M1, Kamiya K2, Matsunaga A2, Kitamura T3, Hamazaki N4, Matsuzawa R, Nozaki K4, Ichikawa T4, Nakamura T1, Yamamoto S1, Kariya H4, Maekawa E5, Meguro K5, Ogura M2, Yamaoka-Tojo M2, Ako J5, Miyaji K3: Interact Cardiovasc Thorac Surg 2020/4; 30 (4): 515-22. (ŽR‰º^Ži1, _’JŒ’‘¾˜Y2, ¼‰i“Ä•F2, –k‘º@—¥3, à_èL–¾4, –ìèN•½4, Žsì‹M•¶4, ’†‘ºŠxŽj1, ŽR–{®•½1, Š¡’J‰p‹I4, ‘OìŒb”ü5, –ڍ•Œ’‘¾˜Y5, ¬‘q@Ê2, “ŒžŠ”ü“ÞŽq2, ˆ¢ŒÃÆ5, ‹{’n@ŠÓ3: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3S‘ŸŒŒŠÇŠO, 4ƒŠƒnƒrƒŠ•”, 5zŠÂŠí“à)

110425. [Œ´’˜] Usefulness of the Simplified Frailty Scale in Predicting Risk of Readmission or Mortality in Elderly Patients Hospitalized with Cardiovascular Disease. Aida K, Kamiya K1, Hamazaki N2, Matsuzawa R, Nozaki K2, Ichikawa T2, Nakamura T3, Yamashita M3, Maekawa E4, Yamaoka-Tojo M1, Matsunaga A1, Ako J4: Int Heart J 2020/5; 61 (3): 571-8. (_’JŒ’‘¾˜Y1, à_èL–¾2, –ìèN•½2, Žsì‹M•¶2, ’†‘ºŠxŽj3, ŽR‰º^Ži3, ‘OìŒb”ü4, “ŒžŠ”ü“ÞŽq1, ¼‰i“Ä•F1, ˆ¢ŒÃÆ4: 1ˆã—Éq¶Šw•”, 2ƒŠƒnƒrƒŠ•”, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4zŠÂŠí“à)

110426. [Œ´’˜] Rising time from bed in acute phase after hospitalization predicts frailty at hospital discharge in patients with acute heart failure. Nozaki K1, Hamazaki N1, Kamiya K2, Ichikawa T1, Nakamura T3, Yamashita M3, Maekawa E4, Matsunaga A2, Yamaoka-Tojo M2, Ako J4: J Cardiol 2020/6; 75 (6): 587-93. (–ìèN•½1, à_èL–¾1, _’JŒ’‘¾˜Y2, Žsì‹M•¶1, ’†‘ºŠxŽj3, ŽR‰º^Ži3, ‘OìŒb”ü4, ¼‰i“Ä•F2, “ŒžŠ”ü“ÞŽq2, ˆ¢ŒÃÆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4zŠÂŠí“à)

110427. [Œ´’˜] Association between sarcopenia and atherosclerosis in elderly patients with ischemic heart disease. Uchida S1, Kamiya K2, Hamazaki N3, Matsuzawa R, Nozaki K3, Ichikawa T3, Suzuki Y1, Nakamura T1, Yamashita M1, Kariya H3, Maekawa E4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: Heart Vessels 2020/6; 35 (6): 769-75. (“à“cãđ¾1, _’JŒ’‘¾˜Y2, à_èL–¾3, –ìèN•½3, Žsì‹M•¶3, —é–Ø—T‘¾1, ’†‘ºŠxŽj1, ŽR‰º^Ži1, Š¡’J‰p‹I3, ‘OìŒb”ü4, “ŒžŠ”ü“ÞŽq2, ¼‰i“Ä•F2, ˆ¢ŒÃÆ4: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“à)

110428. [Œ´’˜] The Effects of tissue flossing and static stretching on gastrocnemius exertion and flexibity. Kaneda H, Takahira N1,Tsuda K, Tozaki K, Kudo S, Takahashi Y, Sasaki S2, Kensuke Fukushima K3, Kenmoku T3: Isokinetics and exercise science 2020/7; 28 (2): 205-13. (‚•½®L1, ²X–؏Gˆê2, •Ÿ“‡Œ’‰î3, Œ©–Ú’q‹I3: 1ˆã—Éq¶Šw•”, 2ƒŠƒnƒrƒŠ•”, 3®ŠO)

110429. [Œ´’˜] Cognitive impairment measured by Mini-Cog provides additive prognostic information in elderly patients with heart failure. Saito H, Yamashita M, Endo Y, Mizukami A, Yoshioka K, Hashimoto T, Koseki S1, Shimode Y, Kitai T, Maekawa E2, Kasai T, Kamiya K3, Matsue Y: J Cardiol 2020/10; 76 (4): 350-6. (¬ŠÖËŽq1, ‘OìŒb”ü2, _’JŒ’‘¾˜Y3: 1ƒŠƒnƒrƒŠ•”, 2zŠÂŠí“à, 3ˆã—Éq¶Šw•”)

110430. [Œ´’˜] Prognostic value of pupil area for all-cause mortality in patients with heart failure. Nozaki K1, Hamazaki N1, Yamamoto S2, Kamiya K3, Tanaka S, Ichikawa T1, Nakamura T2, Yamashita M2, Maekawa E4, Matsunaga A3, Yamaoka-Tojo M3, Ako J4: ESC Heart Fail 2020/10; 7 (5): 3067-74. (–ìèN•½1, à_èL–¾1, ŽR–{®•½2, _’JŒ’‘¾˜Y3, Žsì‹M•¶1, ’†‘ºŠxŽj2, ŽR‰º^Ži2, ‘OìŒb”ü4, ¼‰i“Ä•F3, “ŒžŠ”ü“ÞŽq3, ˆ¢ŒÃÆ4: 1ƒŠƒnƒrƒŠ•”, 2‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 3ˆã—Éq¶Šw•”, 4zŠÂŠí“à)

110431. [Œ´’˜] Efficacy of Exercise Therapy Initiated in the Early Phase After Kidney Transplantation: A Pilot Study. Yamamoto S1, Matsuzawa R, Kamitani T, Hoshi K, Ishii D2, Noguchi F3, Hamazaki N4, Nozaki K4, Ichikawa T4, Maekawa E5, Matsunaga A6, Yoshida K2,7: J Ren Nutr 2020/11; 30 (6): 518-25. (ŽR–{®•½1, Îˆä‘å•ã2, –ìŒû•¶”T3, à_èL–¾4, –ìèN•½4, Žsì‹M•¶4, ‘OìŒb”ü5, ¼‰i“Ä•F6, ‹g“cˆê¬2,7: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2”å”AŠí, 3ŠÅŒì•”, 4ƒŠƒnƒrƒŠ•”, 5zŠÂŠí“à, 6ˆã—Éq¶Šw•”, 7V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110432. [Œ´’˜] Effects of Tissue Flossing and Dynamic Stretching on Hamstring Muscles Function. Kaneda H, Takahira N1, Tsuda K, Tozaki K, Kudo S, Takahashi Y, Sasaki S2, Kenmoku T3: J Sports Sci Med 2020/11; 19 (4): 681-9. (‚•½®L1, ²X–؏Gˆê2, Œ©–Ú’q‹I3: 1ˆã—Éq¶Šw•”, 2ƒŠƒnƒrƒŠ•”, 3®ŠO)

110433. [Œ´’˜] Effect of atrial fibrillation on response to exercise-based cardiac rehabilitation in older individuals with heart failure. Hamazaki N1, Kamiya K2, Fukaya H3, Nozaki K1, Ichikawa T1, Matsuzawa R, Yamashita M4, Uchida S4, Maekawa E3, Meguro K3, Yamaoka-Tojo M2, Matsunaga A2, Ako J3: Ann Phys Rehabil Med 2020/12; 101466. doi: 10.1016/j.rehab.2020.101466. Online ahead of print. (à_èL–¾1, _’JŒ’‘¾˜Y2, [’J‰p•½3, –ìèN•½1, Žsì‹M•¶1, ŽR‰º^Ži4, “à“cãđ¾4, ‘OìŒb”ü3, –ڍ•Œ’‘¾˜Y3, “ŒžŠ”ü“ÞŽq2, ¼‰i“Ä•F2, ˆ¢ŒÃÆ3: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3zŠÂŠí“à, 4‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È)

110434. [Œ´’˜] Preoperative malnutrition is a risk factor for delayed recovery of mobilization after total hip arthroplasty. Nanri Y1, Shibuya M1, Fukushima K2, Uchiyama K3, Takahira N4, Takaso M2: PM R 2021/2. doi: 10.1002/pmrj.12570. Online ahead of print. (“ì—¢—C‘¾1, àF’J^1, •Ÿ“‡Œ’‰î2, “àŽRŸ•¶3, ‚•½®L4, ‚‘Š»Žm2: 1ƒŠƒnƒrƒŠ•”, 2®ŠO, 3ˆã—ÈÀ‘SEŠÇ—, 4ˆã—Éq¶Šw•”)

110435. [Œ´’˜] Reliability and validity of Japanese version of Fugl-Meyer assessment for the lower extremities. Nakazono T1, Takahashi K2, Suzuki Y1, Mizuno K1, Nomura Y1, Hiraga Y1, Matsumoto S, Nishiyama K3, Fukuda M2: Top Stroke Rehabil 2021/3; p.1-8. (’†‰€“NŽ¡1, ‚‹´‘ãŽq2, —é–ؗǘa1, …–ìŒö•ã1, –쑺—DŽq1, •½‰ê‚悵‚Ý1, ¼ŽR˜a—˜3, •Ÿ“c—Ï–ç2: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3”]_Œo“à)

110436. [Œ´’˜] Quadriceps Strength and Mortality in Older Patients With Heart Failure. Nakamura T1, Kamiya K2, Hamazaki N3, Matsuzawa R, Nozaki K3, Ichikawa T3, Yamashita M1, Maekawa E4, Reed Rkin JL, Noda C4, Meguro K4, Yamaoka-Tojo M2, Matsuzawa A2, Ako J4: Can J Cardiol 2021/3; 37 (3): 476-83. (’†‘ºŠxŽj1, _’JŒ’‘¾˜Y2, à_èL–¾3, –ìèN•½3, Žsì‹M•¶3, ŽR‰º^Ži1, ‘OìŒb”ü4, –ì“cçt4, –ڍ•Œ’‘¾˜Y4, “ŒžŠ”ü“ÞŽq2, ¼‰i“Ä•F2, ˆ¢ŒÃÆ4: 1‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“à)

110437. [Œ´’˜] The impact of social anxiety disorder on the duration of speech and language therapy at a medical institution for Japanese individuals who stutter. Yoshizawa K1, Ishizaka I2, Yasuda N1, Yukimoto Y1, Higashikawa M2, Hara Y2, Hata W2, Fukuda M2: Kitasato Med J 2021/3; 51 (1): 10-8. (‹gàVŒ’‘¾˜Y1, Îâˆè‘ã2, ˆÀ“cØ•ä1, á–{—R”ü1, “Œì–ƒ—¢2, Œ´@—R‹I2, `@ŽáØ2, •Ÿ“c—Ï–ç2: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”)

120046. [Œ´’˜] “ú–{l’nˆæÝZ‚—îŽÒ‚̌ċz‹@”\‚Í‹Ø—Í, ˆÚ“®”\—Í, ”F’m‹@”\‚ÆŠÖ˜A‚·‚é. ‘O“c‘ñ–ç1, ão’¼l2, ŒËè@¸, ŽÄ@Šì’2, â–{”üŠì2 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”): —Šw—Ö@Šw 2020/10; 48 (1): 29-36.

120047. [Œ´’˜] ¬l‹h‰¹Š³ŽÒ‚ÌŽ©•ÂƒXƒyƒNƒgƒ‰ƒ€ÇŒXŒü‚¨‚æ‚Ñ’ˆÓŒ‡”@E‘½“®ÇŒXŒü‚ÆŽÐŒð•sˆÀ‚Æ‚ÌŠÖ˜A. ‹gàVŒ’‘¾˜Y1, Îâˆè‘ã2, ˆÀ“cØ•ä1, •Ÿ“c—Ï–ç2, á–{—R”ü1, `@ŽáØ2, “Œì–ƒ—¢2, Œ´@—R‹I2 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”): ‰¹ºŒ¾ŒêˆãŠw 2021/1; 62 (1): 24-32.

120048. [Œ´’˜] •úŽËüŽ¡—ÂðŽó‚¯‚½š‹‰ºáŠQ‚ð—L‚·‚铪èò•”ŠàŠ³ŽÒ‚̐HŽ–¢“|Ž¿“IŒ¤‹†‚É‚æ‚鎡—ÃŒo‰ß‚Å‚Ì•Ï—eƒvƒƒZƒX|. “’–{@“µ1, ´–ì—R”y2, ŽR‰º@‘ñ2, Xˆä“WŽq, ìŠÔŒ’”V•, ‹g–ìáÁ—Žq (1ƒŠƒnƒrƒŠ•”, 2Ž¨•@ˆôAE“ªèòŠO): š‹‰ºˆãŠw 2021/2; 10 (1): 80-91.

522149. [uÀ]y“ÁW: S•s‘Sƒpƒ“ƒfƒ~ƒbƒN‚Ö‚Ì’§ízS•s‘S‚ɑ΂·‚郊ƒnƒrƒŠƒe[ƒVƒ‡ƒ“Ž¡—Ãupdate. à_èL–¾1, ˆ¢ŒÃÆ2 (1ƒŠƒnƒrƒŠ•”, 2zŠÂŠí“à): zŠÂŠí“à‰È 2020/4; 87 (4): 476-81.

522150. [uÀ]y“ÁW: ƒGƒLƒXƒp[ƒg‚ªƒYƒoƒŠ‰ðà!@ ŒÄ‹zŠÇ—‚ÉŠÖ˜A‚·‚éƒKƒCƒhƒ‰ƒCƒ“‚ÌŒ©•ûE“Ç‚Ý•ûEŽg‚¢•ûz@(1) ‚±‚ñ‚È‚Æ‚«, Ž„‚Í‚±‚¤Žg‚¤! —£°‚ƌċzƒŠƒn‚̃KƒCƒhƒ‰ƒCƒ“. à_èL–¾ (ƒŠƒnƒrƒŠ•”): ‚Ý‚ñ‚Ȃ̌ċzŠíRespica 2020/7; 18 (4): 521-31.

[’˜@‘]

620150. [Šwp‘ (•ª’SŽ·•M)]y‹É‚ß‚ézŠÂŠí—Šw—Ö@@zŠÂŠí•a‚ð—L‚·‚銳ŽÒ‚̏áŠQ‘œ‚É’§‚ށzPart II zŠÂŠí—Šw—Ö@‚É•K—v‚È’mŽ¯Eî•ñŽûWE‘ª’èE•]‰¿@7. S‹@”\‚ƌċz‹@”\‚Æ‚ÌŠÖ˜A@1) S”x˜AŠÖ, p.116-21. à_èL–¾ (ƒŠƒnƒrƒŠ•”), •Ò: Ä“¡G”V, ‰Á“¡@_, –Ø‘º‰ë•F, •¶Œõ“°, “Œ‹ž, 2020/7”­s.

620151. [Šwp‘ (•ª’SŽ·•M)]y‹É‚ß‚ézŠÂŠí—Šw—Ö@@zŠÂŠí•a‚ð—L‚·‚銳ŽÒ‚̏áŠQ‘œ‚É’§‚ށzPart III Ž¾Š³‚¨‚æ‚Ñ•aŠú•Ê‚Ì—Šw—Ö@‚Æ’ˆÓ“_@1. •Û‘¶Šú‚Ì–«S•s‘SŠ³ŽÒ‚ɑ΂·‚闝Šw—Ö@, p.166-75. ‰“Œ´^ˆê (ƒŠƒnƒrƒŠ•”), •Ò: Ä“¡G”V, ‰Á“¡@_, –Ø‘º‰ë•F, •¶Œõ“°, “Œ‹ž, 2020/7”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

713056. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Correlation between respiratory muscle weakness and frailty status as risk markers for prognosis in patients with cardiovascular disease (Nursing and Allied Proffesions Investigator Award Runners-Up Prize ŽóÜ‰‰‘è). Hamazaki N1, Kamiya K2, Nozaki K1, Ichikawa T1, Yamashita M3, Uchida S3, Tabata M, Maekawa E4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: ESC Congress 2020 The Digital Experience (2020/8/29-9/1), WebŠJÃ. (à_èL–¾1, _’JŒ’‘¾˜Y2, –ìèN•½1, Žsì‹M•¶1, ŽR‰º^Ži3, “à“cãđ¾3, ‘OìŒb”ü4, “ŒžŠ”ü“ÞŽq2, ¼‰i“Ä•F2, ˆ¢ŒÃÆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È, 4zŠÂŠí“à)

713057. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Kinematic analysis of satic balance and temporal and spatial characteristics of gait in 2- to 3- year-old preterm and full-term infants. Nomura Y1, Sato H2, Kamide K3, Ooka M4, Kemmochi M4: The American Academy for Cerebral Palsy and Developmental Medicine 2020 (2020/9/23-26), WebŠJÃ. (–쑺—DŽq1, ²“¡t•F2, ão”g3, ‘剪–ƒ—4, çݎ@Šw4: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3–¾¯‘åŠw, 4¬Ž™)

722233. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) U-40“Á•ÊŠé‰æ Pros-Cons ‚—îS•s‘S‚É—§‚¿Œü‚©‚¤: —LŽ_‘f‰^“®‚Ì—L—p«. –ìèN•½ (ƒŠƒnƒrƒŠ•”): ‘æ26‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2020/7/18-19), WebŠJÃ.

722234. [Šw‰ï (‘S‘)] (ƒ`[ƒ€ˆã—ЄiˆÏˆõ‰ïƒZƒbƒVƒ‡ƒ“) COVIDŽž‘ã (post COVID‚̐V‚µ‚¢¶Šˆ—lŽ®Žž‘ã‚Ì) ‚É‚¨‚¯‚éS•s‘S‘½EŽí‰î“ü. à_èL–¾ (ƒŠƒnƒrƒŠ•”): ‘æ24‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2020/10/15-17), WebŠJÃ.

723731. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”­Ç5“úˆÈ“à‚̉ºŽˆFugl-Meyer Assessment‚Í2TŠÔˆÈ“à‚Ì•àsŽ©—§‚Ì—\‘ª‚É—L—p‚Å‚ ‚é. ’†‰€“NŽ¡1, …–ìŒö•ã1, –쑺—DŽq1, ‹»’×¢•à1, •½‰ê‚悵‚Ý1, ‚‹´‘ãŽq2, ¼ŽR˜a—˜3, •Ÿ“c—Ï–ç2 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3”]_Œo“à): ‘æ45‰ñ“ú–{”]‘²’†Šw‰ï‘‰ï (2020/8/23-25), WebŠJÃ.

723732. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹}«Šú”]‘²’†ŽÒ‚ɑ΂·‚éADOC‚ð—p‚¢‚½OBP‚ÌŽÀ‘H‚É‚æ‚è•a‘O‚Ì–ðŠ„‚ðÄŠl“¾‚µ‚½1—á. •è@‹ó1, ²X–؏Gˆê1, “cŒû°‹M1, ŽR–{Œb—¢1, •Ÿ“c—Ï–ç2 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”): ‘æ54‰ñ“ú–{ì‹Æ—Ö@Šw‰ï (2020/9/25-10/25), WebŠJÃ.

723733. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Eaton•ª—ÞStage3‚Ì•êŽwCMŠÖßÇ‚ɑ΂·‚é–k—¢Ž®•êŽwCMŠÖß‘•‹ï‚Ì—L—p«. ²X–؏Gˆê1, ¬ÀŒ«Ž¡2, •ì_Žm2, ‚•½®L3, ‚‘Š»Žm2 (1ƒŠƒnƒrƒŠ•”, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ54‰ñ“ú–{ì‹Æ—Ö@Šw‰ï (2020/9/25-10/25), WebŠJÃ.

723734. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’nˆæÝZ‚—«‚É‚¨‚¯‚éŒÄ‹z‹@”\‚̃tƒŒƒCƒ‹‚ւ̉e‹¿: c’f“IŠÏŽ@Œ¤‹†. ‘O“c‘ñ–ç1, ão’¼l2,3, ²“¡t•F2,3, ŽÄ@Šì’2, â–{”üŠì2 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ¤‹†‰È): ‘æ7‰ñ“ú–{—\–h—Šw—Ö@Šw‰ïŠwp‘å‰ï (2020/9/27), WebŠJÃ.

723735. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆã—Ë@ŠÖ‚ðŽóf‚·‚鐬l‹h‰¹ŽÒ‚̃ŒƒWƒŠƒGƒ“ƒX‚ÉŠÖ‚·‚錟“¢. ‹gàVŒ’‘¾˜Y1, Îâˆè‘ã2, ˆÀ“cØ•ä1, ’·’J‰ëN1, •Ÿ“c—Ï–ç2 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”): “ú–{‹h‰¹E—¬’¨«áŠQŠw‰ï‘æ8‰ñ‘å‰ï (2020/10), WEBŠJÃ.

723736. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lH•GŠÖß‘S’uŠ·pŠ³ŽÒ‚É‚¨‚¯‚ép‘Og‘Ì‹@”\‚ƏpŒã14“úˆÈ“à‚ÌŽ©‘î‘Þ‰@‰Â”Û‚Æ‚ÌŠÖ˜A. ‘ŠÔOË1, “ì—¢—C‘¾1, ‘Šì@~2, Šâ£@‘å2, ‚‘Š»Žm2 (1ƒŠƒnƒrƒŠ•”, 2®ŠO): JOSKAS-JOSSM 2020 (‘æ12‰ñ“ú–{ŠÖß‹¾E•GEƒXƒ|[ƒc®Œ`ŠO‰ÈŠw‰ïE‘æ46‰ñ“ú–{®Œ`ŠO‰ÈƒXƒ|[ƒcˆãŠw‰ï) (2020/12/17-19), WebŠJÃ.

733143. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) •\–Ê‹Ø“d}‚É‚æ‚éARCRŒã‚ɏ㎈Ž©d–Ɖׂōs‚¤ŒP—û‚Ì—L—p«. ²X–؏Gˆê1, Œ©–Ú’q‹I2, ’|“àŠ°l1, _•Û•‘¥1, ‚‘Š»Žm2 (1ƒŠƒnƒrƒŠ•”, 2®ŠO): ‘æ17‰ñ“ú–{Œ¨‚̉^“®‹@”\Œ¤‹†‰ï (2020/10/9-10), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJÃ).

733144. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) lHŒÒŠÖß‘S’uŠ·p‚É‚¨‚¯‚épŒã‘Šú‚Ì•às‘¬“x‰ü‘P‚É‚Íáu’ɂ̉ü‘P‚ªŠÖ—^‚·‚é. “ì—¢—C‘¾1, •½‰ê‚悵‚Ý1, Œ©ˆä“c˜a³1, ¼ŠÛƒ‰À1, àF’J^1, ŽO•½—º‘¾1, “àŽRŸ•¶2,3, •Ÿ“‡Œ’‰î3, ‚•½®L4, •Ÿ“c—Ï–ç4 (1ƒŠƒnƒrƒŠ•”, 2ˆã—ÈÀ‘SEŠÇ—, 3®ŠO, 4ˆã—Éq¶Šw•”): ‘æ37‰ñ_“ސ쌧—Šw—Ö@ŽmŠw‰ï (2020/11/22-29), WebŠJÃ.

733145. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ˆê”ʍu‰‰) ‹CŠÇØŠJ‚ðŽ{s‚µ‚½ALSŠ³ŽÒ‚ɑ΂µ, V‚½‚ȃRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“Žè’i‚ÌŠl“¾‚ÉŒü‚¯, ’Z‚¢“ü‰@ŠúŠÔ‚ňӎv“`’B‘•’u‚𓱓ü‚µ‚½Ç—á. •Ÿ“c@–G1, ²X–؏Gˆê1 (1ƒŠƒnƒrƒŠ•”): ‘æ21‰ñ–k—¢ì‹Æ—Ö@Šw‰ïŠwpW‰ï (2020/12/12), WebŠJÃ.


‰h—{•”

[Šwp˜_•¶]

120049. [Œ´’˜] “œ”A•aƒJƒ“ƒoƒZ[ƒVƒ‡ƒ“Eƒ}ƒbƒvTM‚É‚æ‚銴î•‰’S‹y‚ÑŒŒ“œŠÇ—‚Ö‚ÌŒø‰Ê‚ÌŒŸ“¢. ìã—IŽq1, —с@“N”Í2, lŒ©–ƒ”üŽq1, Î–{–]”ü3, ‘åŠÑŒbŽq3, Žç‰®’B”ü4, Žµ—¢áÁ‹`5, ²“¡ÆŽq1 (1‰h—{•”, 2—ÕŒŸŠw, 3ŠÅŒì•”, 4Œ’NŠÇ—ƒZ, 5“à•ª”å‘ãŽÓ“à): “ú–{•a‘Ô‰h—{Šw‰ïŽ 2020; 23 (2): 159-65.

120050. [Œ´’˜] V‹KˆÛŽŒŒ‰t“§ÍŠ³ŽÒ‚Ì”ñŒv‰æ“±“ü‚ª“ü‰@Žž‚̉h—{ó‘Ô‚¨‚æ‚Ñ“úí¶Šˆ“®ì‚É—^‚¦‚é‰e‹¿. ‹g“c•üŽq1, ÂŽR“ŒŒÜ2, “¡ˆä䝎À1, X‰ª—DŽq1, “à“¡³‹g2, ²–ì@—²2, ’|“àN—Y2 (1‰h—{•”, 2t‘Ÿ“à): “ú–{“§ÍˆãŠw‰ïŽGŽ 2021/2; 54 (2): 69-76.

120051. [Œ´’˜] –«ŠÌŽ¾Š³‚É‚¨‚¯‚éƒTƒ‹ƒRƒyƒjƒA‚Æ‚½‚ñ‚Ï‚­Ž¿ÛŽæ—Ê‚ÉŠÖ‚·‚錟“¢. ‹e’r“Þ•äŽq1, ‹›“ˆ°‹I2, “ú‚@‰›2 (1‰h—{•”, 2Á‰»Ší“à): “ú–{–å–¬ˆ³˜´iÇŠw‰ïŽGŽ 2021/3; 27 (1): 34-40.

[Šw‰ïEŒ¤‹†‰ï“™]

713058. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Multidisciplinary Predialyis Team Education for patients with Diabetic Nephropathy, Postponed Hemodialysis Induction, and Prolonged Survival After Hemodialysis Induction. Hitomi M1, Sato T1, Moriya T2: ‘æ80‰ñ•Ä‘“œ”A•aŠw‰ï (ADA2020) (2020/6/12-16), webŠJÃ, Diabetes 2020/6; 69 (Suppl 1): 656-P. (lŒ©–ƒ”üŽq1, ²“¡ÆŽq1, Žç‰®’B”ü2: 1‰h—{•”, 2Œ’NŠÇ—ƒZ)

722235. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) “œ‘ãŽÓˆÙí‡•¹”DP‚Ɖh—{. lŒ©–ƒ”üŽq (‰h—{•”): ‘æ36‰ñ“ú–{“œ”A•aE”DPŠw‰ï”NŽŸŠwpW‰ï (2020/11/14), “Œ‹ž.

722236. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒv) –å–¬ˆ³˜´iÇ‚É‚¨‚¯‚éƒTƒ‹ƒRƒyƒjƒA‚ÌŽÀÛ‚Ƒ΍ô: –«ŠÌŽ¾Š³‚É‚¨‚¯‚éƒTƒ‹ƒRƒyƒjƒA‚Æ‚½‚ñ‚Ï‚­Ž¿ÛŽæ—Ê‚ÉŠÖ‚·‚錟“¢. ‹e’r“Þ•äŽq1, ‹›“ˆ°‹I2, “ú‚@‰›2 (1‰h—{•”, 2Á‰»Ší“à): ‘æ27‰ñ“ú–{–å–¬ˆ³˜´iÇŠw‰ï‘‰ï (2020/10/28-11/18), webŠJÃ, “ú–{–å–¬ˆ³˜´iÇŠw‰ïŽGŽ 2020/10; 26 (3): 122.

722237. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒ`[ƒ€‚ō\’z‚µ‚½tˆÚAƒŒƒVƒsƒGƒ“ƒg‚̉h—{ŠÇ—. ‹g“c•üŽq1, Îˆä‘å•ã2, –ìŒû•¶”T3, ˆä‘º—[•P3, X‰ª—DŽq1, –k“‡˜aŽ÷2, ’|“àN—Y4, ‹g“cˆê¬2,5 (1‰h—{•”, 2”å”AŠí, 3ŠÅŒì•”, 4t‘Ÿ“à, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ54‰ñ“ú–{—Տ°tˆÚAŠw‰ï (2021/2/19), webŠJÃ, ‘æ54‰ñ“ú–{—Տ°tˆÚAŠw‰ïƒvƒƒOƒ‰ƒ€E´˜^W 2020/12; p.82.

722238. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€“™)y‚æ‚­‚í‚©‚éƒVƒŠ[ƒY: “§ÍŠ³ŽÒ‚̉h—{ŠÇ—zƒe[ƒ‰[ƒƒCƒh‚ȉh—{ŠÇ—‚Æ‘½EŽí‚Őt‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ðŽÀ‘H‚µ‚悤. ‹g“c•üŽq1, ÂŽR“ŒŒÜ2 (1‰h—{•”, 2t‘Ÿ“à): ‘æ11‰ñ“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2021/3/20-4/30), webŠJÃ, ‘æ11‰ñ“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒvƒƒOƒ‰ƒ€E´˜^W 2021/3; p.156.

723737. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) H“¹ŠàŽüpŠúƒTƒ|[ƒgƒ`[ƒ€‚ÅŽæ‚è‘g‚Þ‰h—{ŠÇ—: e°Sheet“±“ü‚ÌŒø‰Ê. ‹e’r“Þ•äŽq1, ‹‹vGŽ÷2, ×“c@Œj2, ˜h”ö^—ˆ¤2, X’JGŒõ2,3, VŒ´³‘å2, ŸN’J”ü‹MŽq2, Œ´“cG‹P2, ŽR‰ºŒpŽj2,4, ”äŠé’¼Ž÷2 (1‰h—{•”, 2ã•”Á‰»ŠÇŠO, 3‘—§‘Š–ÍŒ´•a‰@, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2020/12/10-11), “¿“‡ (ƒnƒCƒuƒŠƒbƒhŠJÃ), ‘æ74‰ñ“ú–{H“¹Šw‰ïƒvƒƒOƒ‰ƒ€E´˜^W 2020/12; p.213.

723738. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) dÇŠ³ŽÒ‚É‚¨‚¯‚éƒ^ƒ“ƒpƒNŽ¿“Š—^—Ê‚Æ ƒŠƒ“ƒp‹…Œ¸­Ç‚ɂ‚¢‚Ä. [‘ò²ŒbŽq1,2, •Ð‰ª—Sˆê3, “c‘º@’q3, Žç‰®—¢¹1, ‰““¡¬Žq1, “c‘º’qŽq4, ²“¡ÆŽq1, ˜hàV®G2, ¬¼•q˜Y2 (1‰h—{•”, 2“Œ‹žˆã—Õی’‘åŠw‘åŠw‰@, 3‹~–½, 4ˆã—Éq¶Šw•”): “ú–{ŠO‰È‘ãŽÓ‰h—{Šw‰ï‘æ57‰ñŠwpW‰ï (2020/12/24), webŠJÃ, “ú–{ŠO‰È‘ãŽÓ‰h—{Šw‰ï‘æ57‰ñŠwpW‰ïƒvƒƒOƒ‰ƒ€E´˜^W 2020/12; 54 (5): 25.


•a‰@•a—•”

[Šwp˜_•¶]

110438. [Œ´’˜] Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and Japanese Society of Clinical Cytology: An Interobserver Reproducibility Study and Risk of Malignancy Evaluation on Cytology Specimens.ens. Hiroshima K, Akihiko Yoshizawa A, Takenaka A, Haba R, Kawahara K, Minami Y, Kakinuma H1, Shibuki Y, Miyake S, Kajio K, Miyamoto K, Nagatomo M, Nishimura S, Mano M, Matsubayashi J, Motoi N, Nagao T, Nakatsuka S, Yoshida T2, Satoh Y3: Acta Cytol 2020/9-10; 64 (5): 452-62. (Š`ÀœA–M1, ‹g“c@Œ÷2, ²“¡”Vr3: 1•a—•”, 2•a—, 3ŒÄ‹zŠíŠO)

120052. [Œ´’˜] –{–M‚É‚¨‚¯‚é•a—‘gDŒŸ‘̌ŒèŽè‹Z‚ÌŽÀ‘Ô’²¸|“ú—Õ‹Z¸“xŠÇ—’²¸ƒAƒ“ƒP[ƒg‚É‚æ‚é•ñ|. “Œ@@Šw, ŽR‰º˜a–ç1, Î“cŽ¬, ¼Œ´^“Þ”ü, —с@—TŽi, âªˆê, —é–؏r‹I, ŒÃ‰®Žüˆê˜Y (1•a—•”): ˆãŠwŒŸ¸ 2020/10; 69 (4): 660-70.

320054. [Ç—á•ñ] “]ˆÚ«”xŽîᇂª‹^‚í‚ꂽ‰ŠÇ«‹ØüˆÛ‰è×–EŽîᇂÌ1—á. —é–ؘa‰À“Þ1, Š`ÀœA–M1, ŽR‰º˜a–ç1, ²“¡”Vr2, ˆêŒË¹–¾3, ‹g“c@Œ÷3, ŽOŽ} M3 (1•a—•”, 2ŒÄ‹zŠíŠO, 3•a—): _“ސ쌧—Տ°×–EŠw‰ïŽ 2020/9; 25 (1): 44-9.

[’˜@‘]

620152. [Šwp‘ (•ª’SŽ·•M)]yJAMT‹³–{ƒVƒŠ[ƒY@•iŽ¿•ÛØE¸“xŠÇ—‹³–{z9Í •a—‘gDŒŸ¸, p.215-9. ŽR‰º˜a–ç (•a—•”), ŠÄC: ˆê”ÊŽÐ’c–@l “ú–{—Տ°‰q¶ŒŸ¸‹ZŽt‰ï, ‚¶‚Ù‚¤, “Œ‹ž, 2020/11”­s.

620153. [Šwp‘ (•ª’SŽ·•M)]yJAMT‹³–{ƒVƒŠ[ƒY@•iŽ¿•ÛØE¸“xŠÇ—‹³–{z13Í ˆâ“`ŽqŒŸ¸@2. ‘̍זEˆâ“`ŽqŒŸ¸, p.363-70. ŽR‰º˜a–ç (•a—•”), ŠÄC: ˆê”ÊŽÐ’c–@l “ú–{—Տ°‰q¶ŒŸ¸‹ZŽt‰ï, ‚¶‚Ù‚¤, “Œ‹ž, 2020/11”­s.

[Šw‰ïEŒ¤‹†‰ï“™]

721031. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ƒQƒmƒ€ˆã—ÂɌü‚¯‚½×–EfÞ—¿‚Ì—L—p«‚ɂ‚¢‚Ä. ŽR‰º˜a–ç1, ‹g“c@Œ÷2, ‹vê@Ž÷1, ¼”ö—R‹IŽq3, ²“¡”Vr4, ŽOŽ}@M2 (1•a—•”, 2•a—, 3•a‘ԁEf—ÃŒn, 4ŒÄ‹zŠíŠO): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20-‚V/19), webŠJÃ, “ú–{—Տ°×–EŠw‰ïŽGŽ 2020/5; 59 (•âû1†): 177.

723739. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) —‘‘ƒƒ‰ƒCƒfƒBƒbƒq×–EŽîLeydig cell tumor‚Ì1—á. ‘º“c从Ñ1, Š`ÀœA–M1, âŒû@”E1, ŽR‰º˜a–ç1, ‚‹´”Ž”V2, Š“cç”ü”T3, ‹g“c@Œ÷3, ŽOŽ}@M3 (1•a—•”, 2ˆã—Éq¶Šw•”, 3•a—): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20-‚V/19), webŠJÃ, “ú–{—Տ°×–EŠw‰ïŽGŽ 2020/5; 59 (•âû1†): 213.

723740. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ’†cŠu‚É”­¶‚µ‚½’E•ª‰»Œ^Ž‰–b“÷Žî‚̈ê—á. ’†ìm”ü1, Š`ÀœA–M1, ŠÚ—Ñ–­Žq1, ŽR‰º˜a–ç1, ²“¡”Vr2, ˆêŒË¹–¾3, ‚‹´”Ž”V4, Š“cç”ü”T3, ‹g“c@Œ÷3, ŽOŽ}@M3 (1•a—•”, 2ŒÄ‹zŠíŠO, 3•a—, 4ˆã—Éq¶Šw•”): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20-‚V/19), webŠJÃ, “ú–{—Տ°×–EŠw‰ïŽGŽ 2020/5; 59 (•âû1†): 219.

723741. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‰¡–ä‹Ø“÷Žî‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚½Žq‹{Šà“÷Žî‚̈ê—á. Š`À—D”üŽq1, Š`ÀœA–M1, ’†ìm”ü1, ŽR‰º˜a–ç1, Š“cç”ü”T2, ‚‹´”Ž”V3, ‹g“c@Œ÷2, ŽOŽ}@M2 (1•a—•”, 2•a—, 3ˆã—Éq¶Šw•”): ‘æ61‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2020/6/20-‚V/19), webŠJÃ, “ú–{—Տ°×–EŠw‰ïŽGŽ 2020/5; 59 (•âû1†): 228.

723742. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) 2019”N“x“ú—Õ‹Z•a—ŒŸ¸•W€‰»E¸“xŠÇ—‡“¯ƒAƒ“ƒP[ƒg’²¸‚Ì•ñ. ŽR‰º˜a–ç1, ŒÃ‰®Žüˆê˜Y2, Î“cŽ¬3, “Œ@@Šw4, âªˆê5, ¼Œ´^“Þ”ü6, —с@—TŽi7, —é–؏r‹I8 (1•a—•”, 2’}”g‘åŠw•t‘®•a‰@•a—f’f‰È, 3L“‡‘åŠwˆãŠw•”•t‘®•a‰@•a—f’f‰È, 4“Æ—§s­–@l‘—§•a‰@‹@\”ŸŠÙ•a‰@—Տ°ŒŸ¸‰È, 5Ã‰ªŒ§—§‚±‚Ç‚à•a‰@, 6Ž ‰êˆã‰È‘åŠwˆãŠw•”•t‘®•a‰@, 7“‡ªŒ§—§’†‰›•a‰@ ŒŸ¸‹Zp‰È, 8ŽRŒ`‘åŠw•‘®•a‰@•a—f’f‰È): ‘æ69‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï (2020/9/5-6, 10/1-31), •Ÿ“‡/webŠJÃ, ˆãŠwŒŸ¸ 2020/9; 69 (•Êû): 199.

723743. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒAƒ‹ƒMƒ“Ž_ƒiƒgƒŠƒEƒ€–@ƒZƒ‹ƒuƒƒbƒNì»‚É‚¨‚¯‚é“K³‚ȌŒèE’EŠD–@‚ÌŒŸ“¢. ‰¡ŽR‚¢‚³‚Ý1, ŠÚ—Ñ–­Žq1, âŒû@”E1, ‹vê@Ž÷1, ŽR‰º˜a–ç1, ‹g“c@Œ÷2, ŽOŽ}@M2 (1•a—•”, 2•a—): ‘æ69‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï (2020/9/5-6, 10/1-31), •Ÿ“‡/webŠJÃ, ˆãŠwŒŸ¸ 2020/9; 69 (•Êû): 219.

723744. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‹H‚È”xŽîᇁ@“–‰@‚ÅŒoŒ±‚µ‚½Ciliated muconodular papillary tumors‚̍זE‘œ‚Æ‘gD‘œ. âŒû@”E1, ŽOŒE«Žj2, Š`ÀœA–M1, ŽR‰º˜a–ç1, ˆêŒË¹–¾3, ‹g“c@Œ÷3, ²“¡”Vr2, ŽOŽ}@M3 (1•a—•”, 2ŒÄ‹zŠíŠO, 3•a—): ‘æ59‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2020/11/21-22, 12/11-27), _“ސì/webŠJÃ, “ú–{—Տ°×–EŠw‰ïŽGŽ 2020/11; 59 (•âû2†): 464.

723745. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‘ŸŠí‰¡’f“I_Œo“à•ª”åŽîᇂ̍זEf: ŒÄ‹zŠí_Œo“à•ª”åŽîᇂ̍זEf. Š`ÀœA–M1, ŽR‰º˜a–ç1, ²“¡”Vr2, Š“cç”ü”T3, ‹g“c@Œ÷3, ‘º‰_–FŽ÷3, ŽOŽ}@M3 (1•a—•”, 2ŒÄ‹zŠíŠO, 3•a—): ‘æ59‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2020/11/21-22, 12/11-27), _“ސì/webŠJÃ, “ú–{—Տ°×–EŠw‰ïŽGŽ 2020/11; 59 (•âû2†): 477.

723746. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) p‘OúŽh‹zˆø×–Ef‚ɂĐ„’肵“¾‚½bó‘BÉŽq‰»õóŽîᇂÌ1—á. ‘º“c从Ñ1, Š`ÀœA–M1, ’†ìm”ü1, —é–ؘa‰À“Þ1, ŽR‰º˜a–ç1, Œ¢Ž”@‰~2, Š“cç”ü”T3, ‹g“c@Œ÷3, ‘º‰_–FŽ÷3, ŽOŽ}@M3 (1•a—•”, 2”]ŠO, 3•a—): ‘æ59‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2020/11/21-22, 12/11-27), _“ސì/webŠJÃ, “ú–{—Տ°×–EŠw‰ïŽGŽ 2020/11; 59 (•âû2†): 625.

723747. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”xŠà×–Ef”»’èŠî€‚̍‘Û‰»‚ð–ÚŽw‚µ‚Ä. “ì@—DŽq, Š`ÀœA–M1, ‰ÍŒ´–MŒõ, àF–؍N—Y, ’|’†–¾”ü, ‰Hê—玟, œA“‡ŒšŽO, ŽO‘î^Ži, ‹gàV–¾•F, ²“¡”Vr2 (1•a—•”, 2ŒÄ‹zŠíŠO): ‘æ59‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2020/11/21-22, 12/11-27), _“ސì/WebŠJÃ.

723748. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) COVID-19‘΍ô‚ƍזEŒŸ¸Žm—{¬‹³ˆç: Œ»ó‚Ɖۑè. ¼‘º—R—¢1, ˆ¢•”’¼–ç1, ŽR‰º˜a–ç2, ‚‹´”Ž”V1, ŽOŽ}@M3, ²“¡”Vr4, ŒÃ“c—æŽq1 (1ˆã—Éq¶Šw•”, 2•a—•”, 3•a—, 4ŒÄ‹zŠíŠO): ‘æ59‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2020/11/22), ‰¡•l.


ME•”

[Šwp˜_•¶]

120053. [Œ´’˜] ‰Aˆ³‹zˆø•â•’EŒŒŽg—pŽž‚̃gƒ‰ƒuƒ‹‘Ήž‚ɑ΂·‚é‹zˆøƒAƒEƒgƒŒƒbƒg•t‚«ƒ|[ƒ^ƒuƒ‹‹zˆøŒ¹‚ðŽg—p‚µ‚½‹Ù‹}‘Ήž‚ÉŠÖ‚·‚éŽÀŒ±“IŒŸ“¢. ‘哇O”V1, “ŒžŠŒ\ˆê1, ŒKŒ´ŽÑˆß1, “c’†—D”ü1, ˆÉ“ŒË‘¾1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ÌŠOzŠÂ‹Zp 2021/3; 48 (1): 1-11.

220004. [€Œ´’˜] ‹zˆø‚¨‚æ‚уxƒ“ƒgƒ|ƒ“ƒv‚É‚¨‚¯‚鈳•Â“x’²®•û–@‚̍lˆÄ. ‘哇O”V1, “ŒžŠŒ\ˆê1, ŒÃ•½@‘1, •“cÍ”1, —L”n@Ži1, ŒKŒ´ŽÑˆß1 (1ME•”): “ú–{—Տ°HŠw‹ZŽm‰ï‰ïŽ 2020/9; No.70: 76-8.

520019. [‘à] VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õÇ (COVID-19) ‚ɑ΂·‚éECMOŠÇ—. “ŒžŠŒ\ˆê1,2, ˆÀ–ì@½1, —é–ØŒ’ˆê1, Œã“¡@•1, ‘O’†‘¥•1, –ì“c­G1, ‹{–{‘Žj1, r–؍NK1, •S£’¼Ž÷1 (1“ú–{‘ÌŠOzŠÂ‹ZpˆãŠw‰ïŠwpˆÏˆõ‰ïŠwpˆÏˆõ‰ï, 2ME•”): ‘ÌŠOzŠÂ‹Zp 2020/10; 47 (3): 230-8.

522151. [uÀ]y“ÁW: ‚Ç‚¤–h‚®? –½‚ÌŠë‹@‚É’¼Œ‹‚·‚é‘ÌŠOzŠÂƒgƒ‰ƒuƒ‹z“d‹CŒn“‚ÉŠÖ‚·‚éƒgƒ‰ƒuƒ‹‚̑Ώˆ‚ƈÀ‘S‘΍ô. “ŒžŠŒ\ˆê1, ‘哇O”V1 (1ME•”): Clinical Engineering 2020/11; 31 (12): 1000-7.

[Šw‰ïEŒ¤‹†‰ï“™]

732078. [Šw‰ï (’n•û‰ïEŒ¤‹†‰ï)] (ŠwpƒZƒ~ƒi[) ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì‹³ˆç‚Æ‹Æ–±H•v. •“cÍ”1, “ŒžŠŒ\ˆê1, ŠC˜Vª’q‘ã1, {“¡NŽq1 (1ME•”): ‘æ3‰ñ_“ސ쌧—Տ°HŠw‰ï (2020/11/22), ‰¡•l, _“ސ쌧—Տ°HŠw‹ZŽm‰ïŽ 2020/11; 32: 31.


ˆã—Â̎¿EˆÀ‘S„iŽº

[Šw‰ïEŒ¤‹†‰ï“™]

723749. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚¨‚¯‚銳ŽÒŒë”F–hŽ~‘΍ô‚ÌŒø‰Ê‚ƍ¡Œã‚̉ۑè (‘æˆê•ñ)`‰@“à•ú‘—ŽÀŽ{‘OŒã‚É‚¨‚¯‚銳ŽÒŒë”FŠ„‡‚̕ω»`. ” “c”ü’mŒb1, rˆä—L”ü1, _@ˆê–²1, ´@„Žm2, ’J@Kˆê1, ŽRŒû•‘‰Ô1, ‹e’nO”ü1, Žá—Ñ—Ç—Y1, “àŽRŸ•¶3, ˆ¢ŒÃÆ4 (1ˆã—Â̎¿EˆÀ‘S„iŽº, 2ŠÅŒì•”, 3ˆã—ÈÀ‘SEŠÇ—, 4zŠÂŠí“à): ‘æ15‰ñˆã—Â̎¿EˆÀ‘SŠw‰ïŠwpW‰ï (2020/11/22), WebŠJÃ.

723750. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) v‘¬‚È‹¹œˆ³”—‚̃XƒLƒ‹K“¾‚ɏœ_‚ð‚ ‚Ä‚½“–‰@‚́uBLSƒXƒLƒ‹ƒAƒbƒvƒZƒ~ƒi[v‚ÌŒø‰Ê. ’J@Kˆê1, “àŽRŸ•¶2, ” “c”ü’mŒb1, “y‰®Žu•Û4, ´@„Žm3, _@ˆê–²1, –x]çŒbŽq3, Žá—Ñ—Ç—Y1, rˆä—L”ü1, ’JŒû—zŽq3 (1ˆã—Â̎¿EˆÀ‘S„iŽº, 2ˆã—ÈÀ‘SEŠÇ—, 3ŠÅŒì•”): ‘æ15‰ñˆã—Â̎¿EˆÀ‘SŠw‰ïŠwpW‰ï (2020/11/23), WebŠJÃ.


Š´õŠÇ—Žº

[Šwp˜_•¶]

522152. [uÀ]y˜AÚ: —Տ°ŒŸ¸‹ZŽt‚̂‚Ԃ₫zŠ´õÇ. “ñ–{–öL (Š´õŠÇ—Žº): ‹GŠ§ŽPipette 2020/4; 27: 1.


f—Ïî•ñŠÇ—Žº


—Տ°S—Žº

[Šwp˜_•¶]

110439. [Œ´’˜] Lavender Oil Reduces Depressive Mood in Healthy Individuals and Enhances the Activity of Single Oxytocin Neurons of the Hypothalamus Isolated from Mice: A Preliminary Study. Ogata K1, Ataka K, Suzuki H, Yagi T, Okawa A, Fukumoto T, Zhang B, Nakata M, Yada T, Asakawa A: Evid Based Complement Alternat Med 2020/7; 2020: 5418586. (•ûŒcŽO˜Y1: 1—Տ°S—Žº)

110440. [Œ´’˜] The relationship between premorbid intelligence and symptoms of severe anorexia nervosa restricting type. Ogata K1, Koyama K, Fukumoto T, Kawazu S, Kawamoto M, Yamaguchi E, Fuku Y, Amitani M, Amitani H, Sagiyama K, Inui A, Asakawa A: Int J Med Sci 2021/2; 18 (7): 1566-9. (•ûŒcŽO˜Y1: 1—Տ°S—Žº)

220005. [€Œ´’˜] ƒMƒƒƒ“ƒuƒ‹áŠQ‚É‚¨‚¯‚éS—ŒŸ¸‚ð—p‚¢‚½”F’m‹@”\“Á«‚ÌŒŸØ. •ûŒcŽO˜Y1, ’©‘q’•¶2, ‘êàV‹B–î2, o…—æ“Þ2, ‘åÎ@’q2, ‹{‰ª@“™2 (1—Տ°S—Žº, 2¸_): Œö‰và’c–@lˆä”V“ª•a‰@Œ¤‹†‹I—v—ߘaˆê”N“x 2020/12; P.33-6.


ƒg[ƒ^ƒ‹ƒTƒ|[ƒgƒZƒ“ƒ^[


ˆÚAˆã—ÃŽx‰‡Žº


—Տ°Œ¤‹†Žx‰‡Žº

ƒOƒ[ƒoƒ‹—Տ°Œ¤‹†Žx‰‡ƒZƒ“ƒ^[

[Šwp˜_•¶]

110441. [Œ´’˜] The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG. Kondo E, Tabata T, Suzuki N, Aoki D, Yahata H, Kotera Y1, Tokuyama O, Fujiwara K, Kimura E, Terauchi F, Sumi T, Okamoto A, Yaegashi N, Enomoto T, Sugiyama T: J Gynecol Oncol 2020/11; 31 (6): e94. (¬Ž›—Ç•v1: 1ƒOƒ[ƒoƒ‹—Տ°Œ¤‹†Žx‰‡ƒZ)

110442. [Œ´’˜] Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial. Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M1, Takano M, Nishio S, Fujiwara H, Fujiwara K, Kondo E, Sugiyama T, Tabata T: J Gynecol Oncol 2021/1; 32 (1): e9. )–ì’†”ü˜a1: 1ƒOƒ[ƒoƒ‹—Տ°Œ¤‹†Žx‰‡ƒZ)

[Šw‰ïEŒ¤‹†‰ï“™]

723751. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ARO‚É‚¨‚¯‚郁ƒ“ƒ^[§“xŽÀŽ{‚̏Љ‚æ‚Ñ, §“x‚Ì“±“ü‘OŒã‚É‚¨‚¯‚é“­‚«ˆÕ‚³‚Ì”äŠr`Œ³‹C‚É’·Šú“I‚É“­‚¯‚鉺’nì‚è`. ‹àŽq¹ŠG1, ‘ºã–­Žq1, ŽðˆäˆºŽq1, ÎX‹v”üŽq1, ˆäƒmŒû˜Ð‹B1 (1ƒOƒ[ƒoƒ‹—Տ°Œ¤‹†Žx‰‡ƒZ): ‘æ20‰ñCRC‚ƗՏ°ŽŽŒ±‚Ì‚ ‚è•û‚ðl‚¦‚é‰ï‹c2020 in ’·è (2020/11/3-16), WEBŠJÃ, ƒvƒƒOƒ‰ƒ€E´˜^W 2021; p.100.

723752. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) JCTN‚Å‚ÌCOVID-19‚̗Տ°ŽŽŒ±ƒOƒ‹[ƒv‚ÌŠˆ“®‚ւ̉e‹¿‚Ì’²¸Œ‹‰Ê. â–{²“ÞŽ}, “c糗R”üŽq, ™”öŒ«“ñ, ¬¼‰Ãl, •“cWŽi, ²“¡M–ç, âV“¡–¾Žq, –ì’†”ü˜a1, ’†‘ºŒ’ˆê, •Ÿ“cŽ¡•F (1ƒOƒ[ƒoƒ‹—Տ°Œ¤‹†Žx‰‡ƒZ): ‘æ20‰ñCRC‚ƗՏ°ŽŽŒ±‚Ì‚ ‚è•û‚ðl‚¦‚é‰ï‹c2020 in ’·è (2020/11/3-16), WEBŠJÃ, ƒvƒƒOƒ‰ƒ€E´˜^W 2021; p.131.